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Toxicological profiles are revised and republished as necessary.  For information regarding the update 
status of previously released profiles, contact ATSDR at:
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences (proposed)
Environmental Toxicology Branch (proposed)



































   
     
  




    
 
       




    
    
   
 
     
   
  
 
       
  
 
      
     
 
  
    
     





















   
 
     
    
     
 
     
 
    
     
      
       
 
       
     
       
       
     





 MMAN    vANGANESE
FOREWORD
This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for the toxic substances each profile describes.  Each peer-reviewed profile identifies and
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is
also presented but is described in less detail than the key studies.  The profile is not intended to be an 
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The profiles focus on health and toxicologic information; therefore, each toxicological profile begins with 
a public health statement that describes, in nontechnical language, a substance's relevant toxicological
properties.  Following the public health statement is information concerning levels of significant human 
exposure and, where known, significant health effects. A health effects summary describes the adequacy
of information to determine a substance's health effects. ATSDR identifies data needs that are significant
to protection of public health. 
Each profile:
(A) Examines, summarizes, and interprets available toxicologic information and
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) Determines whether adequate information on the health effects of each substance is
available or being developed to determine levels of exposure that present a significant risk to
human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identifies toxicologic testing needed to identify the types or levels of
exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are federal, state, and local health professionals;
interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staff of the Centers for Disease Control and Prevention and other federal scientists also 
have reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review.  Final responsibility for the contents and views expressed in
this toxicological profile resides with ATSDR. 
Christopher J. Portier, Ph.D. 
Assistant Administrator















    






   
 
  
     
       
 
   vi MANGANESE
*Legislative Background
The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related 
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous 
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise













   
       
       






     
      
        
     
 
       
       
 
   
  
  
     
            




   
     
   
   
 
 
   




          




    
  
      












QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances will find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (death, systemic, immunologic, reproductive), by route of exposure, and by length 
of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies are
reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Section 1.6 How Can (Chemical X) Affect Children?
Section 1.7 How Can Families Reduce the Risk of Exposure to (Chemical X)?
Section 3.7 Children’s Susceptibility
Section 6.6 Exposures of Children
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY) Fax: (770) 488-4178 
E-mail: cdcinfo@cdc.gov Internet: http://www.atsdr.cdc.gov
The following additional material can be ordered through the ATSDR Information Center:
Case Studies in Environmental Medicine: Taking an Exposure History—The importance of taking an 
exposure history and how to conduct one are described, and an example of a thorough exposure
history is provided.  Other case studies of interest include Reproductive and Developmental
Hazards; Skin Lesions and Environmental Exposures; Cholinesterase-Inhibiting Pesticide











     
        
        
    
    
 
 






   
 
 
   
         
      




    






     
    
  
        
 
    





Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident.  Volumes I and II are planning guides to assist first responders and hospital emergency
department personnel in planning for incidents that involve hazardous materials.  Volume III— 
Medical Management Guidelines for Acute Chemical Exposures—is a guide for health care 
professionals treating patients exposed to hazardous materials.
Fact Sheets (ToxFAQs) provide answers to frequently asked questions about toxic substances.
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease,
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta,
GA 30341-3724 • Phone: 770-488-7000 • FAX: 770-488-7015. 
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and
safety in the workplace, recommends standards to the Occupational Safety and Health
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 200 Independence Avenue, 
SW, Washington, DC 20201 • Phone: 800-356-4674 or NIOSH Technical Information Branch, 
Robert A. Taft Laboratory, Mailstop C-19, 4676 Columbia Parkway, Cincinnati, OH 45226-1998 
• Phone: 800-35-NIOSH.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone: 919-541-3212.
Referrals
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone: 202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
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THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1. Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2. Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3. Data Needs Review. The Environmental Toxicology Branch (proposed) reviews data needs 
sections to assure consistency across profiles and adherence to instructions in the Guidance.





























          
 
 
          
  
 





    




        
    
     
   
 
  









A peer review panel was assembled for manganese. The panel consisted of the following members:
1. David Dorman, D.V.M., Ph.D., Associate Dean for Research and Graduate Studies, College of
Veterinary Medicine, Professor of Toxicology, Department of Molecular Biomedical Sciences,
North Carolina State University, Raleigh, North Carolina 27606,
2. Donald Smith, Ph.D., Professor of Environmental Toxicology, University of California, Santa
Cruz, California 95064, and 
3. Wei Zheng, Ph.D., Director of Graduate Studies, School of Health Sciences, Purdue University, 
West Lafayette, Indiana 47907.
These experts collectively have knowledge of manganese’s physical and chemical properties, 
toxicokinetics, key health end points, mechanisms of action, human and animal exposure, and 
quantification of risk to humans.  All reviewers were selected in conformity with the conditions for peer
review specified in Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, 
and Liability Act, as amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
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1.  PUBLIC HEALTH STATEMENT 
This public health statement tells you about manganese and the effects of exposure to it.
The Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation. These sites are then placed on the National Priorities List (NPL) and are targeted for long-term 
federal clean-up activities. Manganese has been found in at least 869 of the 1,699 current or former NPL
sites.  Although the total number of NPL sites evaluated for this substance is not known, the possibility
exists that the number of sites at which manganese is found may increase in the future as more sites are 
evaluated. This information is important because these sites may be sources of exposure and exposure to
this substance may harm you.
When a substance is released either from a large area, such as an industrial plant, or from a container, 
such as a drum or bottle, it enters the environment.  Such a release does not always lead to exposure.  You 
can be exposed to a substance only when you come in contact with it.  You may be exposed by breathing, 
eating, or drinking the substance, or by skin contact.
If you are exposed to manganese, many factors will determine whether you will be harmed. These factors 
include the dose (how much), the duration (how long), and how you come in contact with it.  You must
also consider any other chemicals you are exposed to and your age, sex, diet, family traits, lifestyle, and 
state of health.
   
 








     
 
       
      
        
       
         








   
 
   
       
     
  
 
      
    









   
  
 
     
     
    
 
 




1. PUBLIC HEALTH STATEMENT
1.1 WHAT IS MANGANESE?
Description Manganese is a naturally occurring substance found in many
types of rocks and soil. Pure manganese is a silver-colored 
metal; however, it does not occur in the environment as a pure 
metal. Rather, it occurs combined with other substances such 
as oxygen, sulfur, and chlorine. Manganese is a trace element




Manganese is used principally in steel production to improve 
hardness, stiffness, and strength. It is used in carbon steel,
stainless steel, high-temperature steel, and tool steel, along 
with cast iron and superalloys.
Manganese occurs naturally in most foods and may be added 
to food or made available in nutritional supplements.






• a medical imaging agent
• cosmetics
It may also be used as an additive in gasoline to improve the 
octane rating of the gas.
Small amounts of manganese are used in a pharmaceutical
product called mangafodipir trisodium (MnDPDP) to improve
lesion detection in magnetic resonance imaging of body organs.
Chapters 4, 5, and 6 have more information on the properties and uses of manganese and how it behaves
in the environment.
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1. PUBLIC HEALTH STATEMENT
1.2 WHAT HAPPENS TO MANGANESE WHEN IT ENTERS THE ENVIRONMENT?
Sources Manganese is a normal constituent of air, soil, water, and food.
Additional manganese can be found in air, soil, and water after
release from the manufacture, use, and disposal of manganese-
based products.
Breakdown As with other elements, manganese cannot break down in the
environment. It can only change its form or become attached or
separated from particles. The chemical state of manganese 
and the type of soil determine how fast it moves through the soil
and how much is retained in the soil. In water, most of the 
manganese tends to attach to particles in the water or settle into 
the sediment.
The manganese-containing gasoline additive may degrade in 
the environment quickly when exposed to sunlight, releasing 
manganese.
For more information on manganese in the environment, see Chapter 6.
1.3 HOW MIGHT I BE EXPOSED TO MANGANESE?
Food – primary 
source of exposure
The primary way you can be exposed to manganese is by eating food 
or manganese-containing nutritional supplements.  Vegetarians who 
consume foods rich in manganese such as grains, beans and nuts, as
well as heavy tea drinkers, may have a higher intake of manganese 
than the average person.
Workplace air Certain occupations like welding or working in a factory where steel is
made may increase your chances of being exposed to high levels of
manganese.
Water and soil Because manganese is a natural component of the environment, you 
are always exposed to low levels of it in water, air, soil, and food.
Manganese is routinely contained in groundwater, drinking water and 
soil at low levels. Drinking water containing manganese or swimming 
or bathing in water containing manganese may expose you to low
levels of this chemical.
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1. PUBLIC HEALTH STATEMENT
Air Air also contains low levels of manganese, and breathing air may
expose you to it. Releases of manganese into the air occur from:
• industries using or manufacturing products containing manganese,
• mining activities, and
• automobile exhaust.
Lifestyle traits may also lead to exposure to manganese. People who
smoke tobacco or inhale second-hand smoke are typically exposed to 
manganese at levels higher than those not exposed to tobacco smoke.
See Chapter 6 for more information on how you might be exposed to manganese or its compounds.
1.4 HOW CAN MANGANESE ENTER AND LEAVE MY BODY?
Enter your body
• Inhalation When you breathe air containing manganese, a small amount of the 
manganese will enter your body through your lungs and the remainder
can become trapped in your lungs. Some of the manganese in your
lungs can also be trapped in mucus which you may cough up and 
swallow into your stomach.
• Ingestion Manganese in food or water may enter your body through the digestive 
tract to meet your body’s needs for normal functioning.
• Dermal contact Only very small amounts of manganese can enter your skin when you 
come into contact with liquids containing manganese.
Leave your body Once in your body, manganese-containing chemicals can break down
into other chemicals. However, manganese is an element that cannot
be broken down. Most manganese will leave your body in feces within 
a few days.
For more information on how manganese enters and leaves the body, see Chapter 3. 
1.5 HOW CAN MANGANESE AFFECT MY HEALTH?
This section looks at studies concerning potential health effects in human and animal studies.
General population Manganese is an essential nutrient, and eating a small amount of it
each day is important to stay healthy.
   
 











    
     
      
        
      
         
    
    
 
       
    
 
 
      
    
 
    
     
     
     
      





     





    
     
   
 
         
      
 
   
     
     
   
 
       
        
      
 
     
     
 
 




1. PUBLIC HEALTH STATEMENT
Workers
• Inhalation The most common health problems in workers exposed to high levels
of manganese involve the nervous system. These health effects
include behavioral changes and other nervous system effects, which 
include movements that may become slow and clumsy. This
combination of symptoms when sufficiently severe is referred to as
“manganism.” Other less severe nervous system effects such as
slowed hand movements have been observed in some workers
exposed to lower concentrations in the work place.
The inhalation of a large quantity of dust or fumes containing
manganese may cause irritation of the lungs which could lead to 
pneumonia.
Loss of sex drive and sperm damage has also been observed in men 
exposed to high levels of manganese in workplace air.
The manganese concentrations that cause effects such as slowed hand 
movements in some workers are approximately twenty thousand times
higher than the concentrations normally found in the environment.
Manganism has been found in some workers exposed to manganese
concentrations about a million times higher than normal air
concentrations of manganese.
Laboratory animals
• Inhalation Respiratory effects, similar to those observed in workers, have been 
observed in laboratory monkeys exposed to high levels of manganese.
Laboratory animals
• Oral Manganese has been shown to cross the blood-brain barrier and a 
limited amount of manganese is also able to cross the placenta during 
pregnancy, enabling it to reach a developing fetus.
Nervous system disturbances have been observed in animals after very
high oral doses of manganese, including changes in behavior.
Sperm damage and adverse changes in male reproductive
performance were observed in laboratory animals fed high levels of
manganese. Impairments in fertility were observed in female rodents
provided with oral manganese before they became pregnant.
Illnesses involving the kidneys and urinary tract have been observed in
laboratory rats fed very high levels of manganese. These illnesses
included inflammation of the kidneys and kidney stone formation.
Cancer The EPA concluded that existing scientific information cannot
determine whether or not excess manganese can cause cancer.
Further information on the health effects of manganese in humans and animals can be found in 
Chapters 2 and 3.
   
 








       
 
   
       
 
        
  
     
     
     
    
      
          
     
        
      
 
       
       
 
      
 
    
        
          
    
     




1. PUBLIC HEALTH STATEMENT
1.6 HOW CAN MANGANESE AFFECT CHILDREN?
This section discusses potential health effects in humans from exposures during the period from
conception to maturity at 18 years of age.
Effects in children Studies in children have suggested that extremely high levels of
manganese exposure may produce undesirable effects on brain 
development, including changes in behavior and decreases in the 
ability to learn and remember. In some cases, these same manganese 
exposure levels have been suspected of causing severe symptoms of
manganism disease (including difficulty with speech and walking). We 
do not know for certain that these changes were caused by manganese 
alone. We do not know if these changes are temporary or permanent.
We do not know whether children are more sensitive than adults to the 
effects of manganese, but there is some indication from experiments in 
laboratory animals that they may be.
Birth defects Studies of manganese workers have not found increases in birth 
defects or low birth weight in their children.
No birth defects were observed in animals exposed to manganese 
In one human study where people were exposed to very high levels of
manganese from drinking water, infants less than 1 year of age died at
an unusually high rate. It is not clear, however, whether these deaths
were attributable to the manganese level of the drinking water. The 
manganese toxicity may have involved exposures to the infant that
occurred both before (through the mother) and after they were born.
   
 








        
 
  Avoid inhalation of 
  manganese at work
    High levels of airborne manganese are observed in certain 
       occupational settings such as steel factories or welding areas.  You 
    should take precautions to prevent inhalation of manganese by
     wearing an appropriate mask to limit the amount of manganese you 
 breathe.  
 
  Avoid wearing
manganese dust-
  contaminated work
    clothing in your home
or car 
    Workers exposed to high levels of airborne manganese in certain 
     occupational settings may accumulate manganese dust on their work 
 clothes.   Manganese-contaminated work clothing should be removed 
     before getting into your car or entering your home to help reduce the 
   exposure hazard for yourself and your family. 
 
  Avoid inhalation of       If you weld objects around your home, do so in a well-ventilated area 
  welding fumes at      and use an appropriate mask to decrease your risk of inhaling 
 home  manganese-containing fumes.     Children should be kept away from 
 welding fumes.
 
Diet       Children are not likely to be exposed to harmful amounts of 
 manganese in the diet.     However, higher-than-usual amounts of 
      manganese may be absorbed if their diet is low in iron.     It is important
 to provide your child with a well-balanced diet. 
 
Water    While tap and bottled water generally contain safe levels of 
     manganese, well water may sometimes be contaminated with 
    sufficiently high levels of manganese to create a potential health 
          hazard. If drinking water is obtained from a well water source, it m
   be wise to have the water checked for manganese to ensure the le




Smoking       Manganese is a minor constituent of tobacco smoke.  Avoiding 







1. PUBLIC HEALTH STATEMENT
1.7 HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO MANGANESE?
If your doctor finds that you have been exposed to significant amounts of manganese, ask whether your
children might also be exposed.  Your doctor might need to ask you state health department to investigate.
   
 








          
 
 
       
         
       
 
      
         
 
 
       
     
 
 
         
        
         
       
 
 
   
 
      
  
 
    
   
           
   
           
          
   
 
        
        
           







1. PUBLIC HEALTH STATEMENT
1.8 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO 
MANGANESE?
Detecting exposure Several tests are available to measure manganese in blood, urine,
hair, or feces. Because manganese is normally present in our body,
some is always found in tissues or fluids.
Normal ranges of manganese levels are about 4–15 μg/L in blood, 1– 
8 μg/L in urine, and 0.4–0.85 μg/L in serum (the fluid portion of the 
blood).
Measuring exposure Because excess manganese is usually removed from the body within 
a few days, past exposures are difficult to measure with common 
laboratory tests.  
A medical test known as magnetic resonance imaging, or MRI, can 
detect the presence of increased amounts of manganese in the brain.
However, this type of test is qualitative, and has not been shown to
reliably reflect or predict toxicologically meaningful exposures.
Information about tests for detecting manganese in the body is given in Chapters 3 and 7.
1.9 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO
PROTECT HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  The EPA, the Occupational Safety and Health Administration (OSHA), and the
Food and Drug Administration (FDA) are some federal agencies that develop regulations for toxic
substances.  Recommendations provide valuable guidelines to protect public health, but cannot be
enforced by law. The Agency for Toxic Substances and Disease Registry (ATSDR) and the National
Institute for Occupational Safety and Health (NIOSH) are two federal organizations that develop
recommendations for toxic substances.
Regulations and recommendations can be expressed as “not-to-exceed” levels, that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value that is usually based on levels that
affect animals; they are then adjusted to levels that will help protect humans.  Sometimes these not-to-
exceed levels differ among federal organizations because they used different exposure times (an 8-hour
workday or a 24-hour day), different animal studies, or other factors.
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Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that provides it.  Some
regulations and recommendations for manganese include the following:
Drinking water The EPA has established that exposure to manganese in drinking water at
concentrations of 1 mg/L for 1 or 10 days is not expected to cause any
adverse effects in a child.
The EPA has established that lifetime exposure to 0.3 mg/L manganese is
not expected to cause any adverse effects.  
Bottled water The FDA has established that the manganese concentration in bottled 
drinking water should not exceed 0.05 mg/L.
Workplace air OSHA set a legal limit of 5 mg/m3 manganese in air averaged over an 
8-hour work day.
For more information on regulations and advisories, see Chapter 8.
1.10 WHERE CAN I GET MORE INFORMATION?
If you have any more questions or concerns, please contact your community or state health or
environmental quality department, or contact ATSDR at the address and phone number below.
ATSDR can also tell you the location of occupational and environmental health clinics. These clinics 
specialize in recognizing, evaluating, and treating illnesses that result from exposure to hazardous
substances.
Toxicological profiles are also available on-line at www.atsdr.cdc.gov and on CD-ROM.  You may
request a copy of the ATSDR ToxProfilesTM CD-ROM by calling the toll-free information and technical
assistance number at 1-800-CDCINFO (1-800-232-4636), by e-mail at cdcinfo@cdc.gov, or by writing
to: 
Agency for Toxic Substances and Disease Registry
Division of Toxicology and Human Health Sciences (proposed)
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Organizations for-profit may request copies of final Toxicological Profiles from the following:
National Technical Information Service (NTIS)
5285 Port Royal Road
Springfield, VA 22161
Phone: 1-800-553-6847 or 1-703-605-6000
Web site: http://www.ntis.gov/
















     
  
 
     
          
        
 
    
      
        
 
     
 
 
        
          
   
       
 
           
         
    
 
         
        





2. RELEVANCE TO PUBLIC HEALTH
2.1 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO MANGANESE IN THE
UNITED STATES 
Manganese is a naturally occurring element and an essential nutrient.  Comprising approximately 0.1% of
the earth’s crust, it is the twelfth most abundant element and the fifth most abundant metal. Manganese 
does not exist in nature as an elemental form, but is found mainly as oxides, carbonates, and silicates in 
over 100 minerals with pyrolusite (manganese dioxide) as the most common naturally-occurring form.  
As an essential nutrient, several enzyme systems have been reported to interact with or depend on 
manganese for their catalytic or regulatory function.  As such, manganese is required for the formation of
healthy cartilage and bone and the urea cycle; it aids in the maintenance of mitochondria and the 
production of glucose.  It also plays a key role in wound-healing.  
Manganese exists in both inorganic and organic forms.  An essential ingredient in steel, inorganic
manganese is also used in the production of dry-cell batteries, glass and fireworks, in chemical
manufacturing, in the leather and textile industries and as a fertilizer.  The inorganic pigment known as
manganese violet (manganese ammonium pyrophosphate complex) has nearly ubiquitous use in 
cosmetics and is also found in certain paints.  Organic forms of manganese are used as fungicides, fuel-oil 
additives, smoke inhibitors, an anti-knock additive in gasoline, and a medical imaging agent.  
The average manganese soil concentrations in the United States is 40–900 mg/kg; the primary natural
source of the manganese is the erosion of crustal rock.  Its presence in soil results in vegetable and animal
foods reliably containing varying amounts of the mineral.  As an essential nutrient, manganese is added to 
certain foods and nutritional supplements. Vegetarians often have diets richer in manganese than those 
who select omnivorous diets. 
The most important source of manganese in the atmosphere results from the air erosion of dusts or soils.  
The mean concentration of manganese in ambient air in the United States is 0.02 μg/m3; however, 
ambient levels near industrial sources can range from 0.22 to 0.3 µg/m3.  Manganese is released into
waterways mainly through the erosion of rocks and soils, mining activities, and industrial waste, or by the
leaching of manganese from anthropogenic materials discarded in landfills or soil, such as dry-cell
batteries.  Surface waters in the United States contain a median manganese level of 16 μg/L, with 
99th percentile concentrations of 400–800 μg/L.  Groundwater in the United States contains median
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manganese levels of 5 to 150 μg/L, with the 99th percentile at 2,900 or 5,600 μg/L in rural or urban areas, 
respectively.
The general population is exposed to manganese through consumption of food and water, inhalation of
air, and dermal contact with air, water, soil, and consumer products that contain manganese.  The primary
source of manganese intake is through diet.  The Food and Nutrition Board (FNB) of the Institute of
Medicine (IOM) has set adequate intake (AI) levels for manganese for humans. These levels are 
presented in Table 2-1. 
The inhalation of air contaminated with particulate matter containing manganese is the primary source of
excess manganese exposure for the general population in the United States.  Populations living in close
proximity to mining activities and industries using manganese may be exposed by inhalation to high 
levels of manganese in dust.  Workers in these industries are especially vulnerable to exposure to
manganese dust. Manganese concentrations in soil may be elevated when the soil is in close proximity to 
a mining source or industry using manganese and may therefore pose a risk of excess exposure to children
who ingest contaminated soil.  Manganese is ubiquitous in drinking water in the United States.  Although 
certain water sources in the United States are contaminated with excess manganese, there is little risk of
excessive exposure to manganese through ingestion of fish or shellfish emanating from contaminated 
waters, unless the manganese levels in the fish are extremely high and/or the fish are eaten as subsistence.  
Although many forms of manganese are water-soluble, there is little evidence that dermal contact with
manganese results in significant absorption through the skin.  Thus, dermal contact with manganese is not
generally viewed as an important source of exposure to the population at large.  
Excess exposure to manganese may be revealed by tests to detect heightened levels in body fluids as well
as in hair samples. Normal ranges of manganese levels in body fluids are 4–15 μg/L in blood, 1–8 μg/L
in urine, and 0.4–0.85 μg/L in serum.  Excess manganese in the body characteristically accumulates in the
brain region known as the basal ganglia. This accumulation can be revealed by magnetic resonance 
imaging (MRI) as a distinctive symmetrical high-signal lesion in the globus pallidus region of the basal
ganglia on T1- but not T2-weighted MRI.
2.2 SUMMARY OF HEALTH EFFECTS 
Although low levels of manganese intake are necessary for human health, exposures to high manganese
levels are toxic.  Reports of adverse effects resulting from manganese exposure in humans are associated
   
 









      
 
 Life stage  Age  Males (mg/day)  Females (mg/day) 
	
Infants 0–6 Months 0.003 0.003 
Infants  7–12 Months  0.6  0.6 
Children 1–3 Years 1.2 1.2 
Children 4–8 Years 1.5  1.5  
Children  9–13 Years 1.9 1.6 
Adolescents 14–18 Years 2.2  1.6  
Adults  19 Years and older 2.3 1.8 
 Pregnancy  All ages  — 2.0 
Lactation All ages  — 2.6 
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Table 2-1. Adequate Intake (AI) for Manganese
Source: FNB/IOM 2001
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primarily with inhalation in occupational settings.  Inhaled manganese is often transported directly to the
brain before it is metabolized by the liver. The symptoms of manganese toxicity may appear slowly over
months and years.  Manganese toxicity can result in a permanent neurological disorder known as 
manganism with symptoms that include tremors, difficulty walking, and facial muscle spasms.  These 
symptoms are often preceded by other lesser symptoms, including irritability, aggressiveness, and
hallucinations.  Some studies suggest that manganese inhalation can also result in adverse cognitive 
effects, including difficulty with concentration and memory problems.  Although the workplace is the
most common source of excess inhalation of manganese, frequent inhalation of fumes from welding
activities in the home can produce a risk of excess manganese exposure leading to neurological
symptoms.  Environmental exposures to airborne manganese have been associated with similar preclinical 
neurological effects and mood effects as are seen in occupational studies. Acute or intermediate exposure 
to excess manganese also affects the respiratory system.  Inhalation exposure to high concentrations of
manganese dusts (specifically manganese dioxide [MnO2] and manganese tetroxide [Mn3O4]) can cause 
an inflammatory response in the lung, which, over time, can result in impaired lung function.  Lung
toxicity is manifested as an increased susceptibility to infections such as bronchitis and can result in 
manganic pneumonia.  Pneumonia has also been observed following acute inhalation exposures to 
particulates containing other metals. Thus, this effect might be characteristic of inhalable particulate 
matter and might not depend solely on the manganese content of the particle.
A number of reports indicate that oral exposure to manganese, especially from contaminated water
sources, can produce significant health effects.  These effects have been most prominently observed in 
children and are similar to those observed from inhalation exposure.  An actual threshold level at which 
manganese exposure produces neurological effects in humans has not been established.  However,
children consuming the same concentration of manganese in water as adults are ultimately exposed to a 
higher mg/kg-body weight ratio of manganese than adults (as a consequence of the lower body weight of
children as well as their higher daily consumption volume and greater retention of manganese).  Children 
are also potentially more sensitive to manganese toxicity than adults.  A study conducted in infant
monkeys suggests that soy-based infant formula, which contains a naturally higher concentration of
manganese than human or cow’s milk, may produce mild effects on neurological development, although 
such effects have not been documented in humans.  While many of the studies reporting oral effects of
excess manganese have limitations that preclude firm conclusions about the potential for adverse effects,
these studies collectively suggest that ingestion of water and/or foodstuffs containing increased
concentrations of manganese may result in adverse neurological effects.
   
 








     
    
           
     
    
        
             
     
          
 
   
      
      
 
        
   
            
     
    
 
         
         
      
   
 
     






2.  RELEVANCE TO PUBLIC HEALTH
There is indirect evidence that reproductive outcomes might be affected (decreased libido, impotence, and 
sexual dysfunction have been observed in manganese-exposed men). The available studies on the effect
that manganese has on fertility (as measured by birthrate) is inconclusive.  Two studies in men
occupationally exposed to manganese show adverse effects on reproductive parameters:  one found 
increased sexual dysfunction and the other found reduced sperm quality, but neither measured birthrate in 
wives of affected workers.  Impaired sexual function in men may be one of the earliest clinical
manifestations of manganese toxicity, but no dose-response information is currently available, so it is not
possible to define a threshold for this effect. There is a lack of information regarding effects in women
since most data are derived from studies of male workers.  Developmental data in humans exposed to 
manganese by inhalation are limited and consist mostly of reports of adverse pulmonary effects from
inhaling airborne manganese dust and adverse neurological effects in offspring following ingestion 
exposure.  Animal studies indicate that manganese is a developmental toxin when administered orally and 
intravenously, but inhalation data concerning these effects are scarce and not definitive.  Some studies in 
children suggest that routine exposures to high levels of manganese from contaminated drinking water
may ultimately impair intellectual performance and behavior.
The few available inhalation and oral studies in humans and animals indicate that inorganic manganese 
exposure does not cause significant injury to the heart, stomach, blood, muscle, bone, liver, kidney, skin, 
or eyes.  However, if manganese is in the (VII) oxidation state (as in potassium permanganate), then
ingestion may lead to severe corrosion at the point of contact.  Studies in pigs have revealed a potential
for adverse coronary effects from excess manganese exposure.
There is no evidence that manganese causes cancer in humans.  Although no firm conclusions can be 
drawn from the mixed results in animal studies, there are little data to suggest that inorganic manganese is 
carcinogenic.  The IRIS has provided manganese with a weight-of-evidence classification D—not
classifiable as to human carcinogenicity.
It should be noted that individuals with cirrhosis of the liver, as well as children with a congenital venous
anomaly known as a portosystemic shunt, may be at heightened risk of health deficits from exposure to 
dietary and environmental sources of manganese.  Manganese is ordinarily eliminated from the body
through bile, but cirrhosis and portosystemic shunts impair the normal functioning of the liver and thus
limit the ability of the body to excrete manganese, which then can accumulate in the blood and, 
eventually, the brain.
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A more detailed discussion of the critical targets of manganese toxicity (i.e., the nervous system, 
respiratory system, reproductive system, and development) follows.
Neurological Effects. There is clear evidence from studies of humans exposed to manganese dusts in
mines and factories that inhalation of high levels of manganese can lead to a series of serious and
ultimately disabling neurological effects in humans. This disease, termed manganism, typically begins 
with feelings of weakness and lethargy.  As the disease progresses, a number of other neurological signs
may become manifest.  Although not all individuals develop identical signs, the most common are a slow
and clumsy gait, speech disturbances, a masklike face, and tremors. The neurological symptoms may
improve when exposure ceases; however, in most cases, the symptoms are found to persist for many years 
post-exposure.  In addition, a syndrome of psychological disturbances (hallucination, psychosis)
frequently emerges, although such symptoms are sometimes absent.  As the disease progresses, patients 
develop severe muscle tension and rigidity and may be completely and permanently disabled.  Workplace
inhalation exposure levels producing overt symptoms of manganism have been on the order of 2–22 mg
manganese/m3.  While manganese neurotoxicity has clinical similarities to Parkinson’s disease, it can be
clinically distinguished from Parkinson’s.  Manganism patients present a hypokinesia and tremor that is
different from Parkinson’s patients.  In addition, manganism patients sometimes have psychiatric 
disturbances early in the disease, a propensity to fall backward when pushed, less frequent resting tremor, 
more frequent dystonia, a “cock-walk”, and a failure to respond to dopaminomimetics.
Subclinical neurological effects have been observed in numerous studies of workers exposed to
manganese dusts at lower exposure levels than those associated with symptoms of overt manganism.
These effects include decreased performance on neurobehavioral tests; significantly poorer eye-hand 
coordination, hand steadiness, and reaction time; poorer postural stability; and lower levels of cognitive
flexibility.  Manganese air concentrations producing these effects in chronically exposed workers range 
from about 0.07 to 0.97 mg manganese/m3. 
Studies in communities surrounding manganese industries have also reported associations between
manganese exposure and subclinical neurological effects in adults and children.  In a study of men and
women living close to a manganese alloy production plant, a blood manganese level-age interaction was
observed, with the poorest performance on neurological tests occurring among those >50 years old who 
had the highest blood manganese levels.  Additional studies of environmentally exposed adults reported 
attention impairments, poorer postural stability, and subclinical motor impairments at environmental air
exposures >0.1 μg manganese/m3; however, other potential sources of environmental exposure were not
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accounted for.  In several studies of children, associations have been reported between manganese 
concentrations in blood or hair and motor impairment and deficits in neurodevelopment and intellectual
functions.  
There is also an accumulating body of evidence suggesting that exposure to excess levels of manganese in
drinking water (≥0.2 mg/L) may lead to neurological deficits in children, including poor school
performance, impaired cognitive function, abnormal performance on neurobehavioral tests, and increased 
oppositional behavior and hyperactivity.  Several cases of apparent manganism in both children and 
adults have been reported where exposures to high levels of manganese in drinking water were implicated
as the probable cause.  The symptoms in these case reports are similar to those in individuals with high 
levels of exposure in manganese mining operations.  Taken together, these studies provide added weight
to the evidence for the neurotoxic potential of excessive manganese in children, but one or more of the 
following uncertainties preclude the characterization of causal and dose-response relationships between
the observed effects and manganese exposure:  (1) whether or not the observed effects were solely due to
excess manganese alone or could have been influenced by other drinking water or dietary components;
(2) the lack of quantitative information about manganese levels from different environmental sources
(food, water, and air); and (3) the small sample sizes.
Respiratory Effects. Inhalation exposure to manganese dusts often leads to an inflammatory
response in the lungs of both humans and animals. This generally leads to an increased incidence of
cough and bronchitis and can lead to mild-to-moderate injury of lung tissue along with minor decreases in 
lung function.  In addition, susceptibility to infectious lung disease may be increased, leading to increased
pneumonitis and pneumonia in some manganese-exposed worker populations. These effects have been
reported primarily in workers exposed to fairly high concentrations of manganese dusts in the workplace, 
although there are some data that indicate that, in populations living and attending school near
ferromanganese factories, there was an increased prevalence of respiratory effects.  The risk of lung
injury in people exposed to the levels of manganese typically found in the general environment is
expected to be quite low.  However, exposure to manganese-containing dusts from factories, mining
operations, automobile exhaust, or other sources may be of concern.  It should be noted that these effects
on the lung are not unique to manganese-containing dusts but are produced by a variety of inhalable
particulate matter.  On this basis, it seems most appropriate to evaluate the risk of inflammatory effects on
the lung in terms of total suspended particulate matter (TSP) or particulate matter <10 μm in diameter
(PM10), as well as the concentration of manganese in the air.  Studies involving controlled inhalation
exposures in humans or animals to methylcyclopentadienyl manganese tricarbonyl (MMT), a gasoline 
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additive that improves combustion efficiency, are not available because the compound breaks down 
readily in light to form inorganic manganese compounds.  Rats exposed to high concentrations of car
exhaust containing oxidation products from MMT-containing fuel exhibited labored breathing.   
Reproductive Effects. Impotence and loss of libido are common symptoms in male workers
afflicted with clinically identifiable signs of manganism.  These symptoms could lead to reduced
reproductive success in men.  Impaired fertility (measured as a decreased number of children/married
couple) has been observed in male workers exposed for 1–19 years to manganese dust (0.97 mg/m3) at
levels that did not produce frank manganism.  This suggests that impaired sexual function in men may be
one of the earliest clinical manifestations of manganese toxicity, but no dose-response information is 
available; therefore, it is not possible to define a threshold for this effect.  Evidence obtained in laboratory
mammals indicates that exposure to high levels of manganese may adversely effect sperm quality,
produce decreased testicular weights, and impair development of the male reproductive tract.
No direct effect of manganese toxicity has been observed on fertility in women.  Although many studies
in laboratory mammals have attempted to detect effects of manganese on female fertility, only one study
demonstrated the possibility that excess manganese exposure outside of pregnancy may impair future 
fertility (decreased number of offspring).  
Developmental Effects. There is evidence to suggest that children exposed to high levels of
manganese from environmental sources (airborne, drinking water, dietary) may develop a variety of
adverse developmental effects, particularly neurological effects (as discussed above).  Many studies 
suggest that children exposed to particularly high levels of manganese over a long period of time (months
or years) will eventually develop one or more symptoms, including general cognitive impairment, 
diminished memory, attention deficit, motor impairments, aggressiveness, and/or hyperactivity.
However, it is not clear from any of these studies whether other factors, perhaps environmental or genetic,
are responsible for these changes in the presence of manganese, or whether manganese alone can produce 
these effects.
A potentially serious developmental effect of manganese was suggested by the results of a study where 
high infant mortality in a Bangladesh community was reported in conjunction with the presence of a local
drinking water supply containing high levels of manganese (concentration up to 8.31 mg/L).  Infants
exposed to levels of manganese equal to or greater than those recommended by the World Health 
Organization (WHO) were at the highest risk of mortality prior to 1 year of age.  The nature of this
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epidemiological study, with nutritional deficits in the population anticipated but not documented, prevents
a determination that manganese alone was responsible for the high rate of infant mortality.
Developmental studies involving the use of laboratory animals have detected subtle changes in growth;
(e.g., diminished body weight, in animals provided with relatively high doses of manganese).  These
changes have been observed both when the animals were exposed while in utero or postpartum when the
animals have already been born.  
2.3 MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been made for manganese.  An
MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic 
bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
A User’s Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
Inhalation MRLs for Inorganic Manganese
Acute and Intermediate Inhalation Exposure. MRL values were not derived for acute- or intermediate-
duration inhalation exposures to manganese.  The available data on the toxicity of inhaled manganese 
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were considered inadequate for derivation of acute- or intermediate-duration inhalation MRLs.  Data are 
lacking on whether exposure to inhaled manganese across these durations has any significant adverse 
effects on numerous end points including reports on developmental and reproductive effects. 
Reports of human exposure at acute and intermediate durations (i.e., 15–364 days) indicate adverse 
respiratory and neurological effects, but these reports consist of anecdotal case studies and lack
quantitative exposure values. 
A few animal studies for these durations also evaluated respiratory effects in rodents and monkeys and 
reported no-observed-adverse-effect levels (NOAELs).  Inhalation of particulate manganese compounds 
such as manganese dioxide or manganese tetroxide leads to an inflammatory response in the lungs of
animals, although inhalation of MnCl2 did not cause lung inflammation in rabbits (Camner et al. 1985).
Several acute- and intermediate-duration studies in animals report various signs of lung inflammation 
following periods ranging from 1 day to 10 months at manganese concentrations ranging from 0.7 to 
69 mg/m3 (Bergstrom 1977; Camner et al. 1985; Shiotsuka 1984; Suzuki et al. 1978; Ulrich et al. 1979a, 
1979b).  Bergstrom (1977) and Ulrich et al. (1979a, 1979b) determined NOAELs, which are reported in 
the levels of significant exposure (LSE) table and figure.  Increased susceptibility to lung infection by
bacterial pathogens following inhalation of manganese dusts has been noted in acute animal studies 
(Maigetter et al. 1976).  Conversely, Lloyd Davies (1946) reported no increase in the susceptibility of
manganese-treated mice to pneumococci or streptococci.  
More recently, reversible inflammation (pleocellular inflammatory infiltrates and fibrinonecrotic debris)
in the nasal respiratory epithelium (but not the olfactory epithelium) was observed in young adult male
Crl:CD(SD)BR rats following 13 weeks of inhalation exposure to 0.5 mg manganese/m3 as manganese 
sulfate, but not in rats exposed to 0.1 mg manganese/m3 as manganese sulfate or manganese phosphate
(hureaulite) (Dorman et al. 2004b). The lesions were not apparent in groups of rats assessed 45 days after
the end of exposure, indicating their transient nature.  In studies with young male rhesus monkeys
exposed to 0, 0.06, 0.3, or 1.5 mg manganese/m3 as manganese sulfate 6 hours/day, 5 days/week for
65 days, no nasal histological effects were found in exposed monkeys, but the high exposure level
induced lesions in the lower respiratory tract (mild subacute bronchiolitus, alveolar duct inflammation, 
and proliferation of bronchus-associated lymphoid tissue) (Dorman et al. 2005b). The lower airway
lesions from intermediate-duration exposure appear to have been transient, because they were not found 
in monkeys assessed 45 days after the end of exposure (Dorman et al. 2005b).  These findings in rats and 
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monkeys are consistent with the understanding that inflammation of respiratory tissues from high-level
exposure to inhaled manganese particulates is likely a consequence of the inhaled particulate matter.
Bredow et al. (2007) reported that nose-only inhalation exposure to 2 mg manganese/m3 as manganese 
chloride aerosols 6 hours/day for 5 consecutive days did not cause lung lesions in female GVB/N mice,
but induced a 2-fold increase in pulmonary levels of mRNA for vascular endothelial growth factor
(VGEF), a regulator of proliferation, migration, and formation of new capillaries.  Elevated levels of
VGEF have been associated with respiratory diseases, but current understanding is inadequate to 
understand if this pulmonary gene expression response to manganese is adverse or benign.
There are limited evaluations of neurological end points in animals following intermediate-duration 
inhalation exposure to manganese.  Neurological effects comparable to those observed in humans have 
been reported in monkeys exposed to manganese by parenteral routes (intravenous) for intermediate 
duration (Newland and Weiss 1992), but no reports of the application of sensitive neurobehavioral test
batteries to animals following acute or intermediate-duration inhalation exposure to inorganic manganese
were located.
In monkeys exposed to manganese oxide aerosol concentrations as high as 1.1 mg manganese/m3 
24 hours/day for 9 months, no exposure-related effects on limb tremor or electromyograms were 
observed, even though blood manganese levels were 5-fold higher in exposed compared with control
monkeys (Ulrich et al. 1979a, 1979b, 1979c).  No gross signs of neurological impairment were observed 
in rats exposed by the same protocol to manganese oxide aerosol concentrations as high as 1.1 mg
manganese/m3 (Ulrich et al. 1979a, 1979b, 1979c).  
More recent studies of monkeys exposed to concentrations up to 0, 0.06, 0.3, or 1.5 mg manganese/m3 as 
manganese sulfate 6 hours/day for 65 days reported:  (1) no obvious signs of gross toxicity in the exposed 
monkeys; (2) about 2-fold higher manganese concentrations in most brain regions at 1.5 mg
manganese/m3, except for the globus pallidus which showed manganese concentrations 6-fold greater 
than control concentrations; and (3) a spectrum of exposure-related changes in biochemical markers of
neurotoxicity in various regions of the exposed monkeys, compared with control monkeys (Dorman et al. 
2006a, 2006b; Erikson et al. 2007, 2008).  No published accounts of the application of sensitive 
neurobehavioral test batteries to these animals are available and there are no studies in monkeys reporting
NOAELs and lowest-observed-adverse-effect level (LOAELs) for neurological effects following chronic-
duration exposure.
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Increased locomotor activity has been observed in Sprague-Dawley rats exposed for 90 days (6 hours/day, 
5 days/week) to a manganese phosphate/manganese sulfate mixture at concentrations ≥0.03 mg
manganese/m3 (Salehi et al. 2003) and to manganese sulfate at concentrations ≥0.009 mg manganese/m3 
(Tapin et al. 2006), but this effect was not observed with exposure to hureaulite (manganese phosphate) at
aerosol concentrations as high as 1 mg manganese/m3 (Normandin et al. 2002).  Significant neuronal cell
loss in the globus pallidus and caudate putamen was also observed in Sprague-Dawley rats exposed for
90 day (6 hours/day, 5 days/week) to the manganese phosphate/manganese sulfate mixture at an aerosol
concentration of 3 mg manganese/m3; these changes, however, were not accompanied with signs of
tremor as assessed with electromyographic techniques (Salehi et al. 2006).
MRL values for acute or intermediate durations based on animal studies were not derived, because an
MRL based on animal data would be lower than the proposed chronic-duration inhalation MRL that is
based on effects observed in humans.  It is uncertain if this is due to species differences in susceptibility
to the neurotoxic properties of inhaled manganese or to the testing of humans with sensitive 
neurobehavioral tests that have not been applied to animals following inhalation exposures to manganese.  
It is expected that the chronic MRL for inhaled inorganic manganese would provide protection for
intermediate-duration exposure scenarios. The MRL is based on an analysis of dose-response data for
subtle neurological deficits in occupationally exposed workers with durations of employment from about
5 to 24 years (see Appendix A); the average duration of employment in workers in the principal study was
5.3 years.
• An MRL of 0.0003 mg manganese/m3 (manganese in respirable dust; 0.3 μg manganese/m3) has 
been derived for chronic inhalation exposure (365 days or more) to manganese.
The study chosen to derive the MRL is from an investigation of an occupational cohort involving 92 male
workers in a dry alkaline battery plant (Roels et al. 1992).  They and the 101 age- and area-matched
controls (with no industrial exposure to manganese) were observed for performance on a battery of
neurobehavioral tests.  Manganese workers were exposed for an average (geometric mean) of 5.3 years 
(range: 0.2–17.7 years) to a respirable dust concentration of 215 μg manganese/m3 and a total dust
concentration of 948 μg manganese/m3.  Manganese concentrations were measured with personal
samplers, with respirable dust being <5 microns in diameter. The authors noted that plant exposure 
conditions had not changed considerably in the last 15 years, suggesting that past exposures were 
consistent with those measured at the time of the study.  Performance in measured neurobehavioral tests,
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especially on measures of simple reaction time, eye-hand coordination, and hand steadiness, was 
significantly worse in manganese-exposed workers than in the comparison group.
Manganese-exposed workers performed significantly worse than the controls on the neurobehavioral
tests, with particular differences in simple reaction time, eye-hand coordination, and hand steadiness.  
Dr. Harry Roels provided the data on the manganese-exposed group evaluated in this study.  These data
included individual exposure levels and whether the individual had an abnormal performance in the
neurobehavioral tests (scores below the 5th percentile score of the control group).  Percent precision score
in the eye-hand coordination test was the most sensitive end point among the end points showing
statistically significantly elevated incidences of abnormal scores and was selected as the basis of the 
MRL.  Average exposure concentration for each worker was calculated by dividing the individual lifetime 
integrated respirable concentration (LIRD; calculated by Dr. Roels from occupational histories and 
measurements of workplace air manganese concentrations) by the individual’s total number of years 
working in the factory.  Individuals were grouped into six exposed groups and the control group, and the
average of the range in each group was used in benchmark dose (BMD) modeling of the incidence data 
for number of workers with abnormal percent precision eye-hand coordination scores (see Table A-1 in 
Appendix A).
Available dichotomous models in the EPA Benchmark Dose Software (BMDS version 1.4.1c) were fit to 
the incidence data for abnormal eye-hand coordination scores in workers exposed to respirable
manganese (Roels et al. 1992, Table A-1).  Results from the modeling using a benchmark dose response
of 10% are shown in Table A-2 in Appendix A.  Based on the chi-square and Akaike’s Information 
Criterion (AIC) measures of fit, all of the models provided adequate and comparable fits to the data (the 
quantal linear and Weibull models had the same parameter values). BMCL10 estimates from the different
models showed an approximate 2-fold range from 73 µg/m3 from a one-stage multistage model to 142
µg/m3 from the logistic model. The logistic model was indicated as the best fitting model by the AIC
measure (Table A-2) and was used to provide the point of departure (POD) for the MRL. Previous BMD
analyses of exposure data and incidence data for abnormal eye-hand coordination test scores from the
Roels et al. (1992) study used a quantal linear model to arrive at a BMCL10 value of about 74 µg
respirable manganese/m3 (Agency for Toxic Substances and Disease Registry 2000; EPA 1994c; WHO 
2001). This value is virtually the same as the BMCL10 of 73.2 µg manganese/m3 obtained from the
equivalent multistage model in the current analysis (Table A-2).
   
 








    
   
 
 
   
  
 
   
         
 
            
        
 
          
   
       
      
  
  
     
     
     
            
   
           
      
 
  
     





2.  RELEVANCE TO PUBLIC HEALTH
The MRL of 0.3 µg manganese/m3 was derived by adjusting the POD to a continuous exposure basis
(142 µg manganese/m3 x 5/7 x 8/24) and dividing by an uncertainty factor of 100. 
An uncertainty factor of 10 was used for uncertainty about human variability including possibly enhanced
susceptibility of the elderly, infants, and children; individuals with chronic liver disease or diminished 
hepatobiliary function; and females and individuals with iron deficiency.  The current assessment does 
not use an additional modifying factor of 5 for potentially increased susceptibility in children based on 
differential kinetics in the young (which was used in the Agency for Toxic Substances and Disease
Registry [2000] assessment), because recent toxicokinetic studies in lactating rats and their offspring
exposed to manganese by the oral or inhalation routes suggest that the human variability factor of 10 
provides sufficient protection for differential kinetics in children and adults.  For example, in neonatal rats 
orally exposed to 25 or 50 mg manganese/kg/day (as manganese chloride) from postnatal day (PND) 1
through 21, manganese concentrations in various brain regions were about 2-fold higher than brain 
manganese concentrations in adult rats exposed to the same oral dose levels for 21 days (Dorman et al.
2000).  Similarly, 18-day-old neonatal rats exposed from birth to aerosols of manganese sulfate at 1 mg
manganese/m3, 6 hours/day showed a 2.6-fold increase in striatum manganese concentrations, compared
with controls, while lactating adults exposed to the same aerosol concentration showed a 1.7-fold increase
compared with controls (Dorman et al. 2005a).  Likewise, simulations with physiologically based 
pharmacokinetic (PBPK) models for inhaled manganese in lactating rat dams and offspring indicate that
manganese concentrations in the striatum and olfactory bulb of the brains of PND 19 offspring begin to 
increase when air concentrations exceed 50–100 µg manganese/m3, whereas maternal concentrations 
begin to increase at air concentrations between 100 and 300 µg manganese/m3 (Yoon et al. 2009b).  These
results indicate that at air concentrations above about 0.05–0.1 mg/m3, brain concentrations in neonates
may be elevated, compared with controls, to a greater degree than in lactating dams, but the age-specific 
difference in the tested air concentration range does not appear to be large.  Simulations from a human 
PBPK model for inhaled manganese in lactating mothers and their offspring indicate that average daily
areas under the curve (AUCs) for manganese concentrations in the globus pallidus of the fetus, suckling
neonate, and 3-year-old child from manganese air concentrations increased beyond 10% of background 
concentrations in fetuses and 3-year-old children when air concentrations exceeded 0.01 mg/m3 
(10 µg/m3) and in suckling neonates when air concentrations exceeded 0.001 mg/m3 (1 µg/m3) (Yoon et
al. 2011).  Thus, the inhalation MRL derived herein, 0.3 µg/m3, is below the air concentrations at which 
brain concentrations in human fetuses (10 µg/m3) and nursing infants (1 µg/m3) are predicted to begin to 
rise under normal dietary manganese exposure conditions.  
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An uncertainty factor of 10 was applied for limitations/uncertainties in the database including the lack of
epidemiological data for humans chronically exposed to soluble forms of manganese and the concern that
the general population may be exposed to more soluble forms of manganese than most of the manganese-
exposed workers in the principal and supporting studies.  Evidence from several rat studies indicate that
inhalation of more soluble forms of manganese (e.g., manganese sulfate and manganese chloride) results 
in higher brain manganese concentrations in brains than inhalation of less soluble forms, such as
manganese phosphate, manganese tetroxide or manganese dioxide (Dorman et al. 2004a, 2001a; Roels et
al. 1997).  In addition, data on developmental toxicity for this route and duration of exposure are lacking.  
There is limited information on reproductive effects in females (one study in rat dams) and reported 
effects on male reproductive organs have not been clearly associated with decreased reproductive 
function. Though it is clear that the neurological system is the most sensitive identified target organ for
effects from sub-chronic to chronic-duration inhalation exposure to manganese, data are lacking to fully
characterize the potential risk for all organ systems from chronic inhalation exposure.
Several BMD analyses of results from other epidemiological studies of neurobehavioral end points in
manganese-exposed workers provide support for the MRL (Clewell and Crump 1999; Clewell et al. 2003;
Health Canada 2010).  Estimated BMCL10 values in these analyses were within an approximate 2–4-fold 
range of the POD (142 µg manganese/m3) selected for the chronic inhalation MRL herein.
Dr. Anders Iregren provided ATSDR with individual worker data on total dust manganese exposure and 
performance on neurobehavioral tests for the occupational cohort that participated in his study (Iregren 
1990; Wennberg et al. 1991).  A BMD analysis was performed with these data under contract with
ATSDR (Clewell and Crump 1999) and the lowest BMCL10 value among the end points analyzed was 
0.07 mg respirable manganese/m3 for a 10% change in simple reaction time.  The BMD analysis applied 
K-power and Weibull models to continuous variable data (from 11 different test scores collected by Dr. 
Iregren) using current respirable manganese exposure estimates, age, and vocabulary test results as 
explanatory variables, an assumption that 5% of unexposed subjects had adverse responses, and a 
benchmark response of 10% change from unexposed mean scores.  For each dataset, BMCL10 values from
the Weibull model were lower (by 2–3-fold at the most) than BMCL10 values from the K-Power model.  
Weibull BMCL10 values for the different test score datasets ranged from 0.07 to 0.67 mg respirable 
manganese/m3. Thus, the lowest BMCL10 value from this analysis of test score data from manganese-
exposed workers collected by Iregren (1990; Wennberg et al. 1991) is within a 2-fold range of the 
selected POD of 142 µg manganese/m3 for the MRL.
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Clewell et al. (2003) conducted BMD analyses on data from three neuromotor tests in the Roels et al. 
(1992) study (visual reaction time, eye-hand coordination, and hand steadiness) and from five neuromotor
tests in the Gibbs et al. (1999) study (hole 6 of the hand steadiness test, percent precision of the eye-hand 
coordination test, reaction time in the complex reaction test, root mean square amplitude in the steady
test, and tap time).  Exposure measures in these analyses were recent measures of manganese 
concentrations in respirable dust.  BMCL10 values were 0.257, 0.099, and 0.202 mg manganese/m3 for the
visual reaction time, eye-hand coordination, and hand steadiness data from the Roels et al. (1992) study;
these results were obtained after fitting incidence data for abnormal scores in these tests to a Weibull
model for dichotomous data.  The reported BMCL10 value of 0.099 mg manganese/m3 for the eye-hand 
coordination test is similar to the BMCL10 value of 0.091 mg manganese/m3 obtained with the Weibull
model in the current ATSDR analysis (Table A-2). BMCL10 values from the analyses of outcomes from
the Gibbs et al. (1999) study ranged from 0.09 to 0.27 mg manganese/m3 (averaging the BMCLs within
end points across different BMD models applied to the data).  Clewell et al. (2003) did not have
individual worker data from the Iregren (1990) or Mergler et al. (1994) studies, but based on some
assumptions about exposures (e.g., all workers were exposed to average concentrations for the facilities 
and respirable manganese concentrations were calculated for the workers in the Iregren [1990] study
based on an assumption that 50% of total dust manganese was respirable), they calculated BMCL10 values 
for six end points from the Mergler et al. (1994) study and the simple reaction time end point in the
Iregren (1990) study.  BMCL10 values ranged from about 0.1 to 0.3 mg manganese/m3 from the Mergler et
al. (1994) study end points to 0.1 mg manganese/m3 for the reaction time end point in the Iregren (1990)
study. 
Health Canada (2010) published a human health risk assessment for inhaled manganese in which BMD
analyses were conducted on data for neurobehavioral end points from the study of manganese alloy
workers by Lucchini et al. (1999).  Dose-response data for six tests of fine motor control, two aspects of
memory tests, one test of mental arithmetic, and measured serum prolactin levels were fit to linear models 
using exposure metrics based on an average overall occupational history (ARE) or an average over the
latest 5 years of occupation (ARE5).  Using a linear model, BMCL10 values for the various end points 
were 32–59 and 85–98 µg manganese/m3 for the ARE5 and ARE exposure metrics, respectively.
Regardless of exposure metric, the values are within an approximate 2–4-fold range of the selected POD
of 142 µg manganese/m3, based on eye-hand coordination test scores in workers in the Roels et al. (1992)
study. 
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Neurological effects from repeated inhalation exposure to manganese are well recognized as effects of
high concern based on case reports and epidemiological studies of groups of occupationally exposed 
workers.  A number of epidemiological studies have used batteries of neurobehavioral tests of
neuromotor, cognition, and mood states to study the psychological or neurological effects of exposure to
low levels of manganese in the workplace (Bast-Pettersen et al. 2004; Beuter et al. 1999; Blond and 
Netterstrom 2007; Blond et al. 2007; Bouchard et al. 2003, 2005, 2007a, 2007b; Chia et al. 1993a, 1995;
Crump and Rousseau 1999; Deschamps et al. 2001; Gibbs et al. 1999, Iregren 1990; Lucchini et al. 1995, 
1999; Mergler et al. 1994; Myers et al. 2003a, 2003b; Roels et al. 1987a, 1992, 1999; Summers et al.
2011; Wennberg et al. 1991).  Some of these studies found statistically significant differences between
exposed and non-exposed groups or significant associations between exposure indices and neurological
effects (Bast-Pettersen et al. 2004; Chia et al. 1993a; Iregren 1990; Lucchini et al. 1995, 1999; Mergler et
al. 1994; Roels et al. 1987a, 1992; Wennberg et al. 1991), whereas others have not found significant
associations (Deschamps et al. 2001; Gibbs et al. 1999; Myers et al. 2003a, 2003b; Summers et al. 2011;
Young et al. 2005).  Table A-3 in Appendix A summarizes results from these studies. The neurological
effects associated with prolonged low-level manganese exposure generally have been subtle changes 
including deficits in tests of neuromotor or cognitive functions and altered mood states; they have been 
referred to by various authors as preclinical or subclinical neurological effects. Manganese air
concentrations associated with these effects in chronically exposed workers range from about 0.07 to 
1.59 mg manganese/m3 (manganese in total or inhalable dust measurements; values for manganese in
respirable dust are noted in parentheses in Table A-3). Comparison of the effect levels in these studies 
provides support for selection of the Roels et al. (1992) as the basis of the MRL. The advantage of the 
Roels et al. (1992) study is that individual worker data were available to support a BMD analysis, but
BMD analyses of other epidemiological data for performance on tests of neurobehavior provided 
potential PODs within about 2–4-fold of the POD selected as the basis of the MRL.
Studies in communities surrounding manganese industries have also reported evidence for associations 
between deficits in neurological end points (such as attention impairments, postural stability, and motor
impairments) and increasing biomarkers of manganese exposure in adults and children, but all potential
sources of exposure (e.g., air, diet, drinking water) could not be accounted for in these studies and they do 
not provide useful dose-response data for deriving an MRL for inhaled manganese (Baldwin et al. 1999;
Beuter et al. 1999; Bowler et al. 1999; Hernández-Bonilla et al. 2011; Kim et al. 2011; Menezes-Filho et 
al. 2011; Mergler et al. 1999; Solís-Vivano et al. 2009; Standridge et al. 2008; Riojas-Rodríguez et al. 
2010; Rodríguez-Agudelo et al. 2006).  
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Oral MRLs for Inorganic Manganese
Overview. No oral MRLs were derived for acute-, intermediate-, or chronic-duration oral exposure to 
manganese, even though the limited human data and extensive animal data clearly identify
neurobehavioral changes as the most sensitive effect from intermediate- and chronic-duration oral
exposure to excess inorganic manganese.  However, inconsistencies in the dose-response relationship 
information across studies evaluating different neurological end points under different experimental
conditions in different species, as well as a lack of information concerning all intakes of manganese 
(e.g., dietary intakes plus administered doses), make it difficult to derive intermediate- or chronic-
duration MRLs using standard MRL derivation methodology from the human or animal studies.  New
reports of neurobehavioral effects in children associated with elevated concentrations of manganese in
drinking water were evaluated as the possible basis of an oral MRL for intermediate and/or chronic 
durations of exposure.  However, the data were assessed to be unsuitable for MRL derivation due to
uncertainties about other possible confounding exposures to neurotoxic agents in the drinking water or via
food and/or the lack of information about dietary intakes of manganese by the children.  An interim
guidance value of 0.16 mg manganese/kg/day, based on the Tolerable Upper Intake Level for 70 kg adults 
of 11 mg manganese/day (established by the U.S. FNB/IOM [2001]) is recommended to be used for
ATSDR public health assessments of oral exposure to inorganic forms of manganese.
Acute Oral Exposure. Although neurological effects are expected to be the most sensitive end points
based on epidemiological studies in humans (see Section 3.1), only two acute studies reported 
neurological end points in rodents.  Moreno et al. (2009) administered 0, 4.4, or 13.1 mg manganese/ 
kg/day (as manganese chloride) via gavage for 2 weeks to juvenile C57Bl/6 mice. Increased novelty
seeking behavior in an open arena was reported in males exposed to 4.4 or 13.1 mg/kg/day (time in center
increased 10 and 8%, respectively; 8–10 animals/group). These data identify a free-standing LOAEL of
4.4 mg/kg/day for behavioral alterations; however, the response did not increase with increasing dose.  
Additionally, mice receiving 13.1 mg/kg/day had significantly increased concentrations of dopamine, 
decreased concentration of its metabolite dihydroxyphenylacetic acid (DOPAC), and increased
concentration of the serotonin metabolite 5-hydroxyindolacetic acid (5-HIAA) in the stratum compared 
with control mice (altered 60, 20, and 68%, respectively; 3–4 mice/group).  Additionally, Shukakidze et
al. (2003) reported that a single dose of 50 mg manganese chloride/kg (13.9 mg manganese/kg) to a group 
of 10 white rats caused worsened acquisition of an avoidance reaction in response to unconditioned and
condition stimuli, increased latent period of a conditioned reflex activity, and increased numbers of errors
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and time taken to navigate a maze (compared with controls), beginning on day 5 after dose administration 
and lasting until days 10–15.  
Other acute-duration oral studies found only decreased liver and body weight and decreased leukocyte 
and neutrophil counts in rats at dietary doses of 1,300 mg manganese/kg/day and no effects in mice at
dietary doses up to 2,600 (males) or 3,900 (females) mg manganese/kg/day after 14 days of exposure to 
manganese sulfate in the diet (NTP 1993).  No signs of developmental or maternal toxicity were observed 
in a standard developmental toxicity study of pregnant rats given daily gavage doses of 2,200 mg
manganese/kg/day as manganese chloride on gestation days (GDs) 6–17 (Grant et al. 1997a).  With 
intermediate-duration, no exposure-related effects on fetal body weight or skeletal development or
anomalies were found in pregnant rabbits exposed to 33 mg manganese/kg/day on GDs 6–20, but some
evidence for delayed fetal skeletal development was found in pregnant Sprague-Dawley rats exposed to
the same dose of manganese chloride on GDs 0–21 (Szakmáry et al. 1995).
Of the acute studies, the lowest LOAEL identified was 4.4 mg manganese/kg/day for decreased increased
novelty-seeking behavior in an open field in male juvenile C57Bl/6 mice exposed for 2 weeks by gavage 
(Moreno et al. 2009).  If this was used as the POD for the intermediate-duration oral MRL, a value of
0.004 mg manganese/kg/day would be derived if an uncertainty factor of 1,000 was used (10 for use of a
LOAEL, 10 for extrapolating across species, and 10 for human variability).  However, this rodent-based
value of 0.004 mg manganese/kg/day would be 7.5-fold below the FNB/IOM (2001) recommended AI of
1.8 and 2.3 mg manganese/day for women and men, respectively (approximately 0.03 mg
manganese/kg/day) and 40-fold below the FNB/IOM (2001) recommended Tolerable Upper Intake Level
(UL) of 11 mg/day for adults ≥19 years of age (approximately 0.16 mg manganese/kg/day).  Part of the
apparent discrepancy between this prospective MRL and the recommended dietary intakes is that the 
MRL is based only on manganese intakes above the normal dietary intakes.  Unfortunately, the dietary
intakes of manganese by the rats in the Moreno et al. study (2009) cannot be estimated from the
information provided in the published report.
Intermediate Oral Exposure. With intermediate-duration oral exposure, effects on neurobehavior are
expected to be the most sensitive effects from excessive manganese, particularly during early
developmental periods, based on findings for subtle neurobehavioral effects in epidemiological studies on
manganese-exposed workers (see Section 3.1), higher brain manganese levels and altered brain dopamine 
levels in neonatal rats, compared with adult rats, due to immaturity of the blood-brain barrier and the lack
of biliary excretion in preweanling rats (Aschner et al. 2005; Dorman et al. 2000, 2005a; Kontur and 
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Fechter 1985, 1988), and results from studies of the effects of intermediate-duration oral exposure on 
systemic toxicity end points and neurobehavioral, neurochemical, and neurodevelopmental end points in 
adult and young laboratory animals (Anderson et al. 2007a, 2009; Avila et al. 2008; Calibresi et al. 2001;
Kern and Smith 2011; Kern et al. 2010; Moreno et al. 2009; Reichel et al. 2006; Tran et al. 2002a, 
2002b). 
The discussion that follows provides evidence that, while systemic effects of manganese are not typically
the most sensitive end point of action, some evidence exists to support adverse cardiovascular effects of
manganese at relatively low dose levels, followed by a review of the large number of studies that most
consistently support neurobehavior effects as the most sensitive effects from excessive oral manganese 
exposure.
In standard toxicity studies of intermediate-duration oral exposure to inorganic manganese, marginal
evidence for systemic toxicity was found in rats at doses ≥33 mg manganese/kg/day (increased neutrophil
count and decreased liver weight in males; decreased body weights at higher doses) and in mice at the 
highest administered dose of 1,950 mg manganese/kg/day (decreased hemoglobin, mild hyperplasia of
forestomach, decreased liver and body weight) (NTP 1993).  Corroborative evidence comes from reports 
of decreased red blood cell counts and body weight in mice following 100 days of dietary exposure to one
of several forms of inorganic manganese (manganese acetate, carbonate, oxide, or chloride) at a dose
level of 284 mg manganese/kg/day (Komura and Sakamoto 1991).  
However, other animal studies indicate that excessive oral intake of manganese may present a 
cardiovascular hazard.  Under magnesium deficiency conditions (4.1 mmol Mg/kg diet), swine fed
moderately elevated levels of manganese (about 500 mg manganese/kg diet) died suddenly within
5 weeks and showed necrosis and mineralization of the heart (Miller et al. 2000). This finding was 
supported with subsequent findings of myocardial necrosis and mitochondrial swelling in magnesium-
deficient pigs fed a diet high in manganese (500 mg manganese/kg diet) for 8 weeks (Miller et al. 2004)
and of depressed heart muscle mitochondrial O2 consumption and decreased red blood cells in rats 
consuming a high manganese diet (250 mg manganese/kg diet) under marginal magnesium dietary
conditions; the manganese-induced effects on hematological end points in rats were absent when adequate 
dietary magnesium was provided (Miller et al. 2006).  In another study involving rats supplied with 
adequate and excessive Mn in the diet (10–15 and 45–50 mg manganese/kg diet), aortas from rats with
excessive dietary manganese showed less expression and sulfation of heparin sulfate glycosaminoglycans,
compared with the adequate condition (Kalea et al. 2006). The results from these studies suggest that
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excessive intermediate-duration oral intake of manganese may present a cardiovascular hazard, especially
under magnesium-deficient dietary conditions, but their use as the basis of an intermediate-duration oral
MRL for inorganic manganese is limited due to the lack of reported information to accurately calculate 
daily intakes. Myocardial lesions were not found in rats or mice provided manganese sulfate in the diet
for 2 years at dose levels up to 232 or 731 mg manganese/kg/day, respectively (NTP 1993).  
Numerous studies support the sensitivity of neurobehavioral end points to intermediate-duration oral
doses of manganese.  In humans and nonhuman primates exposed orally for intermediate durations, 
neurobehavioral end points have been examined in healthy adult female subjects given low (0.01 mg
manganese/kg/day) or high (0.3 mg manganese/kg/day) manganese diets for 8 weeks (Finley et al. 2003)
and in infant monkeys fed either a commercial cow’s milk formula (17.5 mg manganese/kg/day), a
commercial soy formula (107.5 mg manganese/kg/day), or a soy formula with added magnesium chloride
(328 mg manganese/kg/day) for 4 months with monkeys tested through 18 months of age (Golub et al. 
2005).  No differences between the low and high dietary-intake states were found in the adult females on
scores for hand-steadiness and self-reported traits such as assertiveness and anger (Finley et al. 2003).
Monkeys provided the highest manganese dose level showed no marked differences from the cow’s milk
controls in gross motor maturation, growth, cerebrospinal fluid levels of dopamine or serotonin 
metabolites, or performance on tests of cognitive end points, but showed decreased activity during sleep
at 4 months and decreased play activity between 1 and 1.5 months.  These results suggest that daily
intakes of 328 mg manganese/kg/day (but not 107.5 mg manganese/kg/day) during neonatal periods may
cause subtle neurobehavioral changes in primates.
In neurobehavioral assessments of rodents orally exposed to inorganic manganese for intermediate 
durations during neonatal periods, subtle neurobehavioral effects have been observed at supplemental
dose levels as low as about 10–20 mg manganese/kg/day (Brenneman et al. 1999; Dorman et al. 2000;
Kern et al. 2010; Kristensson et al. 1986; Moreno et al. 2009; Pappas et al. 1997; Reichel et al. 2006; Tran 
et al. 2002a, 2002b).  Although there are some inconsistencies in the results obtained in these studies
(e.g., Brenneman et al. [1999] found increased motor activity with exposure to 22 mg manganese/kg/day 
after exposure on PNDs 1–49, but Dorman et al. [2000] found no effects of the same dose level on motor
activity after exposure on PNDs 1–21), the weight of evidence suggests that subtle neurobehavioral
effects can occur in rats with intermediate-duration neonatal exposures at doses ≥10–20 mg
manganese/kg/day.
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Findings for histopathological changes in the rat brain following intermediate-duration oral exposure to 
inorganic manganese during neonatal periods are less consistent than the findings for subtle 
neurobehavioral effects.  Chandra and Shukla (1978) reported neuronal degeneration in cortical and 
cerebellar sections from the brains of young rats orally exposed to 0.3 mg manganese/kg/day as
manganese chloride between PND 21 and 51.  In contrast, Kristensson et al. (1986) reported no adverse
histological changes in cerebellum or hippocampus in rats exposed to a much higher dose level of
manganese chloride (150 mg manganese/kg/day) between PND 3 and 44.  Pappas et al. (1997) reported a
decreased cortical thickness in the offspring of rat dams exposed to 120 or 650 mg manganese/kg/day 
from GD 1 through PND 30, but found no immunohistological evidence for increased glial fibrillary 
acidic protein in the cortex, caudate, or hippocampus. Dorman et al. (2000) reported that no adverse
histological changes were found in sections of the following brain regions in Sprague-Dawley rats 
exposed to 11 or 22 mg manganese/kg/day on PNDs 1–21:  olfactory bulbs, cerebral cortex,
hippocampus, basal ganglia, thalamus, hypothalamus, midbrain, and cerebellum.  However, Lazrishvilli et
al. (2009) reported neuronal damage in small proportion of cells (7–10%) and marked gliosis throughout
the brain in the offspring of rat dams exposed to 10 mg manganese/kg/day in feed for 15–20 days before 
pregnancy, during pregnancy, and for 1 month after parturition.  The weight of evidence from these
studies indicates that subtle neurobehavioral effects in neonatally exposed rats are not consistently
associated with histological changes in the brain.
Neurobehavioral effects have also been observed in adult rats orally exposed to inorganic manganese for
intermediate durations.  In several studies, doses inducing these effects were higher than those inducing
subtle neurobehavioral effects after neonatal exposure (Calabresi et al. 2001; Centonze et al. 2001;
Torrente et al. 2005), but in two other studies, neurobehavioral effects were observed at doses as low as
5.6 mg manganese/kg/day (Shukakidze et al. 2003) and 6.5 mg manganese/kg/day (Vezér et al. 2005, 
2007).  Increased open field activity, increased interest in a novel object, and increased signs of fear were 
observed in adult male Wistar rats exposed to drinking water containing 20 mg manganese chloride/L for
10 weeks (estimated doses of 1,310 mg manganese/kg/day), but no effects on radial maze performance,
numbers of neuronal cells or levels of glial fibrillary acidic protein in striatum, or intrinsic
electrophysiological membrane properties of striatal neurons with the exception of a manganese-induced 
increase in the frequency and amplitude of spontaneous excitatory postsynaptic potentials (Calabresi et al.
2001; Centonze et al. 2001).  In an earlier study of adult male Wistar rats exposed to 20 mg manganese 
chloride/L for 13 weeks, no neuronal loss or gliosis was evident in the globus pallidus by either
histological or immunohistochemical examination (Spadoni et al. 2000).  Decreased open field activity
and impaired spatial learning were observed in restraint stressed adult male Sprague-Dawley rats exposed
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to 153 mg manganese/kg/day (but not 76 mg manganese/kg/day) as manganese chloride in drinking water
for 19 weeks (Torrente et al. 2005).  Similarly, decreased locomotor activity, as well as decreased tongue 
protrusion frequency (orofacial dyskinesia measure), were reported in adult Wister rats exposed to
1,280 mg manganese/kg/day (as manganese chloride in drinking water) for 30 days (Avila et al. 2008).
No changes in motor activity or performance in a passive avoidance test were observed in adult male 
Sprague-Dawley rats exposed to 11 or 22 mg manganese/kg/day for 21 days; these doses induced
increased pulse-elicited acoustic startle response with neonatal exposure, but exposure during adulthood 
did not (Dorman et al. 2000).  The lowest intermediate-duration daily dose associated with 
neurobehavioral effects in adult rats is 5.6 mg manganese/kg/day for severely impaired cognitive
performance in a maze test following a 30-day exposure of white rats to manganese chloride in the diet
(strain not otherwise indicated) (Shukakidze et al. 2003).  In another study, decreased open-field
locomotor activity and acoustic startle response and impaired performance in maze learning (a test of
spatial memory) were observed in male adult Wistar rats exposed to gavage doses of 6.5 or 25.9 mg
manganese/kg/day for 10 weeks, compared with controls (Vezér et al. 2005, 2007).  Decreased acoustic
startle response and impaired spatial memory were still evident in exposed rats, compared with controls,
after 5–7 weeks without exposure (Vezér et al. 2005, 2007).  The only intermediate-duration study in 
mice reported no changes in open field activity following adult exposure up to 13.1 mg/kg/day (as 
manganese chloride) via gavage for 8 weeks (Moreno et al. 2009).  However, if adults were previously
exposed as juveniles (PNDs 20–34), subsequent exposure in males (but not females) at 4.4 mg/kg/day for
8 weeks resulted in decreased novelty seeking behavior in the open field.  Additionally, at 13.1 mg/kg/ 
day, total overall movement in the open field was decreased in males.
Several types of reproductive effects have been reported for manganese.  A study by Hafeman et al.
(2007) reported a high mortality rate among infants <1 year of age in a Bangladesh community where 
manganese levels in drinking water were high, but the actual association between the manganese levels in
drinking water and infant mortality is difficult to make with certainty. The average level of manganese 
intake was calculated to be 0.26 mg manganese/kg/day.  Similarly, Spangler and Spangler (2009) reported
that with every log increase in groundwater manganese concentration in North Carolina counties, there
was a 2.074 increase in county level infant deaths per 1,000 live births.  Other reproductive effects 
reported for manganese in intermediate-duration animal studies include 25% decreased pregnancy rate in 
Long-Evans rats (males and females) exposed to manganese oxide in the diet at 180 mg manganese/ 
kg/day (but not 55 mg manganese/kg/day) for 100–224 days (Laskey et al. 1982), increased incidence of
testicular degeneration in male Sprague-Dawley rats exposed to manganese acetate at gavage doses of
137 (but not 69) mg manganese/kg/day for 63 days (Ponnapakkam et al. 2003c), and delayed growth of
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testes and sex accessory glands in CD-1 mice exposed to manganese oxide in the diet at 205 mg
manganese/kg/day (Gray and Laskey 1980).  In Swiss mice exposed for 12 weeks to manganese chloride 
in drinking water, impaired fertility was observed in males at 309 mg manganese/kg/day (but not a
154 mg manganese/kg/day) and in females at 277 mg manganese/kg/day (Elbetieha et al. 2001).  
Decreased sperm motility and sperm counts were observed in CD-1 mice exposed to 4.8 or 9.6 mg
manganese/kg/day as manganese acetate, but no effects on the ability of exposed males to impregnate 
unexposed female mice were found at these doses (Ponnapakkam et al. 2003a).  The results from the
intermediate-duration animal studies suggest that oral exposure to manganese may produce adverse 
effects on reproduction, but at much higher doses than those inducing subtle neurobehavioral effects in 
adult or neonatal rats.
In summary, results from animal studies identify subtle neurobehavioral effects as the critical effect in
rodents from intermediate-duration oral exposure to inorganic manganese.  Potential points of departure 
for an intermediate-duration oral MRL include LOAEL values of 5.6 mg manganese/kg/day for severely 
impaired cognitive performance in a maze test following 30-day dietary exposure of adult white rats 
(Shukakidze et al. 2003); 6.5 mg manganese/kg/day for decreased open-field locomotor activity and
acoustic startle response and impaired performance in maze learning (a test of spatial memory) in male 
adult Wistar rats exposed for 10 weeks by gavage (Vezér et al. 2005, 2007); and 11 mg manganese/ 
kg/day for increased pulse-initiated acoustic startle response in Sprague-Dawley rats exposed (orally by
pipette) on PNDs 1–21 (Dorman et al. 2000).  In contrast, hand steadiness or self-reported scales for
assertiveness or anger were not different in adult female subjects following 8 weeks of exposure to dietary
doses of 0.01 or 0.3 mg manganese/kg/day (Finley et al. 2003).  In young monkeys, decreased activity
during sleep at 4 months and decreased play activity between 1 and 1.5 months were observed following
daily intakes of 328 mg manganese/kg/day (but not 107.5 mg manganese/kg/day), but no effects on gross
motor maturation or performance in cognitive tests were observed at either dose level compared with
controls (Golub et al. 2005).   
The effects noted in the rat study by Shukakidze et al. (2003) are much more severe than effects noted in 
adult rats at reportedly higher dose levels of 1,310 mg manganese/kg/day (Calabresi et al. 2001; Centonze
et al. 2001) or 153 mg manganese/kg/day (Torrente et al. 2005) or in adult rats at comparable reported 
doses of 6.5 mg manganese/kg/day (Vezér et al. 2005, 2007).  Shukakidze et al. (2003) reported that the
exposed rats “showed increased aggresivity, frequently fell from the platform in the maze, and were 
unable to perform the maze test.”  Because the reporting of the experimental conditions in the Shukakidze 
et al. (2003) study is sparse and the severity of effects is so unusual, the results are considered to be 
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outlying results that are not consistent with the rest of the database and not appropriate as the basis of an
MRL.
If the LOAEL of 6.5 mg manganese/kg/day for decreased open-field locomotor activity and acoustic
startle response and impaired performance in maze learning in male adult Wistar rats exposed for
10 weeks by gavage (Vezér et al. 2005, 2007) was used as the POD for the intermediate-duration oral
MRL, a value of 0.007 mg manganese/kg/day would be derived if an uncertainty factor of 1,000 were
used (10 for use of a LOAEL, 10 for extrapolating across species, and 10 for human variability).  
However, this rodent-based value of 0.007 mg manganese/kg/day would be about 4-fold below the
FNB/IOM (2001) recommended AI of 1.8 and 2.3 mg manganese/day for women and men, respectively 
(approximately 0.03 mg manganese/kg/day) and about 23-fold below the FNB/IOM (2001) recommended 
UL of 11 mg/day for adults ≥19 years of age (approximately 0.16 mg manganese/kg/day).  Part of the
apparent discrepancy between this prospective MRL and the recommended dietary intakes is that the 
MRL is based only on manganese intakes above the normal dietary intakes.  Unfortunately, the dietary
intakes of manganese by the rats in the Vezér et al. study (2005, 2007) cannot be estimated from the
information provided in the published report.
Alternatively, using the monkey NOAEL of 107 mg manganese/kg/day for decreased activity during
sleep at 4 months and decreased play activity between 1 and 1.5 months in formula-fed infant monkeys
provided soy-based formula from birth to 4 months of age (Golub et al. 2005), a value of 1 mg
manganese/kg/day would be derived if an uncertainty factor of 100 were used (10 for extrapolating across
species and 10 for human variability).  The monkey-based value would be about 6-fold higher than the
FNB/IOM (2001) UL of 11 mg manganese/day for adults (0.16 mg manganese/kg/day assuming a 70-kg 
body weight).  The formulas fed to the infant monkeys in this study are expected to have been the
principal source of manganese.
For children and adolescents, FNB/IOM (2001) scaled the adult UL values according to reference body
weights for children and adolescents, noting that there were no reports of manganese toxicity in children
and adolescents and that it was not possible to establish UL values for infants (0–12 months).
Based on several surveys, FNB/IOM (2001) reported that average intakes of adults with typical “Western-
type” and vegetarian diets ranged from 0.7 to 10.9 mg/day (0.01–0.156 mg manganese/kg/day, assuming 
a 70-kg body weight).  WHO (2004b) recently calculated an estimated daily intake of about 0.0003 mg
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manganese/kg/day for 70-kg subjects drinking 2 L of water per day at a concentration of 0.010 mg
manganese/L, the median of a survey of manganese in drinking water.
Chronic Oral Exposure. Data on the effects of manganese following chronic oral exposure are less
extensive than intermediate-duration data, but these reports do suggest that neurological effects similar to 
those seen after intermediate-duration exposure may be anticipated following chronic oral exposure to
excess manganese.  In the reports of neurological effects in humans following chronic oral exposure,
there is either uncertainty regarding the exposure level (He et al. 1994; Zhang et al. 1995) or uncertainty
that the effects observed were solely attributable to manganese (Bouchard et al. 2007c, 2011; Holzgraefe
et al. 1986; Kawamura et al. 1941; Kilburn 1987; Kondakis et al. 1989; Wasserman et al. 2006, 2011;
Wright et al. 2006).  There is also no clear understanding of the threshold for manganese
deficiency/sufficiency or toxicity.  Males consuming 0.35 and 0.11 mg manganese/day exhibited 
symptoms of manganese deficiency (Doisy 1973; Friedman et al. 1987, respectively).  But Davis and
Greger (1992) did not report any deficiency symptoms among female subjects, 20% of whom consumed
<1 mg manganese/day, and Finley et al. (2003) did not observe signs of manganese deficiency or toxicity
in adult females with dietary intakes of 0.8 or 20 mg manganese/day for 8 weeks.  Authors of a case study
suspected abuse of vitamin and mineral preparations to be the source for excess manganese and
neurological symptoms observed in their patient (Banta and Markesbery 1977).  
Four epidemiological reports of manganese neurotoxicity in children resulting from manganese exposure 
in drinking water have been recently published.  In two separate cross-sectional studies, Wasserman et al.
(2006, 2011) reported statistically significant relationships for decreasing intelligence scores with 
increasing manganese levels in drinking water in 142–151 children (ages 8–11 years) in Bangladesh.  
Similarly, in a cross-sectional study conducted by Bouchard et al. (2011), a significant negative
association was found between manganese levels in the home tap water and intelligence scores in
362 children from Quebec, Canada.  In previous study by Bouchard et al. (2007c), a statistically
significant relationship between increased levels of oppositional behaviors and hyperactivity and
increased levels of manganese in drinking water in an epidemiological study of 46 children (ages 6– 
15 years), also from Quebec, Canada.
Additionally, three recent case studies suggest that certain children are particularly susceptible to
manganese neurotoxicity from high levels in drinking water, including:  (1) severe neurotoxic symptoms
(inability to walk independently, tendency to fall backward, and development of a “cock-like” walk) and
MRI scan findings consistent with a diagnosis of hypermanganism in a previously healthy 5-year-old 
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female that were associated with elevated drinking water concentrations of manganese (1.7–2.4 mg 
manganese/L), pica, emotional lability, polycythemia, iron deficiency, and elevated levels of plasma 
manganese (Brna et al. 2011); (2) a similar case of severe manganism-like neurotoxic symptoms in a
previously healthy 6-year-old female that were associated with elevated drinking water concentrations of
manganese (1.7–2.4 mg manganese/L), pica, a diet high in manganese-rich foods, and elevated levels of 
plasma manganese (Sahni et al. 2007); and (3) inattentiveness and lack of focus in the classroom and low-
percentile performance in tests of memory in a 10-year-old male with no history of learning problems
associated with elevated manganese in drinking water (1.21 mg manganese/L) (Woolf et al. 2002).  
Although these recent reports cannot causally link the observed neurotoxic effects to excessive 
manganese intakes, they provide added weight to the evidence for the neurotoxic potential of excessive 
manganese in children.  
As shown in the chronic exposure section of the oral LSE table and figure in Chapter 3, estimated daily
intakes from drinking water were calculated as 0.05 mg manganese/kg/day based on the mean manganese 
drinking water concentration for high exposure group of Bangladesh children ages 8–11 (1.111 mg
manganese/L), reference daily water intakes (1.3 L/day), and reference body weights (31.19 kg); 0.07 mg
manganese/kg/day based on the mean manganese drinking water concentration for the fourth quartile
group of Bangladesh 10-year-old children (1.923 mg manganese/L), reference daily water intakes 
(1.3 L/day), and average body weights (22.4 kg) (Wasserman et al. 2006); 0.0003 mg manganese/kg/day 
based on the reported 50th percentile monthly exposure value (8.0 μg/kg/month), assuming 30 days in a
month (Bouchard et al. 2011); 0.02 mg manganese/kg/day for the high-manganese intake children in
Quebec (0.5 mg manganese/L), reference daily water intakes (1.3 L/day) and reference body weights 
(37.2 kg) (Bouchard et al. 2007c); 0.104 mg/ manganese/kg/day for the 5-year-old female (Brna et al. 
2011); 0.103 mg manganese/kg/day for the 6-year-old female (Sahni et al. 2007), and 0.06 mg
manganese/kg/day for the 10-year-old male (Woolf et al. 2002). 
To derive an oral MRL for intermediate and chronic durations, an average of the drinking water LOAELs 
for neurobehavioral effects in the three case reports (Brna et al. 2011; Sahni et al. 2007; Woolf et al. 
2002), the cross-sectional studies of children in Bangladesh (Wasserman et al. 2006, 2011), and the
studies of children in Quebec (Bouchard et al. 2007c, 2011) could potentially serve as a POD for the
MRL.  However, one or more of the following uncertainties associated with these studies of children 
preclude their use as the basis for an intermediate- or chronic-duration MRL:  (1) whether or not the
observed effects were solely due to excess manganese alone or could have been influenced by other
   
 








     
    
 
      
        
  
         
      
     
           
    
     
       
          
      
 
   
 
         
         





     
    




2.  RELEVANCE TO PUBLIC HEALTH
drinking water or dietary components; (2) the lack of information about manganese levels in food and air;
and (3) the small sample sizes.
Interim Guidance Value for Oral Exposure to Inorganic Manganese. As discussed in the preceding
sections, no oral MRLs were derived for acute-, intermediate-, or chronic-duration exposure to inorganic
manganese, but it is recommended that an interim guidance value of 0.16 mg manganese/kg/day be used 
for ATSDR public health assessments. The interim guidance value is based on the Tolerable Upper
Intake Level for adults of 11 mg manganese/day established by the U.S. Food and Nutrition Board/ 
Institute of Medicine (FNB/IOM 2001) based on a NOAEL for Western diets (0.16 mg manganese/kg/day
assuming an adult body weight of 70 kg).  The interim guidance value is well above the FNB/IOM AI
value for manganese for men and women of 2.3 and 1.8 mg manganese/day, respectively (for 70-kg 
individuals, this would result in exposures of 0.033 and 0.026 mg manganese/kg/day, respectively).  The 
interim guidance value is necessary because of the prevalence of manganese at hazardous waste sites and
the fact that manganese is an essential nutrient.  It is recommended that this value be used until more 
information on actual intake levels across environmental media can be obtained.
MRLs for MMT
Inhalation and oral MRL values for acute, intermediate, or chronic exposures to MMT have not been
derived. There are currently insufficient data regarding the systemic toxicity and carcinogenicity of this 
compound via inhalation or oral exposures and no reliable data concerning current environmental or
occupational exposures with appropriate dose-response information.
MRLs for Mangafodipir
MRL values for mangafodipir are not believed to be warranted.  This compound is used in a clinical
environment, is administered intravenously only, and is restricted to a very limited population. Thus, it is
believed unlikely that this compound would be found at hazardous waste sites or other environmental
settings.











    
 
   
    
     
  
 
   
 
         
  
  
     
  
          
      
          
    
 
        
 
          
   
          
          
   
        
         





3. HEALTH EFFECTS 
3.1 INTRODUCTION
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of manganese.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
Manganese is a naturally occurring element found in rock, soil, water, and food.  In humans and animals, 
manganese is an essential nutrient that plays a role in bone mineralization, protein and energy
metabolism, metabolic regulation, cellular protection from damaging free radical species, and formation 
of glycosaminoglycans (Wedler 1994).  Manganese acts as both a constituent of metalloenzymes and an 
enzyme activator.  Enzymes that contain manganese include arginase, pyruvate carboxylase, and 
manganese-superoxide dismutase (MnSOD) (Keen and Zidenberg-Cher 1990; NRC 1989; Wedler 1994).  
Manganese, in its activating capacity, can bind either to a substrate (such as adenosine triphosphate,
ATP), or to a protein directly, thereby causing conformational changes (Keen and Zidenberg-Cher 1990).  
Manganese has been shown to activate numerous enzymes involved with either a catalytic or regulatory
function (e.g., transferases, decarboxylases, hydrolases) (Wedler 1994).  The nutritional role of
manganese is discussed in Section 3.4.  Although manganese is an essential nutrient, exposure to high 
levels via inhalation or ingestion may cause some adverse health effects.
It has been suggested that these adverse health effects, especially neurologic effects, are occurring on a 
“continuum of ...dysfunction” that is dose-related (Mergler et al. 1999).  In other words, mild or unnotice-
able effects may be caused by low, but physiologically excessive, amounts of manganese, and these 
effects appear to increase in severity as the exposure level or duration of exposure increases.  Case reports 
and occupational studies address this continuum of nervous system dysfunction and help to characterize
the apparent dose-response relationship.  It is clear that chronic exposure to manganese at very high levels 
results in permanent neurological damage, as is seen in former manganese miners and smelters.  Chronic 
exposure to much lower levels of manganese (as with occupational exposures) has been linked to deficits
in the ability to perform rapid hand movements and some loss of coordination and balance, along with an 
increase in reporting mild symptoms such as forgetfulness, anxiety, or insomnia.  
   
 








         
   
 
   
   
       
 
  
        
     
          
      
            
        
     
 
     
  
 
   
    
  
   
         
            
          
 
         
    
      
  
       
        
          
40MANGANESE
3. HEALTH EFFECTS
Chemical Forms of Concern. Manganese can exist in both inorganic and organic forms.  This
profile will discuss key manganese compounds in both forms, with inorganic compounds discussed first. 
The inorganic forms include manganese chloride (MnCl2), manganese sulfate (MnSO4), manganese 
acetate (MnOAc), manganese phosphate (MnPO4), manganese dioxide (MnO2), manganese tetroxide 
(Mn3O4), and manganese carbonate (MnCO3).  Emphasis has been placed on the health effects of
compounds containing inorganic manganese in the Mn(II), Mn(III), or Mn(IV) oxidation states, since 
these are the forms most often encountered in the environment and the workplace.  There is evidence in 
animals and humans that adverse neurological effects can result from exposure to different manganese 
compounds; much of this information on toxicity differences between species of manganese is from
reports and experiments of acute exposures to very high doses.  Results from animal studies indicate that
the solubility of inorganic manganese compounds can influence the bioavailability of manganese and
subsequent delivery of manganese to critical toxicity targets such as the brain; however, the influence of
manganese oxidation state on manganese toxicity is not currently well understood.  Manganese in the 
form of permanganate produces toxic effects primarily through its oxidizing capacity.  However, because
of its tendency to oxidize organic material, the permanganate ion is not stable in the environment; thus, 
the probability of exposure to this species around waste sites is considered very low.  For this reason, data 
on exposures to permanganate are only briefly discussed.  
The organic compounds that will be discussed are methylcyclopentadienyl manganese tricarbonyl (MMT)
and mangafodipir.  The latter is a chelate of Mn(II) and an organic ligand, dipyridoxyl diphosphate
(MnDPDP; Mn(II) N,N’-dipyridoxylethylenediamine-N,N’-diacetate 5,5'bis(phosphate)).  These
compounds were chosen for this profile because their toxicity is expected to be mediated by excess
exposure to elemental manganese.  Organic fungicides containing manganese, such as maneb, were not
chosen for discussion in this profile, because their critical toxic effects are expected to be mediated by the 
organic moities of their chemical structure, not by excessive elemental manganese.
MMT is a fuel additive developed in the 1950s to increase the octane level of gasoline and thus improve 
the antiknock properties of the fuel (Davis 1998; Lynam et al. 1999).  Additional information on the
chemical, physical, and environmental properties of MMT is included in Chapter 4.  Exposure to MMT is
expected to be primarily through inhalation or oral pathways, although occupational exposure for gasoline
attendants or mechanics may be more significant via dermal absorption.  Engines using MMT-containing
gasoline and equipped with catalytic converters primarily emit manganese in inorganic phosphate and
sulfate forms and smaller amounts of manganese dioxides can be detected (Mölders et al. 2001; Ressler et
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al. 2000; Zayed et al. 1999a, 1999b).  These findings and observations that MMT is very unstable in light
and degrades quickly in air (Garrison et al. 1995) suggest that human exposure to manganese from the use
of MMT in gasoline is most likely to occur in inorganic forms as a result of the combustion of MMT, 
with the exception of people occupationally exposed to uncombusted gasoline containing MMT.  
However, despite this evidence, there are some reports that MMT levels in the environment increase with
traffic density (Garrison et al. 1995; Zayed et al. 1999a, 1999b); therefore, inhalation and/or ingestion 
exposures to the parent compound are possible.  Exposure and resultant toxicity from MMT’s inorganic
combustion products are covered under the inorganic subsections, while toxicity attributable to MMT is
covered under the organic subsections.  
Mangafodipir is a contrast agent for magnetic resonance imaging (MRI) used primarily (after intravenous 
administration) to detect and characterize neoplastic liver lesions; it has also been found to aid in the
identification of kidney and pancreatic tumors (Federle et al. 2000; Grant et al. 1997a, 1997b; Ni et al.
1997).  The compound is only used in the diagnosis of organ-specific cancers and is found exclusively in 
a clinical setting.  Mangafodipir is injected intravenously; therefore, inhalation, oral, and dermal pathways
of exposure are not a concern.  Because exposure to this compound is pathway-specific and the exposure 
population is inherently limited, toxicity arising from exposure to mangafodipir will be discussed in a 
separate subsection to Section 3.2.4, Diagnostic Uses. 
3.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (death, systemic, immunological, neurological, reproductive, 
developmental, genotoxic, and carcinogenic effects). These data are discussed in terms of three exposure 
periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
   
 









   
        
           
   
           
          
  




   
          
          
           
 
    
     
 
     
 
    
         
  
       
   
 
          
           
   
           
         
42MANGANESE
3. HEALTH EFFECTS
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL and that, in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration and place into perspective the possible significance of these 
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans 
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
Inorganic manganese compounds are not volatile, but they can exist in the air as aerosols or suspended 
particulate matter. Table 3-1 and Figure 3-1 summarize the available quantitative information on the
health effects that have been observed in humans and animals following inhalation exposure to various
inorganic manganese compounds.  All exposure levels are expressed as milligrams of manganese per
cubic meter (mg manganese/m3).  
Many of the studies, especially those dealing with occupational exposures, make the distinction between
respirable and total manganese dust.  Respirable dust is usually defined by a particular dust particle size 
that varies from study to study.  It is typically defined as those particles ≤5 microns; these smaller dust
particles can enter the lower areas of the lungs, including the bronchioles and the alveoli. These particles
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Gd 9-10 or pnd 
37-47 or Gd 
9-10 and pnd 
37-47 
0.71 (decreased APP, COX-2, 
nNOS, GFAP, TGF-beta 
mRNA in the brain) 
HaMai et al. 2006 
(MnSO4) 
Increased transcription 
of genes related to 
oxidative stressor 
inflammation in brain of 
rats exposed during 




























































Table 3-1 Levels of Significant Exposure to Inorganic Manganese - Inhalation (continued) 
LOAEL 
a










Gd 9-10 or pnd 
37-47 or Gd 














Resp 0.3 M 
Resp 1.5 M 
Cardio 0.3 M 
Hemato 0.3 M 
Hepatic 1.5 M 
Renal 1.5 M 
Endocr 1.5 M 
Bd Wt 1.5 M 
NOAEL 
(mg/m³) 
Less Serious Serious 
(mg/m³) (mg/m³) 
0.71 (decreased APP, COX-2, 
nNOS, and GFAP 
mRNA) 




1.5 M (17% decrease in relative
heart weight 90 days
post-exposure)




HaMai et al. 2006 
(MnSO4) 
Dorman et al. 2005c 
(MnSO4) 




of genes related to 
oxidative stressor 
inflammation in brain of 
rats exposed during 
gestation or early 
adulthood. 
Only absolute and 
relative organ weights 
were examined for the 

































































(continuous) Resp 1.1 Ulrich et al. 1979a 
Mn3O4 
No histopathological 
changes in lung or 







Resp 0.1 M 0.5 M (transient inflammatory 
changes in the nasal 
respiratory epithelium) 
Dorman et al. 2004b 
(MnSO4) 
Inflammatory changes 
were no longer present 
45 days after exposure 






Resp 0.1 M Dorman et al. 2004b 
MnPO4 
There were no lesions 
or inflammation 



















Bd Wt 0.03 M 0.3 M (10% decreased body 
weight) 









Bd Wt 0.9 M Tapin et al. 2006 




































Table 3-1 Levels of Significant Exposure to Inorganic Manganese - Inhalation (continued) 
a 













Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/m³) (mg/m³) (mg/m³) Chemical Form Comments 
9 mo 







Resp 3.9 M Camner et al. 1985 
MnCl2 
5 d/wk 
5, 9, or 13 wk 
(IC) 
Hemato 0.167 (decrease in total blood 
proteins (p<= 0.05) at 13 
weeks of exposure that 
persisted 2 weeks after 
exposure ended) 





1.5 M Dorman et al. 2006a 
(MnSO4) 
Only absolute and 
relative brain weight 
were examined. 
15, 33, or 65 d 1.5 (decreased brain GS, Erikson et al 2008with GLT-1, and GLAST (MnSO4)45 or 90 d protein and mRNA andrecovery decreased MT mRNA;6 hr/d increased and decreased5 d/wk brain GSH; increased
inhalation brain TH protein but




































Table 3-1 Levels of Significant Exposure to Inorganic Manganese - Inhalation (continued) 
a 















Frequency NOAEL Less Serious Serious Reference 
(Route) 




0.06 M (altered levels of GS, 
GLT-1 mRNA, GLAST, 
TH mRNA, GLT-1 
mRNA, GLAST mRNA, 
and TH mRNA in the 
brain) 
Erikson et al. 2007 
(MnSO4) 
9 mo 





0.5 M Dorman et al. 2004b 
(MnSO4) 
No changes in GFAP 
levels in the olfactory 





0.1 M Dorman et al. 2004b 
MnPO4 
No changes in GFAP 
levels in the olfactory 





0.11 M (increased free amino 
acid contents; focal glial 
cell proliferation; 
astrocytic nodules) 

































Table 3-1 Levels of Significant Exposure to Inorganic Manganese - Inhalation (continued) 
a 














Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/m³) (mg/m³) (mg/m³) Chemical Form 




0.05 (decreased brain GS 
mRNA, MT mRNA and 
GHS levels in F1 females 
and decreased brain MT 
mRNA and GSH levels 
F1 males) 
Erikson et al. 2005 
(MnSO4) 




0.05 (decreased brain GS and 
TH protein and mRNA, 
MT, and GSH and 
increased GSSG levels 
in F1 rats) 





1 M Normandin et al. 2002 
hureaulite 
90 d 0.03 M (increased locomotor 	 Salehi et al. 20035 d/wk activity)6 hr/d 	 manganese phosphate/sulfate 
mixture 
Comments 
No differences in 
neuronal cell counts 
compared to controls, 
and no changes in 
locomotor and tremor 
assessments. 
There was a significant 
increase in distance 
traveled, but not in rest 
time; increased 
exposure did not result 








































Table 3-1 Levels of Significant Exposure to Inorganic Manganese - Inhalation (continued) 
a 





















Frequency NOAEL Less Serious Serious Reference 
(Route) 




3 M (significant neuronal cell 
loss in the globus 
pallidus and caudate 
putamen) 






0.009 M (increased locomotor 
activity) 
Tapin et al. 2006 
manganese sulfate dihydrate 
9 mo 1.1 	 Ulrich et al. 1979b(continuous) 
Mn3O4 
18 wk 61 F (decreased maternal pup 	 Lown et al. 19845 d/wk retrieval latency)7 hr/d 	 MnO2 
16-32 wk 72 M (increased open-field 	 Morganti et al. 19855 d/wk behavior)7 hr/d 	 MnO2 
90 d 	 Dorman et al. 2006a Only testes weight was1.5 M6 h/d examined. 
5 d/wk 	 (MnSO4) 
18 wk Lown et al. 1984 No effect on number of61 F 5 d/wk pups born.
























































Erikson et al. 2005 
(MnSO4) 
0.05 (decreased brain GS 
mRNA, MT mRNA and 
GHS levels in F1 females 
and decreased brain MT 








Erikson et al. 2006 
(MnSO4) 
0.05 (decreased brain GS and 
TH protein and mRNA, 
MT, and GHS and 
increased GSSG levels 
in F1 rats) 
CHRONIC EXPOSURE 
Systemic 
40 RespHuman 7.5 yr (average duration in Mn 
mine) 
(occup) 
Boojar and Goodarzi 200290 M (increased respiratory 
symptoms and 
prevalence of subjects 
with impaired pulmonary 
function) 
41 RespHuman NS 
(occup) 
Lloyd Davies 1946 
MnO2 
3.6 M (pneumonia) 
42 RespHuman 1-19 yr 
(occup) 
Roels et al. 1987a 
Mn salts and oxides 
0.97 M (cough, decreased lung 
function) 



































Table 3-1 Levels of Significant Exposure to Inorganic Manganese - Inhalation (continued) 
a 











Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/m³) (mg/m³) (mg/m³) Chemical Form Comments 
5.3 yr 
(occup) 
Resp 0.18 Roels et al. 1992 
MnO2 
Endocr 0.18 
66 wk Hemato 0.1 EPA 1977 
Mn3O4 




0.07 M (longitudinal analysis 
showed impaired ability 
to perform fast 
pronation/supination of 
the hands and fast finger 
tapping compared with 
controls) 
Blond and Netterstrom 2007 No impairments of slow 
hand and finger 
movements or 
increased tremor 
intensity were observed 
compared with 
controls. 
24 yr (median 
employment in 
steel plant) 
0.07 M Blond et al. 2007 Cognitive function 
could not be 
distinguished between 
Mn-exposed steel 




Mn alloy plant) 
(occup) 
0.23 M (increased Mn 
impairment with age in 
1/9 neuromotor tests, 
3/12 cognitive tests, and 
1 or 4 sensory tests) 



































Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/m³) (mg/m³) (mg/m³) Chemical Form 




0.23 M (significantly higher 
scores for 2 [depression, 
anxiety] of 9 
neuropsychiatric 
symptoms) 
Bouchard et al. 2007a 




0.23 M (impaired performance 
on 1/5 neuromotor tests 
and enhanced score for 1 
[confusion-bewilderment] 
of 6 mood states) 
Bouchard et al. 2007b 
50 Human 1.1-15.7 yr 
(occup) 
1.59 M (postural sway with eyes 
closed) 
Chia et al. 1995 
MnO2 
51 Human NS 
(occup) 
22 M (bradykinesia, mask-like 
face) 
Cook et al. 1974 
NS 






2.05 Deschamps et al. 2001 
53 Human 12.7 yr 
(mean) 
(occup) 
0.051 Gibbs et al. 1999 
NS 
Comments 
Follow-up to Mergler et 
al. 1994; no significant 
(p<0.05) differences 
between exposed and 
controls in 9 cognitive 
tests. 
No significant effects 
on blood levels of Mn 
or tests of cognition. 
Tests of neuromotor 


































Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/m³) (mg/m³) (mg/m³) Chemical Form Comments 
54 Human 1-35 yr 
(2.6 median) 
(occup) 




55 Human 1-28 yr 0.149 M (decreased 
neurobehavioral 
performance finger 
tapping, symbol digit, 
digit span, additions) 
Lucchini et al. 1995 
(primarily MnO2) (MnOx - Mn 
oxides) 
56 Human 11.5 yr 
(mean) 
(occup) 
0.0967 M (decreased performance 
on neurobehavioral 
exams) 
Lucchini et al. 1999 
MnO2, Mn3O4 
57 Human 16.7 yr (mean) 
(occup) 
0.032 M (decreased motor 
function) 
Mergler et al. 1994 
NS 




0.21 Myers et al. 2003a No associations 
between measures of 
exposure and 
neurobehavioral 
endpoints were found: 



































Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/m³) (mg/m³) (mg/m³) Chemical Form Comments 
59 Human 18.2 yr; mean 
(SD 7.6) 
employment in 
a Mn smelter 
(occup) 
0.85 Myers et al. 2003b Neurobehavioral test 
batteries showed 
significant effects, only 
in a few endpoints and 




60 Human 1-19 yr 
(occup) 




Roels et al. 1987a 
Mn salts and oxides 
61 Human 5.3 yr 
(occup) 
b
0.179 (impaired visual time, 
eye-hand coordination, 
and hand steadiness) 
Roels et al. 1992 
MnO2 
62 Human NS 
(occup) 
2.6 M (tremor, decreased 
reflexes) 
Saric et al. 1977 
NS 
63 Human 1-9 yr 
(occup) 
6 M (psychomotor 
disturbances, weakness, 
pain) 























































5 M (weakness, ataxia, pain) 
1 yr 
(occup) 





30 F (altered DOPA levels) 
66 wk 0.1 
1-19 yr 
(occup) 0.97 M (decreased fertility in males as assessed by 
number of observed vs 
expected children) 
at least 1 yr 
(occup) 
2.82 M (abnormal sperm) 
Reference 
Chemical Form Comments 
Summers et al. 2011 No clinically relevant 




Tanaka and Lieben 1969 
NS 
Whitlock et al. 1966 
NS 




Lauwerys et al. 1985 
Mn salts and oxides 














































Key to Species Frequency NOAEL Less Serious Serious Reference (Route)Figure (Strain) System (mg/m³) (mg/m³) (mg/m³) Chemical Form Comments 
71 Human at least 1 yr 44.4 M (abnormal sperm) Wu et al. 1996 










a The number corresponds to entries in Figure 3-1. 
b The chronic-duration inhalation minimal risk level (MRL) of 0.0003 mg manganese/m3 was derived by using a benchmark dose analysis BMCL10 of 0.142 mg manganese/m3 for 
performance deficits in an eye-hand coordination test. This value was adjusted using the following uncertainty and modifying factors: 10 for human variability, 5/7 for intermittent 
exposure (5 days/week), 8/24 for intermittent exposure (8 hours/day), and 10 for potential differences in toxicity due to the different forms of manganese and other limitations in the 
database. 
APP = amyloid precursor protein; Bd Wt = body weight; Cardio = cardiovascular; COX = cyclooxygenase; d = day(s); DOPA = dihydroxyphenylalanine; Endocr = endocrine; F = 
Female; Gd = gestational day; GFAP = glial fibrillary acidic protein; GLAST = glutamate/aspartate transporter; GLT-1= glutamate transporter-1; Gn pig = guinea pig; GS = glutamine 
synthetase; GSH = reduced glutathione; GSSG = oxidized glutathione; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = immunological/lymphoreticular; LOAEL = 
lowest-observed-adverse-effect level; M = male; mo = month(s); mRNA = messenger ribonucleic acid; MT = metallothionein; nNOS = neuronal nitric oxide synthase; NOAEL = 
no-observed-adverse-effect level; NS = not specified; occup = occupational; pnd = post-natal day; Resp = respiratory; TGF-beta = transforming growth factor beta; TH = tyrosine 
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Figure 3-1 Levels of Significant Exposure to Inorganic Manganese - Inhalation (Continued)
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liver. Total dust represents larger particles that cannot travel as deeply into the lungs as respirable dust,
and will largely be coughed up and swallowed.  Although many of the recent occupational studies have
provided information on the size of the respirable particles that are associated with the exposure levels
documented, some of the occupational studies and historical studies in miners only measure total dust.  
The profile provides, where possible, the different exposure levels in terms of respirable and total dust, 
but does not make a further distinction between particle sizes of the respirable dust.
3.2.1.1 Death 
No conclusive studies have been located that show inhalation exposure of humans to manganese resulting
in death.  Hobbesland et al. (1997a) investigated nonmalignant respiratory diseases as a cause of death in 
male ferromanganese and silicomanganese workers. The authors found a slight excess in the numbers of
deaths caused by pneumonia for manganese furnace workers, but could not discount other work-related
exposures as potential causes of the pneumonia.
In analyses performed several years ago, MMT in gasoline was found to combust primarily to manganese 
tetroxide, but in the low levels currently used in gasolines, it is primarily combusted to manganese 
phosphate and manganese sulfate (Lynam et al. 1999).  Therefore, inhalation exposures to exhaust from
gasoline containing MMT will be discussed with inorganic manganese exposures.  No deaths were
observed in male outbred albino rats and male golden hamsters exposed to the exhaust (either irradiated
or non-irradiated) from automobiles that were fueled with MMT-containing gasoline (Moore et al. 1975).
No other studies were located regarding death in humans or animals after inhalation exposure to inorganic
manganese.
MMT has been used in very few inhalation studies due to the photolability of the compound; its short
half-life in air makes it a very difficult compound to administer to laboratory animals in exposure 
chambers or nose-cones.  Hinderer (1979) evaluated the toxicity of various unspecified MMT
concentrations administered to 10 male Sprague-Dawley rats per exposure group during 1- and 4-hour
exposure periods.  The inhalation LD50 was determined to be 62 mg manganese/m3 (247 mg
MMT/m3*55 mg manganese/218.1 mg MMT=62 mg manganese/m3) for a 1-hour exposure and 19 mg
manganese/m3 for a 4-hour exposure.  No mention was made in the report of steps taken to prevent MMT
photodegradation during the experiment.
   
 








    
 
             
      
 
       
         
    
           
 
  
      
       
   
    
  
        
 
 
   
             
         
 
         
      
           
 
 
     
  
 
   




The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
species and duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
Respiratory Effects. In humans, inhalation of particulate manganese compounds such as manganese
dioxide or manganese tetroxide can lead to an inflammatory response in the lung.  This is characterized
by an infiltration of macrophages and leukocytes, which phagocytize the deposited manganese particles 
(Lloyd Davies 1946).  Damage to lung tissue is usually not extensive, but may include local areas of
edema (Lloyd Davies 1946).  Symptoms and signs of lung irritation and injury may include cough, 
bronchitis, pneumonitis, and minor reductions in lung function (Abdel-Hamid et al. 1990; Akbar-
Khanzadeh 1993; Boojar and Goodarzi 2002; Lloyd Davies 1946; Roels et al. 1987a); occasionally, 
pneumonia may result (Lloyd Davies 1946). These effects have been noted mainly in people exposed to 
manganese dust under occupational conditions, although there is some evidence that respiratory effects 
may also occur in residential populations near ferromanganese factories (Kagamimori et al. 1973;
Nogawa et al. 1973; WHO 1987).  The frequency of effects has been shown to decrease in at least one
population when concentrations of total manganese in falling dust declined (Kagamimori et al. 1973).  It
is likely that the inflammatory response begins shortly after exposure and continues for the duration of the
exposure.
It is important to note that an inflammatory response of this type is not unique to manganese-containing
particles, but is characteristic of nearly all inhalable particulate matter (EPA 1985d). This suggests that it 
is not the manganese per se that causes the response, but more likely the particulate matter itself.
An increased prevalence of pneumonia has also been noted in some studies of workers with chronic 
occupational exposure to manganese dust (Lloyd Davies 1946) and in residents near a ferromanganese 
factory (WHO 1987).  It seems likely that this increased susceptibility to pneumonia is mainly secondary
to the lung irritation and inflammation caused by inhaled particulate matter, as discussed above.
Inhalation of particulate manganese compounds such as manganese dioxide or manganese tetroxide also
leads to an inflammatory response in the lungs of animals, although inhalation of manganese chloride did 
not cause lung inflammation in rabbits (Camner et al. 1985).  Several acute- and intermediate-duration 
studies in animals report various signs of lung inflammation following periods ranging from 1 day to 
10 months at manganese concentrations ranging from 0.7 to 69 mg/m3 (Bergstrom 1977; Camner et al. 
   
 










      
    
    
     
     
  
            
  
   
 
  
     
  
              
      
      
   
        
            
     
      
         
 
      
 
   
    
      
     





1985; Shiotsuka 1984; Suzuki et al. 1978; Ulrich et al. 1979a, 1979b).  Bergstrom (1977) and Ulrich et al. 
(1979a, 1979b) determined NOAELs, which are reported in Table 3-1. Increased susceptibility to lung
infection by bacterial pathogens following inhalation of manganese dusts has been noted in acute animal
studies (Maigetter et al. 1976).  Conversely, Lloyd Davies (1946) reported no increase in the
susceptibility of manganese-treated mice to pneumococci or streptococci.  Bredow et al. (2007) reported 
that nose-only inhalation exposure to 2 mg manganese/m3 as manganese chloride aerosols 6 hours/day for
5 consecutive days did not cause lung lesions in female GVB/N mice, but induced a 2-fold increase in
pulmonary levels of mRNA for vascular endothelial growth factor (VGEF), a regulator of proliferation, 
migration, and formation of new capillaries.  Elevated levels of VGEF have been associated with
respiratory diseases, but current understanding is inadequate to know if this pulmonary gene expression 
response to manganese is adverse or benign.
Moore et al. (1975) exposed male golden hamsters and outbred albino rats to automobile exhaust from a
car that burned MMT-containing fuel.  The animals were exposed to non-irradiated exhaust or irradiated
exhaust; the irradiation served to convert hydrocarbon gases and vapors to particulate form.  Controls for
each species were exposed to clean air. The animals were exposed for 8 hours/day for 56 consecutive 
days.  While the hamsters were fed a diet containing an adequate amount of manganese for normal
development, the rats were divided into two groups:  one group was fed a manganese-sufficient diet
(42.2 μg manganese/g diet) and the other group was fed a manganese-deficient diet (5 μg manganese/g
diet).  After the exposure, the authors observed a thickening of the cuboidal epithelium at the level of the
terminal bronchiole in the golden hamsters. The lesion was not classified as severe and only affected one 
to two sites per lung section.  Further, the lesions did not increase with length of exposure to the exhaust
products (from 1 to 9 weeks).  The incidence of lesions in the lung was 21% after exposure to irradiated 
exhaust, 14% after exposure to non-irradiated exhaust, and 6% after exposure to clean air.
More recently, reversible inflammation (pleocellular inflammatory infiltrates and fibrinonecrotic debris)
in the nasal respiratory epithelium (but not the olfactory epithelium) was observed in young adult male
Crl:CD(SD)BR rats following 13 weeks of inhalation exposure to 0.5 mg manganese/m3 as manganese 
sulfate, but not in rats exposed to 0.1 mg manganese/m3 as manganese sulfate or manganese phosphate
(hureaulite) (Dorman et al. 2004b). The lesions were not apparent in groups of rats assessed 45 days after
the end of exposure, indicating their transient nature.  In studies with young male Rhesus monkeys
exposed to 0, 0.06, 0.3, or 1.5 mg manganese/m3 as manganese sulfate 6 hours/day, 5 days/week for
65 days, no nasal histological effects were found in exposed monkeys, but the high exposure level
induced lesions in the lower respiratory tract (mild subacute bronchiolitus, alveolar duct inflammation, 
   
 








   
   
 
  
         
 
          
 
    
   
 
 
           
         
        
          
     
      
           
          
            
          




   
  
           
       
  





and proliferation of bronchus-associated lymphoid tissue) (Dorman et al. 2005b). The lower airway
lesions from intermediate-duration exposure appear to have been transient, because they were not found 
in monkeys assessed 45 days after the end of exposure (Dorman et al. 2005b).  These findings in rats and 
monkeys are consistent with the understanding that inflammation of respiratory tissues from high-level
exposure to inhaled manganese particulates is likely a consequence of the inhaled particulate matter.
No studies were located concerning respiratory effects in humans following inhalation exposure to MMT.
Male rats exposed to high concentrations of MMT (exposure doses not reported) via inhalation exhibited 
labored breathing during and after 1- and 4-hour exposures (Hinderer 1979).  Gross necropsy or
histopathological analyses on these animals were not performed. 
Cardiovascular Effects. Three studies reported adverse cardiovascular effects after occupational
exposure to manganese.  Saric and Hrustic (1975) observed a lower mean systolic blood pressure in male 
workers at a ferromanganese plant. Manganese concentrations in the plant ranged from 0.4 to 20 mg/m3, 
but specific data on exposure levels were lacking.  More recently, Jiang et al. (1996a) studied the potential
cardiotoxicity of manganese dioxide exposure in 656 workers (547 males, 109 females) involved in 
manganese milling, smeltering, and sintering.  The authors took 181 samples of airborne manganese (not
specified if respirable or total dust), with a geometric mean of 0.13 mg/m3. The workers, whose work
tenure ranged from 0 to 35 years, had a greater incidence of low diastolic blood pressure. The incidence
of this effect was highest in young workers with the lowest tenure in the plant. There was no increase of
abnormal electrocardiograms between workers and their matched controls. The authors surmised that
manganese’s ability to lower the diastolic blood pressure weakens with age as the elasticity of the blood
vessels deteriorates.
Hobbesland et al. (1997b) reported a significantly increased incidence in sudden death mortality for
workers in ferromanganese/silicomanganese plants during their employment period (standardized 
mortality ratio [SMR]=2.47).  The sudden deaths included cardiac deaths and other natural causes.  More
specifically, among furnace workers, who are more likely to be exposed to manganese fumes and dusts
than non-furnace workers, the mortality during active-person time was statistically significantly elevated
(38.7%) compared to non-furnace workers (23.3%; p<0.001).  However, the authors caution that the
association of increased death and manganese exposure is speculative and the increase in sudden death 
could also be caused by common furnace work conditions (heat, stress, noise, carbon monoxide, etc.).
   
 

















   
         
   
     
          
         
      
      
       
  
 
         
  
 
      
        
          
  
   
  
         




No studies on cardiovascular effects from inhalation exposure to MMT in humans or animals were
located.
Gastrointestinal Effects. There are no reports of gastrointestinal effects following inhalation 
exposure to inorganic manganese in humans or animals. 
There are no reports concerning the gastrointestinal effects following inhalation exposure to MMT in 
humans or animals.
Hematological Effects.    Examination of blood from persons chronically exposed to high levels of
manganese in the workplace has typically not revealed any significant hematological effects (Mena et al.
1967; Roels et al. 1987a; Smyth et al. 1973; Whitlock et al. 1966).  The effect of manganese exposure on 
erythrocyte superoxide dismutase activity remains inconsistent; some investigators observed increased
activity among male manganese smelters (Yiin et al. 1996), while others reported decreased activity in
male welders (Li et al. 2004).  However, an increased plasma malondialdehyde level is consistent
between manganese-exposed smelters (Yiin et al. 1996) and welders (Li et al. 2004).  Malondialdehyde is
a product of lipid peroxidation; lipid peroxidation is believed to be a mechanism for cell toxicity.  The
authors observed that plasma malondialdehyde and manganese levels were strongly correlated in exposed
workers and interpreted this response to be an indicator of manganese toxicity via lipid peroxidation.
No studies on hematological effects from inhalation exposure to MMT in humans or animals were 
located.
Hepatic Effects. Even though the liver actively transports manganese from blood to bile (see
Section 3.4.4), there is no information to indicate that the liver is adversely affected by manganese;
however, there are few specific studies on this subject.  In a study by Mena et al. (1967), workers 
chronically exposed to manganese dust in the workplace exhibited no abnormalities in serum levels of
alkaline phosphatase.  Of 13 patients who were hospitalized with chronic manganese poisoning, 1 had a
20% sulfobromophthalein (SBP) retention and 1 had a 12% SBP retention, although histological
examination of a liver biopsy from the latter revealed no abnormal tissue (Mena et al. 1967).  No 
significance was ascribed to the elevated SBP retention.
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Rats exposed to manganese tetroxide dusts for 9 months exhibited no adverse effects or histopathological
lesions; however, slight increases in liver weights were noted (Ulrich et al. 1979b).  These data, although 
limited, indicate that the liver is not significantly injured by manganese.
No studies on hepatic effects from inhalation exposure to MMT in humans or animals were located.
Musculoskeletal Effects. No studies were located concerning musculoskeletal effects from
inhalation exposure to inorganic manganese.
No studies were located concerning musculoskeletal effects from inhalation exposure to MMT in humans 
or animals.
Renal Effects. The kidney is not generally considered to be a target for manganese, but specific 
studies are rare.  No abnormalities in urine chemistry were detected in workers chronically exposed to
manganese dusts in the workplace (Mena et al. 1967), but other more sensitive tests of renal function 
were not performed.   
No studies were located regarding renal effects in animals after inhalation exposure to inorganic 
manganese.
No studies on renal effects from inhalation exposure to MMT in humans or animals were located.
Endocrine Effects. Few studies have measured endocrine effects in humans exposed to inorganic 
manganese. Two studies measured hormonal levels after exposure to manganese. The first study
(Alessio et al. 1989) involved chronic exposure of foundry workers to manganese for approximately
10 years. The exposure levels were reported as 0.04–1.1 mg manganese/m3 (particulate matter) and 0.05– 
0.9 mg/m3 as fumes.  These levels overlap the current American Congress of Governmental Industrial
Hygiene (ACGIH) threshold limit value-time weighted average (TLV-TWA) of 0.2 mg/m3 for particulate, 
but are less than the limit of 1 mg/m3 for manganese fumes.  The study reported both elevated prolactin 
levels and elevated cortisol levels; however, no changes in the levels of follicle stimulating hormone
(FSH) and luteinizing hormone (LH) were noted.
Smargiassi and Mutti (1999) reported effects in a group of workers from a ferroalloy plant who were
exposed occupationally to elevated levels of airborne manganese.  Serum prolactin levels in these workers
   
 









             
   
         
  
 
        
 
         
 
 
       
 
            
    
 
           
  
 
     
              
 
 
         
  
 
    
     
 
 
        




were evaluated in a 1992 study and again in a 1997 study.  Serum prolactin levels, which were
significantly elevated in the earlier analysis, had also increased significantly over the earlier measurement
(p<0.001).  This difference was especially noticeable in those with abnormally high prolactin levels.  
During the five year period between studies, exposure levels were consistent and were not reduced;
therefore, it is unclear whether prolactin levels reflect current or cumulative exposure.
Other elements of endocrine function (reproductive function, etc.) are discussed elsewhere in the text.
No studies were located regarding endocrine effects in animals after inhalation exposure to inorganic 
manganese.
No studies on endocrine effects from inhalation exposure to MMT in humans or animals were located.
Dermal Effects. No studies have been located concerning dermal effects in humans or animals 
following inhalation exposure to inorganic or organic manganese.
Ocular Effects. No studies have been located concerning ocular effects in humans or animals 
following inhalation exposure to inorganic manganese.
There are no studies reporting ocular effects following inhalation exposure of humans to MMT.  One- and 
4-hour exposures to doses of MMT used in lethality studies resulted in conjunctivitis in rats (Hinderer
1979).
Body Weight Effects. No studies were located regarding body weight effects in humans following
exposures to inorganic manganese.
No studies were located regarding body weight effects in humans following inhalation exposure to MMT.
Hinderer (1979) observed a decrease in weight gain in Sprague-Dawley rats during the first 7 days 
following a 1- or 4-hour exposure to unspecified MMT concentrations in an acute toxicity test.  The rats 
resumed their normal weight gain by 14 days post-exposure.  
Metabolic Effects. No studies were located concerning metabolic effects from inhalation of inorganic
manganese in humans or animals.
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No studies were located concerning metabolic effects following inhalation exposure to MMT in humans
or animals.
3.2.1.3 Immunological and Lymphoreticular Effects 
One study on immunological effects in humans following inhalation to inorganic manganese was located.  
Male welders exposed to manganese (0.29–0.64 mg/m3 for an unspecified duration), vibration, and noise
exhibited suppression of the T and B lymphocytes characterized by reductions in serum immunoglobin G
(IgG) and total E-rosette-forming cells (Boshnakova et al. 1989).  However, the welders in this study
were exposed to numerous other compounds, including cobalt, carbon dioxide, and nitric oxide.  
Therefore, it is impossible to determine whether exposure to manganese caused the effects.  It is not
known whether any of these changes are associated with significant impairment of immune system
function.  No studies were located on lymphoreticular effects in humans exposed to manganese by the
inhalation route.  
No studies were located on immunological or lymphoreticular effects in animals exposed to inorganic
manganese by the inhalation route. 
As noted above, inhalation exposure to particulate manganese compounds can lead to an inflammatory
response in the lung (i.e., pneumonitis), and this is accompanied by increased numbers of macrophages
and leukocytes in the lung (Bergstrom 1977; Lloyd Davies 1946; Shiotsuka 1984; Suzuki et al. 1978).  
However, this is an expected adaptive response of the immune system to inhaled particulates, and these 
data do not indicate that the immune system is injured.  Conflicting data are reported concerning
increased susceptibility to bacterial infection after exposure to airborne manganese.  Lloyd Davies (1946)
indicated that manganese exposure did not increase the susceptibility of mice to bacterial infection,
whereas Maigetter et al. (1976) reported that exposure to aerosolized manganese dioxide altered the 
resistance of mice to bacterial and viral pneumonias.
No studies on immunological or lymphoreticular effects from inhalation exposure to MMT in humans or
animals were located.
3.2.1.4 Neurological Effects 
Overview. Neurological effects from repeated inhalation exposure to manganese are well recognized as 
effects of high concern based on case reports and epidemiological studies of groups of occupationally 
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exposed and environmentally exposed people and results from animal inhalation studies.  The highest
NOAEL values and all LOAEL values from each reliable study for neurological effects in each species 
and duration category are recorded in Table 3-1 and plotted in Figure 3-1. 
There is conclusive evidence from studies in humans that inhalation exposure to high levels of manganese
compounds (usually manganese dioxide, but also compounds with Mn(II) and Mn(III)) can lead to a
disabling syndrome of neurological effects referred to as ‘manganism’.
Studies estimating the impact of low-level exposure to manganese on neurological health have employed
a number of sensitive tests designed to detect signs of neuropsychological and neuromotor deficits in the
absence of overt symptoms (Iregren 1990, 1994, 1999).  These analyses allow the comparison of discrete
performance values that are associated with either biological levels of manganese or approximations of
exposure levels. Thus, they allow for the comparison of one exposure group to another without the
subjective description of neurological symptoms that were prevalent in the studies with miners and others 
with frank manganism.  A number of epidemiological studies have used these techniques to study the
psychological or neurological effects of exposure to low levels of manganese in the workplace (Bast-
Pettersen et al. 2004; Beuter et al. 1999; Blond and Netterstrom 2007; Blond et al. 2007; Bouchard et al. 
2003, 2005, 2007a, 2007b; Chia et al. 1993a, 1995; Crump and Rousseau 1999; Deschamps et al. 2001;
Gibbs et al. 1999, Iregren 1990; Lucchini et al. 1995, 1999; Mergler et al. 1994; Myers et al. 2003a, 
2003b; Roels et al. 1987a, 1992, 1999; Summers et al. 2011; Wennberg et al. 1991) or in environmental
media close to manganese-emitting industries (Hernández-Bonilla et al. 2011; Lucchini et al. 2007; Kim
et al. 2011; Menezes-Filho et al. 2011; Mergler et al. 1999; Riojas-Rodríguez et al. 2010; Rodríguez-
Agudelo et al. 2006; Solís-Vivanco et al. 2009; Standridge et al. 2008).  Some of these studies have found 
statistically significant differences between exposed and non-exposed groups or significant associations
between exposure indices and neurological effects (Bast-Pettersen et al. 2004; Chia et al. 1993a; Iregren 
1990; Lucchini et al. 1995, 1999; Mergler et al. 1994; Roels et al. 1987a, 1992; Wennberg et al. 1991), 
whereas others have not found significant associations (Deschamps et al. 2001; Gibbs et al. 1999, Myers
et al. 2003a, 2003b; Summers et al. 2011; Young et al. 2005).  The neurological effects associated with 
prolonged low-level manganese exposure generally have been subtle changes, including deficits in tests 
of neuromotor or cognitive functions and altered mood states; they have been referred to by various
authors as preclinical or subclinical neurological effects. As shown in Table 3-1 and Figure 3-1, 
manganese air concentrations associated with these effects in chronically exposed workers range from
about 0.07 to 0.97 mg manganese/m3 (manganese in total or inhalable dust measurements).  For several of
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these work environments, values of concentrations of manganese in respirable dust (generally particulate 
diameters <10 µm) represented <20–80% of the total dust values.
Manganism from High-Level Occupational Exposure to Inorganic Manganese. There is conclusive 
evidence from studies in humans that inhalation exposure to high levels of manganese compounds
(usually manganese dioxide, but also compounds with Mn(II) and Mn(III)) can lead to a disabling
syndrome of neurological effects referred to as ‘manganism’.  Manganism is a progressive condition that
usually begins with relatively mild symptoms, but evolves to include dull affect, altered gait, fine tremor,
and sometimes psychiatric disturbances.  Some of these symptoms also occur with Parkinson’s disease,
which has resulted in the use of terms such as “Parkinsonism-like disease” and “manganese-induced 
Parkinsonism” to describe those symptoms observed with manganese poisoning. Despite the similarities,
significant differences between Parkinsonism and manganism do exist (Barbeau 1984; Calne et al. 1994;
Chu et al. 1995).  Barbeau (1984) reported that the hypokinesia and tremor present in patients suffering
from manganism differed from those seen in Parkinson’s disease.  Calne et al. (1994) noted other
characteristics that distinguish manganism from Parkinson’s disease: psychiatric disturbances early in the 
disease (in some cases), a “cock-walk,” a propensity to fall backward when displaced, less frequent
resting tremor, more frequent dystonia, and failure to respond to dopaminomimetics (at least in the late
stages of the disease).
Manganism and Parkinson’s disease also differ pathologically.  In humans and animals with chronic
manganese poisoning, lesions are more diffuse, found mainly in the pallidum, caudate nucleus, the
putamen, and even the cortex with no effects on the substantia nigra and no Lewy bodies (Pal et al. 1999;
Perl and Olanow 2007).  In people with Parkinson’s disease, lesions are found in the substantia nigra and
other pigmented areas of the brain (Barbeau 1984).  Moreover, Lewy bodies are usually not found in 
substantia nigra in manganism cases, but are almost always found in cases of Parkinson’s disease (Calne 
et al. 1994; Perl and Olanow 2007).  Manganese appears to affect pathways that are post-synaptic to the
nigrostriatal system, most likely the globus pallidus (Chu et al. 1995).  MRI of the brain reveals
accumulation of manganese in cases of manganism, but few or no changes in people with Parkinson’s
disease; fluorodopa positron emission tomography (PET) scans are normal in cases of manganism, but
abnormal in people with Parkinson’s disease (Calne et al. 1994).  Other studies suggest that manganese 
produces a syndrome described as parkinsonism, distinct from Parkinson’s Disease or manganism
(Lucchini et al. 2007, Racette et al. 2005).  It is likely that the terms Parkinson-like-disease and
manganese-induced-Parkinsonism will continue to be used by those less knowledgeable about the
significant differences between the two.  Nonetheless, comparison with Parkinson’s disease and the use of
   
 








      
      
 
     
            
         
          
      
   
   
          
 
       
   
     
           
            
          
  
 
        
  
           
          
       
   
          
  
       
       
      




these terms may help health providers and health surveillance workers recognize the effects of manganese 
poisoning when encountering it for the first time.
Typically, the clinical effects of high-level inhalation exposure to manganese do not become apparent
until exposure has occurred for several years, but some individuals may begin to show signs after as few
as 1–3 months of exposure (Rodier 1955).  The first signs of the disorder are usually subjective, often
involving generalized feelings of weakness, heaviness or stiffness of the legs, anorexia, muscle pain,
nervousness, irritability, and headache (Mena et al. 1967; Nelson et al. 1993; Rodier 1955; Tanaka and 
Lieben 1969; Whitlock et al. 1966).  These signs are frequently accompanied by apathy and dullness
along with impotence and loss of libido (Abdel-Hamid et al. 1990; Emara et al. 1971; Mena et al. 1967;
Nelson et al. 1993; Rodier 1955; Schuler et al. 1957). Early clinical symptoms of the disease include a 
slow or halting speech without tone or inflection, a dull and emotionless facial expression, and slow and 
clumsy movement of the limbs (Mena et al. 1967; Nelson et al. 1993; Rodier 1955; Schuler et al. 1957;
Shuqin et al. 1992; Smyth et al. 1973; Tanaka and Lieben 1969).  In a study by Wolters et al. (1989), 
6-fluorodopa (6-FD) and 18F-2-fluoro-2-deoxyglucose (FDG) PET were used to investigate the 
neurochemistry of four patients with "early manganism."  FDG PET demonstrated decreased cortical
glucose metabolism.  No anomalies were noted in the 6-FD scans. This led the authors to suggest that, in
early manganism, damage may occur in pathways that are postsynaptic to the nigrostriatal system, and
most likely involve striatal or pallidal neurons.
As the disease progresses, walking becomes difficult and a characteristic staggering gait develops.
Muscles become hypertonic, and voluntary movements are accompanied by tremor (Mena et al. 1967;
Rodier 1955; Saric et al. 1977a; Schuler et al. 1957; Smyth et al. 1973).  Few data are available regarding
the reversibility of these effects. They are thought to be largely irreversible, but some evidence indicates 
that recovery may occur when exposure ceases (Smyth et al. 1973).  Manganism has been documented in
welders and in workers exposed to high levels of manganese dust or fumes in mines or foundries.  
Extreme examples of psychomotor excitement have been observed in manganese miners and, to a lesser
extent, in industrial workers (Chu et al. 1995; Mena et al. 1967; Nelson et al. 1993).  The behavior, 
known as “manganese madness” (Mena 1979) includes nervousness, irritability, aggression, and
destructiveness, with bizarre compulsive acts such as uncontrollable spasmodic laughter or crying,
impulses to sing or dance, or aimless running (Emara et al. 1971; Mena et al. 1967; Rodier 1955; Schuler
et al. 1957).  Patients are aware of their irregular actions, but appear incapable of controlling the behavior.
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The reports of frank manganism (Rodier 1955; Schuler et al. 1957; Smyth et al. 1973) observed in 
manganese miners clearly indicate that the onset of manganism results from chronic exposure to high
concentrations of the metal.  Documented cases indicate that the most important route of exposure is 
inhalation of manganese dusts or fumes, while other pathways such as ingestion of the metal from
mucociliary transport of larger particles and hand-to-mouth activity, may contribute a smaller amount.  
Based on the data provided by Rodier (1955) and Schuler et al. (1957), it appears that the frequency of
manganism cases increased with prolonged exposure, suggesting that the seriousness of the symptoms 
presented increases with cumulative exposure.  For example, Rodier (1955) reports that the highest 
percentage of manganism cases (28, or 24.4%) occurred in miners with 1–2 years experience.  Only six
cases of manganism (5.2%) were reported in males with 1–3 months exposure, and 68% of the cases
reported occurred after exposures >1–2 years in length.  Rodier did not present statistics on the number of
men in the mine who were employed for comparable durations who did not suffer from manganism.  
Schuler et al. (1957) studied fewer manganism cases, but showed that the number of men with 
manganism increased with time spent mining, with the average time delay before onset of the disease 
being 8 years, 2 months.  In fact, the minimum duration of exposure to the metal was 9 months before
signs of manganism became recognizable, and the maximum exposure was 16 years.  However, Schuler
et al. (1957) point out that their study was not intended to “suggest incidence rates” and of the 83 miners
selected for examination of potential manganism, only 9 were chosen as actually suffering from
manganese poisoning.  As with the Rodier (1955) study, the Schuler et al. (1957) study did not discuss the
exposure duration or symptomatology of those men not displaying “frank manganism;” therefore, these
collective data, although suggestive of a cumulative effect of manganism neurotoxicity, must be
interpreted with caution. 
Huang et al. (1998) documented the progression of clinical symptoms of manganism in five surviving
workers (from an original six) chronically exposed to manganese in a ferroalloy plant.  These men were 
exposed from 3 to 13 years and were examined 9–10 years after manganese exposure had ceased.
Neurologic examination revealed a continuing deterioration of health exhibited in gait disturbance, speed 
of foot tapping, rigidity, and writing.  The men had high concentrations of manganese in blood, urine, 
scalp, and pubic hair at the time of the original neurologic evaluation.  Follow-up analyses revealed a
drastic drop in manganese concentrations in these fluids and tissues (e.g., 101.9 μg/g manganese in blood 
from patient 1 in 1987; 8.6 μg/g manganese in blood in 1995).  Further, T1-weighted MRI analysis did
not reveal any high-signal intensity areas.  These data support the progression and permanence of clinical
effects from excess manganese exposure, even when tissue levels of the metal had returned to normal.
Further, it shows that this neurotoxicity can continue in the absence of continuing manganese exposure
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and that a spectrum of responses to excess manganese exposure can be seen depending upon dose, 
duration of exposure, and timing of the observation.  While some subclinical manifestations of manganese
neurotoxicity will resolve, once neuropathology has occurred (in the form of loss of dopaminergic
neurons), then reversal becomes more limited and is restricted to functional compensation.
As shown in Table 3-1 and Figure 3-1, cases of frank manganism have been associated with workplace 
exposure levels ranging from about 2 to 22 mg manganese/m3 (Cook et al. 1974; Rodier 1955; Saric et al.
1977; Schuler et al. 1957; Tanaka and Lieben 1969; Whitlock et al. 1966).  For example, Tanaka and 
Lieben (1969) reported that no cases of frank manganism were diagnosed in 38 workers from
Pennsylvania industrial plants in which estimated air concentrations were below 5 mg manganese/m3, 
whereas 7 cases were diagnosed in 117 workers from plants with air concentrations exceeding 5 mg/m3. 
Whitlock et al. (1966) reported on two cases of frank manganism in workers who were exposed to
estimated air concentrations ranging from 2.3 to 4.7 mg manganese/m3.
Neurological Assessments of Workers Exposed to Low Levels of Inorganic Manganese. In a cross-
sectional epidemiological study of 141 male workers in a manganese dioxide and salt producing plant, 
Roels et al. (1987a) detected preclinical neurological effects (alterations in simple reaction time, 
audioverbal short-term memory capacity, and hand tremor) in workers exposed to 0.97 mg manganese 
(median concentration in total dust)/m3 as manganese dioxide, manganese tetroxide, manganese sulfate,
manganese carbonate, and manganese nitrite for a group average of 7.1 years. End points in exposed
workers were compared with end points in a matched control group of 104 non-exposed male workers 
from a nearby chemical plant. The prevalences of subjective symptoms were similar in exposed and
control workers, except for the elevation of nonspecific symptoms (such as fatigue, tinnitus, trembling of
fingers, and increased irritability) in the exposed workers.  Statistically significant mean deficits were 
found in exposed workers (compared with controls) in tests of simple reaction time (visual), audioverbal
short-term memory capacity, eye-hand coordination, and hand steadiness.  The prevalence of abnormal
values in the neurological tests were not statistically significantly correlated with manganese levels in
blood or urine or duration of employment, with the exception that blood levels of manganese were
correlated with prevalence of abnormal responses in tests of eye-hand coordination and hand steadiness.
Iregren (1990) used neurobehavioral tests (simple reaction time, digit span, finger tapping, verbal ability, 
hand dexterity, and finger dexterity tests from the Swedish Performance Evaluation System, SPES) to 
study adverse effects in 30 male workers from two different manganese foundries exposed to an estimated
median concentration of 0.14 mg manganese (in total dust)/m3 as manganese dioxide for 1–35 years 
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(mean, 9.9 years).  The exposed workers had below-average scores on a number of the tests, such as
reaction time and finger tapping, when compared to matched controls with no occupational manganese
exposure.  
Roels et al. (1992) provided similar results to these earlier reports. Workers in a dry alkaline battery
factory exhibited impaired visual reaction time, hand-eye coordination, and hand steadiness when
exposed to concentrations of manganese dioxide in total dust ranging from 0.046 to 10.840 mg
manganese/m3 and in respirable dust from 0.021 to 1.32 mg manganese/m3 (exposure ranged from 0.2 to 
17.7 years).  A lifetime integrated exposure (LIE) for both total manganese dust and respirable manganese 
was estimated for each of the exposed workers (LIE=∑((C job 1 x T1) + (Cjob 2 x T2) + ... (Cjob n x Tn)),
where C is concentration, T is years of exposure, and LIE is expressed as mg manganese/m3 times year).
Based on the analysis of data by a logistic regression model, it was suggested that there was an increased
risk (odds ratio [OR]=6.43, 95% confidence interval [CI]=0.97–42.7) of decreased hand steadiness at a 
lifetime integrated exposure level of 3.575 mg/m3*year for total dust or 0.730 mg/m3*year for respirable 
dust.  It should be noted that the LIE at which an increased risk of abnormal neurological function occurs
is based on exposures in an occupational setting.  Therefore, periods of exposures would be followed by
periods that would be relatively free of manganese inhalation.  Presumably, during these “rest” periods
the homeostatic mechanism would excrete excess manganese to maintain the manganese concentration
within physiologic limits. Further, the LIE for deleterious neural effects may be biased in favor of a
higher concentration due to the “healthy worker effect” (i.e., the most susceptible individuals are not
incorporated into the study).
Crump and Rousseau (1999) performed a follow-up study of 213 men occupationally exposed to 
manganese, 114 of whom were subjects in the Roels et al. (1987a, 1987b) studies.  Exposure data were
unavailable during the 11 years of study (1985–1996) during which blood and urine samples were taken 
and neurological tests (short-term memory, eye-hand coordination, and hand steadiness) were
administered as in the Roels studies.  Yearly blood and urine manganese levels remained fairly consistent
throughout the study period, and were comparable to the levels reported in the previous studies.  The
authors suggest that the consistency of these data on manganese levels indicates that the airborne 
manganese concentrations to which the subjects were exposed during the study period were likely
comparable to those at the time of the Roels studies. The average age and exposure duration of the 
subjects increased from 36 and 7 years, respectively, in 1985, to 41 and 14 years, respectively, in 1996.  
Variations in year-to-year test results were observed that were not attributable to age of the subject or
exposure to manganese. The authors observed decreases in errors in the short-term memory test (number
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of repeated words and number of errors).  During 1987, 1988, and 1989, the average number of words
remembered on the memory test was lower than in any other year.  However, there was a progressive 
improvement in percent precision and percent imprecision on the eye-hand coordination test during 1985– 
1988 (after 1991, the design of the test was modified and percent imprecision was lower in that year and 
all subsequent testing years). The authors suggest several reasons for the inter-year variability in test 
results (Crump and Rousseau 1999), including variations in test conditions, different groups of workers
being tested in different years, the mood of the workers following a plant restructuring, and increased 
caution on the part of the subjects when answering test questions.  When data analysis was controlled for
year of testing, older workers performed significantly worse than younger workers on total words recalled 
in the memory test, and on percent precision and percent sureness in the eye-hand coordination test.  
Further, blood and urine manganese levels were not significantly associated with performance on memory
or eye-hand coordination tests, but blood manganese was negatively associated with performance on the
hand steadiness test (p<0.05).  Age was not a factor in hand steadiness when the year of test was 
controlled for in the analysis.  Crump and Rousseau (1999) investigated whether individual test scores
worsened with time by studying the group of 114 men from the original Roels et al. (1987a, 1987b)
studies and a subset of 44 long-term employees who had been given both memory and hand steadiness
tests on two occasions, 8 years apart. These analyses revealed decreases in performance over time for a 
particular hole in the hand steadiness test and improvements in repetitions and errors on the memory test, 
both of which were statistically significant.  The authors suggest that the improvements in the memory
test were likely the result of increased caution on the part of the subject. The changes in performance 
over time could not be attributed solely to manganese exposure because it was impossible to control for
age and year of testing in all of the analyses. The authors noted the lack of an age-matched control group 
with which to compare test results and the absence of data caused by workers ending their terms of
employment.  Some have questioned whether inter-year variability in test results, potentially caused by
different test administrators over time, would affect interpretation of the findings.  While this may
contribute to the changes in performance over time seen in the Crump and Rousseau (1999) study, this
factor will potentially impact any study of this type.  The lack of a control group precludes the 
determination of a reliable NOAEL or LOAEL based on the results of this study.   
A study by Mergler et al. (1994) also supports the work of Iregren and Roels.  This epidemiologic study
included 115 (95% of the total) male workers from a ferromanganese and silicomanganese alloy factory
who were matched to other workers from the region with no history of exposure. The groups were
matched on the following variables:  age, sex, educational level, smoking, and number of children.  These
workers were exposed to both manganese dioxide dusts and manganese fumes.  Environmental levels of
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manganese in total dust were measured at 0.014–11.48 mg/m3 (median, 0.151 mg/m3; arithmetic mean,
1.186 mg/m3, geometric mean, 0.225 mg/m3), while manganese levels in respirable dust were 0.001– 
1.273 mg/m3 (median, 0.032 mg/m3; arithmetic mean, 0.122 mg/m3; geometric mean, 0.035 mg/m3), and 
mean duration of exposure was 16.7 years.  The exposed workers had significantly greater blood 
manganese levels, but urinary manganese did not differ between groups.  Manganese workers showed
decreased performance on tests of motor function (including those from the SPES) as compared to 
matched control workers with no manganese exposure.  Using test results obtained from performance of
the groups on the Luria-Nebraska Neuropsychological Battery and other tests, the authors reported that
manganese-exposed workers performed more poorly than controls on tests of motor function, particularly
on tests that required alternating and/or rapid hand movements and hand steadiness.  The exposed workers
also differed significantly from the controls in cognitive flexibility and emotional state.  They also 
exhibited significantly greater levels of tension, anger, fatigue, and confusion.  Further, these workers had
a significantly lower olfactory threshold than controls; this is the first study to report this effect following
inhalation exposure to manganese.  Several follow-up studies of the workers from this manganese alloy
plant are described later in this section (Bouchard et al. 2005, 2007a, 2007b).
Similar effects to those observed in the Mergler et al. (1994) study were observed by Chia et al. (1993a).  
Workers in a manganese ore milling plant exposed to 1.59 mg manganese (mean concentration in total
dust)/m3 exhibited decreased scores in several neurobehavioral function tests including finger tapping, 
digit symbol, and pursuit aiming.  Further, the workers exhibited an increased tendency for postural sway
when walking with their eyes closed (Chia et al. 1995).
An epidemiologic study (Lucchini et al. 1995) also supports findings of these studies concerning the
preclinical neurological effects of manganese exposure. This study, which evaluated performance on
neuromotor tests (seven tests from the SPES, including simple reaction time, finger tapping, digit span, 
additions, symbol digit, shapes comparison, and vocabulary) involved 58 male workers from a ferroalloy
plant.  The workers had been exposed for 1–28 years (mean, 13; standard deviation [SD], 7) to geometric 
mean airborne concentrations of manganese, as manganese dioxide, in total dust as high as 0.070– 
1.59 mg/m3 (geometric means in different areas). These concentrations had decreased in the last 10 years 
to a range of 0.027–0.270 mg manganese (in total dust)/m3. At the time of the study, the exposed workers
were undergoing a forced cessation from work of 1–48 days.  Blood and urine manganese levels were 
analyzed.  A cumulative exposure index (CEI) was calculated for each subject by multiplying the average 
annual airborne manganese concentration in respirable dust characteristic of each job by the number of
years for which this activity was performed.  Significant correlations were found between the log value of
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blood manganese concentrations in exposed workers and the tests of additions, digit span, finger tapping, 
and symbol digit (log values for the last two tests); between the log value of urinary manganese levels and
the performance on the additions test; and between the log value of the CEI and the log value of the
symbol digit score.  Further, a significant correlation on an individual basis was found between external
exposure, represented by CEI, and blood and urine manganese levels.  These results are unique in that
they are the first to suggest that blood and urine manganese concentrations are indicative of exposure on
an individual basis.  As suggested by Lucchini et al. (1995), the correlations may be observable in this
study, when they have not existed in past studies (Roels et al. 1987a, 1992), because the workers were
assessed at a time when they were not currently being exposed to manganese.  In support of this 
possibility, the correlation coefficients between the urine and manganese levels and the CEI increased
with time elapsed since the last exposure to airborne manganese (Lucchini et al. 1995).
Roels et al. (1999) performed an 8-year prospective study with 92 subjects exposed to manganese dioxide 
at a dry-alkaline battery plant (Roels et al. 1992) to determine if poor performance on tests measuring
visual reaction time, eye-hand coordination, and hand steadiness could be improved if occupational
manganese exposure were decreased. The workers were divided into “low” (n=23), “medium” (n=55),
and “high” (n=14) exposure groups depending on location within the plant and job responsibility.  At the
end of the 1987 study, technical and hygienic improvements had been implemented within the plant to 
decrease atmospheric manganese concentrations.  Yearly geometric mean values for airborne total 
manganese dust (MnT) in the “low,” “medium,” and “high” exposure areas decreased in the following
manner, respectively:  ~0.310–~0.160; ~0.900–~0.250; and ~3–~1.2 mg/m3. The cohort decreased from
92 subjects in 1987 to 34 subjects in 1995 due to turnover, retirement, or dismissal, but no worker left due
to neurological signs or symptoms.  A separate group of workers was selected who had prior manganese 
exposure (ranging from 1.3 to 15.2 years). These subjects had left the manganese processing area of the 
plant prior to the end of 1992, and therefore, their exposure to manganese had ceased at that time; these
workers were still employed in other areas of the plant.  The control group consisted of 37 workers 
employed at the same polymer factory that had provided the control population in the previous study
(Roels et al. 1992).  This group, with an average age of 38.5 (range, 32–51 years) allowed for the analysis 
of age as a confounder.  Exposure data (respirable manganese and total manganese dust, MnT) were taken
with personal air samplers.  Time-trend analysis of air sampler data revealed a significant decrease in total
manganese from 1987 to 1995, with a more pronounced decline from 1992 forward.  From 1987 to 1990, 
the authors observed that the precision of the hand-forearm movement (PN1) in the eye-hand coordination
test for the whole cohort worsened, but then got progressively better.  Hand steadiness and visual simple
reaction time variables were inconsistent over time, and time-trends were not observed.  When the cohort
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was divided into exposure groups, and analyzed for performance on the eye-hand coordination test, it was
revealed that in general, the performance on the PN1 aspect of the test improved from 1987 to 1995, 
especially after 1991. The performance of the “low-dose” group was comparable to that of the control
group in 1987 (Roels et al. 1992) and to that of the control group in 1997. The performance of the
“medium-dose” group was intermediate between the “low-dose” and “high-dose” group.  The only 
significant differences in performance were in the “high-dose” group as compared to the “low-dose” 
group during the years 1988–1990 (test scores of 49–51 for the high-dose group and 63–65 for the “low-
dose” group).  However, it was noted that performance on the eye-hand coordination test for the
“medium” and “high-dose” groups was considerably poorer than the controls. 
Significant differences were noted in variables in the hand steadiness test between the exposure groups 
during 1987–1992 (data not reported), when manganese concentrations were at their highest. However,
no readily identified temporal changes in performance among the groups on this test was found, nor with 
the visual reaction time test.  When the authors performed separate time-trend analysis on MnT levels and
PN1 (eye-hand coordination test) values, a significant time effect was present for each variable.  An
analysis of covariance was performed for each exposure group (low, medium, and high) in which log
MnT was considered as covariate in order to adjust for estimation of PN1 variations as log MnT changed
over time. The resultant data suggested that a reduction in log MnT was associated with an improvement
in PN1 for each group. The authors also found that when time was also considered with log MnT as an
interaction term, it did not influence PN1 variations over the years and the effect of time on PN1 values
disappeared when log MnT was maintained as an ordinary covariate. The authors interpreted this to mean
that performance on the eye-hand coordination tests were only related, and inversely so, to the exposure
to manganese.  In other words, when manganese exposure was increased, test performance decreased and
vice versa (Roels et al. 1999).  However, in the high-exposure group, the performance increased from
71 to 83% of that of the control group, and leveled off at this point, despite decreased manganese
exposure occurring from 1991/1992 with most dramatic improvements occurring in 1994.  The authors
suggest that this leveling off of performance by the high-exposure group may be indicative of a
permanent effect of manganese on eye-hand coordination.  The authors tested PN1 values in exposed 
subjects 3 years following a cessation of exposure.  They found that in 20/24, the PN1 values were below
the mean PN1 values of the control group, but 16 of these individuals showed an improvement in 1996 
(percent improvement unspecified).  The remaining four subjects (three “low-exposure” and one
“medium-exposure” subjects) had PN1 values that exceeded the mean value of the control group.  
However, these data indicate that although there was improvement in performance on the coordination 
test, the vast majority of the exposed group still could not perform to the level of an unexposed worker
   
 









         
 
      
            
   
   
            
 
 
           
  
  
         
   
     
      
 
   
   
     
   
        
  
 
         
          
   
          
          
  




3 years after manganese exposure ceased.  In addition, the exposed workers who did perform as well or
better than the control subjects were among the least exposed workers while at the plant.  As discussed
previously, performance of the “low-exposure” group on eye-hand coordination tests during 1992–1995 
was comparable to that of the control groups from 1987 and 1997, indicating that manganese exposure of
these individuals during that time did not severely impact their ability to perform this neurobehavioral
test.  Comparable performance on the tests by the same control group in 1987 and 10 years later, in 1997, 
indicates that age was not a confounder in this study.  None of the variables except visual reaction time
was significantly correlated with age, and the existing correlation in the visual reaction time test only
represented a 3% difference (Roels et al. 1999).  
Lucchini et al. (1999) also investigated differences in neurobehavioral test performance over time as 
exposure to manganese (manganese dioxide and manganese tetroxide) decreased.  The study group 
consisted of 61 men who worked in different areas of a ferroalloy plant.  The plant was divided into three
exposure areas with total manganese dust (geometric mean) values decreasing from 1981 to 1995:  “high-
exposure” values decreased from 1.6 to 0.165 mg/m3; “medium-exposure” values decreased from 0.151 to 
0.067 mg/m3; and “low-exposure” values decreased from 0.57 to 0.012 mg/m3. The authors estimated 
that the annual average manganese concentration in the “medium-exposure” group was 0.0967 mg
manganese in total dust/m3. Respirable dust constituted 40–60% of the total dust value.  Control subjects
consisted of 87 maintenance and auxiliary workers from a nearby hospital who had not been exposed to 
neurotoxins.  The study and control groups were well matched except for years of education and the
percentage of subjects working night shifts.  The study groups answered a questionnaire concerning
neuropsychological and Parkinsonian symptoms and underwent testing to determine the effect of
manganese on neuromotor performance.  Four tests were from the SPES (addition, digit span, finger
tapping, symbol digit) and five timed tasks were from the Luria Nebraska Neuropsychological Battery
(open-closed dominant hand--Luria 1, open-closed non-dominant hand—Luria 2, alternative open-closed
hands—Luria 3, thumb-fingers touch dominant hand—Luria 4, and thumb-fingers touch non-dominant
hand—Luria 5). Individual scores were taken from these subtests, and the sum of the Luria tests was 
taken (Luria sum).  Postural tremor was also measured, as was visual reaction time and coordination
ability via the hand pronation/supination test.  Manganese levels in blood and urine, as well as blood lead 
levels were analyzed prior to each neurobehavioral test.  Manganese levels in both blood and urine were 
significantly elevated in exposed workers compared to controls (p<0.0001).  Blood lead levels were also
significantly higher in the ferroalloy workers (p=0.0002).  The authors noted that the study groups did not
report as many complaints as those reported in the Mergler et al. (1994) study.
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After correcting for age, education, alcohol, smoke, coffee, shift work, and blood lead levels, an analysis 
of test results indicated that performance of the exposed workers was significantly different than that of
controls on all tests except for Luria 5 and Luria sum (Lucchini et al. 1999).  A comparison of SPES test
results from workers tested in 1990 or 1991 and those from this study did not indicate any difference in 
paired t-test values; this indicates that performance did not improve over time or with decreasing
exposure to manganese.  CEI values were calculated (in the same manner as in Lucchini et al. [1995]) for
each exposure group and performance on the neurobehavioral tests was analyzed for correlation to these 
values and to manganese levels in body fluids.  Significant differences were found between those with
low CEI values of <0.5 mg/m3*years, mid CEI values of 0.5–1.8 mg/m3*years, and high CEI values of
>1.8 mg/m3*years and performance on the following tests: symbol digit, finger tapping, dominant and 
non-dominant hand, and digit span.  A positive correlation was observed between the log CEI value and 
these tests, indicating that performance decreased as exposure increased.  No correlations were found
between CEI values and manganese levels in blood and urine; these results differ from the correlation
between CEI and manganese levels in fluids from the previous study (Lucchini et al. 1995).  Lucchini et
al. (1995) estimated a manganese dose (total dust) that would represent the annual airborne manganese 
concentration indicative of neurobehavioral deficit in this study by dividing the geometric mean CEI of
the mid-exposure subgroup, 1.1 mg/m3*years, by the geometric mean value of years of exposure for this
same subgroup, 11.51, yielding a value of 0.096 mg/m3. A comparable respirable dust value would be
0.038 mg/m3 (0.096*0.40). 
Gibbs et al. (1999) studied a population of workers in a U.S. plant that produces electrolytic manganese 
metal. These 75 workers and a well-matched group of control workers with no manganese exposure were
administered a computerized questionnaire concerning neurological health issues (including mood, 
memory, fatigue, and other issues) and were analyzed for performance on several neurobehavioral tests
including hand steadiness (Movemap steady, Movemap square, and tremor meter), eye-hand coordination 
(orthokinisimeter), and rapidity of motion (four-choice reaction time and finger tapping).  The Movemap 
test is a relatively recent test that has not undergone widespread use, and it has not been validated by other
researchers.  Further, although technically sophisticated, the test has not been observed to discriminate 
between exposure groups any better than simpler current methods (Iregren 1999).  Airborne levels of total
and respirable manganese were obtained using personal samplers and were not available for years prior to
1997. Using the arithmetic mean of samples collected in 12 different job categories, exposure was
estimated for the years prior to 1997.  Cumulative exposure values for each worker were estimated for the 
30-day and 12-month exposure periods just prior to neurobehavioral testing.  Multiple regressions of the
test scores were performed using age and each of the following manganese exposure variables 
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individually as explanatory variables:  duration of exposure; 30-day cumulative exposure; 1-year
cumulative exposure; and cumulative occupational exposure to either respirable or total manganese.  Shift
work was also used as a variable in conjunction with age and cumulative 30-day exposure to respirable or
total manganese. The authors threw out outlying data points if they were >3 times the SD of the residual
after a model fit.  Exposures to respirable and total dust were highly correlated (r2, 0.62–0.75), as were
cumulative exposures over the previous 30 days and the previous year (r2, 0.72–0.82); however, lifetime
integrated exposure was not correlated with either 30-day or 12-month exposure values. The average 
exposure value for manganese-exposed workers was estimated at 0.066±0.059 mg/m3 (median, 
0.051 mg/m3) for respirable dust, and 0.18±0.21 mg/m3 for total dust. 
Responses to the questionnaire and performance on the neurobehavioral tests did not differ significantly
between exposed and control groups (Gibbs et al. 1999).  Cumulative years of exposure had an effect on 
tapping speed—speed increased with increased exposure, but only when outliers were included in the
analysis. The authors also reported an inverse correlation between age and performance on tests 
measuring eye-hand coordination but positively correlated between age and complex reaction time.  The
study by Gibbs et al. (1999) is the first to report a lack of poorer performance on neurobehavioral tests by
workers chronically exposed to manganese.  Interestingly, the median exposure estimates for respirable 
dust in this population (0.051 mg/m3) is slightly higher than the lowest level of respirable dust at which
preclinical neurological effects have been seen (0.032 mg/m3) as reported by Mergler et al. (1994).
Gorell et al. (1999) noted a high OR of 10.51 for the development of Parkinson’s disease in individuals
>50 years old who were occupationally exposed to manganese for >20 years, but not for those exposed 
for <20 years.  However, the numbers of individuals with a >20-year exposure was rather small (n=4),
and occupational exposures to other metals (copper, and lead-iron, lead-copper, and iron-copper
combinations) for >20 years were also associated with increased risk for the disease.
In a cross-sectional study of 138 (114 male and 34 female) enamels-production workers, Deschamps et al. 
(2001) administered a questionnaire about neurological symptoms; evaluated performance on
psychological tests of similarity recognition, vocabulary (oral word association), geometrical figure
recognition (visual gestalts), and short-term memory (digit span); and measured levels of manganese in
blood samples.  Results were compared with a control group of 137 nonexposed workers matched for age, 
educational level, and ethnic group.  Exposed workers were employed for a mean duration of 19.87 years
(SD±9) in enamels production.  Mean manganese levels in 15 personal air samples and 15 stationary air
samples collected at the plant during the year preceding the tests were 2.05 mg manganese/m3 (SD 2.52;
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range 0.5–10.2) for total dust and 0.035 mg manganese/m3 for respirable manganese (SD 0.063; range 
0.01–0.293).  Symptoms of asthenia, sleep disturbance, and headache were significantly elevated in
exposed workers, compared with controls, but no significant differences in blood levels of manganese or
performance on the administered tests were found between the exposed and control groups of workers.  
Clinical examination of the exposed subjects revealed no cases of obvious neurological impairment, but
sensitive psychomotor tests of simple reaction times and motor functions were not administered in this
study. 
In a cross-sectional study, Myers et al. (2003a) evaluated results from a health questionnaire and a battery
of neurobehavioral tests administered to 489 workers employed as office workers, miners, surface 
processors, engineers, and other service workers from two South African manganese mines.  Cumulative 
exposure indices for each subject were calculated based on total dust measurements and job history.
Workers were employed in the mines for a mean of 10.8 years (SD=5.5 years; range 1–41 years), had an 
average cumulative exposure index of 2.2 (mg manganese/m3 per year, SD=2.2; range=0–20.8), an 
average exposure intensity of 0.21 mg manganese/m3 (SD=0.14; range, 0–0.99), and an average blood 
manganese concentration of 8.5 µg/L (SD=2.8; range, 2.2–24.1).  Neurobehavioral end points included 
three tests of motor function in the Luria-Nebraska battery (tests 1, 2, and 23), mean reaction time in the
SPES, and three cognitive tests (forward and backward digit span and digit-symbol score).  Multiple
linear regression analysis revealed no significant (p<0.05) associations between any measure of exposure
and questionnaire or test battery outcomes.
In another cross-sectional study, Myers et al. (2003b) evaluated neurobehavioral end points in a group of
509 workers at a South African manganese smelter, compared with a group of unexposed workers from
an electrical fittings assembly plant (remote from the manganese smelter).  Workers were employed for a
mean of 18.2 years (SD 7.6), compared with 9.4 years (SD 7.0) in the control group.  Exposure was 
assessed from manganese determinations in dust from personal air samples, blood samples, and urine 
samples.  Cumulative exposure indices were calculated for each exposed worker based on manganese 
concentrations in “inhalable” dust from personal air samples and job histories. Mean values for exposed
workers were 16.0 mg manganese/m3 per year (SD 22.4) for cumulative exposure index, 0.82 mg
manganese/m3 (SD 1.04) for average intensity of exposure, 12.5 µg manganese/L (SD 5.6) for blood 
manganese, and 10.5 µg manganese/L (SD 20.3) for urine manganese.  Control workers had mean values
of 6.4 µg manganese/L (SD 1.7) for blood manganese and 0.96 µg manganese/L (SD 0.81) for urine
manganese.  Neurobehavioral end points included the Swedish nervous system questionnaire and the
following neurobehavioral test batteries: World Health Organization (WHO) neurobehavioral core test
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battery, SPES, Luria-Nebraska tests, and Danish product development tests (tests of hand steadiness,
tremor, and body sway).  Information collected for potential confounders included age, educational level, 
alcohol and tobacco consumption, neurotoxic exposures in previous work, past medical history, and 
previous head injury.  Multiple linear and logistic regression analyses were conducted to examine
possible exposure-response relationships.  Several tests showed significant (p<0.05) differences between 
exposed and control workers, but no evidence of exposure-response relationships including the following:
the Santa Ana, Benton and digit span WHO tests; hand tapping and endurance tapping SPES tests; one
Luria-Nebraska test (item 2L); several self-reported symptoms (e.g., tiredness, depressed, irritated); and 
increased sway under two conditions (eyes open with or without foot insulation).  Results from two other
tests (WHO digit-symbol test and Luria-Nebraska item 1R) showed differences between exposed and
control groups and some evidence for increased deficits with increasing exposure, but the change with
increasing exposure was greater at lower exposure levels than at higher exposure levels. Results from all
of the remaining tests showed no significant adverse differences between the exposed and control groups.
The authors concluded that “the most likely explanation for few, weak and inconsistent findings with 
implausible or counterintuitive exposure-response relationships is chance, and it is concluded that this is 
essentially a negative study.”
Young et al. (2005) reanalyzed the data collected by Myers et al. (2003b) on the basis of estimated
exposures to manganese in “respirable” dust.  Exposure estimates for each worker (cumulative exposure 
indices in mg manganese/m3 per year and average intensity of exposure in mg manganese/m3) were 
recalculated based on manganese determinations in personal air samplings of respirable dust (collected on
37 mm, 5 µm MCEP membrane filters, as opposed to inhalable dusts of larger particle sizes used to 
estimate exposure in the earlier analyses by Myers et al. [2003b]).  Results from comparisons of mean
performances of exposed and control groups in the neurobehavioral tests and regression analyses to assess 
exposure-response relationships were similar to results from the earlier analyses by Myers et al. (2003b)
based on manganese determinations in inhalable dust.  The authors concluded that the results did not
provide evidence that exposure estimates based on respirable dust provide a more sensitive method to 
detect manganese neurobehavioral effects.
A cross-sectional study by Summers et al. (2011) supports the work of Myers et al. (2003a, 2003b).  
Neuropsychological tests of attention, short-term memory span, information-processing speed, and 
executive functioning (Digit Symbol Coding, Controlled Oral Word Association Test, Trail Making Test,
Matrix Reasoning, and the Stroop Neuropsychological Screening Test) were used to study adverse effects
in 143 employees in a smelting plant exposed to estimated mean concentrations of 0.384 mg/m3 inhalable
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manganese dust or 0.123 mg/m3 respirable manganese dust (as per Australian standards) for 1–29 years
(mean, 10.6 years).  Cumulative exposure indices for both inhalable and respirable manganese dust were 
calculated for each subject based on yearly air-sampling data for each occupational position and job 
history.  Correlational and hierarchical linear regression analysis was conducted to assess associations of
these exposure metrics, along with age, education, and intellectual ability (estimated IQ), with
performance on the neuropsychological tests.  In hierarchical analysis of performance and respirable
manganese cumulative exposure (including age, estimated IQ, and education as explanatory variables),
statistically significant relationships were found for decreasing performance with increasing exposure on
the Trail Making (Part A), Matrix Reasoning, and Stroop color-word tests (measures of attention and
executive function), and for increasing performance with increasing exposure on the Digit Symbol
Coding test. The magnitude of the effects on performance was small, as reflected by the percentages of
the variance in test scores explained by respirable cumulative manganese exposure (ranging from 0.5 to
3.7, depending on the test).  In contrast, estimated IQ and education explained 3.2–24.5% of the variance.  
Summers et al. (2011) concluded that the decrements in performance associated with cumulative
respirable manganese exposure were small and “not of clinical significance”, because the magnitudes of
these effects were smaller than the standard error of measurement in the tests.
Bast-Pettersen et al. (2004) cross-sectionally examined neurobehavioral end points in a group of 100 male
workers in manganese alloy plants and a group of 100 control workers (paired matched for age) from two
plants, one producing silicon metal and microsillica and another titanium oxide slag and pig iron.  
Manganese alloy workers were employed for a mean of 20.2 years (SD 8.6; range 2.1– 41.0 years);
comparable statistics were not reported for the control workers.  Exposure was assessed from manganese 
determinations in dust from personal air samples (collected on 3 days for each subject closely before the 
neurobehavioral assessment), blood samples, and urine samples.  Arithmetic means for manganese 
workers were 0.753 mg manganese/m3 inhalable dust for work room air (geometric mean 0.301; range
0.009–11.5 mg manganese/m3), 189 nmol manganese/L in blood (range 84–426 nmol/L), and 3.9 nmol
manganese/mmol urine creatinine (range 0.1–126.3). The Institute of Occupational Medicine (IOM)
personal samplers used in this study are expected to provide estimates that are approximately 2-fold 
higher than estimates using 25- or 37-mm plastic Millipore personal air samplers used in many earlier
studies to measure “total dust”. Mean levels of manganese in blood (166 nmol manganese/L) and urine
(0.9 nmol manganese/mmol creatinine) of control workers were significantly lower than levels in exposed 
workers.  Neurobehavioral end points included:  two self-administered neuropsychiatric questionnaires;
six tests of cognitive functions (Weschlers adult intelligence scale, digit symbol, trail making test, Stroop
color-word recognition, digit span, and Benton visual retention); and eight tests of motor functions (static
   
 












     
      
  
            
  
 






     
           
           
    
     
     
          
    
 
    
    
   
    
    





hand steadiness, “TREMOR” test, finger tapping, foot tapping, supination/pronation of hand, Luria-
Nebraska thumb/finger sequential touch, simple reaction time, and hand-eye coordination).  Information 
collected for potential confounders included age, years of education, alcohol and tobacco consumption, 
and prevalence of previous brain concussions.  Multiple linear regression analyses were conducted to 
examine the influence of potential confounders and exposure-response relationships for test results.  No
significant (p<0.05) effect of exposure was found in tests for cognitive functions, reaction time, or
symptom reporting.  No statistically significant (p<0.05) differences were found in tests of motor speed, 
grip strength, or reaction time.  Postural tremor as measured in the hand steadiness test was significantly 
(p<0.05) increased in the exposed group compared with the controls and showed an exposure-response 
relationship when the exposed group was regrouped into three groups of increasing duration of
employment.  Results from an alternative test of tremor (“TREMOR”) did not distinguish between the
manganese alloy group and the control group.  The results indicate that the manganese-exposed group of
workers had increased hand tremor compared with the control group, but were indistinguishable from the
control group in other tests of motor function, cognitive function, or symptom reporting. 
Bouchard et al. (2005) reanalyzed results from neurobehavioral tests administered by Mergler et al. 
(1994) to 74 male workers in a manganese alloy plant to examine the influence of age on the tests.  At the 
time of testing, workers had been employed an average of 19.3 years (range 1–27 years) and 71 of the
workers were employed for >10 years.  Based on personal air and stationary air samples 8-hour time-
weighted average manganese concentrations ranged from 0.014 to 11.48 mg manganese/m3 total dust 
(geometric mean=0.225 mg manganese/m3) and from 0.001 to 1.273 mg manganese/m3 respirable dust
(geometric mean=0.035 mg manganese/m3).  The referent group contained 144 workers with no history of
occupational exposure to neurotoxicants who were matched for age, educational level, smoking status,
and number of children.  Mean blood manganese levels were 11.9±5.3 µg/L (range 4.4–25.9 µg/L) in 
exposed workers and 7.2±0.3 µg/L (range 2.8–15.4 µg/L) in controls.  Paired differences between 
exposed and control workers increased significantly (p<0.05) with age for one of nine tests of neuromotor
domain (nine-hole hand steadiness test); 3 of 12 tests of cognitive domain (trail making B [test of visual
conception and visuomotor tracking], delayed word recall [test of learning, recall and attention], and 
cancellation H [test of visuomotor tracking and concentration]); and 1 of 4 sensory domain tests
(vibratometer–vibrotactile perception of the index and toe).  The results suggest that older workers may
be more slightly more susceptible to the neurological effects of low-level manganese exposure than
younger workers.  
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Bouchard et al. (2007a) examined neuropsychiatric symptoms in a group of 71 male workers in a 
manganese alloy plant, 14 years after cessation of exposure, and in a group of 71 unexposed referents of
similar age and education levels from the same geographical region.  Based on personal air and stationary
air samples during the operation of the plant, 8-hour time-weighted average manganese concentrations 
were 0.014–11.48 mg manganese/m3 total dust (geometric mean=0.225 mg manganese/m3) and 0.001– 
1.273 mg manganese/m3 respirable dust (geometric mean=0.035 mg manganese/m3).  The mean number
of years of occupational exposure to manganese was 15.7 (range, 7.4–17.3 years).  The exposed workers 
were participants in the earlier study by Mergler et al. (1994).  Neuropsychiatric symptoms were assessed
by a self-administered questionnaire, the Brief Symptom Inventory, from which scores were determined 
for somatization (psychological distress from perception of bodily dysfunction), obsessive-compulsive 
behavior, interpersonal sensitivity (feeling of personal inadequacy), depression, anxiety, hostility, phobic
anxiety, paranoid ideation, and psychoticism.  Former, manganese workers showed significantly (p<0.05)
higher scores (after adjustment for age, education, and alcohol consumption) for two of the nine
neuropsychiatric symptoms (depression, anxiety), compared with controls.
In a follow-up to the Mergler et al. (1994) study, Bouchard et al. (2007b) evaluated neurobehavioral end 
points in a group of 77 male former workers in a manganese alloy plant, 14 years after cessation of
employment, and in a group of 81 nonexposed referents group-matched for age, education and alcohol
consumption. The groups were initially assessed in 1990 and, for the present study in 2004, in five
neuromotor tests, nine cognitive tests, and six mood state tests.  Based on personal air and stationary air
samples during the operation of the plant, 8-hour time-weighted average manganese concentrations were 
0.014–1.48 mg manganese/m3 total dust (geometric mean=0.225 mg manganese/m3) and 0.001–1.273 mg
manganese/m3 respirable dust (geometric mean=0.035 mg manganese/m3).  Mean years of occupational
exposure to manganese was reported as 15.3 years (maximum=17.3 years).  In the 1994 assessment, 
significant (p<0.05) differences between exposed and control workers were found in scores for one of
five neuromotor tests (Luria Motor Scale), three of nine cognitive tests (cancellation H, digit span, color-
word test), and one (tension-anxiety) of six mood state tests.  In 2004, significant (p<0.05) differences
between the exposed and control workers persisted for one (Luria Motor Scale) of five neuromotor tests, 
none of the nine cognitive tests, and one (confusion-bewilderment) of the six mood states. These results 
indicate that exposure-related effects observed initially in the manganese alloy workers did not progress
in a 14-year period following cessation of employment. 
Neurological Assessments of Environmentally Exposed Populations Exposed to Inorganic Manganese.  
Mergler et al. (1999) studied environmental exposure to manganese and its possible effect on mood 
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(Bowler et al. 1999), neuromotor function (Beuter et al. 1999), and levels of the metal in biological fluids
(Baldwin et al. 1999).  The study group was a community in southwest Quebec, Canada, near which a
former manganese alloy production plant served as a point source for environmental manganese pollution.
Due to the presence of MMT in gasoline in Canada, inhaled manganese from car exhaust is a potential
contributor to manganese exposures experienced in the population studied.  A total of 273 persons
comprised the test population.  These individuals were selected using a stratified random sampling
strategy from the Quebec Health Plan Register, which includes all residents. This strategy helped to
ensure that no selection bias was introduced.  These individuals were administered a test battery including
a computerized neuromotor test, blood sampling, visual function tests from the Neurobehavioral
Evaluation System-2, an extensive neuropsychological test battery, and diverse tests covering such areas 
as olfactory threshold, finger tapping, digit span, and postural sway.  Blood sampling data for the study
subjects (Baldwin et al. 1999) indicated that manganese levels in women (geometric mean=7.5 μg/L)
were significantly higher than in men (6.75 μg/L).  No relationship was found between the overall level of
manganese in blood and those of lead or iron in serum.  However, blood manganese levels were 
negatively correlated with serum iron in women and had a tendency to decrease with increasing age.  
Serum iron levels in men were higher than in women.  The authors analyzed manganese in drinking water
from the study subjects’ residences and analyzed air samples from four different locations for total
manganese particulates and PM10 values. The geometric mean value for manganese in drinking water
was 4.11 μg/L; there was no correlation between individual values in drinking water manganese and 
manganese blood levels. Intersite differences in manganese values in total particulate were not observed
in the air samples, but intersite differences did exist for manganese in PM10 values.  Two geographical
areas were identified where manganese in air contributed to blood manganese levels; serum iron was 
negatively related to blood manganese levels in this analysis (Baldwin et al. 1999).   
The Profile of Moods State and Brief Symptom Inventory self-report scales were used to assess condition
of mood in the study population (Bowler et al. 1999).  The results from these analyses indicated that men
who are older (>50 years) and have higher blood manganese levels (≥7.5 μg/L) showed significant
disturbances in several mood symptoms with significantly increased values for anxiety, nervousness, and 
irritability; emotional disturbance; and aggression and hostility when compared to those with lower levels
of blood manganese.  Neuromotor, neurological, and neurobehavioral analyses revealed that subjects with 
higher blood manganese levels (≥7.5 μg/L) performed significantly worse on a test for coordinated upper
limb movements, with poorest performance in older men (Mergler et al. 1999).  Also in men, proximal
events on the qualified neurological examination, involving arm movements were significantly slower for
those with higher blood manganese, and hand movements (distal events) tended to be in the same 
   
 










          
     
           
    
  
        
          
             
            
           
   
    
      
    
       
 
   
         
   
  
   
          
   
          
  
         
   
  
    
87MANGANESE
3. HEALTH EFFECTS
direction.  No correlation was observed in women.  Other measures of motor performance (e.g., hand-arm 
tremor and tapping movements) were not related to blood manganese levels, although a significant
decrease in tremor frequency dispersion was observed with log MnB (manganese blood level).  For both 
men and women, performance on the learning and memory tests was inversely correlated with manganese 
blood level values, although performance on individual portions of the overall test varied significantly
with gender.  For men, higher levels of manganese in blood were associated with poorer performance on 
list acquisition, delayed auditory recall, and visual recognition following a distracter.  Females, in
contrast, tended to recall fewer geometric shapes, made more errors on the visual reproduction test, but
remembered more numbers on the digit span forward test.  This study is unique in that it is the first to 
study both males and females in an exposed population, and it shows an association between elevated 
manganese blood levels linked to elevated environmental manganese and poor performance on
neurobehavioral and neuropsychiatric tests. This study also reported that neurological effects associated
with higher levels of blood manganese were more likely to be observed in persons >50 years of age.  In
contrast, Roels et al. (1999) reported that age was a significant factor only in performance of the visual
reaction time test, but not for the eye-hand coordination test or the measure of hand steadiness used in
their longitudinal studies.  However, Crump and Rousseau (1999) reported that older age was a
significant factor in poor performance in tests of short-term memory and eye-hand coordination.  
Although there were no statistically significant neurological effects associated with manganese exposure 
among workers of a metal-producing plant evaluated by Gibbs et al. (1999), these investigators also noted 
that test performance in eye-hand coordination and reaction time decreased with increasing age.
Rodríguez-Agudelo et al. (2006) examined neurobehavioral end points in 168 women and 120 men from
eight communities at various distances from manganese extraction or processing plants in the district of
Molango, Mexico.  Manganese levels in PM10 dust in air samples collected from 28 houses were
determined, and the values obtained from the closest monitor were assigned to each of the
288 participants (values ranged from 0 to 5.86 µg manganese/m3).  Concentrations of manganese in
samples of drinking water and maize grain were mostly below detection limits, whereas soil
concentrations ranged from about 6 to 280 mg manganese/kg, with the largest concentrations noted in 
samples collected close to the manganese industrial sites.  Blood samples were collected from each
participant and used for manganese and lead determinations.  Neuromotor tests (which were a Spanish 
adaptation of Luria diagnostic procedures) were administered, and odds ratios (ORs) were calculated for
24 different end points involving hand motor functions using dichotomous assessments of performance
(e.g., normal and poor) after grouping the participants based on associated manganese concentrations in 
air or blood manganese levels.  No associations were found between neuromotor performance and blood 
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levels of manganese or lead.  After grouping the participants into those associated with air concentrations
between 0 and 0.1 µg manganese/m3 and those with concentrations between 0.1 and 5.86 µg
manganese/m3 (approximate midpoint=3 µg manganese/m3), significantly (p<0.05) elevated ORs for poor
performance were calculated for only 3 of the 24 neuromotor end points (two movement coordination, left
hand performance [OR=1.99, 95% CI 1.15–3.43]; change of hand position, left hand performance
[OR=1.98, 95% CI 0.99–3.95], and conflictive reaction, a test of verbal regulation of movement
[OR=2.08. 95% CI 1.17–3.71]).  Although the authors concluded that the results indicate that “there is an 
incipient motor deficit in the population environmentally exposed to large manganese levels,” a more 
likely explanation for the few and inconsistent findings is chance.  This explanation is supported by the
finding that no statistically significant associations were found between any neuromotor function end 
points and blood manganese levels.  In addition, the lack of air monitoring data for individual participants
in the study precludes assigning the “high” air concentration exposure level as a reliable LOAEL or
NOAEL.
Solís-Vivanco et al. (2009) evaluated the same group of subjects with a battery of neuropsychological
tests for cognitive function (general cognitive state, attention, semantic and phonological fluency, 
construction, verbal memory, visual memory coding and recall, and depression). Using logistic
regression analysis with air manganese concentration as an exposure variable, no risk of poor
performance was found with a 0.05 μg/m3 cut-off point.  When using a 0.1 μg/m3 cut-off point, only 1 of
10 cognitive measures had a significantly increased risk of poor performance (attention as measured by
the digit span test, OR = 1.75, CI 1.01–3.06).  Solís-Vivanco et al. (2009) concluded that the attention 
impairments associated with high levels of air manganese exposure are evidence of cognitive impairment 
in the exposed population.  However, similar to the study by Rodríguez-Agudelo et al. (2006), the finding
on this one measure could be due to chance, as there was no association between blood manganese levels 
and cognitive performance.
In the same Molango mining district in central Mexico, a cross-sectional study assessed intellectual
function in 79 children (ages 7–11 years) exposed to an average manganese air concentration of
0.13 μg/m3 for at least 5 years (Riojas-Rodríguez et al. 2010). The children received a medical exam, and
their height and weight were measured.  Intellectual function was assessed with the revised Wechsler
Intelligence Scale for Children. Maternal intelligence was assessed with the Progressive Matrices of the 
Raven test.  Blood and hair samples were collected from the children to measure manganese 
concentrations, along with blood concentrations of lead and hemoglobin.  A control group was comprised 
of 93 unexposed children (ages 7–11 years) from socioeconomically-matched communities from the
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Aqua Blanca district 80 km southeast from the manganese source.  Children in the exposed communities
had significantly elevated mean blood (9.71 μg/L) and hair (12.13 μg/g) manganese concentrations
compared with controls (8.22 μg/L and 0.57 μg/g, respectively).  Statistically significant (p<0.05)
negative associations were found between hair manganese concentrations and verbal and full scale scores.
Blood manganese concentration was inversely, but nonsignificantly, associated with verbal and full scale 
scores.  After adjusting for age and sex, the strongest inverse association between hair concentration and
intellectual function was in young girls, with little evidence of associations in boys at any age.  
Associations with blood concentration were not modified by sex, but age adjustment suggested that the 
inverse relationship was limited to younger participants.  Riojas-Rodríguez et al. (2010) concluded that
findings suggest that air-borne manganese exposure is inversely associated with intellectual function in
young school-age children.  However, manganese exposure from other sources (groundwater, dietary)
was not considered, and association between air concentration and test results were not explored.  
Hernádez-Bonilla et al. (2011) evaluated the same groups of children for motor impairments.  Parameters 
assessed were manual dexterity, (fine) motor coordination, and motor speed (using the grooved pegboard, 
finger tapping, and Santa Ana tests). There was a significant inverse relationship between execution of
the finger tapping test with blood, but not hair, manganese concentration.  Additionally, exposed children 
made significantly more errors in the grooved pegboard test than controls, but this effect was not
associated with blood or hair manganese levels. There was no correlation between manganese 
concentration in blood or hair in any of the other motor function tests.  Hernádez-Bonilla et al. (2011)
concluded that there was only subtle evidence of adverse effects on motor speed and coordination.  
Similar cognitive findings were reported in a cross-sectional study by Menezes-Filho et al. (2011), in 
which intellectual function was assessed in 83 children from 55 families (ages 6–12 years) and their
primary caregivers from the village of Cotegipe in Brazil, which is within a 2-km radius from a ferro-
manganese alloy plant that has been emitting high levels of manganese into the air for 4 decades. The 
height and weight of each child was recorded, and blood and hair samples were collected to measure 
manganese levels.  Blood levels of lead and iron were also measured.  Intellectual function was assessed
in children using the Wechsler Intelligence Scale for Children, version III.  To assess intellectual function 
in primary caregivers (94% mothers), the Raven Progressive Matrix was administered. Caregivers also
provided hair samples for manganese level testing and responded to a questionnaire on sociodemo-
graphics and birth history.  The mean blood and hair manganese concentrations in children were 8.2 and 
5.83 μg/L, respectively.  The mean hair manganese concentration in caregivers was 3.5 μg/L, and levels
correlated with their children's hair manganese concentration.  After adjusting for maternal education and 
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nutritional status, there was a significant (p<0.05) negative association between hair manganese levels in
children and their verbal and full scale scores.  In addition, after adjusting for education years, family
income, and age, there was a significant (p<0.05) negative association between caregiver’s hair
manganese levels and performance on the Raven Progressive Matrix.  Menezes-Filho et al. (2011)
concluded that high manganese exposure, likely via air emissions from the plant, had detrimental effects 
on cognition in both adults and children, especially in the verbal domain.  However, they state that poor
cognitive development in children may also be due in part to lower caregiver IQs.  Additionally, this
study bears the limitations of a cross-sectional design, and causal inferences cannot be made on the 
relationship of manganese exposure and cognitive defects.
In a community-based study, Lucchini et al. (2007) examined possible associations between prevalence of
Parkinsonian disorders and levels of manganese in settled dust collected from communities in the vicinities
of manganese ferroalloy industrial plants in the province of Brescia, Italy.  Parkinsonian patients were 
identified from clinical registers from local hospitals, area neurologists, and records of exemption from
prescription payments, as well as from records of L-Dopa prescriptions; a total of 2,677 Parkinsonian cases 
were identified among 903,997 residents.  SMRs for each of 206 municipalities were calculated based on 
national rates standardized for age and gender.  Municipalities with the highest SMRs were located within
20 km and/or downwind of three manganese alloy industrial plants in the Valcamonica region of Brescia.  
An average standardized prevalence of 492 cases/100,000 residents was observed in the 37 municipalities
of the Valcamonica region. Crude and standardized prevalence rates for the Valcamonica municipalities 
were significantly (p<0.05) higher than rates for the other 169 municipalities of Brescia. Municipality-
based SMRs for Parkinsonian disorders were significantly (p<0.05) associated with manganese levels in
settled dust, and manganese levels in settled dust samples from the 37 municipalities in Valcamonica were 
significantly (p<0.05) higher than levels in samples for the other 169 municipalities. The results suggest
that prolonged environmental exposure to excessive manganese in the Valcamonica region of Brescia may
increase the risk for Parkinsonian disorders, but the results do not identify a reliable NOAEL or LOAEL
that can be expressed in units of manganese air concentrations.  The authors speculated that, even though 
manganese-induced and Parkinsonian neurological disorders are expected to have two distinct target areas
in the brain (the globus pallidus and the substantia nigra, respectively), structural and chemical
interconnections between the brain areas may interact to cause increased risk for Parkinsonian disorders as 
suggested by Weiss (2006).
In a preliminary cross-sectional study, Standridge et al. (2008) evaluated postural balance in 22 residents
(13 females and 9 males; ages 20–59 years old) from a manganese-exposed Ohio community where a
   
 








            
         
  
 
            
 
    
     
               
     






   
  
   
  
         
            
  
 
        
   
  
      





large ferro- and silico-manganese smelter has been active for >50 years.  Subjects had been living within
10 miles of the refinery for at least 3 years, were known not to have a history of manganese occupational
exposure, and had been exposed to estimated mean daily ambient manganese concentrations between 
0.1 and 2.0 μg/m3. The control group was comprised of 22 military subjects (10 females and 12 males;
ages 24–57 years old) who were considered to be unexposed to occupational and environmental
neurotoxicants. Results from a postural sway analysis, along with blood and hair manganese levels, were 
compared with unexposed controls.  Several covariates (age, gender, height, weight, alcohol intake, 
tobacco usage, and blood lead levels) were also recorded.  Postural analysis measures of manganese-
exposed residents were significantly larger than controls in five out of eight postural balance outcomes
(sway area for eyes open on the platform, sway area for eyes open or closed on foam, sway length for
eyes open or closed on the foam).  After adjustment for covariables, a significant positive association was 
found between hair manganese levels and sway area and length (eyes open or closed on the platform).
Standridge et al. (2008) concluded that these preliminary findings suggest subclinical impairment in 
postural balance in manganese-exposed residents.
Kim et al. (2011) conducted a cross-sectional study evaluating motor function in 100 residents from the
same manganese-exposed Ohio community.  Subjects had been living in the community for 10–65 years
and had been exposed to 0.04–0.96 μg/m3 of respirable manganese particulate (mean, 0.18 μg/m3; based
on U.S. EPA dispersion modeling).  Results from the Unified Parkinson's Disease Rating Scale, a postural
sway test, and a comprehensive questionnaire exploring demographics and general health were compared
to 90 unexposed residents from a demographically similar comparison town in Ohio.  Blood samples
were collected from all subjects for ferritin, alanine transpeptidase, gamma-glutamyl transferase,
manganese, mercury, lead, and cadmium levels. There were no significant differences between the 
exposed and comparison groups in regards to manganese blood levels, demographics, or major health 
outcomes.  However, when adjusted for covariates (presence of other neurotoxic metals, factors
aggravating susceptibility to manganese or motor performance, demographics), the manganese-exposed 
residents had a significantly increased risk of abnormal performance on the Unified Parkinson's Disease 
Rating Scale and showed significantly higher postural sway scores.  Kim et al. (2011) concluded that
these subclinical findings may possibly reflect early subtle effects of chronic, low-level manganese 
exposure, but alternatively might be due to chance due to the cross-sectional study design, the small to
medium effect size, and the lack of association between air or blood manganese levels and motor function 
performance.
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Neurological Studies of Animals Exposed by Inhalation to Inorganic Manganese. In several early
animal studies, intermediate or chronic inhalation exposure of monkeys and rats to manganese dusts has
not produced neurological signs similar to those seen in humans (Bird et al. 1984; EPA 1983c; Ulrich 
et al. 1979a, 1979b).  For example, Ulrich et al. (1979a) reported that monkeys continually exposed for 
9 months to aerosols of manganese dioxide at concentrations as high as 1.1 mg manganese/m3 showed no 
obvious clinical signs of neurotoxicity, no histopathological changes in brain tissues, and no evidence for
limb (leg) tremor or electromyographic effects on flexor and extensor muscles in the arm.  However, in a 
chronic study with Rhesus monkeys, decreased levels of dopamine were found in several regions of the
brain (caudate and globus pallidus) (Bird et al. 1984).  Behavioral tests detected signs of neurological
effects in mice (increased open-field activity and decreased maternal pup retrieval latency), although
these are only seen at relatively high exposure levels (60–70 mg manganese/m3) (Lown et al. 1984;
Morganti et al. 1985).  
Several studies provide evidence for associations between decreased neuronal cell counts in the globus 
pallidus and neurobehavioral changes (increased locomotor activity) in rats exposed by inhalation for
13 weeks to a mixture of manganese phosphate/sulfate (at 1.05 mg manganese/m3) or manganese sulfate 
alone (at concentration between 0.009 and 0.9 mg manganese/m3), but not to manganese phosphate alone
at concentrations up to 1.1 mg manganese/m3 (Normandin et al. 2002; Salehi et al. 2003, 2006; Tapin et
al. 2006).  Other 13-week rat inhalation exposure studies reported increased brain manganese 
concentrations and increased locomotor activity after exposure to 3.75 mg manganese/m3 as metallic 
manganese (St-Pierre et al. 2001) and increased brain manganese concentrations with no increases in
olfactory bulb, cerebellar, or striatal concentrations of glial fibrillary acidic protein (GFAP) after exposure
to 0.5 mg manganese/m3 as manganese sulfate or 0.1 mg manganese/m3 as manganese phosphate 
(Dorman et al. 2004b).  GFAP is a widely acknowledged marker of damage to astrocytes.
In male Sprague-Dawley rats, increased locomotor activity (increased distance traveled, but no change in
resting time) was observed after up to 13 weeks of exposure to 0.03 or 3 mg of a manganese
phosphate/sulfate mixture/m3 (6 hours/day, 5 days/week), but not at 0.3 mg/m3 (Salehi et al. 2003).  These
exposure concentrations correspond to 0.01, 0.11, and 1.05 mg manganese/m3.  Assessment of brain
manganese levels, hind limb tremor, and neuropathology of the brain (counts of neuronal cells) found no 
evidence for tremor at any exposure level, but rats at the highest exposure level showed significantly
(p<0.05) increased concentrations of manganese in the frontal cortex, globus pallidus, and caudate
putamen, as well as significantly (p<0.05) decreased neuronal cell counts in the globus pallidus and 
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caudate putamen, compared with control values or to values for rats in the lower exposure groups (Salehi
et al. 2006).  
In similar experiments with male Sprague-Dawley rats exposed to 0, 0.03, 0.3, or 3 mg manganese
sulfate/m3 (Tapin et al. 2006) or 0, 0.03, 0.3, or 3 mg manganese phosphate/m3 (Normandin et al. 2002)
for 13 weeks by the same exposure protocol, some differences in results were obtained. These exposure 
levels correspond to 0.009, 0.09, or 0.9 mg manganese/m3 for manganese sulfate and 0.01, 0.11, or
1.1 mg manganese/m3 for manganese phosphate.  With exposure to manganese phosphate, manganese
levels were significantly (p<0.05) elevated (at 3 mg/m3) in the olfactory bulb, frontal cortex, globus
pallidus, caudate putamen, and cerebellum regions of the brain, but no exposure-related effects were 
found on neuronal cell counts or locomotor activity (Normandin et al. 2002).  In contrast, manganese
sulfate exposure significantly (p<0.05) increased manganese levels in all regions of the brain, and
decreased neuronal counts in the globus pallidus at 0.3 and 3 mg manganese sulfate/m3, compared with 
controls (Tapin et al. 2006).  In addition, the two highest exposure levels of manganese sulfate were 
associated with significantly (p<0.05) increased locomotor activity (distance traveled), increased resting
time, and decreased total ambulatory counts; the lowest exposure level, 0.03 mg manganese sulfate/m3 
also increased the distance traveled end point of locomotor activity (Tapin et al. 2006).  As with the
manganese phosphate/sulfate mixture, neither manganese phosphate nor manganese sulfate exposure was 
associated with hind limb tremors in the rats.  Earlier studies by the same research group, found that
Sprague-Dawley rats exposed to 3.75 mg aerosols of metallic manganese/m3 (6 hours/day, 5 days/week
for 13 weeks) showed significantly (p<0.05) higher manganese concentrations in various regions of the
brain, and higher distance traveled and lower resting time in locomotor tests, compared with controls;
neuronal counts were not assessed in this earlier study (St-Pierre et al. 2001). 
Several studies have examined the influence of inhalation exposure to manganese sulfate on biochemical
end points associated with oxidative stress or inflammation in the brain of rats (Erikson et al. 2005, 2006;
HaMai et al. 2006; Taylor et al. 2006) and monkeys (Erikson et al. 2007, 2008).  Erikson et al. (2005, 
2006) exposed neonatal rats to manganese sulfate (0, 0.05, or 1 mg manganese/m3) during gestation and 
postnatal days (PNDs) 1–18 and examined five brain regions for several biochemical end points 
associated with oxidative stress either on PND 19 (Erikson et al. 2006) or after 3 weeks without exposure
(Erikson et al. 2005).  End points included levels of glutamine synthase (GS) protein and mRNA, 
metallothionein (MT) mRNA, tyrosine hydroxylase (TH) protein and mRNA, and total reduced 
glutathione.  At PND 9, increased manganese concentrations in the striatum (the most consistently
affected region) were associated with decreases in GS, MT, and TH mRNA, and significantly decreased
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levels of glutathione (Erikson et al. 2006), but these were not apparent 3 weeks after cessation of
exposure (Erikson et al. 2005).  However, other end points (such as decreased GS protein) were changed, 
compared with control values, 3 weeks after cessation of exposure (Erikson et al. 2005).  Similar end 
points, as well as levels of mRNA and protein for glutamate transporters, were examined in six brain 
regions of young male Rhesus monkeys exposed to 0, 0.06, 0.3, or 1.5 mg manganese/m3 as manganese 
sulfate for 65 days (Erikson et al. 2007).  Exposure-related changes included decreased MT mRNA in
most regions, decreased TH protein levels in the caudate and globus pallidus, increased GSH in the 
frontal cortex, and decreased GSH in the caudate.  In a follow-up study, Erikson et al. (2008) examined 
similar end points in groups of four Rhesus monkeys exposed to 1.5 mg manganese/m3 for 15 or 33 days
or 65 days with 45 or 90 days of recovery.  The previously reported alterations (MT mRNA, TH protein, 
GSH) were confirmed after 33 days of exposure, and all but the increased GSH levels in the frontal cortex 
persisted at least 90 days after treatment cessation.  Additional persistent effects include decreased GS
protein and glutamate transporter (GLT-1) mRNA and protein in various brain regions and decreased 
glutamate transporter GLAST protein in globus pallidus.  In another study, HaMai et al. (2006) exposed 
three groups of rats to 0 or 0.71 ng manganese/m3 (2 hours/day) as manganese sulfate on gestation days 
(GDs) 9 and 10, on PNDs 37–47, or on GDs 9 and 10 plus PNDs 37–47 and measured brain levels of
mRNA for gene products related to oxidative stress or inflammation.  Gestational exposure was
associated with decreased mRNA for amylid precurson (APP), cyclooxygenase-2 (COX-2), neuronal
nitric oxide synthetase (nNOS), and GFAP, whereas adult exposure was associated with greater
transcriptional decreases for the same gene products as well as transcriptional growth factor beta (HaMai
et al. 2006). The results from these studies indicate that acute- or intermediate-duration inhalation 
exposure to manganese sulfate concentrations ranging from about 0.1 to 1 mg manganese/m3 can
differentially affect brain biochemical markers of neurotoxicity, but understanding of the neurotoxic
mechanism of manganese is inadequate to confidently define any one of the observed changes as 
biologically adverse.
No studies on neurological effects from inhalation exposure to MMT in humans or animals were located.
3.2.1.5 Reproductive Effects
As discussed earlier (see Section 3.2.1.4), impotence and loss of libido are common symptoms in male
workers afflicted with clinically identifiable signs of manganism attributed to occupational exposure to
manganese for 1–21 years (Emara et al. 1971; Mena et al. 1967; Rodier 1955; Schuler et al. 1957).  These
symptoms could lead to reduced reproductive success in men. Impaired fertility (measured as a decreased
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number of children/married couple) has been observed in male workers exposed for 1–19 years to
manganese dust (0.97 mg/m3) at levels that did not produce frank manganism (Lauwerys et al. 1985).  
This suggests that impaired sexual function in men may be one of the earliest clinical manifestations of
manganism, but no dose-response information was presented so it is not possible to define a threshold for
this effect.  Jiang et al. (1996b) performed a reproductive epidemiological study on 314 men in a
manganese plant. The men, from six different factories, performed milling, smeltering, and sintering
duties for up to 35 years. The geometric mean airborne manganese concentration (assumed to be total
dust) was 0.145 mg/m3 as manganese dioxide. The researchers found no significant differences in
reproductive outcomes between exposed and control workers (controls were matched for several factors,
including age, smoking, personal hygiene, living habits, and cultural background).  The incidences of
sexual dysfunction were evaluated through researchers’ questions and judged by the occurrence of two 
positive responses to three potential conditions: impotence, abnormal ejaculation (early ejaculation or
nonejaculation), and lack of sexual desire.  Impotence and lack of sexual desire were higher in the 
exposed group than in the controls (Jiang et al. 1996b).  Wu et al. (1996) reported increased semen 
liquefaction time and decreased sperm count and viability in three groups of men occupationally exposed 
to manganese:  63 miners or ore processors, 38 electric welders in mechanical fields, and 110 electric 
welders in shipbuilding.  Matched controls consisted of 99 men who were employed in the same
occupation and from the same area, but were not exposed to manganese or other reproductive toxins.  The
men had been exposed to manganese for ≥1 year.  Geometric means of total manganese dust (as 
manganese dioxide) ranged from 0.14 mg/m3 for mining operations to 5.5 mg/m3 for manganese powder
processing.  Manganese fume concentrations varied; the mechanical welders were exposed to a 
concentration of 0.25 mg/m3 (geometric mean), while the shipbuilding area concentrations ranged from
geometric means of 6.5–82.3 mg/m3, depending on the location within the ship.  The miners had a
significant percentage (14.3%; p<0.01) of samples with increased liquefaction time, decreased sperm
count (34.9%; p<0.01), and decreased percentage of total viable sperm (33.3% had abnormal counts;
p<0.01) compared to controls.  Welders in shipbuilding had decreased sperm viability levels that were 
significantly different from controls (p<0.01).  Manganese concentrations in semen were significantly
increased compared to controls in the mechanical welders; copper, nickel, chromium, and iron 
concentrations were also elevated in semen in welders in both mechanical and shipbuilding careers.  
Further, stepwise regression analysis of the impact of these other metals on the measured reproductive 
parameters indicated that the higher the nickel concentration, the lesser the semen volume and the greater 
the number of deformed sperm.  Copper in the seminal fluid was also positively linked with the viable
sperm percentage, sperm viability and number of sperm.  Although this study indicates that manganese
exposure can cause sperm toxicity, the presence of other metals prevents any conclusive statements 
   
 










         
  
   
 
        
        
   
  
 
          
   
  
    
   
        
 
 
       
   
   
   
    
   
  
 
     
          
 





concerning its importance.  Gennart et al. (1992) performed a reproductive study on 70 male workers 
exposed to manganese dioxide at a median concentration of 0.71 mg manganese/m3 in total dust for an
average of 6.2 years in a dry alkaline battery plant.  Results from a questionnaire answered by the workers 
and controls in the study and from analysis of birthrates of exposed and control workers revealed no 
difference in birthrates between the groups.
These results in human studies reveal conflicting evidence for whether occupational exposure to
manganese causes adverse reproductive effects.  Effects reported may occur as a secondary result of
neurotoxicity but do not provide information on any direct effect manganese may have on the
reproductive organs.  No information was found regarding reproductive effects in women.
Intratracheal instillation studies in rabbits indicate that single high doses of manganese (158 mg/kg, as
manganese dioxide) can cause severe degenerative changes in the seminiferous tubules and lead to 
sterility (Chandra et al. 1973; Seth et al. 1973).  This effect did not occur immediately, but developed 
slowly over the course of 4–8 months following the exposure.  Direct damage to the testes has not been 
reported in humans occupationally exposed for longer periods, suggesting that this effect may not be of
concern under these exposure circumstances.  However, it is unclear if specific studies to investigate 
possible testicular damage have been performed.  
None of the studies located reported adverse effects in female animals following inhalation exposure to
manganese.  In a study with female mice (Lown et al. 1984), the average number of pups born to exposed 
females was increased when dams were exposed to manganese dioxide before conception through 
gestation.  In a report of a study of tissue manganese concentrations in lactating rats and their offspring
following exposure to manganese sulfate aerosols at 0, 0.05, 0.5, or 1 mg manganese/m3 starting 28 days
prior to breeding through PND 18, no mention was made of reproductive performance variables such as
the percentage of dams that delivered or the number of pups per litter (Dorman et al. 2005a).
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in
each species and duration category are recorded in Table 3-1 and plotted in Figure 3-1.
No studies were located concerning reproductive effects following inhalation exposure to organic 
manganese compounds in humans or animals. 
   
 








    
 
       
    
    
         
   
   
       
 
  
    
   
  
           
 
        
   
  
           
  




        
    
         
   
     




3.2.1.6 Developmental Effects 
Very little information is available on the developmental effects of inorganic manganese from inhalation
exposure.  The incidences of neurological disorders, birth defects, and stillbirths were elevated in a small
population of people living on an island where there were rich manganese deposits (Kilburn 1987).  
However, no conclusions could be reached on the causes of either the neurological effects or the 
increased incidence of birth defects and stillbirths because there were insufficient exposure data.  Control
data were not provided, and the study population was too small for meaningful statistical analysis. 
Although inhalation exposure was not ruled out, the route of exposure was assumed to be primarily oral.
As discussed in Section 3.2.1.4, two studies reported statistically significant inverse relationships between 
an index of exposure to manganese in air (manganese concentration in hair) and intellectual function in 
children living in communities near manganese industries (Menezes-Filho et al. 2011; Riojas-Rodríguez
et al. 2010).  Additionally, Hernández-Bonilla et al. (2011) reported that children living in a manganese
mining area had higher manganese hair concentrations than children from a non-mining area, but did not
show clear performance deficits on several tests of motor skills (grooved pegboard, finger tapping, and
Santa Ana test), compared with the control group of children.  No statistically significant associations
were found for increasing performance deficits with increasing hair concentrations, but a statistically
significant association was found for finger tapping deficits with increasing manganese blood 
concentrations.  The results provide suggestive evidence of an association between environmental
exposure of children to manganese and impaired cognitive abilities, but are inadequate to establish causal
relationships due to the cross-sectional design and inability to control for possible confounding factors.  
The study of motor function did not find clear and consistent evidence for motor function deficits in these
children.
Lown et al. (1984) evaluated the developmental effects of inhaled manganese in mice.  The study
involved exposing dams and non-pregnant female mice to either filtered air or manganese at an average 
concentration of 61 mg/m3 (as manganese dioxide) 7 hours/day, 5 days/week, for 16 weeks prior to 
conception. The authors then exposed the mice to either air or manganese post-conception, irrespective
of preconception exposure.  Once delivered, six pups (three of each sex) were distributed to foster
mothers and then nursed in the absence of exposure to manganese.  The pups were then evaluated on 
postpartum day 7 for weight gain and gross locomotor activity and on day 45 for different behavioral
parameters and learning performance. The authors observed that pups raised by foster mothers that had
been exposed to manganese preconception and filtered air postconception had reduced weights compared 
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to pups raised by foster mothers exposed only to filtered air.  The activity data indicated that there were
no observable differences in activity between pups who had been exposed to manganese in utero and
those that had not.  Therefore, the data did not provide evidence that manganese exposure resulted in
adverse neurological developmental effects.
No studies were located concerning developmental effects in humans or animals following inhalation 
exposure to organic manganese.
3.2.1.7 Cancer
No studies were located regarding carcinogenic effects in humans or animals after inhalation exposure to
inorganic or organic manganese.
3.2.2 Oral Exposure
Although humans are often exposed to significant quantities of inorganic manganese compounds in food 
and water (see Sections 6.4 and 6.5), reports of adverse effects in humans from ingestion of excess 
manganese are limited. Most information on the effects of oral exposure to inorganic manganese is 
derived from studies in animals.  These studies are summarized in Table 3-2 and Figure 3-2, and the
findings are discussed below.  All doses are expressed as mg manganese/kg/day.
Health effects following oral exposure to the organic manganese compound, MMT, were observed in
animals.  Studies involving oral exposure of animals to MMT are summarized in Table 3-3 and 
Figure 3-3. As discussed previously, because inhalation, oral, and dermal pathways are not a concern 
regarding exposure to mangafodipir, this compound’s studies are not presented in an LSE table or figure;
instead, they are discussed in Section 3.2.4.
3.2.2.1 Death 
Three studies have been located in which death in humans may have been caused by the ingestion of
manganese-contaminated water (Hafeman et al. 2007; Kawamura et al. 1941; Spangler and Spangler
2009).  Kawamura et al. (1941) reported death from "emaciation" in two adults who ingested drinking
water contaminated with high levels of manganese.  Hafeman et al. (2007) reported high mortality among
infants <1 year of age in a Bangladesh population where the drinking water supplied by certain local
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Chemical Form Comments 
Holbrook et al. 1975 
MnCl2 
Kostial et al. 1978 
MnCl2 
Kostial et al. 1989 
MnCl2 
Singh and Junnarkar 1991 
MnCl2 
Singh and Junnarkar 1991 
MnSO4 

































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 





















Resp 1300 NTP 1993 
MnSO4 
Cardio 1300 
Hemato 650 M 
1300 F 
1300 M (decreased leukocyte 
and neutrophil counts) 




Bd Wt 650 1300 (57% decreased body 







































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
LOAEL 
Less Serious Serious 
(mg/kg/day) (mg/kg/day) 
a 







































1 x (d 7) 
(GW) 
22 M (increase in 
dihydroxyphenylacetic 
acid and uric acid in 
striatum) 
8.8 M (decrased concentrations 
of dopamine in 
brainstem; glutathione 
depletion potentiated Mn 
effects on dopamine as 
well as concentrations of 
DOPAC and HVA) 
Reference 
Chemical Form Comments 
NTP 1993 
MnSO4 
Desole et al. 1994 
MnCl2 










































Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Rat 14 d 1300 NTP 1993 
(F344/N) (F) MnSO4 
Rat 1 d 13.9 (decreased acquisition of Shukakidze et al. 2003 






4.4 M (increased novelty 
seeking behavior in open 
field) 
Moreno et al. 2009 
(MnCl2*4H2O) 
No difference in the 
total number of 
movements, total 
distance traveled, or in 







4.4 13.1 (increased dopamine, 
decreased dopamine 
metabolite DOPAC, and 
increased serotonin 
metabolite 5HIAA in 
striatum) 






































































































Hemato 180 M Carter et al. 1980 
Mn3O4 
Rat 1 x/d Bd Wt 6 M (rats gained only 44% of Exon and Koller 197528 d(Wistar) amount gained by control Mn3O4(F) rats with normal food 
consumption) 
22 Rat Gd 1 - pnd 24 Bd Wt 910 F (30% decrease in Molina et al. 2011 Effect dose is an 
(Sprague-
Dawley) 











































Key to Species Frequency 






























Chemical Form Comments 
40 F (reduced lung weight) NTP 1993 
MnSO4 
33 M (increased neutrophil 
count) 
155 F (decreased leukocyte 
count) 
33 M (decreased liver weight) 
618 F (decreased liver weight) 




































Key to Species Frequency NOAEL Less Serious Serious Reference 






Renal 87 M (increased incidence of 
glomerulosclerosis/ 
glomerulonephritis or 
urolithiasis [i.e., bile 
stone formation] in 
males) 
Ponnapakkam et al. 2003b 
MnOAc 
Rats sacrificed 
immediately after last 
day of dosing. No 
urolithiasis observed in 







Endocr 33 F Szakmary et al. 1995 
MnCl2 
No effect on secretion 
or peripheral blood 
levels of progesterone 
or 17b-estradiol. 


























Elbetieha et al. 2001 
MnCl2 
Gray and Laskey 1980 
Mn3O4 
No clinical signs or 
changes in body, 
kidney or liver weights. 





























Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 

























Chemical Form Comments 
100 d 
(F) 
Hemato 284 M (decreased red blood cell 
count and white blood 
cell count) 
Komura and Sakamoto 1991 
MnOAc 








Hemato 284 M (decreased white blood 
cell count) 




Hemato 284 M (decreased red blood cell 
count and white blood 
cell count) 
Komura and Sakamoto 1991 
MnCl2 






































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a













































Chemical Form Comments 
NTP 1993 
MnSO4 
1950 M (mild hyperplasia and 
hyperkeratosis of the 
forestomach) 
1950 (decreased hematocrit, 
hemoglobin, and 
erythrocyte count) 
1950 M (reduced liver weight) 
1950 M (13% lower body weight 
compared to controls) 
4.4 M (patchy necrosis, 
decreased ATPase, 
GTPase in stomach and 
small intestine) 


























































155 F (decreased leukocyte 
count) 
Neurological 








4 mo during 
infancy 
(F) 
107.5 M (minimally adverse 
behavioral effects in soy 
and soy+Mn groups: 
decreased activity during 
sleep at 4 months and 
decreased play activity 
between 1-1.5 months) 






240 (delayed air righting 
reflex in F1 pups) 
Ali et al. 1983a 
MnCl2 
Comments 








No marked differences 
from controls in gross 
motor maturation, 
growth, or cognitive 
tests. No effect of Mn 
on CSF DA, HVA or 
5-HIAA. 
No significant 
alterations in the age of 



































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 




























71.1 (decreased Fe levels in 
caudate putamen and 
substantia nigra; 
decreased GABA uptake 
activity in striatal 
synaptosomes) 





68.3 M (decreased 
norepinephrine and iron 
levels, decreased 
norepinephrine uptake, 
and decreased protein 
and mRNA levels of 
norepinephrine and 
alpha-2 adrenergic 
receptors in brain) 














760 1730 (increased oxidative 
stress in striatum) 
Avila et al 2008 
(MnCl2) 
Comments 
Calcium influx in 
striatal slices was also 
decreased at the 
LOAEL. There were no 
differences in rearing 
frequency. 
No evidence of 
increased oxidative 


































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 















Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
2 mo 
(W) 
594 M (increased gamma-





392.5 M (increased L-tyrosine 








13 M (decreased 
norepinephrine levels) 




11 22 (increased spontaneous 
motor activity) 






























Key to Species Frequency NOAEL Less Serious Serious Reference 





1310 M (significantly increased 
open field activity, 
significantly elevated, 
continued interest in a 
novel object and 
increased fear; enhanced 
dopaminergic inhibitory 
control of corticostriatal 
excitatory transmission) 
Calabresi et al. 2001 
MnCl2 
No effects on radial 
maze performance, 
neuronal numbers in 
striatum, levels of 
GFAP and TH in 
striatum, or membrane 






1310 M (increased frequency and 
amplitude of 
spontaneous excitatory 
membrane potentials in 
corticostriatal slices from 
Mn-treated rats 
compared with control 
rats) 






146.7 M (increased activity and 
aggression, turnover of 
striatal dopamine, 






















































Chandra and Shukla 1978 
MnCl2*4H2O 
0.31 M (increased monoamine 
oxidase activity in the 
brain, neuronal 
degeneration in cerebral 
and cerebellar cortex and 
caudate nucleus) 
No evidence of 
behavioral changes or 
locomotor 
disturbances; exposure 






Chandra and Shukla 1981 
MnCl2 
40 M (increase of dopamine, 
norepinephrine, and 
homovanillic acid above 
control levels in striatum 
observed at 15-60 days 
of treatment, followed by 
a decrease of all three 
compounds below control 






1 M Deskin et al. 1980 
MnCl2 
10 M (decreased dopamine 
levels in the 
hypothalamus, significant 
decrease in hypothalamic 
tyrosine hydroxylase 
activity, significant 






































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 














Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/kg) (mg/kg) (mg/kg) Chemical Form Comments 
pnd 0-24 
(GW) 










11 (significant increase in 
pulse elicited startle 
reflex at pnd 21) 




390 M (increased dopamine and 
dopamine metabolite 
levels) 
Eriksson et al. 1987a 
MnCl2 
Gd 7- pnd 21 
(F) 
8 (hematological changes 
indicative of Fe 
deficiency in dams and 
pups; increased levels of 
the inhibitory 
neurotransmitter, GABA, 
in pup brains) 





25 M (increased GFAP protein 
levels in weanling and 
adult brains) 


































Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
58 	 Rat 
(Sprague-
Dawley) 
59 	 Rat 
(Sprague-
Dawley) 
60 	 Rat 
(Sprague-
Dawley) 

















50 M (increased dopamine D2 
receptor in adult 
prefrontal cortex) 
25 M (increased stereotypic 
behavior during radial 
arm test) 
50 M (increased open field 
activity, impaired spatial 
learning during radial arm 
maze, increased protein 
expressoin of D1 and D2 
dopamine receptors and 
dopamine transporter in 
multiple brain regions) 
Kern and Smith 2011 
(MnCl2*4H2O) 
Kern et al. 2010 
(MnCl2) 
Kern et al. 2010 
(MnCl2*4H2O) 
Kontur and Fechter 1985 
MnCl2 
No alteration in open 
field behavior in 
preweaning exposed 
adults. 
No differences milk 
intake, body weight 
gain, hematocrit, or 
behavior during 
elevated plus maze. 
No effect on dopamine 
or norepinephrine 
turnover in the 
forebrain or hiindbrain 



































Key to Species Frequency NOAEL Less Serious Serious Reference 





13.8 Kontur and Fechter 1988 
MnCl2 
No effect on 
monoamine levels or 
their metabolites in the 
striatum, hypothalamus 
or nucleus accumbens. 
63 Rat 44 d 
(GW) 







2.2 M (redistribution of iron in 
body fluids associated 
with upregulation of 
transferritin receptor 
mRNA and 
downregulation of ferritin 
mRNA from the choroid 
plexus and striatum) 
Li et al. 2006 
MnCl2 
Observed effects likely 







10 M 20 M (significant [p < 0.05] 
body weight decrease 
[~9%] and significant [p < 
0.05] increase in 
aspartate, glutamate, 
glutamine, taurine and 
GABA in the cerebellum 
[~20-50%, depending 
upon the amino acid] of 
adult rats) 



































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 













Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
4 wk 
(W) 
15.1 M 26.7 M (increases in striatal Mn 




increased with or without 
Montes et al. 2001 
MnCl2*4H2O 
No effect on bilirubins, 
alanine 
aminotransferase or 
collagen at either dose 





611 M (33% reduction in 
immunoreactive cells 
Morello et al. 2007 
MnCl2*4H2O 
with glutamine 








Gd 1- pnd 30 
(W) 
120 M (significant decrease in 
cortical thickness; with 
Pappas et al. 1997 
MnCl2 




locomotor activity and 
increased rearing in an 



















Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral		 (continued) 
Exposure/ LOAEL 
Duration/ 
a Frequency Key to Species NOAEL Less Serious Serious Reference (Route) Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
70		 Rat 50 d 74.9 M (increased serum levels Ranasinghe et al. 2000 
(Sprague- (NS) of dopamine sulfate, MnSO4 Dawley) L-Dopa, and L-p-tyrosine 




71		 Rat 21 d No change in negative 4.4 M 13.1 M (subtle behavioral effects Reichel et al. 2006 
(Sprague- (NS) 4.4 geotaxis performance; [altered balance in the MnCl2 Dawley) no change in motor neonatal period and 
activity, coordination, or diminished locomotor 
olfactory orientation response to cocaine in 
tasks. adulthood] and 
neurochemical effects in 
adulthood [decreased 




72		 Rat 30 d 5.6 (severely impaired Shukakidze et al. 2003 




73		 Rat 13 wk 3311 M (impaired ability of globus Spadoni et al. 2000 No neuronal loss or 
(Wistar) (W) gliosis (GFAP pallidus neurons to (NS) accumulation) was survive mechanical 
evident in globus dissociation) 
pallidus by either 




































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 















Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form 
90 d 
(W) 
11.8 M (altered brain regional 
dopamine and serotonin 
levels and monoamine 






76 M 153 M (significantly decreased 
open field activity among 
restrained rats, impaired 
spatial learning with or 
without restraint in a 





3.8 7.5 (decreased performance 
in the olfactory 
discrimination [homing 
test] and passive 
avoidance task; striatal 
Tran et al. 2002a 
MnCl2 
dopamine concentrations 
were about 50% lower 
than control values) 
20 d 
(GO) 
7.5 M Tran et al. 2002b 
MnCl2 
Comments 
All MnCl2*4H2O rats 
received 38 mg 
Mn/kg/d for the first 2 
weeks. Other groups 
at these doses were 
restrained 2 hours/day. 
No significant (p <0.05) 
exposure-related 
effects on righting test 
conducted on pnd 6. 
No significant effects in 
either burrowing detour 
task (pnd 50-56) or 





























Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 


























6.5 M (significant decreases in 
spatial memory 
performance, open field 
locomotor activity and 
acoustic startle 
responses; increased 
latency of sensory 
evoked potentials) 




13.8 Weber et al. 2002 
MnCl2*4H2O 
6 mo 2250.7 M (decreased dopamine Gianutsos and Murray 1982
(F) levels) MnCl2 
90 d 205 M (decreased locomotor Gray and Laskey 1980
(F) activity) Mn3O4 
Comments 
Impairment of spatial 
memory performance 
and acoustic startle 
response persisted 
through 5-7 weeks 
without exposure. 
No obvious effect of 
oral exposure during 
pnd 1-21 on 
biochemical measures 































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral 	 (continued) 
a 
Key to Species 
Figure (Strain) 
82 	 Mouse 
(ddY) 
83 	 Mouse 
(C57BL/6N) 
84 	 Mouse 
(C57BL/6N) 




Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
100 d 
(F) 
284 M (decreased motor 
activity) 
Komura and Sakamoto 1991 





43.7 F (increased locomotor 
activity in Mn-treated 
mice; increased Mn 
Liu et al. 2006 
MnCl2 





expressing nitric oxide 
synthase, choline 
acetyltransferase and 
enkephalin in striatum 
and globus pallidus; 
increased astrocytes 
expressing evidence of 
nitric oxide formation) 
8 wks Moreno et al. 2009 No alteration in levels4.4 13.1 (decreased dopamine1 x/d of serotonin or itsand dopamine metabolite (MnCl2*4H2O)(G) 	 metabolite 5-HIAA. NoDOPAC levels in 
differences in openstriatum) 
field behavior. 






































































Kontur and Fechter 1985 
MnCl2 









55 M (significantly decreased 
testicular weight with 
low-Fe diet) 
180 F (significantly decreased 
[~25%] pregnancy rate) 
No effect on litter size, 
ovulations, resorptions, 
preimplantation deaths 
or mean fetal weights. 
No effect on 





Gd 1- pnd 30 
(W) 
Pappas et al. 1997 
MnCl2 
620 F Mn exposure of 
pregnant dams did not 
affect litter sizes or sex 







Ponnapakkam et al. 2003c 
MnOAc*4H20 
68.6 M 137.2 M (increased incidences of 







Szakmary et al. 1995 
MnCl2 
22 F (increase in relative 
weight of liver, thymus, 
and brain) 


































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 






















Elbetieha et al. 2001 
MnCl2 
Elbetieha et al. 2001 
MnCl2 




Ponnapakkam et al. 2003a 
MnOAc 
Ponnapakkam et al. 2003a 
MnOAc 
Comments 
No effects on fertility at 
9.6 mg/kg/day when 
treated males were 
mated with unexposed 
females. 
Fertility endpoints were 
not affected at 9.6 mg 
Mn/kg/day. Fertility 
was not affected when 















44 F (increased uterine 




205 M (delayed growth of testes 








2.4 M 4.8 M (decreased sperm 








309 M (statistically significantly 
impaired male fertility) 
277 F (implantation number 
reduced by 17% and the 
number of viable fetuses 





































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 
















Frequency NOAEL Less Serious Serious Reference 
(Route) 











33 F Szakmary et al. 1995 
MnCl2 
107.5 M (minimally adverse 
effects in soy and 
soy+Mn groups: 
decreased activity during 
sleep at 4 months and 
decreased play activity 
between 1-1.5 months) 
Golub et al. 2005 
MnCl2 
240 (delayed air righting 
reflex in F1 pups) 
Ali et al. 1983a 
MnCl2 
11 22 (~20% decrease in body 
weight at pnd 49) 
Brenneman et al. 1999 
MnCl2 
11 22 (increased spontaneous 
motor activity) 
Brenneman et al. 1999 
MnCl2 
Comments 
No marked differences 
from controls in gross 
motor maturation, 
growth, or cognitive 
tests. No effect of Mn 
on CSF DA, HVA or 
5-HIAA. 
No significant 
alterations in the age of 



































Key to Species Frequency NOAEL Less Serious Serious Reference 





1 M 10 M (decreased dopamine 
levels in the 
hypothalamus, significant 
decrease in hypothalamic 
tyrosine hydroxylase 
activity, significant 
increase in hypothalamic 
monoamine oxidase 
activity) 











Deskin et al. 1981 
MnCl2 
105 Rat 21 d 
1 x/d 
(GW) 
11 (significant increase in 
pulse elicited startle 
reflex at pnd 21) 





Gd 7- pnd 21 
(F) 
8 (hematological changes 
indicative of Fe 
deficiency in dams and 
pups; increased levels of 
the inhibitory 
neurotrnasmitter, GABA, 
Garcia et al. 2006 
NS 



















Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a Frequency Key to Species NOAEL Less Serious Serious Reference (Route) Figure (Strain) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
107 Rat pnd 1-21 25 M (increased GFAP protein Kern and Smith 2011 
(Sprague- 1 x/d levels in weanling and (MnCl2) Dawley) (G) adult brains) 
25
1150
108 Rat pnd 1-21 Kern and Smith 2011 No alteration in open 25 M 50 M (increased dopamine D2 




109 Rat 14-21 d 13.8 Kontur and Fechter 1988 No effect on 
(Long- Evans) (GO) 13.8 monoamine levels or MnCl2 their metabolites in the 
striatum, hypothalamus 
or nucleus accumbens. 
1187
110 Rat 44 d 150 (ataxia) Kristensson et al. 1986 
(GW) 150
430 MnCl2 
111 Rat 15-20 days 4.4 (gliosis) Lazrishvili et al 2009 No change in the 
































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 













Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Gd 1 - pnd 24 
(W) 
910 (decreased anxiety 
behavior on elevated 
plus apparatus; altered 
iron pharmacokinetics -
decreased tissue uptake 
of iron, increased levels 
of zinc protoporphyrin 
levels) 
Molina et al. 2011 
(MnCl2*4H2O) 
Effect dose is an 
average of reported 





Gd 1 - pnd 24 
(W) 
910 (decreased tissue uptake 
of iron, increased levels 
of zinc protoporphyrin 
levels) 
Molina et al. 2011 
(MnCl2*4H2O) 
No change in intestinal 
absorption of iron, 




non-heme iron levels) 
Gd 1- pnd 30 
(W) 
120 M 620 M (transient decrease 
(~20%) in pup body 
weight on pnd 9-24; 
difference not apparent 
on pnd 90) 
Pappas et al. 1997 
MnCl2 
No maternal toxicity 
from Mn; brain Mn not 
significantly elevated at 
120 mg/kg/day; no 
effects on brain levels 































Key to Species Frequency NOAEL Less Serious Serious Reference 






4.4 M 13.1 M (subtle behavioral effects 
[altered balance in the 
neonatal period and 
diminished locomotor 
response to cocaine in 
adulthood] and 
neurochemical effects in 
adulthood [decreased 
dopamine binding sites in 
the striatum]) 
Reichel et al. 2006 
MnCl2 
No change in negative 
geotaxis performance; 
no change in motor 








33 (increased retardation in 
skeletal/organ 
development) 







3.8 7.5 (decreased performance 
in the olfactory 
discrimination [homing 
test] and passive 
avoidance task; striatal 
dopamine concentrations 
were about 50% lower 
than control values) 














































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
Exposure/ LOAEL 
Duration/ 
a FrequencyKey to Species 	 NOAEL Less Serious(Route)Figure (Strain) System (mg/kg/day) (mg/kg/day) 
118 Rat 20 d 7.5 M
(Sprague- (GO)
Dawley)
119 Rat 21 d 13.8
(CD) (IN) 





121 Human </= 1 yr 
(W) 




0.26 (increased fatality among 
children <1 year of age) 
200 M (14% survival compared 
to 49% in controls) 
Reference 
Chemical Form 
Tran et al. 2002b 
MnCl2 
Weber et al. 2002 
MnCl2*4H2O 
Szakmary et al. 1995 
MnCl2 






significant (p < 0.05) 
effects in either 
burrowing detour task 
pnd 50-56) or passive 
avoidance task (pnd 
60-69). 
No obvious effect of 
oral exposure during 
pnd 1-21 on 
biochemical measures 




No effect on fetal body 
weights or skeletal 
































Key to Species Frequency NOAEL Less Serious Serious Reference 










Cardio 65 M 
Gastro 200 M 
232 F 
Hemato 65 M 
Renal 200 M (increased severity of 
chronic progressive 
nephropathy) 
































































Resp 585 M 
731 F 
Cardio 585 M 
731 F 
Gastro 177 M 
226 F 
585 M (hyperplasia, erosion) 
Hemato 177 M 
731 F 
585 M (increased hematocrit, 
hemoglobin, and 
erythrocyte counts) 
Musc/skel 585 M 
731 F 
Hepatic 585 M 
731 F 
Renal 585 M 
731 F 
Endocr 585 M (thyroid follicular 
hyperplasia and 
dilatation) 
64 F (thyroid follicular 
hyperplasia) 
Dermal 584 M 
732 F 
Bd Wt 584 M 
223 F 





Chemical Form Comments 
NTP 1993 
MnSO4 
732 F (ulceration and 
inflammation of the 

































































0.104 F (pica, emotional lability, 
personality changes, 
speech impairments, loss 
of balance and 
coordination, inability to 
walk) 
128 Human 50 yr 
(W) 
0.0048 0.059 (mild neurological signs) 




0.103 F (pica, emotional lability, 
personality changes, 
speech impairments, loss 
of balance and 
coordination, inability to 
walk) 
Reference 





Brna et al 2011 
NS 
Kondakis et al. 1989 
NS 




































Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
130 Human 10 yr or more 0.009 Vieregge et al. 1995
(W) NS 
131 Human 10 yr 0.04 0.07 (significantly reduced Wasserman et al. 2006 No statistically 
(W) significant effects onperformance on NS Full-Scale IQ testing,Full-Scale IQ test, 
performance or verbalperformance and verbal 
tests.tests in children) 
132 Human 8 yr or more 
(W) 
0.015 0.081 (significantly reduced 
performance on 
perceptual reasoning and 
working memory 
subscales in children) 
Wasserman et al. 2011 
(NS) 
133 Human 5 yr 
(W) 
0.06 M (Mn possibly producing 
deficit in free retrieval 
skills, affecting general, 
verbal and visual 
memory and learning 
skills; inattentiveness; 
lack of focus in 
classroom) 






6.9 M (weakness, rigidity, 
neuronal loss and 
depigmentation of the 
substantia niagra) 
































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral 	 (continued) 
a 
Key to Species 
Figure (Strain) 
135 	 Rat 
(Wistar) 
136 	 Rat 
(Sprague-
Dawley) 
137 	 Mouse 
(ddY) 
138 	 Mouse 
(ddY) 
139 	 Mouse 
(ddY) 















Chemical Form Comments 
2 yr 
(W) 
40 (altered neurotransmitter 
uptake) 












275 M (decreased locomotor 
activity) 




275 M (decreased locomotor 
activity) 




275 M (decreased dopamine 
and increased 











































Table 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (continued) 
a 















Frequency NOAEL Less Serious Serious Reference 
(Route) 
System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
12 mo 
(F) 
275 M (decreased locomotor 
activity) 




45 M (significant [p < 0.05] 
decreases in dopamine 
and homovanillic acid 
Komura and Sakamoto 1994 
MnCl2 












































Key to Species Frequency NOAEL Less Serious Serious Reference 
Figure (Strain) (Route) System (mg/kg/day) (mg/kg/day) (mg/kg/day) Chemical Form Comments 
Developmental 
146 Rat 1 gen 420 M (altered neurotransmitter Ali et al. 1985 










a The number corresponds to entries in Figure 3-2. 
ATPase = adenosine triphosphatase; Bd Wt = body weight; Cardio = cardiovascular; CSF = cerebrospinal fluid; d = day(s); DA = dopamine; DOPAC =  dihydroxyphenylacetic acid; 
Endocr = endocrine; F = Female; (F) = feed; (G) = gavage; GABA = gamma-aminobutyric acid; Gastro = gastrointestinal; Gd = gestational day; GFAP = glial fibrillary acidic protein; 
Gn pig = guinea pig; (GO) = gavage in oil; (GW) = gavage in water; GTPase = glucose-6-phosphatase; Hemato = hematological; 5-HIAA = 5-hydroxy-indoleacetic acid; HVA = 
homovanillic acid; Immuno/Lymphoret = immunological/lymphoreticular; (IN) = ingestion; LD50 = lethal dose, 50% kill; LH = luteinizing hormone; LOAEL = 
lowest-observed-adverse-effect level; M = male; Metab = metabolic; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; NS = not specified; 


































































Figure 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral 




8m 8m 8m 8m 8m 8m 
8m 8m 8m 8m 8m 8m 
15r 17r 
7r 7r 7r 7r 7r 7r 7r 7r 7r 11r 16r 
6r1000 
5r











LD50/LC50c-Cat -Human f-Ferret n-Mink Cancer Effect Level-Humans  Minimal Risk Level 
d-Dog k-Monkey j-Pigeon o-Other  Cancer Effect Level-Animals  LOAEL, More Serious-Humans  for effects 
r-Rat m-Mouse e-Gerbil LOAEL, More Serious-Animals  LOAEL, Less Serious-Humans  other than 
p-Pig h-Rabbit s-Hamster LOAEL, Less Serious-Animals  NOAEL - Humans  Cancer 





























































33m 33m 33m 33m 33m 33m 33m 33m 33m 33m 33m19r 19r 
1000 33m 33m 33m 33m 22r
19r 
23r 23r 23r 23r 23r23r 23r 23r 23r 
29m 30m 31m 32m 29m 32m27m
18r 28m 28m20r 23r 23r 
100 24r 23r 
23r 







LD50/LC50c-Cat -Human f-Ferret n-Mink Cancer Effect Level-Humans  Minimal Risk Level
 Cancer Effect Level-Animalsd-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-Humans  for effects
 LOAEL, More Serious-Animalsr-Rat m-Mouse e-Gerbil LOAEL, Less Serious-Humans  other than
 LOAEL, Less Serious-Animalsp-Pig h-Rabbit s-Hamster NOAEL - Humans  Cancer 





Figure 3-2 Levels of Significant Exposure to Inorganic Manganese - Oral (Continued)












































80m 86m 42r 
47r 48r 61r 
1000 
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57r 66r58r 59r 60r46r 53r 65r 
53r 66r62r 79r 
25r 84m 71r45r 74r46r 54r10 52r 65r 
56r 76r 77r 78r72r 





















o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans























































































o-Other   Cancer Effect Level-Animals
  LOAEL, More Serious-Animals
  LOAEL, Less Serious-Animals
  NOAEL - Animals
  Cancer Effect Level-Humans
  LOAEL, More Serious-Humans
  LOAEL, Less Serious-Humans
  NOAEL - Humans
  Minimal Risk Level
   for effects
   other than
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o-Other  Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
 LOAEL, More Serious-Humans
LOAEL, Less Serious-Humans
NOAEL - Humans

















































138m 139m 140m 141m 144r144r 
100 












c-Cat -Human f-Ferret n-Mink Cancer Effect Level-Humans  Minimal Risk LevelLD50/LC50
d-Dog k-Monkey j-Pigeon o-Other  Cancer Effect Level-Animals  LOAEL, More Serious-Humans  for effects 
r-Rat m-Mouse e-Gerbil LOAEL, More Serious-Animals  LOAEL, Less Serious-Humans  other than 
p-Pig h-Rabbit s-Hamster LOAEL, Less Serious-Animals  NOAEL - Humans  Cancer 





























































12.5 M (increase in mortality, 
LD50=50 mg MMT/kg or 
13 mg Mn/kg) 





















58 F (LD50) 
30 M (distended lungs with 
bloody fluid, hemorrhage, 
perivascular and alveolar 
edema) 
Hinderer 1979 





Resp 7.6 11.3 (severe fibrinopurulent 
pneumonia with 
prominent macrophage 
infiltrate of lungs) 
Hysell et al. 1974 All rats from 3.8 and 
7.6 mg Mn/kg bw/d 
groups survived and 
appeared normal 14 
days post-exposure. 
Hepatic 7.6 11.3 (hepatic parenchymal 






























Key to Species Frequency (Route)Figure (Strain) 
CHRONIC EXPOSURE 
Systemic 








Less Serious Serious 
(mg/kg) (mg/kg) 
11 M (>10% decrease in body 
weight in exposed group) 
Reference 
Chemical Form 








11 M (increase in spontaneous 
motor activity on day 80) 





11 M (changes in brain 
neurochemistry) 
Komura and Sakamoto 1994 
a The number corresponds to entries in Figure 3-3. 
Bd Wt = body weight; d = day(s); (F) = feed; F = Female; GO) = gavage in oil; LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; mo = month(s); 

















































c-Cat -Human f-Ferret n-Mink Cancer Effect Level-HumansLD50/LC50 Minimal Risk Level 
d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-HumansCancer Effect Level-Animals  for effects 
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-HumansLOAEL, More Serious-Animals  other than 
p-Pig h-Rabbit s-Hamster NOAEL - HumansLOAEL, Less Serious-Animals  Cancer 






































7m 8m 9m 
c-Cat -Human f-Ferret n-Mink Cancer Effect Level-HumansLD50/LC50 Minimal Risk Level 
d-Dog k-Monkey j-Pigeon o-Other  LOAEL, More Serious-HumansCancer Effect Level-Animals  for effects 
r-Rat m-Mouse e-Gerbil LOAEL, Less Serious-HumansLOAEL, More Serious-Animals  other than 
p-Pig h-Rabbit s-Hamster NOAEL - HumansLOAEL, Less Serious-Animals  Cancer 




















   
 








    
    
   
 
    
              
        
             
      
  
       
  
         
   
 
 
       
    
    
 
       
   
          
    
   
     
 
    
  
  
        





1941) and 3.2.2.6 (Hafeman et al. 2007; Spangler and Spangler 2009), several aspects of these three
reports suggest that factors other than, or in addition to, high levels of manganese in drinking water may
have been responsible for the deaths.
In animals, most studies indicate that manganese compounds have low acute oral toxicity when provided 
in feed.  In rats, daily doses of 1,300 mg manganese/kg/day (as manganese sulfate in the feed) for 14 days 
did not affect survival (NTP 1993).  Survival was decreased in male rats fed 200 mg manganese/kg/day
(as manganese sulfate) for 2 years (NTP 1993). The cause of death was attributed to increased severity of
nephropathy and renal failure; however, female rats fed 232 mg manganese/kg/day (as manganese sulfate)
for 2 years were not affected in this manner (NTP 1993).  Similarly, doses as high as 2,251 mg 
manganese/kg/day (as manganese chloride) in the diet were tolerated by male mice (females were not
tested) for 6 months without lethality (Gianutsos and Murray 1982). The survival of both male and 
female mice was also unaffected by feeding as much as 731 mg manganese/kg/day (as manganese sulfate)
for 2 years (NTP 1993).  
In contrast to these studies, when exposure is by gavage (usually as highly concentrated solutions of
manganese chloride in water), measured LD50 values for 1–21 days of exposure range from 225 to 
1,082 mg manganese/kg/day in mice and rats (Holbrook et al. 1975; Kostial et al. 1978, 1989; Rehnberg
et al. 1980; Singh and Junnarkar 1991; Smyth et al. 1969).  These results suggest that gavage dosing with
a bolus of a concentrated soluble manganese compound in water may not be a good model for
determining the toxic effects of manganese ingested by humans from environmental sources.  Bolus 
dosing produced death in animals at concentrations near the daily dose levels tolerated in food or drinking
water by the same strains and species of animals subjected to longer durations of exposure.  It is possible 
that bolus dosing circumvents the homeostatic control of manganese absorption.  It should be noted that
the concentrations used in the bolus dosing studies are much higher than even excess levels to which 
certain humans are typically exposed.
In a study where young pigs were fed a diet moderately high (1.7 mg manganese/kg/day) in manganese 
but deficient in magnesium, all eight pigs consuming the high manganese diet died within 5 weeks
following convulsive seizures; only two of the pigs in a group without supplemental manganese died 
(Miller et al. 2000).  Further studies suggested that high dietary manganese could exacerbate magnesium
deficiency in heart muscle, thus creating a complicating factor in the deaths of the magnesium-deficient
pigs (Miller et al. 2000).  
   
 








          
   





        
 
 
             
          
     
           
     
    
 
 
      
     
 
             
   
 
    
 
        
        
        
       
     
              




In conclusion, route of exposure and animal species and strain differences, as well as sex, may account for
some of the observed variations in the lethality of manganese.  In addition, deficiencies in certain 
essential nutrients, such as magnesium, may increase the lethal potential of excess manganese.
No studies were located concerning death in humans following ingestion of MMT.
MMT, dissolved in oil and administered by gavage, was found to have LD50 values of 15 mg
manganese/kg in the male and female Sprague-Dawley rat and 58 mg manganese/kg in the adult female 
CD-1 mouse (Hinderer 1979).  
Hysell et al. (1974) administered via gavage increasing amounts of MMT (dissolved in oil) to adult
COBS rats, 10 animals/group.  No lethality was observed at the lowest two doses of 3.8 and 7.5 mg
manganese/kg, but 5/10 rats died within 2–6 days postdosing at a dose of 11.3 mg manganese/kg.
Increasing numbers of rats died at higher doses, with decreasing times of death post-dosing; complete
mortality occurred at the highest dose of 37.5 mg manganese/kg.  The survivors appeared normal by
14 days.  The LD50 (14-day) was estimated at 14.6 mg manganese/kg.
Hanzlik et al. (1980a) determined the 14-day LD50 for purified MMT administered in corn oil via gavage
to adult male Sprague-Dawley rats to be 12.5 mg manganese/kg (95% confidence interval, 9.5–16.8 mg
manganese/kg).  The animals survived similar times post-dosing as those in the Hysell et al. (1974) study. 
All LD50 values from each reliable study for death in each species and duration category are recorded in
Table 3-3 and plotted in Figure 3-3.
3.2.2.2 Systemic Effects
In general, there is a lack of data concerning systemic toxic effects in humans who have ingested
manganese. This is likely due to the strong homeostatic control the body exerts on the amount of
manganese absorbed following oral exposure; this control protects the body from the toxic effects of
excess manganese.  Studies in humans and animals provide limited data regarding the effects of
manganese ingestion on systemic target tissues. This information is discussed below and is organized by
target tissue. Table 3-3 and Figure 3-3 present the highest NOAEL and all LOAEL values from each
reliable study for these effects for each species and each duration category.
   
 








            
  
 
          
         
          
         
          
        
      
 
        
  
          
      
     
  
  
       
 
              
       
     
 
            
     
 
  
        
            
      




Respiratory Effects. No studies were located regarding respiratory effects in humans after oral
exposure to inorganic manganese.
No respiratory effects were reported in mice fed up to 3,900 mg manganese/kg/day (as manganese 
sulfate) or rats fed 1,300 mg manganese/kg/day (as manganese sulfate) for 14 days (NTP 1993).  Male
rats fed manganese sulfate for 13 weeks showed no respiratory effects at 520 mg manganese/kg/day;
however, females exhibited decreased lung weight at 40–618 mg manganese/kg/day (NTP 1993).  No 
respiratory effects were noted in mice of either sex fed 122–1,950 mg manganese/kg/day (as manganese 
sulfate) for 13 weeks (NTP 1993), in rats fed up to 232 mg manganese/kg/day (as manganese sulfate), or
in mice fed up to 731 mg manganese/kg/day (as manganese sulfate) for 2 years (NTP 1993).  
The lungs of adult male Sprague-Dawley rats administered one dose of MMT via gavage in corn oil
(31.25 mg manganese/kg) showed signs of hemorrhage and alveolar and perivascular edema, with an 
accumulation of proteinaceous material in the alveoli. As early as 12 hours following gavage 
administration of this same dose, the lung/body weight ratio increased to 2.5 times the control value
(Hanzlik et al. 1980).  Hinderer (1979) observed dark red lungs in Sprague-Dawley rats and CD-1 mice 
administered sublethal doses (values unspecified) of MMT in an acute toxicity study.  Gross necropsy of
the lungs of COBS rats administered one dose of MMT in Wesson oil (dose range, 20–37.5 mg 
manganese/kg) revealed severe congestion and the release of a serosanguinous fluid upon sectioning;
histopathology of lungs from rats dying within 24 hours post-exposure showed severe congestion, 
perivascular and alveolar edema, and alveolar hemorrhage (Hysell et al. 1974). Sections of lungs from
rats surviving until 14 days post-exposure revealed extensive areas of consolidation, thickened alveolar
septa and focal areas of alveolar macrophage activity.
Cardiovascular Effects. No studies were located regarding cardiovascular effects in humans after
oral exposure to inorganic manganese.
In a 1993 National Toxicology Program (NTP) study, no cardiovascular effects (pathological lesions)
were observed in mice or rats fed 3,900 or 1,300 mg manganese/kg/day, respectively, for 14 days.  No 
cardiovascular effects were observed in rats or mice exposed for 13 weeks to doses as high as 1,950 mg
manganese/kg/day (as manganese sulfate) or for 2 years to doses as high as 731 mg manganese/kg/day (as 
manganese sulfate) (NTP 1993).
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In a study of weanling male Sprague-Dawley rats provided with a diet supplemented with 55 mg
manganese/kg/day for 14 weeks, Kalea et al. (2006) found that the level of uronic acid in aortas of the 
manganese-supplemented group was significantly (p<0.05) higher than in a group of rats fed a diet with
adequate manganese (5.5 mg manganese/kg/day).  Among heparan sulfate glycosaminoglycans, aortas 
from manganese-supplemented rats contained higher concentrations of total galactosaminoglycans and 
decreased concentration of hyaluronan and heparan sulfate (50% less heparan sulfate) when compared to 
aortas from rats consuming diets with adequate manganese.  Heparan sulfate chains of aortas from
manganese-supplemented rats contained 41% higher concentration of non-sulfated units compared to 
those of rats fed the adequate manganese diet (Kalea et al. 2006). These results raise concern about the 
potential for manganese to influence vascular chemistry in deleterious ways, creating increased
vulnerability to cardiovascular events.
In the course of investigating a mechanism to explain the sudden deaths in pigs from high doses of
manganese (Miller et al. 2000), studies were conducted in which pigs were fed either low (3.4 mg/kg/day)
or adequate dietary magnesium (6.8 mg/kg/day) along with high (55 mg/kg/day) or low doses
(5.5 mg/kg/day) of manganese (Miller et al. 2004).  No differences in heart muscle ultrastructure were 
observed; however, marked myocardial necrosis and mitochrondrial swelling were observed in pigs fed 
high dietary manganese in combination with low magnesium (13.9 mg magnesium/kg/day; Miller et al. 
2004).  In pigs fed high manganese and adequate magnesium, no swelling of myocardial mitrochondria
was observed. These results suggest that high manganese, when fed in combination with low magnesium, 
disrupts mitochondrial ultrastructure (Miller et al. 2004).  In another related study, when rats were
provided with high dietary manganese (13.8 mg manganese/kg/day as manganese carbonate) for 8 weeks,
heart muscle oxygen consumption was depressed, although no effects of manganese on hematologic 
variables were observed (Miller et al. 2006).  No effects of manganese were observed on heart muscle 
activities for Ca+2 ATPase, liver glutathione peroxidase, or brain glutathione peroxidase at doses as high 
as 55 mg manganese/kg/day (Miller et al. 2006).  The depression in heart muscle oxygen consumption 
produced by high dietary manganese presents yet another possible mechanism by which high doses of
manganese can produce adverse cardiovascular events.
No studies were located regarding the cardiotoxic effects of MMT in either humans or animals following
oral exposure.
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans after
oral exposure to manganese, except for one case report of a child who accidentally ingested some 
   
 








   
          
   
 
          
        
             
   
    
         
          
            
          
     
 
 
            
          
    
             
    
 
           
      
      
     
          
        
 
             
           




potassium permanganate (Southwood et al. 1987).  This led to severe local corrosion of the mouth, 
esophagus, and stomach due to the caustic effects of potassium permanganate on the tissue, but there was
no evidence of systemic toxicity.
Adverse gastrointestinal effects have been reported in guinea pigs and mice but not in rats.  Guinea pigs 
administered 4.4 mg manganese/kg/day (as manganese chloride by gavage) did not suffer any gross 
abnormalities in either the stomach or small or large intestines as a result of treatment but did have patchy
necrosis and decreased adenosine triphosphatase and glucose 6-phosphatase levels in both the stomach 
and small intestine (Chandra and Imam 1973).  This study differs from the others in its delivery of
manganese (by gavage); the gavage treatment may have partially or completely contributed to the adverse 
effects seen in the stomach and small intestine of the guinea pigs.  No gastrointestinal effects were 
observed in female mice fed 1,950 mg manganese/kg/day (as manganese sulfate in food) or rats fed up to
618 mg manganese/kg/day (as manganese sulfate in food) for 13 weeks, but male mice exhibited mild
hyperplasia and hyperkeratosis of the forestomach at 1,950 mg manganese/kg/day, also in food (NTP
1993).
In a 1993 NTP study, rats fed as much as 232 mg manganese/kg/day (as manganese sulfate) for 2 years 
showed no gastrointestinal effects; however, mice treated with manganese sulfate for 2 years exhibited
hyperplasia, erosion, and inflammation of the forestomach at 585 mg manganese/kg/day for males and
731 mg manganese/kg/day for females. The acanthosis was judged by the authors to be a result of direct
irritation of the gastrointestinal epithelium and to be of minor consequence.  
No studies were located concerning gastrointestinal effects following oral exposure to MMT in humans.
Hinderer (1979) observed discolored intestinal tracts in Sprague-Dawley rats and fluid-filled intestines
and spotting of the intestine in CD-1 mice dosed by gavage with high concentrations (values not
provided) of MMT in a 14-day toxicity study.  Hysell et al. (1974) observed that single lethal doses of
20–37.5 mg manganese/kg (as MMT, given by gavage) produced small intestines that were distended 
with clear watery contents and thin, friable walls.
Hematological Effects. In a dietary study with female subjects (Davis and Greger 1992), no changes 
in hematocrit, serum transferrin, or serum ferritin were reported following supplementation with
0.25 mg manganese/kg/day for 119 days.  Vieregge et al. (1995) found no effects on hemoglobin, 
ceruloplasmin, or copper and iron levels in serum for a population of 40-year-old people who had 
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ingested at least 0.3 mg manganese/L in drinking water for a minimum of 10 years. These data indicate 
that exposure to increased manganese in water did not result in observable hematological toxicity.
Alterations in hematological parameters have been reported in rats and mice, although they were found to 
vary depending on species, duration, and the form of manganese administered.  No conclusive evidence
regarding a significant functional deficit has been reported.  In mice fed 284 mg manganese/kg/day for
100 days, red blood cell count was decreased by manganese acetate and manganese chloride; white blood
cell count was decreased by manganese acetate, manganese chloride, and manganese dioxide; and
hematocrit was decreased by manganese carbonate (Komura and Sakamoto 1991). However, manganese
carbonate had no effect on red blood cells or white blood cells, manganese dioxide had no effect on red 
blood cells or total hematocrit, and manganese acetate and manganese chloride had no effect on total
hematocrit.  It has been suggested that the manganese-related effects on red blood cells may be related to
the displacement of iron by manganese. The significance of the other hematological effects was not
noted. In a study in rats and mice dosed with manganese sulfate for 14 days, 13 weeks, or 2 years, minor
changes in hematology parameters were reported; these changes varied depending on species, dose, and
duration, and the study authors did not consider them to be clearly related to compound administration 
(NTP 1993).  No significant hematological effects were observed in mice exposed to 180 mg
manganese/kg/day (as manganese tetroxide) for 224 days (Carter et al. 1980).  In a study where male
Sprague-Dawley rats were fed 55 mg manganese/kg/day as manganese carbonate for 8 weeks,
significantly decreased hematocrit and hemoglobin levels were observed (Miller et al. 2006).  However, 
an even lower level of dietary manganese carbonate (35.8 mg manganese/kg/day) fed to male Sprague-
Dawley rats in a diet containing a relatively low concentration of magnesium (200 mg magnesium/kg
feed/day) for 4 weeks also produced significantly decreased hematocrit and hemoglobin levels (Miller et
al. 2006).  Thus, the potential for dietary manganese to produce adverse effects on red blood cells may be
further modulated by the relative availability of magnesium in the diet.
No studies were located concerning hematological effects following oral exposure to MMT in humans or
animals.
Musculoskeletal Effects. No studies were located regarding musculoskeletal effects in humans after
oral exposure to inorganic manganese.
In young rats, high concentrations of manganese chloride in the diet (218–437 mg manganese/kg/day) led
to rickets (Svensson et al. 1985, 1987); however, this was found to be due to a phosphate deficiency
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stemming from precipitation of manganese phosphate salt (MnHPO4) in the intestine rather than to a
direct biological effect of manganese on bone formation.  No significant musculoskeletal effects were
observed in mice or rats fed up to 731 mg manganese/kg/day for 2 years (NTP 1993).
No studies were located concerning musculoskeletal effects following oral exposure to MMT in humans
or animals.
Hepatic Effects.  A single study of human oral exposure of manganese investigated potential
hepatotoxicity by analyzing liver enzymes in serum.  Vieregge et al. (1995) reported no effects on 
bilirubin, alkaline phosphatase, glutamic pyruvic transaminase, glutamic oxalacetic transaminase, or
gamma glutamyl transferase in humans, ≥40 years old, who had ingested well water containing
≥0.30 mg/L for at least 10 years. These limited data indicate that chronic exposure to elevated levels of
manganese did not result in observable liver toxicity in this population.
In animals, a variety of histological changes in subcellular organelles (e.g., rough and smooth 
endoplasmic reticulum, Golgi apparatus) were observed in the livers of rats exposed to 12 mg
manganese/kg/day for 10 weeks (as manganese chloride) (Wassermann and Wassermann 1977).
However, these changes were not considered to be adverse but to be adaptive, possibly in response to
increased manganese excretion in the bile (see Section 3.4.4).  Reductions in liver weight have also been 
reported in male Fischer 344 rats fed 1,300 mg manganese/kg/day (as manganese sulfate) for 14 days.  
However, these effects were not seen in B6C3F1 mice fed dosages up to 3,900 mg manganese/kg/day (as 
manganese sulfate) for 14 days (NTP 1993).  Similarly, no treatment-related evidence of liver damage 
based upon organ weight, histology, or liver function tests were found in male Wistar rats dosed with 
271 mg manganese/kg/day (as manganese chloride) in drinking water for 2 or 4 weeks (Rivera-Mancía et
al. 2009).  In rats fed up to 618 mg manganese/kg/day (as manganese sulfate) for 13 weeks, decreased
liver weights were reported in males at ≥33 mg manganese/kg/day and females at 618 mg
manganese/kg/day (NTP 1993).  When mice were fed 122–1,950 mg manganese/kg/day (as manganese 
sulfate) for 13 weeks, the females showed no hepatic effects; however, the males exhibited both relative
and absolute reduced liver weights at 1,950 mg manganese/kg/day (NTP 1993).  In CD-1 mice, no hepatic
changes were seen in males fed 205 mg manganese/kg/day (as manganese tetroxide) (Gray and Laskey
1980).  No significant hepatic histological changes were observed in either mice or rats exposed for
2 years, with rats fed up to 232 mg manganese/kg/day (as manganese sulfate), and mice fed up to 731 mg
manganese/kg/day (as manganese sulfate) (NTP 1993).  Additionally, Avila et al. (2008) reported no 
evidence of increased oxidative stress in the liver in Wistar rats, as measured by thiobarbituric acid
   
 








    
    
 
    
 
         
           
        
   
        
         
        
       
           
       
      
 
             
    
 
   
   
         
      
         
    
           
    
           




reactive substance (TBARS) production, δ-aminolevulinate-dehydratase (δ-ALA-D) activity, and protein
carbonylation, at doses up to 1,730 mg manganese/kg/day (as manganese chloride in drinking water) for
30 days. 
There are no studies concerning hepatic effects following oral exposure to MMT in humans. 
Hinderer (1979) observed mottling of the liver in CD-1 mice administered high doses (unspecified) of
MMT via gavage in a 14-day acute toxicity study.  Histological evaluation of livers of adult male
Sprague-Dawley rats administered 31.3 mg manganese/kg/day (as MMT) revealed scattered hepatocytes 
throughout the lobule that contained cytoplasmic vacuoles (Hanzlik et al. 1980b).  Twelve hours after
administration of the same dose, no changes in plasma glutamic pyruvic transaminase (GPT) or liver
glucose 6-phosphatase (G6P) activities were observed.  After the death of 8/14 animals at this dose level
(24 hours post-dosing), there were still no changes in plasma GPT, liver G6P, or hepatic triglycerides 
(Hanzlik et al. 1980b).  Hysell et al. (1974) observed that COBS rats that were gavage-dosed with 20– 
37.5 mg manganese/kg (as MMT) once and died within 24 hours post-dosing had livers with acute 
centrolobular passive congestion. This damage progressed to hepatic parenchymal necrosis and
leukocytic infiltration in those rats surviving 48–72 hours (15–37.5 mg manganese/kg/day), and extensive 
cytoplasmic vacuolar change in rats surviving to 14 days.   
Renal Effects. No studies were located regarding renal effects in humans after oral exposure to
inorganic manganese.
In animal studies, no significant renal histopathological changes were observed in any of the following:
mice and rats fed up to 3,900 or 1,300 mg manganese/kg/day (as manganese sulfate) for 14 days (NTP
1993); mice exposed to 205 mg manganese/kg/day (as manganese tetroxide) in their diet for 90 days
(Gray and Laskey 1980); mice or rats fed up to 1,950 mg manganese/kg/day for 13 weeks (NTP 1993); or
mice fed up to 731 mg manganese/kg/day for 2 years and female rats fed 232 mg manganese/kg/day (as 
manganese sulfate) (NTP 1993).  Additionally, Avila et al. (2008) reported no evidence of increased 
oxidative stress in the kidney in Wistar rats, as measured by TBARS production, δ-ALA-D activity, and
protein carbonylation, at doses up to 1,730 mg manganese/kg/day (as manganese chloride in drinking
water) for 30 days.  Contrary to these findings, increased severity of chronic progressive nephropathy was 
noted in male rats fed 200 mg manganese/kg/day (as manganese sulfate) for 2 years (NTP 1993).  In 
addition, glomerulosclerosis/nephritis and urolithiasis (kidney stones) were observed in male, but not
   
 








     
 
 
         
 
   
        
     
   
              
      
 
     
 
           
    
       
 
   
        
     
         
       
              
            
 
       
   
 
         
 
 




female, Sprague-Dawley rats exposed to dietary doses ≥87 mg manganese/kg/day for 63 days 
(Ponnapakkam et al. 2003b). 
No studies were located concerning renal effects in humans following oral exposure to MMT.
Hanzlik et al. (1980b) observed occasional vacuolar degeneration of proximal convoluted tubules of the
kidney in Sprague-Dawley rats administered a single gavage dose of 31.3 mg manganese/kg (as MMT).
Histopathologic renal effects observed within 24 hours of a gavage dose of 20–37.5 mg manganese/kg 
(Hysell et al. 1974) included hyaline droplet change, cytoplasmic vacuolation of the proximal convoluted 
tubules, and distention of the glomerular space and tubule lumens with a finely granular material that 
stained lightly basophilic.  Within 48 hours post-dosing, there was severe tubular degeneration in the form
of nuclear pyknosis and cell lysis.  Animals surviving the administration of 3.75–25 mg manganese/kg 
did not have any adverse renal effects.
Endocrine Effects. No studies were located regarding endocrine effects in humans after oral
exposure to inorganic manganese; however, other elements of endocrine function (e.g., reproductive
effects) following oral exposure to inorganic manganese are discussed elsewhere.
In mice fed up to 3,900 mg manganese/kg/day (as manganese sulfate) and rats fed 1,300 mg
manganese/kg/day (as manganese sulfate) for 14 days, no endocrine effects (pathological lesions) were 
observed (NTP 1993).  The adrenal gland was assessed for atypical cells and hyperplasia.  In the pituitary
gland, the pars distalis was assessed for cyst, hyperplasia, and hypertrophy.  The pars intermedia was
checked for cysts.  C-cells and hyperplasia were examined in the thyroid gland.  No endocrine effects
were observed in mice or rats fed up to 1,950 mg manganese/kg/day (as manganese sulfate) for 13 weeks.
A 2-year study in rats fed up to 232 mg manganese/kg/day (as manganese sulfate) reported no endocrine 
effects (NTP 1993).  However, in a 2-year mouse study, thyroid follicular hyperplasia and dilatation were
observed in males fed 584 mg manganese/kg/day, and thyroid follicular hyperplasia was observed in 
females fed 64 mg manganese/kg/day (NTP 1993).
No studies were located regarding endocrine effects in humans or animals following oral exposure to
MMT.
Dermal Effects. No studies were located regarding dermal effects in humans after oral exposure to
inorganic manganese.
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In animals, no significant dermal histopathological changes were observed in mice or rats exposed for
2 years to doses up to 731 or 232 mg manganese/kg/day, respectively, (NTP 1993).
No studies were located regarding dermal effects following oral exposure to organic manganese.
Ocular Effects. No studies were located regarding ocular effects in humans after oral exposure to
inorganic manganese.
In animals, no significant ocular histopathological changes were observed in mice or rats exposed for
2 years to average oral doses of 731 or 232 mg manganese/kg/day (as manganese sulfate), respectively
(NTP 1993).
No studies were located regarding ocular effects in humans or animals after oral exposure to organic
manganese.
Body Weight Effects. No studies were located regarding body weight effects in humans after oral
exposure to inorganic manganese.
In some animal studies, lower body weights were observed in rats and mice in manganese-dosed groups.  
For example, an NTP study (1993) reported decreases in body weight gain of 57% in male rats and 20%
in female rats fed 1,300 mg manganese/kg/day (as manganese sulfate in food) for 14 days.  Similarly,
Avila et al. (2008) reported decreases in body weight gain of 50% (sex unspecified) in Wistar rats fed
760 mg manganese/kg/day (as manganese chloride in drinking water).  Exon and Koller (1975) reported 
that rats fed daily doses of manganese tetroxide as low as 6 mg manganese/kg/day (mean ingestion value
over the duration of the experiment) for 28 days gained only 44% as much weight over the course of the
study as control rats.  No changes in eating habits in this lowest dose group were observed, although rats
in the highest dose group at 4,820 mg manganese/kg/day did exhibit decreased weight gain due to 
starvation and the effects of the manganese.  No histopathological changes were reported in the exposed
animals. The authors suggested that the decrease in weight gain might have been due to manganese 
interference in metabolism of calcium, phosphorous, and iron.
In chronic studies, a similar sex-related difference in the response to this effect was reported.  By the end
of a 2-year exposure to the maximum daily dose of 200 mg manganese/kg/day (as manganese sulfate in
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food), male rats had a final mean body weight that was 10% lower than that of controls; however, 
females’ mean body weights were not significantly different from those of controls throughout the study
at all dose levels (232 mg manganese/kg/day was the maximum dose for female rats) (NTP 1993).  Food 
intake (as mg/kg/day) was similar for exposed groups and control groups and for males and females (NTP
1993).
Laskey et al. (1982) investigated body weight changes in a study of adverse reproductive toxicity in male 
and female Long-Evans rats exposed to manganese.  Pregnant dams were fed 0, 350, 1,050, and 3,500 mg
manganese/kg/day (in conjunction with a low-iron diet [20 mg iron/kg/day] or a diet adequate in iron 
[200 mg iron/kg/day]); the pups were continued on their respective diets from day 14 to 15 postpartum to 
the end of the study (224 days).  Manganese treatment did not have any effect on body weight, in either
sex fed adequate iron.  In iron-deficient male rats, however, body weights were significantly decreased
from controls at 24 days postpartum in the 1,050 mg manganese/kg/day diet and at all doses at 40- and 
60-day time points.  Interestingly, body weight was not significantly different in iron-deficient male rats 
fed manganese at 350 mg/kg/day at 100 days and at 224 days (no dose group had weight values
significantly different from control at day 224).  Female body weights were only significantly different in 
the highest dose at day 24 and in the remaining two manganese doses at day 60.  Body weights were not
significantly different from controls for the remainder of the study.  Significant mortality in both sexes
from the highest manganese group fed an iron-deficient diet limited the available data.
In a study designed to evaluate developmental effects of manganese exposure, groups of pregnant
Sprague-Dawley rats were exposed to 4.79 mg manganese/mL (as manganese chloride in drinking water)
from GD 1 through PND 24 (Molina et al. 2011).  Mean body weights of exposed dams were decreased 
by 15 and 28% at the end of gestation and lactation, respectively, compared with controls; the difference
was statistically significant (p<0.05) at the end of lactation, but not at the end of gestation.  Water
consumption was significantly decreased in treated animals during gestation and lactation (24 and 29%
lower than controls, respectively).  Based on body weight and water intake, the study authors calculated 
daily manganese doses during gestation and lactation as 565 and 1,256 mg manganese/kg/day, 
respectively.
No studies were located concerning body weight effects following oral exposure to MMT in humans.  
Hanzlik et al. (1980b) observed no significant differences in acutely exposed rats at a dose of 31.3 mg
manganese/kg as MMT.  Hinderer (1979) also observed normal weight gain in surviving Sprague-Dawley
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rats and CD-1 mice administered doses of MMT ranging from 7 to 159 mg manganese/kg in a one-dose
14-day lethality study.
In a chronic study, Komura and Sakamoto (1992b) administered 11 mg manganese/kg/day (as MMT) in
chow to male ddY mice for 12 months.  A 12% decrease in weight gain was observed at 9 months
between exposed mice and mice fed unmodified chow, increasing to a 17% difference at 12 months.  All
differences in these time points were statistically significant. There was no observed difference in food
intake between the exposed and control groups.
Metabolic Effects. No studies were located regarding metabolic effects following oral exposure to
inorganic manganese in humans or animals.
No studies were located regarding metabolic effects following oral exposure to MMT in humans or
animals.
3.2.2.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological or lymphoreticular effects in humans after oral 
exposure to inorganic manganese.  
Alterations in white blood cell counts have been reported in rats and mice following oral exposure to 
manganese.  One NTP study reported immunological effects in rodents treated for 13 weeks, but not in 
those treated for 2 years (NTP 1993).  Mice were fed 122–1,950 mg manganese/kg/day (as manganese 
sulfate) for 13 weeks. Males exhibited decreased leukocyte counts at ≥975 mg manganese/kg/day;
however, these effects may not have been treatment-related; females were unaffected.  For 13 weeks, rats 
were fed 33–520 mg manganese/kg/day (males) and 40–618 mg manganese/kg/day (females); neutrophil
counts were increased in males at ≥33 mg manganese/kg/day, lymphocytes were decreased in males at
≥130 mg manganese/kg/day, and total leukocytes were decreased in females at ≥155 mg manganese/ 
kg/day (NTP 1993).  Rats fed up to 232 mg manganese/kg/day (as manganese sulfate) and mice fed up to
731 mg manganese/kg/day (as manganese sulfate) for 2 years exhibited no gross or histopathological 
changes or organ weight changes in the lymph nodes, pancreas, thymus, or spleen (NTP 1993).  Komura
and Sakamoto (1991) reported decreased white blood cell counts in mice following dosing at 284 mg
manganese/kg/day with manganese acetate, manganese chloride, or manganese dioxide for 100 days.  It is 
not known if any of these changes are associated with significant impairment of immune system function.
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No studies were located regarding immunological or lymphoreticular effects following oral exposure to 
MMT in humans or animals.
3.2.2.4 Neurological Effects 
Manganism Effects in Humans—Oral Exposure to Inorganic Manganese.  Although inhalation 
exposure to high levels of manganese is known to result in a syndrome of profound neurological effects in 
humans (see Section 3.2.1.4, above), there is only limited evidence that oral exposure leads to the severe
neurological effects associated with high-level occupational exposure to manganese.
An outbreak of a disease with manganism-like symptoms was reported in a group of six Japanese families 
(about 25 people) exposed to high levels of manganese in their drinking water (Kawamura et al. 1941).  
Noted symptoms included a masklike face, muscle rigidity and tremors, and mental disturbance.  Five 
people were severely affected (2 died), 2 were moderately affected, 8 were mildly affected, and 10 were
not affected. These effects were postulated to be due to the contamination of well water with manganese 
(14 mg/L) that leached from batteries buried near the well.  Although many of the symptoms reported 
were characteristic of manganese toxicity, several aspects of this outbreak suggest that factors in addition
to manganese may have contributed to the course of the disease.  First, symptoms appeared to have 
developed very quickly.  For example, two adults who came to tend the members of one family developed
symptoms within 2–3 weeks.  Second, the course of the disease was very rapid, in one case progressing
from initial symptoms to death in 3 days.  Third, all survivors recovered from the symptoms even before 
the manganese content of the well had decreased significantly after removal of the batteries. Thus, while 
there is no doubt that these people were exposed to manganese, there is considerable doubt that all of the
features of this outbreak (particularly the deaths) were due to manganese alone.
A manganism-like neurological syndrome has been noted in an aboriginal population living on an island 
near Australia where environmental levels of manganese are high (Kilburn 1987).  Symptoms included 
weakness, abnormal gait, ataxia, muscular hypotonicity, and a fixed emotionless face.  Although it seems 
likely that excess manganese exposure is an etiologic factor in this disease (based on occupational
exposure data from a study where exposure was assumed to be primarily by inhalation although oral
exposure was not ruled out), absence of data on dose-response correlations and absence of data from a 
suitable control group preclude a firm conclusion on the precise role of manganese (Cawte et al. 1987).  It
is possible that other factors besides manganese exposure may have contributed to the neurological
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effects, including genetic factors, dietary deficiencies in antioxidants and calcium, and excess alcohol
consumption (Cawte et al. 1989).  Also, it should be noted that if manganese intake is a causal factor for
neurological damage, exposure of the population evaluated in this study could occur not only through the
oral route (e.g., food, water, soil), but also by inhaling manganese-containing dusts in environmental or
workplace air (Cawte et al. 1987).
Other Neurologic Effects in Adults—Oral Exposure to Inorganic Manganese. Kondakis et al. (1989)
reported that chronic intake of drinking water containing elevated levels of manganese (1.8–2.3 mg/L) led
to an increased prevalence of neurological signs in the elderly residents (average age, 67 years) of
two small towns in Greece. Effects in these residents were compared with effects in similarly aged
residents in a town where manganese levels were 0.004–0.015 and 0.082–0.25 mg/L.  These levels are 
within and slightly above levels found in U.S. drinking water, respectively (see Section 6.4.2).  Over
30 different neurological signs and symptoms were evaluated, each being weighted according to its
diagnostic value for Parkinsonism.  Based on this system, the average neurological scores for the 
residents of the control town (0.004–0.015 mg manganese/L), the town with mid-range levels (0.08– 
0.25 mg manganese/L), and the town with elevated manganese (1.8–2.3 mg manganese/L) were 2.7, 3.9, 
and 5.2, respectively.  Results from this study suggest that higher-than-usual oral exposure to manganese
might contribute to an increased prevalence of neurological effects in the aged population.
However, there are a number of limitations to this study that make this conclusion uncertain.  First, no 
details were reported regarding which neurological signs or symptoms were increased, so it is difficult to 
judge if the differences were due to effects characteristic of manganism or to nonspecific parameters.
Second, the weighting factors assigned to each neurological symptom were based on the symptom’s 
diagnostic value for Parkinsonism; however, there are clinically significant differences between
manganism and Parkinsonism.  Therefore, the weighting scheme should have placed more weight on
those symptoms (e.g., sleep disorders, emotional lability, weakness, fatigue, and irritability) reported in 
humans with manganism, such as manganese-exposed miners.  The report does not indicate whether
efforts were made to avoid bias in the examiner or in the study populations.  Nonetheless, the use of the 
weighting scheme does strengthen the authors' assertion of an association between elevated manganese 
concentration in the water source and increased susceptibility to neurological symptoms in older
populations.  Although the subjective parameters included in this scoring are indicative of alterations in 
mood or emotional state, and affective disorders often accompany other more objective nervous system
effects, the authors did not state whether individuals who experienced neurological signs did, in fact, 
ingest higher levels of manganese than unaffected individuals. The authors reported that the populations
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in the towns were very similar to each other, but they provided few data to substantiate this.  In this 
regard, even small differences in age, occupational exposures, or general health status could account for
the small differences observed.  Thus, this study suggests, but does not prove, that chronic oral intake of
high levels of manganese can lead to neurological changes in humans.
A study by Vieregge et al. (1995) reported no difference in performance on neurological function studies
by people who had ingested well water with high concentrations of manganese.  These individuals
(high-exposure group), ages ≥40 years, were exposed to manganese at a minimum concentration of
300 μg manganese/L in water for at least 10 years.  The controls consisted of a matched group of people
who ingested well water with a manganese concentration no higher than 0.05 mg/L.  Mean blood 
manganese concentrations in the high-concentration group were 8.5±2.3 μg/L compared to the control
value of 7.7±2.0 μg/L.  Performance on motor coordination tests in the ‘high-exposure’ group was no 
different than the performance of the control group.  The authors noted that they could not control for the
ingestion of water from sources other than the wells described. Ingestion of manganese in food is also a 
major contributor, but the authors did not report an estimate of manganese levels ingested from
foodstuffs.  However, these possible confounders were considered negligible because no differences 
between groups were revealed in a risk factor analysis for nutritional factors performed by the authors and
because manganese concentrations in the blood were not statistically different between the two groups.  
Manganese drinking water levels for the ‘control group’ in this study were within the range of levels 
reported in U.S. drinking water (see Section 6.4.2).  As with the report by Kondakis et al. (1989), a
limitation of this study is the use of a neurological assessment scale for ‘Parkinsonian signs’ rather than
an evaluation of symptoms associated with manganism, though the authors observed no ‘detectable’
neurological impairment. 
Goldsmith et al. (1990) investigated a cluster of Parkinson's disease in the southern region of Israel. They
reported an increased prevalence of Parkinsonism particularly among those 50–59 years old, which 
suggested early onset of the disease. The authors believed that a potential environmental cause was the 
water source common to residents in the region where the cluster of Parkinson’s disease was observed.
Although the authors reported that the water samples examined showed a “substantial excess of aluminum
and a smaller excess of iron and manganese,” the concentrations were not reported.  Soil samples were 
reported to contain excess concentrations of manganese as well as beryllium, chromium, europium, and 
ytterbium, though no quantitative values were provided.  The residents were connected to a national water
system, so it could not be determined when the water supply may have become contaminated with excess
levels of manganese and other metals.  Moreover, there was no clear evidence that persons living in the
   
 








   
          
             
         
 
 
       
    
          
          
 
 
        
          
       
      
   
  
 
   
           
           
    
 
 
   
    
 
  
         
  





region were actually exposed to a contaminated water supply.  Although identified as a cluster of
Parkinson’s disease rather than manganism, the authors suggested that the disease cluster might be related
to an environmental source.  However, the limitations in this study make it difficult to make any clear
association between chronic oral intake of excess levels of manganese and the prevalence of neurological
disease.
Iwami et al. (1994) studied the metal concentrations in rice, drinking water, and soils in Hohara, a small
town on the Kii peninsula of Japan.  This town reportedly had a high incidence of motor neuron disease.  
The researchers observed that a significantly increased manganese content in local rice and a decreased
concentration of magnesium in drinking water were positively correlated with the incidence of motor
neuron disease in Hohara (r2=0.99). 
Evidence of neurological effects following oral manganese exposure has been noted in case studies of
adults, as well.  For example, in a case report of a man who accidentally ingested low doses of potassium
permanganate (about 1.8 mg manganese/kg/day) for 4 weeks, the man began to notice weakness and
impaired mental capacity after several weeks (Holzgraefe et al. 1986).  Although exposure was stopped
after 4 weeks, the authors reported that a syndrome similar to Parkinson's disease developed after about
9 months.  Though suggested by the appearance of a syndrome resembling Parkinsonism, it is difficult to 
prove that these neurological effects were only caused by exposure to the manganese compound.  The
authors speculated that the ingested MnO4– was reduced to Mn(II) or Mn(III); however, while this would 
be expected, it was not measured.  Since MnO4– is a corrosive agent, it seems likely that it may have 
caused significant injury to the gastrointestinal tract (the patient did experience marked stomach pain),
perhaps leading to a larger-than-normal gastrointestinal absorption of manganese.
In another study, Banta and Markesbery (1977) reported on a case involving a 59-year-old man with no 
occupational or environmental exposure to manganese.  The man exhibited dementia and neuromuscular
deficiencies including bradykinesia, shuffling gait, retropulsion, and rigidity in the upper extremities.
Masked faces with infrequent blinking and stooped posture were also observed.  Manganese
concentrations were significantly elevated in serum, urine, hair, feces, and cerebrum.  Although the
authors posit that the man may have had Alzheimer’s disease as well as manganese toxicity, they question
how the individual could build up significant body stores of manganese in the absence of occupational
exposure or any other known source of excess manganese. The authors suggest that the manganese 
overload may have been caused by abuse of vitamins and minerals.
   
 








          
    
  
         
          
    
    
       
             
 
   
   
         
         
          
         
         
        
     
    
            
     
         
 
              
         
  
 
             
 
           
        




An association has been suggested between violent behavior and excess manganese exposure; this was
investigated by measuring the correlation between the manganese content in hair and violent behavior in 
prison subjects and controls (Gottschalk et al. 1991).  The prisoners did have significantly higher hair
manganese content than controls, but further research was indicated to determine whether manganese was 
a causative factor in violent behavior. The highest concentrations of manganese demonstrated in the hair
samples (1.8–2.5 ppm) were, however, within the control ranges reported by Kondakis et al. (1989) (0– 
13 ppm) and Huang et al. (1989) (0.1–2.2 ppm for scalp and 0.3–9.8 ppm for pubic hair).  Another factor
to be considered in the interpretation of these results is the hair color composition within the samples
evaluated.  At least one study (Cotzias et al. 1964) has reported that manganese content was greater in
dark hair when compared to that found in lighter colored hair.  Another study showed that manganese
accumulated in melanin-containing tissues including the melanin from human hair (Lydén et al. 1984).  In 
their study of inhabitants living in Angurugu on Groote Eylandt, Australia, Stauber et al. (1987) found 
that samples of grey hair from one elderly Aborigine participant had the same manganese content as the 
individual’s black hair. The white hairs of a local dog also had the same manganese content as the dog’s 
black hairs.  Based on this evidence, these investigators stated that there was no evidence to support
previous reports that dark colored hair concentrated more manganese than light hair. The average 
manganese content in scalp hair among male and female Aborigine residents was 3.5–5-fold greater than
the average scalp hair manganese in male and female Caucasian residents, respectively.  The authors 
cautioned that interpretation of data on manganese content in scalp hair should take into consideration 
endogenous as well as potential exogenous sources.  Moreover, long-term manganese exposure that may
be associated with adverse effects may not be represented by manganese content in hair growth from only
a few months (Stauber et al. 1987). Thus, further investigations are needed to determine whether
manganese content can vary significantly due to hair color pigment alone.
Manganese has also been associated with amyotrophic lateral sclerosis (ALS). In a human study, spinal
cord samples from ALS patients were found to have higher manganese concentrations in the lateral 
fasciculus and anterior horn than in the posterior horn (Kihira et al. 1990).  Also, ALS patients exhibited a
positive correlation between manganese and calcium spinal cord content, whereas controls exhibited a
negative correlation. It was suggested that an imbalance between manganese and calcium in ALS patients
plays a role in functional disability and neuronal death.  There was also some indication from previous
studies that an excess intake of manganese in drinking water may have caused this imbalance, although
data to support this were not presented.  While this is suggestive of an association between manganese 
and ALS, it is equally plausible that ALS leads to an imbalance in manganese-calcium metabolism.
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No neuropsychological effects were found in a study by Finley et al. (2003) of healthy, nonsmoking, 
premenopausal women were studied in a research project using a crossover design to determine the 
combined effects of very low or high dietary manganese with foods containing either saturated or 
unsaturated fats on measures of neuropsychological and basic metabolic function.  Women were fed for
8 weeks at one of two doses of manganese (0.01 or 0.3 mg manganese/kg/day), with one-half of the
subjects receiving 15% energy as cocoa butter and the other half receiving 15% energy as corn oil.  Blood
draws and neuropsychological tests (involving tests of steadiness and ability to control muscular tremor, 
signs of Parkinson's and related neurologic diseases, as well as tests to determine a range of components
related to hostility and anger) were given at regular intervals during the dietary periods.  Manganese
intake did not affect any neurological measures and only marginally affected psychologic variables.
Neurologic Effects in Children—Oral Exposure to Inorganic Manganese. A number of studies have 
examined the potential for adverse neurological outcomes from childhood exposure to manganese-
contaminated drinking water and/or food (Bouchard et al. 2007c, 2011; Claus Henn et al. 2010, 2011; 
Farias et al. 2010; He et al. 1994; Kim et al. 2009; Wasserman et al. 2006, 2011; Zhang et al. 1995). 
Two early studies (He et al. 1994; Zhang et al. 1995) reported adverse neurological effects in children 
(aged 11–13) who were exposed to excess manganese in well water and in foods fertilized with sewage 
water.  However, these two studies have several flaws that preclude their use as substantial support for the 
link between ingestion of excess manganese and the incidence of preclinical neurological effects in
children.  These studies utilized a group of 92 children pair-matched to 92 controls who lived in a nearby
region. The pairs were matched for age, sex, grade, family income level, and parental education level; in
addition, all children lived on farms.  Although the groups were well matched, the duration and amount of
manganese uptake from the flour (from wheat fertilized with sewage) and drinking water containing
excess levels was not well characterized.  Moreover, the studies did not indicate if nutritional status, such 
as low iron or calcium intake, which could greatly enhance manganese uptake, were evaluated as 
potential confounding factors.
The exposed population drank water with average manganese levels of 0.241 mg/L (He et al. 1994; Zhang
et al. 1995).  The control group drank water containing 0.04 mg manganese/L. These values were 
measured over 3 years, although it was not stated if the children were exposed during the entire 3 years,
or what the children’s daily manganese intakes were. The exposed children performed significantly more
poorly (p<0.01) in school and on neurobehavioral exams than control students.  School performance was
measured as mastery of the native language and other subjects; neurobehavioral performance was 
   
 








             
         
       
         
        
   
          
       
           
      
   
    
           
          
 
  
         
  
        
        
 
 
      
     
             
          
          
          
        




measured using the WHO core test battery.  However, the report did not state what measures, if any, were 
taken to ensure that the individuals administering the tests were blind to the exposure status of the subject.
Such safeguards would be necessary to prevent the introduction of bias in measurement and analysis of
the performance data of the subjects. The exposed children’s hair, blood, and urine manganese levels 
were significantly increased relative to controls.  A simple correlation analysis indicated the performance 
of exposed children on five of the six of the neurobehavioral tests administered (digit span, Santa Ana
manual dexterity, digit symbol, Benton visual retention test, and pursuit aiming test) was inversely
correlated with hair manganese levels.  Although the authors reported that iron, copper, and zinc were
measured in blood and hair, no other metals were measured in these tissues.  Because the exposed group 
presumably ingested food from sources irrigated with sewage, the children may have been exposed to 
increased levels of other metals, such as lead or mercury.  The authors indicate that the children were 
exposed to increased manganese in their diet from excess levels in foodstuffs and drinking water.  Of the
foodstuffs evaluated (cabbage, spinach, potatoes, eggplant, sorghum, and flour), only wheat flour
contained excess manganese compared to that from the control area.  Although the total amount of
manganese ingested from the wheat flour and drinking water was not estimated, the authors suggest that
the elevated manganese level in drinking water was the key factor contributing to the observed effects.  
The authors report that children ingesting food and water containing elevated manganese showed poor
performance in neurobehavioral tests and poorer school performance when compared to children from a
control area.  Because exposure levels and duration were not well defined, these studies as reported are 
not rigorous enough to establish causality between ingestion of excess manganese and preclinical
neurological effects in children.  Nonetheless, these studies are strongly suggestive that subclinical
neurobehavioral effects often seen in industrial workers exposed to excess manganese via inhalation are 
observed in children.
Wasserman et al. (2006) conducted a cross-sectional investigation of intellectual function on 142 10-year-
old children in Araihazar, Bangladesh, who had consumed tube-well water with an average concentration
of 793 µg manganese/L and 3 µg arsenic/L. The children received a medical examination and their
weight, height, and head circumferences were measured.  Intellectual function was assessed on tests 
drawn from the Wechsler Intelligence Scale for Children, version III, by summing weighted items across 
domains to create verbal, performance, and full scale raw scores (the tests were adapted for use in this 
particular population). Maternal intelligence was assessed with Raven's Standard Progressive Matricies, a 
non-verbal test considered relatively free of cultural influences.  Children provided urine specimens for
measuring urinary arsenic and creatinine and provided blood samples for measuring blood lead, arsenic,
manganese, and hemoglobin concentrations.  To assess the dose-response relationship between 
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manganese in well water and intellectual function, children were stratified into four approximately equal
sized groups, based on well water manganese levels. The results of the intelligence tests are displayed in
Table 3-4.
The results indicated that, unadjusted for other contributors, children in group 1 (i.e., those with estimated 
mean dose of 0.006 mg manganese/kg bw/day), when compared with the other three groups, had higher
full scale scores; groups 2 (estimated mean dose of 0.02 mg manganese/kg bw/day) and 4 (estimated
mean dose of 0.07 mg manganese/kg bw/day) were significantly different. The unadjusted result for
performance scores revealed that group 2 had a significantly lower score than group 1.  In the verbal test,
group 4 had a significantly lower unadjusted score than group 1.
After adjustment for sociodemographic factors, groups 1 and 4 were significantly different on all three
tests, with group 4 performing more poorly (Table 3-4).  Although groups 2 and 3 (estimated mean dose
of 0.04 mg manganese/kg bw/day) performed more poorly on average than group 1, the averages from
groups 2 and 3 were not statistically significantly different from group 1.  Therefore, children consuming
the largest amounts of manganese from well water, estimated to be on average 0.07 mg manganese/kg
bw/day, are considered to have shown significant decrements in all forms of intellectual performance
tested.
Wasserman et al. (2011) conducted a similar epidemiological study in Araihazar, Bangladesh, evaluating
the intellectual function of 151 8–11-year-old children using the updated 4th edition of the Intelligence
Scale for Children, from which raw scores for verbal comprehension, perceptual reasoning, working
memory, processing speed indices, and full scale were calculated (the tests were adapted for use in this
particular population).  Maternal intelligence was measured on a population-adapted Wechsler
Abbreviated Scale of Intelligence.  The weight, height, and head circumferences of each child was
measured, as were concentrations of lead, manganese, arsenic, and selenium in blood samples.  To assess
the relationship between manganese in well water and intellectual function, children were divided into 
two approximately equal sized groups, with either "low" or "high" (>500 μg/L) well water manganese
levels (estimated daily manganese doses from water consumption are 0.015 and 0.081 mg/kg/day for the
“low” and “high” groups, respectively).  Average manganese concentrations in blood for the low and high
groups were 14.58 and 15.49 μg/L, respectively.  Before adjustment for other confounders, blood 
concentrations of manganese and arsenic were significant (p<0.05) explanatory variables for deficits in
full scale scores, verbal comprehension scores, working memory scores, and perceptual reasoning scores 
(the latter only for manganese), but not in processing speed scores; the magnitudes of these effects were 
   
 









    
 
  
       
    
     
     
     
 
              
         
            
       
 












Table 3-4.  Scores on Intelligence Tests
Quartiles by mean calculated dose of manganese (mg/kg bw/day)a 
Test type 0.006 0.02 0.04 0.07
Full-scale 81.7±3.1 73.0±4.1 74.0±3.7 60.7±5.2b 
Performance 64.6±2.7 56.4±3.2 56.9±2.8 45.6±4.8b 
Verbal 17.6±0.8 16.6±0.9 17.0±1.0 14.3±1.3b 
aAdjusted scores by four groups of water manganese for full-scale, performance, and verbal raw scores. In each 
case, adjustments were made for maternal education and intelligence, type of housing, child height, head 
circumference, and access to TV. Scores represent mean ± standard error on the mean.
bAdjusted score significantly different from lowest dose group, p<0.05.
Source: Wasserman et al. 2006
   
 









         
   
   
 
   
  
  
            
       
   
   
 
         
       
     





    
          
  
 
   
  
 
          
      
           
MANGANESE 167
3. HEALTH EFFECTS
small, reflected by the finding that blood concentrations of arsenic and manganese together explained
<5% of the variances in test scores.  After adjustment for sociodemographic factors, negative associations 
between blood manganese concentration and both working memory and perceptual reasoning domains
remained statistically significant.
A pilot study conducted by Bouchard et al. (2007c) found significant associations between hair levels of
manganese and certain behavioral end points.  The study involved a group of children (24 boys and 
22 girls) from Quebec, Canada whose homes received drinking water from one of two wells; one well
provided water with a relatively high level of manganese (610 μg/L; W1) and the second well provided 
water with a much lower level of manganese (160 μg/L; W2).  The children, aged 9–13, had estimated 
average exposure levels of 0.02 mg manganese/kg/day (W1) and 0.007 mg manganese/kg/day (W2).  The
children with exposure to water from the high-manganese well had significantly higher (p<0.05) levels of
manganese in their hair than those children exposed to water from the low-manganese well.  Moreover,
the children with high concentrations of manganese in their hair demonstrated significantly more (p<0.05)
oppositional behaviors (e.g., breaking rules, getting annoyed or angered) and more hyperactivity than 
children with lower manganese hair concentrations (after adjustment of scores for age, sex, and income).  
No manganese-related differences were observed for tests related to cognitive problems (disorganization,
slow learning, lack of concentration).  Although this report is a pilot study, it nonetheless suggests the
possibility that exposure to relatively high levels of manganese in water can influence behavior in
children.  
More recently, Bouchard et al. (2011) conducted a cross-sectional study assessing the intellectual function 
of 362 school-aged children (6–13 years old) from eight municipalities in southern Quebec exposed to 1– 
2,700 μg/L of manganese in their home tap water (median value, 34 μg/L).  For each child, total
manganese intake was estimated from both the diet and water consumption (including direct water
ingestion and for water incorporated in food preparations) using a food frequency questionnaire orally
administered to the mother.  Estimated manganese intakes from water consumption ranged from 0 to 
0.03 mg/kg/day (50th percentile, 0.0003 mg/kg/day), while estimated manganese intakes from dietary
sources were >2 orders of magnitude higher than estimated water intakes ranging from 0.01 to 
0.44 mg/kg/day (50th percentile, 0.08 mg/kg/day).  Mothers also provided information on covariates, 
including socioeconomic status indicators, home cognitive stimulation, and maternal depression.  
Cognitive abilities in children were assessed with the Wechsler Abbreviated Scale of Intelligence and
maternal nonverbal intelligence was assessed with the Raven’s Progressive Matrices Test.  Hair samples 
were collected from each child for measurement of manganese concentration.  In unadjusted analyses,
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there were significant negative associations between full scale, verbal, and performance scores, and both
tap water and hair manganese concentrations. The estimated dietary manganese intake was not
significantly (p>0.05) correlated with intellectual performance scores.  After adjusting for covariates,
negative associations remained statistically significant (p<0.05) between tap water manganese 
concentrations or estimated manganese water intake and full scale and performance scores (not verbal
scores) and between hair manganese concentration and full scale scores.  Using a fully adjusted regression
model, predicted IQ scores for children with 1 and 216 µg manganese/L tap water concentrations differed
by 6.2 Full Scale IQ points.  The results demonstrated associations between manganese concentrations in
tap water or estimated manganese intakes from water and intellectual impairment in children, but no
associations between estimated manganese intakes from diet and intelligence scores.  Bouchard et al.
(2011) concluded that the findings support the hypothesis that low-level, chronic exposure in drinking
water is associated with intellectual impairments in children, acknowledged that inferences that can be 
drawn from the study are limited due to the cross-sectional design, and suggested that the findings should 
be replicated in another study.
Other studies have evaluated possible associations between manganese blood levels and cognitive
function in school-aged children (Kim et al. 2009), attention-deficit/hyperactivity disorder (ADHD) in 
school-aged children (Farias et al. 2010), and mental and psychomotor development scores in children 
from 12 to 36 months of age (Claus Henn et al. 2010).  The children in these studies were not known to 
have been exposed to any particularly high levels of manganese in the environment, and were expected to 
have been exposed to manganese principally via the oral route, as expected for the general population. 
In a cross-sectional study, Kim et al. (2009) evaluated the intellectual function of 261 school-aged Korean 
children (mean age 9.7 years) with mean blood manganese and lead concentrations of 14.3 μg/L (range
5.3–29.02 μg/dL) and 1.73 μg/dL (range 0.42–4.91 μg/dL), respectively.  Children included in the study
were recruited from four different Korean cities.  Cognitive function was assessed with the abbreviated 
form of the Korean Educational Development Institute-Wechsler Intelligence Scales, which individually 
scores vocabulary and, arithmetic (verbal IQ), picture arrangement and block design (performance IQ),
and full scale IQ.  Caregivers (e.g., mothers or fathers) completed an extensive questionnaire about
demographics and other potential covariates for cognitive development.  Linear regression analysis, both 
before and after adjustment for covariates, showed a significant (p<0.05) inverse association between
blood manganese and full scale and verbal IQs.  The same results were found for blood lead levels.  The
effect was small, as the blood manganese and blood lead levels explained only 4% of the variances in the 
full scale IQ and 5% of the variances in the verbal IQ. However, there was an increase in the percentages 
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of the variances explained when the blood levels of both metals were entered as predictive variables,
suggesting a joint action of lead and manganese concentrations on full scale and verbal IQs in the 
children.  Further analysis separated the children into two groups: low manganese (blood concentrations 
<14 μg/L, n=131) and high manganese (blood concentrations >14 μg/L, n=130).  There was no difference
in mean blood lead concentration between the high and low manganese groups.  Linear regression 
analysis showed lead to be a significant predictive variable for full scale and verbal IQ scores in the high
manganese group, but not in the low manganese group.  The results are consistent with joint toxic action 
of lead and manganese on full scale and verbal IQ scores in these children, but the design of the
experiment is inadequate to conclude whether the joint action is additive, greater than additive, or less 
than additive.
Another study in school-aged children (ages 7–15 years) investigated the potential relationship between
ADHD and manganese exposure by comparing blood manganese levels in 96 students diagnosed with 
ADHD and 35 controls (Farias et al. 2010).  Treatment-naive students diagnosed either ADHD-combined 
type (n=50) or ADHD-inattentive type (n=24) had significantly (p<0.05) elevated mean serum manganese 
levels (4.5 and 5.2 μg/L, respectively), compared with controls (3.5 μg/L).  Students with ADHD-
combined type (n=21) or ADHD-inattentive type (n=11) who were currently being treated with stimulants 
had manganese levels that were significantly lower than treatment-naïve students with ADHD (2.9 and 
2.8 μg/L, respectively), and not significantly different from controls.  No differences were noted in 
whole-blood iron, magnesium, calcium, or potassium between groups.  The results provide evidence for
an association between increased manganese blood levels and ADHD, but provide inadequate evidence to 
establish a causal relationship with this disorder.
In a prospective study, Claus Henn et al. (2010) examined possible associations between early postnatal
manganese blood levels and developmental scores in 486 infants from Mexico City.  Blood samples were 
obtained at 12 months (n= 296) and 24 months (n=475), and analyzed for manganese and lead 
concentrations.  Child neurodevelopment was assessed at 6-month intervals from 12 to 36 months using
the Mental and Psychomotor Development Indices (MDI, PDI) from the Bayley Scales of Infant
Development-II, Spanish version.  Twelve- and 24-month manganese concentrations were correlated and
declined over time (24.3 and 20.3 μg/L, respectively), and 24-month blood lead concentration was
positively associated with 24-month manganese blood concentration.  A statistically significant
association was found between 12-month MDI scores and 12-month blood manganese concentrations, 
adjusting for potential confounding variables including blood lead, gender, and maternal IQ and 
education.  The data were consistent with an inverted U-shaped regression model:  12-month MDI scores 
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increased with 12-month manganese concentrations up to about 25 μg/L and decreased at higher
concentrations.  The highest 12-month MDI score of 97.7 points was predicted to occur at 24.4 μg/L;
lower scores of 93.9 and 94.2 points were predicted for the 5th and 95th percentile values of 18.1 and 
32.5 μg/L, respectively.  No statistically significant associations were found between MDI scores at 24 or
36 months and 24-month manganese blood concentrations or between PDI scores and blood manganese 
concentrations at any time point.  The results suggest that the mental development of infants at 12 months
of age is more susceptible to either deficient or excessive intakes of manganese than at 24 or 36 months.
In a companion study, Claus Henn et al. (2011) evaluated manganese-lead interactions in the same group
of children.  At 12 months, but not 24 months, there was a significant manganese-blood interaction 
among children in the highest manganese exposure group (5th quintile).  In this quintile, MDI scores and 
PDI scores were decreased 2.23 and 1.24 points per μg/dL increase in lead, respectively, compared with 
0.07 and 0.27 points per μg/dL increase in lead in the lower four quintiles of manganese exposure.  Claus 
Henn et al. (2011) concluded that the results suggest a possible synergism between lead and excessive 
manganese to impair development of mental and psychomotor skills during the first year of life. The 
study design, however, is inadequate to discern if the possible interaction is additive or greater than 
additive.
There are also individual case reports that supply further evidence of potential neurological effects in 
children from exposure to drinking water contaminated with high levels of manganese.  Sahni et al. 
(2007) report a case history of a previously healthy Canadian 6-year-old girl who lived with her family in
an urban center in Canada.  Since 2000, the child’s family had spent summers at their nearby cottage, 
characterized as weekend visits in June, followed by full-time residence in July and August.  While the 
municipal water used at the primary residence of the family had non-detectable levels of manganese, the 
cottage well used between 2000 and 2003 was found to have manganese concentrations of 1.7–2.4 mg/L.  
A neighboring cottage well used in 2004 had 1.7–2.2 mg manganese/L, while spring water used in 2004 
had non-detectable levels. The child’s estimated intake from well water exposure was 0.103 mg
manganese/kg/day.  In 2005, municipal water was brought to the cottage for drinking, but well water was
used for washing and cooking.  A food history demonstrated that the family consumed more manganese-
rich foods, such as pineapples and leafy green vegetables, than a typical Canadian family.  However, the 
family was not vegetarian. The patient and her 7-year-old, asymptomatic sister had very similar diets,
with the exception that the sister consumed soy milk due to lactose intolerance.  No inhalation exposures
to manganese were identified.  No industrial releases of manganese were reported in the vicinity of either
residence.  No other possible source of manganese involving occupational exposures, hobbies among
family members, etc., was identified.  The patient presented with pica and emotional lability in August
   
 








     
 
     
           
 
             
         
      
      
      
 
  
        
   
     
     
 
          
       
           
  
 
         
 
        
         
  
       
          
           
MANGANESE 171
3. HEALTH EFFECTS
2004. Over the following months, she developed progressive behavioral and neurologic symptoms.  She 
became withdrawn and less verbal, with stuttered and slurred speech.  Her balance, coordination, and fine
motor skills declined; eventually (in November 2004), she could no longer stand independently, tended to 
fall backward, and demonstrated a high steppage "cock-like" gait.  An MRI indicated hyperintensity in 
the basal ganglia, indicative of high manganese accumulation. The patient demonstrated high levels of
manganese in whole blood (39.7 µg/L).  The patient also had severe iron deficiency and polycythemia, 
which was attributed to elevated cobalt.  Her blood levels of lead were normal.  While her liver
manganese was elevated, her liver function was normal, as was her blood copper level.  Other members of
the family had elevated blood levels of manganese (1.9–2.8 µg/L) when tested between March and June
2005. The patient's symptoms abated to a large degree when she was treated with phlebotomies for the
polycythemia and ethylene-diamine tetraacetic acid chelation for the manganese overload and iron
therapy.  These treatments occurred from November 2004 through July 2005, when her iron 
supplementation stopped.  By August 2005, the patient’s condition had deteriorated, with her pica
returning; she fell frequently and needed assistance where she was previously independent.  Phlebotomies 
and oral iron therapy were resumed in October 2005. The authors concluded that a metabolic disorder
involving divalent metals (manganese, iron, and cobalt) interacting with environmental exposures was the 
most likely explanation for the patient's symptoms.
Brna et al. (2011) describe a very similar case in a previously healthy 5-year-old girl, whose primary
exposure was also determined to be from elevated well-water manganese levels (1.7–2.4 mg/L) at her
family’s country vacation home.  The child’s estimated intake from well water exposure was 0.104 mg
manganese/kg/day.  The child presented with a recent history of intermittent urinary incontinence, pica, 
behavioral changes, speech difficulties, social withdrawal, and gross and fine motor incoordination.  
Upon admission, she could not walk independently.  Neurological examination revealed a narrow-based, 
high stepping gait, retropulsion with preserved strength, deep tendon reflexes, and sensation.  She had 
mild truncal ataxia and subtle action tremor.  Clinical chemistry revealed polycythemia without 
abnormalities in the bone marrow.  She had elevated hemoglobin, decreased mean cell volume, increased 
red blood cell distribution, decreased serum iron, and elevated total iron binding capacity.  She also had 
elevated serum cobalt levels and profoundly elevated whole-blood and serum manganese levels (723 and 
38 nmol/L, respectively).  Cranial MRI revealed bilateral symmetric hyperintense signals in the basal
ganglia, brainstem, and cerebellum on T1-weighted imaging, consistent with a diagnosis of
hypermanganism.  Like the previous case, her parents also had elevated serum manganese levels (29.5– 
42.8 nmol/L), but their whole-blood levels were normal and they were clinically well.  Her 7-year-old 
sister had normal manganese levels and no symptoms.  Treatment with phlebotomy (for polycethemia),
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iron infusions, a manganese-free diet, and calcium ethylenediaminetetraacetic acid (EDTA) chelation
therapy improved her condition somewhat.  At age 10, she was able to walk 40 m unaided with an
improved stepping gait, but regularly used an electric wheelchair for mobility.  Her neurological status
was stable, with improved speech, behavioral, and fine motor skills.  
Woolf et al. (2002) describe the case of a 10-year-old boy whose sole source of drinking water at home
over a 5-year period was from a well on the family's property in a Boston, Massachusetts suburb.  The
well water tested after 5 years of use had a manganese concentration of 1.21 ppm (estimated intake:
0.06 mg manganese/kg/day). The child had elevated blood levels of manganese (serum concentration of
0.90 µg/100 mL, compared to reference normal of <0.265 µg/100 mL) and whole-blood manganese
concentration of 3.82 µg/100 mL (reference normal:  <1.4 µg/100 mL).  The child’s urinary excretion of
manganese was found to be 8.5 µg/L over a 24-hour period (reference normal:  <1.07 µg/L).  Although no 
other member of the family exhibited elevated blood concentrations of manganese, the child and his
brother each had elevated manganese levels in hair samples (the patient's level was 3,091 ppb; the 
brother's was 1,988 ppb; reference normal:  <260 ppb hair).  At this time, the family switched to bottled
drinking water, but continued to use the well water for other purposes (bathing, etc.).  The child exhibited 
no evidence of illness or tremors.  A detailed neurologic examination was normal.  His balance with his 
eyes closed was good, but he did not coordinate rapid alternating motor movement well.  His fine motor
skills were normal and he had no sensory deficits.  A battery of neuropsychologic tests revealed that while
the child's global cognitive skills were intact, he had striking difficulties in both visual and verbal memory
(14th and 19th percentiles, respectively), suggesting a deficit in free retrieval skills, and had a general
memory index at the 13th percentile and learning index at the 19th percentile.  The child was in 5th grade 
at the time of testing and had no history of learning problems, although teachers had persistently reported 
difficulties with listening skills and following directions. The authors report that the findings from the
neuropsychological testing are consistent with the toxic effects of manganese, although the authors 
indicate that a causal relationship cannot be inferred in this case.
Though limited, these case reports also provide further evidence for a link between ingestion of elevated
levels of manganese and learning or behavioral problems in children.  Other studies have found that
manganese levels in hair are higher in learning-disabled children than in normal-functioning children 
(Collipp et al. 1983; Pihl and Parkes 1977).  The route of excess exposure is not known, but is presumed 
to be mainly oral. These observations are consistent with the possibility that excess manganese ingestion
could lead to learning or behavioral impairment in children as suggested by the results from other
epidemiological studies (Bouchard et al. 2007c, 2011; Claus Henn et al. 2010; Farias et al. 2010; He et al.
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1994; Kim et al. 2009; Wasserman et al. 2006, 2011; Zhang et al. 1995).  However, an association of this
sort is not sufficient to establish a cause-effect relationship because a number of other agents, including
lead, might also be involved (Pihl and Parkes 1977).  Moreover, other potentially confounding factors
(e.g., health and nutritional status) must be taken into consideration in interpreting such studies.
Neurologic Effects in Humans with Liver Dysfunction—Oral Exposure to Inorganic Manganese.
Several studies report the link between hepatic encephalopathy and an increased manganese body burden 
following chronic liver disease in adults (Hauser et al. 1994; Pomier-Layrargues et al. 1998; Spahr et al. 
1996) and children (Devenyi et al. 1994) and in individuals with surgically-induced portacaval shunts
(PCS) (Hauser et al. 1994). The manganese exposure in these studies was assumed to originate from a 
normal diet.  Hepatic encephalopathy comprises a spectrum of neurological symptoms commonly
occurring in individuals with chronic liver disease; these symptoms include varying degrees of mental
dysfunction, although extrapyramidal symptoms may also be identified during a clinical examination 
(Spahr et al. 1996).  
In the Hauser et al. (1994) study, two men aged 49 and 65 years, both with chronic liver disease, and one
56-year-old man with cirrhosis of the liver and a portacaval shunt, showed a variety of neurological 
symptoms including bradykinesia, postural tremor of the upper extremities, and gait disturbances, as well
as a decrease in cognitive function. These men all had significant elevations (p<0.05) in blood
manganese as compared to healthy male and female controls, and had hyperintense signals in the basal
ganglia bilaterally as measured by T1-weighted MRI. Similar elevations of blood manganese were 
reported in a population of 57 cirrhotic patients with an absence of clinical encephalopathy (Spahr et al. 
1996).  Blood manganese was elevated in 67% of the patients and was significantly higher in those 
patients with previous portacaval anastomoses or transjugular intrahepatic portosystemic shunt. MRI
signal hyper intensity was observed in the globus pallidus; the elevated blood manganese levels were 
significantly correlated with the intensity of the signal in affected patients.  Neurological evaluation of
extrapyramidal symptoms using the Columbia rating scale indicated a significant incidence of tremor,
rigidity, or akinesia in ~89% of the patients, although there was no significant correlation between blood 
manganese level and these symptoms.
Similar results were observed in a young girl with Alagille’s syndrome (involving neonatal cholestasis
and intrahepatic bile duct paucity) with end-stage cholestatic liver disease who exhibited several
neurological dysfunctions including dystonia, dysmetria, propulsion, retropulsion, and poor check
response bilaterally (Devenyi et al. 1994). The girl had elevated blood manganese (27 μg/L compared to 
   
 









             
        
   
    
 
   
    
      
  
   
   
    
    
 
     
         
    
   
        
   
   
        
           
       
 
   
  
    






normal value of ~9.03 μg/L) and exhibited hyperintense MRI signal in the basal ganglia.  After a liver
transplant, the MRI signal abated and the blood manganese level returned to normal. This study and
those in adults indicate that the increased manganese body burden (as evidenced by increased manganese 
blood and brain levels) may contribute to the resultant neurological symptoms and encephalopathy in 
individuals with cirrhosis or chronic liver disease.
Rose et al. (1999) evaluated brain manganese levels in 12 autopsied cirrhotic individuals who died from
hepatic coma and 12 control subjects with no history of hepatic, neurological, or psychiatric disorders at
time of death.  Neutron activation analysis of the brain tissue revealed an increase in manganese content
in the cirrhotic individuals, particularly in the globus pallidus, which had 186% more manganese than that
of controls (significant at a level of p<0.001).  Significant, although less extreme, increases in manganese 
were also found in the putamen and caudate nucleus from cirrhotic patients.  However, the increased brain
manganese did not correlate with patient age, the etiology of the cirrhosis, or the history of recurrent
hepatic encephalopathy (reported in 6 patients).
Neurologic Effects in Adult Animals—Oral Exposure to Inorganic Manganese. A few animal studies 
have observed effects that are comparable to clinical signs seen in people with manganism.  Gupta et al. 
(1980) reported that monkeys given 25 mg manganese/kg/day (as manganese chloride) for 18 months
developed weakness and muscular rigidity (however, no data were provided to support these
observations).  Rats dosed with 150 mg manganese/kg/day (as manganese chloride) developed a rigid and
unsteady gait after 2–3 weeks, but this was a transient condition that was not apparent by 7 weeks 
(Kristensson et al. 1986).  In addition, in two separate studies, the authors reported a decrease in
spontaneous activity, alertness, muscle tone, and respiration in mice dosed once with 58 mg
manganese/kg/day by gavage (Singh and Junnarkar 1991) and staggered gait and histochemical changes 
in two third-generation mice treated with 10.6 mg manganese/kg/day (as manganese chloride) in drinking
water (Ishizuka et al. 1991).   
Most other early studies in animals reported changes in brain chemical end points, including
concentrations of neurotransmitters or alterations in motor activity with both hypo- and hyperactivity
reported.  As shown in Table 3-3 and Figure 3-3, changes of this sort have been reported at oral exposure
levels that ranged from about 1 to >2,000 mg manganese/kg/day (as manganese chloride, manganese 
acetate, or manganese tetroxide) (e.g., Bonilla 1978b; Bonilla and Prasad 1984; Chandra 1983; Eriksson 
et al. 1987a; Gianutsos and Murray 1982; Gray and Laskey 1980; Komura and Sakamoto 1991, 1992b;
Lai et al. 1984; Nachtman et al. 1986; Subhash and Padmashree 1991).  
   
 









        
      
    
  
         
 
        
   
       
  
     




        
  
         
  
         
 
  
   
   
  
 
              
       
   
      
   




More recent studies have continued investigations of brain chemistry alterations in animals following
acute- to intermediate-duration oral exposure to manganese (Avila et al. 2008; Calabresi et al. 2001;
Desole et al. 1997; Lipe et al. 1999; Liu et al. 2006; Morello et al. 2007; Ranasinghe et al. 2000).  In 
particular, studies have focused on the dopaminergic system due to observed motor dysfunction following
manganese exposure and similarities between manganism and parkinsonism (Calabresi et al. 2001;
Desole et al. 1997; Ranasinghe et al. 2000).  Additionally, a few studies have reported neuropathology 
following manganese exposure, as evidenced by neuronal damage and/or increased oxidative stress (Avila 
et al. 2008; Liu et al. 2006; Spadoni et al. 2000).  Studies of the effects of manganese on a variety of
behavioral assessments in rats also have been conducted; these studies have found changes in measures 
related to fear, locomotor activity, and cognitive performance (Calabresi et al. 2001; Shukakidze et al. 
2003; Torrente et al. 2005; Vezér et al. 2005, 2007).  In some of these studies, electrophysiological 
changes in the brain were associated with behavioral changes (Calabresi et al. 2001; Vezér et al. 2005,
2007).
In a study by Lipe et al. (1999), groups of 30-day-old and 90-day-old male Sprague-Dawley rats were 
exposed to10 or 20 mg manganese/kg/day as manganese chloride for 30 days.  A dose-dependent
decrease in body weight gain was found in the adult, but not the weanling rats.  Significant (p<0.05)
increases were observed in concentrations of aspartate, glutamate, glutamine, taurine, and
gamma-aminobutyric acid (GABA) in the cerebellum of the adult rats dosed with 20 mg
manganese/kg/day; this increase also appeared to be dose dependent.  A significant (p<0.05) decrease in
the concentration of glutamine was observed in caudate nucleus and hippocampus of weanling rats dosed 
with 10 mg manganese/kg/day.  A significant (p<0.05) increase in GABA concentration in the caudate
nucleus of weanlings was observed in the 20 mg manganese/kg/day group.  A significant (p<0.05)
decrease in the concentration of glutamine in the caudate nucleus and hippocampus was found in 
weanlings of the 10 mg manganese/kg group.  
In a study by Morello et al. (2007), groups of adult male Wistar rats had free access to either normal
drinking water or to a water solution providing 611 mg manganese/kg/day as manganese chloride, with
treatment lasting for 13 weeks.  A significant reduction in the number of immunoreactive cells for
glutamine synthetase was observed in the globus pallidus for manganese-treated animals compared with
controls (33% reduction).  No effect of manganese was observed in the sensorimotor cortex or striatum, 
nor was there any effect observed for other manganoproteins tested.
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In a study by Ranasinghe et al. (2000), groups of male Sprague-Dawley rats were provided daily 
with 0 (n=2), 74.9 (n=4), or 149.8 mg (n=4) mg manganese/kg/day, administered as manganese sulfate;
another control group of two rats received 20 mg sodium/day.  All animals were treated for 50 days.  
Mean manganese concentrations in liver, brain, heart, and kidney were elevated in the low- and high-dose
groups, compared with untreated sodium controls, but statistical analyses of these data were not
performed.  A decrease was observed in dopamine serum levels in manganese-treated rats compared to
controls; the sulfated form was increased in both dose groups compared to controls (12–13 times; from
0.014 nmol/mL in controls to 0.179 nmol/mL in the 20 mg manganese group).  Increases were also
observed in L-dopa and L-dopa sulfate in both treatment groups.  No treatment-related differences were 
observed in serum levels of L-P tyrosine or its L-P tyrosine sulfate.
In a study by Desole et al. (1997), groups of 3-month-old male Wistar rats were given gavage doses of
0 or 8.8 mg manganese/kg/day as manganese chloride in water for 6 days.  Other groups of control or
manganese-treated rats received 20 mg/kg buthionine (S,r) sulfoximine0ethyl ester (BSO-E) by 
intraperitoneal injection twice daily (1 hour before gavage treatment) on days 4, 5, 6, and 7.  Rats were 
sacrificed on day 7, and brainstem samples were extracted for determination of concentrations of
dopamine, dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), and noradrenaline (NA), as
well as concentrations of reduced glutathione, ascorbic acid, dehydroascorbic acid, and uric acid (the
latter being indicators of oxidative stress potential).  Compared with controls, manganese treatment alone 
increased concentrations of GSH (10–14%) and uric acid (28–45%) in striatum and brainstem, without
affecting ascorbic acid concentrations, increased concentrations of DOPAC and HVA in striatum, without
affecting dopamine, and decreased brainstem concentrations of dopamine.  As expected, BSO-E treatment
alone decreased GSH concentrations in striatum (23%) and brainstem (35%), without affecting striatal or
brainstem concentrations of ascorbic acid, dehydroasocrbic acid, or uric acid or striatal concentrations of
dopamine, DOPAC, or HVA; however, brainstem concentrations of dopamine were decreased by this
treatment.  Compared with controls, manganese plus BSO-E treatment decreased concentrations of GSH
and ascorbic acid in striatum (42 and 22%, respectively) and brainstem (23 and 22%, respectively) and 
increased concentrations of dihydroxyascorbic acid and uric acid; these results are indicative of a 
heightened oxidative stress condition.  In addition, manganese plus BSO-E treatment decreased striatal
concentrations of dopamine, DOPAC, and HVA and brainstem concentrations of dopamine and 
noradrenaline. The magnitude of the manganese plus BSO-E treatment changes were mostly larger than
changes seen in all other experimental groups. The results indicate that the manganese treatment
decreased brainstem concentrations of dopamine without affecting neurochemical indicators of oxidative
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stress and that a glutathione depleted condition potentiated the effects of manganese on brainstem and 
striatal concentrations of dopamine, DOPAC, and HVA.   
Calabresi et al. (2001) measured locomotor activity, fear, and learning and memory in male Wistar rats 
treated with either tap water as drinking water or a solution of manganese chloride (1,310 mg
manganese/kg/day) as drinking water for 10 weeks.  Brain manganese levels ranged from 3 to
approximately 4 times higher than controls.  Manganese-treated rats were significantly (p<0.001) more
active than control rats in the open field.  Manganese-treated rats showed progressively and significantly
more interest in the "novel" object over three trials than the control rats (p<0.001; an average of four 
contacts for manganese-treated animals compared to an average of <2 for controls on the third trial).
Manganese-treated animals also produced significantly (p<0.05) more fecal boluses (indicative of
heightened fearfulness) in the open field than control rats over the three trials.  No major differences were 
observed between treatment groups in the eight-arm radial maze test, with the manganese-treated animals 
taking significantly (p<0.01) more 45 degree angle turns than the control rats.  An enhanced 
dopaminergic inhibitory control of the corticostriatal excitatory transmission via presynaptic D2-like
dopamine receptors in corticostriatal slices obtained from the manganese-treated rats was observed. The 
use of agonists acting on presynaptic purinergic, muscarinic, and glutamatergic metabotropic receptors 
revealed normal sensitivity.  Membrane responses recorded from single dopaminergic neurons following
activation of D2 dopamine autoreceptors were also unchanged following manganese intoxication.  The
authors suggest that the behavioral symptoms described in the "early" clinical phase of manganism may
be produced by an abnormal dopaminergic inhibitory control on corticostriatal inputs (Calabresi et al. 
2001).  
Spadoni et al. (2000) studied groups of male, PND 20 Wister rats provided with either access to drinking
water or 3311 mg manganese/kg/day in drinking water, with treatment lasting for 13 weeks.  No neuronal
loss or gliosis was detected in the globus pallidus with either treatment.  However, the majority of GP
neurons from manganese-treated rats died following brief incubation in standard dissociation media.  
Patch-clamp recordings in the whole-cell configuration were not tolerated by surviving GP neurons from
manganese-treated rats.  Manganese-treated GP cells, but not striatal cells, demonstrated an unusual
response to glutamate, since repeated applications appeared to produce irreversible cell damage.
Liu et al. (2006) studied 12-week-old female C57Bl/6 mice, paired as littermates from timed pregnant
dams, that received by gavage either water or 43.7 mg manganese/kg/day as manganese chloride for
8 weeks prior to sacrifice. Manganese-treated mice had significantly (p<0.05) increased levels of
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manganese in the striatum and decreased locomotor activity and striatal dopamine content.  Neuronal
injury in the striatum and globus pallidus was observed, especially in regions proximal to the
microvasculature.  Neuropathological assessment revealed marked perivascular edema, with hypertrophic 
endothelial cells and diffusion of serum albumin into the perivascular space.  Immunofluorescence studies
revealed the presence of apoptotic neurons expressing neuronal NOS choline acetyltransferase, and
enkephalin in both the striatum and globus pallidus.  Soma and terminals of dopaminergic neurons were
morphologically unaltered in either the substantia nigra or striatum.  Regions with neuronal injury
contained increased numbers of reactive astrocytes that coexpressed inducible NOS2 and localized with 
areas of increased neuronal staining for 3-nitrotyrosine protein adducts, a marker of NO formation.  The
data suggest a possible role for astrocyte-derived NO in injury to striatal-pallidal interneurons from
manganese intoxication.  
Avila et al. (2008) investigated open field behaviors and orofacial dyskinesia in adult Wistar rats (5/group 
of unspecified gender) exposed to drinking water containing 0, 2.8, or 6.9 mg manganese/mL (0, 10, or
25 mg MnCl2/mL) for 30 days.  Using an allometric equation for drinking water consumption (EPA 1988)
and averages of mean body weights reported for exposure day 0 and 30, estimated doses are:  0, 760, or
1,730 mg manganese/kg/day.  Behavioral tests (open field, orofacial dyskinesia measures) were 
performed on days 0 and 30.  On day 30, animals were sacrificed and the striatum and hippocampus were 
dissected for slice preparation.  Some striatum slices were used to measure calcium influx. The remaining
striatum tissue and the hippocampus were homogenized for biochemical analyses measuring oxidative 
stress indices (TBARS production, δ-ALA-D activity, protein carbonylation).  In both exposed groups, 
animals exhibited significantly (p<0.05) decreased motor activity in the open-field test and decreased
tongue protrusion frequency.  Frequency of vacuous chewing movement was significantly (p<0.05)
decreased only in the high-dose group. There were no differences in rearing frequency in either treated
group compared with controls.  Calcium influx in the striatum was significantly (p<0.05) decreased in 
both treatment groups compared with controls. TBARS levels were significantly elevated and ALA
activity was significantly decreased in the striatum, but not hippocampus, of animals in the high-dose
group.  Protein carbonylation in exposed groups did not differ from controls in either region. The results
indicate an association between manganese-induced decreases in motor activity in rats and increased
markers of oxidative stress in the striatum.
Vezér et al. (2005, 2007) evaluated multiple neurobehavioral end points in young adult male Wistar rats
treated by water gavage with 0, 6.5, or 25.9 mg manganese/kg/day for 10 weeks.  Rats were tested in an 
eight-arm radial maze test (spatial learning and memory test) and an open field test (locomotor ability).  
   
 








     
     
          
  
         
  
        
    
           
 
        
          
      
      
      
    
    




    
  
   
        
    
      
            
          
  
  




Rats were also tested for amphetamine-induced locomotor activity, acoustic startle response, and prepulse
inhibition.  At 5 and 10 weeks of treatment, as well as at the end of the post-treatment period 8 weeks 
later, electrophysiological testing was performed, including recording of cortical evoked potentials as well
as spontaneous electrical activity in the hippocampus.  Immunohistochemistry was performed to detect
changes in density of glial fibrillary acid protein (GFAP) immunoreactive structures in the hippocampal
CA1region.  Blood and tissue samples (from the cortex and hippocampus) were collected in the 5th and 
10th treatment and 12 post-treatment week.  Blood and tissue levels of manganese were determined.
Manganese accumulation was first seen in blood and then in brain of high-dose rats.  Decreased short-
and long-term spatial memory performance (at least p<0.05) and decreased spontaneous open field
activity (p<0.05) were observed in both low- and high-dose groups, compared with controls.  The number
of acoustic startle responses, as well as their associated prepulse inhibition of the acoustic startle 
responses, were decreased in manganese-treated animals. The latency of sensory evoked potentials 
increased and their duration decreased.  Manganese levels returned to normal at the end of the post-
treatment period, but impairment of long-term spatial memory remained, as well as the decrease in
number of acoustic startle responses in high-dose rats. Prepulse inhibition responses returned to normal.  
Open field activity returned to normal at the end of post-treatment, but a residual effect could be observed 
under the influence of D-amphetamine.  The electrophysiological effects partially returned to normal
during post-treatment.  Significantly (p<0.05) high percentages of area showing GFAP immunoreactivity
were observed in the dentate gyrus (but not in the striatum radiatum or striatal oriens) in the low- and 
high-dose groups, compared with controls.
Another factor that could potentiate the neurotoxicity of manganese was explored by Torrente et al. 
(2005), with rats subjected to restraint stress along with manganese exposure.  Groups of 15 adult male
Sprague-Dawley rats (250–300 g) were dosed for 2 weeks with either plain drinking water or drinking
water providing 38.2 mg manganese/kg/day as manganese chloride. The manganese chloride group was 
then split into two groups, with drinking water doses of 76 and 153 mg manganese/kg/day provided for
another 19 weeks.  One-half of the animals in each group were subjected to restraint stress for 2 hours
daily by placing them in metacrilate cylindrical holders.  Animals treated with 153 mg manganese/kg/day
with restraint traveled a significantly shorter distance than control restraint animals (38% decrease;
p<0.05).  Manganese concentrations in brain and cerebellum were significantly elevated in exposed 
groups, compared with controls.  Body weight and food consumption were significantly decreased 
(p<0.05) in the exposed groups, compared with control values.  Terminal body weights were 86 and 51%
of control values in the low- and high-dose unrestrained groups and 90 and 56% in the respective
restrained groups.  Open field activity was significantly decreased (p<0.05) in the high-dose restrained
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groups.  Spatial learning was also impaired in high-dose rats with or without restraint); for example,
unrestrained high-dose rats showed significantly (p<0.05) increased latency to find a hidden platform in 
the water maze test on days 1, 2, 3, 4, and 5 of testing.
In a study by Shukakidze et al. (2003), groups of white rats were tested for cognitive performance in a
multipath maze.  Group I served as a control group, which was trained in the maze for 10 days, fed 
normal feed for 30 days, and then retested.  Groups II and III, instead of receiving normal feed, received 
dosed feed at 5.6 or 13.9 mg manganese/kg/day (as manganese chloride).  Groups IV and V were dosed 
the same doses as Groups II and III, respectively, but received the doses for 30 days prior to maze 
training.  Groups II and III received normal feed for the next 90 days prior to retesting for 10 days.  An 
additional group of animals received a single dose (undefined route) prior to 10 days of training in the
maze.  Both groups of rats dosed after training (Groups II and III) showed moderate disruption of their
acquired skill in the maze compared to controls.  Group III also demonstrated increased "aggressivity".
Both groups that were exposed prior to training (Groups IV and V) were entirely unable to learn the
maze.  When these rats were reassessed after a 3-month period without excess manganese, they remained 
unable to learn the maze.  After training, 8/12 rats in the group with the single dose (Group VI) mastered 
the maze; 4/12 required assistance from the experimenter to orient themselves.  Groups of 9 (control) and 
10 (manganese-treated) rats were tested in an active avoidance of conditioned and unconditioned stimuli
paradigm.  Manganese-treated rats received by mouth 13.9 mg manganese/kg/day (as manganese 
chloride) in water 1 hour prior to the experiment on day 1.  Rats were tested over 16–17 days.  Manganese
treatment resulted in significant and reversible behavioral change, with manganese exposure leading to
worsened acquisition of the avoidance reaction in response to unconditioned and conditioned stimuli, 
increased latent period of conditioned reflex activity, and increased numbers of errors and time taken to 
navigate a maze, beginning on day 5 of the experimental period and lasting until day 10–15, depending on 
the end point.
Neurological Effects in Young Animals—Oral Exposure to Inorganic Manganese.  Numerous studies
have evaluated the effect of early postnatal and juvenile manganese exposure on neurodevelopment in
animals.  Several have reported biochemical changes in the brain, including alterations in the
dopaminergic, noradrenergic, serotonergic, or gabaergic systems; increased monoamine oxidase; and
decreased iron levels (Anderson et al. 2007a, 2009; Chandra and Shukla 1978; Deskin et al. 1981;
Dorman et al. 2000; Kern et al. 2010; Kern and Smith 2011; Kristensson et al. 1986; Moreno et al. 2009;
Reichel et al. 2006; Tran et al. 2002a, 2002b).  Additionally, many studies have reported altered behavior
following developmental manganese exposure, including hyperactivity, altered social interactions, 
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transient ataxia, altered acoustic startle, impaired learning, and increased stereotypic behaviors (Dorman
et al. 2000; Golub et al. 2005; Kern and Smith 2011; Kern et al. 2010; Kristensson et al. 1986; Moreno et
al. 2009; Tran et al. 2002a, 2002b). While results from these studies are varied, taken together, they
indicate that excess manganese exposure during early postnatal development can lead to alterations in
brain chemistry and behavioral development.  
Studies of manganese in Rhesus monkeys by Golub et al. (2005) were prompted by the observation that
soy-based formulas provided to human infants contain relatively high levels of manganese and thus may
pose a potentially toxic hazard to early neurological development.  Groups of eight male infant Rhesus
monkeys were fed a commercial cow's milk based formula (Similac containing 50 µg manganese/L as 
control, providing 17.5 mg manganese/kg/day), a commercial soy protein based formula (soy containing 
300 µg manganese/L, providing 107.5 mg manganese/kg/day), or the same soy formula with added
manganese chloride for a final concentration of 1,000 µg manganese/L (soy plus manganese, providing
328 mg manganese/kg/day).  Formulas were exclusively fed to infants starting on the day of birth and 
extending through 4 months of age, at which time monkeys were transitioned to standard laboratory diet.  
A behavioral test battery was administered over an 18-month period.  The battery included measures of
motor, cognitive, and social skills, as well as tests related to the dopamine system (reward delay, fixed
interval dopamine drug response).  Infants that did not generate sufficient data in each test to permit
evaluation were excluded from data analyses.  Growth and levels of the dopamine metabolite HVA and
the serotonin metabolite 5-hydroxyindolacetic acid (5-HIAA) in CSF at 4, 10, and 12 months of age were
also measured.  No significant differences between groups were observed for body weights and levels of
dopamine and serotonin metabolites in cerebrospinal fluid.  
Monkeys fed soy supplemented with manganese were consistently more active during 12 weekly
7-minute observation periods, compared with control and soy monkeys.  "Motor behaviors" were
observed in seven of eight soy plus manganese monkeys, compared with three of eight in soy monkeys
and three of eight in control monkeys.  Assessment of gross motor maturation during these observation 
periods did not detect clear differences between the groups.  Both soy and soy plus manganese groups
showed some changes in activity/sleep patterns.  Compared with controls at 4 months, the 4-month 
monkeys fed soy plus manganese showed 50% less activity (p<0.05) during the sleep portion of the
sleep/wake cycle (this change was not seen at 8 months).  At 8 months (but not at 4 months), both soy and 
soy plus manganese monkeys showed significantly (p<0.05) longer sleep periods and shorter longest time
inactive during awake periods than controls.  Social interactions were assessed during 16 sessions in 
which each monkey was paired with another monkey in the study.  In these sessions, both soy and soy
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plus manganese monkeys demonstrated ~66% less time (p<0.05) in chase or rough play and more time in 
clinging activity compared with control monkeys.  
Significant group differences were not consistently observed in more highly structured tests to assess 
cognitive functions including learning, memory, and attention than controls (p<0.05 for 328 mg
manganese/kg/day and p<0.01 for 107.5 mg manganese/kg/day).  For example, a response latency
decrease was observed in a reward delay response task in the soy group by 50% compared to control, but
no significant difference (although a 20% reduction) was observed in the soy plus manganese group.  The
authors noted that more formal tests of cognitive functions would be most appropriately administered at
more mature ages.
Other studies in neonatal animals have detected neurostructural and neurochemical changes at
supplementary doses similar to or slightly above dietary levels (1–10 mg manganese/kg/day) (Chandra 
and Shukla 1978; Deskin et al. 1980), suggesting that young animals might be more susceptible to 
manganese than adults.
Kristensson et al. (1986) investigated the developmental effects of manganese chloride on 3-day-old male
rat pups.  The authors dosed the pups with 150 mg manganese/kg/day by gavage in water for 41 days.  
The pups developed a transient ataxia on days 15–22, which was resolved by the end of the dosing period.  
The exposed pups also had increased levels of manganese in the blood and the brain (7–40-fold increase 
in 15- and 20-day-old rats, with cortex and striatum concentrations being relatively equal).  In 43-day-old 
rats, the increases in brain manganese levels were less than those observed in younger rats (i.e.,
approximately 3 times the control levels), but the striatal levels were higher than in the cortex.
Manganese treatment decreased the concentration of homovanillic acid (metabolite of dopamine) in the 
striatum and the hypothalamus, but not in other brain regions.  No other monoamines and metabolites
were affected.  In a similar study, neonatal rats given bolus doses of manganese chloride in water of
0.31 mg manganese/kg/day for 60 days suffered neuronal degeneration and increased brain monoamine
oxidase on days 15 and 30 of the study, but did not show any clinical or behavioral signs of neurotoxicity
(Chandra and Shukla 1978).   
Deskin et al. (1980, 1981) also found changes in brain chemistry in rat pups dosed with manganese.  In
the first study, male rat pups were administered 0, 1, 10, or 20 mg manganese/kg/day (as manganese 
chloride) via gavage in 5% sucrose solution for 24 days postnatal.  The authors observed that the two 
highest doses resulted in decreased dopamine levels in the hypothalamus, while the highest dose resulted 
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in a significant decrease in brain tyrosine hydroxylase activity and a significant increase in monoamine 
oxidase activity in the hypothalamus.  Hypothalamic norepinephrine was unaffected by any manganese 
dose, and no significant changes in neurochemistry were noted in the corpus striatum.  The authors
suggested that the observed effects were probably due to decreased activity of tyrosine hydroxylase and
increased levels of monoamine oxidase.
The second study (Deskin et al. 1981) involved dosing male rat pups with 0, 10, 15, or 20 mg
manganese/kg/day (as manganese chloride) via gavage in 5% sucrose solution, for 24 days starting at
birth.  The authors performed neurochemical analyses of hypothalamus and corpus striatum as before and
observed that serotonin was increased in the hypothalamus at the highest dose, but was not elevated 
significantly in the striatum.  Acetylcholinesterase levels were significantly decreased in the striatum at
the highest dose, but were unchanged in the hypothalamus.  The authors believed that the decrease in 
acetylcholinesterase to be of minor functional significance given that other mechanisms can also regulate 
acetylcholine metabolism.
A study by Kontur and Fechter (1988) reported no difference in levels of monoamines and related
metabolites in neonatal rats at 22 mg manganese/kg/day as manganese chloride (14–21 days), although 
Dorman et al. (2000) reported elevated striatal DA and DOPAC in 21-day-old rats administered the same 
high daily dose used by Kontur and Fechter (1988) from PND 1 to 21.  Effect of manganese treatment on 
neurobehavior was also evaluated in this study.  There was a significant decrease in body weight gain in
pups at the highest manganese exposure dose.  Although there were no statistically significant effects on
motor activity or performance in the passive avoidance task in the neonates, manganese treatment induced 
a significant increase in amplitude of the acoustic startle reflex at PND 21.  However, in adult rats, the
amplitude of the acoustic startle reflex was significantly decreased compared to the control at the lowest
dose tested.
Reichel et al. (2006) studied the effects of manganese in male Sprague-Dawley rats that were born and
dosed daily with an oral dose of 0, 4.4 or 13.1 mg manganese/kg/day as manganese chloride on
postpartum days 1–21.  Locomotor activity was assessed (distance traveled horizontally; PNDs 10–14), as
was olfactory orientation (PNDs 9–13), negative geotaxis (PNDs 8–12) and balance and coordination 
(PND 90).  Day of eye opening, pinna detachment, and incisor eruptions was also evaluated.  Mean body
weights at PND 21 were decreased by about 2 and 3% in the low- and high-dose groups, respectively, 
compared with controls.  Manganese concentrations in striatum were elevated in the high dose group, 
compared with control, at PND 14 (~4-fold) and PND 21 (~2-fold), but not at PND 90.  Manganese levels
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were not measured in the low-dose group.  No exposure-related effects were noted on developmental
landmarks (eye opening, pinna detachment, incisor eruption), basal motor activity during the neonatal
period (PNDs 10–14) and adulthood (PND 90), or olfactory discrimination of home cage bedding during
the neonatal period.  The only behavioral end point affected during the neonatal period was a significant
(p<0.05) increase in mean latencies to rotate 180° on the inclined plane of a negative geotaxis task.  At
PND 90, dopamine transporter binding sites in the striatum were decreased by about 20 and 60% in the
low- and high-dose groups, respectively; only the high-dose value was significantly different (p<0.05)
from the control.  At PND 90, the locomotor activating effects of 20 mg/kg cocaine were significantly
(p<0.05) decreased in the neonatally exposed manganese high dose group, compared with controls. The
results indicate that neonatal exposure of rats to excess manganese caused subtle behavioral effects 
(altered balance in the neonatal period and diminished locomotor response to cocaine in adulthood) and 
neurochemical effects in adulthood (decreased dopamine binding sites in the striatum).   
In a study by Tran et al. (2002a), Sprague-Dawley PND 1 litters were culled to 10–12 pups per dam and 
then were supplemented from PNDs 1–20 with 0, 0.7, 3.8, or 7.5 mg manganese/kg/day as manganese
chloride provided by mouth.  Male and female pups were used.  Righting test (PND 6), homing test
(olfactory discrimination; PND 10), and passive avoidance (PND 32) were performed.  Striatal dopamine
levels were also determined after sacrifice on PND 40. Brain tissue analyses for iron, copper, zinc, and
manganese content were performed on animals sacrificed on PNDs 14, 21, and 40.  Animals were not
dosed after PND 20. The two highest dose groups of rats took approximately twice as long (2 seconds) as
control and 0.7 mg manganese/kg/d (approximately 1 second) to right themselves; this result was not
statistically significant.  In the homing test of olfactory discrimination, the 7.5 mg manganese/kg/day
group took significantly longer to reach their goal compared to controls and the 3.8 mg manganese/kg/day
group (the 0.7 mg manganese/kg/day group performed similarly to the control).  The control group 
required approximately 40 seconds; the high-dose group required 75 seconds (an 88% increase in the
high-dose group over the control).  In the passive avoidance task, there was a positive linear trend, with 
the highest dose group showing a 3-fold increase in the number of footshocks received over the control.  
The 3.8 mg manganese/kg/d group showed a 2-fold increase in the number of footshocks over the control.  
A negative linear relationship was also observed in striatal dopamine concentrations, with the high-dose
group having approximately half the dopamine concentration of the control.  No dose-related trends over
time points were observed in manganese content of tissues. The highest dose group showed some 
statistically significant (p<0.05) increases in manganese in brain tissue.  No changes were seen in iron,
copper, or zinc tissue concentration.  Both males and females were used in behavioral tests since 
ANOVAs showed no interactive effects of treatment or sex.
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In a companion study, Tran et al. (2002b) explored whether there were lasting behavioral and 
neurochemical changes following manganese exposure.  Again, Sprague-Dawley rat pups received
dietary supplementation in the form of 0, 0.7, 3.8, or 7.5 mg manganese/kg/day (as manganese chloride).  
Male and female pups were sacrificed during infancy and at weaning (18–24 per treatment group) for
tissue analyses of trace elements.  Twenty-four rats were sacrificed at PND 35 for dopamine analysis 
(Tran et al. 2002a). The 32 remaining rats, all males, no longer received treatment.  Behavioral testing
began with a burrowing detour test (PNDs 50–56) and ended with a passive avoidance test (PNDs 60–64).  
No statistically significant results for any individual treatment group for any behavioral task or striatal 
dopamine levels.  A statistically significant positive trend was observed for passive avoidance 
(approximately 50% more footshocks in highest dose group, compared with control).  The control had 
approximately 2 times the striatal dopamine levels of the two highest dose groups on animals sacrificed
on PND 65.  
Kern et al. (2010) evaluated Sprague-Dawley rat pups administered 0, 25, or 50 mg manganese/kg/day as
manganese chloride in 25% sucrose vehicle via micropipette from PND 1 to 21.  Dose groups were
balanced across sex within each of 26 litters, each culled to 10 pups with an approximate 2:1 male to 
female ratio.  On PND 23, 15– 20 and 7 males per group were tested in open area and the elevated plus 
maze activities, respectively.  Groups of 15–20 males were evaluated on PNDs 27–46 on the radial arm
maze.  Blood and tissue samples were collected on PND 24 (8–12/sex/group) and PND 36 (females only, 
number unspecified) for measurement of hematocrit and blood and brain manganese levels.  On PND 24, 
an additional 4–7 males/group were sacrificed for immunohistochemical analysis of dopamine transporter
(DAT) and dopamine D1 and D2 receptors in several brain regions.  Following treatment, manganese
blood levels were increased 2–3-fold at PND 24 (p<0.05), but hematocrit levels were not altered.  Males
in the 50 mg/kg/day group had significantly (p<0.05) increased activity in the open field and significantly
impaired spatial learning in the radial arm maze.  All treated males had increased stereotypical behavior
in the radial arm maze (p<0.05). There were no differences in behavior during the elevated plus maze
test.  Additionally, there were significant decreases in dopamine D1 and D2 receptors and dopamine
transporter in multiple brain regions from males from the 50 mg/kg/day group.   
In a follow-up study, Kern and Smith (2011) evaluated the effects of preweaning manganese exposure on
the adult dopaminergic system, behavior, and astrocytic activation.  Sprague-Dawley rat pups were 
exposed to 0, 25, or 50 mg manganese/kg/day using the experimental design described above.  On 
PNDs 97–98, 15–20 adult males per group were evaluated in the open area test. Blood and tissue samples 
   
 








      
       
   
   
   
     
      
  
 
         
          
       
 
          
           
  
 
        
     
      
   
 
  
    
        
        
             
          
       
    
  
    
    
MANGANESE 186
3. HEALTH EFFECTS
were collected on PND 24 (8–12/sex/group) and PND 107 (10 males/group) for measurement of blood 
and brain manganese levels.  Additionally, 4–7 males per group were sacrificed for immunohistochemical 
analysis of dopamine transporter, dopamine D1 and D2 receptors, and GFAP levels in the brain were
sacrificed on PNDs 24 and 107.  Preweaning exposure to manganese did not lead to significantly (p>0.05)
elevated manganese levels in the blood or brains of adult rats.  However, exposure at 50 mg/kg/day led to 
significantly (p≤0.05) increased densities of dopamine D2 receptors in the prefrontal cortex of adult
brains (in contrast to decreased dopamine receptor and transporter densities in weanling brains).  
Astrocyte activation was significantly (p<0.05) increased in both weanling (prefrontal cortex) and adult
rats (medial striatum) with preweaning exposure at 25 or 50 mg/kg/day.  At 50 mg/kg/day, additional
regions in the adult brain had significantly increased atrocytic activation (prefrontal cortex, nucleus 
accumbens).  In the open field, there were no measureable differences in activity in adults (compared to
increased activity in weanlings reported in the previous study).  However, a residual effect could be
observed under the influence of D-amphetamine.  Kern et al. (2011) concluded that preweaning
manganese exposure leads to lasting molecular and functional impacts in multiple brain regions of adult
animals, long after brain manganese levels return to normal.  However, it appears that behavioral effects 
may be reversible.
In order to determine if developing animals are more susceptible to the neurochemical and
neurobehavioral effects of manganese exposure, Moreno et al. (2009) exposed mice as juveniles, as
adults, or as both juveniles and adults.  Littermates from timed-pregnant C57Bl/6 mice were paired in 
control and manganese-exposed groups, receiving 0, 4.4, or 13.1 mg manganese/kg/day as manganese
chloride via gavage from PND 20 to 24 and again from week 12 to 20.  Additional animal groups were
exposed only from PND 20 to 24 or from week 12 to 20.  Open field activity was measured every other
day during early exposure (11–18 animal/group), and every other week thereafter (8–10 animals/group).  
Following treatment, animals were sacrificed.  Brain levels of dopamine and its metabolite DOPAC, and
serotonin and its metabolite 5-HIAA, were measured in the striatum of 3–4 animals per group.  Brain 
levels of manganese, iron, and copper were also measured in three animals per group.  In all treated
animals, brain regions with the highest levels of manganese were striatum, substantia nigra, and cortex.
Only modest increases in copper and iron brain levels were detected.  In the open field, juvenile-only
exposed males, but not females, spent significantly (p<0.05) less time in the margins of the open field 
(increased novelty-seeking behavior).  Adult-only exposed mice did not display any open field behavioral
alteration.  However, male mice exposed at both ages spent significantly (p<0.05) more time in the
margins of the open field (decreased novelty seeking behavior).  Additionally, males exposed to 
13.1 mg/kg/day at both ages made significantly (p<0.05) fewer movements.  Several alterations in the
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dopaminergic system were reported in all groups.  In juveniles exposed to 13.1 mg/kg/day, dopamine
levels were significantly (p<0.05) increased, but DOPAC levels were significantly decreased. Therefore,
the DOPAC:dopamine ratio (an indicator of dopamine turnover) was increased in this group.  In contrast, 
mice with adult-only exposure at 13.1 mg/kg/day and all manganese-treated mice exposed at both ages 
had significantly (p<0.05) decreased dopamine and DOPAC levels.  In the serotonergic system, the only
significant (p<0.05) finding was increased 5-H1AA in juvenile-only exposed mice at 13.1 mg/kg/day.  
These results indicate that developing mice are more sensitive to neurobehavioral and neurochemical
effects of manganese exposure than adult animals, and that previous juvenile exposure increases
susceptibility to these effects from manganese exposure in adults.
Weber et al. (2002) evaluated indicators of oxidative stress in Charles River CD rat pups that were dosed
(by mouth with micropipette) according to average pup weight for each litter starting on PND 1 and 
continuing until PND 21 at doses of 0 (nanopure water vehicle), 6.9, or 138 mg manganese/kg/day.  Pups
were sacrificed on PND 21, and samples of cerebellum and cerebral cortex were collected and frozen in
liquid nitrogen, with manganese concentrations evaluated in brain tissue.  Also evaluated were 
cerebrocortical and cerebellar metallothionein (MT) mRNA levels, glutamine synthetase (GS) activity,
GS protein levels, and total glutathione (GSH) levels. High-dose manganese exposure significantly
increased (p<0.05) total cerebrocortical GSH when compared to control without changes observed in any
of the other measures. The same change was apparent with the high-dose manganese exposure on
cerebellar GSH, although slight differences in the standard error of the mean prevented reaching
statistical significance.  However, it should be noted that these measures actually decreased with respect
to the control in the low dose manganese group.  Overall, data do not appear to support an effect of
manganese exposure on measured biochemical variables indicative of oxidative stress.
Neurologic Effects in Animals with Liver Dysfunction—Oral Exposure to Inorganic Manganese.  
Several animal studies have evaluated the potential for hepatic dysfunction to enhance the neurotoxicity
of manganese (Montes et al. 2001, 2006; Rivera-Mancia et al. 2009; Rose et al. 1999).
Rose et al. (1999) reported the effects on manganese body burden (exclusively from the diet) in rats with
either induced cirrhosis of the liver, acute liver failure (induced by portacaval anastomosis followed by
hepatic artery ligation), or a surgically-administered portacaval shunt (PCS). Brain manganese levels in
these three groups of rats were compared to control rats and sham-operated rats.  PCS and sham-operated 
rats were evaluated 4 weeks following surgery, while cirrhotic rats were studied 6 weeks following
surgery.  Rats with acute liver failure were studied 15–18 hours following devascularization at coma stage 
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of encephalopathy.  Manganese levels were statistically significantly increased as compared to non-
treated controls and sham-operated controls in both cirrhotic and PCS rats in the frontal cortex, globus
pallidus, and caudate/putamen; manganese levels were highest in the globus pallidus.  For example, in the 
globus pallidus, brain manganese was increased 57% in the PCS rats as compared to the control rats 
(p<0.0001).  However, the level of manganese in the globus pallidus in the PCS rats was significantly
elevated as compared to cirrhotic rats, indicating that shunting is a strong determinant of manganese
deposition in the brain.  
Montes et al. (2001) also explored the potential for hepatic disease to potentiate the toxic effects of
manganese by observing effects on levels of specific neurotransmitters. Groups of male Wistar rats were 
assigned to one of six treatments:  (1) sham operated; (2) bile duct ligated (BDL); (3) sham operated with 
15.1 mg manganese/kg/day supplied as manganese chloride in drinking water; (4) BDL with 15.1 mg
manganese/kg/day in drinking water; (5) sham operated with 26.7 mg manganese/kg/day in drinking
water; or (6) BDL with 26.7 mg manganese/kg/day in drinking water.  The BDL condition models a 
cirrhotic-type condition in the rats.  Rats received this treatment for 4 weeks beginning at surgery.  At the 
end of treatment, rats were weighed and killed.  Total bilirubins (as well as conjugated and unconjugated 
forms) increased over control in all BDL groups, but there was no significant effect of manganese
treatment. There was also no effect of manganese on alanine aminotransferase levels or on collagen,
although these measures were significantly increased by BDL.  However, the combination of BDL and 
manganese exposure produced 2- and 4-fold increases (p<0.001) of striatal manganese content at the
15.1 and 26.7 mg manganese/kg/day doses, respectively, while BDL alone did not produce changes.
Striatal DA content was significantly decreased compared to control in BDL rats; the addition of 26.7 mg
manganese/kg/day to BDL produced an approximate 33% increase in dopamine (DA) content over BDL
alone.  The highest dose of manganese produced 2-fold striatal HVA increases over control in both sham-
operated and BDL rats.  BDL and manganese treatment at 15.1 mg manganese/kg/day each individually
produced 2-fold increases over control levels in striatal DA turnover, measured as HVA/DA; the 
combination of BDL with manganese at 15.1 mg manganese/kg/day produced the same result as each
condition individually.  The sham-operated and BDL high dose rats each had HVA/DA levels of nearly
3 times the control level; all of these differences were significant (p<0.05). These results suggest that
hepatic dysfunction can, indeed, potentiate the neurotoxicity of manganese.
In another study, Montes et al. (2006) explored the potential role of hepatic dysfunction as a potentiator of
the toxic effects of manganese on neuronal damage produced by oxidative stress.  Groups of male Wistar
rats were assigned to one of four treatments (n=6–9 in each group): (1) sham operated; (2) BDL;
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(3) sham operated with 26.7 mg manganese/kg/day (as manganese chloride) in drinking water; or
(4) BDL with 26.7 mg manganese/kg/day in drinking water.  Rats received this treatment for 4 weeks 
beginning at time of surgery.  Compared with sham-operated controls, BDL treatment with or without
manganese caused significant (p<0.05) increases (>2-fold) in gamma glutamyltranspeptidase and alanine 
aminotransferase activities, collagen, and glycogen levels, but manganese alone did not increase these
indices of liver damage.  Manganese or BDL treatments alone caused moderate, statistically significant
(p<0.05) increases (~20%) in manganese content in the striatum and globus pallidus.  Manganese contents
in both regions were further and markedly increased by the BDL and manganese treatment (300–400%
increase).  Levels of nitric oxide (NO) were not consistently changed in either brain region in manganese-
alone or BDL plus manganese-treated rats compared with sham-operated controls, with the exception that
the NO levels in the globus pallidus were decreased (p<0.05) by ~25% in BDL and BDL plus manganese
rats.  Constitutive nitric oxide synthetase (NOS) activities in the globus pallidus were decreased (but not
to a statistically significant degree) in BDL and BDL plus manganese-treated rats.
In a similar study, Rivera-Mancía et al. (2009) investigated alterations in brain astocytes in manganese-
exposed male Wistar rats with and without liver damage.  Similar experimental groups were used 
(number of rats/group not specified: (1) sham operated; (2) BDL; (3) sham operated with 1 mg
manganese/mL (as manganese chloride) in drinking water; or (4) BDL with 1 mg manganese/mL (as 
manganese chloride) in drinking water.  Rats received this treatment for 2 or 4 weeks beginning at time of
surgery.  Using an allometric equation for drinking water consumption (EPA 1988) and average reported 
body weight, the estimated dose in manganese-exposed groups is 271 mg/kg/day.  Brain levels of
manganese were measured in the cortex, striatum, and globus pallidus.  Altered and normal astrocytes
were counted in the same regions.  Manganese or BDL treatment, alone or in concert, led to significantly
(p<0.05) elevated manganese levels in all three brain regions tested. The number of damaged astrocytes 
was significantly (p<0.05) increased in animals from both BDL groups compared to the sham-operated 
control. However, manganese exposure in either sham operated or BDL animals did not increase the 
extent of astrocyte damage.  This indicates that short-term manganese exposure alone, either with or
without liver damage, did not induce gliosis in the cortex, striatum, or globus pallidus in rats.
Neurological Effects in Iron-Deficient Animals—Oral Exposure to Inorganic Manganese. Studies
reporting competition between iron and manganese in absorption indicate the impact an iron-poor diet
will have on manganese uptake in the human (Chandra and Tandon 1973; Davis et al. 1992a, 1992b;
Diez-Ewald et al. 1968; Mena et al. 1969; Rehnberg et al. 1982; Thomson et al. 1971).  Further, 
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competition between manganese and iron at the blood-brain barrier has been reported (Aschner and 
Aschner 1990), indicating that excesses of either metal will affect the brain distribution of the other.  
A recent study in rats has been conducted to determine the mechanism by which iron is regulated at the
blood-brain barrier and the blood-cerebrospinal fluid (B-CSF) barrier and how manganese may alter these 
processes (Li et al. 2006).  Additionally, two studies by Anderson et al. (2007a, 2009) have explored the
interplay between iron deficiency and manganese supplementation and its ultimate potential for
modulating neurotransmission in the neonatal rat brain.  These studies, together with gestational exposure
studies evaluating altered iron metabolism (Garcia et al. 2006, 2007; Jarvinen and Ahlström 1975; Molina
et al. 2011; see Section 3.2.2.6), suggest that manganese-mediated alterations in iron pharmacokinetics
may, at least in part, underlie some of the observed adverse neurological effects associated with elevated
manganese exposure.
Li et al. (2006) dosed groups of 7–8-week-old male Sprague-Dawley rats were with sterile saline (control)
or manganese chloride dissolved in sterile saline at 2.2 or 6.6 mg manganese/kg/day; rats were dosed
daily via gavage for 5 consecutive days/week (weekdays only) for 30 days.  Serum iron concentrations 
were found to be significantly decreased (p<0.05) at 2.2 and 6.6 mg manganese/kg/day (50 and 66% of
control value, respectively.  In contrast, iron concentrations in the cerebrospinal fluid (CSF) were
significantly (p<0.05) increased at 2.2 and 6.6 mg manganese/kg/day (136 and 167% of control values). 
Manganese produced a dose-dependent increase of binding of IRP1 to iron-responsive element-containing
RNA in (percentage increase of high-dose group over control indicated in parentheses): the choroid 
plexus (+70%); in capillaries of striatum (+39%), hippocampus (+56%), and frontal cortex (+49%); and 
in brain parenchyma of striatum (+67%), hippocampus (+39%), and cerebellum (+28%).  Manganese
exposure significantly increased the expression of TfR mRNA in choroid plexus and striatum with a
reduction in the expression of Ft mRNA.  The results indicate that intermediate-duration oral exposure to 
excess manganese decreased serum iron concentrations and increased iron concentrations in the CSF.
These changes were associated with: (1) increased binding of iron regulatory proteins and mRNA
containing iron responsive element in several brain regions and (2) upregulation of transferritin receptor
mRNA and down-regulation of ferritin mRNA in choroid plexus and striatum. 
In a study by Anderson et al. (2007a), male and female PND 1 Sprague-Dawley rats were divided into
groups receiving either a control diet (35 mg iron/kg, 10 mg manganese/kg diet and drinking water) or a
diet with manganese supplementation (same as control diet with 1 g/L of manganese chloride added to 
drinking water for a final dose of 71.1 mg manganese/kg/day).  Rats were sacrificed after 6 weeks of
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treatment.  Additional females and males (n=6 per group) were provided with an iron-deficient diet 
(4 mg/kg iron, 10 mg manganese/kg diet and drinking water) and an iron deficient/manganese 
supplemented diet (same iron-deficient diet plus 1 g manganese chloride/L water).  Manganese exposure 
significantly (p<0.05) reduced iron concentrations in the caudate putamen and the substantia nigra from
male and female rats.  In female rats, manganese exposure also significantly reduced iron levels in the
caudate putamen. The largest decrease was seen in the female caudate putamen, where iron levels 
dropped by approximately 66% compared to controls and the female substantia nigra, where iron levels
dropped by approximately 75% compared to controls. Manganese concentrations in the brain were seen
to increase over controls most prominently in the female globus pallidus (approximately 60%).  A
significant negative correlation (p<0.05) was observed between synaptosomal manganese concentration 
and 3H-GABA uptake in rats of both sexes.  3H-GABA levels were significantly reduced from controls in 
both males and females (by approximately 50%).  In rats provided with an iron-deficient diet, few
differences were observed between the iron-deficiency condition and the iron-deficiency plus manganese 
condition.  In males, iron levels were approximately 10 times higher in the caudate putamen of iron-
deficient animals than in the animals that were iron-deficient and manganese-supplemented.
In a more recent study by Anderson et al. (2009), a similar paradigm was used to evaluate the effect of
manganese exposure and iron deficiency on the noradrenergic system.  Groups of male weanling
Sprague-Dawley rats were divided into the four groups described above (24/group), with the exception 
that a final dose of 68.3 mg manganese/kg/day was attained in manganese-exposed animals (the previous
study used an average dose between males and females).  Rats were sacrificed after 6 weeks of treatment.
Again, manganese exposure significantly (p<0.01) reduced extracellular iron concentrations and 
increased extracellular manganese concentrations in the caudate putamen.  A significant negative 
correlation (p<0.01) was observed between synaptosomal manganese concentration and 3H-NE uptake in 
the locus coeruleus.  In manganese-treated animals, extracellular NE concentrations were significantly
(p<0.01) decreased, and, in general, NE transporter and receptor proteins and mRNA levels were 
decreased across the brain. Again, in rats provided with an iron-deficient diet, few differences were 
observed between the iron-deficiency condition and the iron-deficiency plus manganese condition.
Neurological Effects—Oral Exposure to MMT. No studies regarding neurological effects following oral
exposure to MMT by humans were identified. 
Komura and Sakamoto (1992b) administered 11 mg manganese/kg/day (as MMT) to ddY mice in food 
for 12 months.  To measure differences in behavior between exposed and control mice that were fed
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normal chow, spontaneous motor activity was measured at regular intervals during exposure to determine 
differences in behavior between exposed and control mice fed normal chow.  The authors observed a
significant increase in spontaneous activity at day 80; no other significant differences were noted.  In a 
separate study (Komura and Sakamoto 1994), the authors analyzed brain levels of different neurotrans-
mitters and metabolites after identical MMT treatment.  MMT resulted in a 66% decrease in dopamine 
(DA; p<0.05) and a 95% decrease in normetanephrine (NMN; p<0.01) in the hypothalamus; in the
hippocampus, DA was unchanged, while the level of DOPAC was reduced 41% (p<0.05), and the
3-methoxytyramine (3MT) level increased 3.5-fold (p<0.01).  In the midbrain, the only significant 
changes noted were an almost 6-fold increase in 3MT (p<0.01) and a 1.75-fold increase of HVA, a 
metabolite of DOPAC via conjugation by catechol-o-methyl transferase (p<0.05). In the cerebral cortex,
HVA was decreased by 61%, norepinephrine (NE) by 64%, and epinephrine by 43% (all were p<0.05)
due to MMT administration.  In the cerebellum, DOPAC was decreased 51% (p<0.05), while NMN was
increased 7.7-fold (p<0.01).  Finally, in the medulla oblongata, DOPAC was decreased by 45% (p<0.05), 
HVA was decreased by 55% (p<0.01), and serotonin (5HT) was decreased 81% (p<0.01); metanephrine
was increased approximately 2.75-fold in the medulla (p<0.05).  
Through analysis of the distribution of manganese in the different brain regions of the mice, the authors 
observed relationships between manganese content and neurotransmitter levels.  For example, a weak
relationship was found between the manganese level in the corpus striatum and the level of NE. There 
was no relationship between the increase in HVA and the manganese levels in this same region. The 
relationship between the increase in 3MT and manganese levels in the midbrain was weak, as was the
relationship between DOPAC and manganese levels in the cerebellum.  There were no relationships 
between amines and manganese levels in the hippocampus, cerebral cortex, or medulla oblongata, 
although some changes were found.  A significant correlation was found between the level of NMN and
manganese in the cerebellum.  As discussed more fully in Section 3.4.2, the cerebellum contained the 
most manganese of any brain region following MMT administration (Komura and Sakamoto 1994).  
3.2.2.5 Reproductive Effects
There are no available studies evaluating reproductive effects in humans following oral manganese 
exposure.  
In a 14-day study in rats, no changes in testicular weight were reported at 1,300 mg manganese/kg/day
(NTP 1993).  However, several intermediate-duration studies in rats and mice indicate that manganese 
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ingestion can lead to delayed maturation of the reproductive system in males.  One study investigated the 
effect of 1,050 mg manganese (as manganese tetroxide)/kg/day, provided to weanling mice and their
dams starting when the pups were 15 days old (Gray and Laskey 1980).  On day 30, the mice were
weaned and maintained on the high-manganese diet until killed for analysis at 58, 73, or 90 days old.  The
growth and general appearance of the weanling rats appeared normal.  At time of death, preputial gland, 
seminal vesicle, testes, and body weights were measured.  The high-manganese diet resulted in a 
significant decrease in growth of these reproductive tissues but no growth retardation of the body and no 
change in liver or kidney weights.
A later study by Laskey et al. (1982) evaluated the reproductive functioning of male and female Long-
Evans rats that had been exposed to 0, 350, 1,050, and 3,500 mg manganese/kg/day (in conjunction with a
low-iron diet [20 mg iron/kg/day] or a diet adequate in iron [200 mg iron/kg/day]) while in utero (dams 
were fed the described diets during gestation) and from day 14 to 15 postpartum.  The rats were
maintained on the diet throughout the remainder of the study (224 days). The rats were mated at 100 days 
postpartum and the reproductive success of these matings was evaluated.  
In males, manganese treatment resulted in decreased testes weights (testes weights analyzed with body
weight as a covariable) observed at 40 days (at the 1,050 and 3,500 mg manganese/kg/day dose levels)
and 100 days (at the 1,050 mg manganese/kg/day dose level) of age, only when administered with the
low-iron diet.  Hormone levels in male rats were also evaluated.  No treatment-related effect was seen in
40-day-old males.  At 60 and 100 days of age, however, dose-related decreases in serum testosterone 
were observed, while serum LH (luteinizing hormone) levels remained relatively unchanged.  Luteinizing
hormone (LH) is secreted by the pituitary to stimulate testosterone production in the Leydig cells.
Testosterone levels control LH production through a negative feedback loop.  An increase in testosterone
would normally be associated with a subsequent decrease in LH. The decrease in testosterone 
simultaneous with a stable LH levels suggests that manganese is targeting the Leydig cells. Manganese 
treatment in both iron regimens prevented the normal decrease in serum follicle-stimulating hormone
(FSH) from 60 to 100 days.  In addition, manganese only negatively affected epididymal sperm counts at
100 days in the iron-deficient group.  When serum concentrations of LH, FSH, and testosterone and 
epididymal sperm counts from the 60- and 100-day-old rats were used to predict the reproductive age of
the males, the 60-day-old animals were predicted correctly.  Of the 100-day-old animals, 2/12 controls,
7/12 at 350 mg manganese/kg, and 12/12 at 1,050 mg manganese/kg were classified as 60 days old.  
These data indicate that manganese induced a significant maturational delay in the reproductive organs of
the male rat (Laskey et al. 1982).
   
 









        
  
    
          
        
          
    
         
  
           
        
       
 
          
 
 
   
 
           
      
               
           
    
           
       
      
  
            
     
 
           




To further assess the mechanism of toxicity of manganese in the pre-weanling rat, Laskey et al. (1985)
dosed rats from birth to 21 days of age with particulate manganese tetroxide in 50% sucrose solution by
gavage at doses of 0, 71, or 214 mg manganese/kg/day.  They then assessed the hypothalamic, pituitary, 
and testicular functions in the rat by measuring the endogenous or stimulated serum concentrations of
FSH, LH, and testosterone at 21 or 28 days of age.  LH-releasing hormone (LH-RH) was used to
stimulate the pituitary-testicular axis to secrete FSH, LH, and subsequently testosterone; human chorionic 
gonadotropin (hCG) was used to stimulate acutely (2-hour time period) the testicular secretion of
testosterone and repeatedly (7-day time period) to assess the ability of the Leydig cells to maintain
maximal testosterone synthesis and secretion.  Some rats from both control and manganese-dosed groups
were castrated to determine the effect this would have on the study end points.  Manganese treatment had
only a slight effect on body and testes weights, while no effects were observed on unstimulated or
stimulated FSH or LH serum levels.  In addition, manganese did not affect endogenous or acute
hCG-stimulated serum testosterone concentrations, but did decrease serum testosterone level following
repeated hCG stimulation. Liver manganese at the 71 mg/kg/day manganese dose was significantly
elevated over controls in both castrated (8.42±7.23 mg/kg for treated vs. 1.96±0.22 mg/kg for controls)
and noncastrated (3.36±0.91 mg/kg for treated vs. 1.81±0.11 mg/kg for controls) rats.  In addition, 
hypothalamic manganese concentrations were significantly increased at the 71 mg/kg/day dose in both 
castrated (6.10±3.0 mg/kg in treated vs. 0.59±0.11 mg/kg in controls) and noncastrated (3.73±1.18 mg/kg 
in treated vs. 0.65±0.057 mg/kg in controls) rats. The authors speculate that since their earlier results had
shown changes in male reproductive development in postpubertal animals with minimal manganese 
concentrations in tissues (Gray and Laskey 1980; Laskey et al. 1982), it seemed likely that the changes in
this later study (Laskey et al. 1985) would result from high manganese concentrations in the 
hypothalamus, pituitary, or testes, with the tissue with the highest manganese concentration being the site
of the toxic reproductive effect.  However, the results from this latest study reveal that manganese had no
effect on the hypothalamus or pituitary to produce LH or FSH in pre-weanling rats, despite the increased
manganese concentrations. Rather, the data indicate that it is delayed production of testosterone, shown
by the inability of the Leydig cells to maintain maximum serum concentrations of the hormone, which 
results in the delayed sexual maturation. This delay in testosterone was not significant enough, however, 
to impair rodent fertility at manganese doses as high as 1,050 mg/kg/day (Laskey et al. 1982).  
A slight decrease in pregnancy rate was observed in rats exposed to 3,500 mg manganese/kg/day (as 
manganese tetroxide) in the diet for 90–100 days prior to breeding (Laskey et al. 1982).  Since both sexes
were exposed, it is not possible to conclude whether the effect was in males, females, or both.  However, 
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this exposure regimen did not have significant effects on female reproductive parameters such as ovary
weight, litter size, ovulations, or resorptions (Laskey et al. 1982).
Manganese was found to affect sperm formation and male reproductive performance in other
intermediate-duration oral studies (Elbetieha et al. 2001; Joardar and Sharma 1990; Ponnapakkam et al. 
2003a, 2003c).  Joardar and Sharma (1990) administered manganese to mice, as potassium permanganate
or manganese sulfate, at 23–198 mg/kg/day by gavage for 21 days. The treatment resulted in sperm head
abnormalities, and the percentage of abnormal sperm was significantly elevated in all exposed mice as 
compared to controls.  Increased incidences of testicular degeneration occurred in male Sprague-Dawley
rats exposed for 63 days to doses ≥137.2 mg manganese/kg/day as manganese acetate, but not at
68.6 mg/kg/day (Ponnapakkam et al. 2003c).  Impaired male fertility was observed in male mice exposed
to manganese chloride in drinking water for 12 weeks before mating with unexposed females at a daily
dose level of 309 mg manganese/kg/day, but not at doses ≤154 mg manganese/kg/day (Elbetieha et al. 
2001).  In the 309-mg/kg/day group, 17 pregnancies occurred in 28 mated females, compared with 
26 pregnancies out of 28 females mated with controls.  At lower dose levels in another study, decreased
sperm motility and sperm counts were observed in male CD-1 mice after 43 days of exposure to 
manganese acetate at doses of 4.6 or 9.6 mg manganese/kg/day, but these doses did not impair the ability
of these males to impregnate unexposed females (Ponnapakkam et al. 2003a).
In another intermediate feeding study, Jarvinen and Ahlström (1975) administered varying doses of
manganese sulfate, from nutritionally deficient levels to excess amounts, to Sprague-Dawley female rats 
for 8 weeks prior to mating.  The rats were continued on manganese diet (0.75, 4.5, 10, 29, 94, or 187 mg
manganese/kg/day) until GD 21.  The authors found no effect of manganese on maternal weight gain, 
implantation number, resorptions, or percentage of dead fetuses.  The authors did observe that manganese 
doses of 94 mg manganese/kg/day and higher resulted in significant increases in liver manganese 
concentrations, whereas nonpregnant females had liver manganese concentrations that were unchanged,
irrespective of dose. These data suggest that pregnancy allows the female to develop significant liver
manganese stores, and it is possible these stores may be mobilized during gestation or at a future time.
The authors also noted that pregnant rats had consistent liver iron concentrations, whereas nonpregnant
rats developed a dose-dependent decrease in liver iron concentrations.  Further, the highest dose in dams
caused a significant increase in fetal manganese content.
Szakmáry et al. (1995) studied the reproductive effects of manganese chloride, administered by gavage to
pregnant rabbits and rats at concentrations of 0, 11, 22, and 33 mg manganese/kg/day on GDs 6–20 in the
   
 








     
          
           
    
 
 
         
      
             
     
     
              
       
         
          
 
      
     
        
           
 
 
         
         
  
 
            
          
 





rabbit and throughout gestation in the rat.  Manganese did not result in any reproductive effect in the
rabbit, but the highest manganese dose did cause an increase in postimplantation loss in the rat.  In
13-week dietary studies, no gross or histopathological lesions or organ weight changes were observed in
reproductive organs of rats fed up to 618 mg manganese/kg/day or mice fed 1,950 mg manganese/kg/day, 
but the reproductive function was not evaluated (NTP 1993).
More recent oral studies indicate that ingested manganese does not result in female reproductive toxicity
when rat dams were exposed during pregnancy, but impaired female fertility was observed when female 
mice were exposed to manganese in drinking water for 12 weeks before mating with unexposed males.
The first study involved a dose of 22 mg manganese/kg/day administered as manganese chloride by
gavage to female rats on days 6–17 of gestation (Grant et al. 1997a).  No treatment-related mortality,
clinical signs, changes in food or water intake, or body weights were observed in the dams.  In the second
study (Pappas et al. 1997), manganese chloride was provided to pregnant rats in drinking water at doses
up to 620 mg manganese/kg/day throughout gestation.  The manganese did not adversely affect the health
of the dams, litter size, or sex ratios of the pups.  More extensive analyses of female reproductive organs 
were not performed.  Similarly, Kontur and Fechter (1985) found no significant effect on litter size in 
female rats exposed to manganese chloride in drinking water except at concentrations so high (1,240 mg
manganese/kg/day) that water intake by the dams was severely reduced.  In contrast, Elbetieha et al. 
(2001) reported that decreased numbers of implantations and viable fetuses were observed in female 
Swiss mice exposed to manganese chloride in drinking water at a dose level of 277 mg manganese/kg/day
for 12 weeks before mating with unexposed males.
In a 2-year NTP study, no adverse reproductive effects (lesions in reproductive organs) from manganese 
sulfate exposure were reported for rats at up to 232 mg manganese/kg/day or mice at up to 731 mg
manganese/kg/day (NTP 1993).
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in
each species and duration category are recorded in Table 3-3 and plotted in Figure 3-3.
No studies were located regarding reproductive effects in humans or animals following oral exposure to 
MMT.
   
 








    
 
      
       
            
    
           
   
  
 
            
  
             
      
  
         
   
     
          
  
     
                 
  
    
              
        
   
           
         
           
     





3.2.2.6 Developmental Effects 
Developmental Effects in Humans—Oral Exposure to Inorganic Manganese. Very little information is
available on the developmental effects of manganese in humans.  The incidences of neurological
disorders and the incidences of birth defects and stillbirths were elevated in a small population of people 
living on an island where there were rich manganese deposits (Kilburn 1987); however, the lack of
exposure data, the small sample sizes, and the absence of a suitable control group preclude ascribing these 
effects to manganese.  The route of exposure was assumed to be primarily oral, but inhalation exposure
was not ruled out.
Potential developmental effects of manganese were suggested by the results of a study by Hafeman et al.
(2007), where high infant mortality in a Bangladesh community was reported in conjunction with the
presence of a local drinking water supply containing high levels of manganese. The Health Effects of
Arsenic Longitudinal Study (HEALS) was conducted on 11,749 participants 18–70 years of age living in
Araihazar, Bangladesh.  Data on the reproductive history of the 6,707 women in this population were
collected and samples were taken of drinking water from all of the wells in the study region.  Manganese 
concentrations were determined for a total of 1,299 wells, representing the drinking water supply of
3,824 infants <1 year old.  Eight-four percent of infants were exposed, directly or through maternal
intake, to water manganese levels above 0.4 mg/L with manganese concentrations ranging from 0 to
8.61 mg/L, for an average calculated daily intake of 0.26 mg manganese/kg/day.  Of the 3,837 children 
born to women who reported to drink from the same well for most of their childbearing years, 335 of
them died before reaching 1 year of age.  Infants exposed to greater than or equal to the 0.4 mg/L WHO
(2004b) standard for manganese in drinking water had an elevated mortality risk during the first year of 
life compared to unexposed infants (OR=1.8; 95% CI, 1.2–2.6).  Adjustment for water arsenic indicators 
of social class and other variables and potential confounders did not appreciably alter the results. When
the population was restricted to infants born to recently married parents (marriage year 1991 or after), the 
elevation was larger (OR=3.4; 95% CI, 1.5–7.9).  Although the results of the study suggest that the
presence of high levels of manganese in the water may be responsible for the high infant mortality
observed here, information provided by the authors on mechanism of manganese exposure suggests that
infant exposure to the high levels of manganese in the water may be complex (i.e., would likely require 
direct rather than indirect or fractionated exposure, such as that occurring through breast milk or by
in utero exposure).  The authors also indicate that it is not possible to infer that the manganese is solely
responsible for the high rate of infant mortality documented in this study
   
 








           
 
        
       
  
 
    





        
        
 
         
           
         
      
   
        
   
          
 
         
        
 
 
   
           
          
          




Similarly, results from a pilot ecologic study in North Carolina suggest an association between increased
risk for infant mortality and increased groundwater manganese concentration (Spangler and Spangler
2009).  County-level infant mortality rates and the percent of low birth weight births were obtained from
the North Carolina Center for State Health Statistics database, combined for the years 1997–2001.  
Groundwater concentration values ranging from 0.003 to 0.346 mg/L (mean, 0.078 mg/L) were obtained
from the North Carolina Geological Survey groundwater database, which contains 5,778 samples from all
100 counties in North Carolina from 1973 and 1979.  Analysis revealed that county-level infant mortality
rates were significantly (p<0.05) associated with logarithmically transformed groundwater manganese 
concentration.  With every log increase in concentration, there was a 2.074 increase in county level infant
deaths per 1,000 live births.  Percent of babies born with low birth weight was not associated with 
manganese groundwater concentration.  However, as in Hafeman et al. (2007), potential sources of
manganese exposure (dietary, inhalation) and potential confounders were not examined.  Taken together, 
these two studies provide inadequate evidence to establish a causal relationship between elevated
manganese exposure in drinking water and increased infant mortality rates.
As discussed in Section 3.2.2.4, several studies have evaluated adverse neurological results in children
with increased oral exposure to manganese and/or elevated hair or blood concentration of manganese 
(where the route of exposure is presumed to be mainly oral).  Several studies have reported an inverse
relationship between manganese exposure in school-aged children and intellectual function (Bouchard et
al. 2011; Kim et al. 2009; Wasserman et al. 2006, 2011).  Elevated manganese exposure has also been 
associated with poor performance on the WHO neurobehavioral core tests (the emotional status test was 
omitted) (He et al. 1994; Zhang et al. 1995), increased oppositional behavior and hyperactivity (Bouchard
et al. 2007c), and ADHD (Farias 2010).  Additionally, elevated manganese levels in 12-month-old infants
were associated with decreased mental development scores (Claus Henn et al. 2010).  Although observed
effects in these studies cannot be causally linked to manganese exposure exclusively, taken together, they
support the hypothesis that oral exposure to elevated manganese may be detrimental to
neurodevelopment.
Standard Developmental Studies in Animals—Oral Exposure to Inorganic Manganese.  In animals, 
standard developmental toxicity studies have not found distinct effects on fetal survival, gross fetal
malformations, or skeletal or visceral malformations or alterations.  For example, acute administration of
manganese chloride by gavage to pregnant rats at a dose of 22 mg manganese/kg/day on GDs 6– 
17 resulted in no adverse fetal developmental effects, measured as weight gain, gross malformations, or
skeletal malformations (Grant et al. 1997a).  In another study, Szakmáry et al. (1995) studied the
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developmental toxicity of manganese in the rabbit and rat. The metal, as manganese chloride, was
administered by gavage during the whole period of gestation in the rat, and during organogenesis (day 6– 
20) in the rabbit at concentrations of 0, 11, 22, and 33 mg/kg/day. In the rabbit, manganese treatments did
not result in decreases in fetal weights, skeletal retardation, or extra ribs, or in an increase in fetuses
afflicted with major anomalies.  In the rat, the highest dose resulted in retardation of development of the
skeleton and internal organs.  In addition, manganese at the highest dose caused a significant increase in
external malformations, such as clubfoot.  However, when pups from dams treated at the same dose were 
allowed to grow for 100 days after birth, no external malformations were observed, indicating that these
effects were self-corrected.  No significant differences were found in any of the groups concerning the
development of the ears, teeth, eyes, forward motion, clinging ability, body posture correction reflex, or
negative geotaxis reflex.
Reproductive Development Studies in Animals—Oral Exposure to Inorganic Manganese. Several
animal studies of the effects of manganese on reproductive development show developmental effects
(Gray and Laskey 1980; Laskey et al. 1985, 1982).  
One study involved pre-weanling mice (Gray and Laskey 1980) that were fed 1,050 mg manganese/ 
kg/day (as manganese tetroxide) beginning on PND 15.  On days 58, 73, and 90, mice were sacrificed and 
reproductive organ (preputial gland, seminal vesicle, and testes) weights and body weights were
measured.  The manganese decreased the growth of these reproductive organs, but had no effect on body
growth or liver or kidney weights.  
In another study, Laskey et al. (1982) evaluated the effect of dietary manganese exposure on rats during
gestation and continued during nursing and after weaning at doses of 0, 350, 1,050 or 3,500 mg 
manganese/kg/day.  The manganese was given in combination with either 20 or 200 mg iron/kg/day (the
former is deficient in iron, the latter is adequate). Manganese treatment was lethal at the highest dose in
the iron-deficient diet, but had no effect on male or female body weight at any age in animals receiving an 
iron-sufficient diet.  In the iron-poor diet, body weights of males were significantly depressed (p<0.05)
through day 100 of the study, whereas the females’ body weights were depressed only through day 60.  
Select females and males were mated at day 90–100 of the study and the reproductive outcomes were
analyzed. The manganese treatment did not have any significant adverse effects at any dose except to
significantly decrease the number of pregnancies at the highest dose (p<0.05).  Litter size, ovulations, 
resorptions, preimplantation deaths, and fetal weights were unaffected by the metal. Testes weights in
males were significantly decreased from controls only when administered manganese in conjunction with
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an iron-poor diet:  at day 40 at 1,050 and 3,500 mg manganese/kg/day and at day 100 at 1,050 mg/kg/day.
Hormone levels in male rats were also evaluated.  No effect was seen from manganese treatment in
40-day-old male rats.  At 60–100 days of age, however, dose-related decreases in serum testosterone were 
observed, when age-related increases were expected and no increase in serum LH was observed.  
Manganese given in both iron regimens prevented the normal decrease in serum follicle-stimulating
hormone (FSH) from 60 to 100 days.  Manganese decreased epididymal sperm count only when given
with the iron-poor diet as measured at 100 days.  
A third study involved gavage administration of 0, 71, or 214 mg manganese/kg/day (as manganese 
tetroxide) to pre-weanling rats from birth to 21 days of age (Laskey et al. 1985).  Functioning of the
hypothalamus, pituitary, and testicular tissues were measured by assaying endogenous or stimulated
serum concentrations of FSH, LH, and testosterone at days 21 or 28.  No manganese-related effects were 
observed on unstimulated or stimulated FSH or LH serum levels.  In addition, manganese did not affect 
endogenous or acute hCG-stimulated serum testosterone concentrations but did decrease serum
testosterone level following chronic hCG stimulation.  Liver and hypothalamic manganese concentrations
were significantly increased in treated rats given the 71 mg/kg/day dose over controls.  The authors
hypothesized that the manganese had an unknown affect on the testicular Leydig cell that resulted in the
delayed production of testosterone. This delayed production was presumably causing the delayed 
reproductive maturation seen in the earlier study (Gray and Laskey 1980), but was not enough to affect
fertility outcomes at doses as high as 1,050 mg/kg/day (Laskey et al. 1982).
Neurodevelopmental Studies in Animals—Oral Exposure to Inorganic Manganese. As discussed in 
Section 3.2.2.4, numerous studies have reported altered neurochemistry and/or neurobehavior following
neonatal or juvenile manganese exposure (Anderson et al. 2007a, 2009; Chandra and Shukla 1978;
Deskin et al. 1981; Dorman et al. 2000; Golub et al. 2005; Kern and Smith 2011; Kern et al. 2010;
Kristensson et al. 1986; Moreno et al. 2009; Reichel et al. 2006; Tran et al. 2002a, 2002b). Similarly,
many animal studies have examined neurological end points in animals repeatedly exposed during
gestation or through gestation into early postnatal development.  End points evaluated include
neurochemistry (Lai et al. 1984), neurobehavior (Ali et al. 1983a; Pappas et al. 1997), and neuropathology
(Lazrishvilli et al. 2009; Pappas et al. 1997).  Additionally, two studies have evaluated the potential
relationship between altered iron metabolism following manganese exposure and changes in
neurochemistry (Garcia et al. 2006) and neurobehavior (Molina et al. 2011).  While results from these
studies are varied and inconsistent, taken together, the weight-of-evidence suggests that excess 
   
 








          
 
 
     
 
         
  
   
 
          
  
  
   
      
 
    
 
     
        
 
    
           
  
     
             
        
          
           
  
          
          
     




manganese exposure during development can lead to alterations in brain chemistry and behavioral
development.  
Lai et al. (1984) studied the effect of chronic dosing of 40 mg manganese/kg/day (as manganese tetroxide 
given in drinking water) to neonatal rats that were exposed from conception, throughout gestation, and up 
to 2 years of age.  The authors found that manganese treatment led to small decreases in choline 
acetyltransferase activities in cerebellum and midbrain of 2-month-old rats.  The regional distribution of
glutamic acid decarboxylase or acetylcholinesterase was unchanged.
Ali et al. (1983a) conducted a gestational study investigating the neurological effects of excess 
manganese in drinking water on rats maintained on either a normal or low-protein diet.  Manganese
exposure originated 90 days prior to mating and continued throughout gestation and nursing.  The
offspring of rats who drank the equivalent of 240 mg manganese as manganese chloride/kg/day had pups
with delayed air righting reflexes.  No treatment-related effects were observed in body weight or brain 
weight in pups from dams fed the normal amount of protein.  Significant delays in age of eye opening and 
development of auditory startle were observed only in the pups of dams fed protein-deficient diets.
An intermediate drinking water study in pregnant rats (Pappas et al. 1997) investigated the developmental
neurotoxicity of manganese chloride doses of either 120 or 620 mg manganese/kg/day given on GDs 1– 
21. Following birth, the dams were continued on manganese until weaning at PND 22.  When the dams
were removed, the pups were continued on the same manganese doses until PND 30.  Male pups were
observed on several days subsequent to exposure in a number of behavioral tests that measured
spontaneous motor activity, memory, and cognitive ability.  The manganese-treated rats’ performance 
was not significantly different from control rats.  Pups from the highest-dose group exhibited a
significantly decreased weight gain on several days post-dosing, as well as an increased activity level on
PND 17 that was no longer evident by PND 30.  The high-dose rats were not overactive on other days,
and the decreased weight gain was resolved by PND 90.  Neurochemical analyses of the brains from
treated pups indicated that brain manganese concentrations were significantly elevated in the high-dose
group, as compared to controls.  Brain enzyme and dopamine concentrations were not significantly
different between groups, but cortical manganese concentrations were significantly elevated in the high-
dose group.  Cortical thickness was significantly different in several areas of the brains of pups in the 
high-dose group but was only found to be significantly different in one area of the low-dose group.  The
significance of the cortical thinning is not clear.
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Lazrishvilli et al. (2009) reports gliosis following developmental exposure to manganese in three groups
of rat pups (12/group) from mothers receiving 0, 10, or 20 mg manganese chloride/kg/day (0, 4.4, or
8.7 mg manganese/kg/day) in feed for 15–20 days before pregnancy, during pregnancy, and for 1 month 
after parturition.  Pups were sacrificed on postnatal day 40, and brains were removed and fixed for
histological and morphological assessment and estimations of manganese content. Manganese was 
significantly elevated in cerebral cortex in both treatment groups, but not other brain regions (striatum, 
diencephalon, mesencephalon, or medulla oblongata).  There was no difference in the number of neurons, 
and only a small proportion (7–10%) of neurons showed significant damage (pyknotic and swollen cells).  
However, there was a significant (p<0.05), dose-related increase in the number of glial cells and the glial
index throughout the brain (gliosis).  This is in contrast to negative findings for gliosis in adult rats
following exposure to 147 mg manganese/kg/day for 2 or 4 weeks (Rivera-Mancía et al. 2009, see
Section 3.2.2.4).
Developmental Effects on Iron Metabolism in Animals—Oral Exposure to Inorganic Manganese. In a
longer-duration intermediate study, Jarvinen and Ahlström (1975) fed female rats up to 187 mg manga-
nese/kg/day (as manganese sulfate) for 8 weeks prior to conception.  The rats were continued on 
manganese treatment until the 21st day of gestation. The unborn pups from dams administered 94 mg
manganese/kg/day had significantly decreased weights as compared to the other groups.  No gross 
malformations were observed in the fetuses, and alizarin-stained bone preparations revealed no 
abnormalities in any dose group.  However, fetuses from dams fed the highest manganese dose had 
significantly higher concentrations of manganese in their bodies than fetuses from the other groups.  
These data indicate that a level of 187 mg manganese/kg/day overwhelmed the rat’s homeostatic control
of manganese and the metal accumulated in the fetus. The highest manganese dose also resulted in a 
significant decrease in the iron content of the fetuses.
Garcia et al. (2006, 2007) studied the relationship between dietary manganese and dietary iron on brain 
chemistry and neurotransmission.  In one study, groups of 5–7 dams were fed diets containing 35 ppm
iron (control) or 8 mg manganese/kg/day and 35 ppm iron (manganese-supplemented) from GD 7 through 
PND 7 (Garcia et al. 2006).  On PND 4, pups born to control dams were pooled and randomly cross-
fostered to dams fed one of the two diets such that initial mean litter weights were equivalent.  Pups were 
exposed to each of these diets via maternal milk from PND 4 to 21 as well as via direct ingestion of chow
(beginning around PND 11) and were euthanized on PND 21.  In the dams, the high manganese diet
induced changes in hematological parameters similar to those seen with iron-deficiency:  50% decrease in
plasma iron (without significant decreases in hemoglobin) and increased plasma transferrin and total iron
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binding capacity.  Compared with controls, manganese-exposed pups showed decreased hemoglobin 
(about 20%), decreased plasma levels of iron (about 70%), increased plasma tranferrin and total iron 
binding capacity (about 10%), increased brain concentrations of manganese, chromium, and zinc, 
decreased brain iron levels, increased protein expression of divalent metal transporter-1 (DMT-1) and 
transferrin receptor (TfR) in all brain regions, increased GABA concentrations, and increased ratios of
GABA to glutamate concentrations.  Because GABA is an inhibitory amino acid and glutamate is an
excitatory amino acid, the authors suggested that the manganese treatment induced enhanced inhibitory
transmission in the brain of the pups. The results indicate that manganese treatment altered transport and
distribution of iron in developing rat pups and induced perturbations in brain levels of the
neurotransmitter, GABA.
In a further study by Garcia et al. (2007), groups of 5–7 GD 7 timed-pregnant Sprague-Dawley rats were 
fed one of three experimental diets: control (35 mg Fe/kg diet; 10 mg manganese/kg diet), low iron (3 mg
Fe/kg diet; 10 mg manganese/kg diet), or low iron with supplemented manganese (3 mg Fe/kg diet, 
100 mg manganese/kg diet).  On PND 4, pups born to the control dams were pooled and randomly
cross-fostered to dams fed one of the two iron-deficient diets, such that initial mean litter weights were
approximately equivalent.  The pups received these diets via maternal milk from PND 4 to 21, at which 
time the pups were sacrificed.  Levels of essential metals in the brain were measured (in cerebellum,
cortex, hippocampus, striatum, and midbrain) by inductively coupled plasma-mass spectrometry.
Increases in brain levels in low iron/manganese-treated rats (compared to control and low iron) were seen
for the following metals: copper, manganese (~50%), chromium (~150%), cobalt (~150%), molybdenum
(~25%), zinc (~130%), aluminum (~130), and vanadium (~150%).  A decrease in brain iron levels was
observed for low iron animals; low iron/manganese-treated rats had iron levels significantly higher than
the low iron animals.
Molina et al. (2011) investigated the effect of manganese exposure during development on iron 
metabolism.  Pregnant Sprague-Dawley rats (3/group) were exposed to 0 or 4.79 mg manganese/mL (as 
manganese chloride in drinking water) from GD 1 through PND 24.  Based on body weight and water
intake, study authors calculated daily manganese doses in the exposed group to be 565 and 
1,256 mg/kg/day during gestation and lactation, respectively.  Offspring were culled to 12 per dam at
PND 2, with approximate equal male to female ratio.  Iron pharmacokinetics were measured in all pups 
on PND 25, after which they were sacrificed to evaluate the intestinal expression of divalent metal
transporter 1 (DMT1), blood and brain levels of manganese, liver and brain levels of non-heme iron, and 
blood zinc protoporphyrin levels.  Overall tissue uptake of iron was lower and zinc protoporphyrin levels
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were significantly decreased in manganese-exposed pups, compared with controls.  Intestinal absorption 
of iron was not altered, nor was expression of duodenal DMT1 by manganese exposure. Hematocrit and
non-heme iron levels were not altered in exposed pups.  Additionally, before sacrifice, 4 pups/sex/dam
were tested on the elevated plus apparatus on PND 24.  Pups demonstrated significantly (p<0.05) lower
anxiety-related behavior on several measures from this paradigm.  These finding indicate that
developmental exposure to manganese leads to alterations in anxiety-like behaviors, which may be 
mediated through manganese-induced changes in iron metabolism.
Developmental Studies in Animals—Oral Exposure to MMT. No studies of developmental effects 
following oral exposure to MMT in humans or animals were located.
3.2.2.7 Cancer
No studies were located regarding carcinogenic effects in humans after oral exposure to inorganic
manganese.
Chronic (2-year) feeding studies in rats and mice have yielded equivocal evidence for the carcinogenic 
potential of manganese.  For example, rats exposed to up to 232 mg manganese/kg/day as manganese 
sulfate for 2 years showed no increases in tumor incidence (NTP 1993).  Mice fed up to 731 mg
manganese/kg/day as manganese sulfate for 2 years had a marginally increased incidence of thyroid gland
follicular cell adenomas (high-dose animals) and a significantly increased incidence of follicular cell
hyperplasia (NTP 1993); this was considered by NTP to be "equivocal evidence of carcinogenic activity
of Mn(II) sulfate monohydrate in male and female B6C3F1 mice" (there was "no evidence of carcinogenic
activity" in rats in this study).
No studies were located regarding carcinogenic effects in humans or animals following oral exposure to 
MMT.
3.2.3 Dermal Exposure 
For inorganic manganese compounds, dermal exposure is not a typical pathway of exposure because 
manganese does not penetrate the skin readily.  For organic manganese, dermal exposure is a possibility
with all compounds discussed in this profile.  This exposure pathway is most likely, however, with MMT, 
where occupational workers (mechanics, workers in the gasoline industry, pesticide manufacturers and
sprayers) are likely to handle large quantities of these compounds.
   
 









         
 
 
   
 
   
 
         




    
 




    
 
          
    
             
   
 
 
            
 
 





No studies were located regarding the any health effects in humans or animals after dermal exposure to 
inorganic manganese.
3.2.3.1 Death 
No studies were located regarding death in humans from dermal exposure to MMT. 
Hinderer (1979) reported LD50 values for rabbits (strain and sex were unreported) that were administered
varying doses of “neat” commercial MMT on abraded skin in the trunk area for 24 hours.  These values, 
generated by four different laboratories, ranged from 140 to 795 mg/kg.  Although this dose range is
wide, the author reported that it was analogous to the wide oral LD50 range given for the compound in 
other reports.
3.2.3.2 Systemic Effects
Respiratory Effects. No studies were located regarding respiratory effects in humans or animals 
following dermal exposure to MMT.
Cardiovascular Effects.    No studies concerning cardiovascular effects following dermal exposure to 
MMT in humans or animals were located.
Gastrointestinal Effects. No studies were located regarding gastrointestinal effects in humans 
following dermal exposure to MMT.  Hinderer (1979) observed bloody diarrhea in rabbits exposed 
dermally to MMT; the compound was obtained as commercial grade, “neat,” and applied to shaved skin
for 24 hours.  No histopathology was performed to ascertain the presence of lesions on the gastrointestinal
tract.
Hematological Effects. No studies were located regarding hematological effects in humans or
animals following dermal exposure to MMT.
Musculoskeletal Effects. No studies regarding musculoskeletal effects in humans or animals 
following dermal exposure to MMT were located.
   
 








       






          
  
 
          




            
            
             
    
  
 
            
 
 
           
    
 








Hepatic Effects.  Hinderer (1979) observed that rabbits that underwent dermal application of a
commercial “neat” solution of MMT for 24 hours on shaved skin had discoloration of the liver and 
swollen liver.  No histopathology was performed. 
Renal Effects.    Hinderer (1979) observed that rabbits that underwent dermal application of a
commercial “neat” solution of MMT for 24 hours on shaved skin had discoloration of the kidneys and 
swollen and congested kidneys.  No histopathology was performed.
Endocrine Effects. No studies were located regarding endocrine effects in humans or animals 
following dermal exposure to MMT.
Dermal Effects. No studies were located regarding dermal effects in humans following dermal
exposure to MMT.  Hinderer (1979) observed that rabbits exposed dermally to commercial “neat” MMT
on shaved skin for 24 hours developed edema and erythema.  Further dermal irritation tests performed 
showed that MMT is a moderate skin irritant.  Campbell et al. (1975) exposed male albino rats dermally
to MMT for 24 hours on closely clipped dorsolateral aspects of the trunk that were either abraded or
allowed to remain intact; skin reactions were evaluated and scored at 24 hours and again 48 hours later.  
By comparing skin reactions following exposure to a test rating that categorized irritancy levels, MMT
was determined to be safe for intact or abraded skin contact.  However, the authors note that MMT in
concentrated form is absorbed through the skin, and dermal absorption or interactions with other materials
or factors were not incorporated into their study. 
Ocular Effects. No studies were located regarding ocular effects in humans or animals following
dermal exposure to inorganic manganese.
Hinderer (1979) performed a standard Draize irritation test with commercial “neat” MMT in rabbits and
found the compound not to be an eye irritant.
Body Weight Effects. No studies were located regarding body weight effects in humans or animals 
following dermal exposure to inorganic manganese. 
Rabbits exposed dermally to commercial “neat” MMT exhibited slight body weight loss, although the
actual amount was not reported (Hinderer 1979).
   
 








           
 
 
         
 
 
     
 
  
     
 
     
   
 
    
 
    
    
 




    
 
       
  
 
     
  
 
    
 




Metabolic Effects. No studies were located regarding metabolic effects in humans or animals 
following dermal exposure to inorganic manganese. 
No studies were located regarding metabolic effects in humans or animals following dermal exposure to
MMT.
3.2.3.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects following dermal exposure
to inorganic manganese in either humans or animals.
No studies regarding immunological and lymphoreticular effects following dermal exposure to MMT in 
humans or animals were located.
3.2.3.4 Neurological Effects 
No studies were located regarding neurological effects following dermal exposure to inorganic
manganese in either humans or animals.
Rabbits exposed to “neat” commercial grade MMT on shaved areas of their trunks for 24 hours
experienced the following reported symptoms:  polypnea, vocalization, excitation, ataxia, tremors, 
cyanosis, and convulsions (Hinderer 1979).
3.2.3.5 Reproductive Effects
No studies were located regarding reproductive effects in humans or animals following dermal exposure
to inorganic manganese.
No studies were located regarding reproductive effects in humans or animals following dermal exposure
to organic manganese.
3.2.3.6 Developmental Effects 
No studies were located regarding reproductive effects in humans or animals after dermal exposure to
inorganic manganese.
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No studies were located in humans or animals concerning developmental effects following dermal
exposure to MMT.
3.2.3.7 Cancer
No studies were located regarding carcinogenic effects in humans or animals after dermal exposure to
inorganic manganese.
No studies were located regarding carcinogenic effects in humans or animals after dermal exposure to
MMT.
3.2.4 Diagnostic Uses
Manganese is a paramagnetic element that can contain up to five unpaired electrons in its ionic form.  The 
unpaired electrons can facilitate T1 relaxation (in MRI) by interacting with hydrogen nuclei of water
molecules (Earls and Bluemke 1999).  This T1 relaxation provides a contrast in signal during MRI from
normal cells and tumor cells because normal cells will take up the metal, whereas the cancerous cells take 
up little or no manganese (Toft et al. 1997a).  The Mn2+ ion is the ion of choice because it is most readily
found in the body.  However, because increased amounts of other sources of Mn2+, especially manganese 
chloride, were found to have a high acute toxicity (as discussed in the previous sections), it is necessary to
chelate the Mn2+ ion with another molecule that might decrease the toxic nature of the free ion.  One such 
chelate is the fodipir molecule, or dipyridoxal diphosphate. The result is mangafodipir, Mn(II)-N,N’-di-
pyridoxylethylendiamino-N,N;-diacetate-5,5'-bis(phosphate), or manganese dipyridoxal diphosphate
(MnDPDP).  This clinical imaging agent is primarily used in the detection of hepatobiliary tumors, as it is
preferentially taken up by parenchymatous cells.  However, as other organs have parenchymatous cells,
the compound is also useful in the detection of kidney, pancreas, and adrenal gland tumors (Earls and 
Bluemke 1999).  
This section will discuss the adverse effects of administration of mangafodipir. This section will not 
discuss the efficacy of mangafodipir as a contrast agent in the identification of abdominal cancer.
Because this compound is used primarily in the detection of liver and other parenchymatous tumors, it is
found exclusively in hospitals and other clinical settings. It is only administered intravenously; therefore,
all subsequent studies discussed entail an intravenous exposure route.  Because the toxicity of
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mangafodipir is mediated by manganese, the doses will be in mg manganese/kg body weight, rather than
in terms of the parent compound.
3.2.4.1 Death
There are no reports of lethality in humans following administration of mangafodipir.
Administration of mangafodipir can occur either all at once (bolus) or over a specific timed period 
necessary to give the entire amount of a precalculated dose (slow infusion).  The latter method has been 
found to be better tolerated in a clinical setting (Bernardino et al. 1992; Lim et al. 1991; Padovani et al. 
1996).
Mangafodipir was found to cause lethality in both sexes of Swiss-Webster mice with an LD50 of 2,916 mg
manganese/kg after slow infusion of 15 seconds (Larsen and Grant 1997).  The compound had an LD50 of
103 mg/kg in both sexes of the same rodent when administered in a bolus dose (Larsen and Grant 1997), 
showing the increased toxicity in the bolus administration.  When given as a slow infusion over 5 minutes
in both sexes of the CD-1 mouse, the compound had an LD50 value of 157 mg/kg, and when given at a
rate of 1.2 mL/second in BOM:NMRI male mice, the LD50 was 211 mg/kg.  In another study, the LD50 in
both sexes of the Swiss-Webster mouse was found to be 290 mg/kg, when given as a slow infusion over
approximately 2.5 minutes (Elizondo et al. 1991).  One male and one female beagle dog given a single
slow infusion (lasting ~110 seconds) of 160 mg/kg mangafodipir, as well as the one male given 
120 mg/kg, died prior to the second day of the experiment; the remaining female given 120 mg/kg was
sacrificed due to a moribund condition on day 3 of the experiment (Larsen and Grant 1997).  Dogs of both 
sexes given 83 or 99 mg/kg survived the 14-day observation period.  A single slow infusion (lasting
5 minutes) at a dose of 160 mg/kg did not result in lethality in the Sprague-Dawley rat (Larsen and Grant
1997).
Death was not observed in Sprague-Dawley rats administered nine doses of 16 mg manganese/kg/day (as 
mangafodipir) given over 3 weeks (Elizondo et al. 1991; Larsen and Grant 1997).  Moribund condition 
prompted the sacrifice of one male and one female beagle dog on days 12 and 21, respectively, of a
21-day exposure period in which the animals were administered 5.4 mg/kg/day manganese (as
mangafodipir), whereas a lower dose of 1.6 mg/kg/day did not result in death or sacrifice of any treated 
dogs (Larsen and Grant 1997).  Moribund condition also prompted the sacrifice of a single male 
Cynomolgus monkey on day 18 of a mangafodipir-dosing regimen involving 16 mg manganese/kg/day
   
 








      
     
   
          
    
 
   
 
              
 
 




       





         
         




              
       
  
   





doses also given 3 times/week for 3 weeks (Larsen and Grant 1997).  The authors did not indicate the
precise cause of lethality in the sacrificed dogs; however, they noted the dogs’ livers showed histological
signs of cholangiohepatitis, fibroplasia, bile duct proliferation, and hepatocyte necrosis, with cortical
tubular necrosis in the kidneys.  The sacrificed monkey had a serum chemistry profile indicative of renal
failure and associated liver toxicity.
3.2.4.2 Systemic Effects
Respiratory Effects. No reports were located concerning respiratory effects in humans following
dosing with mangafodipir.
A single dose of 160 mg manganese/kg as mangafodipir in Sprague-Dawley rats of both sexes resulted in
dyspnea (Larsen and Grant 1997).
Cardiovascular Effects.    Mangafodipir, when administered to humans in timed doses in clinical
studies has resulted in transient facial flushing and increased blood pressure at doses as low as 0.2 mg
manganese/kg (facial flushing) (Bernardino et al. 1992; Lim et al. 1991; Padovani et al. 1996; Wang et al. 
1997).  
Slow infusion of mangafodipir at doses of 16.5 mg manganese/kg resulted in no cardiotoxicity in mongrel
dogs of either sex (Karlsson et al. 1997). The dogs suffered from medically-induced acute ischaemic
heart failure; cardiotoxicity was measured as the depression of cardiovascular function, with specific 
measured end points being aortic pressure, pulmonary artery pressure, right atrial pressure, cardiac output,
and heart rate (Karlsson et al. 1997).  Sprague-Dawley rats suffered no cardiotoxicity (as measured by
histomorphological evaluation) after a single administration of mangafodipir at doses as high as 63 mg/kg
(Larsen and Grant 1997). 
Rats administered nine doses (3 times/week for 3 weeks) of 16 mg manganese/kg did not suffer any
adverse cardiovascular effects as measured by histomorphological analyses (Larsen and Grant 1997).  
Twenty-one days of daily administration of 5.4 mg manganese/kg in beagle dogs resulted in reduced heart
rate by the end of the treatment (Larsen and Grant 1997).  Cynomolgus monkeys administered 16 mg/kg
for 3 days/week for 3 weeks resulted in flushing of the face, but no other measured cardiovascular effects 
(Larsen and Grant 1997). 
   
 









    
    




    
       
   
 
           
        
   
  
 
            
          
           
  
   
 
           
    
 
            
         
  
   
          
              
 




Gastrointestinal Effects.    Incidences of gastrointestinal effects in humans following injection with 
mangafodipir have been limited to rare complaints of nausea or vomiting that are short-lived (15 seconds
to 5 minutes in length) and not dose- or administration rate-dependent (bolus vs. infusion) (Bernardino et
al. 1992; Lim et al. 1991; Padovani et al. 1996; Wang et al. 1997).  A dose of 81 mg manganese/kg as
mangafodipir in beagle dogs of both sexes resulted in vomiting, diarrhea, and decreased food
consumption (Larsen and Grant 1997).
Vomiting was observed in Cynomolgus monkeys of both sexes after administration of nine doses of
16 mg manganese/kg, given 3 times/week for 3 weeks (Larsen and Grant 1997). No other gastrointestinal
effects in animals were reported.
Hematological Effects. No hematological changes (versus pretreatment values) were noted in three 
different studies that included 13 healthy males (Wang et al. 1997), 54 healthy males (Lim et al. 1991), or
96 human volunteers of both sexes with known or suspected focal liver tumors (Bernardino et al. 1992)
administered up to 1.4 mg manganese/kg as mangafodipir (either via bolus or slow infusion).  
A single dose of 63 mg manganese/kg as mangafodipir in both sexes of Sprague-Dawley rats resulted in
no adverse hematological effects (Larsen and Grant 1997).  Intermediate studies of adverse effects were 
also negative.  Doses as high as 16 mg/kg given 3 times/week for 3 weeks to Sprague-Dawley rats 
(Elizondo et al. 1991; Larsen and Grant 1997) or Cynomolgus monkeys, or 5.4 mg/kg in beagle dogs
dosed daily for 21 days, failed to induce any adverse hematological effects (Larsen and Grant 1997).
Musculoskeletal Effects. No reports of musculoskeletal effects in humans or animals following
mangafodipir administration were located.
Hepatic Effects. Blood chemistry analyses revealed no significant changes in liver enzymes in
several volunteers, either with or without tumors, given mangafodipir at doses up to 1.4 mg
manganese/kg (Bernardino et al. 1992; Lim et al. 1991; Wang et al. 1997). Three individuals dosed with 
0.55 mg manganese/kg and one dosed with 1.4 mg/kg had increased serum alanine aminotransferase;
however, there was no dose response with these results and the maximum increase in the enzyme was to
70 International Units (IU)/l (the upper limit of the normal range is 45 IU/l) (Lim et al. 1991).
A single dose of up to 63 mg manganese/kg administered to both sexes of Sprague-Dawley rats did not
produce any adverse hepatic effects as observed by histomorphological analyses (Larsen and Grant 1997).  
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The administration of nine total doses of mangafodipir, three per week, at 16 mg manganese/kg/day per
dose, resulted in an increased incidence (relative amount unreported) in hepatic microgranulomas in
female Sprague-Dawley rats, but no effect on liver enzymes as measured by serum chemistry (Elizondo et
al. 1991; Larsen and Grant 1997).  Twenty-one daily doses of 1.6 mg/kg/day resulted in an increase in 
serum enzymes (alanine aminotransferase, ornithine carbamyl transferase, glutamine dehydrogenase,
alkaline phosphatase, gamma-glutamyl transferase), as well as bilirubin and cholesterol, in both sexes of
beagle dogs, while a higher dose of 5.5 mg/kg/day resulted in increased liver enzymes and liver weight
and changes in liver pathology (cholangiohepatitis, fibroplasia, bile duct proliferation, and hepatocyte
necrosis) (Larsen and Grant 1997).  The authors noted that altered serum albumin:globulin ratios and 
increased prothrombin time were indicative of decreased liver protein synthesis.  When dogs at this high 
dose were allowed a 4-week recovery period, healing of the liver was observed; specific measures of
healing were not provided, although resolution of lesions in other affected organs, such as the kidneys, 
was mentioned. The authors also noted that increased serum levels of liver enzymes and decreased liver
protein synthesis were reversible effects in dogs allowed a recovery period.  Doses of 0.54 mg/kg/day did 
not have any effect on the liver (Larsen and Grant 1997).  In both sexes of the Cynomolgus monkey, nine
total doses of 16 mg/kg/day given 3 times/week for 3 weeks, resulted in increases in liver enzymes 
(alanine aminotransferase, gamma-glutamyl transferase), as well as increases in bilirubin and relative 
liver weights in males, and focal hepatitis/cholangiolitis in one male at the end of the dosing period.  
When the monkeys were given a 2-week recovery period following a 3-week administration of the 
highest dose, only one male had a liver lesion, which was in the process of healing.  Doses of
1.6 mg/kg/day in this primate did not cause any adverse hepatic effects (Larsen and Grant 1997).
Renal Effects.    Administration of mangafodipir at up to 1.4 mg manganese/kg in a few human studies
has not resulted in any adverse renal effects as measured by blood chemistry or urinalysis (Bernardino et
al. 1992; Wang et al. 1997).
Single doses of mangafodipir up to 63 mg manganese/kg given to Sprague-Dawley rats did not cause 
renal effects as measured by blood chemistry, urinalysis, gross necropsy, and histopathology (Larsen and 
Grant 1997).  Sprague-Dawley rats of both sexes given nine doses (thrice weekly for 3 weeks) of
16 mg/kg manganese did not show any adverse renal effects as measured by urinalysis, blood chemistry,
and histomorphological analysis (Elizondo et al. 1991; Larsen and Grant 1997).  Daily administration of
mangafodipir over 21 days in both sexes of the beagle dog at concentrations up to 6 mg/kg resulted in 
cortical tubular necrosis of the kidneys at this highest dose, as well as decreased glomerular filtration rate,
as indicated by high serum carbamide and creatinine levels. There were no measurable effects at
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≤1.6 mg/kg (Larsen and Grant 1997).  Administration of nine doses of mangafodipir, also given thrice
weekly for 3 weeks, at individual concentrations of 16 mg manganese/kg to Cynomolgus monkeys of
both sexes resulted in increased kidney weights and enzymes, as well as creatinine, urea, and other
inorganic ions.  Doses of 1.6 mg/kg over the same time period did not result in any adverse effect (Larsen
and Grant 1997).
Endocrine Effects. No studies were located regarding endocrine effects in humans or animals 
following administration of mangafodipir.
Dermal Effects. No studies were located regarding dermal effects in humans or animals following
intravenous administration of mangafodipir.
Ocular Effects. No studies were located concerning ocular effects in humans following
administration of mangafodipir.
Cynomolgus monkeys administered nine individual doses at 16 mg/kg over 3 weeks and beagle dogs
given up to 6 mg/kg daily for 21 days did not have any adverse ocular effects from the mangafodipir
treatment (Larsen and Grant 1997).
Body Weight Effects. No reports were located concerning body weight effects in humans following
mangafodipir dosing.
Mice given acute doses of mangafodipir as high as 275 mg manganese/kg and rats administered a dose of
160 mg/kg did not suffer any body weight effects (Larsen and Grant 1997). 
Rats (Elizondo et al. 1991; Larsen and Grant 1997) and monkeys (Larsen and Grant 1997) administered
nine doses of mangafodipir over 3 weeks at doses as high as 16 mg manganese/kg did not have any
treatment-related effects on body weight.  Dogs administered 21 daily doses of the compound suffered 
decreased body weight (unspecified decrease) at 5.4 mg/kg, but no effect at 1.6 mg/kg (Larsen and Grant
1997).  There were no significant treatment-related adverse effects on body weight of male and female 
rats or female rabbits used in reproductive studies with mangafodipir (Blazak et al. 1996; Grant et al.
1997a; Treinen et al. 1995), except for a transient decrease in body weight during weeks 2–5, 9, and 10 in 
male rats administered 6 mg manganese/kg/day for 85 days (Grant et al. 1997a).  The authors noted that
the decrease was significant when compared to controls, but did not report actual data. 
   
 









          
 
 





          
               
            
    
         
   
 
 
   
 




   
       
 
   
                
      
      
     
    





Metabolic Effects. No studies were located regarding metabolic effects in humans or animals 
following administration of mangafodipir.
3.2.4.3 Immunological and Lymphoreticular Effects 
No studies were located regarding immunological or lymphoreticular effects in humans following
exposure to mangafodipir.
Injection of mangafodipir 3 times/week for 3 weeks in Sprague-Dawley rats at doses of 1.6, 6.3, or 16 mg
manganese/kg resulted in eosinophilia in females only at the highest dose, but had no effect in males. The 
authors stated they are unsure of the clinical importance of this effect as it was only seen at repeated high
doses (Larsen and Grant 1997).  Daily dosing of mangafodipir in beagle dogs of both sexes at doses of
1.6 mg manganese/kg for 21 days resulted in a decrease in eosinophils and an increase in toxic
neutrophils (absolute amounts not reported) (Larsen and Grant 1997).  A lower dose of 0.54 mg/kg had no 
immunological effect.
3.2.4.4 Neurological Effects 
No statistically significant increases in adverse neurological effects in humans following mangafodipir
administration were reported.  In one study, four subjects given doses ranging from a low of 0.17 mg/kg
to a high of 1.4 mg/kg complained of light-headedness or dizziness (Lim et al. 1991).  Five of 96 patients
administered mangafodipir complained of a headache following dosing; only two of these five, given 
varying doses of mangafodipir ranging from 0.17 to 1.4 mg manganese/kg, could be attributed to the
contrast agent (Bernardino et al. 1992).  No other neurological effects were reported in human studies.
Single doses of mangafodipir ranging from 8.3 to 275 mg manganese/kg in mice and a single dose of
160 mg/kg in rats, resulted in decreased activity and abnormal gait and stance (Larsen and Grant 1997).
Mongrel dogs infused once with mangafodipir at doses of 0.55, 3.3, or 16.5 mg manganese/kg did not
have any treatment-related changes in plasma catecholamines or physiological signs of sympathetic 
activation as compared to the undosed controls (Karlsson et al. 1997).  In a separate study, beagle dogs 
receiving either single doses ranging from 83 to 160 mg/kg or 21 daily doses at 5.4 mg manganese/kg
suffered decreased appetite as measured by decreased food consumption; when the dogs were allowed a 
recovery period following the repeated dosing, the food consumption normalized within the first 2–3 days
(Larsen and Grant 1997).
   
 












   
     
      
   
          




    
    
           
 
  
        
  
 
   
 
   
 
 
      
  
 
         





Rats and monkeys administered nine doses of up to 16 mg/kg each did not have any observable
neurotoxic effects (Larsen and Grant 1997).
Grant et al. (1997a) did observe behavioral changes in the pups of Sprague-Dawley dams exposed to 0, 
0.6, 1.1, or 2.2 mg manganese/kg on GDs 6–17.  Although no significant effects were observed at the
lowest dose, the exposed pups suffered a significant decrease in grasp/holding time and a 10–11%
decrease in body weight at PNDs 4 and 7 at the 1.1 mg/kg dose.  At the highest dose, pup weight was
significantly decreased at PNDs 4, 7, 14, and 21; performance on grasp/holding, negative geotaxis, and 
surface righting tests was also significantly impaired.  In addition, postnatal survival was decreased on
days 0–4 (56 vs. 95.9% in the control group) and 4–21 (78.9 vs. 100% in the control group) at the highest
dose (Grant et al. 1997a). 
Current studies do not provide evidence on the potential for neurotoxicity following clinical exposure to 
mangafodipir.  In general, studies on neurological effects in humans or animals following mangafodipir
exposure did not involve a long observation period.  Because deposition of manganese in the brain can be 
significantly delayed following exposure, it is possible that the studies to date were terminated prior to the 
onset of potential neurotoxicity.  However, neurotoxicity in humans or animals has not been reported 
following single exposures to manganese, even at high doses.  Studies on toxicokinetics of other
manganese compounds also indicate that a single exposure is not likely to result in significant
neurological effects.  For further information on distribution, refer to Section 3.4 Toxicokinetics.
3.2.4.5 Reproductive Effects
No studies were located regarding reproductive effects in humans following administration of
mangafodipir.
A single dose of 160 mg/kg in male Sprague-Dawley rats resulted in no adverse effects in testes as
measured by organ weight and histomorphological analysis (Larsen and Grant 1997).
Male Sprague-Dawley rats dosed nine times in 3 weeks with 16 mg manganese/kg as mangafodipir
suffered a decrease in absolute testes weights, but no relative decrease in weight and no 
histomorphological effects (Larsen and Grant 1997). 
   
 








         
   
  
           
      
        
  
   
  
     
    
     




    
  
 




            
         
        
 
   
 





Injection of pregnant Sprague-Dawley rats with up to 4.4 mg manganese/kg as mangafodipir, on GDs 6– 
8, 9–11, 12–14, or 15–17 (all during organogenesis) resulted in no evidence of reproductive toxicity as
measured by pregnancy rate, numbers of corpora lutea, implantations or resorptions (Treinen et al. 1995).  
Further, daily intravenous administration of doses up to 2.2 mg manganese/kg throughout GDs 6–17 did 
not result in any significant changes in pregnancy rate, corpora lutea, implantations, or resorptions
(Treinen et al. 1995).  However, Grant et al. (1997a) observed a >50% rate of post-implantation loss in
pregnant Sprague-Dawley rats administered 2.2 mg manganese/kg as mangafodipir during GDs 6–17.  
Doses of 0.6 and 1.1 mg/kg resulted in postimplantation loss rates that were similar to that of the control
group.  There were no obvious differences in compound administration or animal husbandry between the
two studies that would indicate why such disparate results would occur.  Intravenous dosing of New
Zealand white rabbits with up to 1.1 mg manganese/kg/day on GDs 6–17 did not cause reproductive
toxicity in one study (Grant et al. 1997a), but a dose of 3.3 mg manganese/kg/day during GDs 6–18 in the
same species resulted in a significant increase (3-fold) in post-implantation loss (Blazak et al. 1996).  This
latter dose corresponds to a 12-fold increase over the one-time human clinical dose (Earls and Bluemke 
1999).
Mangafodipir dosing in female Sprague-Dawley rats for 22 total days, starting prior to conception and 
ending on the 7th day of gestation at a dose of up to 6 mg manganese/kg, did not result in any adverse
reproductive effects (Grant et al. 1997a).
Male Sprague-Dawley rats dosed for 84–85 days with 0, 0.6, 2, or 6 mg manganese/kg as mangafodipir
did not show any signs of reproductive toxicity as measured by histomorphological analyses.  Although 
absolute testes weights in the intermediate dose group were reduced compared to controls, relative 
weights were not, and in the absence of histopathological findings, this reduction is not considered an 
adverse effect. The treated rats were bred with females to determine if mangafodipir dosing had any
effect on fertility.  Pregnancy rates, and the number of corpora lutea, implantations, or resorptions were
unaffected by parental treatment (Grant et al. 1997a).
3.2.4.6 Developmental Effects 
No studies were located regarding developmental effects in humans following intravenous exposure to 
mangafodipir.
   
 








            
    
   
          
    
       
    
  
 
   
    
           
  
        
         
   
 
 
   
          
  
     
 
  
   
         
           
  
 
          





Treinen et al. (1995) tested the sensitivity of different gestational periods to the administration of
mangafodipir in Sprague-Dawley rats.  Pregnant rats were dosed with 0, 1.1, 2.2, or 4.4 mg manganese/kg
on 3 consecutive days:  GDs 6–8, 9–11, 12–14, or 15–17.  The 1.1 mg/kg dose given on days 15–17 
resulted in a significant increase in skeletal malformations in fetuses (10/113 fetuses vs. 0/106 in the 
control group; p<0.05).  A higher dose of 2.2 mg/kg also caused a significant increase in malformations
when given on GDs 12–14 (10 out of 104 fetuses affected) and days 15–17 (21/143) (both p<0.05), and 
the 4.4 mg/kg dose caused increases in malformations when given on days 9–11(5/83), 12–14 (45/128), 
and 15–17 (98/129) (all p<0.05).  The malformations seen in this study included angulated or irregularly
shaped clavicle, femur, fibula, humerus, ilium, radius, tibia, ulna, and/or scapula (Treinen et al. 1995).  
The offspring of Sprague-Dawley rats dosed with 0, 0.1, 0.3, or 1 mg manganese/kg as mangafodipir
daily throughout GDs 6–17 had a significant increase (p<0.05) in abnormal limb flexures (38/270 fetuses
affected) and skeletal malformations (141/270 fetuses affected) only at the highest dose (Treinen et al.
1995).  These malformations included the same ones listed for the segmented teratology study above.  In 
a separate experiment evaluating the teratology of mangafodipir administration on GDs 6–17 in pregnant
Sprague-Dawley rats, Treinen et al. (1995) observed a significant increase (p<0.05) in skeletal
malformations in offspring of rats dosed with 2.2 mg manganese/kg (86/92 fetuses affected) compared to 
controls.  In both the segmented and continuous teratology studies, no maternal toxicity was observed.
Fetuses from Sprague-Dawley females dosed with 0, 0.6, 1.1, or 2.2 mg manganese/kg on GDs 6–17 
exhibited a statistically significant increase in wavy ribs at 0.6 mg/kg (20.5% of the viable fetuses 
impacted vs. 0.7% at the control dose; p<0.05).  At the intermediate dose, there was a statistically
significant increase in the number of fetuses with abnormalities (20 out of 159 viable fetuses) including
distortion or misshaping of one or more of the following bones:  humerus, radius, ulna, scapula, clavicle, 
femur, tibia, and fibula; in addition, 56.6% of the viable fetuses had wavy ribs and the fetuses weighed 
14% less than controls (p<0.05).  At 2.2 mg/kg, there was a significant decrease in fetal viability
(56% decrease; p<0.05), a greater increase in fetuses with abnormalities (45 out of 64 viable fetuses,) and 
a greater percentage (85.9%) with wavy ribs (Grant et al. 1997a). These effects were observed in the 
absence of maternal toxicity.  By contrast, when the mangafodipir was administered for 22 days prior to 
conception and up to GD 7 in the same species at doses of 0, 0.6, 2, and 6 mg manganese/kg/day, no 
adverse effects on the number of viable fetuses, fetal weight, or the number of fetuses with abnormalities 
were reported (Grant et al. 1997a). These teratogenic studies indicate that developmental toxicity
resulting from mangafodipir dosing is highly dependent on the time-frame of administration.
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Grant et al. (1997a) also observed behavioral changes in the offspring of Sprague-Dawley dams 
administered 0, 0.6, 1.1, or 2.2 mg manganese/kg on GDs 6–17.  The exposed pups suffered a significant
decrease in grasp/holding time and a 10–11% decrease in body weight at PNDs 4 and 7 at the 1.1 mg/kg 
dose, but no significant effects at the lower dose (Grant et al. 1997a).  At the highest dose, pup weight
was significantly decreased at PNDs 4, 7, 14, and 21, and performance on grasp/holding, negative
geotaxis, and surface righting tests was significantly impaired.  In addition, postnatal survival was
decreased on days 0–4 (56 vs. 95.9% in the control group) and 4–21 (78.9 vs. 100% in the control group)
at the highest dose (Grant et al. 1997a). These effects occurred at doses that did not cause observable 
maternal toxicity.
Mangafodipir administration in New Zealand white rabbits at doses of 0, 0.3, 0.55, or 1.1 mg
manganese/kg on GDs 6–18 resulted in incomplete ossification of the sternebrae at 1.1 mg/kg in one
study (Grant et al. 1997a), but no significant effects on fetotoxicity or fetal weight; this dose did not result
in any maternal toxicity.  In a separate study, mangafodipir at doses as high as 3.3 mg manganese/kg in 
the same strain of rabbit for the same period of exposure did not result in any significant increases in 
external, skeletal, or visceral malformations in a separate teratology study (Blazak et al. 1996). This dose
did result in an 11% decrease in fetal weight (although this value was not statistically significant in the
study, it is considered a significant developmental effect) and a 20% decrease in the number of viable 
fetuses (also not statistically significant).  It is not readily apparent why two studies with similar dosing
regimens would obtain such conflicting results.  A comparison between rat and rabbit gestational studies
indicates that the rabbit is a much less sensitive model for reproductive and developmental toxicity
induced by mangafodipir.
3.3 GENOTOXICITY
There is some evidence from a study on occupationally exposed welders that manganese may cause 
chromosomal aberrations; the welders were exposed to other potentially toxic compounds including
nickel (known to cause chromosomal aberrations) and iron; therefore, the observed increase in 
chromosomal aberrations cannot be attributed solely to manganese (Elias et al. 1989).  Mutagenicity
studies in both bacteria and mammalian strains are equivocal. While manganese sulfate was shown to not
be mutagenic to Salmonella typhimurium strains TA97, TA98, TA100, TA1535, or TA1537 either in the
presence or absence of S9 from Aroclor 1254-induced liver from rats or Syrian hamsters (Mortelmans et
al. 1986), it was shown to be mutagenic to strain TA97 elsewhere (Pagano and Zeiger 1992).  In yeast
(Saccharomyces cerevisiae strain D7), a fungal gene conversion/reverse mutation assay indicated that
   
 










   
 
        
    
       
    
   
           
          
  
          
            
  
      
     
     
  
  
          




    
    
 
         
   
       




manganese sulfate was mutagenic (Singh 1984).  Manganese chloride was reportedly not mutagenic in 
S. typhimurium strains TA98, TA100, and TA1535, but it was mutagenic in strain TA1537, and 
conflicting results were obtained for TA102 (De Méo et al. 1991; Wong 1988).
In vitro assays in mammalian cells also gave conflicting results concerning manganese mutagenicity.
Manganese chloride produced gene mutations in cultured mouse lymphoma cells (Oberly et al. 1982).  
Manganese chloride caused DNA damage in vitro using human lymphocytes at a concentration of 25 µm
without metabolic activation, but not at the lower tested concentrations of 15 and 20 µm (Lima et al. 
2008).  The compound also caused DNA damage in human lymphocytes using the single-cell gel assay
technique in the absence of metabolic activation, but caused no DNA damage when S9 was present
(De Méo et al. 1991).  Manganese sulfate induced sister chromatic exchange in Chinese hamster ovary
(CHO) cells in both the presence and absence of S9 from Aroclor 1254-induced rat liver (Galloway et al.
1987).  In a separate assay, manganese sulfate also induced chromosomal aberrations in CHO cells in the 
absence of S9 but not in its presence (Galloway et al. 1987). Manganese chloride caused chromosome 
aberrations in human lymphocytes without metabolic activation, but only when treated in the G2 phase of
the cell cycle; treatment in the G1, G1/S, and S1 phases of the cell cycle did not result in chromosome
aberrations (Lima et al. 2008).  The compound was also found to be clastogenic in root tip cells of Vicia
faba (Glass 1955, 1956), but not in cultured FM3A cells in the absence of metabolic activation (Umeda
and Nishimura 1979).  Potassium permanganate caused chromosomal aberrations in FM3A cells (Umeda
and Nishimura 1979), but not in a primary culture of cells from Syrian hamster embryos when tested in 
the absence of metabolic activation (Tsuda and Kato 1977). Manganese chloride caused cell
transformation in Syrian hamster embryo cells (Casto et al. 1979).  A list of in vitro study results is given
in Table 3-5. 
Manganese chloride did not produce somatic mutations in Drosophila melanogaster fruit flies in one
study (Rasmuson 1985), and manganese sulfate did not induce sex-linked recessive lethal mutations in
germ cells of male D. melanogaster (Valencia et al. 1985).
In vivo assays in mice showed that oral doses of manganese sulfate or potassium permanganate caused
micronuclei and chromosomal aberrations in bone marrow (Joardar and Sharma 1990).  In contrast, oral
doses of manganese chloride did not cause chromosomal aberrations in the bone marrow or
spermatogonia of rats (Dikshith and Chandra 1978).  A list of in vivo study results is given in Table 3-6.
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Table 3-5.  Genotoxicity of Manganese In Vitro
Results
Species (test
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Table 3-5.  Genotoxicity of Manganese In Vitro
Results
Species (test With Without
system) Compound End point Strain activation activation Reference
Eukaryotic organisms:
Fungi:






MnCl2 Gene mutation L5178Y TK+/- No data + Oberly et al.
1982
Syrian hamster MnCl2 Enhancement of No data + Casto et al.
embryo cells SA7 1979
transformation








Human MnCl2 Chromosomal No data + Lima et al.
lymphocytes aberrations (G2 2008
phase)




E. coli and S. MnDPDP Gene mutation E. coli: – – Larsen and 






CHO cells MnDPDP Forward – – Larsen and 
mutation Grant 1997
MnDPDP Chromosomal – – Larsen and 
aberration Grant 1997
– = negative result; + = positive result; ± = weakly positive result; CHO = Chinese hamster ovary;
DNA = deoxyribonucleic acid; Mn(CH3COO)2 = manganese acetate; MnCI2 = manganese chloride;
MnDPDP = mangafodipir; Mn(NO3)2 = manganese nitrate; MnSO4 = manganese sulfate; Rec = recombination
   
 









       
 
           
   





    
    
 
  
      





   
 
   
 
   
 
   
 
   
 
 
              




Table 3-6.  Genotoxicity of Manganese In Vivo









– Valencia et al. 1985 









Oral – Dikshith and Chandra
1978
Albino mouse MnSO4 Chromosomal
aberrations
Oral + Joardar and Sharma 
1990
Albino mouse KMnO4 Chromosomal
aberrations
Oral + Joardar and Sharma 
1990
– = negative result; + = positive result; KMnO4 = potassium permanganate; MnCl2 = manganese chloride;
MnSO4 = manganese sulfate
   
 








         
    
   
 
     
 
 
          
    
 
         





       
 
 
       
   
          
   
  
          
    
 
 
        
 
 




The results of in vitro studies show that at least some chemical forms of manganese have mutagenic 
potential.  However, as the results of in vivo studies in mammals are inconsistent, no overall conclusion 
can be made about the possible genotoxic hazard to humans from exposure to manganese compounds.
Genotoxicity data concerning MMT was not available.
One study was located regarding genotoxic effects in humans following inhalation exposure to 
manganese.  In this study, the incidences of chromosomal aberrations in three groups of welders with 
occupational exposures (10–24 years) to metals including manganese, nickel, and chromium were
examined (Elias et al. 1989).  An increase in chromosomal aberrations was found in the group working
with the metal active gas welding process; however, since their exposures included nickel as well as 
manganese, the authors could not attribute the results to any one metal exposure (nickel is known to cause
chromosomal aberrations by the inhalation route).  The median manganese concentrations during the
survey were 0.18 mg/m3 for respirable dust and 0.71 mg/m3 for total dust.  No information was available 
regarding the genotoxicity of manganese alone.
No studies were located regarding genotoxic effects in humans after oral exposure to inorganic 
manganese.
In male Swiss albino mice, manganese sulfate and potassium permanganate have both been found to be
clastogenic, and their effects were found to be dependent primarily on the concentration (not duration) of
exposure (Joardar and Sharma 1990).  In this in vivo study, oral doses were administered at varying levels 
over a 3-week period.  The manganese sulfate doses were 10.25, 20.25, and 61 mg/100 g body weight, 
and the potassium permanganate doses were 6.5, 13, and 38 mg/100 g body weight.  Sperm head 
abnormalities and the frequency of chromosomal aberrations in bone marrow cells and micronuclei were 
significantly increased.  In male rats, repeated oral doses of 0.014 mg manganese/kg/day (as manganese 
chloride) for 180 days did not produce any significant chromosomal damage in either bone marrow or
spermatogonial cells (Dikshith and Chandra 1978).
No studies were located regarding genotoxic effects in animals after inhalation exposure to inorganic 
manganese.
No studies were located concerning genotoxic effects in humans or animals following inhalation or
exposure to MMT.
   
 









    
 
 
   
 
 
      
         
 
 
   
    
   
 
           
   
  
      
  
 
           
 
    
 
 
    
    
 
          





Manganese is required by the body and is found in virtually all diets.  As discussed in Chapter 6, adults
consume between 0.7 and 10.9 mg of manganese per day in the diet, with higher intakes for vegetarians
who may consume a larger proportion of manganese-rich nuts, grains, and legumes than non-vegetarians 
(WHO 2004b).  Manganese intake from drinking water is substantially lower than intake from food.  
Exposure to manganese from air is considered negligible as compared to intake from diet, although 
persons in certain occupations may be exposed to much higher levels than the general public (see 
Section 6.7).
Even though daily dietary intake of manganese can vary substantially, adult humans generally maintain 
stable tissue levels of manganese through the regulation of gastrointestinal absorption and hepatobiliary
excretion (Andersen et al. 1999; Aschner and Aschner 2005; Aschner et al. 2005; Roth 2006).  Following
inhalation exposure, manganese can be transported into olfactory or trigeminal presynaptic nerve endings
in the nasal mucosa with subsequent delivery to the brain, across pulmonary epithelial linings into blood 
or lymph fluids, or across gastrointestinal epithelial linings into blood after mucociliary elevator clearance 
from the respiratory tract (Aschner and Dorman 2006; Dorman et al. 2006a; Roth 2006).  Manganese is
found in the brain and all other mammalian tissues, with some tissues showing higher accumulations of
manganese than others.  For example, liver, pancreas, and kidney usually have higher manganese
concentrations than other tissues (Dorman et al. 2006a).  The principal route of elimination of manganese
from the body is fecal elimination via hepatobiliary excretion; contributions from pancreatic, urinary, and 
lactational elimination are expected to be small (Dorman et al. 2006a).  Excess manganese is expected to
be eliminated from the body rapidly.  For example, following the intravenous bolus injection of
manganese chloride in rats, manganese concentrations in plasma return to normal levels within 12 hours
(Zheng et al. 2000).
3.4.1 Absorption 
3.4.1.1 Inhalation Exposure 
No studies were located regarding the absolute amount of manganese that is absorbed by humans or
animals after inhalation exposure to manganese dusts.
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In general, the extent of inhalation absorption is a function of particle size, because size determines the
extent and location of particle deposition in the respiratory tract.  Manganese from smaller particles that
are deposited in the lower airway is mainly absorbed into blood and lymph fluids, while manganese from
larger particles or nanosized particles deposited in the nasal mucosa may be directly transported to the 
brain via olfactory or trigeminal nerves.  Alternatively, particles deposited in the upper or lower
respiratory tract may be moved by mucociliary transport to the throat, where they are swallowed and enter
the stomach. The latter process is thought to account for clearance of a significant fraction of manganese-
containing particles initially deposited in the lung.  Thus, manganese may be absorbed in the nasal
mucosa, in the lung, and in the gastrointestinal tract following inhalation of manganese dust.  However, 
the relative amounts absorbed from each site are not accurately known.
Absorption of manganese deposited in the lung is expected to be higher for soluble forms of manganese
compared with relatively insoluble forms of manganese (Aschner et al. 2005).  Evidence in support of this
hypothesis comes from studies in which 3-month-old male Sprague-Dawley rats were given intratracheal
doses (1.22 mg manganese/kg) of relatively soluble (manganese chloride) or insoluble (manganese 
dioxide) forms of manganese (Roels et al. 1997).  Peak concentrations of manganese in blood were 
observed earlier after manganese chloride intratracheal administration (0.5 hour) compared with 
manganese dioxide (168 hours after administration).  Peak concentration of manganese in blood were
about 4-fold higher in rats exposed to manganese chloride than in rats exposed to manganese dioxide
(Roels et al. 1997).  Confirmatory evidence has been presented by Dorman et al. (2001a, 2004b).  For
example, rats exposed to manganese sulfate (0.1 mg manganese/m3, 6 hours/day, 5 days/week for
13 weeks) showed higher olfactory bulb and striatum manganese concentrations than rats exposed to
0.1 mg manganese/m3 manganese phosphate (hureaulite) (Dorman et al. 2004b).
Results consistent with nasal uptake of manganese and transport to the brain along neuronal tracts have
been obtained in several animal studies (Brenneman et al. 2000; Dorman et al. 2001a, 2002a; Elder et al. 
2006; Fechter et al. 2002; Henriksson et al. 1999; Lewis et al. 2005; Normandin et al. 2004; Thompson et
al. 2011; Tjälve and Henriksson 1999; Tjälve et al. 1996; Vitarella et al. 2000).  For example, following
intranasal administration of 4 μg/kg 54Mn (as manganese chloride) to weanling Sprague-Dawley rats,
whole-body autoradiography showed that the olfactory bulb contained the vast majority of measured 
manganese at 1, 3, and 7 days post-dosing (90, 69, and 47%, respectively) with values decreasing to a low
of 16% at 12 weeks (Tjälve et al. 1996).  Significant uptake of manganese by other brain regions was not
observed until the third day, when the basal forebrain, cerebral cortex, hypothalamus, and striatum had 
21, 2, 3, and 1% of the measured label, respectively (Tjälve et al. 1996).  Subsequent experiments with
   
 








   
   
        
    
    
            
  
      
        
     
  
           
 
             
          
  
 
   
    
   
 
   
 
     
        
    
          
 
         
     
     




varying doses of manganese chloride showed that the uptake of manganese into the olfactory epithelium
and the transfer to the brain olfactory bulb leveled off at the highest doses, indicating that these are 
saturable processes (Henriksson et al. 1999).  Following single, 90-minute, nose-only inhalation 
exposures of 8-week old male CD rats to aerosols of manganese chloride (0.54 mg 54Mn/m3; Brenneman 
et al. 2000) or manganese phosphate (0.39 mg 54Mn/m3; Dorman et al. 2002a), peak concentrations of
radioactivity in the brain olfactory bulb (at 1–3 days after exposure) were about 20- or 4-fold higher, 
respectively, than peak concentrations in the striatum at 21 days after exposure. Results consistent with
transport of manganese to the brain along olfactory neurons have also been obtained in rats exposed to
manganese phosphate aerosols in inhalation chambers (0, 0.03, 0.3, or 3 mg manganese/m3) 6 hours/day
for up to 14 days (Vitarella et al. 2000).  Elevated concentrations of manganese were observed in the 
olfactory bulb, striatum, and cerebellum at the 0.3 and 3 mg manganese/m3 exposure levels, compared
with control levels, and concentrations in the olfactory bulb were about 1.4–2.4-fold higher than 
concentrations in the striatum (Vitarella et al. 2000).  Elevated manganese concentrations were also found
in the olfactory bulb, striatum, and cerebellum, following 90 days of inhalation chamber exposure
(6 hours/day, 5 days/week) of young (6 weeks old at start) male or female CD rats or aged (16 months old
at start) male CD to aerosols of either manganese sulfate or manganese phosphate (“hureaulite”) at an
exposure concentration of 0.1 mg manganese/m3 (Dorman et al. 2004b).  Regardless of age or gender, the
olfactory bulb showed the highest elevation in manganese concentration, compared with other brain 
tissues, and concentrations in the olfactory bulb were higher in rats exposed to soluble manganese than in 
rats exposed to relatively insoluble manganese phosphate (Dorman et al. 2004a).  Following 12 days of
inhalation exposure of rats to ultrafine manganese oxide particles (30 nm diameter; about 0.5 mg
manganese dioxide/m3), Elder et al. (2006) reported that manganese concentrations in the olfactory bulb 
were increased by 3.5-fold over controls, compared with 2-fold increased concentrations in lungs.  Lung
lavage analysis showed no signs of pulmonary inflammation following 11 days of exposure, but several
markers of inflammation were noted in the olfactory bulb including increase tumor necrosis factor-α 
mRNA and protein.  Elder (2006) argued that these results are consistent with the direct transport of the
nanosized particles from the nasal mucosa via the olfactory neuronal tract to the olfactory bulb, noting 
that when the right nares were occluded, manganese only accumulated in the left olfactory bulb.
Elevated concentrations of manganese have also been observed in the trigeminal ganglia of rats and mice 
at 0, 7, and 14 days following nose-only inhalation exposure to aerosols of manganese chloride at a 
concentration of about 2 mg manganese/m3, 6 hours/day, 5 days/week for 2 weeks (Lewis et al. 2005).  
The latter results are consistent with uptake of manganese in the nasal respiratory epithelium and 
subsequent transport to the brain via trigeminal neurons.  In Rhesus monkeys exposed to 1.5 mg
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manganese/m3 manganese sulfate for 65 days, olfactory epithelium, olfactory bulb, and trigeminal nerve
manganese concentrations were increased by about 17-, 8-, and 2-fold over concentrations in air control
monkeys (Dorman et al. 2006a). These results are consistent with the hypothesis that the nasal olfactory
transport route may be more important than the trigeminal neuron transport route.  Support for this
hypothesis comes from studies showing that in rats with more than 90% of neurons and supporting cells
destroyed in the olfactory epithelium, transport of radiolabelled manganese to the brain was markedly
inhibited, compared with normal rats, 7 days following intranasal instillation of a single dose of 54MnCl2 
(7.5 µCi/kg); brain concentrations of radiolabel in rats with damaged olfactory epithelium were about
90% lower than concentrations in normal rats (57.22 versus 5.58 nCi/g; Thompson et al. 2011). The
relative importance of the nasal route of manganese absorption (and delivery to the brain) in humans 
(versus lung absorption and transport across the blood-brain barrier) has not been quantified, but it may
be less important in humans than in rats because the olfactory bulb accounts for a larger part of the central
nervous system and the olfactory epithelium accounts for a larger proportion of the nasal mucosa in rats 
compared with humans (Aschner et al. 2005; Dorman et al. 2002a).  Using a pharmacokinetic model
describing the olfactory transport and blood delivery of manganese in rats, Leavens et al. (2007)
calculated that 21 days or 8 days following acute inhalation exposure of rats to 54MnCl2 or 54MnHPO4, 
respectively, direct olfactory transport accounted for the majority of label in the olfactory bulb, but only a
small percentage (≤3%) of the label in the striatum.  In normal rats 7 days after nasal instillation of a
single dose of 54MnCl2, the mean concentrations of radiolabel in the olfactory bulb were about 10-, 12-, 
9-, 25-, 25-, and 41-fold higher than concentrations in the cortex, hippocampus, basal ganglia, substantia
nigra, brain stem, and cerebellum, respectively (Thompson et al. 2011). These results indicate that the 
olfactory bulb is the principal site of accumulation for manganese absorbed and transported to the brain 
via the nasal route, and that distribution to other brain regions is restricted.
Absorption of manganese deposited in the lung or nasal mucosa of rats is expected to be influenced by
iron status, with enhanced absorption under iron-deficient conditions and diminished absorption under
iron-excess conditions.  Following intratracheal administration of 54Mn-manganese chloride, 54Mn blood
concentrations were lower in male Sprague-Dawley rats fed a high-iron diet (about 10,000 ppm Fe), 
compared with concentrations in rats fed a control iron (210 ppm Fe) diet (Thompson et al. 2006).  These
results are consistent with diminished pulmonary absorption of manganese under iron-loaded conditions.  
Supporting this interpretation, 4 hours after 54Mn administration, levels of 54Mn (expressed as a 
percentage of the instilled dose) were higher in the lungs of high-iron rats, compared with control rats, but
generally lower in other tissues in high-iron versus control rats (Thompson et al. 2006).  In rats fed the
high-iron diet, mRNA levels for divalent metal transporter 1 (DMT1—a transport protein that facilitates 
   
 








         
   
  
       
   
  
     
      
       
 
    
       
   
   
 
  
    
 
     
 
          
     
          
         
   
  
      
    
           
     
 
         
 
        
MANGANESE 228
3. HEALTH EFFECTS
membrane transport of divalent iron and manganese) were decreased in the bronchus-associated
lymphatic tissue of high-iron rats, compared with control rats (Thompson et al. 2006).  In Belgrade rats, 
homozygous (b/b) for a mutation in DMT1 that impairs transport function and fed 500 ppm Fe in the diet, 
54Mn blood levels following intranasal administrations of 54Mn-manganese chloride were markedly (2– 
5-fold) lower than those in blood of anemic heterozygous (+/b) rats fed a 20 ppm Fe diet (Thompson et al. 
2007).  For example, levels of 54Mn remaining in the blood 4 hours after administration were 0.022 and 
0.115% of the instilled dose in the homozygous (b/b) and anemic heterozygous (+/b) rats, respectively (a
5-fold difference).  Intermediate levels of 54Mn in blood were found in heterozygous (+/b) rats fed the
500 ppm Fe diet (Thompson et al. 2007).  In Sprague-Dawley rats, levels of DMT1 protein in the
olfactory epithelium were 1.5- to 2.5-fold greater under anemic conditions (20 ppm Fe in diet for
3 weeks), compared with iron-sufficient conditions, 200 ppm Fe in diet for 3 weeks (Thompson et al. 
2007).  These results are consistent with the hypothesis that up- and down-regulation of DMT1 plays a
role in enhanced nasal absorption of manganese under iron-deficient conditions and diminished 
absorption under iron-excess conditions, respectively.
No studies were located regarding the absorption of organic manganese compounds following inhalation 
exposure in either humans or animals.
3.4.1.2 Oral Exposure
The amount of manganese absorbed across the gastrointestinal tract in humans is variable, but typically
averages about 3–5% (Davidsson et al. 1988, 1989a; Mena et al. 1969).  Data were not located on the
relative absorption fraction for different manganese compounds, but there does not appear to be a marked
difference between retention of manganese ingested in food (5% at day 10) or water (2.9% at day 10)
(Davidsson et al. 1988, 1989a; Ruoff 1995).  In humans, manganese absorption tends to be greater from
manganese chloride (in demineralized water) than from foods (labeled intrinsically or extrinsically with
54Mn); however, the biological half-life of manganese from either manganese chloride or food is the same 
(EPA 1995b; Johnson et al. 1991).  In human adults, supplementation of the diet with manganese sulfate
for 12–35 weeks at a level approximately 2 times the normal dietary intake caused a 30–50% decrease in
absorption of a tracer dose of 54MnCl2 (Sandstrom et al. 1990).  
Results from animal studies indicate that the gastrointestinal absorption of manganese is rapid and
expected to be higher for soluble forms of manganese compared with relatively insoluble forms of
manganese.  Following a single gavage dose of 6 mg manganese/kg as manganese chloride to rats,
   
 








    
      
 
         
  
         
   
         
      
        
              
     
 
         
        
         
        
   
   
   
       
  
 
       
    
 
  
        
            
      
          




maximal plasma concentrations were attained rapidly (Tmax=15 minutes) (Zheng et al. 2000).  From
analysis of time course of plasma concentrations following oral and intravenous administration, the oral
bioavailability for manganese was calculated to be 13.9% (Zheng et al. 2000).  Roels et al. (1997) noted 
that in 3-month-old male rats, gavage administered manganese chloride (24.3 mg manganese/kg) reached
a maximal level in blood, 7.05 μg/100 mL, within the first 30 minutes post-dosing (first time point
measured), whereas manganese from manganese dioxide, administered in the same fashion, did not reach
a maximal level in blood of 900 ng/100 mL until 144 hours (6 days) post-dosing.  Following four weekly
gavage doses of manganese chloride at 24.3 mg manganese/kg per dose, significant increases in
manganese concentration were observed in blood and the cerebral cortex, but not cerebellum or striatum, 
as compared to controls; for identical doses of manganese dioxide, manganese levels were significantly
increased only in blood. The lack of significant increase in manganese levels in any brain region
following administration of the dioxide is likely due to the delayed uptake of manganese in the blood.  
One study showed that, in full-term infants, manganese is absorbed from breast milk and cow’s milk
formulas that were either unsupplemented or supplemented with iron, copper, zinc, and iodine (Dorner et
al. 1989). Manganese intake was greater in the formula-fed infants than in the breast-fed infants due to
the higher manganese content of the formula.  However, breast-fed infants retained more of their daily
intake of manganese (40%) than did the formula-fed infants (20%).  It must be noted that the full-term 
infants evaluated in this study were 2–18 weeks old, and the data did not stratify intake and retention 
amounts by age.  Further, the data did not indicate if there were similar proportions of manganese taken
up from breast milk as compared to the formulas.  A study by Davidson and Lönnerdal (1989)
demonstrated the in vitro receptor-mediated uptake of manganese from lactoferrin; the authors speculated
that this may lead to the absorption of manganese from breast milk in human infants.  
There is some evidence to suggest that gastrointestinal absorption of manganese is age-dependent.  
Dorner et al. (1989) have shown that infants, especially premature infants, retain a higher proportion of
manganese than adults.  Animal studies also support this finding.  For example, Rehnberg et al. (1980, 
1981, 1982) dosed 1-day-old rat pups with up to 214 mg manganese/kg/day (as manganese tetroxide) for
up to 224 days, then measured manganese concentrations in tissues. The authors noted that intermediate 
and chronic exposure of rats to manganese tetroxide in water or food resulted in much larger increases in
tissue levels in young rats (1–15 days in intermediate studies, 24–40 days in chronic study) than in older
rats. These increases in neonates were judged to be due to the neonates' greater absorption of manganese 
as a result of a slower rate of transport through the gut (Rehnberg et al. 1985).  Similar results have been 
reported in rats exposed to manganese chloride (Kostial et al. 1978).  However, such age-dependent
   
 








         
         
   
           
    




   
       
            
      
          
                
      
    
      
  
 
          
  
            
   
         
     
         
   
           
     




differences in tissue retention of manganese could also be due to differences in excretory ability (Cotzias 
et al. 1976; Miller et al. 1975) or to age-related changes in dietary intake levels of iron and manganese 
(Ballatori et al. 1987).  Dorner et al. (1989) found that both pre-term and full-term infants had active 
excretion of manganese; in fact, some infants had negative manganese balances. Animal studies show
that absorption and/or retention of manganese is higher in neonates, but returns to the level of older
animals at approximately post-GD 17–18 (Kostial et al. 1978; Lönnerdal et al. 1987; Miller et al. 1975;
Rehnberg et al. 1981).  Available studies (Dorner et al. 1989) do not provide adequate data to determine
when this transition takes place in human infants.
One of the key determinants of absorption appears to be dietary iron intake, with low iron levels leading
to increased manganese absorption. Mena et al. (1969) administered oral 54Mn and 39Fe to subjects with
iron-deficiency anemia (ranging in age from 13 to 44 years old) and measured manganese and iron uptake 
with whole-body autoradiography.  The uptake of manganese by anemic subjects was 7.5% while in non-
anemic subjects, it was 3.0%. This is probably because both iron and manganese are absorbed by the 
same transport system in the gut.  The activity of this system is inversely regulated by dietary iron and
manganese intake levels (Chandra and Tandon 1973; Diez-Ewald et al. 1968; Rehnberg et al. 1982;
Thomson et al. 1971).  Interaction between iron and manganese occurs only between nonheme iron and 
manganese.  Davis et al. (1992a) demonstrated that increasing dietary intakes of nonheme iron, but not
heme iron, depressed biomarkers of manganese status (i.e., serum manganese concentrations and
lymphocyte manganese-dependent superoxide dismutase activity).
Studies of oral absorption of manganese in animals have yielded results that are generally similar to those
in humans.  Manganese uptake in pigs, which have similar gastrointestinal tracts to humans, has been 
measured using labeled manganese administered orally (Finley et al. 1997). The mean absorption rates 
for different times post-dosing were 5% 1–6 hours post-dosing, 7% 6–12 hours post-dosing, and 3.8%
12–24 hours post-dosing. Gastrointestinal uptake of manganese chloride in rats has been estimated to be 
2.5–8.2% (Davis et al. 1993; Pollack et al. 1965).  Uptake is increased by iron deficiency (Pollack et al.
1965) and decreased by preexposure to high dietary levels of manganese (Abrams et al. 1976a; Davis et
al. 1992b).  In a rat study, the intestinal transfer of the calcium ion and manganese ion was found to be
competitive, and the authors suggested that there is a common mechanism for their transfer in the
intestines (Dupuis et al. 1992).  High dietary intakes of phosphorus (Wedekind et al. 1991) and calcium
(Wilgus and Patton 1939) have also been demonstrated to depress manganese uptake in chicks. 
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Manganese absorption has also been found to vary according to manganese intake; in rats with
manganese-deficient diets, absorption was at least 2-fold higher than in rats whose diets contained an 
adequate amount of manganese (as manganese carbonate) (Davis et al. 1992b).
Two studies in suckling rat pups found differing absorptions of manganese from different milks and 
formulas.  The first study (Lönnerdal et al. 1987) found that the percent of 54Mn (added to the food source
as an extrinsic label) retained (measured as whole-body retention) in 14-day-old pups fed breast milk, 
cow milk, cow milk formula, and soy formula, was 82, 90, 77, and 65%, respectively.   
The latter study (Lönnerdal et al. 1994) found that 13-day-old rat pups fed 54Mn (from manganese 
chloride that was incubated with the food for at least 24 hours prior to feeding) in breast milk, cow milk, 
and several different manufacturers’ cow milk formulas had similar absorption values. These pups 
absorbed (measured as whole-body retention) 80% of the label from breast milk, 83% from cow milk, and 
63–90% from the cow milk formulas, with the two lowest retention values being significantly lower than
the others.  In this latter study, manganese absorption from soy formulas was significantly lower than the
other milks and formulas tested, ranging from 63 to 72%. 
The inherent concentration of manganese in each of these food sources from the first study was 0.01, 
0.04, 0.05, and 0.30 μg/mL, respectively (Lönnerdal et al. 1987).  Therefore, when the retention of the
label was multiplied by the actual manganese concentration of the food, the total amounts of absorbed 
manganese were 0.004, 0.018, 0.019, and 0.097 μg/dose fed, respectively.  These data indicate that infants
fed cow milk formula may retain 5 times more manganese, and infants fed soy formula may retain
25 times more manganese than breast-fed infants.  Although the latter results differ significantly from
those observed earlier, the researchers report that the similar relative values for manganese absorption
were indicative of significant efforts made to optimize both the relative concentrations and the
bioavailability of minerals and trace elements in the manufactured formulas.
No studies were located regarding absorption of manganese following oral exposure to MMT in humans.  
Several studies (Hanzlik et al. 1980a, 1980b; Hinderer 1979; Hysell et al. 1974; Komura and Sakamoto 
1992a, 1992b) indicate that absorption is occurring because toxicity is observed following MMT
exposure; however, no absorption rates or relative amounts were provided in these studies.  The plasma 
temporal pattern of manganese following oral administration of MMT has been studied in male Sprague-
Dawley rats (Zheng et al. 2000).  Following oral gavage of 20 mg MMT/kg, manganese appears in the
plasma with a Cmax between 2 and 12 hours after dosing.  When nearly equivalent oral doses of MMT
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(5.6 mg manganese/kg) or manganese chloride (6 mg manganese/kg) were administered, the Cmax
(0.93 mg manganese/mL) following oral MMT was about 3-fold higher than that following oral
manganese chloride (0.30 mg manganese/mL) (Zheng et al. 2000). 
3.4.1.3 Dermal Exposure 
The only available human study regarding dermal exposure to manganese discussed a case report of a 
man burned with a hot acid solution containing 6% manganese.  The authors speculated that manganese 
absorption had occurred across the burn area (Laitung and Mercer 1983) because the man had slightly
elevated urinary manganese levels (11–14 vs. 1–8 mg/L).  In most cases, manganese uptake across intact
skin would be expected to be extremely limited.
No studies were located regarding absorption of organic manganese in humans or animals following
dermal exposure.  
3.4.2 Distribution 
Manganese is a normal component of human and animal tissues and fluids.  In humans, most tissue 
concentrations range between 0.1 and 1 μg manganese/g wet weight (Sumino et al. 1975; Tipton and 
Cook 1963), with the highest levels in the liver, pancreas, and kidney and the lowest levels in bone and fat
(see Table 3-7). Manganese levels in the blood, urine, and serum of healthy, unexposed subjects living in 
the Lombardy region of northern Italy were 8.8±0.2, 1.02±0.05, and 0.6±0.014 μg/L, respectively (Minoia
et al. 1990).  Serum manganese concentrations in healthy males and females in Wisconsin were 1.06 and 
0.86 μg/L, respectively (Davis and Greger 1992; Greger et al. 1990).  Although precise inhalation 
exposure data were not available for humans, chronic occupational exposure studies have shown that
higher levels of inhalation exposure generally correspond with higher blood or urine manganese levels for
groups, but that individual measurements may not correspond to individual exposure or be reliable
exposure predictors (Abdel-Hamid et al. 1990; Alessio et al. 1989; Jarvisalo et al. 1992; Roels et al. 1992;
Siqueira et al. 1991). 
Studies investigating manganese levels in human fetal tissues or fluids are very few.  Widdowson et al.
(1972) measured manganese in fetal livers from 29 unborn infants (ranging in gestational age from 20 to 
41 weeks) and from 5 adults. The fetal manganese levels ranged from 0.09 to 0.23 mg/100 g wet weight
with a mean of 0.14 mg/100g wet weight, while the mean of the five adults was 0.18 mg/100 g wet
weight (range of values not reported). The highest fetal manganese value of 0.23 mg/100 g wet weight
   
 








       
 
     
     
  
 







      
      
      
     
      
      
      
      
     
     
     
      
      
      
 




Table 3-7.  Manganese Levels in Human and Animal Tissues
Tissue concentrations (μg manganese/g wet weight)
Humans Rats Rabbits
Tipton and Sumino et al. Rehnberg et al. Fore and
Tissue Cook (1963) (1975) (1982) Morton (1952)
Liver 1.68 1.2 2.6–2.9 2.1 
Pancreas 1.21 0.77 No data 1.6 
Adrenals 0.20 0.69 2.9 0.67 
Kidney 0.93 0.56 0.9–1.0 1.2 
Brain 0.34 0.30a 0.4 0.36 
Lung 0.34 0.22 No data 0.01 
Heart 0.23 0.21 No data 0.28 
Testes 0.19 0.20 0.4 0.36 
Ovary 0.19 0.19 No data 0.60 
Muscle 0.09 0.09 No data 0.13 
Spleen 0.22 0.08 0.3 0.22 
Fat No data 0.07 No data No data 
Bone (rib) No data 0.06 No data No data 
Pituitary No data No data 0.5 2.4 
aAverage of cerebrum and cerebellum
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was from one of the two infants at 41 gestational weeks of age when analyzed. The data indicate that
fetal liver manganese levels throughout the latter half of gestation are comparable to those in the adult.
Concentrations of manganese also have been measured in the blood of pregnant women, as well as in the
plasma of cord blood of preterm and full-term infants (Wilson et al. 1991).  Manganese concentrations in 
full-term (37–42 weeks gestation) infants were 5.5±1.5 μg/L, slightly higher than the preterm (27– 
36 weeks gestation) infants’ values of 5.0±1.1 μg/L, but the difference was not statistically significant.  
There were no correlations between the levels in infants and mothers. The higher manganese levels in
cord blood of gestationally older infants, along with the higher manganese level in the oldest fetus from
the Widdowson et al. (1972) study, suggest that manganese levels may rise slightly as the fetus 
approaches birth; however, there are inadequate data points to make a strong argument for this possibility.  
Serum manganese values of 180 healthy Venezuelan infants decreased consistently from a high value of
0.45 μg/L (mean of 22 infants) at 5 days of age to a low value of 0.29 μg/L (mean of 40 infants) at
12 months of age (Alarcón et al. 1996).  The level of manganese at 12 months was the only measurement
that was statistically different than the 5-day value.  The values were not statistically different between
the sexes.  Rükgauer et al. (1997) obtained very different results in their analyses of serum manganese 
levels in German children, adolescents, and adults. The authors evaluated 137 children (aged 1 month– 
18 years); the mean serum manganese level for all children was 1.4 μg/L (range 0.17–2.92 μg/L).  When 
the children were separated by age, the serum manganese values were found to decrease from a mean
value of 2.12 μg/L (age 0–1 year) to a minimum of 0.98 μg/L (age 14–18 years).  Adults (age 22– 
75 years) had a mean value of 0.79 μg/L. These data indicate that children had much higher manganese 
levels in serum than those levels shown by the other studies.  It is unknown why this latter study indicates
results that are vastly different from those reported in the earlier studies.  Rükgauer et al. (1997) took
precautions to prevent manganese contamination of their experimental materials during sampling and 
analysis.  Also, the authors reported that the subjects were healthy and were not suffering from nutritional
diseases or metabolic disorders and were not taking medicines containing trace elements.  However, the 
children and adolescent subjects were chosen from a pediatric hospital after seeking medical attention on
non-nutrition related matters.  Therefore, this population may not be a representative sample of the 
general population.  Animal studies, by contrast, suggest that distribution of manganese in the infant and 
young child may be very different from the adult.
Levels in tissues from animals fed a normal diet are generally similar but, perhaps are slightly higher than 
those in humans (Fore and Morton 1952; Rehnberg et al. 1982).  Levels of manganese in the milk of rats 
   
 








        
       
 




     
  
        
     
 
 
             
          
          
  
        
  
      
       
 
          
           
 
 
    
 
    
    
           
      




fed a normal diet averaged 0.054 μg/g (Miller et al. 1975).  Data on changes in tissue levels following
acute exposures to excess manganese are presented in exposure-specific subsections later in this chapter.
Manganese is also found in breast milk for the continuing metabolic nutrition of the infant.  One study
reported manganese concentrations from 82 normal, healthy French women of 12±5.6 μg/L at postpartum
day 2 in human colostrum decreasing to 3.4±1.6 μg/L at postpartum day 6 in breast milk (Arnaud and 
Favier 1995).  Another study reported an average manganese concentration in breast milk of 6.2 μg/L
using 2,339 samples from mothers of 20 full-term and 6 preterm infants (Dorner et al. 1989).  Collipp et
al. (1983) have reported concentrations of manganese in breast milk of 10 μg/L.  These reports, however, 
did not address the dietary manganese intake of the nursing mothers.  It is unknown whether mothers
exposed to increased concentrations of manganese have higher-than-usual levels of the metal in breast
milk.
Manganese is distributed throughout all cells in the body; therefore, it is present in germ cells.  However,
existing studies in humans and animals are not sufficient to predict if distribution of excess manganese 
into germ cells might result in heritable genetic changes.  Manganese is constantly present in human
tissues and, therefore, is able to enter germ cells.  One human study involving inhalation exposure to
nickel and manganese observed chromosomal aberrations in welders working with these metals (Elias et
al. 1989).  However, the presence of nickel is a confounding factor, as it is known for causing
chromosomal changes.  Studies in animals are equivocal; there are not enough data to make predictions as 
to the likelihood for excess exposures of manganese to cause heritable genetic changes.
Concentrations of manganese in select human and animal tissues are presented in Table 3-7 and 
concentrations of manganese in plasma and serum in infants of differing ages and adults are presented in
Table 3-8.
3.4.2.1 Inhalation Exposure 
Following inhalation exposure of mice to manganese dust, for a short period of time the concentration of
manganese in the lung is approximately proportional to the concentration of manganese in the air (Adkins
et al. 1980c).  However, as noted earlier, some of the particles that are deposited in the lung are 
transported to the gastrointestinal tract (Mena et al. 1969).  The rate of particle transport from the lungs
has not been quantified in humans, but half-times of elimination in animals range from 3 hours to 1 day 
(Adkins et al. 1980c; Bergstrom 1977; Newland et al. 1987).
   
 









      
 
   
   
    
   
    
    
    
    
    
    
    
    
 
            
       
     
































Concentration (μg/L) (mean±2 standard deviations)
Age Serumc Plasma
5 Daysa 0.45±0.12 (22)
1 Month 0.41±0.11 (20)
3 Months 0.39±0.13 (22)
5 Months 0.39±0.10 (14)
7 Months 0.38±0.09 (20)
10 Months 0.37±0.11 (20)
11 Months 0.36±0.12 (22)
12 Months 0.29±0.10 (40)
1 Month–18 yearsb 1.4±1.25
22–75 Years 0.79±0.63
aData from infants 5 days–12 months in age are from Alarcón et al. (1996). Data are from mixed-sex groups. No 
statistically significant differences in manganese concentrations were found between sexes.
bData from Rükgauer et al. (1997).
cValue in parentheses is the number of subjects.
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Table 3-8.  Manganese Levels in Human Serum/Plasma
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The relative increases in tissue levels of manganese following inhalation exposure to inorganic forms of
manganese have received considerable investigation in animals.
Increases of 20–60% in manganese levels in the kidney and spleen were noted in mice 24–48 hours after
exposure to manganese dioxide (Adkins et al. 1980c). Rats exposed to an aerosol containing 0.0003 mg
54Mn/m3 for 1 hour had manganese levels in the liver, lung, kidney, and brain of 0.0495, 0.1366, 0.0141, 
and 0.0014 ng 54Mn/organ, respectively, 5 days after exposure (Wieczorek and Oberdörster 1989b).  
Sheep exposed to welding fumes for 3 hours exhibited a 40-fold increase in lung manganese content
(Naslund et al. 1990).  Preferential accumulation of manganese in specific locations of the brain 
(including the caudate nucleus, globus pallidus, and substantia nigra) was noted in one monkey exposed 
to an aerosol of manganese chloride (20–40 mg/m3) several hours/day for 3–5 months (Newland et al.
1989). This preferential uptake could play a role in the characteristic neurological effects of manganese 
(see Section 3.5).
Roels et al. (1997) investigated the distributional differences in rats exposed to manganese in two forms 
(manganese chloride and manganese dioxide) administered via intratracheal injection (intended to
simulate inhalation), by gavage (oral administration) and via intraperitoneal injection.  When
administered intratracheally once a week for 4 weeks, 1.22 mg manganese/kg as manganese chloride
resulted in a 68% steady-state increase in blood manganese concentration after the dosing period.  This
dose also resulted in significantly increased concentrations of manganese in the rat cerebellum (27%
increase that approached statistical significance), striatum (205% increase), and cortex (48% increase), 
compared with control rats.
When rats were administered the same amount of manganese under the same dosing regimen, with
manganese in the form of manganese dioxide, similar, but less striking, results were observed (Roels et al.
1997).  Manganese concentrations in the blood were increased by 41%, and in the cerebellum, striatum, 
and cortex by 31, 48, and 34%, respectively, over the control rats.
Tjälve et al. (1996) investigated the distribution of manganese in brain tissues, liver, and kidneys of
young male rats following intranasal injection of 54MnCl2. Radiography data indicated that 1 day after
dosing, the olfactory bulb contained 90% of the manganese (measured as μg/100g wet weight) in the
measured tissues, while the basal forebrain contained 6% of the manganese.  Concentrations of
manganese in the basal forebrain increased to 21 and 28% of the measured total at 3 and 7 days post-
   
 








   
     
              
  
 
   
 
    
     
  
       
          
    
 
        
      
     
         
            
   
         
     
            
           
          
 
            
   
 
        
   
          




dosing, respectively.  Manganese in the cerebral cortex, hypothalamus, striatum, and hippocampus were
also maximal at 7 days post-dosing.  Manganese values in liver and kidneys were approximately 1% of
the total measured for the first 7 days, and then decreased steadily until 12 weeks. These results were 
compared to distribution of manganese following intraperitoneal injection, in which no brain region 
showed preferential distribution at 1, 7, or 21 days post-dosing (Tjälve et al. 1996).  In another study, 
Gianutsos et al. (1997) found a dose-dependent accumulation of manganese in the olfactory bulb and 
tubercle following intranasal injection of manganese chloride into one nostril.  Injection of 200 μg 
manganese resulted in maximally elevated levels in the olfactory bulb (400% higher than the uninjected 
side), with levels in the tubercle half that in the bulb within 12 hours post-exposure; these levels remained
elevated for 3 days.  Two injections of 200 μg manganese doubled the level of manganese in the striatum
compared to saline-injected controls; single doses did not increase tissue manganese levels.  No other
brain regions were noted and blood manganese levels were not changed with any treatment. These data 
indicate that the olfactory mucosa is an important pathway for distribution of manganese into the brain. 
Vitarella et al. (2000) exposed adult rats to airborne doses of particulate manganese, as manganese 
phosphate, at 0, 0.03, 0.3, 3 mg manganese/m3.  The particles had a mean diameter of 1.5 μm.  Exposures
lasted for 6 hours/day for either 5 days/week (10 exposures) or 7 days/week (14 exposures). The
following tissues were analyzed for manganese content using neutron activation analysis:  plasma,
erythrocytes, olfactory bulb, striatum, cerebellum, lung, liver, femur, and skeletal muscle.  Increased
manganese concentrations were reported in olfactory bulb, lung, femur, and skeletal muscle following
exposure to 3 mg/m3 (after either dosing regiment); a lower dose of 0.3 mg/m3 resulted in increased
manganese concentrations in olfactory bulb, and lung (14-day dose regimen only).  Striatal manganese 
levels were increased at the two highest doses only after 14 days of exposure.  However, concentrations in
the cerebellum were similarly elevated, which was interpreted by the authors to indicate that 
accumulation of manganese was not selective for the striatum.  Red blood cell and plasma manganese 
levels were increased only in rats exposed to the highest dose for the 10-day exposure period.  These data 
indicate that even at lower doses manganese can accumulate in the olfactory bulb and that the neuronal
pathway to the brain is significant for inhaled manganese in rodents.
Thompson et al. (2011) reported that in normal rats 7 days after nasal instillation of a single dose of
54MnCl2, the mean concentration of radiolabel in the brain olfactory bulb was about 9–41-fold higher than 
concentrations in other brain regions.  As discussed in Section 3.4.1, these results indicate that the 
olfactory bulb is the principal site of accumulation for manganese absorbed and transported to the brain
via the nasal route, and that distribution from the olfactory bulb to other brain regions may be restricted.
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Although the results from the studies by Tjälve et al. (1996), Vitarella et al. (2000), and Thompson (2011)
indicate that manganese can be transported via the olfactory neural pathway from the nasal mucosa to the 
olfactory bulb of the brain and, to a limited degree, to other brain regions in rodents, the relative
importance of this pathway to the delivery of manganese to basal ganglia sites of neurotoxicity is 
uncertain.  Statistical mapping of functional olfactory connections in rat brains using MRI following nasal
administration of manganese chloride could readily detect connections to the olfactory bulb, but could not
detect connections to other brain regions (Cross et al. 2004).  Mainstream manganese entry into the brain 
from blood occurs through capillary endothelial cells of the blood-brain barrier and through the cerebral
spinal fluid via the choroid plexuses (Bock et al. 2008; Crossgrove and Yokel 2005).  A number of
transport mechanisms (including facilitated diffusion, active transport, transferrin-mediated transport, 
divalent metal transporter-1 mediation, store-operated calcium channels) have been proposed to transport
manganese across the blood barrier, but current understanding is inadequate to determine the predominant
mechanism of transport (Aschner et al. 2005; 2007; Crossgrove and Yokel 2004, 2005; Roth 2006). 
A concern that inhaled manganese, compared with ingested manganese, may more readily result in
manganese accumulation in the brain, a principal toxicity target of manganese, has led to recent detailed
investigations of manganese concentrations in various brain regions and in other tissues following
inhalation exposure of animals to environmentally relevant forms of manganese.  These studies have 
investigated manganese concentrations in tissues of young male and female CD rats exposed by
inhalation to manganese sulfate or manganese tetroxide for 14 days at concentrations of 0, 0.03, 0.3, or
3 mg manganese/m3 (Dorman et al. 2001a), young male CD rats given low- (2 ppm), sufficient- (10 ppm), 
or high-manganese (100 ppm) diets for 67 days, followed by inhalation exposure to manganese sulfate for
14 days at concentrations of 0, 0.092, or 0.92 mg manganese/m3 (Dorman et al. 2001b), young male and 
female CD rats or aged male CD rats after 90 days of inhalation exposure to manganese sulfate at 0.01,
0.1, or 0.5 mg manganese/m3 or manganese phosphate at 0.1 mg manganese/m3 (Dorman et al. 2004a), 
maternal CD rats and offspring after inhalation exposure to manganese sulfate at 0, 0.05, 0.5, or 1.0 mg
manganese/m3 starting 28 days prior to breeding through PND 18 (Dorman et al. 2005a, 2005b), and 
young male Rhesus monkeys after inhalation exposure to manganese sulfate at 0.06, 0.3 or 1.5 mg
manganese/m3 for 15, 33, or 65 exposure days (Dorman et al. 2006a).  
The results from these animal studies indicate that tissue manganese concentrations in the brain depended
on aerosol concentration, exposure duration, and brain region.  Tissue manganese concentrations
generally increased with increasing air concentrations and durations of exposure. With repeated
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exposures at the highest air concentrations (≥0.92 mg manganese/m3), manganese concentrations in brain 
regions were elevated, compared with control animals, showing the following order: olfactory
bulb>striatum>cerebellum.  Illustrative data for maternal CD rats (Dorman et al. 2005a) and young
Rhesus monkeys (Dorman et al. 2006a) exposed to manganese sulfate are shown in Tables 3-9 and 3-10, 
respectively.  Comparison of manganese concentrations across tissues shows the following order in
exposed maternal rats: liver > pancreas > olfactory bulb > lung > striatum ≈ femur > milk > cerebellum
>> whole blood (Table 3-9).  In young Rhesus monkeys after 65 days of exposure, the order was:  bile >
olfactory epithelium > pituitary > liver > pancreas ≈ globus pallidus > olfactory bulb > kidney > putamen 
> caudate > cerebellum > heart >skeletal muscle > frontal cortex > lung > parietal bone ≈ femur >> blood 
(Table 3-10). 
Brain tissues from the monkeys were dissected into more regions than the rat brains and, immediately
following 65 days of exposure to the highest exposure concentration, showed the following order of
elevated manganese concentrations:  pituitary>globus pallidus>olfactory bulb>putamen>caudate>
cerebellum>frontal cortex>trigeminal nerve (see Table 3-10). These results are consistent with the 
evidence that the human striatum, globus pallidus, and substantia nigra are the primary neurotoxicity
target for manganese (Aschner et al. 2005; Pal et al. 1999).  Three- to 5-fold increases (over air control
values) in mean manganese tissue concentrations were found in the globus pallidus, putamen, and caudate
in monkeys exposed to 1.5 mg manganese/m3 manganese sulfate for 65 days, but levels were <3-fold 
increased in the frontal cortex and cerebellum, two brain regions not generally associated with manganese 
neurotoxicity (Dorman et al. 2006a; Table 3-10).  
Comparison with the rat results in Table 3-9 suggests that rodents do not accumulate manganese in the 
basal ganglia (i.e., the collection of deep regions of the brain including the striatum [comprised of the
caudate and putamen]) to the same relative degree as primates, a difference that may be related to findings 
that overt signs of manganese neurotoxicity are more readily detected in nonhuman primates than rodents 
(Aschner et al. 2005; Bock et al. 2008; Newland 1999).  Recent corroborative findings showed that
marmosets, a nonhuman primate, accumulated more manganese in the brain (especially in the basal
ganglia and the visual cortex) than rats following intravenous injection of equivalent mg/kg body weight
doses of manganese chloride (Bock et al. 2008). The mechanisms by which manganese accumulates in
the basal ganglia of primates are poorly understood (Aschner et al. 2005; Bock et al. 2008; Brenneman et
al. 1999; Dorman et al. 2006b), but Bock et al. (2008) have hypothesized that primates may accumulate 
relatively more manganese in the basal ganglia than rodents because of a relatively larger cerebral spinal
fluid space in lateral ventricles adjacent to the basal ganglia.
   
 









        
       
      




    
      
      
      
     
     
     
     
     
     
      
 
      
 












Table 3-9.  Terminal Mean (±Standard Error on the Mean) Tissue Manganese
Concentrations (µg Manganese/g Tissue Wet Weight) in Maternal CD Rats 
Exposed to Aerosols of Manganese Sulfate 6 Hours/Day, 7 Days/Week
Starting 28 Days Prior to Breeding Through Postnatal Day 18
Exposure concentration (mg manganese/m3)
Tissue 0 0.05 0.5 1.0
Whole blood 0.08±0.04 0.06±0.02 0.06±0.01 0.05±0.01
Olfactory bulb 0.56±0.05 0.71±0.04a 1.40±0.07a 1.73±0.07a 
Striatum 0.51±0.02 0.54±0.02 0.74±0.02a 0.89±0.02a 
Cerebellum 0.50±0.02 0.52±0.02 0.60±0.01a 0.61±0.03a 
Lung 0.22±0.03 0.37±0.02 0.86±0.07a 1.05±0.06a 
Liver 3.21±0.15 3.04±0.09 3.37±0.15 4.28±0.76a 
Femur 0.62±0.07 0.61±0.04 077±0.05 0.89±0.06a 
Pancreas 1.66±0.13 1.80±0.19 1.29±0.28 1.91±0.23
Milk 0.21±0.08 0.20±0.06 0.47±0.06 0.77±0.10a 
Group size (n) 8 10 9 8
aSignificantly (p<0.05) different from control mean value.
Source: Dorman et al. 2005a
   
 









       
     
    
      
      
 
   
       
 
        
 
      
        
        
        
        
        
       
       
        
       
         
 
        
 
       
       
        
       
        
        
       
          
        

	
Exposure to air 1.5 mg manganese/m3 
Exposure (days) 65 15 33 65 65 (+45)a 65 (+90)a 
Tissue
Olfactory tissues
Olfactory 0.49±0.01 6.10±0.39b 7.34±0.70b 7.10±2.01b 0.65±0.04 0.69±0.11
epithelium
Olfactory bulb 0.31±0.01 2.19±0.44b 2.29±0.26b 2.40±0.18b 0.35±0.02 0.31±0.02
Olfactory tract 0.30±0.06 0.77±0.19b 0.84±0.11b 1.12±0.08b 0.18±0.02 0.22±0.02
Olfactory cortex 0.19±0.01 0.43±0.04b 0.45±0.01b 0.42±0.01b 0.26±0.01 0.21±0.01
Brain
Globus pallidus 0.48±0.04 1.92±0.40b 2.41±0.29b 2.94±0.23b 1.09±0.03b 0.59±0.12
Putamen 0.36±0.01 1.01±0.08b 1.50±0.14b 1.81±0.14b 0.58±0.03b 0.44±0.02
Caudate 0.34±0.02 0.93±0.11b 1.37±0.13b 1.72±0.10b 0.57±0.03 0.43±0.02
Frontal cortex 0.25±0.03 0.36±0.01b 0.52±0.03b 0.47±0.02b 0.26±0.01 0.23±0.01
Cerebellum 0.44±0.01 0.85±0.06b 0.96±0.05b 1.10±0.11b 0.66±0.04 0.61±0.10
Pituitary 0.84±0.12 3.79±0.38b 5.60±0.33b 6.19±0.61b 3.01±0.91b 1.54±0.18
Trigeminal 0.17±0.05 0.27±0.02 0.51±0.14b 0.42±0.08b 0.18±0.01 0.17±0.02 
nerve
Organs
Femur 0.13±0.02 0.27±0.04b 0.13±0.03 0.20±0.03 0.12±0.02 0.09±0.01
Heart 0.16±0.03 0.25±0.05 0.50±0.03b 0.62±0.05b 0.23±0.3 0.27±0.01
Kidney 1.14±0.12 2.65±0.14b 3.04±0.09b 2.61±0.30b 1.38±0.13 1.27±0.14 
Liver 2.49±0.09 2.96±0.34 3.28±0.22 3.52±0.45b 2.88±0.27 2.04±0.06
Lung 0.15±0.03 0.39±0.06b 0.35 ±0.02b 0.33±0.04b 0.09±0.01 0.06±0.01
Pancreas 1.59±0.11 2.89±0.14b 2.38±0.34b 2.95±0.24b 1.41±0.270. 1.53±0.10 
Skeletal muscle 0.15±0.03 0.22±0.03 0.22±0.02 0.58±0.19b 19±0.02 0.12±0.01
Parietal bone 0.08±0.04 0.48±0.16b 0.56±0.18b 0.25±0.04 0.17±0.03 0.16±0.04











Table 3-10.  Mean (±Standard Error on the Mean) Tissue Manganese 
Concentrations (µg Manganese/g Tissue Wet Weight) in Young 
Male Rhesus Monkeys Exposed to Aerosols of Manganese
Sulfate (1.5 mg Manganese/m3) 6 Hours/
Day, 5 Days/Week for Up to 65 Days
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Table 3-10.  Mean (±Standard Error on the Mean) Tissue Manganese 
Concentrations (µg Manganese/g Tissue Wet Weight) in Young 
Male Rhesus Monkeys Exposed to Aerosols of Manganese
Sulfate (1.5 mg Manganese/m3) 6 Hours/
Day, 5 Days/Week for Up to 65 Days
Exposure to air 1.5 mg manganese/m3 
Exposure (days) 65 15 33 65 65 (+45)a 65 (+90)a 
Tissue
Fluids
Bile 0.89±.22 7.38±.78b 4.40±.89b 7.60±1.68b 1.17±0.28 0.77±0.13
0.010±.001 0.016±.06 0.022±.002 0.026±0.00 0.021±0.002 0.013±.001Blood a 3b b 
0.000±.000 0.000±.000 0.001±.000 0.005±0.00 0.000±0.000 0.000±.000Urine 1b 
Group size (n) 6 4 4 4 4 4
aThese monkeys were sacrificed 45 or 90 days after the 65-day exposure period.
bSignificantly (p<0.05) greater than mean value for air control rats.
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The high concentrations of manganese in bile sampled from manganese-exposed monkeys (compared 
with air control values in Table 3-10) are reflective of the hepatobiliary excretion of manganese.  It is 
currently unknown whether or not the high manganese concentrations attained in the pituitary glands of
these monkeys has any effect on normal pituitary function; in this study, exposed monkeys showed no 
difference in serum levels of luteinizing hormone (LH), a hormone that stimulates production of
testosterone by the Leydig cells of the testes (Dorman et al. 2006a).
In pregnant rats repeatedly exposed to inhaled manganese, the placenta appears to partially limit the 
transport of manganese to the developing fetus (Dorman et al. 2005b).  After inhalation exposure to 
manganese sulfate at 0, 0.05, 0.5, or 1.0 mg manganese/m3 starting 28 days prior to breeding through 
PND 18, samples of maternal tissues (whole blood, lung, pancreas, liver, brain, femur, and placenta) and 
fetal tissues (whole blood, lung, liver, brain, and skull cap) were collected and analyzed for manganese
concentrations.  Elevated (p<0.05) manganese concentrations were observed in exposed maternal rats 
(compared with air control rats) in the following tissues: brain and placenta at 0.5 and 1.0 mg
manganese/m3 and lung at 0.05, 0.5, and 1.0 mg manganese/m3. In contrast, statistically significant 
elevations of manganese concentrations in sampled fetal tissues were observed only in the liver at 0.5 and 
1.0 mg manganese/m3. In pups born and allowed to live up to PND 19 (and sampled for tissue
evaluations at PNDs 1, 14, and 19), statistically significant (p<0.05) elevated manganese concentrations 
(compared with air control values) were observed in blood, liver, and bone samples from exposed 
neonatal rats at concentrations ≥0.05 mg manganese/m3, starting at PND 1 (Dorman et al. 2005a).  As
shown in Table 3-11, elevated brain manganese concentrations were observed in exposed neonates
starting at PND 14 (but not at earlier time points); tissue concentrations increased with increasing
exposure concentration (Dorman et al. 2005a).  At PND 19, mean manganese concentration in the
striatum was about 2.6-fold higher in offspring exposed to 1 mg manganese/m3, compared with air control
means (Table 3-11).  In contrast, the mean striatum concentration at PND 19 in maternal rats exposed to
1 mg manganese/m3 was about 1.7-fold increased, compared with controls (Table 3-11).  At the lowest
concentration tested, 0.05 mg/m3 (50 µg/m3), no statistically significant increase in manganese 
concentrations in maternal striatum or cerebellum occurred, and increases in manganese concentrations in 
brain regions of offspring at PND 19, were modest compared with controls (1.4–1.7-fold, Table 3-11).  
The results from this study suggest that the brain in developing fetuses and neonates is partially protected 
from excess manganese by the placenta, and that the neonatal period, compared with adulthood, is
relatively more susceptible to increased manganese concentration in brain tissues with inhalation
exposure to manganese sulfate aerosol concentrations between 0.05 and 1 mg manganese/m3. 
   
 









        















          
         
         
         
         
 
          
    
      
              
                 
       
       
 






















Table 3-11.  Manganese Concentrations in Brain Tissues of Lactating CD Rats and
Offspring Exposed to Aerosols of Manganese Sulfate
Mean maternal concentrations at Mean offspring concentrations
PND 18 (µg manganese/g)b (µg manganese/g)c 
OlfactoryAir levela 
Brain/striatum Cerebellum bulb(mg Olfactory
manganese/m3) Striatum Cerebellum bulb PND 1 PND 14 PND 19 PND 19 PND 19
0 0.51±0.02 0.50±0.02 0.56±0.04 0.39 0.19 0.37 0.34 0.36
0.05 0.54±0.02 0.52±0.02 0.71±0.04d 0.42 0.35d 0.63d 0.51d 0.52d 
0.5 0.74±0.02d 0.60±0.01d 1.40±0.07d 0.45 0.59d 0.83d 0.64d 0.70d 
1 0.89±0.02d 0.61±0.03d 1.73±0.07d 0.50 0.55d 0.97d 0.72d 0.76d 
aRats were exposed for 6 hours/day starting 28 days prior to breeding through postnatal day (PND) 18 as reported by
Dorman et al. (2005a, 2005b).
bMean±SEM from Table 3 in Dorman et al. (2005a).
cMeans from Figure 4 in Dorman et al. (2005a). Bar graphs were digitized to obtain numerical estimates of means for
male and female offspring combined. At PNDs 1 and 14, whole brain tissues were analyzed. At PND 19, brains were 
dissected into striatum, cerebellum, and olfactory bulb before analysis.
dSignificantly (p<0.05) different from air control mean.
PND = postnatal day; SEM = standard error of the mean
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Consistent with the empirical observations in Table 3-11, PBPK model predictions of manganese
concentrations in striatum, olfactory bulb, and cerebellum in PND 19 offspring of rat dams exposed by
inhalation under the exposure scenarios used by Dorman et al. (2005a, 2005b) indicated that brain
concentrations did not begin to increase in offspring until air concentrations exceeded 0.05–0.1 mg/m3 
(Yoon et al. 2009a, 2009b).  A human PBPK model developed to predict average daily AUC for
manganese concentrations in the globus pallidus of the fetus, suckling neonate, and 3-year-old child from
airborne manganese concentrations indicated that globus pallidus concentrations progressively increased
beyond 10% of baseline concentrations in fetuses and 3-year-old children when air concentrations
exceeded 0.01 mg/m3 (10 µg/m3) and in suckling neonates when air concentrations exceeded 0.001 mg/m3 
(Yoon et al. 2011).
In an examination of the distribution of manganese in young adult male and female CD rats (28 days at
start) and aged male CD rats (16 months at start) following 90-day inhalation exposure to manganese
sulfate or manganese phosphate, no evidence was found for a gender or age effect on delivery of
manganese to the striatum or on the order of manganese concentrations in tissues (pancreas> olfactory
bulb > femur > testes), but gender or age-related differences in tissue manganese concentrations in other
brain regions, as well as in the lung, pancreas, femur, and testis, were noted (Dorman et al. 2004a).  
Following a 90-day inhalation exposure to 0.5 mg manganese/m3 manganese sulfate, young adult male 
rats had significantly (p<0.05) higher olfactory bulb, blood, femur, and pancreas manganese
concentrations than aged male rats, and aged male rats had significantly higher testis manganese 
concentrations than young male rats.  Young male rats exposed to 0.5 mg manganese/m3 had significantly
higher olfactory bulb, blood, and lung manganese concentrations than similarly exposed female rats, and 
female rats exposed to 0.5 mg manganese/m3 had significantly higher cerebellum manganese 
concentrations than control females.  Young male and female rats exposed to 0.5 mg manganese/m3 for 
90 days had increased 54Mn clearance rates than air-exposed controls, but similarly-exposed aged male 
rats did not display increased 54Mn clearance rates, compared with controls (Dorman et al. 2004a).  No 
age-related effects were observed on the order of manganese concentrations in the various tissue.
Manganese concentrations in striatum of young male rats exposed to 0.1 mg/m3 manganese sulfate were
about 1.7-fold higher than concentrations in young male rats identically exposed to manganese phosphate
(Dorman et al. 2004a).  These results are consistent with results from 14-day inhalation studies (Dorman 
et al. 2001a) and intratracheal instillation studies (Roels et al. 1997) indicating that inhalation of more
soluble forms of manganese (e.g., manganese sulfate and manganese chloride) results in higher
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manganese concentrations in the brain than inhalation of less soluble forms, such as manganese 
phosphate, manganese tetroxide, or manganese dioxide.  Olfactory bulb and striatal concentrations were
about 2.5- and 3-fold higher, respectively, in rats exposed for 14 days by inhalation to 3 mg/m3 
manganese sulfate, compared with rats exposed identically to manganese phosphate (Dorman et al.
2001a).
No studies were located regarding distribution of manganese in human or animals following inhalation 
exposure to MMT or mangafodipir.
3.4.2.2 Oral Exposure
Excess manganese uptake has occurred in humans following oral exposure, presumably via the diet, when 
the individuals suffered from chronic liver disease or some other liver dysfunction (cirrhosis, portacaval
shunt, etc.).  In these instances, excess manganese was shown to accumulate in certain regions of the 
brain, as determined by T1-weighted MRI or neutron activation analysis (Devenyi et al. 1994; Fell et al. 
1996; Hauser et al. 1994, 1996; Pomier-Layrargues et al. 1998; Rose et al. 1999; Spahr et al. 1996). 
These studies show that manganese preferentially accumulates in the basal ganglia, especially the globus 
pallidus, and the substantia nigra.
Rats given a single oral dose of 416 mg manganese/kg body weight (as manganese chloride tetrahydrate)
exhibited little tissue accumulation of manganese 14 days later (Holbrook et al. 1975).  Studies in animals
indicate that prolonged oral exposure to manganese compounds results in increased manganese levels in
all tissues, but that the magnitude of the increase diminishes over time (Kristensson et al. 1986; Rehnberg
et al. 1980, 1981, 1982).  Table 3-12 provides illustrative data based on rats exposed to 214 mg
manganese/kg(body weight)/day (as manganese tetroxide) for up to 224 days.  As the data reveal, large 
increases in tissue levels of manganese compared with the controls occurred in all tissues over the first
24 days, but levels tended to decrease toward the control levels as exposure was continued.  This pattern 
is thought to be due to a homeostatic mechanism that leads to decreased absorption and/or increased 
excretion of manganese when manganese intake levels are high (Abrams et al. 1976a; Ballatori et al. 
1987; Mena et al. 1967).  Davis et al. (1992b) and Malecki et al. (1996b) demonstrated that rats fed 
elevated levels of manganese for several weeks had increased tissue manganese concentrations, despite 
increased gut endogenous losses of manganese, as biliary manganese. This reflected several factors.
Although the percentage of manganese absorbed decreased, the total amount of manganese absorbed
increased when higher levels of manganese were fed. Moreover, although the total amount of manganese 
   
 









       
 
      
     
     
    
    
     
 
           
             
 




Table 3-12.  Manganese Levels in Rat Tissue After Oral Exposure
Tissue concentrations (percent of control)a 
Tissue 24 Days 60 Days 224 Days
Liver 810 137 138
Kidney 430 102 128
Brain 540 175 125
Testes 260 125 100
aValues presented are the ratio (expressed as a percentage) of tissue levels of manganese in animals receiving
3,550 ppm manganese in the diet (as manganese tetroxide) compared to animals receiving a normal diet (50 ppm).
Source: Rehnberg et al. 1980
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lost in bile increased when manganese intake increased, the percentage of manganese intake lost in bile 
remained constant at ~1% of manganese intake (Malecki et al. 1996b).  
A study measuring the retention of a single oral dose of radiolabeled manganese in adult and neonatal rats 
indicated that retention of the label 6 days after exposure was much greater in pups (67%) than in adults
(0.18%); the addition of manganese to the animals' drinking water decreased radiolabel retention in pups 
and adults (Kostial et al. 1989).
The distributional differences in rats exposed to either manganese chloride or manganese dioxide by
gavage were investigated by Roels et al. (1997).  After administration of 24.3 mg manganese/kg body 
weight (as manganese chloride) once weekly for 4 weeks, the authors analyzed blood and brain 
concentrations of the metal.  Manganese concentrations were significantly elevated in the blood
(approximately 83% increase over controls) and the cortex of the brain (approximately 39% increase over
controls).  Gavage administration of manganese dioxide, by contrast, did not significantly increase the
amount of manganese in blood or any section of the brain.  In addition, administration of manganese as 
manganese chloride by gavage caused roughly the same amount of increased manganese in the blood as
intratracheal administration of manganese in the same form; it did not cause as significant an increase of
manganese in the cortex (Roels et al. 1997). These data indicate that inhalation exposure to manganese in
the form of manganese chloride or manganese dioxide causes accumulation of manganese in the brain
more readily than oral exposure.
Acute manganese exposure in drinking water was found to alter brain regional manganese levels in 
neonatal rats; after 5 days of exposure, the highest level was in the striatum (12.05 μg/g wet weight) and 
the lowest level was in the cerebral cortex (0.85 μg/g wet weight) (Chan et al. 1992).  After 10 days, the 
highest concentrations were in the pons and medulla and the lowest were in the hypothalamus.  Regional
manganese differences were less pronounced in weanling and adult rats.  A study by Lai et al. (1991)
confirms that intermediate exposure to manganese in drinking water increases brain manganese 
concentrations; rats exposed from conception to 120 days at 0.04 or 0.4 mg manganese/kg/day had mean
brain manganese levels of 0.36–0.72 μg/g in the low-dose animals and 0.62–1.35 μg/g in the high-dose
animals, compared to 0.21–0.38 μg/g in controls.
In a dietary study, elevated manganese levels were found in the organs of male mice fed manganese 
chloride, manganese acetate, manganese carbonate or manganese dioxide at 284 mg manganese/kg/day
for 100 days; levels of manganese in the liver and kidney were significantly higher in the animals exposed
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to manganese acetate or manganese carbonate than in those exposed to manganese chloride or manganese 
dioxide (Komura and Sakamoto 1991).  In a 1993 NTP study, mice and rats chronically fed manganese
sulfate generally exhibited elevated tissue levels of manganese; the manganese levels in the liver and 
kidney were higher than the levels in the brain.
No studies were located concerning disposition of manganese in humans or animals following oral
exposure to MMT or mangafodipir.
3.4.2.3 Dermal Exposure 
No studies were located regarding tissue distribution of manganese in humans or animals after dermal
exposure to inorganic manganese.
No studies were located regarding tissue distribution of manganese in humans or animals after dermal
exposure to organic manganese.
3.4.2.4 Other Routes of Exposure
No studies were located regarding tissue distribution of inorganic manganese in humans after exposure 
via other routes of exposure.   
A number of studies have been conducted that investigated various facets of the distribution of inorganic 
manganese in animal models. The studies utilized a number of routes of administration, and the results 
suggested that route may play an important role in distribution.  In an intraperitoneal study performed in 
monkeys, manganese was reported in all tissues studied.  The highest levels were found in the pancreas,
liver, and kidney, and the lowest levels were found in the blood; levels in the central nervous system were 
found to decrease more slowly than those in other tissues (Dastur et al. 1971).  Calves injected
intravenously with 54Mn were found to have 3-fold higher liver manganese concentrations and 13-fold 
higher pancreatic manganese concentrations than calves fed manganese (Carter et al. 1974).  Davis et al.
(1993) observed that rats injected intraportally with free 54Mn or 54Mn complexed with transferrin and rats
injected intraperitoneally with free 54Mn accumulated more manganese in the pancreatic tissue and less in
the liver than those rats that were either fed 54Mn or injected intravenously in the portal vein with an
albumin-54Mn complex.  The similarity in the distribution of the injected manganese-albumin complex 
and the free manganese in the diet when compared to the distribution of manganese when it was
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administered by other routes or complexed with other proteins suggests that the route of administration 
and type of complexed protein may cause differences in the transport of manganese in the sera.
Roels et al. (1997) studied the effect of intraperitoneal administration of manganese chloride and 
manganese dioxide on distributional differences of manganese in rats.  Doses of 1.22 mg manganese/kg
as manganese chloride given once per week for 4 weeks resulted in significant increases (when compared
to controls) in blood (approximately 60%), striatum (34%), and cortex (36%) concentrations of
manganese; no changes were observed in the cerebellum. Identical dosing of rats with manganese 
dioxide resulted in significant increases in manganese levels in blood (79%), cerebellum (40%), striatum
(124%), and cortex (67%) over those in controls.  These data indicate that administration of manganese
dioxide by this route resulted in greater accumulation of manganese in the brain than did manganese
chloride.
The distribution of manganese in the brain was investigated using Cebus (Newland and Weiss 1992;
Newland et al. 1989) and Macaque (Newland et al. 1989) monkeys given intravenous injections of
manganese chloride that reached a cumulative dose of 10–40 mg manganese/kg.  Magnetic resonance 
images indicated hyper-intensity of the globus pallidus and substantia nigra consistent with an 
accumulation of manganese in these areas (Newland and Weiss 1992; Newland et al. 1989).  Substantial
accumulation of manganese was also noted in the pituitary at low cumulative doses (Newland et al. 1989).  
London et al. (1989) reported a rapid localization of manganese in the choroid plexus observed on MRI;
similarly, radiotracer studies of manganese injected into the intracerebroventricular space revealed that
radiolabeled manganese was located in the choroid plexus within 1 hour and was located in the rat dentate
gyrus and CA3 of the hippocampus 3 days post-dosing (Takeda et al. 1994).  
No studies were located regarding disposition of MMT in humans following other routes of exposure, but
toxicokinetics of MMT following parenteral administration has received some research attention in 
animals.
Young adult male rats were administered MMT dissolved in propylene glycol via subcutaenous injection 
at a dose of 1 mg manganese/kg (McGinley et al. 1987).  Control rats received vehicle alone.  The rats
were sacrificed 1.5, 3, 6, 12, 24, 48, or 96 hours post-injection.  Levels of manganese in the control
animals were measured in the blood (0.09±0.01 mg/kg), lung (1.51±0.22 mg/kg), liver
(2.49±0.36 mg/kg), kidney (1.29±0.23 mg/kg), and brain (0.45±0.01 mg/kg).  These values were assumed 
by the authors to originate from the feed given to the rats and were subtracted from similar values 
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analyzed for MMT-treated rats to determine the amount of manganese in these tissues and fluids that
originated from MMT.  Maximum accumulation of MMT-derived manganese was measured 3 hours after
dosing and was found primarily in the following four tissues:  lung (~9 mg/kg); kidney (3.9 mg/kg); liver
(2.75 mg/kg); and blood (~0.75 mg/kg).  Concentrations of manganese in these four tissues was still
elevated (~1 mg/kg) at 96 hours post-dosing.  Brain manganese concentrations were not significantly
elevated over control levels in MMT-treated animals (McGinley et al. 1987). 
Gianutsos et al. (1985) administered 0, 11, or 22 mg manganese/kg as MMT (dissolved in propylene
glycol) to male adult mice via subcutaneous injection to determine distribution of manganese.  Control
mice received vehicle alone.  Mice were sacrificed at different time points after dosing.  The experiment
was divided into an acute study (one dose) or a “chronic study” (ten doses). The brain manganese level
24 hours after the single dose of MMT at 11 mg/kg was 0.93±0.07 μg/g; the value after 22 mg/kg was 
1.35±.09 μg/g.  Both values were significantly different from the control value of 0.61±0.08 μg/g.  The
brain manganese level in the mice administered 10 doses of 11 mg/kg each was 1.37±0.27 μg/g; after
10 doses of 22 mg/kg, the value was 3.33±0.15 μg/g; both were significantly greater than the control
value of 0.64±0.06 μg/g, and were significantly different than the levels reported after the acute exposure.  
Manganese levels in the brains of mice given a single dose of MMT at 22 mg manganese/kg were 
compared with those following injection of the same manganese dose as manganese chloride; mice were 
sacrificed at different time points from 1–24 hours post-dosing.  The brain manganese levels following
MMT exposure increased from a low at 1 hour to a maximum at 24 hours of ~1.4 μg/g wet weight.  The
manganese level in brain after manganese chloride exposure followed the same increasing trend over the 
24 hour analysis period, but was higher at each time point, with a maximum value of >2.0 μg/g wet
weight (Gianutsos et al. 1985).  
Clinical studies involving cancer patients or healthy volunteers have analyzed the usefulness of
mangafodipir as a contrast agent for the identification of certain abdominal tumors.  Although these
studies do not necessarily quantify the amount of manganese, or mangafodipir, in particular tissues, they
are useful tools in identifying the location of the metal; also relative proportions of manganese among two
or more tissues that contain the metal can be observed by differences in signal from these imaging studies.
Several studies have shown the qualitative presence of manganese in the liver due to increased signal in
that organ following mangafodipir administration of 0.17–0.83 mg manganese/kg upon T1-weighted MRI
(Bernardino et al. 1992; Lim et al. 1991; Padovani et al. 1996; Wang et al. 1997).  Two studies show that
the human liver takes up more of the manganese from mangafodipir than any other organ:  the signal from
   
 








   
               
     
    
            
      
              
    
           
 
 
     
            
     
         
 
           
  
 
        
        
 
          
          
    
 
      
  
       
   
          
    




the liver was roughly 2 times the amount from the spleen after dosing with 0.55 mg manganese/kg (Lim
et al. 1991); the liver signal after dosing with 0.55 mg manganese/kg had reached a 100% increase over
baseline signal by 20 minutes following post-dosing, whereas the maximal signal from other organs was 
only 80% in the pancreas, ~30% in the spleen, ~90% in the renal medulla, and 50% in the choroid plexus, 
all at the same dose. The renal cortex was the only other tissue to reach a 100% increase over baseline 
signal at 0.55 mg manganese/kg.  Dosing with 0.25 mg manganese/kg (the clinically used dose for current
MRI testing of patients) resulted in a similar distribution pattern, although the signal was decreased
compared to the higher dose.  The signal from the renal cortex at the lower dose had a maximum of 80%
over baseline, whereas the signal in the liver at this dose was ~75% of the baseline value (Wang et al.
1997).
Several studies have determined the distribution of manganese in tissues of animals following intravenous
administration of mangafodipir.  Grant et al. (1994) reported that in rats injected with 2 times the clinical 
dose of [54Mn] mangafodipir (0.55 mg manganese/kg), the carcass retained 8% of the label and the tissues
retained 7% of the label; individual tissue concentrations of manganese were not reported.
Gallez et al. (1997) injected adult male mice once with 0.25 mg manganese/kg as [54Mn] mangafodipir
(clinical dose) and determined the tissue manganese content at time points ranging from 15 minutes to 
3 months post-dosing.  Brain concentration of 54Mn did not reach a maximum value of 0.26±0.04 (value 
is the percent of injected dose/g tissue) until 24 hours post-dosing; this value was not different than the 
brain manganese content of mice injected with manganese chloride. This maximum value was still 
observed in the brain 2 weeks post-dosing, but measurements taken at 1 and 3 months post-dosing were
below the detection limit. By contrast, manganese from manganese chloride was still detectable, although
not at maximal levels, at 3 months’ time.  Liver manganese reached a maximum value of 7.5±1.4 (percent
dose/g tissue) 15 minutes post-dosing and then decreased to below the detection limit 1 month later. 
Male and female Sprague-Dawley rats injected with [54Mn] mangafodipir at a dose of 5.5 mg
manganese/kg had the following distribution of labeled manganese 30 minutes post-dosing (values are 
given in percent injected dose/g tissue):  liver, 1.3; kidney, 1.2; heart, 0.25; spleen, 0.2; blood, 0.3; small
bowel, 1.3; large bowel, 0.5; muscle, 0.1; and brain, negligible.  Distribution of manganese in tissues of
rats injected with labeled manganese chloride was compared to the previous results, and for all tissues, the 
label was greater after administration with the chloride than from the mangafodipir, with the exception of
kidney and large bowel, but these differences were not significant (Elizondo et al. 1991).  
   
 








        




    
          
 
        
    
      
        
 
    
             
         
 
      
    
   
     
 
        
 
  
   
     
  
 
   
     




The distribution of label in male and female Sprague-Dawley rats injected with either [54Mn] or [14C]
mangafodipir at a dose of 0.39 or 0.55 mg manganese/kg, respectively, was studied by Hustvedt et al.
(1997).  The plasma concentration of labeled manganese reached a peak of 10.2 μg/mL at 5 minutes post-
dosing and was quickly distributed into the following organs (values given as μg equivalents of
compound/g):  pancreas, 10.2; liver, 4.0; kidneys, 3.6; testes/ovaries, 1.7; spleen, 1.0; heart, 0.9; and
brain, 0.69.  When the bile duct was cannulated, the distribution of an equivalent dose of mangafodipir
showed an increased retention of labeled manganese in all organs but the brain (0.62): pancreas, 17.2;
liver, 12.3; kidneys, 10.1; testes/ovaries, 5.6; small intestine, large intestine and heart, 2.1; and spleen, 
1.9. By contrast, tissue retention of 14C from radiolabeled mangafodipir was very low:  pancreas, 0.016;
liver, 0.045; kidneys, 0.067; testes/ovaries, 0.015; spleen, 0.023; small intestine, 0.012; large intestine, 
0.019; heart, 0.017; and brain, 0.009.  These data indicate that manganese dissociates from the fodipir
moiety after mangafodipir administration and partitions into the tissues listed above.
The tissue distribution of normal and bile-cannulated dogs following administration of [54Mn] or [14C]
mangafodipir was also studied (Hustvedt et al. 1997). Doses of 0.55 manganese/kg were used except for
the normal dogs when the manganese was labeled; the dose in this case was 0.38 mg/kg.  The general
pattern of distribution of manganese and carbon was similar to that seen with rats, except the
concentrations were increased in the dog.  The values for normal dogs were taken 168 hours post-dosing
for both forms of labeled mangafodipir; the bile-cannulated dogs were analyzed 24 hours post-dosing.  
The maximum concentration of 54Mn in the plasma following dosing was 13.1 μg/mL at the end of the
infusion period. The plasma concentrations declined rapidly with a terminal half-life of approximately 
15 minutes.  In the normal dog and bile-cannulated dog, the tissue distribution was as follows (the values 
for the bile-cannulated dog are given in parentheses; all values are in μg equivalents of compound/g): 
liver, 8.7 (79.8); pancreas, 8.1 (2.5); kidneys, 6.6 (37.5); bile, 5.9 (no sample); testes/ovaries, 2.2 (3.2);
brain, 0.79 (1.1); spleen, 0.65 (26.6); and heart, 0.62 (3.1).  The distribution of labeled carbon in normal
(or bile-cannulated dogs) was the following:  kidneys, 0.79 (4.1); liver, 0.13 (0.48); bile, 0.059 (no 
sample); testes/ovaries, 0.05 (0.079); pancreas, 0.015 (0.11); heart, 0.015 (0.035); spleen, 0.007 (0.15);
and brain, not detected (not detected).  These data indicate that in the dog, as in the rat, the manganese
cation is retained by the tissues, but the fodipir moiety is not.
Distribution of 54Mn and 14C following mangafodipir administration was also studied in the pregnant rat
(Hustvedt et al. 1997).  Whole-body autoradiography of a section of the rat made at different time points
revealed that the kidney had retained the highest amount of labeled manganese; later time points showed a
distribution similar to those seen in the rat and dog studies mentioned previously with the pancreas and 
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liver causing the most intense signal upon autoradiography.  By 24 hours, fetal livers and bones were
clearly seen, but placental radioactivity had decreased substantially.  Fat deposits also contained a
significant amount of the radioactivity at 24 hours.  By contrast, radioactivity from labeled carbon in the
mangafodipir was relatively uniformly distributed throughout the pregnant rat at 5 minutes and 1 hour
post-dosing, with the highest levels in the kidneys.  At 24 hours, virtually all tissues were
indistinguishable from background. 
The human distribution studies have involved much shorter observation times than the animal studies,
with maximal increase in MRI signal in human studies observed in minutes following administration. 
These studies have shown the liver to accumulate the highest amount of manganese from the administered
dose of mangafodipir.  This is an important limitation since the brain, the primary target of manganese 
neurotoxicity, may not accumulate a significant amount of manganese until much later, possibly after the
current experiments in humans and animals were truncated.  Experiments in rats and dogs, both normal
and bile-cannulated, indicate that the brain does not accumulate a significant amount of manganese
following administration of mangafodipir at levels much higher than the recommended clinical dose of
the agent (Hustvedt et al. 1997), even at 168 hours post-dosing in the dog.  Gallez et al. (1997) reported 
that manganese accumulation in the brain of adult mice following injection of a clinical dose of
mangafodipir did not reach maximal levels until 24 hours post-dosing.  This would indicate that the
human distribution studies were terminated prematurely.  However, while brain accumulation of
manganese following mangafodipir administration is similar to that from manganese chloride, the 
manganese is not present after 2 weeks, whereas manganese from the inorganic compound was present,
although at a decreased amount, 3 months following dosing (Gallez et al. 1997).  These data indicate that
single, clinical doses of mangafodipir are not likely to cause persistent accumulation of manganese in the 
brain. 
3.4.3 Metabolism
Manganese is capable of existing in a number of oxidation states, and limited data suggest that inorganic
manganese may undergo changes in oxidation state within the body.  Circumstantial support for this
hypothesis comes from the observation that the oxidation state of the manganese ion in several enzymes
appears to be Mn(III) (Leach and Lilburn 1978; Utter 1976), while most manganese intake from the
environment is either as Mn(II) or Mn(IV) (see Chapter 6).  Another line of evidence is based on
measurements of manganese in tissues and fluids using electron spin resonance (ESR), which detects the 
unpaired electrons in Mn(II), Mn(III), and Mn(IV).  When animals were injected with manganese 
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chloride, levels of manganese increased in bile and tissues, but only a small portion of this was in a form
that gave an ESR signal (Sakurai et al. 1985; Tichy and Cikrt 1972).  This suggests that Mn(II) is
converted to another oxidation state (probably Mn(III)), but it is also possible that formation of complexes
between Mn(II) and biological molecules (bile salts, proteins, nucleotides, etc.) results in loss of the ESR
signal without oxidation of the manganese ion.
Evidence by Gibbons et al. (1976) suggests that oxidation of manganese occurs in the body.  It was
observed that human ceruloplasmin led to the oxidation of Mn(II) to Mn(III) in vitro, and although the
process was not studied in vivo, it is a likely mechanism for manganese oxidation in the blood. These 
authors also noted that manganese oxidation led to a shift in manganese binding in vitro from α2-macro-
globulin to transferrin and that in vivo clearance of Mn(II)-α2-macroglobulin from cows was much more
rapid than the clearance of Mn(III)-transferrin (Gibbons et al. 1976).  This suggests that the rate and
extent of manganese reduction/oxidation reactions may be important determinants of manganese retention 
and toxicity in the body.   
As demonstrated in a study by Komura and Sakamoto (1991), tissue levels of manganese in rats were 
affected by the form in which the manganese was administered in the diet; levels of manganese were 
significantly higher in animals fed manganese acetate or manganese carbonate than in animals fed
manganese chloride or manganese dioxide.
Reaney et al. (2006) compared brain concentrations of manganese, dopamine, and gamma amino butyric
acid in female retired breeder Long Evans rats exposed to cumulative intraperitoneal doses of 0, 30, or
90 mg manganese/kg of Mn(II) chloride or Mn(III) pyrophosphate.  Rats were given intraperitoneal doses 
of 0, 2, or 6 mg manganese/kg, 3 times/week for 5 weeks.  In Mn(III)-treated rats, brain manganese 
concentrations (analyzed in the striatum, globus pallidus, thalamus, and cerebrum regions) and blood 
concentrations were higher than brain concentrations in Mn(II)-treated rats.  The only other marked 
changes in end points between the two treatment groups was that the highest Mn(III) exposure group 
showed a 60% increased dopamine level in the globus pallidus (compared with controls), whereas the
comparably treated Mn(II) rats showed a 40% decrease in globus pallidus dopamine level. These results
suggest that manganese valence state can influence tissue toxicokinetic behavior, and possibly toxicity.
MMT. Following intravenous administration in the male rat, MMT was metabolized to hydroxyl-
methylcyclopentadienyl manganese tricarbonyl (CMT-CH2OH) and carboxycyclopentadienyl manganese
tricarbonyl (CMT-COOH), both of which are present in urine (Hanzlik et al. 1980a).  Metabolites are also
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present in the bile, as indicated by the fecal recovery of 3H from the ring structure in MMT following
intravenous or intraperitoneal administration of radiolabeled compound to rats (Hanzlik et al. 1980a, 
1980b).  After intravenous dosing of MMT in rats, 11% of the radiolabel was recovered in feces within
30 minutes (Hanzlik et al. 1980b). These metabolites have not been characterized; however, the 
administration of phenobarbitol to the rat doubled the biliary excretion of the metabolite (Hanzlik et al.
1980a).
In vitro studies showed that rat liver microsomes activated with NADPH and molecular oxygen 
metabolized MMT (Hanzlik et al. 1980b).  Preliminary studies with pooled liver microsomes from 5 to 
6 normal or phenobarbital-induced rats showed that reaction rates of metabolism were linear for the first
20 minutes.  MMT and aminopyrine, a positive control compound that is metabolized exclusively by
cytochrome P450, showed parallel responses to changes in incubation conditions (i.e., NADPH
dependence, inhibition by carbon monoxide, induction by phenobarbital).  Liver microsomes metabolized 
MMT with an estimated KM of 78 μM and a Vmax of 3.12 nmol/mg protein/minute.  When the studies
were done with liver microsomes from phenobarbital-treated rats, the KM remained the same, but the Vmax 
doubled (Hanzlik et al. 1980b).  Lung microsomes were equally capable of metabolizing MMT, but
phenobarbital induction did not enhance the response. 
In humans, an infusion of the clinical dose of MnDPDP (5 μmol/kg or 0.25 mg/kg) is rapidly 
dephosphorylated to manganese dipyridoxyl monophosphate (MnDPMP).  This metabolite has been 
measured in human blood as quickly as 18 minutes after the beginning of infusion of the contrast agent, 
and is still measurable 1.3 hours after the start of the infusion (Toft et al. 1997a).  MnDPMP was not
observed in the blood after the first 18 minutes.  The monophosphate is then fully dephosphorylated to 
manganese dipyridoxyl ethylenediamine (MnPLED); this compound has been isolated in blood from
18 minutes after the start of an infusion until 40 minutes after the start. Transmetallation of either
MnDPDP, MnDPMP, or MnPLED with zinc can occur, forming ZnDPDP, ZnDPMP, or ZnPLED.  
ZnDPDP has been identified in the bloodstream during the first 18 minutes of an infusion of 0.25 mg
manganese/kg as MnDPDP.  ZnDPMP has been detected in the blood from 18 to 40 minutes following
the start of the infusion, and ZnPLED has been measured in the blood from 18 minutes to 8.33 hours
following the start of the infusion. The major metabolite detected in urine was ZnPLED (Toft et al.
1997a).  Figure 3-4 depicts the metabolism of mangafodipir in the human. 
To study mangafodipir metabolism in the dog, Toft et al. (1997c) injected three male and female beagles
with 0.55, 1.7, or 5.5 mg manganese/kg and took timed blood samples post-dosing to analyze for the
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presence of metabolites.  Mangafodipir was rapidly metabolized by dephosphorylation and 
transmetallation at all three doses.  After infusion with 0.55 mg/kg, MnPLED was the primary metabolite 
observed in the bloodstream 1 minute after the end of the infusion period, and MnDPDP was present at a
concentration lower than the five metabolites.  At 30 minutes post-dosing, ZnPLED was the main 
metabolite.  However, at 5.5 mg/kg, MnPLED was the main metabolite at all sampling times (1, 5, and 
30 minutes). The authors estimated that the ratios of manganese metabolites to zinc metabolites were 1,
2, and 3.5 at doses of 0.55, 1.7, or 5.5 mg manganese/kg, respectively; these data are consistent with the
authors’ hypothesis that the limited availability of free or loosely bound plasma zinc governs the initial
transmetallation reaction (Toft et al. 1997c).
In vitro experiments with radiolabeled MnDPDP and whole blood or plasma from human donors indicate
that mangafodipir undergoes a rapid transmetallation with zinc that is nearly complete within 1 minute
after the start of incubation, followed by a relatively slow dephosphorylation process.  The primary
metabolite after a 90-minute incubation of whole blood with MnDPDP was MnDPMP, followed by
CaDPDP/DPDP, Mn(III)DPDP (suggested as an artifact due to high pH and oxygen), and MnPLED. 
Experiments using 14C-DPDP indicate that this chelate cannot enter red blood cells; therefore, the zinc 
contained within the cells is unavailable for binding to this compound.  Binding of manganese ion to
serum proteins was observed as well, indicating that dissociation of the metal from the chelate had
occurred during incubation (Toft et al. 1997b).
3.4.4 Elimination and Excretion 
In humans, absorbed manganese is removed from the blood by the liver where it conjugates with bile and 
is excreted into the intestine.  Biliary secretion is the main pathway by which manganese reaches the 
intestines where most of the element is excreted in the feces (Bertinchamps et al. 1965; Davis et al. 1993;
Malecki et al. 1996).  However, some of the manganese in the intestine is reabsorbed through 
enterohepatic circulation (Schroeder et al. 1966).
Small amounts of manganese can also be found in urine, sweat, and milk (EPA 1993b).  Urinary excretion
of manganese by healthy males was 7.0 nmole/g creatinine (7.0 nmole=385 ng=0.385 μg) (Greger et al.
1990).  Similarly, urinary manganese excretion by women was 9.3 nmole/day.  Moreover, urinary
excretion of manganese was not responsive to oral intake of manganese (Davis and Greger 1992).  Dorner
et al. (1989) showed that some infants fed breast milk and formula suffered negative manganese balances 
due to high fecal excretion.  However, animal studies indicate that in the young, excretion is not well-
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developed and may result in increased retention of the element.  For example, in mice, rats, and kittens,
there is an almost complete absence of excretion during the neonatal period (Cotzias et al. 1976).  
However, data in neonatal rats indicate that manganese retention rates decrease to rates observed in adult
animals.  This is indirect evidence that excretion may mature during the end of the neonatal period though 
the exact time frame across species is unknown.
3.4.4.1 Inhalation Exposure 
In humans who inhaled manganese chloride or manganese tetroxide, about 60% of the material originally
deposited in the lung was excreted in the feces within 4 days (Mena et al. 1969).  Chronically exposed 
male workers were reported to have urine manganese levels that were significantly higher than unexposed
persons; for example, male foundry workers had a mean manganese level of 5.7 μg/L compared to 
0.7 μg/L in unexposed controls (Alessio et al. 1989).  Other studies have reported significantly increased 
levels of urinary manganese in men occupationally exposed to airborne manganese dusts and fumes 
(Lucchini et al. 1995; Roels et al. 1987a, 1992).  Mergler et al. (1994) did not report a significant
difference in urinary manganese levels between the exposed and control groups in their occupational
study.  The differences in urinary excretion may be due to differences in duration or extent of exposure.  
A listing of these occupational studies that measured exposure levels of manganese and the resultant
levels of the metal in biological samples is provided in Table 3-13. 
Rats exposed to either manganese chloride or manganese tetroxide by intratracheal instillation excreted
about 50% of the dose in the feces within 3–7 days (Drown et al. 1986).  Monkeys exposed to an aerosol
of 54MnCl2 excreted most of the manganese, with a half-time of 0.2–0.36 days (Newland et al. 1987).  
However, a portion of the compound was retained in the lung and brain.  Clearance of this label was 
slower, occurring with half-times of 12–250 days.  These data do not provide information on how much 
of the manganese excreted in the feces after inhalation exposure was first absorbed and then excreted via 
the bile versus the amount simply transported directly from the lung to the gastrointestinal tract where it 
may have been absorbed.  In addition, because these investigators measured manganese using gamma 
spectrometry techniques, the relatively long elimination half-times from the brain may have been 
influenced by manganese present in skull bones.  In monkeys exposed to 1.5 mg manganese/m3 
manganese sulfate for 65 days, manganese concentrations were elevated (compared with air control
values) in many brain regions and other tissues; 45 days following cessation of exposure, concentrations 
remained elevated in the olfactory cortex, globus pallidus, putamen, pituitary gland, and blood, but
returned to air control values by 90 days after exposure (Dorman et al. 2006a).  Based on these data,
   
 









       
 
   





        
       
      
        
       
     
        
       
     
        
        
      
        
   
 
    



















Roels et al. (1987b)
Exposed 34.3±9.6 0.97a (total dust) 1.36b±0.64 (1.22)c 4.76b (0.4)c 
Non-exposed 38.4±11.3 0.57b±0.27 (1.59)c 0.30b (0.15)c 
Roels et al. (1992)
Exposed 31.3±7.4 0.179a (respirable dust) 0.81c 0.84c 
Non-exposed 29.3±8.0 0.68c 0.09c 
Chia et al. (1993a)
Exposed 36.6±12.2 1.59b (total dust) 2.53c 6.1c (μg/L)
Non-exposed 35.7±12.1 2.33c 3.9c (μg/L)
Mergler et al. (1994)
Exposed 43.4±5.4 0.032a (respirable dust) 1.12b (1.03)c 1.07b (0.73)c 
Non-exposed 43.2±5.6 0.72b (0.68)c 1.05 (0.62)c 
Lucchini et al. (1999)
Exposed 42.1±8.3 0.0967 (respirable dust) 0.97b (0.92)c 1.81b (1.53)c 
(CEI/years)




CEI = cumulative exposure index
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Dorman et al. (2006a) calculated elimination half-lives of about 15–16 days for the globus pallidus and 
putamen, suspected neurotoxicity targets of manganese.
Rat studies have demonstrated that urinary excretion of manganese 1 day following inhalation exposure
was increased 200- and 30-fold when the animals were treated with the chelating agents 
1,2-cyclohexylene-aminetetraacetic acid (CDTA) and diethylene triamine pentaacetic acid (DTPA),
respectively, but fecal excretion was not altered (Wieczorek and Oberdörster 1989b).
No studies were located regarding excretion of manganese in either humans or animals following
inhalation exposure to organic manganese.
3.4.4.2 Oral Exposure
Humans who ingested tracer levels of radioactive manganese (usually as manganese chloride) excreted
the manganese with whole-body retention half-times of 13–37 days (Davidsson et al. 1989a; Mena et al.
1969; Sandstrom et al. 1986).  The route of manganese loss was not documented, but was presumed to be
mainly fecal after biliary excretion.  Serum manganese concentrations in a group of healthy men and
women in Wisconsin were 1.06 and 0.86 μg/L, respectively (Davis and Greger 1992; Greger et al. 1990).  
Urinary excretion of manganese by men was 7.0 nmole/g creatinine (Greger et al. 1990).  Similarly, 
urinary manganese excretion of women was 9.3 nmole/day.  Moreover, urinary excretion of manganese
was not responsive to oral intake of manganese (Davis and Greger 1992).
In a more recent study, young rats fed 45 mg manganese/kg/day were found to absorb 8.2% of the
manganese ingested and to lose approximately 37% of the absorbed manganese through endogenous gut
secretions (Davis et al. 1993).
The daily excretion of manganese from mice ingesting 11 mg manganese/kg as MMT in their daily diet
was 5.4% of their daily intake (Komura and Sakamoto 1992b).  In a comparison of plasma manganese 
kinetics following oral administration of MMT or manganese chloride in male rats, MMT-derived 
manganese was eliminated extremely slowly, having an average elimination half-time of 55.2 hours, 
compared with 4.56 hours for manganese chloride (Zheng et al. 2000).  Rats receiving MMT showed an 
apparent oral clearance (CL/F) of 0.09 L.hours-1.kg-1, which was about 37-fold less than the oral clearance 
of manganese chloride (CL/F = 3.2 L.hours-1.kg-1).  Accordingly, the AUC in MMT rats was about
37-fold higher than that in manganese chloride rats who received equivalent dose of manganese.  A
   
 








        
          
   
 
   
   
 
    
 
        
    
 
      
 
         
   
 
         
       
        
          
          
 
     
   
      
     
 
   
     
       





gender difference in manganese toxicokinetics following oral MMT exposure was also observed; female 
rats showed higher mean AUC and longer half times of plasma manganese than male rats (93.1 versus 
51.8 mM hours and 68.4 versus 42.0 hours, respectively (Zheng et al. 2000).
No other studies were located regarding excretion of manganese from organic manganese compounds in 
either humans or animals.
3.4.4.3 Dermal Exposure 
No studies were located regarding excretion of inorganic or organic manganese in humans or animals 
after dermal exposure to manganese.
3.4.4.4 Other Routes of Exposure
No studies were located regarding excretion of manganese by humans after exposure to inorganic
manganese via other routes of exposure.
Rats exposed to manganese chloride by intravenous injection excreted 50% of the dose in the feces within
1 day (Klaassen 1974) and 85% by day 23 (Dastur et al. 1971), indicating that biliary excretion is the
main route of manganese clearance.  Only minimal levels were excreted in urine (<0.1% of the dose 
within 5 days) (Klaassen 1974).  Direct measurement of manganese levels in bile revealed concentrations 
up to 150-fold higher than in plasma, indicating the existence of either an active transport system
(Klaassen 1974) or some sort of trapping mechanism (Tichy and Cikrt 1972).  Based on the difference in 
blood levels following portal or femoral injection, Thompson and Klaassen (1982) estimated that about
33% of the manganese burden in blood is removed in each pass through the liver.  Apparently, some
manganese can cross directly from the blood to the bile (Bertinchamps et al. 1965; Thompson and 
Klaassen 1982), but most appears to be secreted into the bile via the liver (Bertinchamps et al. 1965).  
The chemical state of manganese in bile is not known, but a considerable fraction is bound to bile
components (Tichy and Cikrt 1972).  This material is apparently subject to enterohepatic recirculation, 
since biliary manganese is reabsorbed from the intestine more efficiently than free Mn(II) (Klaassen
1974).  The amount of manganese that contributes to total body burden following reabsorption from
enterohepatic recirculation is not known. 
   
 








         
           
  
     
  
 
        
          
    
 
   
 
       
 
      
        
      
            
            
 
    
   
 
  
       
    
 
     
  
       
 
 




While biliary secretion appears to be the main pathway by which manganese is excreted into the 
intestines, direct transport from blood across the intestinal wall may also occur (Bertinchamps et al. 1965;
Garcia-Aranda et al. 1984).  The relative amount of total excretion attributable to this pathway was not
quantified by Bertinchamps, but it appears to be only a fraction of that attributable to biliary secretion 
(Bertinchamps et al. 1965).
Manganese originating from mangafodipir administered at clinical (0.25 mg/kg) and more than twice the
clinical dose (0.55 mg/kg) is primarily excreted in the feces via the bile in both humans and animals 
(Grant et al. 1994; Hustvedt et al. 1997; Toft et al. 1997a; Wang et al. 1997).  In contrast to the chelate, 
DPDP, manganese is incompletely cleared from the body 24 hours after administration, and roughly 7– 
8% of a dose is still retained in the body after 1 week (Hustvedt et al. 1997). 
3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.  
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and 
Krishnan 1994; Andersen et al. 1987).  These models are biologically and mechanistically based and can 
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.  
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
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Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true
complexities of biological systems. If the uptake and disposition of the chemical substance(s) are 
adequately described, however, this simplification is desirable because data are often unavailable for
many biological processes. A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-5 shows a conceptualized representation of a PBPK model.
If PBPK models for manganese exist, the overall results and individual models are discussed in this 
section in terms of their use in risk assessment, tissue dosimetry, and dose, route, and species 
extrapolations.
PBPK models for manganese are discussed below, including descriptions of an initial conceptual PBPK
model for manganese (Andersen et al. 1999) and the development of whole-body adult rat and monkey
PBPK models (Nong et al. 2008, 2009; Teeguarden et al. 2007a, 2007b, 2007c), a PBPK model for
manganese transport from the olfactory mucosa to the striatum (Leavens et al. 2007), a whole-body PBPK
model for gestation and lactation in the rat (Yoon et al. 2009a, 2009b), and human whole-body PBPK
models for adults and for fetal and neonatal exposures (Schroeter et al. 2011; Yoon et al. 2011).
   
 








       
    
   
 
 
           
            
       
 










Figure 3-5.  Conceptual Representation of a Physiologically Based
Pharmacokinetic (PBPK) Model for a 
Hypothetical Chemical Substance











































Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance. The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation.
Source: adapted from Krishnan and Andersen 1994
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Initial Conceptual PBPK Model for Manganese (Andersen et al. 1999). A qualitative PBPK model for
manganese disposition in humans and animals was initially developed by Andersen et al. (1999).  This
model represented the current understanding of manganese nutrition and toxicology, and because several
data gaps existed concerning manganese pharmacokinetics, this model was anticipated to change with
time (Andersen et al. 1999).  The model, shown in Figure 3-6, was not designed to be quantitative in 
nature. The authors indicated that several data gaps prevented such an evaluation of manganese uptake,
distribution, and excretion.  For instance, there were inadequate data concerning oxidation rates for 
manganese in blood, uptake rates of protein-bound forms by the liver, neuronal transfer rates within the
central nervous system, and quantitative data on systems controlling manganese uptake via the intestines 
and liver (such as transport mechanism in the intestines) (Andersen et al. 1999).  Andersen et al. (1999)
suggested that an approach to setting acceptable exposure levels for an essential, but neurotoxic, nutrient
such as manganese could be based on predicting exposure levels by any route that would increase brain
manganese concentrations to a small fraction (e.g., 10–25%) of the variation observed in the general
human population.  Reliable and validated multiple-route PBPK models for multiple species, including
humans, are needed to take this approach to setting acceptable exposure levels.  Efforts to develop such
models in rats, monkeys, and humans have been recently described (Leavens et al. 2007; Nong et al. 
2009, 2008; Schroeter et al. 2011; Teeguarden et al. 2007a, 2007b, 2007c; Yoon et al. 2011, 2009a, 
2009b).
Whole-Body Rat PBPK Models (Nong et al. 2008; Teeguarden et al. 2007a, 2007b, 2007c). Utilizing
pharmacokinetic and tissue manganese concentration data from several published studies of manganese in
rats and mice, recent efforts have developed PBPK models for manganese in rats that include processes 
involved in homeostatic regulation of tissue levels of manganese taken up by ingestion and by inhalation 
(Nong et al. 2008; Teeguarden et al. 2007a, 2007b, 2007c).  Two PBPK model structures were developed 
and evaluated for their ability to account for kinetics of manganese in the liver and brain striatum
following inhalation and dietary administration of soluble forms of inorganic manganese.  The data sets
used to evaluate the models were: (1) tissue manganese concentrations in rats receiving diets containing 2,
10, or 100 ppm manganese for 13 weeks and elimination kinetics for an intravenous tracer dose of
54Mn-manganese chloride (Dorman et al. 2001b); (2) tissue manganese concentrations and tracer kinetics
in rats fed a 100-ppm diet and exposed to 0, 0.03, 0.3 or 3 mg manganese/m3 manganese sulfate 
6 hours/day for 14 consecutive days (Dorman et al. 2001a); and (3) tissue manganese concentrations 
(sampled at 0, 45, and 90 days after exposure) in rats fed a 10-ppm diet and exposed to 0, 0.1, or 0.5 mg
manganese/m3 for 6 hours/day, 5 days/week for 90 days (Dorman et al. 2004b).  
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Figure 3-6. Qualitative PBPK Model for Manganese
Liver 
Intestine 















Source: Andersen et al. 1999
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Structures of the models are shown in Figure 3-7. Model A is based on regulation of tissue
concentrations by simple partitioning with slow inter-compartmental transfer from free manganese in
tissues to deeper tissue stores of manganese (“diffusion-controlled tissue partitioning”; Nong et al. 2008;
Teeguarden et al. 2007a, 2007b, 2007c).  Model B features saturable binding of manganese in liver and 
brain with equilibrium binding constants defined by slow association and dissociation rate constants
(Nong et al. 2008).  Both models contain a submodel for deposition and absorption in the nose and lung
shown schematically in Figure 3-8 (Teeguarden et al. 2007c). 
Nong et al. (2008) Model A Description and Development. Model A contains six compartments:  the 
respiratory tract, brain striatum, liver, kidneys, bone, and slowly perfused tissues (Figure 3-7).  The
respiratory tract is divided into two subcompartments: nasopharyngeal tissues and lung (Figure 3-8).  
Table 3-14 lists parameters of Model A as described by Teeguarden et al. (2007c).  Each of the six
compartments is subdivided into a conventional flow-limited compartment connected to the blood and 
tissue stores that are not readily equilibrated with blood moving through the tissue compartment.  First-
order clearance rate constants (e.g., kInBrnC and koutBrnC) determine the transfer of manganese from
the flow-limited compartment to the deep compartment of each tissue. The clearance rate constants,
together with the blood flow to the tissue (e.g., QBrnC) and the tissue partition coefficients (e.g., PBrn), 
determine the steady-state concentrations and the rate of change manganese in each of the tissues,
according to differential equations that are described in detail by Teeguarden et al. (2007c).
Physiological parameters were taken from the literature and included values for blood flows, organ 
volumes, and food intake rate (Table 3-14). The initial (basal) concentrations of manganese in the tissues 
(Table 3-14) were taken from literature values as described by Teeguarden et al. (2007c). Remaining
model parameters were estimated by fitting the model to experimental data.  Fractions of manganese in
the shallow versus deep compartments of each tissue (e.g., fBrn and FDBrn, Table 3-14) were calibrated 
to obtain the best fit to intraperitoneal 54Mn clearance data collected by Furchner et al. (1966).  Partition 
coefficients (e.g., PBrn, Table 3-14) and clearance rate constants into and out of deep compartments (e.g., 
kInBrnC, kOutBrnC) were calibrated with 54Mn kinetic data collected by Furchner et al. (1966) and 
steady-state tissue manganese concentration data collected by Wieczorek and Oberdörster (1989c). The 
fraction of manganese absorbed from the gut (FDietUp) was assumed to be 0.8%. The rate of biliary
excretion from liver (kBile0C) was determined by matching the rate of manganese excreted from liver
against the amount of manganese taken up from the diet, while maintaining steady-state levels of
   
 








             



































          
 




   
 
  
   
  
Figure 3-7. Schematic Structures of Nong et al. (2008) PBPK Models A and B for
Manganese in CD Rats*
Model A Model B 
Inhaled Mn Inhaled Mn 























Lung and nose 
Brain blood 
PA12 PA21 



















































Diet Bile Diet Bile 
*Values and descriptions of model parameters are in Tables 3-14, 3-15, and 3-16.
Source: Nong et al. 2008
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Figure 3-8. Schematic of Models for Nasopharyngeal and Lung Deposition of
Manganese and Transport to Blood in the Nong et al. (2008) PBPK
































Source: Teeguarden et al. 2007c
   
 









             
         
 
    
       
       
       
      
   
    
    
    
    
     
    
    
    
    
    
    
    
    
    
    
   
    
     
  
   
   
    
    
   
   
   
  
      
       
   
     







Table 3-14. Parameter Values in the Teeguarden et al. (2007c) PBPK Model for
Manganese in CD Rats (Nong et al. 2008) Model A
Parameter Valuea 
BW Body weight (kg) 0.325b 
QCC Cardiac output (L/hour for 1-kg animal) 14.6 
QPC Alveolar ventilation (L/hour for 1-kg animal) 30.0 
Blood flows (fraction of cardiac output)
QSlowC Slow 0.534 
QBoneC Bone 0.122 
QBrnC Brain 0.02 
QKidC Kidneys 0.141 
QLivC Liver 0.183 
Tissue volumes (fraction of body weight)
VArtC Arterial blood 0.0224 
VBldC Blood 0.0676 
VSlowC Slow 0.738 
VBoneC Bone 0.021 
VDBoneC Bone deep compartment 0.052 
VBrnC Brain 0.006 
VKidC Kidneys 0.007 
VLivC Liver 0.034 
VLungC Lung 0.007 
VNasPhaCc Nasopharyngeal 0.0038 
VTraBroCc Tracheobronchial 0.01107 
VPulmonC Pulmonary 0.01107 
VVenC Venous blood 0.0452 
Partition coefficients
Pslow Slow 0.4 
PBone Bone 30 
PBrn Brain 0.1 
PKid Kidneys 1.25 
PLiv Liver 5.0 
PLung Lung 0.3 
Pnaspha Nasopharyngeal 0.3 
Clearance rates
kBile0C Biliary excretion (L/hour-kg body weight) 2.0 
kFeces Loss in feces (L/hour-kg body weight) 0.0001 
Clearance rates (/h)
kInSlowC Into deep slow compartment 0.017 
kInBoneC Into deep bone compartment 0.105 
   
 
    
 
 
 Parameter  a Value   
 kInBrnC  Into deep brain compartment 0.011  
 kInKidC   Into deep kidney compartment 0.146  
 kInLivC    Into deep liver compartment 0.621  
kInNPC   Into deep nose compartment 0.035  
 kInLungC   Into deep lung compartment 0.035  
kOutSlowC     Out of deep slow 0.0035  
 kOutBoneC    Out of deep bone 0.00085  
 kOutBrnC    Out of deep brain 0.00056  
kOutKidC    Out of deep kidneys 0.0034  
 kOutLivC    Out of deep liver 0.007  
kOutNPC    Out of deep nose 0.0035  
 kOutLungC    Out of deep lung 0.0035  
   Initial concentrations of manganese (μg/L)  
 CArt0  Arterial blood 10.0  
CBld0  Blood 10.0  
CSlow0  Slow 110.0  
CDSlow0   Deep slow 110.0  
CBone0  Bone 650.0  
CDBone0   Deep bone compartment 650.0  
CBrn0  Brain 450.0  
CDBrn0  Deep brain 450.0  
CKid0  Kidneys 1000.0  
CDKid0  Deep kidneys 1000.0  
CLiv0  Liver 2600.0  
CDLiv0  Deep liver 2600.0  
CLung0  Lung 250.0  
CDLung0  Deep lung 250.0  
CNose0  Nose 0.0  
 CDNose  Deep nose 0.0  
CVen0   Venous blood 10.0  
 Fractional coefficients    
fDepNPc   Particles deposited nasopharyngeal 0.2  
 fDepTBc  Particles deposited tracheobronchial 0.21  
c fDepPu    Particles deposited pulmonary 0.07  
d       Fraction of manganese in shallow versus deep tissue  
       (ratios of volumes; not separately estimated model parameters)  
fSlow  Slow 0.5  






             








Table 3-14. Parameter Values in the Teeguarden et al. (2007c) PBPK Model for
Manganese in CD Rats (Nong et al. 2008) Model A
   
 








             
         
 
    
    
    
    
    
   
   
   
   
   
   
   
       
         
 
           
         
         
 
            
       
  
         
       
 








Table 3-14. Parameter Values in the Teeguarden et al. (2007c) PBPK Model for
Manganese in CD Rats (Nong et al. 2008) Model A
Parameter Valuea 
fBrn Brain 0.05 
fDBrn Deep brain 0.95 
fKid Kidneys 0.25 
fDKid Deep kidneys 0.75 
fLiv Liver 0.4 
fDLiv Deep liver 0.6 
fLung Lung 0.1 
fDLung Deep lung 0.9 
FDNose Deep nose 0.9 
fDBody Body 0.5 
Dosing parameters
InFac1 Dietary intake factor for first diet 0.05 
FDietUp Fraction of manganese in diet that is absorbed 0.008
aPhysiological parameters are consistent with those reported by Brown et al. (1997). Rate constants were fit to
available experimental data on the kinetics of Mn in the various tissues. Rate constants fitted to the control steady-
state Mn tissue concentrations reported by Furchner et al. (1966) and used to simulate ip and inhalation experiments
are shown.
bDefault body weight. Some body weights were lower (0.25) to represent study conditions.
cThe deposition lung region of the lung is the sum of the tracheobronchial and pulmonary tissue 
(fDepLu=fDepTB+fDepPu; VDepLuC=VTraBroC+VPulmonC).
dThis fraction is not an independently estimated variable. Instead, the fraction represents the ratio of the two rate 
constants, kin and kout, for each tissue.
Source: Teeguarden et al. 2007c
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manganese in all tissues and matching the turnover of 54Mn for each tissue (Teeguarden et al. 2007c).  For
inhaled manganese, fractional depositions in the nasopharyngeal (fDepNP = 0.2), tracheobronchial
(fDepTB = 0.21), and pulmonary (fDeppu = 0.07) regions were taken from the EPA (1994a) respiratory
tract deposition model for 1.1-µm aerosols. The model assumed that deposited aerosols dissolved
immediately and that there was no clearance from the airway lumen to the gut via mucociliary transport;
this assumption is valid for soluble manganese forms such as manganese chloride and manganese sulfate,
but would not be valid for less-soluble forms of manganese such as manganese phosphate (Nong et al.
2008; Teeguarden et al. 2007c).
Nong et al. (2008) described further refinements to model A parameters shown in Table 3-15. Daily
manganese dietary intake (FDietUp) and biliary elimination rate constants (kBileC) were first calibrated for
different levels of manganese in the diet (2, 10, 100, and 125 ppm; Table 3-15) by fitting the model to the
observed steady-state tissue manganese concentration data for rats exposed to 2, 10, or 100 ppm
manganese in the diet for 13 weeks (Dorman et al. 2001b).  After this refinement, clearance rates for the 
liver and brain striatum (kIn and kOut values shown in Table 3-15) were refined by fitting the model to 
tissue manganese concentration data from the 14-day inhalation study by Dorman et al. (2001a). 
Nong et al. (2008) Model B Description and Development.  Model B contains a similar structure to
Model A, except that manganese concentrations in the liver and brain striatum are dependent on capacity-
limited binding of manganese (Figure 3-7).  In addition, uptake from striatal blood to striatal tissues is
described with diffusion terms (PA12 and PA21, Figure 3-7).  The diffusion terms were included to account
for observations of preferential increases in some brain regions compared with other tissues, such as liver
or blood, following inhalation exposure to manganese (see Dorman et al. 2006a for review).  The
diffusion terms are thought to reflect movement of manganese across the blood-brain barrier (Nong et al. 
2008).  In Model B, the total amounts of manganese in the liver and brain striatum tissues are dependent
on concentrations of free circulating manganese, the binding capacity of the tissue, and the concentrations 
of bound manganese in tissue stored (Nong et al. 2008).  Differential equations to describe changes (with 
time) in amounts of free or bound manganese in the liver and the brain striatum are described in detail by
Nong et al. (2008).  Table 3-16 lists binding rate constants (e.g., kaBrnC, kdBrnC), binding capacities
(Bmax,Brain, Bmax.Liver), brain diffusion constants (PA12 and PA21), and partition coefficients in Model B.  
Liver and brain striatum binding capacity levels were first determined by fitting the model to steady-state 
tissue concentration data from the 13-week dietary study by Dorman et al. (2001b), using starting values
for the tissue binding parameters that were estimated based on clearance rate values (kIn and kout) for
liver and brain striatum in Model A.  Tissue binding parameters (e.g., kaBrnC, kdBrnC) and brain 
   
 









           
 
     
    
    
    
    
    
     
    
       
     
        
     
 
    
    
    
    
Table 3-15.  Refined Parameter Values in Nong et al. (2008) Model A
Parametera Manganese level in diet Biliary excretion (/h/kg)
kBileC 2 ppm manganese 0.19 
10 ppm manganese 0.28
100 ppm manganese 0.60
125 ppm manganese 0.60
Tissue clearance rates (/h/kg)
kInLivC Into deep liver compartment 0.621
kInBrnC Into deep brain compartment 0.011
kOutLivC Out of deep liver compartment 0.007
kOutBrnC Out of deep brain compartment 0.00039
Dosing parameters: diet level Fraction of manganese in diet that is
of manganese absorbed
FDietUp 2 ppm manganese 0.044
10 ppm manganese 0.018
100 ppm manganese 0.004
125 ppm manganese 0.003
 
       
  
 




aThe remaining parameters are described in Teeguarden et al. (2007c). Clearance rates are scaled to the body
weight (BW−0.25).
Source: Nong et al. 2008
   
 









           
 
  
   
      
      
      
      
    
      
      
   
     
     
  
    
    
 
    
     
 








Table 3-16. Parameter Values in Nong et al. (2008) Model B
Parametersa Values
Tissue binding rate constantsa 
kaBrnC Association striatum constant (/h/μg/kg) 0.000176 
kaLivC Association liver constant (/h/μg/kg) 0.06772 
kdBrnC Dissociation striatum constant (/h/kg) 0.00002 
kdLivC Dissociation liver constant (/h/kg) 0.0054196 
Tissue binding constants (μg/kg)
Bmax,brain Maximal binding striatum constant 3,300 
Bmax,liver Maximal binding liver constant 1,000 
Brain diffusion constants (/hour/kg)
PA12 Influx brain tissue constant 1 
PA21 Efflux brain tissue constant 0.16 
Partition coefficient
Pbrain Brain (striatum):blood 1.0 
Pliver Liver:blood 1.08 
aThe remaining parameters are described in Teeguarden et al. (2007c).
bRate constants are scaled to the BW-0.25 and maximal binding capacities are scaled to BW-0.75 .
Source: Nong et al. 2008
   
 








     
 
 
   
          
            
    
    
     
    
  
 
           
  
   
      
   
     




         
      
    
  
        
          
        







diffusion constants (PA12 and PA21) were then refined by fitting the model to the 14-day-inhalation tissue 
concentration data from Dorman et al. (2001a). 
Evaluation of Nong et al. (2008) Models A and B.  Nong et al. (2008) compared the abilities of Models
A and B to predict: (1) whole-body elimination kinetics of 54Mn in rats fed a 100-ppm diet for 13 weeks
(data from Dorman et al. 2001b); (2) liver and brain striatum manganese concentration data in rats 
exposed to 0.03, 0.3, or 3 mg manganese/m3 for 6 hours/day for 14 consecutive days (Dorman et al. 
2001a); (3) whole-body elimination kinetics of 54Mn in rats following 14-day inhalation exposure to 3 mg
manganese/m3; and (4) liver and brain striatum manganese concentrations in rats during and following a
90-day inhalation exposure period to 0.1 or 0.5 mg manganese/m3 (Dorman et al. 2004b).  Both models
adequately predicted observed 54Mn elimination kinetics data, but Model B much more accurately
predicted liver and brain striatum manganese concentration data during and following 14- or 90-day 
inhalation exposures. Model A consistently overestimated liver and brain striatum manganese 
concentration, particularly at concentrations of 0.1, 0.3, or 0.5 mg manganese/m3 (as shown in Figures 4 
and 7 of Nong et al. 2008).  Nong et al. (2008) concluded that the evaluation of the models “highlighted 
the importance of tissue binding in maintaining relatively constant tissue concentrations across a wide 
range of inhaled concentrations.”  Nong et al. (2008) mentioned that the next steps in model development
would be to extend tissue binding in Model B to all other tissues in the models for which appropriate data
are available for calibrating tissue-specific binding rate constants.
PBPK Model for Manganese Transport from the Olfactory Mucosa to Striatum (Leavens et al. 2007).  
Leavens et al. (2007) developed a pharmacokinetic model describing the olfactory transport and blood 
delivery of manganese to the striatum in rats following acute inhalation exposure to manganese chloride 
or manganese phosphate.  Figure 3-9 shows the structure of the model, which presumes that manganese 
undergoes axonal transport from the olfactory mucosa (OM) to the olfactory bulb (OB), followed by
serial transport to the olfactory tract and tubercle (OTT) and then to the striatum (S).  Tables 3-17 and 
3-18 list values of the model parameters for soluble manganese chloride and relatively insoluble 
manganese phosphate, respectively.  Each of the compartments in the model (containing a left and right
nasal cavity) is connected by blood and each is comprised of pools of free and bound manganese.  The 
rates of transport between tissue compartments and between bound and free pools are modeled as first-
order transport processes.  Tables 3-17 and 3-18 show measured values for compartment volumes, values 
for blood clearance into olfactory compartments (e.g., ClOM/blood), values for rate constants for efflux from
compartments to blood (e.g., kblood/OM), values for transport rate constants between compartments (e.g., 
kOM/el), and binding rate constants in the olfactory compartments (e.g., OM free to bound, kOM/f.b and  
   
 








         
          





















Figure 3-9. Schematic of the Leavens et al. (2007) Model to Describe Olfactory
and Blood Delivery of Manganese to the Left Side of the Brain Isilateral to the 
Olfactory Mucosa (OM) in the Left Nasal Cavity*
Blood 
Bound Bound Bound Bound 
Left Muscosa Left Bulb 
Left Tract & 





















f s · kOTT el 








             
  
 





*The model structure for the right side is identical. Values and descriptions of model parameters are in Tables 3-16,
3-17, and 3-18.
Source: Leavens et al. 2007
   
 









           
        
 
       
       
       
       
       
       
       
        
        
       
   
       
        
        
        
      
          
         
        
         
    
      
        
       
          
    
     
      
      
      
       
        
        
        
 
        
     
           
          
 












































   
  
 
   
   
   


















Table 3-17. Parameter Values for Manganese Chloride in the Leavens et al. (2007)
PBPK Model for Olfactory Transport of Manganese in Rats
Parameter Description Value Units Source 
Compartment volumes
V Left OM LOM 0.059 mL Measureda 
V Left OBLOB 0.031 mL Measureda 
V Left OTTOTTL 0.030 mL Measureda 
V Left striatumLS 0.032 mL Measureda 
V Right OM ROM 0.065 mL Measureda 
V Right OBROB 0.038 mL Measureda 
V Right OTTOTTR 0.046 mL Measureda 
V Right striatumRS 0.042 mL Measureda 
Blood clearance into olfactory compartments
Cl Influx to OM OMblood 4x10-4 mL/hour Estimated 
Cl Influx to OBOBblood 1x10-5 mL/hour Estimated 
Cl Influx to OTTOTTblood 6x10-4 mL/hour Estimated 
Cl Influx to striatumbloodS 3x10-5 mL/hour Estimated 
Rate constants for olfactory compartments efflux to blood 
k Efflux from OM to bloodbloodOM 1x10-6 hour-1 Estimated 
k Efflux from OB to blood bloodOB 1x10
-6 hour-1 Estimated 
k Efflux from OTT to blood bloodOTT 0.0 hour-1 Estimated 
k Efflux from striatum to blood S
blood 1x10-6 hour-1 Estimated 
Olfactory transport rate constants
k OM to OBOMel 0.022 hour-1 Estimated 
k OB to OTTOBel 0.037 hour-1 Estimated 
k OTT to striatumOTTel 0.094 hour-1 Estimated 
f Fraction of OTT loss rate to striatumS 0.001 Unitless Estimated 
Binding rate constants in olfactory compartments
k OM free to bound OMf:b 0.006 hour-1 Estimated 
k OB free to bound OBf:b 0.0047 hour-1 Estimated 
k OTT free to bound OTTf:b 0.0043 hour-1 Estimated 
k Striatum free to bound Sf:b 0.0026 hour-1 Estimated 
k OM bound to free OMb:f 1x10-6 hour-1 Constantb 
k OB bound to free OBb:f 1x10-6 hour-1 Constantb 
k OTT bound to free OTTb:f 1x10-6 hour-1 Constantb 
k Striatum bound to free Sb:f 1x10-6 hour-1 Constantb 
aUnpublished results measured in CD rats used in Brenneman et al. (2000) study. Plugged and unplugged exposure 
data were averaged together because they were not significantly different.
bNot possible to estimate both constants for the binding; therefore, the rate constants for the bound to free
manganese were set to a low rate to allow slow removal of manganese tracer from the bound compartment.
Source: Leavens et al. 2007
   
 









         
         
 
       
       
       
       
       
       
       
        
        
       
   
      
       
       
        
      
          
        
        
        
    
      
        
       
          
    
     
      
       
      
       
        
        
        
 
        
     
           
          
 












































   
  
 
   
   
   














Table 3-18. Parameter Values for Manganese Phosphate in the Leavens et al.
(2007) PBPK Model for Olfactory Transport of Manganese in Rats
Parameter Description Value Units Source 
Compartment volumes
V Left OM LOM 0.085 mL Measureda 
V Left OBLOB 0.038 mL Measureda 
V Left OTTOTTL 0.025 mL Measureda 
V Left striatumLS 0.05 mL Measureda 
V Right OM ROM 0.074 mL Measureda 
V Right OBROB 0.038 mL Measureda 
V Right OTTOTTR 0.04 mL Measureda 
V Right striatumRS 0.035 mL Measureda 
Blood clearance into olfactory compartments
Cl Influx to OM OMblood 0.0017 mL/hour Estimated 
Cl Influx to OBOBblood 0.0018 mL/hour Estimated 
Cl Influx to OTTOTTblood 0.0016 mL/hour Estimated 
Cl Influx to striatumbloodS 1.8x10-5 mL/hour Estimated 
Rate constants for olfactory compartments efflux to blood 
k Efflux from OM to bloodbloodOM 3x10-6 hour-1 Estimated 
k Efflux from OB to blood bloodOB 0.0 hour
-1 Estimated 
k Efflux from OTT to blood bloodOTT 1x10-6 hour-1 Estimated 
k Efflux from striatum to blood S
blood 1.5x10-5 hour-1 Estimated 
Olfactory transport rate constants
k OM to OBOMel 0.011 hour-1 Estimated 
k OB to OTTOBel 0.036 hour-1 Estimated 
k OTT to striatumOTTel 0.099 hour-1 Estimated 
f Fraction of OTT loss rate to striatumS 0.033 Unitless Estimated 
Binding rate constants in olfactory compartments
k OM free to bound OMf:b 0.00086 hour-1 Estimated 
k OB free to bound OBf:b 0.0014 hour-1 Estimated 
k OTT free to boundOTTf:b 0.0031 hour-1 Estimated 
k Striatum free to bound Sf:b 0.024 hour-1 Estimated 
k OM bound to free OMb:f 1x10-6 hour-1 Constantb 
k OB bound to free OBb:f 1x10-6 hour-1 Constantb 
k OTT bound to free OTTb:f 1x10-6 hour-1 Constantb 
k Striatum bound to free Sb:f 1x10-6 hour-1 Constantb 
aUnpublished results measured in CD rats used in Dorman et al. (2000) study. Plugged and unplugged exposure 
data were averaged together because they were not significantly different.
bNot possible to estimate both constants for the binding; therefore, the rate constants for the bound to free
manganese were set to a low rate to allow slow removal of manganese tracer from the bound compartment.
Source: Leavens et al. 2007
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OM bound to free, kOM/b.f).  Equations for mass balance, clearance, and free concentrations of manganese 
for each of the compartments are described in detail by Leavens et al. (2007). 
Model parameters were estimated by optimization procedures using kinetics data from rats exposed nose-
only for 90 minutes to 54Mn-manganese chloride (Brenneman et al. 2000) or 54Mn-manganese phosphate 
(Dorman et al. 2002a).  In each experiment, one group was exposed with both nostrils unplugged, while a
second group was exposed with the right nostril plugged.  Blood concentrations were not measured in
either of these studies, but 54Mn concentrations in the kidney, liver, and pancreas were measured and
reported. The mean concentration in these three organs is used to represent blood concentration in the 
model, and the data were used to obtain parameters for equations describing first-order absorption and 
elimination into a single compartment; values for the parameters under plugged and unplugged
conditions, obtained through model optimization procedures, are listed in Table 3-19. The optimized 
model was used to predict the percentage of 54Mn that was transported into each compartment either via 
direct olfactory transport or blood delivery.  For manganese chloride, olfactory transport was predicted to 
deliver >97–99% of the tracer in the left or right olfactory bulbs, 40–76% of the tracer in the left or right 
olfactory tract and tubercle, and only 4–8% of the tracer in the left or right striatum under plugged or
unplugged conditions.  For manganese phosphate, the respective predictions were 38–59% in the
olfactory bulbs, 86–90% in the olfactory tract and tubercle and 77–83% in the striatum.  Leavens et al. 
(2007) cautioned against the predictions for the striatum, since the model overpredicted striatum
concentrations at the later time points for the plugged exposures to manganese chloride or manganese 
phosphate and the unplugged exposures to manganese phosphate (Figures 4–7 in Leavens et al. 2007).
Whole-body Rat and Monkey PBPK Models (Nong et al. 2009).  Nong et al. (2009) modified the Nong
et al. (2008) rat Model B by adding:  (1) saturable binding to all tissues with association and dissociation 
rate constants; (2) preferential accumulation of manganese in brain regions, such as the striatum and
globus pallidus; (3) respiratory and olfactory uptake based on regional particle deposition within the
respiratory tract; (4) inducible biliary excretion; and (5) variable dietary absorption depending on the
manganese content in food substances. The model structure contains compartments for liver, bone, lung, 
nasal cavity, blood, and brain (cerebellum, olfactory bulb, striatum and pituitary and manganese intakes
from the diet and by inhalation.  In the model, inhaled manganese is absorbed following deposition of
particles on the nasal and lung epithelium.  In the nose, absorbed free manganese is largely absorbed into 
the systemic blood and a smaller portion is transported directly into the olfactory bulb.  Free manganese is 
transported in the blood and stored as bound manganese in each tissue, as determined by a binding
capacity (Bmax) and association and dissociation rate constants for each tissue (ka, kd; Figure 3-10).  Each 
   
 









        
        
     
 
     
a Parameter  Description  


Units  Source   Plugged  Unplugged
Manganese chloride exposures 
b  CӨ  Initial deposited concentration  261 791 ng/g Estimated 
 ka  First-order absorption             0.0068           0.005 hour-1  Estimated 
K  First-order elimination rate           0.057           0.063 hour-1  Estimated 
constant 
Manganese phosphate exposures  
b  CӨ  Initial deposited concentration  171 376 ng/g Estimated 
 ka  First-order absorption              0.0035             0.0034 hour-1  Estimated 
K  First-order elimination rate            0.083           0.124 hour-1  Estimated 
constant 
 
       
        
              
 
















Table 3-19. Parameter Values for Describing Blood Concentrations
in the Leavens et al. (2007) PBPK Model for
Olfactory Transport of Manganese in Rats
Value
aEstimated pharmacokinetic parameters for mean of liver, kidney, and pancreas concentration reported in 
Brenneman et al. (2000). See text for equation and details.
bEqual to FX0/Vb, where X0 is initial dose, F is fraction dose bioavailable for absorption, and Vb is the blood volume.
Source: Leavens et al. 2007
   
 








      










Figure 3-10.  Physiologically Based Pharmacokinetic Model Structure Describing 
Tissue Manganese Kinetics in Adult Rats*
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*Schematic A is the structure of the full model. Schematic B describes substructures for deposition and absorption in
the nose and lung. Manganese in the nose is absorbed largely into the systemic blood and a small portion moves
directly to the olfactory bulb. Every tissue has a binding capacity, Bmax, with affinity defined by association and 
dissociation rate constants (Ka, Kd). Free manganese (Mnf) moves in the blood throughout the body and is stored in 
each tissue as bound manganese (Mnb). Influx and efflux diffusion rate constants (Kin, kout) allow for differential
increases in manganese levels for different tissues. QP, QC, and Qtissue refer to pulmonary ventilation, cardiac
output, and tissue blood flows.
Source: Nong et al. 2009
   
 








    
    
          
              
   
 
     
  
  
   
    
   
         
    
           
     
 
       
          
 
   
     
 
         
    
 
      
  
         
      






compartment contains influx and efflux diffusion rate constants (kin and kout) allowing for differential 
increases for different tissues (Figure 3-10).  Differential equations to describe changes in amounts of free 
or bound manganese in the tissue compartments, as well as numerical values of final model parameters,
are described in detail by Nong et al. (2009). Model parameters were first calibrated with steady-state 
tissue concentrations measured by Dorman et al. (2001b) in rats fed two diets differing in manganese
concentrations (10 and 125 ppm) to arrive at dose-dependent fractional gastrointestinal absorption and 
biliary excretion.  Model parameters (including tissue:blood partition coefficients, binding rate constants
and influx and efflux diffusional rate constants) were then refined by fitting the model to the 14-day 
inhalation tissue concentration data from Dorman et al. (2001a), including data for striatum, cerebellum, 
and olfactory bulb.  Model simulations were consistent with empirical observations of brain tissue
concentrations following 14-day inhalation exposures to 0.03, 0.3, or 3 mg manganese/m3 collected by
Dorman et al. (2001a).  The model was used to predict tissue concentrations following 90-day exposures
of rats and compared with empirical tissue concentrations measured in two different 90-day inhalation 
studies (Dorman et al. 2004; Tapin et al. 2006).  Model predictions for the highest exposure concentration 
(3 mg/m3) overestimated measured tissue concentrations, but when the rate constant for biliary excretion
was increased about 2-fold, better fit to the 90-day high-concentration data was obtained.
To develop the monkey model, physiological parameters were scaled to adult monkey values and model
parameters were adjusted to fit the model to manganese tissue concentrations collected by Dorman et al.
(2006a) from monkeys exposed by inhalation to manganese sulfate aerosols at concentrations up to 
1.5 mg/m3 for 90 days.  Simulations from the final monkey model for 90-day inhalation exposure to
1.5 mg/m3 followed by 80 days after exposure were consistent with time-dependent rises in measured
concentrations in liver, pituitary, globus pallidus during exposure, and post-exposure declines in pituitary
and globus pallidus measured concentrations, but the model overestimated measured concentrations in the 
lung (during and after exposure) and in the liver after exposure.
Whole-body PBPK Model in Pregnant Rats and Fetuses (Yoon et al. 2009a). The adult rat model
developed by Nong et al. (2009) was extended to develop a PBPK model that would predict fetal
manganese dose and manganese disposition in rat dams and fetuses following maternal exposures (dietary
and inhalation) to manganese. The tissue concentration data used to parameterize the model were those 
for rats exposed to 10 ppm in the diet and exposed by inhalation to manganese sulfate aerosols at 0, 0.05, 
0.5, or 1 mg manganese/m3, starting from 28 days before breeding and continuing through a 14-day 
mating period until GD 20 (Dorman et al. 2005a, 2005b).  The model structure for the dams contains
compartments as in the Nong et al. (2009) adult rat model, plus a placenta through which fetal exposure
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occurs via two separate pathways operating simultaneously:  a bidirectional diffusion process described
by a maternal to fetal diffusion rate (ktrans1) and a fetal blood to placenta diffusion rate constant
(ktrans 2C) and a saturable, active transport, maternal to fetal process described by a Vmax and 
Michaelis-Menten constant (Km) (see Figure 3-11).  Compartments in the fetus included the lung, liver, 
brain blood, whole brain, bone, and rest of body, each with association and dissociation rate constants
(Figure 3-11). Differential equations to describe changes in amounts of free or bound manganese in the 
tissue compartments, as well as numerical values of final model parameters, are described in detail by
Yoon et al. (2009a).  In general, parameters from the original adult model were modified to accommodate
different life stages (i.e., pregnancy and fetal development), first using control group tissue concentration 
data to estimate gestation-specific parameters for dietary only exposure, and then refined by fitting to 
inhalation-exposure data for pregnancy and fetal development periods.  Model simulations of maternal
and fetal tissue concentrations on GD 20 were visually similar to empirical measurements made by
Dorman et al. (2005a).
Whole-body PBPK Model in Lactating Rat Dams and Fetuses (Yoon et al. 2009b). This model was 
developed in parallel to the development of the gestation and fetal rat model (Yoon et al. 2009a).  The
lactating maternal model had the same compartments as the Nong et al. (2009) adult rat model, plus a
mammary gland compartment partitioned from the “rest of body” compartment in the adult model.  The
mammary gland compartment was assigned the same tissue binding parameters, maximum binding
capacity, and partition coefficient as the “rest of body” compartment (see Figure 3-12).  The model
included a milk compartment described as a mass of manganese transferred from the dam to the nursing
pup, with a variable rate of milk production over the lactational period (Figure 3-12).  Manganese transfer
from the mammary gland to milk was described as a first-order clearance process.  In pups, daily dose
was determined by three intake sources:  diet, milk, and inhalation, and compartments were the same as 
those in the original adult rat model (see Figure 3-12). As described in more detail by Yoon et al. 
(2009b), the model incorporated time- and dose-dependent changes in the dams and offspring in 
manganese-specific kinetic parameters for specific tissues (e.g., maternal gastrointestinal uptake and
biliary excretion, maximal binding capacities in growing pup compartments, and developmental changes
in gastrointestinal uptake and biliary elimination), as well as in physiological parameters, such as 
maternal and fetal body weight, tissue volumes, and cardiac outputs.  Manganese-specific kinetic 
parameters were calibrated using tissue concentration data collected by Dorman et al. (2005a, 2005b)
from lactating rat dams and offspring exposed to 10 ppm manganese in the diet, and 0, 0.05, 0.5, or 1 mg
manganese/m3 from PND 1 to 18 for dams and PND 19 for pups.  The calibration process was described 
in more detail by Yoon et al. (2009b).  Model simulations of tissue concentrations in rat dams (at the end 
   
 








       




                
           
           
      
 







Figure 3-11.  Model Structure for Simulating Manganese Exposure During 
Gestation in the Rat*
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*Manganese is present in the body as either free (Mnf) or bound form (Mnb). Every tissue (dam and fetus) has a
binding capacity (B) and dissociation rate constants (ka, kd). “_F” is used to distinguish fetal parameters from those 
of the dam. Maternal manganese is transferred to the fetuses through the placenta in the free form. QP, QC, and 
Qtissue refer to pulmonary ventilation, cardiac output, and tissue blood flows.
Source: Yoon et al. 2009a
   
 








         
   
 







Figure 3-12. Model Structure for Predicting Manganese Tissue Levels in 
Lactating Rat Dams and Pups*
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*The diagram describes manganese kinetics in rat dams and pups. Manganese is present in the body as either free 
(Mnf) or bound form (Mnb). Every tissue (dams and pups) has a binding capacity (B) and dissociation rate constant
(ka, kd). Parameters for the pups are distinguished from those of the dam using “_p.” Maternal manganese is
transferred to the pups through milk in the free form. QP, QC, and Qtissue refer to pulmonary ventilation, cardiac
output, and tissue blood flow. Fdeptissue refers to fractional depositions in respiratory tissues.
Source: Yoon et al. 2009b
   
 










      
            
        
     
      
     
  
           
 
 
      
   
 
  
   
   
    
   
 
  
     
  
   
     
 
    
  
         
        
   




of lactation) and offspring (at PND 19 at the end of exposure, and at PNDs 45 and 63) were visually
similar to tissue concentrations reported by Dorman et al. (2005b).  The model simulations and empirical
results indicated that at the end of the inhalation exposure period (PND 19), concentrations in the striatum
and olfactory bulb of offspring began to increase (compared with control values) when air concentrations 
exceeded 0.05–0.1 mg/m3; maternal concentrations in these brain regions began to increase at somewhat
higher air concentrations between 0.1 and 0.3 mg/m3. These results indicate that at given air
concentrations above about 0.05–0.1 mg/m3, brain concentrations in neonates may be elevated, compared
with controls, to a greater degree than in lactating dams, but the age-specific difference in the tested air
concentration range does not appear to be large.  Yoon et al. (2009b) concluded that these results indicate
that neonates are not at an especially increased risk to striatal manganese due to differences in
pharmacokinetic factors.
Whole-body PBPK Model in Adult Monkeys and Humans (Schroeter et al. 2011). The PBPK model
developed for monkeys (Nong et al. 2009) was scaled to humans to predict inhalation exposure conditions
associated with increased brain manganese concentrations and extended to include intravenous,
intraperitioneal, and subcutaneous exposure routes and a series of gastrointestinal compartments
consistent with the physiology of manganese absorption and elimination (see Figure 3-13 for model
structure).  The models were extended to allow comparative analysis of kinetic data from studies of
nonhuman primates and humans exposed by these routes to soluble, carrier-free, radiolabeled 54Mn.  
Modifications from the Nong et al. (2009) monkey model included adjustments of dissociation rate
constants and maximal binding capacities so that each brain region contained about 60% bound 
manganese under diet-only exposure, refinement of diffusion parameters to simulate the rise in brain 
manganese concentrations during inhalation exposure and subsequent decline during post-exposure
displayed by the data collected by Dorman et al. (2006a), and refinement of a dose-dependent influx term
for the globus pallidus and pituitary regions.  Physiological parameters in the human model were either
scaled from the monkey model or obtained from the literature.  Dietary absorption and biliary excretion 
were calibrated using human whole-body elimination kinetic data from earlier studies of humans given 
intravenous tracer amounts of 54Mn.  Initially, diffusion rate constants and tissue binding capacities were 
scaled from monkey values, and association and dissociation rate constants were adjusted to attain 80%
bound manganese in brain regions.  Additional refinements to model parameters were necessary to
maintain tissue levels within expected values with only dietary manganese exposure.  More details 
concerning final parameters for the human and monkey models are provided by Schroeter et al. (2011).  
Model simulations adequately described whole-body elimination kinetic data for monkeys given 54Mn by
intraperitoneal (Dastur et al. 1971), intravenous (Furchner et al. 1966), or oral administration (Furchner et
   
 








      






	Figure 3-13.  Physiologically Based Pharmacokinetic Model Structure Describing
Manganese Tissue Kinetics in Adult Monkeys and Humans*
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*In each tissue department, the amount of bound manganese is in equilibrium with the assumed binding capacity
(Btissue) and free manganese. Tissue-binding processes are controlled by association and dissociation rate constants
(ka, kd). Free manganese (Mnf) moves in the blood throughout the body and is stored in each tissue as bound 
manganese (Mnb). Influx and efflux diffusion rate constants (Kin and kout) control preferential increases in free 
manganese in brain regions. QP, QC, and Qtissue refer to pulmonary ventilation, cardiac output, and tissue blood 
flows.  
Source: Schroeter et al. 2011
   
 














          
 
     
          
  
   
    
 
   
 
 
      
    
 
           
  
 
          
       
 
       
  
    
 
 
   
 
           
 




           










al. 1966), fecal excretion data for monkeys following subcutaneous or inhalation exposures to 54Mn 
(Newland et al. 1987), and whole-body retention data in humans following intravenous injection 
(Mahoney and Small, 1968; Mena et al. 1967) or ingestion of 54Mn (Davidsson et al. 1988; Mahoney and 
Small 1968).  Model simulations of manganese concentrations in the globus pallidus in adult humans with 
a normal diet following 90 days of inhalation exposure to air concentrations ranging from 0.0001 to 
>10 mg manganese/m3 indicated that concentrations increased slightly by about 5% over background 
levels at 0.1 mg/m3 and dramatically increased at higher air concentrations (see Figure 3-14).
Whole-body PBPK Model in Humans during Gestation and Neonatal Periods (Yoon et al. 2011). Yoon 
et al. (2011) developed a series of PBPK models to describe manganese kinetics during fetal and neonatal 
development in humans and to predict internal manganese concentrations in the developing brain.  The
models were based on the basic structure of the rat gestation and lactation model developed by Yoon et al. 
(2009a, 2009b), with modifications based on cross-species extrapolations in developing monkey (Nong et
al. 2009) and adult human models (Schroeter et al. 2011).  The human models incorporated:
(1) pertinent physiological parameters in human females during gestation and lactation from
previously published human pregnancy and lactation PBPK models;
(2) female-specific functional residual capacity, breathing frequency, and tidal volume in the adult
human male model developed by Schroeter et al. (2011) describing manganese particle deposition;
(3) higher basal levels of absorption and biliary excretion of manganese in adult females compared
with males; 
(4) characteristics of the placental transfer of manganese in the rat model with parameter
modifications based on observations of placental and fetal manganese concentrations in humans;
(5) a diffusional clearance from free manganese in mammary tissues to describe manganese milk
secretion as in the Yoon et al. (2009b) rat model, with adjustment of the diffusion rate constant
with data for human manganese milk concentrations during lactation from several published 
studies; 
(6) higher fractional gut absorption of manganese in suckling neonates, compared with adults;
(7) inducible biliary excretion of manganese in neonates, at rates lower than in adults;
(8) transitions of neonatal characteristics of gut absorption and biliary excretion to those of adults;
(9) enhanced brain uptake of manganese during fetal and postnatal development; and
(10) adjustment of tissue binding parameters in fetal tissue to be consistent with published manganese
concentration data from human fetal autopsy tissues and in neonatal tissues to be consistent with

















Figure 3-14.  Simulated End-of-Exposure Tissue Total Manganese Levels in Rat 

Striatum and Monkey and Human Globus Pallidus* 
Rat striatum data:  Dorman et al. (2004a); Tapin et al. (2006) 
Monkey globus pallidus data:  Dorman et al. (2006a) 
Rat striatum:  simulation, Nong et al. (2009) 
Monkey globus pallidus: simulation, Schroeter et al. (2011) 
Human globus pallidus: simulation, Schroeter et al. (2011) 












   
  






3.  HEALTH EFFECTS 
The simulated rat striatal manganese levels are from Nong et al. (2009) and are compared with data 
(mean ± standard error) from Dorman et al. (2004a) and Tapin et al. (2006). The simulated monkey globus 
pallidus manganese levels are compared with data from Dorman et al. (2006a).  Rats and monkeys were 
exposed 6 hours/day, 5 days/week for 90 days.  Humans were exposed 8 hours/day, 5 days/week for 
90 days.
Source:  Schroeter et al. 2011
   
 








       
 
 
         
        
         
     
       
  
       
 
  
    
 
 
     
      
 
       
           
  
    
       
          
   
        








More details on model structure, model equations, and model parameters and their development are 
provided by Yoon et al. (2011).  
Model simulations of placental and fetal tissue manganese concentrations in the absence of airborne 
manganese were consistent with published data for humans with background air manganese exposure;
with increasing air concentrations of manganese, placental and fetal globus pallidus concentrations began
to rise at 0.01 mg/m3 (18 and 11% increase, respectively, over 0 mg/m3 values).  Model simulations of
human milk manganese concentrations at various lactation stages were consistent with published data for
humans with background air manganese exposure; simulated milk concentrations rose with increasing air
concentration, showing <10% increase at 0.01 mg/m3. Simulated average daily AUC for manganese 
concentrations in the globus pallidus of the fetus, suckling neonate, and 3-year-old child from manganese
air concentrations increased beyond 10% of background concentrations in fetuses and 3-year-old children 
when air concentrations exceeded 0.01 mg/m3 (10 µg/m3) and in suckling neonates when air
concentrations exceeded 0.001 mg/m3 (1 µg/m3) (Yoon et al. 2011).
3.5 MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
Absorption. Manganese absorption occurs primarily through the diet; however, absorption via the
lungs can be significant for occupationally exposed persons or for those exposed to excess levels of
airborne manganese, such as downwind of a manganese point source.  Manganese absorption through the
gut may occur through a nonsaturable simple diffusion process through the mucosal layer of brush border
membranes (Bell et al. 1989) or via an active-transport mechanism that is high-affinity, low-capacity, and
rapidly saturable (Garcia-Aranda et al. 1983). Manganese particles that are too large to enter the alveoli
(>10 microns in diameter) remain in the upper respiratory tract, where they are coughed up by
mucociliary transport and swallowed.  Differences in solubility of manganese compounds deposited in the
alveolar regions may impact the rate at which manganese will be absorbed, but manganese is bioavailable 
when deposited in these regions (Drown et al. 1986).
Diets high in iron have been shown to suppress manganese absorption, and conversely, iron-poor diets
increase manganese uptake (Lönnerdal 1997, Lönnerdal et al. 1994).  Phosphorus (Wedekind et al. 1991)
and calcium (Wilgus and Patton 1939) have also been found to decrease manganese uptake. 
   
 








       
       
  
     
            
     
 
             




         
       




      
        
       
           
   
 
   
      










Distribution. Review articles by Aschner and Aschner (1991) and Aschner et al. (2005, 2007)
summarize some of the available data regarding the distribution of manganese.  Dietary manganese,
thought to be absorbed as Mn(II), enters portal circulation from the gastrointestinal tract and is bound to 
α2-macroglobulin or albumin in the plasma.  After delivery to the liver, the major portion of Mn(II) is
secreted in the bile, but some may be oxidized by ceruloplasmin to Mn(III).  The Mn(III) enters systemic 
circulation conjugated with plasma transferrin; once this complex enters a neuron, it dissociates, and from
there, the manganese is transported to axon terminals.  For example, Sloot and Gramsbergen (1994)
observed that radiolabeled manganese injected into the striatum or substantia nigra of rat brain is
transported in an anterograde direction through both γ-amino-butyric acid-producing striato-nigral and
dopaminergic nigro-striatal fibers.
Other studies, however, argue for the transport of Mn(II) into the brain.  For example, Murphy et al. 
(1991) measured the kinetics of manganese transport in the brains of adult male rats using a perfusion
technique. The rats were infused with increasing concentrations of [54Mn]Cl2; blood and brain samples
were analyzed for manganese at varying time points. The data indicated a saturable mechanism for
transporting Mn(II) into the choroid plexus, and influx into the cerebral cortex was also near saturation at
the highest plasma concentration of manganese used.  Influx into other brain regions (e.g., caudate
nucleus, hippocampus, hypothalamus) and cerebrospinal fluid (CSF) showed non-saturable transport of
the cation.  The authors suggested that the non-saturable transport into these brain regions resulted from
passive diffusion of manganese down a concentration gradient from ventricular cerebrospinal fluid
because some of these brain regions have components adjacent to the ventricles and manganese 
concentrations in these regions were below levels in the CSF. The authors also noted that at all plasma 
manganese concentrations tested (from 0.8 to 78 nmol/mL), the transfer coefficient for manganese uptake
into the choroid plexus was significantly higher than in any other area of the central nervous system.  For
example, at 0.08 nmol/mL, the transfer coefficients for the CSF and the choroid plexus were 
16.2±2.43x10-6 mL/second*g and 23,800±2,910x10-6 mL/second*g, respectively.  Even after correcting
for differences in compartment size, influx of manganese into the choroid plexus was an order of
magnitude greater than influx into CSF. 
Rabin et al. (1993) also measured transport of [54Mn]Cl2 in adult rats using a similar technique.  In this
study, the authors used three perfusates (whole blood, plasma/serum, and saline) to determine brain
uptake in environments that facilitated or prevented protein binding of the metal.  The authors reported 
that uptake of manganese into the cortex, hippocampus, caudate nucleus, and choroid plexus was greater
and more rapid when saline was used rather than with whole blood.  When EDTA-saline was used as the 
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perfusate, uptake was not significantly different than zero, indicating that divalent manganese was the 
form taken up by the brain.  The transfer coefficients of Mn(II) from saline in the different regions of the
brain (frontal, parietal, and occipital cortex regions; hippocampus; caudate nucleus; and thalamus-
hypothalamus) ranged from 5 to 10x10-5 mL/second*g, whereas that of the choroid plexus was
727x10-3 mL/second*g. The authors noted that the transfer coefficients were greater than that expected
for passive diffusion and suggested a facilitated blood-brain barrier transport by a channel or carrier
mechanism (Rabin et al. 1993). These findings of a rapid uptake mechanism and concentrated uptake into
the choroid plexus are consistent with results reported by Murphy et al. (1991).  Separate binding studies
performed by the authors determined that albumin, transferrin, α2-macroglobulin added to the manganese
during perfusion significantly decreased brain uptake of the cation in all brain regions. The authors were 
uncertain whether Mn(II) in the form of low-molecular mass solutes was taken up at the blood-brain 
barrier.  However, based on other literature and their own unpublished results, they suggest that the free
ion is the species transported.
Other studies have also revealed the rapid appearance of manganese in the choroid plexus.  Ingersoll et al.
(1995) demonstrated that manganese levels in the lateral choroid plexus were 44 and 24 times higher than
levels in CSF, and blood, respectively, 4 hours after intraperitoneal injection of 10 mg manganese/kg.
However, manganese concentration in the choroid plexus did not change significantly following
intrathecal administration of this same dose. This demonstrated that manganese in the blood could be 
sequestered by the choroid plexus, whereas little to no transfer of manganese from CSF to the choroid 
plexus occurred.  Intrathecal administration of manganese increased manganese concentrations in all
brain regions examined while there were only slight changes in brain manganese concentrations after
intraperitoneal administration.  Moreover, intrathecal administration of manganese decreased spontaneous 
motor activity with no effect on motor activity following intraperitoneal dosing.  The authors suggested 
that these results indicated that the brain is protected from high concentrations of manganese through 
sequestering in the choroid plexus, but this mechanism could become overwhelmed with rising levels of
blood manganese such that manganese could then “leak’ from the choroid plexus into CSF and thereby
enter the brain.  This interpretation appears to be consistent with the findings of London et al. (1989).  In 
these studies, 50 and 100 mg/kg manganese was administered intraperitoneal doses 5 and 10 times that
used by Ingersoll et al. (1995).  Using MRI images, these doses were shown to concentrate in the 
ventricles, the pineal gland, and the pituitary gland and the authors indicated that this high concentration 
of manganese appeared in the ventricular CSF because it crossed the barrier of the choroid plexus.
Takeda et al. (1994) used autoradiography to also show that manganese in selected brain regions was
taken up via the CSF from the choroid plexus.  Moreover, Zheng et al. (1998) observed that, in a
   
 








      
     
   
         
 
         
   
      
   
  
            
  
       





          
          
          
    
 
  
     
   
    
   
   
 
       
              
MANGANESE 296
3. HEALTH EFFECTS
subchronic manganese intoxication rat model, the increases in manganese concentrations observed in
targeted brain regions were closely related in magnitude to that of CSF manganese, but not to that of
serum manganese.  The observations of Takeda et al. (1994) and Zheng et al. (1998) support the view that
manganese in the CSF serves as the main source for manganese distribution in brain tissues.
Recent reviews of the state of the science have emphasized that manganese can enter the brain via three 
pathways: (1) from the nasal mucosa to the brain olfactory bulb via olfactory neural connections;
(2) from the blood through capillary endothelial cells of the blood-brain barrier; and (3) from the blood 
through the cerebral spinal fluid via the choroid plexuses (Aschner et al. 2005; Bock et al. 2008;
Crossgrove and Yokel 2005).  Current understanding is inadequate to determine which of these pathways 
may predominate in cases of severe manganism or cases of subtle neurological impairment in nonhuman
primates or humans.  A number of transport mechanisms (including facilitated diffusion, active transport,
transferrin-mediated transport, divalent metal transporter-1 mediation, store-operated calcium channels)
have been proposed to transport manganese across the blood barrier or into the choroid plexus, but current
understanding is inadequate to determine the predominant molecular mechanism of transport in either of
the pathways (Aschner et al. 2005, 2007; Crossgrove and Yokel 2004, 2005; Roth 2006).
3.5.2   Mechanisms of Toxicity  
The central nervous system is the primary target of manganese toxicity.  Although it is known that 
manganese is a cellular toxicant that can impair transport systems, enzyme activities, and receptor
functions, the principal manner in which manganese neurotoxicity occurs has not been clearly established
(Aschner and Aschner 1991; Aschner et al. 2007).
Mn(III) has been found to be more cytotoxic to human neural cells as a manganese pyrophosphate
complex (MnPPi) than as a manganese-transferrin complex (MnTf) (Suarez et al. 1995).  Specifically, 
human neuroblastoma cells (cell line SH-SY5Y) grown in culture showed effects of cytotoxicity from
30 μM MnPPi but did not show the same signs of cytoxicity from MnTf (membrane damage and cell
granulation and aggregation) until concentrations of 60 μM were reached (Suarez et al. 1995).  Both 
manganese complexes inhibited mitochondrial enzyme activity, but MnTf was slightly more toxic than 
MnPPi in this respect (Suarez et al. 1995).  
Neuropathological changes are detectable in the basal ganglia of humans with manganism, and the 
specific area of injury appears to be primarily in the globus pallidus; the substantia nigra is sometimes
   
 








              
    
       
           
    
         
          
     
   
       
         
  
  
   
   
  
 
        
      
         
  
    
 
       




    
     
        




affected, but generally to a lesser extent (Katsuragi et al. 1996; Yamada et al. 1986).  Studies in
nonhuman primates have produced similar findings (Newland and Weiss 1992; Newland et al. 1989).
Limited evidence suggests that dopamine levels in the caudate nucleus and putamen are decreased in
manganism patients (Bernheimer et al. 1973).  Similarities in the behavior of manganism patients to those
with Parkinson’s disease have prompted some to refer to manganism as "manganese-induced 
Parkinsonism" or "Parkinson-like disease."  Further, the two diseases do affect functional related regions
of the brain, but Parkinsonism is believed to be due to the selective loss of subcortical neurons whose cell
bodies lie in the substantia nigra and whose axons terminate in the basal ganglia (which includes the 
caudate nucleus, the putamen, the globus pallidus, and other structures).  These nigral neurons use
dopamine as their neurotransmitter, and treatment of Parkinson patients with levo-dopa (the metabolic
precursor to dopamine) often relieves some of the symptoms of Parkinson's disease (Bernheimer et al.
1973).  Some investigators have reported that oral levo-dopa can temporarily improve symptoms of
manganese-induced neurotoxicity (Barbeau 1984).  However, most studies show that manganism patients
typically do not respond to levo-dopa treatment (Calne et al. 1994; Chu et al. 1995; Huang et al. 1989),
indicating that they have likely suffered degeneration of the receptors and neurons that normally respond
to this neurochemical (Chu et al. 1995).
The precise biochemical mechanism by which manganese leads to this selective destruction of
dopaminergic neurons is not known, but many researchers believe that the manganese ion, Mn(II), 
enhances the autoxidation or turnover of various intracellular catecholamines, leading to increased
production of free radicals, reactive oxygen species, and other cytotoxic metabolites, along with a
depletion of cellular antioxidant defense mechanisms (Barbeau 1984; Donaldson 1987; Garner and 
Nachtman 1989b; Graham 1984; Halliwell 1984; Liccione and Maines 1988; Parenti et al. 1988; Verity
1999).  Oxidation of catechols is more efficient with Mn(III), than with Mn(II) or Mn(IV) (Archibald and 
Tyree 1987).  Formation of Mn(III) may occur by oxidation of Mn(II) by superoxide (O2-) In cases of
exposure to Mn(VII), it is likely that a reduction to the Mn(II) or Mn (III) state occurs (Holzgraefe et al.
1986), but this has not been demonstrated.
Hussain et al. (1997) studied the effects of chronic exposure of manganese on antioxidant enzymes, 
including manganese superoxide dismutase (MnSOD).  MnSOD is an antioxidant enzyme located 
primarily in the mitochondria that contains manganese as a functional component.  MnSOD protects
against oxidative injury by catalyzing the dismutation of O2-, Hussain et al. (1997) found that
administration of 0, 1.1, and 2.2 mg manganese/kg/day (as manganese chloride), 5 days/week for
3 months, resulted in increased MnSOD in the hippocampus, cerebellum, and brainstem.  Other areas of
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the brain were not affected and other antioxidant enzymes, such as Cu,ZnSOD and glutathione peroxidase
(GPx), were not increased. The researchers suggest that since a critical role of MnSOD is to protect 
against oxidative injury, the increase of this enzyme after manganese exposure may reduce the risk of
oxidative stress induced by that exposure.  Thus, this protective mechanism would have to be
overwhelmed in cases of manganese toxicity.  Additionally, the authors suggest that, since MnSOD was
altered while Cu,ZnSOD and Gpx were unchanged, manganese may not affect cytosolic enzymes like 
Cu,ZnSOD.  In support of this point, the authors also mention other reports that suggest that these 
antioxidant enzymes are independently regulated (Mossman et al. 1996; Warner et al. 1993; Yen et al. 
1996).
Supporting evidence for the hypothesis that high levels of manganese exert neurotoxicity through 
oxidation is provided by Desole et al. (1994).  The authors observed that 22 mg manganese/kg/day (as 
manganese chloride) administered orally in 6-month-old rats resulted in increased concentrations of
DOPAC (an oxidation product of DA) and uric acid, but left DA levels unchanged.  Daily doses of 44 or
66 mg manganese/kg/day resulted in significantly decreased concentrations of DA, glutathione, ascorbic
acid, and DOPAC, and increased concentrations of uric acid in the rat striatum when compared to 
controls. The researchers also measured levels of these metabolites in the rat striatal synaptosomes,
which were used as a model for neuronal terminals.  Here, DA levels were unchanged at 22 mg
manganese/kg/day but were decreased at the two highest doses.  DOPAC levels remained constant at all
three dose levels. Thus, the DOPAC/DA ratio was significantly increased at 44 and 66 mg
manganese/kg/day in the synaptosomes.  While the authors suggest that these data support other findings 
that manganese oxidizes dopamine (Segura-Aguilar and Lind 1989), the decrease in DA could be the
result of decreased production or release of the chemical, rather than increased oxidation.  Catabolism of
adenosine triphosphate (ATP) forms xanthine and hypoxanthine, both of which are metabolized by
xanthine oxidase. The products of this metabolism are uric acid and superoxide radical anion (Desole et
al. 1994).  The increase in uric acid production in rat striatum following oral dosing with 44 or 66 mg
manganese/kg (as manganese chloride) suggests that manganese induces oxidative stress mediated by
xanthine oxidase. Desole et al. (1995) expanded their studies to investigate the protective effect of
allopurinol, a xanthine-oxidase inhibitor, to 3-month-old rats exposed to manganese.  In this study, 
allopurinol was administered by gavage at a dose of 300 mg/kg/day for 4 days.  Manganese 
(87 mg/kg/day) was also administered by gavage, for 7 days, either alone or with allopurinol; the
allopurinol decreased the striatal ratio of DOPAC and homovanillic acid (HVA) to dopamine.  When 
given in conjunction with manganese, allopurinol antagonized the manganese-induced increase in 
DOPAC levels and the (DOPAC + HVA)/DA ratio. Together, the two studies suggest that manganese-
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induced oxidative stress through the formation of reactive oxygen species may be a mechanism for
manganese neurotoxicity, and allopurinol may protect against this oxidative stress in the striatum and 
brainstem of young rats.
Experiments such as the one by Desole et al. (1994) indicate that overexposure of rats to manganese 
results in increased dopamine turnover in the rat striatum.  However, patients with basal ganglia 
dysfunction caused by manganese had normal striatal fluorodopa uptake on PET scan, indicating that the
nigrostriatal pathway was intact (Wolters et al. 1989). Seven intravenous injections of manganese 
chloride into Rhesus monkeys resulted in an extrapyramidal syndrome characterized by bradykinesia,
facial grimacing, and rigity, with gliosis of the globus pallidus and the substantia nigra par reticularis 
(Olanow et al. 1996). These intravenous injections, however, would have resulted in a highly elevated
but transient increase in blood manganese levels.  Striatal dopamine and homovanillic acid levels were 
within normal ranges; yet, there was clear evidence of manganese-induced neurotoxicity.  Interestingly, 
none of the symptoms improved after levo-dopa administration, supporting findings in humans that
manganism does not respond to levo-dopa treatment (Chu et al. 1995; Huang et al. 1989).
While there are a number of studies that support the hypothesis that manganese exerts its neurotoxicity
through oxidation, a study by Sziráki et al. (1999) has demonstrated atypical antioxidative properties of
manganese in iron-induced brain lipid peroxidation and copper dependent low density lipoprotein
conjugation.  However, the underlying mechanisms of the antioxidant effects are not clear.  Brenneman et
al. (1999) measured reactive oxygen species (ROS) in the brains of neonatal rats administered up to
22 mg manganese/kg/day for up to 49 days (dosing was only 5 days/week from day 22 to 49).  On PND
21, no increase in ROS was seen in the striatum, hippocampus, or hindbrain of exposed rats at any dose, 
compared to controls administered water only.  In the cerebellum, ROS levels were significantly
increased to the same extent at both dose levels, as compared to controls.  Manganese levels were not
increased significantly in the cerebellum at any dose level, but were increased in the striatum, and the rest
of the brain at the high dose level, when measured at PND 49.  Mitochondrial manganese was not
significantly elevated in the cerebellum or striatum, but was elevated in the rest of the brain at this high
dose level, also at PND 49.  These data do not support the hypothesis that oxidative damage is a 
mechanism of action in manganese-induced neurotoxicity in the rat.  
As reviewed Taylor et al. (2006), the available literature contains results both in support of and 
inconsistent with oxidative stress involvement in manganese neurotoxicity.  Recent support for oxidative
stress involvement includes the finding that co-treatment of rats with the antioxidant, N-acetylcysteine,
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and intraperitoneal injections of high doses of manganese chloride (50 mg/kg, once or daily for 4 days)
prevented the development of pathological changes observed following injection of manganese chloride
alone (Hazell 2006).  Likewise, mouse catecholaminergic cells (CATH.a) were protected from the 
cytotoxicity of 50–1000 µM manganese by supplementation of the culture media with 5 mM glutathione
or 10 mM N-acetylcysteine (Stredrick et al. 2004).  In contrast, in a series of studies of neonatal rats, adult
male and female rats, or senescent male rats exposed by inhalation to manganese sulfate or manganese 
phosphate at concentrations up to 3 mg manganese/m3 with acute exposure durations or 1 mg
manganese/m3 with subchronic exposure durations (Dorman et al. 2001a, 2004a, 2005a), no consistent
exposure-related changes were found in the following markers of oxidative stress in various brain regions:
glutathione, metallothionein, and glutamine synthetase (Taylor et al. 2006). 
Mn(II) may also be involved in neurotoxicity.  The neurotoxicity of Mn(II) has been linked to its ability
to substitute for Ca(II) under physiological conditions (Aschner and Aschner 1991), and the intestinal
transfers of Ca(II) and Mn(II) have been shown to be competitive in vivo (Dupuis et al. 1992).  Although 
the mechanism for Mn(II) transport into brain cells is uncertain, Mn(II) preferentially accumulates in the
mitochondria in the areas of the brain that are associated with manganism and neurological symptoms.  
Manganese is taken up into mitochondria via the calcium uniporter, and once there, Mn(II) inhibits
mitochondrial oxidative phosphorylation.  Gavin et al. (1992) observed that Mn(II) can inhibit
mitochondrial oxidative phosphorylation when incubating isolated mitochondria with Mn(II) at
concentrations >1 μM.  Recently, it has also been shown that intramitochondiral Mn(II) can inhibit the
efflux of Ca(II), which may result in a loss of mitochondrial membrane integrity (Gavin et al. 1999).  At
the same time, intramitochondrial Mn(II) can also inhibit oxidative phosphorylation and decrease energy
production.  However, Brouillet et al. (1993) has suggested that the impaired oxidative metabolism
induced by manganese is indirectly linked to an excitotoxic process that results in neuronal degeneration.  
Because manganese accumulates in the mitochondria and is associated with impaired energy production, 
these authors compared the effects of intrastriatal injection of manganese with effects produced by known
mitochodral toxins, aminooxyacetic acid and 1-methyl-4-phenylpyridinium.  Lesions produced by these
compounds can be blocked through an inhibition of the glutamatergic N-methyl-D-aspartate (NMDA)
receptor or by the removal of the cortical glutamatergic input into the striatum by decortication.  Thus,
these lesions are termed “excitotoxic lesions.”  It was shown that decortication or pre-treatment with the 
NMDA noncompetitive antagonist, MK-801, could reverse or ameliorate neurochemical changes induced
by intrastriatal injection of manganese. These authors also showed that intrastriatal manganese treatment
also interfered with energy metabolism, ATP concentrations were significantly reduced by 51% and 
lactate levels were increased by 97%. There is additional evidence that the glutamatergic excitatory
   
 








        
   
            
        
         
 
   
              
 
   
            
       
         
           
    
 
 
   
          
  
   
            
            
        
  
          
   
         
 
 
          




system may play a role in manganese toxicity.  Recent studies in genetically epilepsy-prone rats have 
suggested that there are abnormalities in manganese-dependent enzymes.  Although the manganese-
dependent enzymes are believed to be unrelated to seizure activity in these animals, it is suggested that
there is a link between the low manganese concentrations in glial cells and elevated glutamate levels due 
to low glutamine synthetase activity (Critchfield et al. 1993).
Mn(II) (from manganese chloride) has also been shown to inhibit mitochondrial aconitase activity to a
significant level in the frontal cortex of male rats dosed with 6 mg manganese/kg/day for 30 days (Zheng
et al. 1998).  Aconitase levels in striatum, hippocampus, and substantia nigra were decreased in treated 
rats, but not to a significant extent.  Aconitase, which catalyzes the interconversion of L-citrate to
isocitrate, via cis-aconitate, requires iron as a cofactor at its active center (Zheng et al. 1998).  When the 
authors incubated brain mitochondrial fractions with Mn(II), aconitase activity was decreased; the 
addition of excess iron [Fe(II)] revived the enzyme activity.  These data suggest that the similarity of
manganese and iron facilitates their proposed interaction at the subcellular level; however, the data do not
prove that Mn(II) is the form of manganese that is exerting the inhibitory effect.
Conversely, Suarez et al. (1995) did not observe cytotoxicity in cultured cells exposed to 100 μM Mn(II).  
The discrepancy noted in this study, and that of Gavin et al. (1992) may have occurred because of a
protective effect of the cell membrane; if the cell membrane protects the cytosol, which typically has a 
low manganese concentration, then the Mn(II) concentration may be too low to affect the mitochondria
through uniport uptake (Suarez et al. 1995).  Another explanation is that mitochondrial uptake of Mn(II) 
occurs, but toxic effects require that cells be exposed much longer than isolated mitochondria (Suarez et
al. 1995).  It has also been established that manganese accumulation in the brain varies between regions,
particularly in developing animals; this region-specific accumulation may alter the metabolism and
homeostasis of manganese (Chan et al. 1992).  In addition, it has been demonstrated that the manganese
concentration in the central nervous system, in particular the ventral mesencephalon, can be reduced by
cocaine, a dopamine reuptake inhibitor, or by reserpine, a dopamine depleting agent (Ingersoll et al. 
1999). This suggests that the dopamine reuptake carrier is linked to a transport mechanism for
manganese.
In vitro studies of rat brain mitochondria have demonstrated that there is no apparent mechanism for
Mn(II) clearance other than the slow Na+ independent mechanism; it is suggested that Ca(II) and Mn(II)
may accumulate in the brain mitochondria during manganese intoxication (Gavin et al. 1990).  Other
theories regarding the mode of neurotoxicity for manganese (and other metal ions) include toxicity caused 
   
 











           
     
           
  
        
    
        
  
 
   
      
      
        
    
    
           
        
     
         
 
 
   
         
   
   
  
    
    
   




by the formation of hydroxyl radicals during the manganese-catalyzed autooxidation of hydrazines (Ito et
al. 1992).
It has been suggested that the mechanism of manganese neurotoxicity may in part involve complex
interactions with other minerals (Lai et al. 1999).  In a developmental rat model of chronic manganese
toxicity, administration of manganese in drinking water was associated with increased levels of iron,
copper, selenium, zinc, and calcium in various regions of the brain.  Moreover, the subcellular distribution
of various minerals was differentially altered following manganese treatment.  Iron deficiency is
associated with increased manganese burden in the central nervous system of rats, while administration of
excess iron significantly decreases manganese uptake (Aschner and Aschner 1990). The biochemical
mechanisms underlying the interactions between manganese and other minerals are unclear.
Subtle deficits in fine motor and cognitive function in chronically exposed young adult male
Cynomologus macaques monkeys have been associated with manganese impairment of in vivo
amphetamine-induced dopamine release in the striatum, without detectable changes in markers of striatial
dopamine terminal integrity, and with decreased cerebral cortex N-acetylaspartate/creatine ratio (Guilarte 
et al. 2006a, 2006b; Schneider et al. 2006).  In these studies, four monkeys (5–6 years old at the start)
were given intravenous injections of manganese sulfate, 10–15 mg/kg or 3.26–4.89 mg manganese/kg,
once per week for an average of 34.2 weeks. Three additional monkeys without excess manganese 
exposure or behavioral evaluations were used as a control group for post-mortem analyses of the brain
(Guilarte et al. 2006a).  Prior to manganese exposure, the monkeys were trained to perform tests for
cognitive and motor function; overall behavior was assessed by ratings and videotaped analysis 
(Schneider et al. 2006).  By the end of the exposure period, monkeys developed deficits in spatial working
memory, showed modest decreases in spontaneous activity and manual dexterity, and showed increased 
frequency of compulsive-type behaviors such as compulsive grooming (Schneider et al.  2006).  At study
termination, mean manganese concentrations were elevated in exposed monkeys, compared with control
monkeys, in the following brain regions:  globus pallidus (3.30 versus 0.72 µg/g tissue); caudate
(1.18 versus 0.38 µg/g tissue); putamen (1.5 versus 0.48 µg/g tissue); and frontal white matter
(0.57 versus 0.17 µg/g tissue) (Guilarte et al. 2006b; Schneider et al. 2006).  Positron emission
tomography (PET) analysis found changes in amphetamine-induced release of dopamine in the striatum
(up to 60% decrease compared with baseline values), but no significant changes in striatal dopamine
receptor binding potentials (Guilarte et al. 2006a).  Post-mortem chemical and immunohistochemical
analysis of caudate and putamen tissue found no evidence for exposure-related changes to levels of
D2-dopamine receptor (D2-DAR), dopamine receptor (DAT), tyrosine hydroxylase, or dopamine and its
   
 








   
        
            
        
           
 
    
        
          
   
          
  
 
         
     
  
   
         
  
   
    
            
            
   
         
         
        





metabolite, homovanillic acid (Guilarte et al. 2006a). Using 1H-magnetic resonance spectroscopy,
concentrations of creatine (Cr), N-acetylaspartate (NAA), choline, and myo-inositol were measured.
Decreases (relative to baseline) in the NAA/Cr ratio were measured in the parietal cortex and frontal
white matter, but not in the striatum (Gulilarte et al. 2006b).  Guilarte et al. (2006b) suggested that the
changes in the NAA/Cr ratio are indicative of neuronal degeneration or dysfunction in the parietal cortex
that may also be associated with the neurobehavioral changes noted in the monkeys.  Subsequent gene
expression profiling in the frontal cortex of these monkeys found changes consistent with cellular stress
responses that the investigators proposed may help to explain the subtle cognitive effects noted (Guilarte 
et al. 2008). The collective results from these studies suggest that subtle neurobehavioral changes noted
in epidemiological studies of chronically exposed workers (see Section 3.2.1.4 and Appendix A) may be
similar to those noted in these monkeys and may be related to manganese-induced functional changes and 
gene expression changes noted in the striatum and the cerebral cortex.
As reviewed by Fitsanakis et al. (2006), most mechanistic research on manganese neurotoxicity has 
focused on perturbations of the dopaminergic system, but there is evidence to suggest that early
consequences of manganese neurotoxicity may involve perturbations of other neurotransmitters including
GABA and glutamate in the basal ganglia and other brain regions.  For example, there is evidence to 
suggest that manganese decreases the ability of astrocytes to clear glutamate from extracellular space
(Erikson and Aschner 2002, 2003), increases the sensitivity of glutamate receptors to glutamate (see
Fitsanakis and Aschner 2005 and Fitsanakis et al. 2006 for review), and perturbs glutamine-glutamate-
GABA interconversions in frontal cortex and basal ganglia of rats (Zwingmann et al. 2004, 2007).  When 
rat striatum was perfused with artificial cerebrospinal fluid with 200 nM manganese, GABA levels in the 
perfusate were decreased by about 60% compared with controls, but no effects on levels of glutamate,
aspartate or glycine in the perfusate were observed (Takeda et al. 2003).  In the perfused rat hippocampus, 
200 nM manganese caused a 50% decrease in the levels of GABA, glutamate, and aspartate in the 
perfusate (Takeda et al. 2002).  The results from the studies of Takeda et al. (2002, 2003) suggest that
there are differential regional effects of manganese on the release of different neurotransmitters.
Fitsanakis et al. (2006) concluded that additional research is needed to better understand the
interdependence of neurotransmitters, including dopamine, glutamate, and GABA and their relationships
to manganese neurotoxicity. 
   
 








     
 
      
        
   
 
 
   
 
   
            
        
           
    
        
       
    




   
   
 
 
        
  
          
    
 
     
     
   
   
MANGANESE 304
3. HEALTH EFFECTS
3.5.3 Animal-to-Human Extrapolations 
As discussed in Section 3.2, the available literature on toxicological analysis of manganese in humans and
animals is quite extensive. However, due to the wide dose ranges administered, the variety of responses,
and the differences in measured end points, comparisons of effects across species is not straightforward.
Rodent models have primarily been used to study manganese neurotoxicity.  These studies have reported
mostly neurochemical, rather than neurobehavioral, effects (Brouillet et al. 1993; Chandra 1983; Chandra
and Shukla 1978, 1981; Daniels and Abarca 1991; Deskin et al. 1980, 1981; Eriksson et al. 1987a;
Gianutsos and Murray 1982; Parenti et al. 1986; Singh et al. 1979; Subhash and Padmashree 1991), as
very few studies investigated neurobehavioral effects. It has been suggested that this focus may reflect
difficulties in characterizing behavioral changes following basal ganglia damage in the rodent (Newland
1999).  Other techniques, such as those used to identify basal ganglia damage as a result of exposure to 
neuroleptics (Newland 1999), may be refined to further exploit the rodent model as a predictor of
neurobehavioral change in the human.  The usefulness of the rat model for manganese neurotoxicity is 
also limited because the distribution of manganese in brain regions is dissimilar to that of the human
(Chan et al. 1992; Brenneman et al. 1999; Kontur and Fechter 1988; Pappas et al. 1997).  Studies to date
have used exposure routes such as inhalation, intravenous, intraperitoneal, or subcutaneous, with few 
exceptions (Brenneman et al. 1999; Dorman et al. 2000, 2002, 2004a, 2005a, 2006b; Lown et al. 1984;
Morganti et al. 1985; Pappas et al. 1997).
The rabbit has also been used as a model for manganese toxicity in a few studies (Chandra 1972;
Szakmáry et al. 1995).  The only available neurotoxicity study using the rabbit (Chandra 1972) reported 
that the species, when dosed intratracheally with 253 mg manganese/kg body weight (inferred as a one-
time dose), developed hindlimb paralysis (a response not typically observed in humans exposed to excess
manganese) after an observation period of 18 months.  The animals also exhibited wide-spread neuronal
degeneration in the brain.  This study suggests that rabbits and humans may be qualitatively similar in the
manifestation of neurobehavioral effects.  However, further studies are needed to determine if the two
species manifest comparable symptoms within the same dose range.
The nonhuman primate has been a useful model for predicting neurotoxicity in the human as the monkey
presents neurobehavioral responses to toxicants that are very similar to those observed in humans
(Eriksson et al. 1987b; Golub et al. 2005; Gupta et al. 1980; Newland and Weiss 1992; Olanow et al. 
1996).  Further, the monkey also undergoes neurochemical changes (Bird et al. 1984) as a result of
   
 








       
   
 
 
          
  
    
    
  
       
        
         
         
 
 
      
    




   
    
    
   
  
 
        
 
           
         
       




manganese exposure.  Studies have shown that monkeys exposed to manganese injected either
intravenously or subcutaneously exhibit symptoms very similar to those observed in miners and others
exposed to manganese, including ataxia, bradykinesia, unsteady gait, grimacing, and action tremor
(Eriksson et al. 1992a, 1992b; Newland and Weiss 1992; Olanow et al. 1996).  In addition, monkeys
exhibiting these effects show accumulation of manganese in the basal ganglia as observed by MRI
(Eriksson et al. 1992b; Newland and Weiss 1992), as do humans who are either exposed to, or are unable
to clear, excess manganese (Devenyi et al. 1994; Fell et al. 1996; Hauser et al. 1994; Ono et al. 1995;
Pomier-Layrargues et al. 1998; Rose et al. 1999; Spahr et al. 1996).  However, primate studies showing
these neurobehavioral effects have involved routes of administration that do not mimic environmental
exposures, and although the effects in monkeys are qualitatively similar, it is currently unknown whether
the effects are seen at the same dose metric as those in humans.  Newland (1999) proposes using MRI
techniques to relate the administration of certain amounts of manganese with a corresponding MRI signal
in the brain and the resultant neurobehavioral effects. This technique might be very useful in developing
a true dose-response relationship for manganese neurotoxicity in both the monkey and human. 
Mechanisms of manganese toxicity in vivo are likely to be comprised in part by unique characteristics of
the exposed individual, as well as by general physiology and exposure route.  Multiple route PBPK
models have recently been developed for predicting manganese brain concentrations in adult rats,
monkeys, and humans and during gestation and lactation (Leavens et al. 2007; Nong et al. 2008;
Schroeter et al. 2011;Teeguarden et al. 2007a, 2007b, 2007c; Yoon et al. 2011, 2009a, 2009b).  As
discussed by Yoon et al. (2011), confidence in predictions from the human models may improve with 
more information on the normal range and fluctuation of human brain manganese concentrations during
early postnatal periods, the relationship between blood manganese concentrations and target tissue 
dosimetry, and the extent of induction of neonatal biliary excretion.  Further extension of the models to 
other suspected susceptible populations, such as the elderly and individuals with liver dysfunction, also 
would be useful.
3.6 TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
The potential hazardous effects of certain chemicals on the endocrine system are of current concern
because of the ability of these chemicals to mimic or block endogenous hormones. Chemicals with this 
type of activity are most commonly referred to as endocrine disruptors. However, appropriate
terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
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develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents.  The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and 
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering,
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
Studies of endocrine effects in humans following manganese exposure are very limited.  Alessio et al. 
(1989) reported the elevation of serum prolactin and cortisol in chronically-exposed workers, while no 
changes in prolactin, FSH, or LH levels were observed in an occupational study involving shorter
exposure periods (Roels et al. 1992).  Lucchini et al. (1995) reported elevated serum prolactin levels in 
ferromanganese workers; 20 of those workers still showed elevated prolactin levels 5 years later after
exposure to consistent levels of airborne manganese (Smargiassi and Mutti 1999). In fact, the serum
prolactin levels had increased significantly over the previous values.  Although these changes are minor, 
changes in prolactin secretion may have effects on different physiological functions, including loss of
libido and impotence in men, and infertility and change in menstrual cycle in women.
No studies of endocrine effects in animals following airborne manganese exposure were located.  Short-
term animal studies and some of the long-term animal studies were negative for endocrine effects 
   
 








    
         
    
   
   
  




         
 
 
         
   
   
          
          
  
   
    
   
           
           
          
         
            
 
         
      
        




following oral exposure to manganese (NTP 1993).  One intermediate study reported a decrease in 
circulating testosterone and a significant increase in substance P in the hypothalamus and neurotensin in
the pituitary in rats dosed intraperitoneally with 6.6 mg manganese/kg/day as manganese chloride (Hong
et al. 1984).  Two other studies in rats reported that manganese tetroxide in food, given at a dose of
350 mg manganese/kg/day for 224 days (starting on day 1 of gestation and continuing for 224 days)
(Laskey et al. 1982) and 214 mg manganese/kg/day given up to 28 days (Laskey et al. 1985), resulted in 
reduced testosterone levels in male rats. The biological significance of this effect is unknown because the 
decrease had no result on fertility in the latter study (Laskey et al. 1985), and there were no observed 
effects on the hypothalamus or pituitary.  
A current interest in endocrine effects of manganese revolves around the possibility that developmental
manganese exposure may influence the timing of puberty.  One study performed on 23-day-old female 
rats in which manganese was provided by a single, intraventricular administration of 0, 0.01, 0.02, 0.04, 
or 0.17 mg manganese/kg as manganese chloride found that, at the three highest doses, manganese 
stimulated a dose-responsive increase in luteinizing hormone (LH) levels (Pine et al. 2005).  A dose of
2 mg manganese/kg/day, provided to another group of female pups by daily gavage from PND 12 to 29
significantly advanced the average age of puberty (by approximately 1 day) as well as produced
significant increases in serum levels of LH, follicule stimulating hormone (FSH), and estradiol (E2) (Pine
et al. 2005).  In a follow-up study by Hiney et al. (2011), a dose of 10 mg manganese chloride/kg/day
(4.4 mg manganese/kg/day) by gavage from PND 12 to 29 in another group of female pups resulted in 
elevated gene expression levels of IGF-1, COX-2, and LHRH in the hypothalamus (genes involved in 
neuroendocrine axis control of puberty onset).  Additionally, the release of LHRH and prostaglandin E2 
was increased in the median eminence of treated females in vitro. Taken together, the results from these
two studies suggest a role for manganese in regulating the timing of puberty in female rats and suggest
that excess manganese exposure may accelerate the onset of puberty.  Manganese also appears to have 
pubertal effects in male rats; an oral gavage dose of 11 mg manganese/kg/day provided daily on PNDs
15–48 or 15–55 produced significantly increased LH, FSH, and testosterone at 55 days of age (Lee et al.
2006).  Increases in both daily sperm production and efficiency of spermatogenesis were also observed, 
suggesting that manganese may be a stimulator of prepubertal LHRH/LH secretion and thus facilitate the 
onset of male puberty.  In vitro experiments using medial basal hypothalamic implants from adult male 
Sprague-Dawley rats showed that manganese at 500 µM increased LHRH release, nitric oxide synthase 
activity, and the content of cyclic cGMP in the medial basal hypothalamus (Prestifilippo et al. 2007).  The
inhibition of nitric oxide synthase with a competitive inhibitor prevented the manganese-induced increase 
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in LHRH release. The results of these in vitro studies provide added evidence of the ability of manganese
to modulate levels of LHRH, even in adult animals (Prestifilippo et al. 2007).
3.7 CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when all biological systems will have fully developed. Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to hazardous chemicals, but whether there is 
a difference depends on the chemical (Guzelian et al. 1992; NRC 1993).  Children may be more or less
susceptible than adults to health effects, and the relationship may change with developmental age 
(Guzelian et al. 1992; NRC 1993).  Vulnerability often depends on developmental stage.  There are
critical periods of structural and functional development during both prenatal and postnatal life, and a
particular structure or function will be most sensitive to disruption during its critical period(s).  Damage
may not be evident until a later stage of development. There are often differences in pharmacokinetics 
and metabolism between children and adults.  For example, absorption may be different in neonates 
because of the immaturity of their gastrointestinal tract and their larger skin surface area in proportion to
body weight (Morselli et al. 1980; NRC 1993); the gastrointestinal absorption of lead is greatest in infants
and young children (Ziegler et al. 1978).  Distribution of xenobiotics may be different; for example, 
infants have a larger proportion of their bodies as extracellular water, and their brains and livers are 
proportionately larger (Altman and Dittmer 1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek
1966; Widdowson and Dickerson 1964).  The infant also has an immature blood-brain barrier (Adinolfi
1985; Johanson 1980) and probably an immature blood-testis barrier (Setchell and Waites 1975). Many
xenobiotic metabolizing enzymes have distinctive developmental patterns.  At various stages of growth
and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the
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child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns who all have a low glomerular filtration rate and have not developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
Prenatal and early postnatal developmental effects of manganese have largely been unstudied in humans.  
Potential developmental effects of manganese were suggested by the results of a study by Hafeman et al.
(2007) that reported high mortality among infants <1 year of age in a Bangladesh population where the
drinking water supplied by certain local wells contained high levels of manganese. Similarly, Spangler
and Spangler (2009) reported increased infant mortality rates in counties in North Carolina with higher
groundwater manganese concentrations after accounting for such confounders as low birth weight, 
economic status, education, and ethnicity.  However, it cannot be determined if the observed effects in
these studies were solely due to excess manganese alone or could have been influenced by other drinking
water or dietary components.  An older study by Kilburn (1987) showed that a native population living on 
an island with rich manganese deposits suffered increased neurological disorders and incidences of birth
defects.  Manganese exposure was most likely via inhalation and oral routes.  However, since this study
involved small sample sizes and lacked exposure concentrations and a suitable control group, these 
effects cannot be ascribed to manganese alone.
Two early studies investigated increased respiratory complaints and symptoms at a junior high school
situated 100 m from a manganese alloy plant in Japan (manganese concentrations in total dust at a 
200 meter perimeter around the plant were 0.004 mg/m3 [3.7 μg/m3]) (Kagamimori et al. 1973; Nogawa et
al. 1973).  The initial study showed that the incidences of self-reported respiratory illnesses among
children in the exposed school were much higher than those of a control school 7 km away from the plant
(Nogawa et al. 1973).  Further, evaluations of respiratory fitness showed significant decreases in several
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parameters. When the installation of dust catchers resulted in a decreased manganese concentration in
total dust, complaints of illness decreased, and the test results improved (Kagamimori et al. 1973). These 
respiratory effects were not unique from those observed in adults exposed to airborne manganese.
Further, it was not reported if other compounds were present in the dust generated by the plant, which
might have contributed to or caused the reported illnesses.  It is possible that these effects might have 
been triggered by the dust and were not specific to manganese.
The possibility of neurological effects in children environmentally exposed to manganese is a continuing
area of epidemiological research.
In early studies, children who have been exposed to elevated levels of inorganic manganese presumably
through diet (either a normally ingested diet or through total parenteral nutrition, TPN) have shown signs
of motor disorders (e.g., dystonia, dysmetria, propulsion, retropulsion, poor check response bilaterally)
similar to those observed in cases of frank manganism (Devenyi et al. 1994; Fell et al. 1996).  In a few of
the cases, the presence of liver dysfunction indicated a decreased ability to clear excess manganese 
(Devenyi et al. 1994; Fell et al. 1996), but some of the children with apparently normal livers also 
exhibited motor disorders (Fell et al. 1996).  Several children also exhibited hyperintense signals on MRI
resulting from increased exposure to manganese due to cholestatic end-stage liver disease (Devenyi et al.
1994) and from high concentrations of the element in TPN, either in the presence (Fell et al. 1996) or
absence (Fell et al. 1996; Ono et al. 1995) of liver disease.  The Ono et al. (1995) study involved a child 
on TPN for more than 2 years; although this child did have increased blood manganese and hyperintense
signals in the basal ganglia as shown by MRI, the authors did not report any observable signs of
neurotoxicity.  A similar lack of observable neurotoxicity was reported in two siblings fed TPN with high 
manganese concentrations (0.2 mmol manganese/kg/day) for several months (the brother for 63 months
total starting at age 4 months; the sister for 23 months total starting at age 1 month) (Kafritsa et al. 1998).  
Both children had elevated blood manganese levels and showed hyperintense signals in the basal ganglia 
(especially the globus pallidus and subthalamic nuclei) on MRI.  Reduction of manganese concentration
in the TPN resulted in a gradual loss of signal on MRI analysis (becoming comparable to normal scans)
and a decrease in blood manganese levels as measured in three subsequent annual exams.  These 
equivocal results indicate that there are considerable differences in susceptibility to the neurotoxic effects 
of excess manganese in children.
Two other earlier studies show that children who drank water containing manganese at average 
concentrations of at least 0.241 mg/L (Zhang et al. 1995) and ate food with increased manganese content
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(He et al. 1994) for 3 years performed more poorly in school (as shown by mastery of their native
language, mathematics, and overall grade average) and on the WHO neurobehavioral core test battery 
than those students who drank water with manganese ≤0.04 mg/L.  These neurobehavioral tests are
among those administered to workers occupationally exposed to manganese to determine the presence of
early neurological deficit (Chia et al. 1993a; Iregren 1990; Lucchini et al. 1995; Mergler et al. 1994;
Roels et al. 1987a, 1992).  These concentrations are much lower than the ones to which adults were
exposed in the Kondakis et al. (1989) study.  In this study, ingestion of drinking water with excess
manganese (1.8–2.3 mg/L) was linked to the onset of unspecified neurological symptoms in an aged 
population (average age, over 67 years). Though there are limitations, this and other environmental
studies in adults (Baldwin et al. 1999; Beuter et al. 1999; Goldsmith et al. 1990; Kawamura et al. 1941;
Kondakis et al. 1989; Mergler et al. 1999) and two studies in children (He et al. 1994; Zhang et al. 1995)
indicate that both adults and children can manifest similar neurological deficits that are potentially linked 
to ingesting excess manganese.  However, these reports are lacking well-characterized and quantitative 
exposure data that would indicate whether children and adults experience neurological effects at the same 
or different exposure levels.  Existing studies do not allow estimations of the quantitative susceptibility of
children to the preclinical effects of excess manganese exposure.  They do indicate, though, that children 
can develop symptoms of neurotoxicity after oral exposure to manganese that are similar to those effects 
seen in adults environmentally or occupationally exposed to the metal.  Further, these studies indicate that
neurological effects may be a concern for children exposed to excess manganese from the environment or
from a hazardous waste site.
The investigations by He et al. (1994) and Zhang et al. (1995) showed that children with poorer school
performance had higher manganese hair content than children from the control area.  Other studies have 
found that manganese levels in hair are higher in learning disabled children than in normal children 
(Collipp et al. 1983; Pihl and Parkes 1977).  The route of excess exposure is not known, but it is
presumed to be mainly oral.  These observations are consistent with the possibility that excess manganese 
ingestion could lead to learning or behavioral impairment in children.  However, an association of this
sort is not sufficient to establish a cause-effect relationship since a number of other agents, including lead,
might also be involved (Pihl and Parkes 1977).
Several recent reports continue to implicate elevated manganese exposure with impaired
neurodevelopment.  Four epidemiological reports of manganese neurotoxicity in children resulting from
manganese exposure in drinking water have been published.  In two separate cross-sectional studies,
Wasserman et al. (2006, 2011) report statistically significant relationships for decreasing intelligence 
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scores with increasing manganese levels in drinking water in 142–151 children (ages 8–11 years) in 
Bangladesh.  Similarly, in a cross-sectional study conducted by Bouchard et al. (2011), a significant
negative association was found between manganese levels in the home tap water and intelligence scores 
in 362 children from Quebec, Canada.  In previous study by Bouchard et al. (2007c), a statistically
significant relationship between increased levels of oppositional behaviors and hyperactivity and
increased levels of manganese in drinking water in an epidemiological study of 46 children (ages 6– 
15 years), also from Quebec, Canada.
The findings from Farias et al. (2010) support of the hyperactivity findings by Bouchard et al. (2007c).  
This cross-sectional study of 96 students (ages 7–15 years) diagnosed with ADHD and 35 controls reports
that students diagnosed with, but not treated for, ADHD had significantly elevated serum manganese 
levels.  However, in students treated for ADHD with stimulants, manganese levels were not different
from controls and were significantly lower than untreated ADHD students.  The source of manganese 
exposure in this study was not determined, but is presumed to be primarily oral.  
Additionally, three recent case studies suggest that certain children are particularly susceptible to
manganese neurotoxicity from high levels in drinking water, including:  (1) severe neurotoxic symptoms 
(inability to walk independently, tendency to fall backward, and development of a “cock-like” walk) and
MRI scan findings consistent with a diagnosis of hypermanganism in a previously healthy 5-year-old 
female that were associated with elevated drinking water concentrations of manganese (1.7–2.4 mg 
manganese/L), pica, emotional lability, polycythemia, iron deficiency, and elevated levels of plasma 
manganese (Brna et al. 2011); (2) a similar case of severe manganism-like neurotoxic symptoms in a
previously healthy 6-year-old female that were associated with elevated drinking water concentrations of
manganese (1.7–2.4 mg manganese/L), pica, a diet high in manganese-rich foods, and elevated levels of
plasma manganese (Sahni et al. 2007); and (3) inattentiveness and lack of focus in the classroom and low-
percentile performance in tests of memory in a 10-year-old male with no history of learning problems
associated with elevated manganese in drinking water (1.21 mg manganese/L) (Woolf et al. 2002).  
Increased exposure to elevated airborne manganese near industrial sites has also been associated with
altered neurodevelopment.  Two studies evaluated 79 children (ages 7–11 years) from the Molango 
mining district in Mexico exposed to an average manganese air concentration of 0.13 μg/m3 for at least
5 years.  Riojas-Rodríguez et al. (2010) reported a significant inverse relationship between manganese
exposure and full scale and verbal IQs, while Hernández-Bonilla et al. (2011) reported a subtle negative 
association of manganese exposure on motor speed and coordination.  Similarly, Menezes-Filho et al.
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(2011) evaluated cognitive performance in 83 children from 55 families living near a ferromanganese
alloy plant in Brazil that has been emitting high levels of manganese into the air for 4 decades.  Elevated
manganese exposure was inversely associated with intellectual function in both children and adults.
However, direct correlations between air manganese concentrations and cognitive function were not
evaluated in these studies. Likewise, other sources of environmental exposure (i.e., dietary, water) were 
not considered.  
Recent evidence suggests that the critical time-point for adverse neurodevelopmental effects from
elevated manganese exposure is as early as 12 months of age.  In a prospective study, Claus Henn et al.
(2010) reported a U-shaped nonlinear relationship between blood manganese levels and Mental
Development Index scores at 12 months in 486 infants from Mexico City.  However, by 24 months, 
manganese levels were not correlated with neurodevelopment using the Bayley Scales of Infant
Development-II, Spanish version. These findings are consistent with manganese as both an essential
nutrient and a toxicant, and identify 12 months as a potential critical developmental window for
manganese exposure.
Taken together, these recent studies provide added weight to the evidence for the neurotoxic potential of
excessive manganese in children, but one or more of the following uncertainties preclude the 
characterization of causal and dose-response relationships between the observed effects and manganese 
exposure:  (1) whether or not the observed effects were solely due to excess manganese alone or could
have been influenced by other drinking water or dietary components; (2) the lack of quantitative
information about manganese levels from different environmental sources (food, water, and air); and 
(3) the small sample sizes.
Developmental studies in animals following inhalation exposure to manganese are sparse.  One study
exists (Lown et al. 1984) in which pregnant mice were exposed to a high concentration of airborne
manganese or filtered air for 17 days preconception and then exposed to either the same concentration of
manganese or filtered air postconception.  Their pups were then fostered to adult females who had 
experienced the same inhalation exposures as the mothers (no manganese exposure, pre- or post-
conception exposure, or both).  The pups of exposed mothers had decreased body weight, but exhibited
no differences in activity compared to pups from mothers exposed to air, irrespective of exposure history.  
In neonatal rats orally exposed to 25 or 50 mg manganese/kg/day from PNDs 1 through 21, manganese
concentrations in various brain regions were about 2-fold higher than brain manganese concentrations in 
adult rats exposed to the same oral dose levels for 21 days (Dorman et al. 2000).  At the highest dose
   
 








          
  
    
         
    
  
        
      
   
           
   
  
 
    
           
 
            
 
  
   
          
   
    
              
  
     
            
        
  
    





level, neonatal rats showed an increased acoustic startle response, but exposure-related changes in other
neurological end points (clinical signs, motor activity, and passive avoidance) were not found (Dorman et
al. 2000).  In another study, inhalation exposure of female CD rats to manganese sulfate, starting 28 days
prior to breeding through PND 18, caused elevated manganese concentrations in exposed maternal rats 
(compared with air control rats) in the following tissues:  brain and placenta at 0.5 and 1.0 mg
manganese/m3 and lung at 0.05, 0.5, and 1.0 mg manganese/m3 (Dorman et al. 2005a).  In contrast, 
statistically significant elevations of manganese concentrations in sampled fetal tissues were observed
only in the liver at 0.5 and 1.0 mg manganese/m3, and elevated brain manganese concentrations were only
observed in offspring after PND 14.  The results from this study suggest that the brain in developing
fetuses is partially protected from excess manganese by the placenta, and that the neonatal period is 
sensitive to increased manganese concentration in brain and other tissues under exposure to elevated
airborne manganese concentrations.
Oral studies in animal models, whether involving the dosing of pregnant dams or sucklings, reveal a
variety of neurochemical and physiological changes as a result of manganese exposure. The majority of
studies have involved manganese chloride.  One study in rats reported that pups exposed in utero 11 days 
during gestation to a relatively low concentration of manganese chloride (22 mg/kg; by gavage in water)
did not have any observable decrease in weight gain, nor any gross or skeletal malformations upon 
necropsy (Grant et al. 1997a).  Another study (Szakmáry et al. 1995) that also administered manganese
chloride in water by gavage to pregnant rats at the slightly higher concentration of the 33 mg
manganese/kg/day throughout the entire gestation period reported a delay of skeletal and organ
development as well as an increase in skeletal malformations, such as clubfoot, in unborn pups.  These
malformations, however, were self-corrected in pups allowed to grow to 100 days of age.  In addition, the
same dose and route did not result in any observable developmental toxicity in the rabbit (Szakmáry et al.
1995).  Rat pups exposed during gestation and after birth to manganese at relatively high concentrations
of 120–620 mg/kg in drinking water suffered no observable adverse effects at the low dose and only
transient adverse effects (decrease in weight and hyperactivity) at the high dose (Pappas et al. 1997).
Similar transient body weight decreases and increases in motor activity were observed in neonatal rats 
administered 22 mg manganese/kg/day (as manganese chloride), by mouth or gavage, for up to 49 days
(Brenneman et al. 1999; Dorman et al. 2000).  Jarvinen and Ahlström (1975) fed pregnant rats varying
doses of manganese sulfate in food for 8 weeks prior to and during gestation.  Fetuses taken at 21 days 
did not show gross abnormalities, but did have significantly increased body burdens of manganese from
mothers fed 187 mg/kg/day. 
   
 








          
           
   
  
   
      
   
    
  
   
        
   
  
           
  
   
      
         
 
    
        
    
  
 
          
        
  









Rat pups from a generational study in which the male and female parents were exposed to 240–715 mg
manganese/kg/day (as manganese chloride in drinking water) in either a diet adequate or deficient in
protein (Ali et al. 1983a) suffered a delayed air righting reflex (independent of protein content of diet) and 
showed significant alterations in the age of eye opening and development of auditory startle when 
produced by parents fed low-protein diets with 240 mg manganese/kg/day in water.  Kontur and Fechter
(1988) administered up to 1,240 mg manganese/kg/day as manganese chloride in drinking water to
pregnant rats during days 0–20 of gestation.  Although the authors found increased manganese levels in 
the fetus, there were no measurable effects on dopamine or norepinephrine turnover in the pup brain, or in 
the development of a startle response.  However, in a study with both gestational and postnatal exposure
(GD 1–PND 24), Molina et al. (2011) reported decreased anxiety behavior on the elevated plus apparatus
on PND 24 in rat pups from pregnant dams exposed to 4.79 mg manganese/mL (as manganese chloride in
drinking water). Based on body weight and water intake, the study authors calculated daily manganese
doses during gestation and lactation as 565 and 1,256 mg/kg/day, respectively.  In a postnatal exposure
study, an increased amplitude in acoustic startle reflex was observed at PND 21 in neonatal rats 
administered 22 mg manganese/mg/day (as manganese chloride) by mouth from PND 1 to 21 (Dorman et
al. 2000).  Significant increases in brain dopamine and DOPAC concentrations in select brain regions in 
these animals as well as increased brain manganese concentrations were reported. This study
demonstrated that neonates treated with manganese showed neurological changes, whereas no effects
were observed in the adult animals treated similarly.  Lazrishvili et al. (2009) reported marked gliosis in 
rat pups (PND 40) from dams exposed to 4.4 mg manganese/kg/day (as manganese chloride) before, 
during, and for 1 month following pregnancy.  This is in contrast to the lack of evidence for astrocytic 
alterations in adult rats exposed to 147 mg manganese/kg/day (as manganese chloride in drinking water)
for up to 1 month (Rivera-Mancía et al. 2009).  
Neonatal rats given manganese chloride in drinking water for 44 days at a dose of 150 mg manganese/ 
kg/day developed a transient ataxia on days 15–20 of the treatment and had decreased levels of
homovanillic acid in the hypothalamus and striatum on day 15 but not day 60 (Kristensson et al. 1986).  
Neonatal rats given bolus doses of manganese chloride in water of 1 mg manganese/kg/day for 60 days 
suffered neuronal degeneration and increased monoamine oxidase on days 15 and 30 of the study, but did 
not show any clinical or behavioral signs of neurotoxicity (Chandra and Shukla 1978).  Similarly, 
neonatal rats given bolus doses of manganese chloride in 5% sucrose at doses of 0, 1, 10 or 20 mg
manganese/kg/day for 24 days after birth showed decreased levels of dopamine, but not norepinephrine,
in the hypothalamus (Deskin et al. 1980); doses of 20 mg/kg/day caused a decrease of tyrosine 
hydroxylase activity and an increase in monoamine oxidase activity in the hypothalamus.  In a follow-up 
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study, Deskin et al. (1981) gave 0, 10, 15 and 20 mg manganese/kg/day (as manganese chloride in 5%
sucrose by gavage) to neonatal rats from birth to age 24 days.  The authors found that the highest dose
resulted in increased serotonin in the hypothalamus and decreased acetylcholinesterase in the striatum.
However, the authors did not indicate that the acetylcholinesterase decrease was important given other
mechanisms involved in the metabolism of this neurochemical.  Another neonatal study reported
increased locomotor activity when rats were dosed with 10 mg/kg cocaine in adulthood (but no increased
locomotor activity without cocaine challenge) following oral exposure to 13.1 mg manganese/kg/day (but
not 4.4 mg manganese/kg/day) on PNDs 1–21 (Reichel et al. 2006). 
A growing area of research is lasting adverse effects from early exposure to manganese. Tran et al.
(2002a) reported an impaired olfactory-mediated homing ability and passive avoidance of footshocks and 
decreased striatal dopamine levels in male Sprague-Dawley rats exposed to oral doses of 17.2 mg
manganese/kg/day (but not 8.6 mg manganese/kg/day) as manganese chloride on PNDs 1–20.  Evidence
indicates that alterations in passive avoidance behavior and dopamine expression persist into adulthood,
long after manganese exposure has ceased (Tran et al. 2002b).  Kern and colleagues (Kern and Smith
2011; Kern et al. 2010) reported increased open field activity, impaired spatial learning, increased brain 
expression of dopamine receptors (D1, D2) and dopamine transporter proteins, and increased glial
activation in neonatal (PND 24) Sprague-Dawley rats exposed to oral doses of 50 mg manganese/kg/day 
(but not 25 mg manganese/kg/day) as manganese chloride on PNDs 1–21.  In rats tested as adults 
(following cessation of exposure at PND 21), open field activity returned to baseline and the only change
in the dopaminergic system was increased dopamine D2 receptor in the prefrontal cortex; however, 
increased glial activation remaine.  In another study, Moreno et al. (2009) examined the differential
effects of juvenile-only exposure, adult-only exposure, and juvenile followed by adult exposure up to 
13.1 mg/kg/day (as manganese chloride via gavage) on both neurochemical and behavioral end points in 
C57Bl/6 mice.  Open-field activity was altered in juvenile-only and juvenile+adult exposure, but not
adult-only exposure.  All groups had dopaminergic system alterations, with the magnitude of changes 
being the greatest in juveniles.  Only juvenile-exposed mice had alterations in the serotonergic system.
Together, these studies suggest that developing mice may be more sensitive to manganese exposure, and 
that developmental exposure has lasting effects on neurochemical and behavioral end points and later
susceptibility to exposure.
Several studies evaluated the effects of manganese in the diet on reproductive development in the pre-
weanling rodent.  Gray and Laskey (1980) fed mice 1,050 mg manganese/kg/day (as manganese 
tetroxide) in the diet beginning on PND 15 and continuing for 90 days. The manganese caused decreased
   
 








            
            
            
   
              
 
 
        
           
   
             
 
         
   
   
         
    
  
         
  
  
      
 
 
            
  
 
            
   
 





growth of the testes, seminal vesicles, and preputial gland.  Later studies evaluated the effect of excess 
manganese via the diet and gavage on development of the rat (Laskey et al. 1982, 1985). These studies 
reported that 350 mg manganese/kg/day (as manganese tetroxide in food fed to pregnant rats and resulting
male offspring for a total of 224 days) (Laskey et al. 1982) or 214 mg manganese/kg/day (as manganese 
tetroxide by gavage in water given for 28 days) (Laskey et al. 1985) reduced testosterone levels in
developing rats.
Studies involving intravenous or subcutaneous exposure routes of pregnant dams indicate that doses of
manganese chloride as low as 1.1 mg manganese/kg/day administered on GDs 6–17 in the rat (Grant et al.
1997a; Treinen et al. 1995) and 14 mg/kg/day administered on GDs 9–12 in the mouse (Colomina et al. 
1996) can result in decreased fetal body weight and skeletal abnormalities.
The data indicate that animals may suffer adverse developmental effects after inhalation, oral, and
intravenous exposures of their pregnant mothers, but results are mixed.  Taken together, the evidence 
from environmental studies in humans and studies in animals suggests that younger children can be
affected by exposures to excess manganese.  Only one study is available that compared the incidence of
adverse neurological effects in neonates and adults exposed to excess manganese (Dorman et al. 2000).  
Another recent study (Dorman et al. 2005b) showed that fetal brains were protected from excess
manganese when their mothers were exposed to air concentrations as high as 1 mg manganese/m3 
manganese sulfate for 28 days before mating through PND 18, but increased brain manganese
concentrations developed in the offspring by PND 14.  Additional information may help to quantitatively
characterize the potential differences in susceptibility to manganese-induced effects in young and adult
animals.
No studies currently exist on the health effects arising in children as a result of exposure to organic 
manganese.  Therefore, predictions concerning potential effects must be made from extrapolations from 
existing animal studies.
Weanling mice who ingested 11 mg manganese/kg/day as MMT for 12 months exhibited a significant
increase in spontaneous activity at day 80, but no other behavioral differences throughout the exposure
period (Komura and Sakamoto 1992b).  Concentrations of certain neurotransmitters and dopamine
metabolites were modified in different brain regions, but the relationship to manganese levels in the 
affected regions was weak to none (Komura and Sakamoto 1994).
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Developmental studies in rats involving intravenous exposure of pregnant dams to mangafodipir during
organogenesis (days 6–17) indicate that the compound targets the skeletal system, resulting in irregularly
shaped bones at doses as low as 1 mg manganese/kg/day (Grant et al. 1997a; Treinen et al. 1995).  
Further, application of specific doses of the compound during segmented time periods in organogenesis
causes the same skeletal defects (Treinen et al. 1995). When the compound is administered from 22 days 
prior to conception until GD 7, at up to 6 mg manganese/kg/day, no developmental effects were observed 
(Grant et al. 1997a).  These data further indicate that animals developing during organogenesis are 
particularly susceptible to developmental toxicity from mangafodipir exposure.  Further, behavioral
changes and significant decreases in body weight were observed in rat pups delivered from dams dosed
with 1.1 mg manganese/kg/day, while decreased survival was observed in pups from dams given 2.2 mg
manganese/kg/day on GDs 6–17.  
In contrast to the rat, available studies suggest that the rabbit is far less susceptible to the developmental
effects of mangafodipir.  One study reported only decreased ossification in fetal sternebrae at 1.1 mg
manganese/kg/day when given to dams on GDs 6–17 (Grant et al. 1997a); a similar study in the same
species reported no observable developmental toxicity at 2.2 mg manganese/kg/day, but a significant
decrease in fetal weight and viable fetuses, with no skeletal abnormalities, at a dose of 3.3 mg manganese/ 
kg/day also given during organogenesis (Blazak et al. 1996). 
In total, these developmental studies indicate that organic manganese can induce adverse developmental
effects in the unborn and young, with effects ranging from slight biochemical changes in the brain to 
structural changes to changes in functional development.  However, the majority of studies have involved 
very high exposure doses.  
The developmental toxicity of elemental manganese has been shown in large part by comparison studies
between manganese chloride and mangafodipir (Blazak et al. 1996; Grant et al. 1997a; Treinen et al.
1995).  While these studies have provided much information as to the targeted teratogenicity of
manganese during organogenesis, they have generally involved intravenous exposures, which are not
particularly relevant to the general population.  Further, it is likely that the majority of women who may
be exposed to mangafodipir are beyond child-bearing age, since clinical subjects with suspected liver
tumors that merit use of the compound to assist in diagnosis are often over 50 years old (mean values;
Bernardino et al. 1992).  Should child-bearing women be exposed to the compound in a clinic
environment, the doses required to induce developmental toxicity in animals greatly exceed the clinical
dose (Blazak et al. 1996; Grant et al. 1997a; Treinen et al. 1995).  
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The pharmacokinetics of manganese in infants is known to be different than in adults.  Balance studies, 
although limited, show that there is high retention of manganese during the neonatal period (Dorner et al. 
1989).  Formula-fed infants had an apparent manganese absorption of around 20% (Davidsson et al. 1988;
1989b), compared to absorption in adults, which is shown to be around 3–5% (Mena et al. 1969).  The
increased absorption may be a compensatory mechanism due to the low concentration of manganese in
mother’s milk (Collipp et al. 1983; Dorner et al. 1989; Lönnerdal et al. 1987) and to the increased 
metabolic needs of infants as compared to adults, since manganese is required for adequate bone 
mineralization, as well as for connective tissue synthesis (Hurley and Keen 1987).  Alternatively, the 
increased absorption may be due to decreased excretion in the very young (Kostial et al. 1978; Lönnerdal
et al. 1987; Miller et al. 1975; Rehnberg et al. 1981), although at least one study indicates that both pre-
term and full-term infants actively excrete manganese (Dorner et al. 1989).  Some studies have indicated
that infants, who acquire all of their manganese in the first 4 months of life from human milk or milk
formulas, ingest very different amounts of manganese due to the differing manganese content of these
food sources.  More specifically, studies showed that due to the low manganese concentration of human 
milk (4–10 μg/L) and its higher concentration in cow’s milk formulas (30–75 μg/L) and soy formulas
(100–300 μg/L) (Dorner et al. 1989; Lönnerdal et al. 1987), more manganese was absorbed from the
formula (with absorption rate from all sources being roughly equal).  Recent changes in nutritional status 
of infant formulas have resulted in a more nutritionally balanced absorption of manganese when 
compared to human milk and cow’s milk formulas (~80–90%), with absorption of manganese from soy
milk formulas being slightly lower (~70%; Lönnerdal et al. 1994).  However, given the existing
differences in inherent manganese concentrations between the different food sources, reports still suggest
that infant intake of manganese from milk formulas is 10–50 times that of a breast-fed infant (Lönnerdal
1997).  Animal studies show that absorption and/or retention of manganese is similar to that of older
animals at approximately post-gestational day 17–18 (Kostial et al. 1978; Lönnerdal et al. 1987; Miller et
al. 1975; Rehnberg et al. 1981).  However, when this transition takes place in human infants has not been 
clearly defined.
Animal studies also show increased absorption of manganese in the young.  For example, Kostial et al.
(1989) found that rat pups retained a greater proportion (67%) of a single oral dose of radiolabeled 
manganese than adult rats (0.18%).  Bell et al. (1989) found that manganese absorption in rat pups (using
isolated brush border membrane vesicles from the intestine) is nonsaturable and appears to occur
primarily by diffusion.  In the older rat, however, a high affinity, low capacity, active-transport
mechanism for manganese absorption appears to be present (Garcia-Aranda et al. 1983).
   
 









   
   




    
       
     
 
   
          
  
        
               
      
  
           
     
        
         
 
           
     
 
    
    
            
     
             




Several elements, including iron (Davis et al. 1992a), phosphorus (Wedekind et al. 1991), and calcium
(Wilgus and Patton 1939) are known to decrease manganese absorption in adults and animals.  Iron-poor
diets result in increased manganese absorption in humans (Mena et al. 1969) and in rats (Pollack et al.
1965).  These interactions have not been studied in infants or children, but are expected to occur.
Manganese is known to cross the placenta and has been detected in cord blood in healthy full-term and 
pre-term infants.  It is unknown whether mothers exposed to increased concentrations of manganese will
pass on toxic amounts of the metal to their unborn children via the blood.  However, as manganese is an 
essential nutrient and is part of the human body at all times, it is expected to be found in all tissues and 
fluids of the infant.  Manganese is also naturally found in breast milk (typical concentrations in mature
milk range from 4 to 10 μg/L) (Collipp et al. 1983).  No studies exist concerning breast milk
concentrations of mothers exposed to increased concentrations of manganese, but milk manganese 
concentrations increased with increasing exposure levels in lactating female rats exposed by inhalation to
manganese sulfate at 0.05, 0.5, or 1 mg manganese/m3 for 28 days before mating through PND 18 
(Dorman et al. 2005a).  The mean milk concentration was statistically significantly increased, compared
with air control levels, however, only at the highest exposure level.  It is unclear if manganese stored in
the brain, bone, or in another depot, in excess amounts, could be mobilized to affect a developing fetus.
However, one study by Jarvinen and Ahlström (1975) showed that pregnant rats fed 94 mg manganese/ 
kg/day (as manganese sulfate) for 8 weeks accumulated the metal in their livers in contrast to non-
pregnant females. Further, at a daily dose of 187 mg/kg/day, increased manganese concentrations were 
found in 21-day-old fetuses.  These data suggest that homeostatic control of pregnant mothers regulated
the distribution of the metal at lower concentrations, but this control was circumvented at high daily
concentrations, resulting in liver excesses and distribution in the developing fetus.  Although the fetuses
in this study showed no physical abnormalities, no neurochemical or neurobehavioral studies were 
performed to determine potential adverse effects on these relevant end points.
Transferrin is one of the proteins responsible for binding and transporting both iron and manganese
throughout the body.  One study (Vahlquist et al. 1975) reported no correlation between infant cord blood 
and maternal blood transferrin levels. The same study reported an increase in plasma transferrin from
1.68±0.60 mg/mL in blood from infants at 6 weeks of age, to a peak of 2.60±0.27 mg/mL at 10 months, 
with values stabilizing at these adult levels throughout 16 years of age. The authors did not comment as 
to the statistical difference, if any, of these values.
   
 








        
    
            
    
    
 
    
        
        
 
              
  
   
         
             
         
    
         
 
      
 
          
          
 
 
           
         
         
         
  
          
    




There are no established biomarkers consistently used as indicators for overexposure to manganese in
either adults or children.  Elevated blood concentrations and hyperintense signals in the globus pallidus on
T1-weighted MRI have been observed in children with increased exposure to manganese (Devenyi et al.
1994; Fell et al. 1996; Kafritsa et al. 1998; Ono et al. 1995).  However, the same limitations of these 
indicators of overexposure in adults (wide range of blood manganese in normal populations, high cost
and, hence, low availability of MRI) apply to children.  Blood manganese has generally been poorly
related to current levels of exposure or cumulative exposure index (Smargiassi and Mutti 1999).  Elevated 
blood manganese alone does not constitute an adequate indicator of manganese overexposure. There are 
no pediatric-specific biomarkers of exposure or effect. See Section 3.8.1 for further information.
Studies suggest that children may differ from adults in their susceptibility to the toxic effects of
manganese due to toxicokinetic differences (i.e., increased absorption and/or retention).  Qualitative
similarities exist between respiratory and neurological effects seen in adults and children suffering from
extreme manganese exposure. While infant and animal studies indicate that the young have an increased
uptake of manganese, and distribution of the element in certain tissues may differ with age, studies that 
reveal quantitative levels of manganese associated with discrete frank effects in both adults and children
are lacking.  The studies to date (namely absorption, distribution and excretion studies in animals) suggest
a pharmacokinetic susceptibility to manganese that is different in children than in adults.
3.8 BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
A biomarker of exposure is a xenobiotic substance or its metabolite(s) or the product of an interaction
between a xenobiotic agent and some target molecule(s) or cell(s) that is measured within a compartment
of an organism (NAS/NRC 1989). The preferred biomarkers of exposure are generally the substance 
itself, substance-specific metabolites in readily obtainable body fluid(s), or excreta.  However, several
factors can confound the use and interpretation of biomarkers of exposure.  The body burden of a
substance may be the result of exposures from more than one source. The substance being measured may
be a metabolite of another xenobiotic substance (e.g., high urinary levels of phenol can result from
exposure to several different aromatic compounds).  Depending on the properties of the substance (e.g., 
biologic half-life) and environmental conditions (e.g., duration and route of exposure), the substance and 
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all of its metabolites may have left the body by the time samples can be taken.  It may be difficult to
identify individuals exposed to hazardous substances that are commonly found in body tissues and fluids
(e.g., essential mineral nutrients such as copper, zinc, and selenium).  Biomarkers of exposure to 
manganese are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an
organism that, depending on magnitude, can be recognized as an established or potential health
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by manganese are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to Manganese 
Manganese can be measured with good sensitivity in biological fluids and tissues (see Section 7.1), and 
levels in blood, urine, feces, and hair have been investigated as possible biomarkers of exposure.  As a
group, workers exposed to a mean concentration of 1 mg manganese/m3 had higher levels of manganese 
in the blood and the urine than unexposed controls (Roels et al. 1987b). The group average levels in
blood appeared to be related to manganese body burden, while average urinary excretion levels were
judged to be most indicative of recent exposures.  A study by Lucchini et al. (1995) is the only evidence 
that suggests that blood and urine levels were correlated with manganese exposure on an individual basis.
This study differed from others in that it involved exposure to manganese dioxide and measured adverse
effects in workers after exposure ceased, whereas other studies involved current exposures, and some, like
Roels et al. (1987b) involved exposure to numerous manganese compounds (salts and oxides).  The
findings of Lucchini et al. (1995) suggest that blood and urine levels of manganese, on an individual
basis, are positively correlated with exposure levels in the few weeks following cessation of exposure.  In
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a study of chronically exposed workers who were evaluated while exposure was ongoing, Lucchini et al.
(1999) found a positive correlation between manganese levels in total dust and in blood of exposed 
workers.  This correlation did not exist for cumulative exposure index and blood levels of the metal.  
Other studies have indicated that on an individual basis, the correlation between the level of workplace 
exposure and the levels in blood or urine is not a reliable predictor of exposure (Jarvisalo et al. 1992;
Roels et al. 1987b, 1992; Smyth et al. 1973).  However, two studies (Jarvisalo et al. 1992; Roels et al. 
1992) suggest that blood and urinary manganese levels may be used to monitor group exposure, such as
exposure in an occupational setting.  Also, a study (Siqueira et al. 1991) of ferromanganese workers
indicated that exposed workers had elevated levels of plasma and urinary urea and decreased levels of
urinary calcium, HDL cholesterol, and plasma inorganic phosphate.  The study authors concluded that
measurement of these parameters may be useful in the early detection of manganese poisoning.  Although
manganese may play a role in a metabolic pathway or other biological function involving these products, 
it is unclear what physiological significance these parameters have as related to manganese toxicity.
There was no significant correlation between fecal excretion of manganese and occupational exposure to 
the metal (Valentin and Schiele 1983).  A recent study on environmental exposure to manganese
(Baldwin et al. 1999) in southwest Quebec, Canada, indicates that significantly higher levels of blood 
manganese are correlated with high levels of airborne manganese.  In this study, air samples were taken in
four geographic areas around a former ferroalloy plant (point source for airborne manganese).  The air
samples, which were for total dust and PM10 levels, were taken for 3 consecutive days in the summer.
Using a geometric algorithm, 297 blood manganese values from nearby residents in seven postal zones
were separated into two geographical areas corresponding to the point source. Higher blood manganese 
values in men and women were located in the geographic area with the higher airborne manganese values.
It is notable that the air samples taken were limited in number and were taken only in the summer.
However, the authors mentioned that the data were consistent with samples taken in an adjacent urban 
area and were consistent with potential exposure sources.  Further, at the time of sampling, the ferroalloy
plant was not in use and exposure data indicated that airborne levels of manganese decreased dramatically
at a point 25 km downwind of the plant after the plant closed (Zayed et al. 1994). Thus, manganese 
exposure of the population in the Baldwin et al. (1999) study is likely to have been greater in the past;
current blood manganese levels may be analogous to those observed in occupational workers undergoing
a forced layoff (Lucchini et al. 1995).  These data, combined with the occupational studies, indicate that
there may be a plateau level of homeostatic control of the metal.  At low levels, blood manganese 
concentrations would be related to intake from food, water, and air; large differences in individual blood 
manganese levels would be observed.  At high exposure levels, such as in occupational environments, a 
   
 








     
          
 
         
    
   
       
 
           
        
         
  
   
  
 
    
 
    
        
             




     
    
            
 
          
         
       





higher but still non-toxic level of blood manganese may be maintained by homeostatic control (i.e., a 
plateau level is reached); alternatively, that level may be exceeded.
These data also indicate that blood manganese levels can be an indicator of exposure to environmental
manganese. These data indicate that manganese in blood or urine may be useful in detecting groups with 
above-average current exposure, but that measurements of manganese in these body fluids in individuals
may only be related to exposure dose after the exposure has ceased.
In addition to individual variability, another factor that limits the usefulness of measuring manganese in
blood, urine, or feces as a measure of excess manganese exposure is the relatively rapid rate of
manganese clearance from the body.  As discussed in Section 3.4, excess manganese in blood is rapidly
removed by the liver and excreted into the bile, with very little excretion in urine (Klaassen 1974;
Malecki et al. 1996b).  Thus, levels of manganese in blood or urine are not expected to be the most
sensitive indicators of exposure.
Serum prolactin (PRL) has been shown to be a possible biomarker of manganese action of dopamine
neurotransmission (Smargiassi and Mutti 1999).  Manganese acts on the tuberoinfundibular dopaminergic
system, which exerts tonic inhibition of PRL secretion.  Serum PRL levels observed in workers 
occupationally exposed to manganese were shown to be consistent with mechanistic studies as they were 
distinctly higher than unexposed workers.  It is still unclear whether or not serum PRL levels indicate
recent or cumulative exposure. The value of PRL as a biomarker is called into question by the Roels et al.
(1992) study in which serum PRL levels were not increased in workers chronically exposed to airborne
manganese.
Lymphocyte manganese-dependent superoxide dismutase activity increases with increased manganese 
uptake (Yiin et al. 1996).  It has been suggested that this enzyme, in conjunction with serum manganese
levels, may be helpful in assessing low and moderate levels of manganese exposure (Davis and Greger
1992; Greger 1999).  MnSOD has been shown to be elevated in women ingesting 15 mg of supplemental
manganese/day, while levels have been shown to be depressed in the heart and liver of manganese 
deficient animals. MnSOD is important as a possible biomarker because its levels can be related to
oxidative damage.  Its sensitivity as a biomarker depends on factors that induce oxidative stress or effect
manganese bioavailability including diets high in polyunsaturated fatty acids and strenuous physical
exercise (Greger 1999).  
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Brain MRI scans and a battery of specific neurobehavioral tests (Greger 1998) may be useful in assessing
excessive manganese exposure even among industrial workers exposed to airborne manganese (Nelson
et al. 1993).  These scans also have been successfully used to identify accumulation of manganese in the 
brains of children exposed to excess manganese (Devenyi et al. 1994; Fell et al. 1996; Ihara et al. 1999;
Kafritsa et al. 1998; Ono et al. 1995; Sahni et al. 2007).  Levels in feces could be useful in evaluating
relatively recent high-level exposures but would not be expected to be helpful in detecting chronic low-
level exposures. These methods are potentially useful biomarkers, but require additional evaluation to
determine their validity.
While it is well established that exposure to excess manganese can result in increased tissue levels in
animals, the correlations among exposure levels, tissue burdens, and health effects have not been
thoroughly investigated in humans or animals.  Also, since homeostatic mechanisms largely prevent
fluctuations of manganese concentration in whole blood and since manganese is mainly excreted by the 
biliary route, it is not believed possible to identify a biological marker to assess the intensity of exposure
or concentration in the target organ (Lauwerys et al. 1992).  As noted by Rehnberg et al. (1982), 
manganese levels in tissues are subject to homeostatic regulation via changes in absorption and/or
excretion rates. While exposure to very high levels may overwhelm these mechanisms, continuous
exposure to moderate excesses of manganese does not appear to cause a continuous increase in tissue 
levels (Rehnberg et al. 1982).  Moreover, even if tissue levels are increased in response to above-average 
exposure, levels are likely to decrease toward the normal level after exposure ceases.  For example, the 
level of manganese in the brain of a subject with severe manganism was not different from the normal
level (Yamada et al. 1986).  For these reasons, measurement of tissue levels of manganese at autopsy or
possibly biopsy may be of some value in detecting current exposure levels but is not useful in detecting
past exposures.  Evaluation of manganese exposure by analysis of tissue levels is also not readily
applicable to living persons except through the collection of biopsy samples.
MRI has been used to track manganese distribution in the brains of monkeys (Dorman et al. 2006b;
Newland and Weiss 1992; Newland et al. 1989) and humans (Kafritsa et al. 1998; Klos et al. 2005; Nolte
et al. 1998; Park et al. 2003; Rose et al. 1999; Uchino et al. 2007; Wolters et al. 1989).  In addition, it has
been used to assay hyperintense signaling in the globus pallidus and other brain areas of individuals with 
chronic liver disease (Devenyi et al. 1994; Hauser et al. 1994, 1996; Klos et al. 2005; Nolte et al. 1998;
Park et al. 2003; Pomier-Layrargues et al. 1998; Spahr et al. 1996; Uchino et al. 2007), individuals on 
chronically-administered TPN (Kafritsa et al. 1998; Nagatomo et al. 1999; Ono et al. 1995), and 
individuals with symptoms characteristic of manganism (Nelson et al. 1993).  Although data addressing
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the sensitivity and specificity of MRI as an indicator for body burden or exposure are limited, the 
technique is being used to identify individuals who are likely to have increased stores of manganese in
brain and potentially in other tissues, as well.  For example, the hyperintense signaling in the brain is
typically coincident with elevated blood manganese levels (Devenyi et al. 1994; Hauser et al. 1994, 1996;
Kafritsa et al. 1998; Klos et al. 2005; Nagatomo et al. 1999; Nolte et al. 1998; Ono et al. 1995; Park et al. 
2003; Pomier-Layrargues et al. 1998; Spahr et al. 1996; Uchino et al. 2007).  Dorman et al. (2006b)
evaluated the use of the pallidal index (PI—ratio of hyperintensities in the globus pallidus and the
adjacent subcortical frontal white matter) and the T1 relaxation rate (R1) from MRI to reflect manganese 
concentrations determined by analytical chemistry in brain regions of monkeys repeatedly exposed by
inhalation to aerosols of manganese sulfate at several concentrations ≥0.06 mg.  Increases in the PI and 
R1 were correlated with the pallidal manganese concentration, but increased manganese concentrations in
white matter confounded the PI measurements.  Dorman et al. (2006b) suggested that R1 can be used to 
estimate regional brain manganese concentrations and that this technique may be used as a reliable 
biomarker of occupational manganese exposure.
Neutron activation has been shown to be a possible means of in vivo measurement of manganese in the 
liver and possibly other tissues and organs, including the brain (Arnold et al. 1999; Rose et al. 1999).
Minimum detection levels are low enough to distinguish between normal and elevated concentrations.
Scalp hair has also been investigated as a possible biomarker of manganese exposure. While some 
studies have found a correlation between exposure level and manganese concentration in hair (Collipp 
et al. 1983), use of hair is problematic for several reasons.  For example, exogenous contamination may
yield values that do not reflect absorbed doses, and hair growth and loss limit its usefulness to only a few
months after exposure (Stauber et al. 1987).  Manganese has also been reported to have a strong affinity 
for pigmented tissues (Lydén et al. 1984), and Hurley and Keen (1987) and Sturaro et al. (1994) have
reported that manganese concentrations in hair vary with hair color.  Further, hair may be contaminated 
by dye, bleaching, or other materials.  Thus, it is not surprising that other studies have found no 
correlation between individual hair levels and the severity of neurological effects in manganese-exposed 
persons (Stauber et al. 1987).  A study that investigated the correlation between potentially toxic metal
content in hair and violent behavior found an association between manganese and violent behavior, but it
was not conclusively established that manganese was the causative factor (Gottschalk et al. 1991). He 
et al. (1994) observed that poor performance in school and on neurobehavioral tests was inversely
correlated with hair levels of manganese. The manganese exposure in this study was via drinking water
and certain foods.  Several studies have found that manganese levels in hair are higher in learning
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disabled children than in nondisabled children (Collipp et al. 1983; Pihl and Parkes 1977).  The route of
excess exposure is not known but is presumed to be mainly oral.  However, an association of this sort is
not sufficient to establish a cause-effect relationship since a number of other agents, including lead, might
also be involved (Pihl and Parkes 1977).  Other studies have found statistically significant associations 
between hair manganese levels and behavioral deficits (Bouchard et al. 2007c; Wright et al. 2006), subtle
motor deficits (Hernández-Bonilla et al. 2011; Standridge et al. 2008) and decreased intellectual function 
(Bouchard et al. 2011; Menezes-Filho et al. 2011; Riojas-Rodríguez et al. 2010). These studies suggest
that hair manganese levels can provide meaningful exposure assessments.
Clara cell protein CC16 is a potential biomarker for exposure to MMT, because the protein decreases in
both BALF and serum following MMT exposure (Bernard and Hermans 1997; Halatek et al. 1998), 
possibly due to decreased synthesis and/or protein secretion due to loss of producing cells (Halatek et al. 
1998).  The protein can be quantified in serum or urine, but no dose-response studies on the potential
biomarker have been performed. 
There are no known biomarkers of exposure that are specific for children; any biomarkers applicable for
use in adults should be applicable for children.  For example, manganese-induced hyperintense signals on
MRI have been seen in children (Devenyi et al. 1994; Kafritsa et al. 1998; Ono et al. 1995; Sahni et al. 
2007) as well as adults (Hauser et al. 1994, 1996; Nagatomo et al. 1999; Pomier-Layrargues et al. 1998;
Spahr et al. 1996).
3.8.2 Biomarkers Used to Characterize Effects Caused by Manganese
The principal adverse health effects associated with exposure to manganese are respiratory effects (lung
inflammation, pneumonia, reduced lung function, etc.) and the neurological syndrome of manganism and 
preclinical neurological effects.  Although the respiratory effects are similar in many different exposure
studies (Kagamimori et al. 1973; Lloyd Davies 1946; Nogawa et al. 1973), there are no specific 
biomarkers of effect other than reduced lung function.  The fully developed disease can be diagnosed by
the characteristic pattern of symptoms and neurological signs (Mena et al. 1967; Rodier 1955), but the
early signs and symptoms are not specific for manganese.  Careful neurological and psychomotor
examination in conjunction with known exposure to manganese may be able to detect an increased
incidence of preclinical signs of neurological effects in apparently healthy people (Iregren 1990; Roels
et al. 1987a).  However, these signs are not sufficiently specific for preclinical effects of manganese to
reliably identify whether an individual has been exposed to excess levels for a prolonged period.  In 
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addition, no biochemical indicator is currently available for the detection of the early neurotoxic effects of
manganese. There are no specific biomarkers that would clearly indicate long-term exposure to excess
manganese.
Idiopathic Parkinsonism and manganism can be difficult to distinguish due to some similarity in the
symptoms (Kim et al. 1999).  Idiopathic Parkinsonism is marked by neurodegeneration in the
dopaminergic nigrostriatal pathway, while manganism induced damage occurs postsynaptic to the 
nigrostriatal system.  PET with 18F-dopa afforded a differentiation between manganism and idiopathic
Parkinsonism in isolated patients with manganese exposure by indexing the integrity of the dopaminergic
nigrostriatal pathway.
Measurement of altered levels of dopamine and other neurotransmitters in the basal ganglia has proven to
be a useful means of evaluating central nervous system effects in animals (e.g., Bonilla and Prasad 1984;
Eriksson et al. 1987a, 1987b), and these changes are often observed before any behavioral or motor
effects are apparent (Bird et al. 1984).  No noninvasive methods are currently available to determine 
whether there are decreased dopamine levels in the brain of exposed humans, but decreased urinary
excretion of dopamine and its metabolites has been noted in groups of manganese-exposed workers
(Bernheimer et al. 1973; Siqueira and Moraes 1989).  However, the relationship between manganese 
effects on peripheral versus central dopamine levels has not been clearly defined, and given the lack of
change in dopamine content in substantia nigra of humans exposed to manganese, the relevance of the 
animal studies to central nervous system disorder is questionable.
Smargiassi et al. (1995) evaluated platelet monoamine oxidase (MAO) and serum dopamine
β-hydroxylase (DBH) activities in 11 men occupationally exposed to manganese via inhalation in a
ferroalloy plant.  Exposed workers, in general, had lower MAO activities, but similar DBH activities, in
comparison to 15 nonexposed control males.  However, a positive dose-effect relationship was observed
in the exposed group between a Cumulative Exposure Index (CEI) and DBH activity (r2=0.40, p<0.05).  
The CEI took into account the average annual respirable or total manganese concentrations in dust, the
ventilation characteristic of each working area, the number of years that each worker spent in a given
area, and all of the areas that a worker had been during his job history.  The authors proposed that DBH, 
which is an expression of catecholamine release, might be increasing dose-dependently in response to 
reduced turnover of MAO.  The authors cautioned however, that while the data appear interesting, they
should be investigated in a larger study population, with careful analysis of possible confounding factors
(Smargiassi et al. 1995). 
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Reduced urinary excretion of 17-ketosteroids (perhaps as a consequence of decreased testosterone
production) has been noted in many patients with neurological signs of manganism (Rodier 1955), but it
has not been determined whether this change is detectable prior to the occurrence of neurological effects.  
Although the urinary excretion of manganese is generally not related to oral manganese intake, Davis and
Greger (1992) have suggested that the concentration of manganese in serum, combined with lymphocyte
manganese-dependent superoxide dismutase activity, may be helpful in assessing low and moderate levels 
of manganese exposure.  Manganese superoxide dismutase is activated by manganese, thus it is sensitive 
to the overall manganese balance. Therefore, increased manganese concentrations will affect an
increased manganese superoxide dismutase level. There is no clear link between activity of superoxide 
dismutase and the harmful effects of manganese. Therefore, the potential usefulness of this technique as a
biomarker of effect requires further evaluation.
The Clara cell protein CC16 is a potential biomarker for pulmonary effects from exposure to MMT
(Bernard and Hermans 1997; Halatek et al. 1998).  Damage of Clara cells by MMT causes a significant
reduction in the levels of this protein in the BALF, but does not affect its level in serum.  The protein can
be quantified in serum or urine as well.  However, no dose-response studies on the potential biomarker
have been performed.  Further, the protein has only been studied following intraperitoneal administration 
of MMT.  It is unknown if CC16 levels will change following other exposure pathways.
For more information on biomarkers for renal and hepatic effects of chemicals see ATSDR/CDC
Subcommittee Report on Biological Indicators of Organ Damage (Agency for Toxic Substances and 
Disease Registry 1990) and for information on biomarkers for neurological effects see OTA (1990).
3.9 INTERACTIONS WITH OTHER CHEMICALS
There is clear evidence from studies in animals that the gastrointestinal absorption (and hence the 
toxicity) of manganese is inversely related to dietary iron concentrations. That is, high levels of nonheme 
iron lead to decreased manganese absorption and toxicity, and low levels of iron lead to increased 
manganese absorption and toxicity (Chandra and Tandon 1973; Davis et al. 1992a, 1992b; Diez-Ewald
et al. 1968; Rehnberg et al. 1982).  Conversely, high levels of dietary manganese lead to decreased iron 
absorption (Davis et al. 1992b; Diez-Ewald et al. 1968; Garcia et al. 2006, 2007; Li et al. 2006;
Rossander-Hulten et al. 1991; Thomson et al. 1971).  Short-term effects of this sort are believed to be the 
result of kinetic competition between iron and manganese for a limited number of binding sites on 
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intestinal transport enzymes (Thomson et al. 1971), while longer-term effects of iron deficiency or excess 
are thought to be due to adaptive changes in the level of intestinal transport capacity (Cotzias 1958).  The
studies reporting competition between iron and manganese in absorption clearly indicate the impact an 
iron-poor diet will have on manganese uptake in the human (Chandra and Tandon 1973; Davis et al. 
1992a, 1992b; Diez-Ewald et al. 1968; Mena et al. 1969; Rehnberg et al. 1982; Thomson et al. 1971).  
Further, competition between manganese and iron at the blood-brain barrier has been reported (Aschner
and Aschner 1990), indicating that excesses of either metal will affect the brain distribution of the other.  
Johnson and Korynta (1992) found that, in rats, dietary copper can also decrease manganese absorption 
and increase manganese turnover; dietary ascorbate supplementation had minimal effects on manganese 
absorption.  However, there is insufficient information to determine the significance of these observations
for health effects in humans exposed to copper and manganese by the oral route.
Mn(II) pretreatment reduces Cd(II)-induced lethality (Goering and Klaassen 1985).  Cadmium has been 
noted to have an inhibitory effect on manganese uptake (Gruden and Matausic 1989).  In addition, 
manganese appears to be capable of increasing the synthesis of the metal-binding protein metallothionine
(Waalkes and Klaassen 1985).  Data from a study by Goering and Klaassen (1985) suggest that
manganese pretreatment increases the amount of Cd+2 bound to metallothionine, thereby decreasing
hepatotoxicity due to unbound Cd+2. The significance of these observations for health effects in humans 
exposed to cadmium and manganese by the oral or inhalation routes is not clear.
High dietary intakes of phosphorus (Wedekind et al. 1991) and calcium (Wilgus and Patton 1939) were
shown to depress manganese utilization in chicks.  Low levels of calcium and iron may act synergistically
to affect manganese toxicity by increasing absorption, but it is not known whether ensuring iron plus
calcium sufficiency will reduce the toxic effects of manganese once it has been absorbed (Cawte et al.
1989).  Thus, the importance of these observations to humans exposed to manganese by the oral or
inhalation routes is not clear.
Ethanol has been suspected of increasing the susceptibility of humans to manganese toxicity (e.g., Rodier
1955), but evidence to support this is limited.  Singh et al. (1979) and Shukla et al. (1976) reported that
concomitant exposure of rats to ethanol and manganese (as manganese chloride in drinking water) led to
higher levels of manganese in the brain and liver than if manganese were given alone; the higher levels 
were accompanied by increased effects as judged by various serum or tissue enzyme levels (Shukla et al.
1978).  Although the authors referred to these effects as "synergistic," the data suggest that the effects 
were more likely additive. Based on the report in humans and evidence in animals, the effects of
   
 











       
        
    
    
     
 
            
          
     







    
      
 
    
 
 
         
 
            
  
    
 





manganese on humans may be enhanced by the consumption of ethanol, but additional investigation is
needed. 
There is some evidence from a study in animals that chronic administration of drugs such as 
chlorpromazine (an antipsychotic) results in increased levels of manganese in the brain, including the 
caudate nucleus (Weiner et al. 1977).  Chronic chlorpromazine treatment sometimes results in tardive
dyskinesia, and manganese deposition in the brain might contribute to this condition.  It has not been
determined whether excess manganese exposure increases the risk of chlorpromazine-induced dyskinesia.
Intramuscular injection of animals with metallic nickel or nickel disulfide (Ni3S2) normally leads to a high
incidence of injection-site sarcomas, but this increased incidence is reduced when the nickel is injected
along with manganese dust (Sunderman et al. 1976).  The mechanism of this effect is not clear, but
natural killer cell activity normally undergoes a large decrease following nickel injection, and this is 
prevented by the manganese (Judde et al. 1987).  However, the significance that these observations have 
for human health effects resulting from exposure to nickel and/or manganese by the oral or inhalation 
routes is not clear.
One study found that allopurinol, when administered orally to rats, antagonized the oxidative effects of
manganese in the striatum and brainstem (Desole et al. 1994).  The authors suggest that allopurinol, a
xanthine oxidase inhibitor, may exert its protective effect by inhibiting both dopamine oxidative
metabolism and xanthine oxidase-mediated production of reactive oxygen species.
3.10 POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to manganese than will most
persons exposed to the same level of manganese in the environment. Reasons may include genetic 
makeup, age, health and nutritional status, and exposure to other toxic substances (e.g., cigarette smoke).  
These parameters result in reduced detoxification or excretion of manganese, or compromised function of
organs affected by manganese.  Populations who are at greater risk due to their unusually high exposure
to manganese are discussed in Section 6.7, Populations with Potentially High Exposures.
A number of researchers have observed that there is a wide range in individual susceptibility to the
neurological effects of inhaled manganese dusts (Rodier 1955; Schuler et al. 1957; Smyth et al. 1973;
Tanaka and Lieben 1969).  For example, Rodier (1955) reported that the majority of manganism cases in 
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miners occurred after 1–2 years of exposure to the metal, with only six cases observed occurring with 1– 
3 months exposure.  Schuler et al. (1957) showed that in his group of miners, the average time for
manifestation of manganism was 8 years, 2 months, with a minimum exposure of 9 months required for
symptoms to present.  However, the reason for this variable susceptibility is not clear.  One likely factor is 
a difference in work activities and level of exertion.  Another is that rates of manganese absorption and/or
excretion can vary widely among individuals (Saric et al. 1977a).  These toxicokinetic variations may be
due to differences in dietary levels of iron and differences in transferrin saturation (Chandra and Tandon
1973; Davis et al. 1992a, 1992b; Mena et al. 1969; Thomson et al. 1971), to differences in dietary levels
of other metals (Chowdhury and Chandra 1987; Gruden and Matausic 1989) or of calcium (Cawte et al. 
1989), or to different levels of alcohol ingestion (Schafer et al. 1974).  Another factor that might be
relevant is dietary protein intake: low-level protein intake appears to increase the effect of manganese on
brain neurotransmitter levels in exposed animals (Ali et al. 1983a, 1983b, 1985). However, a genetic
basis for the wide difference in susceptibility cannot be ruled out.  
One group that has received special attention as a potentially susceptible population is the very young.  
This is mainly because a number of studies indicate that neonates retain a much higher percentage of
ingested or injected manganese than adults, both in animals (Keen et al. 1986; Kostial et al. 1978;
Rehnberg et al. 1980) and in humans (Zlotkin and Buchanan 1986). The basis for high manganese
retention in neonates is not certain, but is presumably a consequence of increased absorption (Mena et al. 
1974; Rehnberg et al. 1980) and/or decreased excretion (Kostial et al. 1978; Miller et al. 1975; Rehnberg
et al. 1981), possibly because maternal milk is low in manganese (Ballatori et al. 1987).  Regardless of the
mechanism, the result of the high retention is increased levels of manganese in the tissue of exposed
neonatal animals (Miller et al. 1975; Rehnberg et al. 1980, 1981), especially in the brain (Kontur and 
Fechter 1985, 1988; Kostial et al. 1978; Kristensson et al. 1986; Miller et al. 1975; Rehnberg et al. 1981).
This increase has caused several researchers to express concern over possible toxic effects in human
infants exposed to manganese in formula (Collipp et al. 1983; Keen et al. 1986; Zlotkin and Buchanan 
1986).  At least one recent report indicates that an infant’s rate of absorption of manganese from infant
formulas, cow’s milk, and breast milk is similar (Lönnerdal et al. 1994), resulting mainly from recent
modifications to formulas to optimize the bioavailability of several essential minerals. There is some 
limited evidence that prenatal or neonatal exposure of animals to elevated levels of manganese can lead to
neurological changes in the newborn (Ali et al. 1983a; Chandra and Shukla 1978; Deskin et al. 1980, 
1981; Dorman et al. 2000; Kristensson et al. 1986); other studies have either not observed any
neurochemical or neurophysiological effects in young animals exposed to excess manganese or the effects 
have been transient (Kontur and Fechter 1988; Kostial et al. 1978; Pappas et al. 1997).  Currently, there is
   
 








         
   
            
   
       
             
   
      
            
    
        
        
 
        
   
    
 
         
      
          
  
       
      
        
              
          
            
 
     
     
 
         




only one report that indicates that neonatal animals showed adverse neurological effects at a dose of
manganese that had no effect on adults (Dorman et al. 2000).  Brain concentrations of manganese were 
elevated in the neonates, but not in the adult animals given comparable doses of manganese for similar
durations.  The concern is that the young may be more susceptible due to increased absorption and/or
retention and the potential toxicity from higher circulating levels of the metal.  A few studies have 
reported increased blood and brain levels of the metal, either because of an inability to clear manganese 
due to chronic liver disease (Devenyi et al. 1994) or to an excess in parenteral nutrition (Kafritsa et al.
1998; Ono et al. 1995).  However, observable neurological signs associated with manganese toxicity were 
only reported in the case of chronic liver disease (Devenyi et al. 1994).  Although data suggest that
children, particularly infants, are potentially more susceptible to the toxic effects of manganese, available 
evidence indicates that individual susceptibility varies greatly.  Current information is not sufficient to
quantitatively assess how susceptibility in children might differ from adults.
Elderly people might also be somewhat more susceptible to manganese neurotoxicity than the general
population.  Neurological effects were observed in older persons consuming manganese levels similar to 
levels found in U.S. surface water and groundwater (Deverel and Millard 1988; EPA 1984; Kondakis et
al. 1989).  The neurological effects observed in a group of families exposed to manganese in their
drinking water were reportedly more severe among the older persons, whereas there was little effect in the
youngest (Kawamura et al. 1941).  Further, occupational studies indicate that older workers represent the
largest numbers of manganese poisoning cases (Rodier 1955; Tanaka and Lieben 1969). More recent
occupational (Crump and Rousseau 1999; Gibbs et al. 1999) and environmental (Mergler et al. 1999)
manganese exposure studies indicate that increasing age was a factor in poorer performance on certain
neurobehavioral tests.  For example, Beuter et al. (1999) and Mergler et al. (1999) reported that
performance on tests that required regular, rapid, and precise pointing movements was significantly
decreased in exposed individuals, especially in those 50 years of age and over with high blood manganese 
levels. These reports suggest that older persons may have a greater susceptibility to adverse effects from
inhaled or ingested manganese.  One factor that could contribute to this increased susceptibility is a loss 
of neuronal cells due to aging or to accumulated neurological damage from other environmental 
neurotoxicants (Silbergeld 1982).  Homeostatic mechanisms might become less effective in aged
populations, which leads to higher tissue levels of manganese following exposure (Silbergeld 1982).
Mena et al. (1969) noted that the oral absorption of manganese was increased in individuals with iron-
deficiency anemia.  Altered nutritional status might be another predisposing factor.  The inverse relation-
ship of manganese absorption and iron-status has also been reported in animal models (Davis et al. 1992a, 
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1992b). It has been suggested that anemic persons may be more susceptible to the toxic effects of
manganese because of enhanced absorption of iron and manganese through similar uptake mechanisms 
(Cotzias et al. 1968).  Baldwin et al. (1999) reported an inverse relationship between serum iron and 
blood manganese levels in individuals environmentally exposed to airborne manganese.  
Another group of potential concern is people with liver disease. This is because the main route of
manganese excretion is via hepatobiliary transport (see Section 3.4.4), so individuals with impaired 
biliary secretion capacity would be expected to have a diminished ability to handle manganese excesses.
In support of this hypothesis, Hambidge et al. (1989) reported that in a group of infants and children
receiving parenteral nutrition, children with liver disease had higher average plasma concentrations of
manganese than children without liver disease.  Devenyi et al. (1994) also observed increased blood 
manganese concentrations, abnormal MRI scans indicative of increased manganese in the brain, and
dystonia similar to that of patients with manganism, in an 8-year-old girl suffering from cholestatic liver 
disease.  Hauser et al. (1994) reported increased blood and brain manganese in two patients with chronic
liver disease and one with cirrhosis of the liver and a portacaval shunt.  All three exhibited some form of
neuropathy, including postural tremor of the upper extremities and a general lack of alertness, along with 
failure to concentrate and follow simple commands.  In a later study, Hauser et al. (1996) did not observe
movement disorders, but did observe the increased blood manganese concentrations and abnormal MRI
scans in a group of adults with failing livers.  Other studies have shown the link between increased 
deposition of manganese in the blood and/or the brains of humans with cirrhosis of the liver or chronic
liver disease (Pomier-Layrargues et al. 1998; Rose et al. 1999; Spahr et al. 1996).
Patients on parenteral nutrition may be at risk for increased exposure to manganese.  Forbes and Forbes 
(1997) observed that 31 of 32 adults treated with total parenteral nutrition (TPN) due to intestinal failure
had increased manganese concentrations in their blood.  Nagatomo et al. (1999) observed elevated blood 
manganese levels and hyperintense signals in the basal ganglia upon T1-weighted MRI in two elderly
patients receiving TPN.  Both patients exhibited severe symptoms associated with manganese exposure 
(masked facies, marked rigidity, hypokinesia).  When manganese supplementation in the TPN was
reduced, the blood and brain levels returned to normal.
Children receiving parenteral nutrition have also been shown to have increased blood manganese
concentrations with accompanying hyperintense signals in the globus pallidus as observed by MRI (Fell
et al. 1996; Kafritsa et al. 1998; Ono et al. 1995).  Fell et al. (1996) studied a group of 57 children 
receiving parenteral nutrition, 11 of whom had a combination of hypermanganesemia and cholestasis.
   
 








      
 
      
           
        
     
          
         
  
    
       
           
    
  
  
          
         
     
      
 
    




       
          
 




Four of these 11 patients died; the 7 survivors had whole blood manganese concentrations ranging from
34–101 μg/L.  Four months after reduction or removal of manganese from the supplementation, the blood 
concentration of manganese decreased by a median of 35 μg/L.  Two of the seven survivors had
movement disorders, one of whom survived to have a MRI scan.  The scan revealed bilateral
symmetrically increased signal intensity in the globus pallidus and subthalamic nuclei. These signals 
were also observed in five other children—one from the original group exhibiting cholestasis with 
hypermanganesemia and five more given parenteral nutrition chronically with no liver disease. These 
results indicate that the cholestatic condition is not necessary for manganese to accumulate in the brain.
A supporting study is provided by Ono et al. (1995) who observed increased blood manganese
concentrations and hyperintense signals on MRI in the brain of a 5-year-old child on chronic parenteral
nutrition due to a gastrointestinal failure. Five months after the manganese was removed from the 
parenteral solution, blood manganese levels returned to normal, and the brain MRI scans were almost
completely free of abnormal signals.  Further, the authors reported no neurological effects from exposure 
to manganese.  Kafritsa et al. (1998) reported results similar to those of Ono et al. (1995).  In the latter
study, two siblings, one 9 years old and the other 2 years old, had been administered TPN chronically
since the ages of 4 and 1 month(s), respectively.  While elevated blood and brain manganese levels were 
reported (via laboratory analyses and MRI), no adverse neurological or developmental effects were 
observed.  Once the manganese supplementation was reduced, the MRI signals abated, and the blood
manganese levels returned to a normal range.
Although human interindividual variability is great concerning the ability to tolerate excess amounts of
manganese in the body, these data indicate that, in general, children and the elderly may be more 
susceptible than young and middle-aged adults due to differential toxicokinetics and potential adverse
effects superimposed on normal decline in fine motor function with age. 
With respect to the respiratory effects of inhaled manganese (e.g., bronchitis, pneumonitis), people with
lung disease or people who have exposure to other lung irritants may be especially susceptible. This is 
supported by the finding that the inhalation of manganese dusts by manganese alloy workers caused an 
increased incidence of respiratory symptoms (e.g., wheezing, bronchitis) in smokers, but not in 
nonsmokers (Saric and Lucic-Palaic 1977b).
   
 








      
 
        
        
 
   
    
  
 










     
 
     
  
      
         
    
   
 
 
       
         
 
          
       
      





3.11 METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to manganese.  However, because some of the treatments discussed may be experimental and
unproven, this section should not be used as a guide for treatment of exposures to manganese.  When 
specific exposures have occurred, poison control centers and medical toxicologists should be consulted 
for medical advice.  The following texts provide specific information about treatment following exposures
to manganese.
Leikin JB, Paloucek JB.  2002.  Leikin and Paloucek's poisoning and toxicology handbook.  Hudson, OH:
Lexi-Comp, Inc., 773-774.
Schonwald S. 2004.  Manganese.  In:  Dart RC, eds.  Medical toxicology.  3rd ed.  Philadelphia, PA:
Lippicott Williams & Wilkins, 1433-1434.
WHO.  1999. Concise international chemical assessment document 12.  Manganese and its compounds.  
Geneva:  United Nations Environment Programme.  International Labour Organisation.  World Health
Organization.  http://whqlibdoc.who.int/publications/1999/924153012X.pdf. August 04, 2008.
3.11.1 Reducing Peak Absorption Following Exposure 
There is substantial evidence to indicate that an interaction between iron and manganese occurs during
intestinal absorption (Chandra and Tandon 1973; Diez-Ewald et al. 1968; Keen and Zidenberg-Cher
1990; Mena et al. 1969; Rehnberg et al. 1982).  Cawte et al. (1989) cite low levels of iron and calcium as
"synergistic factors" that impact on the toxic effects associated with manganese exposures.  In a dietary
study investigating the effects of copper, iron, and ascorbate on manganese absorption in rats, these
substances were all found to influence manganese absorption, depending in part on their relative
concentrations (Johnson and Korynta 1992).  
Evidence from these reports suggests that it may be possible to reduce the uptake of manganese and
thereby circumvent the potential for toxic effects caused by current and future exposure to excess 
manganese through specific dietary supplementation.  For example, sufficient iron or calcium stores, as 
opposed to a deficiency in these or other minerals, may reduce manganese absorption, and thus reduce 
potential toxicity.  It is not known whether ensuring iron and calcium sufficiency will reduce the toxic
effects of manganese once it has been absorbed into the body because information on critical levels of
manganese at target sites is not available.  No consistent clinical data are available documenting benefit
from ipecac or dilution after ingestion of metallic, inorganic, or organic manganese (Schonwald 2004).
   
 








      
 
          
  
 
      
     
         
 
 
            
   
            
     
   
   
            
       
       
        
          
           
            
 
              
 
  
    
            
        
 
   




3.11.2 Reducing Body Burden
Inhaled manganese is readily absorbed by the lungs, although some may be retained there.  Larger
particles of dust containing manganese may be transported by mucociliary transport from the throat to the
gut (Drown et al. 1986).  Manganese in the gut may be directly absorbed either by a simple diffusion 
process (Bell et al. 1989) or by a high-affinity, low-capacity, active-transport mechanism (Garcia-Aranda
et al. 1983).  Once in the plasma, manganese is reportedly transported by transferrin; however, 
information on the mechanism of uptake in extrahepatic tissues is limited (Keen and Zidenberg-Cher
1990).
In severe cases of manganese poisoning, chelation therapy may be recommended in order to reduce the
body burden of manganese and to help alleviate symptoms.  Chelation therapy with agents such as EDTA
may alleviate some of the neurological signs of manganism, but in cases where it has been used, not all
patients have shown improvement, and some of the improvements have not always been permanent
(Cook et al. 1974; Schonwald 2004).  Nagatomo et al. (1999) recently reported the use of Ca-EDTA 
treatment to reduce the body burden of two elderly patients with increased blood and brain levels of
manganese. These patients exhibited masked faces, hypokinesia, and rigidity that are among the clinical
signs of manganese poisoning.  The potential use of calcium disodium ethylenediaminetetracetate (CaNa2 
EDTA) for the management of heavy metal poisoning was investigated in dogs by Ibim et al. (1992).  
CaNa2 EDTA-treated dogs (without excess manganese exposure) were found to have decreased
manganese levels in their hair. It is possible that the decrease was partially associated with mobilization
and redistribution of this element from storage as well as from soft tissues. The authors, however,
cautioned that the use of CaNa2 EDTA could adversely affect the metabolism of manganese.
In an attempt to treat seven welders with manganism, a solution of 20% CaNa2 EDTA was administered
intravenously at the dose of 1.0 g daily for 3 days followed by a pause for 4 days.  The therapy continued 
for 2–4 courses of this treatment, depending upon the improvement of symptoms.  The symptoms, as well
as blood manganese concentrations and urinary manganese concentrations, were monitored before and 
after each course of treatment.  EDTA treatment resulted in increased manganese excretion in urine and
decreased manganese concentrations in the blood; however, the patients did not show significant
improvement in their symptoms (Crossgrove and Zheng 2004).  A lack of improvement after EDTA
chelation has also been observed in an additional case study of an adult worker (Jiang et al. 2006).  It is
postulated that four carboxyl groups in the EDTA structure, which are essential to its chelating property,
render the molecule poorly lipophilic, thus preventing it from effectively crossing the blood-brain barrier.  
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Thus, EDTA appears to successfully chelate and remove the extracellular manganese ions in the blood, 
but with limited access to brain parenchyma, it cannot effectively chelate and remove manganese ions 
from the brain.  Because EDTA cannot significantly remove manganese from damaged neurons, it
appears to be of very limited therapeutic value for more advanced cases of manganism.
Cyclohexylene-aminotetraacetic acid (CDTA) and dimercaptol-1-propanesulphonic acid sodium salt
(DTPA) were shown to decrease tissue manganese content in rats following inhalation exposure, but it is 
unknown whether the effects of manganese were alleviated (Wieczorek and Oberdörster 1989a, 1989b).
The use of the anti-tuberculosis drug para-aminosalicylic acid (PAS) to treat manganism has been
reported (Jiang et al. 2006).  The patient in this case study had palpitations, hand tremor, lower limb 
myalgia, hypermyotonia, and a distinct festinating gait.  She received 6 g PAS per day through an 
intravenous drip infusion for 4 days and rest for 3 days.  Fifteen courses of this treatment were
administered to the patient.  At the end of PAS treatment, the patient’s symptoms were reportedly
significantly alleviated, and handwriting recovered to normal.  A reexamination at 17 years after PAS
therapy found a general normal presentation in clinical, neurologic, brain MRI, and handwriting
examinations.  Her gait improved, and although it did not improve to an entirely normal status, it could be
described as passable.  A literature survey of more than 90 cases using PAS (Jiang et al. 2006) indicates a 
significant therapeutic benefit.
A study in monkeys reported a long half-life of manganese in the brain following inhalation exposure
(Newland et al. 1987).  Given that neurotoxicity is of concern with manganese exposure, knowledge of
the mechanisms behind this longer half-life in the brain may be central to the development of mitigation 
methods.  Newland et al. (1987) reported that this long half-life reflected both redistribution of
manganese from other body depots and a slow rate of clearance from the brain. A later study reported 
that elevated levels in the brain persisted after inhalation exposure (due to redistribution), whereas for
subcutaneous exposure, levels declined when administration was stopped (Newland et al. 1989).  The
authors observed that the accumulation of manganese in the brain was preferential in specific regions, but
was unrelated to the route of exposure (Newland et al. 1989).  They also reported that there are no known 
mechanisms or "complexing agents" that have been shown to remove manganese from the brain.
Few data are available regarding the reversibility of the neurological injury produced by prolonged excess 
manganese exposure. The effects are thought to be largely irreversible, and treatment for manganese 
intoxication is mainly supportive (Schonwald 2004). However, some evidence indicates that recovery
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may occur when exposure ceases (Smyth et al. 1973).  Anti-Parkinsonian drugs, such as levo-dopa, have
been shown to reverse some of the neuromuscular signs of manganism (Ejima et al. 1992; Rosenstock et
al. 1971), but these drugs can produce a variety of side effects, and reports have indicated that they are not
effective in improving the symptoms of neurotoxicity in manganism patients (Calne et al. 1994; Chu et al.
1995; Cook et al. 1974; Haddad et al. 1998; Huang et al. 1989; Schonwald 2004).  Para-aminosalicylic 
acid was used successfully to treat two patients who exhibited neurological signs of manganese 
poisoning; one person made an almost complete recovery and the other was significantly improved.  The
mechanism for this treatment is unknown (Shuqin et al. 1992).  Parenti et al. (1988) has proposed the use
of antioxidants such as vitamin E, but the effectiveness of this treatment has not been further evaluated.
3.11.3 Interfering with the Mechanism of Action for Toxic Effects
The oxidation state of manganese may influence both its retention in the body (see Section 3.4.3) and its
toxicity (see Section 3.5).  Therefore, it is possible that interference with the oxidation of manganese 
could be a method for preventing manganese cellular uptake and toxicity.  Regarding retention, one study
suggests that clearance is much more rapid for divalent manganese than for trivalent manganese (Gibbons 
et al. 1976).  Regarding neurotoxicity, Mn(III) appears to be more efficient in enhancing the oxidation of
catechols than either Mn(II) or Mn(IV) (Archibald and Tyree 1987).  Thus, it is plausible that reducing
the formation of Mn(III) could possibly both enhance elimination and prevent neurotoxicity, but no 
studies were located that evaluate this theory.
Ceruloplasmin is involved in the oxidation of iron and has also been involved in the oxidation of divalent
manganese ion to the trivalent state (Gibbons et al. 1976).  Selective inhibition of this oxidative function 
may be a method of mitigating the toxic effects of exposure to manganese.  However, inhibition of the
oxidation of manganese might also result in adverse effects on transport and cellular uptake of other
essential metals, especially iron.  Furthermore, it is not completely clear how the oxidation state of
manganese is related to its normal function in neural cells or how this role is altered in manganese 
toxicity.  Both Mn(II) and Mn(III) have been reported as components of metalloenzymes (Keen and 
Zidenberg-Cher 1990; Leach and Lilburn 1978; Utter 1976).
Manganese has been shown to catalyze the oxidation of dopamine in vitro; Cawte et al. (1989) reported 
that the toxicity induced by manganese resulted from the depletion of dopamine and the production of
dopamine quinone and hydrogen peroxide through this mechanism.  Antioxidants were tested for their
ability to inhibit the dopamine oxidation induced by manganese, and it was found that ascorbic acid and 
   
 









   
         
       
        
 
             
     
         
       
 
    
 
   
           
       
  
   
      
 
          
 
 
           
  
 
        
 
            
          
   
           
    




thiamine completely inhibited dopamine oxidation both in the presence and absence of manganese.  The
report did not include data on background oxidation levels nor on the extent of dopamine oxidation in the
absence of manganese.  Results from treatment with antioxidants were viewed as evidence for their use in
mitigating the adverse effects of manganese.  However, because dopamine oxidation was inhibited to
some degree in the absence of manganese, these data could alternately be interpreted as suggesting a more 
complex mechanism than the direct action of manganese for inducing dopamine oxidation and subsequent
cell toxicity.  Further investigation of the inhibition of manganese oxidation as a possible mitigation
method should be preceded by additional studies to elucidate the role of manganese in its various 
oxidation states in normal neuronal cell metabolism and to determine whether oxidative stress is a 
primary mechanism for neurotoxicity mediated by manganese exposure.
3.12 ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of manganese is available. Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the
initiation of a program of research designed to determine the health effects (and techniques for developing
methods to determine such health effects) of manganese.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of Manganese
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
inorganic manganese are summarized in Figure 3-15. The purpose of this figure is to illustrate the
existing information concerning the health effects of manganese.  Each dot in the figure indicates that one
or more studies provide information associated with that particular effect. The dot does not necessarily
imply anything about the quality of the study or studies, nor should missing information in this figure be
interpreted as a “data need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying 
Substance-Specific Data Needs Related to Toxicological Profiles (Agency for Toxic Substances and 
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Disease Registry 1989), is substance-specific information necessary to conduct comprehensive public 
health assessments.  Generally, ATSDR defines a data gap more broadly as any substance-specific 
information missing from the scientific literature.
As the upper part of Figure 3-15 reveals, studies in humans exposed to inorganic manganese have focused
mainly on intermediate and chronic inhalation exposure and the resulting neurological effects.  There are
several reports of humans exposed by ingestion and these too have focused on neurological effects.  
Reproductive effects have been studied in men exposed to manganese by inhalation, but other effects
have generally not been formally investigated.
Inorganic manganese toxicity has been investigated in numerous animal studies, both by the oral and the
inhalation routes.  These studies have included most end points of potential concern. The dermal route
for inorganic manganese has not been investigated, but there is no evidence that this exposure pathway is 
a human health concern.  Dermal contact to MMT is expected to occur mainly in occupational settings, 
and no human dermal contact with mangafodipir is expected to occur.  In addition, organic compounds
are degraded to some extent in the environment. Thus, dermal effects from organic manganese 
compounds are not expected to be of great concern for the general population or to persons near
hazardous waste sites.
3.12.2 Identification of Data Needs 
Presented below is a brief review of available information and a discussion of research needs.  Although
data are lacking, dermal studies to inorganic manganese are not discussed since there is no evidence that
this exposure pathway is a human health concern.  
Acute-Duration Exposure. Studies in animals and humans indicate that inorganic manganese 
compounds have very low acute toxicity by any route of exposure.  An exception is potassium
permanganate, which is an oxidant that can cause severe corrosion of skin or mucosa at the point of
contact (Southwood et al. 1987).  Acute inhalation exposure to high concentrations of manganese dusts
(manganese dioxide, manganese tetroxide) can cause an inflammatory response in the lung, which can 
lead to impaired lung function (Maigetter et al. 1976; Shiotsuka 1984).  However, this response is
characteristic of nearly all inhalable particulate matter (EPA 1985d) and is not dependent on the
manganese content of the particle.  Large oral doses of highly concentrated solutions of manganese salts 
given by gavage can cause death in animals (Holbrook et al. 1975; Kostial et al. 1978; Smyth et al. 1969), 
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but oral exposures via food or water have not been found to cause significant acute toxicity (Gianutsos
and Murray 1982; NTP 1987a, 1987b).  Exposure of mice (Moreno et al. 2009) and rats (Shukakidze et al.
2003) to acute oral doses of about 13 mg manganese/kg as manganese chloride has been associated with
behavioral changes, but dietary intakes of manganese in these studies were not measured.  Since the acute 
database is incomplete and studies demonstrating a dose-response are not available, acute MRLs were not
derived.  In order to derive acute MRL values, further studies may be helpful to define the threshold for
adverse effects following acute exposure to manganese.  However, any MRL derived for the oral route 
would have to take into consideration that manganese is an essential nutrient.
Acute-duration exposure studies in animals exposed to MMT via inhalation or via a dermal pathway are
lacking.  The dermal pathway is very important, because MMT in gasoline that may be spilled on the skin 
could penetrate and become absorbed.  Although the photolability of the compound is an important
obstacle for any animal study, carefully planned and executed analyses of the toxicity of this compound to 
animal models through these exposure pathways are needed. 
The likelihood for exposure to mangafodipir is small and clinical trials in humans have shown a great
tolerance for a controlled exposure to the compound. Toxicity studies in several different animal species 
have been performed, including reproductive and developmental studies (and more specifically, 
teratogenic analysis).  Although behavioral data in the young who have been exposed during gestation are
relatively limited, human gestational exposure to this compound is not believed to be very likely.  Reports
of neurological effects have been limited to complaints of headaches in clinical trials. Further evaluation
of these effects relative to the distribution of manganese to the brain during clinical use is warranted.
Mangafodipir is administered intravenously, which bypasses homeostatic control of the compound.  
Although animal studies indicate that a single, clinical dose does not cause accumulation of manganese in
the brain for longer than 2 weeks (Gallez et al. 1997), human studies have not monitored central nervous 
system distribution of manganese following mangafodipir injection for longer than half an hour (Lim et
al. 1991).  In addition, given the neurotoxic effects of excess manganese, evaluation of patients treated
with mangafodipir for neurological sequelae are needed.
Intermediate-Duration Exposure. Intermediate-duration inhalation exposure of humans to 
manganese compounds can lead to central nervous system effects (Rodier 1955). However, reliable 
estimates of intermediate-duration NOAELs or LOAELs for neurotoxicity in humans are not available.  
Epidemiological studies in occupationally exposed human populations that help define the intermediate-
duration exposure levels (<356 days of exposure) that are associated with neurological effects would be
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valuable.  In the interim, it is expected that the chronic MRL for inhaled inorganic manganese would 
provide protection for intermediate-duration exposure scenarios. The MRL is based on an analysis of
dose-response data for subtle neurological deficits in groups of occupationally exposed workers with 
average durations of employment from about 5 to 24 years (see Table A-3 in Appendix A); the average
duration of employment in workers in the principal study for the MRL was 5.3 years.  
Intermediate-duration inhalation studies in animals have yielded NOAEL and LOAEL values for
biochemical and neurobehavioral effects (EPA 1977; Morganti et al. 1985; Ulrich et al. 1979a, 1979b), 
but the range of exposure levels associated with these effects is too wide (an order of magnitude) to define
a threshold.  Although neurological effects were observed in animals, symptoms characteristic of
manganese toxicity (e.g., ataxia, tremor, etc.) are not typically observed in rodent species (with the 
exception of one study in which ataxia was seen only transiently) (Kristensson et al. 1986).  Other rodent
studies indicated decreases in motor activity (Gray and Laskey 1980; Komura and Sakamoto 1991), 
increased activity and aggression (Chandra 1983; Shukakidze et al. 2003), delayed reflexes (Ali et al.
1983a), or deficits in learning (Shukakidze et al. 2003; Vezér et al. 2005, 2007) the effects are not
consistent and are observed over a wide dose range.  For these reasons, it is concluded that these data are 
not sufficient to derive an intermediate-duration inhalation MRL.  Other animal intermediate-duration 
studies provide evidence for associations between decreased neuronal cell counts in the globus pallidus 
and neurobehavioral changes (increased locomotor activity) in rats exposed by inhalation for 13 weeks to 
a mixture of manganese phosphate/sulfate (at 1.05 mg manganese/m3) or manganese sulfate alone (at
concentrations between 0.009 and 0.9 mg manganese/m3), but not to manganese phosphate alone at
concentrations up to 1.1 mg manganese/m3 (Normandin et al. 2002; Salehi et al. 2003, 2006; Tapin et al. 
2006).  Other 13-week rat inhalation exposure studies reported increased brain manganese concentrations 
and increased locomotor activity after exposure to 3.75 mg manganese/m3 as metallic manganese (St-
Pierre et al. 2001) and increased brain manganese concentrations with no increases in olfactory bulb, 
cerebellar, or striatal concentrations of GFAP after exposure to 0.5 mg manganese/m3 as manganese 
sulfate or 0.1 mg manganese/m3 as manganese phosphate (Dorman et al. 2004b). Other animal studies 
have examined the influence of inhalation exposure to manganese sulfate on biochemical end points 
associated with oxidative stress or inflammation in the brain of rats (Erikson et al. 2005, 2006; HaMai et
al. 2006; Taylor et al. 2006) and monkeys (Erikson et al. 2007, 2008).  The results from these studies
indicate that acute- or intermediate-duration inhalation exposure to manganese sulfate concentrations 
ranging from about 0.1 to 1.5 mg manganese/m3 can differentially affect brain biochemical markers of
neurotoxicity, but understanding of the neurotoxic mechanism of manganese is inadequate to confidently
define any one of the observed changes as biologically adverse.
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Intermediate-duration oral exposure of humans to manganese has been reported to cause neurotoxicity in 
two cases (Holzgraefe et al. 1986; Kawamura et al. 1941), but the data for quantitating exposure levels are
too limited to define the threshold or to judge whether these effects were due entirely to manganese 
exposure.  An epidemiological investigation of people who have ingested high levels of manganese may
provide valuable information on the health risk of intermediate-duration oral exposure and may provide
sufficient dose-response data from which to derive an MRL.  Additional oral studies in animals including
rodents may be valuable in revealing cellular and molecular mechanisms of manganese neurotoxicity;
studies on nonhuman primates would probably be the most helpful in estimating a MRL because they
appear to be the most suitable animal model for manganese-induced neurological effects comparable to
effects observed in humans.  However, any MRL derived for the oral route would have to take into
consideration that manganese is an essential nutrient and account for manganese intake from daily dietary
sources.
Intermediate-duration studies of inhalation and oral exposure to MMT in humans and animals are lacking.  
Animal studies of this duration evaluating systemic toxicity from exposure to MMT and typical
environmental concentrations of its combustion products would be helpful to determine body burdens that
might be anticipated for the general population in areas that use this compound.  Further, these studies
would be helpful in determining mechanisms of toxicity and expected adverse effects in exposed 
populations.
Due to the nature of mangafodipir administration, which typically occurs only once in a subject, no 
intermediate-duration studies in humans have been identified for this compound.  Although there are a
few intermediate-duration studies in animals (Grant et al. 1997a; Larsen and Grant 1997; Treinen et al. 
1995), they have focused primarily on reproductive and developmental effects.  Studies of the potential 
neurological effects of exposure to this compound are lacking, although the reason for this may be due to 
the lack of evidence that the compound distributes in the central nervous system.  As discussed
previously, the exposure to mangafodipir is expected to be very limited due to the compound’s clinical
use.  There are no identified data needs for this compound.
Chronic-Duration Exposure and Cancer. As discussed in Sections 2.3 and 3.2.1.4, and 
Appendix A, a number of epidemiological studies have used sensitive techniques to study the
psychological or neurological effects of exposure to low levels of manganese in the workplace (Bast-
Pettersen et al. 2004; Beuter et al. 1999; Blond and Netterstrom 2007; Blond et al. 2007; Bouchard et al.
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2003, 2005, 2007a, 2007b; Chia et al. 1993a, 1995; Crump and Rousseau 1999; Deschamps et al. 2001;
Gibbs et al. 1999, Iregren 1990; Lucchini et al. 1995, 1999; Mergler et al. 1994; Myers et al. 2003a, 
2003b; Roels et al. 1987a, 1992, 1999; Summers et al. 2011; Wennberg et al. 1991) or in environmental
media close to manganese-emitting industries (Hernández-Bonilla et al. 2011; Lucchini et al. 2007; Kim
et al. 2011; Menezes-Filho et al. 2011; Mergler et al. 1999; Riojas-Rodríguez et al. 2010; Rodríguez-
Agudelo et al. 2006; Solís-Vivanco et al. 2009; Standridge et al. 2008).  Some of the occupational studies
have found statistically significant differences between exposed and non-exposed groups or significant
associations between exposure indices and neurological effects (Bast-Pettersen et al. 2004; Chia et al.
1993a; Iregren 1990; Lucchini et al. 1995, 1999; Mergler et al. 1994; Roels et al. 1987a, 1992; Wennberg
et al. 1991), whereas others have not found significant associations (Deschamps et al. 2001; Gibbs et al. 
1999, Myers et al. 2003a, 2003b; Summers et al. 2011; Young et al. 2005).  Analyses of dose-response
relationships for changes in neurobehavioral tests in several of these studies (Gibbs et al.1999; Iregren et
al. 1990; Lucchini et al. 1999; Mergler et al. 1994; Roels et al. 1992; Wennberg et al. 1991) provide the
basis of the current chronic inhalation MRL for inorganic manganese (as described in Chapter 2 and 
Appendix A)
Additional studies involving follow-up evaluation of previously exposed occupational cohorts may be
useful to provide information on threshold levels that are correlated with observed preclinical effects.  
Additional studies of populations living close to manganese-emitting industries that clearly quantify
exposure sources (dietary, water consumption, airborne) also may be useful to better describe
neurotoxicological potentials of low-level exposure to airborne manganese.
In early animal studies, intermediate or chronic inhalation exposure of monkeys and rats to manganese 
dusts did not produce neurological signs similar to those seen in humans (Bird et al. 1984; EPA 1983c;
Ulrich et al. 1979a, 1979b).  For example, Ulrich et al. (1979a) reported that monkeys continually
exposed for 9 months to aerosols of manganese dioxide at concentrations as high as 1.1 mg
manganese/m3 showed no obvious clinical signs of neurotoxicity, no histopathological changes in brain 
tissues, and no evidence for limb (leg) tremor or electromyographic effects on flexor and extensor
muscles in the arm.  However, in a chronic study with Rhesus monkeys, decreased levels of dopamine
were found in several regions of the brain (caudate and globus pallidus) (Bird et al. 1984).  Behavioral
tests detected signs of neurological effects in mice (increased open-field activity and decreased maternal
pup retrieval latency), although these are only seen at relatively high exposure levels (60–70 mg 
manganese/m3) (Lown et al. 1984; Morganti et al. 1985).  More recent animal intermediate-duration 
inhalation studies provide evidence for decreased neuronal cell counts in the globus pallidus and 
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neurobehavioral changes (Normandin et al. 2002; Salehi et al. 2003, 2006; Tapin et al. 2006); increased 
brain manganese concentrations and increased locomotor activity (St-Pierre et al. 2001); increased brain 
manganese concentrations without increases in GFAP (Dorman et al. 2004b); and increased biochemical
end points associated with oxidative stress or inflammation in the brain (Erikson et al. 2005, 2006; HaMai
et al. 2006; Taylor et al. 2006) and monkeys (Erikson et al. 2007, 2008).  The results from these studies
indicate that acute- or intermediate-duration inhalation exposure to manganese sulfate concentrations 
ranging from about 0.1 to 1.5 mg manganese/m3 can differentially affect brain biochemical markers of
neurotoxicity, but understanding of the neurotoxic mechanism of manganese is inadequate to confidently
define any one of the observed changes as biologically adverse.
Chronic inhalation studies in animal models (Bird et al. 1984; EPA 1977; Newland et al. 1989; Olanow et
al. 1996) indicate that while non-human primates are very sensitive to the neurological effects of
manganese at very low doses (depending on exposure route), rodent models do not exhibit the same
neurological symptoms as humans and monkeys despite the administration of high doses through 
inhalation, oral, and intravenous exposure routes.  Although there is an apparent difference in 
susceptibility, neurological effects have been observed in rodents treated with manganese.  Additional
studies in animals could be valuable to increase our understanding of the mechanism of manganese-
induced disease and the basis for the differences between humans and animals.
Some data on neurological or other health effects in humans from repeated or chronic oral intake of
manganese exist (Bouchard et al. 2007c, 2011; Cawte et al. 1987; He et al. 1994; Holzgraefe et al. 1986;
Kawamura et al. 1941; Kilburn 1987; Kondakis et al. 1989; Vieregge et al. 1995; Wasserman et al. 2006, 
2011; Wright et al. 2006; Zhang et al. 1995).  The majority of these studies are limited by uncertainties in 
the exposure routes, total exposure levels, duration of exposure, or the influence of other confounding
factors; none of these studies adequately assessed daily dietary manganese intake.  Eight studies 
(Bouchard et al. 2007c, 2011; Brna et al. 2011; He et al. 1994; Sahni et al. 2007; Wasserman et al. 2006, 
2011; Zhang et al. 1995) indicate concentrations of manganese in drinking water that may be associated
with preclinical neurological effects in children, but the studies have several limitations.
As discussed in Section 2.3, no oral MRLs were derived for acute-, intermediate-, or chronic-duration oral
exposure to manganese, even though the limited human data and extensive animal data clearly identify
neurobehavioral changes as the most sensitive effect from intermediate- and chronic-duration oral
exposure to excess inorganic manganese.  However, inconsistencies in the dose-response relationship 
information across studies evaluating different neurological end points under different experimental
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conditions in different species, as well as a lack of information concerning all intakes of manganese (e.g.,
dietary intakes plus administered doses), make it difficult to derive intermediate- or chronic-duration 
MRLs using standard MRL derivation methodology from the animal studies.  An interim guidance value
of 0.16 mg manganese/kg/day is recommended for ATSDR public health assessments. The interim
guidance value is based on the Tolerable Upper Intake Level for adults of 11 mg manganese/day
established by the FNB/IOM (2001) based on a NOAEL for Western diets.  The interim guidance value is
necessary because of the prevalence of manganese at hazardous waste sites and the fact that manganese is 
an essential nutrient.
Additional chronic oral studies, especially epidemiological studies in populations exposed to high levels
of either inorganic and organic manganese in the environment, particularly the combustion products of
MMT in areas of high traffic density, would be valuable for evaluating the potential for adverse effects 
from oral exposure to excess manganese from the environment in addition to that ingested through dietary
intake.
No studies or anecdotal reports were located that described cancer associated with exposure of humans to
inorganic manganese.  Chronic oral exposure of rats and mice to high doses of manganese sulfate has 
provided equivocal evidence of carcinogenic potential (NTP 1993); however, the lack of evidence for the 
carcinogenic potential of manganese in humans and the equivocal evidence in animals suggest that the 
potential for cancer may be low.  Further animal studies are not needed at this time.
MMT has not been found to induce tumor formation in rodents (Witschi et al. 1981) and additional
studies measuring this end point would be useful to corroborate the limited database.  Though no studies
of carcinogenesis involving mangafodipir exposure were identified, there are no data needs regarding this
end point with this compound. 
Genotoxicity. One study was located regarding the genotoxic effects of inorganic manganese in
humans.  An increase in chromosomal aberrations was observed in welders exposed to manganese;
however, the welders were also exposed to nickel (known to cause chromosomal aberrations) and iron, so
the observed increase could not be attributed solely to manganese (Elias et al. 1989).  Some in vivo
studies in fruit flies and rats have been negative (Dikshith and Chandra 1978; Rasmuson 1985; Valencia
et al. 1985), but manganese has been found to be clastogenic in mice (Joardar and Sharma 1990).  In vitro
studies in bacteria, yeast, and cultured mammalian cells have yielded mixed, but mainly positive, results 
(Casto et al. 1979; De Méo et al. 1991; Joardar and Sharma 1990; Kanematsu et al. 1980; Nishioka 1975;
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NTP 1993; Oberly et al. 1982; Orgel and Orgel 1965; Singh 1984; Ulitzur and Barak 1988; Wong and 
Goeddel 1988; Zakour and Glickman 1984).  Additional studies, especially in cultured mammalian cells,
heritable cell types, or in lymphocytes from exposed humans, would be valuable in clarifying the
genotoxic potential of manganese.  As for organic manganese, no genotoxicity studies were located
regarding MMT and studies measuring this end point are needed.  Genotoxicity studies for mangafodipir
have shown negative effects (Grant et al. 1997a).
Reproductive Toxicity. Men who are exposed to manganese dust in workplace air report decreased
libido and impotency (Emara et al. 1971; Mena et al. 1967; Rodier 1955), and may suffer from sexual
dysfunction (Jiang et al. 1996b) and decreased sperm and semen quality (Wu et al. 1996).  In addition, 
studies in animals indicate that manganese can cause direct damage to the testes (Chandra et al. 1973;
Seth et al. 1973).  While the Jiang et al. (1996b) study suggests testicular damage in occupationally
exposed men, additional epidemiological studies involving these subjects or other exposed groups to 
more fully evaluate reproductive function would be valuable.  Results from such studies may provide
definitive exposure-response data on reproductive function (e.g., impotence, libido, and number of
children).  
Additional studies in animals are needed to determine whether the testes are damaged directly from
exposure to manganese.  Information on adverse reproductive effects in women is not available.  Data 
from studies in female animals indicate that manganese can cause post-implantation loss when
administered through both oral and subcutaneous exposure routes in female mice and rats (Colomina et al.
1996; Sánchez et al. 1993; Szakmáry et al. 1995; Treinen et al. 1995).  To establish more clearly whether
or not this is a human health concern, two types of studies would be valuable.  First, single-generation
reproductive studies of female animals exposed by the inhalation route could be done.  Then, if strong
evidence for concern is found in animals from these studies, epidemiological studies that included women 
and men exposed in the workplace would be valuable to assess the effects of manganese on reproductive 
function.
Developmental Toxicity.    There is a growing body of human data on potential developmental effects
of excess manganese, although these studies are generally confined to studies of neurodevelopmental
effects as observed in children. The incidences of stillbirths and malformations have been studied in an
Australian aboriginal population living on an island where environmental levels of manganese are high
(Kilburn 1987), but small population size and lack of data from a suitable control group preclude
determining whether reported incidence of developmental abnormalities is higher than average.  Hafeman
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et al. (2007) reported high mortality among infants <1 year of age in a Bangladesh population where the
drinking water supplied by certain local wells contained high levels of manganese. Similarly, Spangler
and Spangler (2009) reported increased infant mortality rates in counties in North Carolina with higher
groundwater manganese concentrations after accounting for such confounders as low birth weight, 
economic status, education, and ethnicity.  Two studies investigated neurobehavioral and school
performances (He et al. 1994; Zhang et al. 1995) of children exposed to excess levels of manganese in
water and food.  However, these studies did not report data on either lengths of exposure to the metal or
on excess manganese intake compared to control areas.  More recent investigations include
epidemiological studies that have detected altered behavioral and cognitive performance among children
exposed to excess levels of manganese in their local drinking water (Bouchard et al. 2007c, 2011;
Wasserman et al. 2006, 2011). These results suggest the neurotoxic potential of excessive manganese 
exposure to children, but these studies have uncertainties that preclude the establishment of causal
relationships between the observed effects and manganese exposure. The studies are limited in their
ability to address several important concerns, such as whether manganese alone is responsible for the 
observed effects and the contribution of dietary manganese levels as well as inhalation exposure levels 
and small sample sizes.  Studies evaluating developmental effects with clear analysis of exposure levels 
and duration are needed to estimate dose-response relationships of manganese toxicity in children.  
Several developmental studies have been performed in animals, but they are mainly limited to rodent
species and have measured limited developmental end points.  One study in pregnant mice that inhaled
manganese resulted in decreased pup weight and a transient increase in activity (Lown et al. 1984).  Other
studies have indicated that oral exposure to manganese adversely affects reproductive development in
male mice (Gray and Laskey 1980) and rats (Laskey et al. 1982, 1985).  A single study on rats involving
oral exposure indicated that manganese caused a transient decrease in pup weight and increased activity 
(Pappas et al. 1997).  Another study involving gavage dosing reported skeletal abnormalities in unborn 
pups, but these effects were resolved in pups allowed to grow to 100 days of age (Szakmáry et al. 1995).  
Neurobehavioral effects have been shown in neonates given excess manganese orally from PND 1 to 21
(Dorman et al. 2000; Reichel et al. 2006; Tran et al. 2002a).  Several studies have shown neurochemical
changes in offspring of dams exposed to increased manganese concentrations (Lai et al. 1991; Garcia et
al. 2006, 2007) or in neonatal animals dosed with excess manganese (Anderson et al. 2007a, 2009;
Chandra and Shukla 1978; Deskin et al. 1981; Dorman et al. 2000; Kern and Smith 2011; Kern et al. 
2010; Kristensson et al. 1986; Moreno et al. 2009; Reichel et al. 2006; Tran et al. 2002a, 2002b).  Also of
interest is the possibility that developmental manganese exposure may influence the timing of puberty;
such results have been observed in studies of both male and female rats (Lee et al. 2006; Pine et al. 2005).
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Studies conducted in infant Rhesus monkeys found that soy-based infant formulas (which contain higher
manganese levels than cow’s milk) and a soy-based infant formula supplemented with manganese 
produced behavioral changes that may be comparable to those implicated in attention deficit-hyperactivity
disorders (Golub et al. 2005).  Several studies have shown neurobehavioral changes in rodents as well
(Dorman et al. 2000; Kern and Smith 2011; Kern et al. 2010; Kristensson et al. 1986; Moreno et al. 2009;
Tran et al. 2002a, 2002b).
Other studies indicate that injected manganese is more toxic to a developing fetus than inhaled or ingested
manganese.  Manganese injected subcutaneously or intravenously during the gestation period causes 
serious effects on skeletal development and ossification, but studies to date using this exposure pathway
have not measured neurological deficits in pups or young rodents.  The relevance to humans of results
from these injection studies is unclear.
The monkey is increasingly regarded as a more appropriate model for neurological end points; however, 
monkey studies are extremely expensive and will be limited for this reason.  Evaluation of appropriate 
end points in rodent assays by the oral and inhalation route are needed so that these models can be used to
increase the body of knowledge of the developmental toxicity of manganese.  Further, the one
developmental study involving inhalation exposure (Lown et al. 1984) had many complications;
additional studies involving neurobehavioral effects in animals following gestational and postnatal 
exposure to airborne manganese are necessary.  A few developmental studies have involved sectioning
fetuses to detect internal malformations (Blazak et al. 1996; Grant et al. 1997a; Szakmáry et al. 1995;
Treinen et al. 1995).  However, these studies have primarily administered the manganese intravenously,
except for Szakmáry et al. (1995).  Additional teratogenesis studies that assess bone malformations 
following inhalation and oral exposures using a wide range of doses are needed given that manganese 
overexposure affects the developing skeletal system (Blazak et al. 1996; Grant et al. 1997a; Szakmáry et
al. 1995; Treinen et al. 1995).  In order to improve the accuracy of the development of an oral MRI for 
manganese, additional developmental neurotoxicology studies using a functional observational battery
design and using a wide range of well-established measures in rodents and primates would be useful
(Moser 2000).
Immunotoxicity. Studies in animals indicate that injection or consumption of manganese compounds
can cause significant changes in the functioning of several cell types of the immune system (NTP 1993;
Rogers et al. 1983; Smialowicz et al. 1985, 1987).  However, it is not known whether these changes are 
associated with significant impairment of immune system function.  Further studies are needed to 
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determine whether these effects also occur after inhalation exposure in animals or humans.  If so, a 
battery of immune function tests would be valuable in determining if observed changes result in a
significant impairment of immune system function.
Neurotoxicity. Studies in humans exposed to high levels of manganese dust in the workplace provide 
clear evidence that the chief health effect of concern following manganese exposure is injury to the 
central nervous system (Emara et al. 1971; Mena et al. 1967; Rodier 1955; Schuler et al. 1957; Smyth 
et al. 1973).  As discussed previously, a number of epidemiological studies have used batteries of
neurobehavioral tests of neuromotor, cognition, and mood states to study the neurological effects of
exposure to low levels of manganese in the workplace. Analyses of dose-response relationships for
changes in neurobehavioral tests in several of these studies (Gibbs et al.1999; Iregren et al. 1990;
Lucchini et al. 1999; Mergler et al. 1994; Roels et al. 1992; Wennberg et al. 1991) provide the basis of the
current chronic inhalation MRL for inorganic manganese (as described in Chapter 2 and Appendix A). 
Additional follow-up studies to further evaluate the reversibility of manganese-induced effects and define 
threshold exposure levels above which manganese-induced neurological effects are irreversible may be 
useful
Studies in communities surrounding manganese industries have also reported evidence for associations 
between deficits in neurological end points (such as attention impairments, postural stability, and motor
impairments) and increasing biomarkers of manganese exposure in adults and children, but all potential
sources of exposure (e.g., air, diet, drinking water) could not be accounted for in these studies and they do 
not provide useful dose-response data for deriving an MRL for inhaled manganese (Baldwin et al. 1999;
Beuter et al. 1999; Bowler et al. 1999; Hernández-Bonilla et al. 2011; Kim et al. 2011; Menezes-Filho et 
al. 2011; Mergler et al. 1999; Solís-Vivano et al. 2009; Standridge et al. 2008; Riojas-Rodríguez et al. 
2010; Rodríguez-Agudelo et al. 2006).  More studies that include analyses of both sexes and assess the 
relationship between environmental sources of excess manganese, altered manganese body burden, and
the potential for adverse effects may be useful. Further studies may be useful to determine whether
manganese from MMT and/or its unique combustion products contribute to airborne manganese
concentrations that can be associated with adverse effects (e.g., respiratory or neurological effects).
The evidence for neurotoxicity in humans following oral exposure to manganese is inconclusive due to 
several limitations in the majority of these reports (Bouchard et al. 2007c, 2011; Holzgraefe et al. 1986;
Kawamura et al. 1941; Kilburn 1987; Kondakis et al. 1989; Wasserman et al. 2006, 2011).  One report in 
Japanese adults (Iwami et al. 1994) showed the link between eating food with concentrations of
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manganese on the high end of the normal range of a typical Western diet (5.79 mg manganese ingested
per day) and low intake concentrations of magnesium associated with an increased incidence of motor
neuron disease.  Six studies in children (Bouchard et al. 2007c, 2011; He et al. 1994; Wasserman et al. 
2006, 2011; Zhang et al. 1995) indicated that those who ingested drinking water and/or who ate food with
increased concentrations of manganese (≥0.241 mg/L) for at least 3 years had measurable deficits in
performance on certain tests.  In addition, the children exposed to manganese performed more poorly in 
school compared to non-exposed control students (who drank water with manganese concentrations no 
higher than 0.04 mg/L), as measured in mastery of Chinese, performance in mathematics, and overall
grade average (Zhang et al. 1995).  These studies show that both adults and children show adverse
neurological effects from oral exposure to excess manganese.
Studies in rodents and nonhuman primates indicate that oral intake of high doses of manganese can lead 
to biochemical and behavioral changes indicative of nervous system effects (Bonilla and Prasad 1984; 
Chandra 1983; Gupta et al. 1980; Kristensson et al. 1986; Lai et al. 1984; Nachtman et al. 1986), and this
is supported by intravenous studies in monkeys (Newland and Weiss 1992).  Rodents do not appear to be
as susceptible to manganese neurotoxicity as humans; however, a study by Newland and Weiss (1992)
indicates that Cebus monkeys would be a reasonable animal model.  More recent studies demonstrated
LOAEL values of 5.6 mg manganese/kg/day for severely impaired cognitive performance in a maze test
following 30-day dietary exposure of adult white rats (Shukakidze et al. 2003); 6.5 mg manganese/kg/day 
for decreased open-field locomotor activity and acoustic startle response and impaired performance in
maze learning (a test of spatial memory) in male adult Wistar rats exposed for 10 weeks by gavage (Vezér
et al. 2005, 2007); 11 mg manganese/kg/day for increased pulse-initiated acoustic startle response in
Sprague-Dawley rats exposed on PNDs 1–21 (Dorman et al. 2000); and 328 mg manganese/kg/day (but
not 107.5 mg manganese/kg/day) for decreased activity during sleep and decreased play activity but no 
effects on gross motor maturation or performance in cognitive tests in young monkeys (Golub et al. 
2005).  In contrast, hand steadiness or self-reported scales for assertiveness or anger were not different in
adult human female subjects following 8 weeks of exposure to dietary doses of 0.01 or 0.3 mg
manganese/kg/day (Finley et al. 2003).  Further studies in animals may help determine the basis for the
apparent differences in route and species susceptibility.
Additional studies in animals concerning the cellular and biochemical basis of manganese neurotoxicity,
including a more detailed analysis of precisely which neuronal cell types are damaged and why, are 
needed.  For example, Lazrishvilli et al. (2009) observed gliosis in the brains of 40-day-old pups of rat
dams administered 4.4 or 8.7 mg manganese/kg/day in the diet before, during, and after pregnancy, but
   
 








     
    
 
 
       
         
         
  
      
  
      
  
        
  
 
      
 
          
         
           
          
          
            
          
           
   
     
       
   
            
          





Rivera-Mancia et al. (2007) did not find gliosis in the brains of adult rats exposed to 147 mg
manganese/kg/day.  Further studies may prove helpful in elucidating mechanism(s) of toxic action and 
could potentially lead to developing methods for mitigating adverse effects induced by manganese. 
Epidemiological and Human Dosimetry Studies. As already noted, there are numerous
epidemiological studies of workers exposed to manganese dusts in air, and the clinical signs and
symptoms of the resulting disease are well established.  However, these studies have only involved males 
and have mostly involved the inhalation route of exposure.  Additional epidemiological studies on 
populations exposed to manganese dust in the workplace or local environments (e.g., such as near
foundries, populations exposed to manganese emissions from MMT-burning automobiles, particularly
those living in areas of high-traffic density, and populations exposed to above-average oral intakes [either
through water and/or food]) may help to strengthen conclusions on dose-response relationships and no-
effect exposure levels. This would be helpful in evaluating potential risks to people who may be exposed 
to above-average manganese levels near hazardous waste sites.
Biomarkers of Exposure and Effect.
Exposure.  Studies in humans have shown that it is difficult to estimate past exposure to manganese by
analysis of manganese levels in blood, urine, feces, or tissues (Roels et al. 1987b; Smyth et al. 1973;
Valentin and Schiele 1983; Yamada et al. 1986). This is the result of several factors:  (1) manganese is a 
normal component of the diet and is present in all human tissues and fluids, so above average exposure 
must be detected as an increase over a variable baseline; (2) manganese is rapidly cleared from the blood
and is excreted mainly in the feces, with very little in the urine; and (3) manganese absorption and
excretion rates are subject to homeostatic regulation, so above average exposures may result in only small
changes in fluid or tissue levels.  Probably the most relevant indicator of current exposure is manganese 
concentrations in tissues, but at present, this can only be measured in autopsy or biopsy samples.  Studies
on new, noninvasive methods capable of measuring manganese levels in vivo, either in the whole body or
in specific organs (e.g., brain), would be very helpful in identifying persons with above average exposure.
Dorman et al. (2006b) evaluated the use of the pallidal index (PI—ratio of hyperintensities in the globus
pallidus and the adjacent subcortical frontal white matter) and the T1 relaxation rate (R1) from MRI to
reflect manganese concentrations determined by analytical chemistry in brain regions and concluded that
R1 can be used to estimate regional brain manganese concentrations and be used as a reliable biomarker
of occupational manganese exposure.
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Effect. The principal biological markers of toxic effects from manganese exposure are changes in the 
levels of various neurotransmitters and related enzymes and receptors in the basal ganglia (Bird et al.
1984; Bonilla and Prasad 1984; Eriksson et al. 1987a, 1987b).  Noninvasive methods to detect preclinical
changes in these biomarkers or in the functioning of the basal ganglia need to be developed to help 
identify individuals in whom neurological effects might result.  Research to determine the correlation
between urinary excretion levels of neurotransmitters, neurotransmitter metabolites, and/or
17-ketosteroids (Bernheimer et al. 1973; Rodier 1955; Siqueira and Moraes 1989) and the probability or
severity of neurological injury in exposed people is also needed.  Measurements of MnSOD as a 
biomarker of effect may also be helpful (Greger 1999), but there is a lack of information concerning the
relationship of this enzyme to manganese toxicity.
Research in the use of Clara cell protein CC16 may be useful in identifying populations at risk from
exposure to MMT; however, the majority of exposure to this compound is expected to arise from
inhalation and ingestion of its combustion products.  Therefore, increased use of MMT in gasolines
necessitates the development of biomarkers of exposure to inorganic manganese compounds, as discussed
previously.   
Absorption, Distribution, Metabolism, and Excretion. The toxicokinetics of manganese 
absorption, distribution, and excretion have been studied in both humans and animals.  The oral
absorption rate is about 3–5% in humans (Davidsson et al. 1988, 1989a; Mena et al. 1969), but the rate
may vary depending on age and dietary iron and manganese intake levels (Chandra and Tandon 1973;
Diez-Ewald et al. 1968; Rehnberg et al. 1982; Thomson et al. 1971).  Information is needed on the
relative proportion of manganese that is absorbed via the gut following mucociliary transport of particles
from the lung to the stomach.  The oral absorption rate may depend on the chemical form of manganese 
ingested, but data on this are sparse. Data on the differences in uptake as a function of chemical species
(manganese dioxide, manganese tetroxide) and particle size would also be valuable in assessing human
health risk from different types of manganese dusts.  Absorption of manganese deposited in the lung is
expected to be higher for soluble forms of manganese compared with relatively insoluble forms of
manganese (Aschner et al. 2005; Roels et al. 1997).  Results consistent with nasal uptake of manganese 
and transport to the brain along neuronal tracts have been obtained in several animal studies (Brenneman 
et al. 2000; Dorman et al. 2001a, 2002a; Elder et al. 2006; Fechter et al. 2002; Henriksson et al. 1999;
Lewis et al. 2005; Normandin et al. 2004; Tjälve and Henriksson 1999; Tjälve et al. 1996; Vitarella et al. 
2000).  Following nasal instillation of solutions of manganese chloride or sonicated suspensions of
ultrafine insoluble manganese oxide particles to rats, similar manganese concentrations were found in the
   
 








    
 




        
  
         
     
   
 
          
 
             
   
        
         
    
 
   
 
          
  
           
            
     
 
             
   
   
    




brain olfactory bulb (Elder et al. 2006).  These results suggest that ultrafine particles can be distributed 
from the nasal mucosa to the brain olfactory bulb.  Absorption of manganese deposited in the lung or
nasal mucosa of rats is expected to be influenced by iron status, with enhanced absorption under iron-
deficient conditions and diminished absorption under iron-excess conditions (Thompson et al. 2006, 
2007).
Manganese appears to be distributed to all tissues, including the brain (Aschner et al. 2005, 2007;
Kristensson et al. 1986; Rehnberg et al. 1980, 1981, 1982).  Inhaled manganese appears to be distributed 
more extensively to the brain than ingested manganese and there are differences in distribution between
different forms of manganese (manganese chloride compared with manganese dioxide or manganese 
phosphate) (Dorman et al. 2001a, 2004b; Roels et al. 1997).  Addtional research would be useful in 
understanding how particle size and solubility of manganese forms influence distribution of manganese to 
and within the brain.  In addition, the metabolism of manganese (specifically, the degree and the rate of
oxidation state interconversions) has not been thoroughly investigated.  Data on this topic are needed to 
understand the mechanism of manganese toxicity and would help in evaluating the relative toxicity of
different manganese compounds.  Excretion of manganese is primarily through the feces (Drown et al.
1986; Klaassen 1974; Mena et al. 1969); because the rate of excretion is an important determinant of
manganese levels in the body, further studies would be valuable on the biochemical and physiological
mechanisms that regulate manganese excretion.
Additional studies would be useful to more fully elucidate the pharmacokinetic mechanisms responsible 
for uptake, distribution, and excretion in humans and animals, including studies to determine the
following: control rates and processes for uptake of ingested manganese by the intestines and liver,
including uptake rates of protein-bound forms by the liver; oxidation rates of manganese in the blood and
tissues; relative speciation of Mn(II vs. III) in blood transport mechanisms into the central nervous 
system, including transfer rates; competition between manganese and iron in terms of transport processes;
and distribution following long-term exposures to assess potential storage depots.
Andersen et al. (1999) suggested that an approach to setting acceptable exposure levels for an essential,
but neurotoxic, nutrient such as manganese could be based on predicting exposure levels by any route that
would increase brain manganese concentrations to a small fraction (e.g., 10–25%) of the variation 
observed in the general human population.  Reliable and validated multiple-route PBPK models for
multiple species, including humans, are needed to take this approach to setting acceptable exposure
levels.  Efforts to develop such models in rats, monkeys, and humans have been described, including the
   
 








   
  
  
   
    









         
       
  
  
      
         
         
  
    
   
 
          
 
 
    
    
    




development of models for gestational and postnatal periods (Leavens et al. 2007; Nong et al. 2008;
Schroeter et al. 2011;Teeguarden et al. 2007a, 2007b, 2007c; Yoon et al. 2011, 2009a, 2009b).  As
discussed by Yoon et al. (2011), confidence in predictions from the human models may improve with 
more information on the normal range and fluctuation of human brain manganese concentrations during
early postnatal periods, the relationship between blood manganese concentrations and target tissue 
dosimetry, and the extent of induction of neonatal biliary excretion.
Data on the pharmacokinetics of mangafodipir are sufficient for environmental assessment purposes.  
Additional studies concerning absorption, distribution, metabolism, and excretion of MMT, via
inhalation, ingestion, and dermal exposures, would be very helpful.
Comparative Toxicokinetics. Several papers have reviewed the fairly extensive literature showing
differences in the expression of manganese neurotoxicity in humans, nonhuman primates, and rodents
(Aschner et al. 2005; Gwiazda et al. 2007; Newland et al. 1999).  Aschner et al. (2005) concluded that
manganese-exposed monkeys show overlapping effects to those observed in patients with manganism
(e.g., retention of manganese in the basal ganglia and loss of dopamergic neurons), but similar changes in 
regional brain manganese concentrations, neurochemical concentrations, and neuropathological effects 
have been observed less consistently in rodents.  Likewise, Gwiazda et al. (2007) concluded from their
analysis of estimated internal cumulative doses associated with neurobehavioral, histological, and 
neurochemical changes in manganese-exposed animals that the range of adverse internal cumulative 
doses extended more than 2 orders of magnitude above the lowest estimated doses associated with subtle
neurological deficits in manganese-exposed workers. The reasons for these differences are poorly
understood, but may be due to interspecies differences in toxicokinetics or toxicodynamics (i.e., 
differences in tissue sensitivities).  As discussed in the previous section, recent extrapolations of animal
PBPK models to humans may be improved by more information on the normal range and fluctuation of
human brain manganese concentrations during early postnatal periods, the relationship between blood 
manganese concentrations and target tissue dosimetry, and the extent of induction of neonatal biliary
excretion (Yoon et al. 2011).
Methods for Reducing Toxic Effects.    In general, the methods which provide the greatest
likelihood of reducing toxic effects are the same as those aimed at reducing body burden (see
Section 3.11.2). The recommended methods for the mitigation of manganese toxicity (manganism) are
mainly supportive (Schonwald 2004).  Administration of anti-Parkinson drugs, such as levo-dopa, is of
little use (Calne et al. 1994; Chu et al. 1995; Cook et al. 1974; Schonwald 2004; Huang et al. 1989;
   
 








         
    
    
          
        
      
           
          
       
 
        
 
      
    
    
 
         
  
         
   
         
        
        
    
            
         
 
 
   






Leikin and Paloucek 2002).  Chelation therapy with agents such as ethylenediaminetretraacetic acid
(EDTA) has reportedly been effective in reducing some of the symptoms (Schonwald 2004; Haddad and 
Winchester 1990), but was not effective in all cases (Crossgrove and Zheng 2004; Jiang et al. 2006).  
Studies on the efficacy of newly developed methods to reduce the toxic effects of manganese are needed.
The available data indicate that para-aminosalicylate has been successfully used to treat neurological
symptoms of manganese poisoning in several patients (Shuqin et al. 1992; Jiang et al. 2006).  The use of
the antioxidant vitamin E has also been proposed to mitigate manganese-induced effects (Parenti et al.
1988).  Additional studies on the efficacy of these treatments are needed.  Further evaluation for the
mitigation of effects from excess exposure to manganese is also needed.
Methods for reducing toxic effects have not been identified for MMT.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
Children have been identified as a potentially susceptible population because of their high absorption
and/or retention of manganese as compared to adults.  Although some available studies indicate that tissue
concentrations of human fetuses are comparable to adults, animal studies indicate that neonates retain
higher tissue concentrations than adult animals.  Researchers hypothesize that this increased retention of
manganese may lead to neurotoxicity. Existing data indicate that the adverse neurological effects of
manganese overexposure from intravenous and oral sources are qualitatively similar in children and
adults.  One study has reported that neonates are more susceptible to the effects of oral exposure to excess 
manganese than adults (Dorman et al. 2000).  Additional quantitative information on the levels of
manganese that result in adverse effects in children as compared to adults for inhalation, oral, and
intravenous exposures are needed.  Further, analysis of existing data from effects observed in the clinical
setting might be helpful.
There are inadequate data on the pharmacokinetics of manganese in children.  Although two studies
provided typical serum manganese levels in differing ages of healthy children (Alarcón et al. 1996;
Rükgauer et al. 1997), no studies have provided any data on the distribution of manganese in infants or
adolescents.  Studies in animals, particularly nonhuman primates, are needed to clearly elucidate the
pharmacokinetic handling of manganese in neonates and the young (absorption, metabolism, distribution, 
elimination).  There are no PBPK models for children, embryos, fetuses and pregnant women, infants and 
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lactating women, or adolescents.  Such models would be very informative if they could assist in the
identification of depots for manganese storage under conditions of excess exposure, as well as the 
nutritional needs of these age groups for the compound.  One study was available that would provide
information on the concentrations of manganese that might be found in the developing fetus of a highly-
exposed mother (Jarvinen and Ahlström 1975).  Further studies of this nature, especially those that
measure neurological end points in live offspring following excess exposure, are needed.  Similarly, data
are needed to determine whether increased amounts of manganese might be present in the breast milk of a 
mother with significantly elevated blood or tissue manganese concentrations.
There are likely to be multiple mechanisms of manganese toxicity and most of these have probably been 
elucidated. However, there is a deficiency in our knowledge of how these mechanisms act singly or in
combination to explain the different functional deficits observed in children versus adults.  There are
inadequate data to determine whether metabolism of manganese is different in children than in adults.
Manganese is necessary for normal functioning of certain enzymes.  However, there are no definitive data 
to indicate that children might need more manganese than adults for normal body processes.  A few
studies suggest that children may have a higher need for manganese than adults, based on the increased
retention of manganese in the brains of certain neonatal animals, but this hypothesis has not been proven.  
Additional studies are necessary to determine the nutritional requirements of children for manganese,
especially in infants for which FNB/IOM has not provided any guidelines.
Studies indicate that children exposed to increased concentrations of inorganic manganese, either via the 
diet, due to inability to clear the compound from the body or through parenteral nutrition, develop 
neurological dysfunction similar to that of adults (Devenyi et al. 1994; Fell et al. 1996; He et al. 1994;
Zhang et al. 1995).  Other data exist that indicate that children may not be as susceptible as adults to the 
adverse neurological effects of inorganic manganese (Kawamura et al. 1941), but the limitations in this 
report make predictions about susceptibility inconclusive.  Additional animal studies comparing the
potential for inorganic manganese to induce neurological effects in different age groups are needed to
help understand the susceptibility of the young compared to adults.
The mechanism of action of inorganic manganese toxicity has not been identified.  Studies in humans
indicate that children and adults with increased manganese deposition in the globus pallidus and other
basal regions suffer neuromuscular deficits.  It has been suggested that manganese accelerates the 
autoxidation of catecholamines and contributes to oxidative stress in these affected regions of the brain.  
Further research is needed to more completely elucidate the mechanism of inorganic manganese toxicity.
   
 









           
          
           
 
 
   
  
      
 
    
 
 





There are no dependable biomarkers of exposure or effect that are consistently used in a clinical setting.
However, MRI scans have been used in both adults and children to determine whether manganese is 
accumulating in certain brain regions. More data are needed to determine the sensitivity and specificity
of this method.
Available data do not indicate that there are any interactions of manganese with other compounds that
occur only in children.  Interactions with compounds in adults are expected to also occur in children.  
Data concerning the significance of any interactions of manganese with other compounds are needed.
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies 
Ongoing studies pertaining to manganese have been identified and are shown in Table 3-20.
   
 









     
 
 Investigator  Affiliation  Research description  
	Sponsor
  Aschner, Judy L  Vanderbilt Brain manganese deposition in  National Institute of 
 University  high risk neonates  Environmental Health Sciences  
 Aschner, Michael  Vanderbilt   Mechanisms of manganese  National Institute of 
 University  neurotoxicity  Environmental Health Sciences  
 Berkowitz, Bruce A  Wayne State  Manganese-enhanced MRI   National Eye Institute 
 University    studies of retinal
neovascularization  
 Brain, Joseph D Harvard    Manganese, iron, cadmium, and  National Institute of 
 University   lead transport from the  Environmental Health Sciences 
  environment to critical organs  
Culotta, Valeria C  Johns Hopkins   Intracellular pathways of  National Institute of 
 University   manganese trafficking  Environmental Health Sciences 
  Dees, WL  Texas A&M   Actions of manganese on  National Institute of 
 University neuroendocrine development  Environmental Health Sciences 
 Dietrich, Kim  University of    Early lead exposure, ADHD, and  National Institute of 
Cincinnati    persistent criminality: Role of  Environmental Health Sciences 
  genes and environment
 Erikson, Keith M   University of    Neurotoxicology of dietary  National Institute of 
 North Carolina iron/manganese interactions  Environmental Health Sciences 
Greensboro 
 Glasfeld, Arthur Reed College   Mechanism and specificity in    National Institute of General
manganese homeostasis   Medical Sciences 
  Graziano, Joseph H, Columbia   Research description: Health  National Institute of 
Grazi  University    effects and geochemistry of  Environmental Health Sciences 
 arsenic and manganese 
   Guilarte, Tomas R   Johns Hopkins    Molecular and behavioral effects  National Institute of 
 University    of low level Mn exposure  Environmental Health Sciences 
   Gunter, Thomas E  University of  Mitochondrial role in manganese  National Institute of 
Rochester   toxicity  Environmental Health Sciences 
  Hu, Howard, MD  Brigham and   Gene-metal interactions and  National Institute of 
Women's  Parkinson's disease  Environmental Health Sciences 
Hospital 
Kanthasamy, Iowa State   Mechanisms of manganese  National Institute of 
Anumantha  University   neurotoxicity  Environmental Health Sciences 
 Gounder, G  
  Klimis-Zacas, D  University of    Manganese, arterial functional   Department of Agriculture 
Maine   properties, and metabolism as Hatch 
   related to cardiovascular disease
  Klimis-Zacas, D  University of    Manganese, arterial functional   Department of Agriculture 
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 Investigator  Affiliation  Research description  Sponsor
  Klimis-Zacas, D  University Of  Manganese, proteoglycan-    Department of Agriculture NRI
Maine  lipoprotein interactions, and Competitive 
   arterial wall functional properties 
 Korrick, Susan A  Brigham and  Metal and organochlorines  National Institute of 
Women's     exposure: Impact on adolescent  Environmental Health Sciences 
Hospital  behavior and cognition  
 Liu, Bin  University of Combined dopaminergic  National Institute of 
Florida    neurotoxicity of manganese and  Environmental Health Sciences 
LPS 
  Miller, Gary W Emory    Neurotoxicity of nanomaterials:   National Institute of 
 University    Evaluation of subcellular redox  Environmental Health Sciences 
 state 
 Nass, Richard  Vanderbilt    Molecular genetics of manganese  National Institute of 
Michael  University   induced dopamine neuron toxicity  Environmental Health Sciences 
  Oberley, Larry W  University of   Oxidative stress and metabolism  National Institute of 
Iowa research cluster   Environmental Health Sciences 
  Pecoraro, Vincent L  University of    Structural models for multinuclear    National Institute of General
  Michigan at manganese enzymes   Medical Sciences 
Ann Arbor 
  Rao, Rajini   Johns Hopkins    Secretory pathway calcium and    National Institute of General
  University manganese pumps   Medical Sciences 
  Shine, James P Harvard   Exposure assessment of children  National Institute of 
 University  and metals in mining waste  Environmental Health Sciences 
  Smith, Donald R  University of   Role of manganese in  National Institute of 
California neurodegenerative disease  Environmental Health Sciences 
Santa Cruz 
 Srinivasan, Chandra 		California State  Superoxide dismutases and ionic  National Institute on Aging 
 University manganese in aging 
Fullerton 
 Tjalkens, Ronald B 		 Colorado State  Manganese and basal ganglia  National Institute of 
 University-Fort   dysfunction: Role of NO  Environmental Health Sciences  
Collins  
  Weisskopf, Marc G 		 Harvard   Metal neurotoxicity  National Institute of 
 University  Environmental Health Sciences 
 		Wessling-Resnick, Harvard    Influence of iron status on the  National Institute of 
Marianne 		  University   neurotoxicity of inhaled  Environmental Health Sciences 
manganese 
 Williams, Michael T 		 Children's     Effect of lead, manganese, and  National Institute of 
 Hospital   stress during development  Environmental Health Sciences 
 Medical
 Center,
 Cincinnati  
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 Investigator  Affiliation  Research description  Sponsor
  Wright, Robert O,  Brigham and   Metal mixtures and  National Institute of 
MD Women's  neurodevelopment  Environmental Health Sciences 
Hospital 
  Zheng, Wei Purdue    Choroid plexus as a target in  National Institute of 
 University   metal-induced neurotoxicity  Environmental Health Sciences 
 West Lafayette 
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1 CHEMICAL IDENTITY
Table 4-1 lists common synonyms, trade names, and other relevant information regarding the chemical
identity of manganese and several of its most important compounds. 
4.2 PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of manganese is located in Table 4-2.
   
 









       
 
  





      




    
      
     
       
     
      
     
     

	
Table 4-1.  Chemical Identity of Manganese and Compoundsa 
Characteristic Information
Chemical name Manganese Mn(II) chloride Manganese sulfate





Registered trade name(s) Cutavalb; Manganb No data Sorba-spray manganeseb 
Chemical formula Mn MnCl2 MnSO4 
Chemical structure Cl O O 
2+ 2+Mn SMn Mn 
OCl O 
Identification numbers:
CAS registry 7439-96-5 7773-01-5 7785-87-7
NIOSH RTECS 009275000b 009625000b OP1050000b 
EPA hazardous waste No data No data No data
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping No data No data No data
HSDB 00550b 02154b 02187b 
NCI No data No data No data
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Chemical name Manganese (II, III) Manganese dioxide Potassium permanganate
oxide
Synonym(s) Manganese Manganese peroxide; Permanganic acid;
tetroxide; mangano- manganese binoxide; potassium salt; chameleon 
manganic oxidec manganese black; mineralc 
battery manganese
Registered trade name(s) No data No data No data
Chemical formula Mn3O4 MnO2 KMnO4 
Chemical structure
O 
O Mn O K+ O Mn O 
O 
Identification numbers:
CAS registry 1317-35-7 1313-13-9 7722-64-7
NIOSH RTECS OP0900000b No data SD6475000b 
EPA hazardous waste No data No data No data 
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping No data No data UN1490b, IMDG 5.1b 
HSDB No data No data 01218b 
NCI No data No data No data
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Table 4-1.  Chemical Identity of Manganese and Compoundsa 
Characteristic Information
Chemical name Mn(II) carbonate Mangafodipir Methylcyclopentadienyl
manganese tricarbonyl
(MMT)
Synonym(s) Carbonic acid; Mangafodipir trisodiumd; MMT; manganese,






Registered trade name(s) No data Teslascand; Win 59010d AK-33X; Antiknock-33; CI-2;
Combustion Improver-2b 
Chemical formula MnCO3 C22H24MnN4O14P2H3Na3 C9H7MnO3 
Chemical structure
O 




CAS registry 598-62-9 140678-14-4 12108-13-3
NIOSH RTECS No data OO9163250 48184
EPA hazardous waste No data No data No data
OHM/TADS No data No data No data
DOT/UN/NA/IMDG shipping No data No data No data
HSDB 00790b No data 2014
NCI No data No data No data
aAll information obtained from Sax and Lewis 1987, except where noted.
bHSDB 2008.
cO’Neil et al. 2006.
dRTECS 2007.
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; OHM/TADS = Oil and Hazardous Material Technical Assistance Data System;
RTECS = Registry of Toxic Effects of Chemical Substances
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Property Manganese Mn(II) chloride Manganese sulfate
Molecular weight 54.94b 125.85b 151.00b 
Color Steel-grayb Pink Pale rose-red
Physical state Solid Solid Solid
Melting point 1,244 °Cc 650 °C 700 °C
Boiling point 2,095 °Cb 1,412 °Cb 850 °C (decomposes)
Density at 20 °C 7.26 g/cm3 b at 20 °C 2.325 g/cm3 at 25 °C b 3.25 g/cm3 d 
Odor No data No data Odorless
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water at 20 °C Decomposes No data No data
Acids Reacts with diluted mineral
acids with evolution of
hydrogen and formation of
divalent manganous saltsb 
No data No data





Log Kow No data No data Not applicable 
Log Koc No data No data Not applicable
Vapor pressure at 20 °C 1 Pa at 955 °Cc 1,000 Pa at 760 °Cc No data
Henry's law constant at 25 °C No data Not applicable Not applicable
Autoignition temperature No data Noncombustible No data
Flashpoint No data No data No data
Flammability limits Flammable and 
moderately explosive in 
dust form when exposed to 
flamed 
No data No data
Conversion factors Not applicable Not applicable Not applicable
Explosive limits
Reactivity
Mixture of aluminum and 
manganese dust may
explode in air. Mixtures
with ammonium nitrate 
may explode when heatedd 
No data
Hydrogend; when heated 
above 200 °C in presence 
of nitrogen, forms nitrode;
violent reaction with NO2 
and oxidants;
incandescent reaction with 
phosphorous, nitryl
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Table 4-2.  Physical and Chemical Properties of Manganese and Compoundsa 
Manganese (II, III) Potassium
Property oxide Manganese dioxide permanganate
Molecular weight 228.81b 86.94b 158.03b 
Color Brownish-blackb Black Purple
Physical state Solid Solid Solid
Melting point 1,564 °C Loses oxygen at 535 °Cd <240 °C (decomposes)
Boiling point No data No data No data
Density at 20 °C No data 5.0 g/cm3 d 2.703 g/cm3 
Odor No data No data Odorless
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water at 20 °C Insoluble Insoluble No data
Acids Soluble in hydrochloric Soluble in hydrochloric Soluble in sulfuric acid
acid acid
Organic solvents No data No data Soluble in acetone 
Partition coefficients:
Log Kow Not applicable No data No data 
Log Koc Not applicable No data No data
Vapor pressure at 20 °C No data No data No data
Henry's law constant at 25 °C Not applicable No data No data
Autoignition temperature No data No data No data
Flashpoint No data No data No data
Flammability limits No data No data No data
Conversion factors Not applicable Not applicable Not applicable
Explosive limits No data No data No data 
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manganese tricarbonyl (MMT)f 
Molecular weight 114.95 757.4e 218.1
Color Pinkc No data Yellow to dark orange
Physical state hexagonal, crystalsc Liquid (solution for Liquid, solid below 2 °C
infusion)
Melting point Decomposes No data 1.5 °Cd 
Boiling point No data No data 232 °C
Density at 20 °C 3.70 g/cm3 c 1.537 g/cm3 b 1.39 g/cm3 
Odor No data No data Faint, pleasant
Odor threshold:
Water No data No data No data
Air No data No data No data
Solubility:
Water at 20 °C Insoluble 459.6 g/Lb Insoluble
Acids Soluble in dilute acidc No data No data
Organic solvents No data 23 g/L (methanol); Readily soluble in hydrocarbons
0.8 g/L (ethanol); and the usual organic solvents
0.6 g/L (acetone);
1.1 g/L (chloroform)b 
including hexane, alcohols,
ethers, acetone, ethylene glycol,
lubricating oils, gasoline and 
diesel fuelb 
Partition coefficients:
Log Kow No data -5.62b No data
Log Koc No data No data No data
Vapor pressure at 20 °C No data No data Ranges from 8 mm Hg at 100 °C
to 360.6 mm Hg at 200 °Cb
Henry's law constant at 25 °C No data No data No data
Autoignition temperature No data No data No data
Flashpoint No data No data 110 °C
Flammability limits No data No data No data
Conversion factors Not applicable No data No data
Explosive limits No data No data No data
Reactivity No data No data Light (decomposes)
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aAll information obtained from Sax and Lewis 1987, except where noted.




fData for MMT from NIOSH 2005 unless otherwise noted.
   
 














4. CHEMICAL AND PHYSICAL INFORMATION
This page is intentionally blank. 












   
 
         
           
    
        
 
   
   
 
   
   
 
      
   
  
        
   
      
 
    
  
      
 






   
            
MANGANESE 373
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5.1 PRODUCTION
Tables 5-1 and 5-2 list the facilities in each state that manufacture or process manganese, the intended
use, and the range of maximum amounts of manganese that are stored on site.  The data listed in
Tables 5-1 and 5-2 are derived from the Toxics Release Inventory (TRI09 2011).  Only certain types of
facilities were required to report. Therefore, this is not an exhaustive list.
Manganese is an abundant element comprising about 0.1% of the earth's crust (Graedel 1978).  It does not
occur naturally as a base metal, but is a component of over 100 minerals, including various sulfides, 
oxides, carbonates, silicates, phosphates, and borates (NAS 1973).  The most commonly occurring
manganese-bearing minerals include pyrolusite (manganese dioxide), rhodocrosite (manganese
carbonate), and rhodanate (manganese silicate) (EPA 1984; NAS 1973; Windholz et al. 1983).
Most manganese ore is smelted in electric furnaces to produce ferromanganese, a manganese-iron alloy
widely used in the production of steel (EPA 1984; NAS 1973).  Approximately 2 tons of manganese ore 
are required to make 1 ton of ferromanganese (NAS 1973).  Production of manganese metal is achieved 
by aluminum reduction of low iron-content manganese ore, and electrolytically from sulfate or chloride 
solution (Lewis 2001).  Manganese with <0.1% metallic impurities can be produced electrolytically from
a manganese sulfate solution (EPA 1984; Lewis 2001).
Manganese compounds are produced either from manganese ores or from manganese metal.  For
example, manganese chloride is produced by the reaction of hydrochloric acid with manganese oxide
(Pisarczyk 2005).  Manganese carbonate and manganese sulfate are produced by dissolving manganese 
carbonate ore (rhodochrosite) or Mn(II) oxide in sulfuric acid (Pisarczyk 2005).  Potassium permanganate
may be manufactured by the one-step electrolytic conversion of ferromanganese to permanganate, or by a 
two-step process involving the thermal oxidation of manganese(IV) dioxide of a naturally occurring ore
into potassium manganate(VI), followed by electrolytic oxidation to permanganate (Pisarczyk 2005).
Most manganese is mined in open pit or shallow underground mines (EPA 1984; NAS 1973).  Manganese 
ores were previously mined in the United States, but no appreciable quantity has been mined in the United
States since 1978 (USGS 2007).  The only mine production of manganese in the United States consisted
of small amounts of manganiferous material having a natural manganese content of <5%. This type of
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Table 5-1.  Facilities that Produce, Process, or Use Manganese
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AK 6 0 99,999 1, 5, 12, 13, 14
AL 113 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AR 75 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AZ 44 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CA 123 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CO 42 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 14
CT 31 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
DE 6 100 999,999 1, 3, 4, 5, 8, 10
FL 50 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
GA 78 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 14
HI 7 0 99,999 1, 2, 3, 4, 5, 7, 8, 9, 12
IA 113 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ID 15 0 9,999,999 1, 3, 4, 5, 7, 8, 9, 12, 13
IL 194 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IN 192 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KS 61 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KY 113 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
LA 70 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MA 42 0 49,999,999 1, 2, 3, 4, 5, 7, 8, 9, 11, 12, 14
MD 44 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ME 25 0 999,999 1, 2, 3, 5, 6, 8, 9, 11, 12, 13
MI 173 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MN 63 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MO 85 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MS 42 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14
MT 11 10,000 999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12
NC 104 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ND 19 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12
NE 49 0 49,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14
NH 17 0 49,999,999 1, 2, 4, 5, 7, 8, 9, 11, 12, 13
NJ 73 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
NM 9 1,000 9,999,999 1, 2, 3, 5, 6, 8, 9, 11, 12, 14
NV 39 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NY 106 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OH 249 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OK 83 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
   
 

















    
                  
                  
            
           
                 
                
                  
                  
                  
                  
         
                  
                  
                  
              
 
   
      
 
   
   
   
 
   
 
   
   
    
   
    
   
    
   
 










5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Table 5-1.  Facilities that Produce, Process, or Use Manganese
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
OR 65 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PA 234 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PR 14 0 999,999 2, 3, 4, 7, 8, 9, 11, 12
RI 16 0 999,999 2, 3, 4, 8, 9, 11, 12
SC 70 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
SD 36 0 49,999,999 1, 2, 3, 5, 7, 8, 9, 10, 11, 12, 13, 14
TN 114 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
TX 175 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 71 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
VA 61 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
VT 4 0 999,999 2, 4, 7, 11, 12
WA 73 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WI 143 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WV 49 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WY 12 0 999,999 1, 2, 3, 5, 8, 9, 11, 12, 13, 14
aPost office state abbreviations used.
bAmounts on site reported by facilities in each state.
cActivities/Uses:
1. Produce 6.  Impurity 11. Chemical Processing Aid
2. Import 7. Reactant 12. Manufacturing Aid 
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses
4.  Sale/Distribution 9. Article Component 14. Process Impurity
5. Byproduct 10. Repackaging
Source: TRI09 2011 (Data are from 2009)
   
 


















    
               
                  
                  
                 
                  
                 
                  
     
                 
                  
                  
         
                  
               
                  
                  
                  
                 
                  
                 
                  
           
                  
                  
                  
                  
                
                  
               
                 
             
                  
             
                  
                  
                  
Table 5-2.  Facilities that Produce, Process, or Use Manganese Compounds
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
AK 19 0 49,999,999 1, 2, 3, 5, 7, 8, 10, 11, 12, 13, 14
AL 155 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AR 82 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
AZ 72 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
CA 115 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CO 72 0 499,999,999 1, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
CT 36 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
DC 3 1,000 99,999 12
DE 39 0 9,999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13, 14
FL 103 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
GA 109 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
HI 6 100 999,999 1, 5, 7, 9, 10
IA 101 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ID 38 0 49,999,999 1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IL 204 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
IN 187 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KS 75 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
KY 97 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
LA 66 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MA 33 0 999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
MD 76 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ME 19 0 9,999,999 1, 5, 6, 8, 12, 13, 14
MI 182 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MN 73 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MO 90 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MS 78 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
MT 27 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 12, 13, 14
NC 131 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
ND 24 1,000 9,999,999 1, 3, 5, 7, 8, 9, 10, 11, 12, 13, 14
NE 59 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14
NH 14 0 99,999 1, 2, 3, 5, 7, 8, 9, 12, 13
NJ 95 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NM 36 0 10,000,000,000 1, 3, 4, 5, 7, 9, 12, 13, 14
NV 42 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
NY 123 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OH 292 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
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Table 5-2.  Facilities that Produce, Process, or Use Manganese Compounds
Minimum Maximum 
Number of amount on site amount on site 
Statea facilities in poundsb in poundsb Activities and usesc 
OK 61 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
OR 54 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PA 265 0 99,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
PR 23 0 999,999 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12
RI 5 10,000 999,999 8, 11
SC 111 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
SD 17 0 9,999,999 1, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
TN 151 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
TX 211 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
UT 88 0 999,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
VA 76 0 9,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
VT 5 0 99,999 1, 5, 7, 8
WA 80 0 49,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WI 113 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WV 72 0 499,999,999 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
WY 26 0 999,999 1, 3, 4, 5, 7, 9, 12, 13, 14
aPost office state abbreviations used.
bAmounts on site reported by facilities in each state.
cActivities/Uses:
1. Produce 6.  Impurity 11. Chemical Processing Aid
2. Import 7. Reactant 12. Manufacturing Aid 
3. Onsite use/processing 8. Formulation Component 13. Ancillary/Other Uses
4.  Sale/Distribution 9. Article Component 14. Process Impurity
5. Byproduct 10. Repackaging
Source: TRI09 2011 (Data are from 2009)
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
material was produced in South Carolina for use in coloring brick (USGS 2007).  Essentially all 
manganese ore used in manganese production in the United States is now imported (USGS 2007).
Currently, there are 3,703 facilities in the United States that indicate that they produce, process, or use 
manganese (TRI09 2011). These facilities are scattered across the United States, with the largest numbers 
in Ohio (249), Pennsylvania (234), and Illinois (194).  Over  4,300 facilities are involved in the 
distribution or use of manganese or manganese compounds (TRI09 2011).  Tables 5-1 and 5-2 list the
number of facilities in each state, the ranges of the maximum amounts stored at each facility, and the uses 
of the material (TRI09 2011).
The organomanganese compound methylcyclopentadienyl manganese tricarbonyl (MMT) is produced in 
either of the following ways:  via the reaction of manganous chloride, cyclopentadiene, and carbon 
monoxide in the presence of manganese carbonyl and an element of group II or IIIA, or via the reaction of
methylcyclopentadiene with manganese carbonyl (EPA 1984; Sax and Lewis 1987).  According to data
submitted to the EPA by the American Chemistry Council Petroleum Additives Panel, MMT is 
manufactured by adding methylcyclopentadienyl dimer to a dispersion of sodium metal in diethylene
glycol dimethyl ether under a nitrogen environment (EPA 2006b).  Keeping the mixture at elevated 
temperature yields sodium-methylcyclopentadienyl, which is an intermediate in the reaction process. 
Manganese chloride is added to the stirred mixture containing the sodium methylcyclopentadienyl
intermediate. The reaction eventually yields bis(methylcyclopentadienyl)manganese as a second 
intermediate of the reaction process. The reaction vessel is then pressurized with carbon monoxide,
which results in the formation of MMT, which is separated from the reaction mixture via vacuum
distillation (EPA 2006b). 
No production data from facilities that manufacture or process MMT were found. According to data from
the 2007 Directory of Chemical Producers, only one company located in Orangeburg, South Carolina
produces MMT in the United States (SRI 2007).  
Mn(II) dipyridoxyl diphosphate (MnDPDP), or mangafodipir trisodium, is classified as a drug or
therapeutic agent, and no production data were found for it.
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5.2 IMPORT/EXPORT
The United States does not produce manganese and is 100% import reliant (USGS 2007).  Import and 
export data for manganese are provided in Table 5-3. Demand for manganese metal comes primarily
from the aluminum and steel industry (USGS 2007).  Manganese consumption in 2007 was about 13%
lower than that of 2006, owing to constant demand by the domestic steel industry and reduction of
producer and consumer stocks.  From January through August of 2007, domestic steel production was
1.4% lower than that for the same period in 2006 (USGS 2008).  The United States imports the bulk of its
manganese ore from Gabon, 65%; South Africa, 19%; Australia, 7%; Ghana, 2%; and other nations, 7%
(USGS 2007).  Ferromanganese is imported from South Africa, 51%; China, 14%; Mexico, 6%; Republic
of Korea, 5%; and other nations, 24% (USGS 2007). 
There were no data located regarding the import or export of MMT or mangafodipir.  
5.3 USE 
Metallic manganese (ferromanganese) is used principally in steel production to improve hardness,
stiffness, and strength.  It is used in carbon steel, stainless steel, high-temperature steel, and tool steel,
along with cast iron and superalloys (EPA 1984; NAS 1973).  According to data obtained from the
U.S. Geological Society (USGS), manganese ore was consumed primarily by eight firms with plants
principally in the east and midwest United States (USGS 2008).  The majority of ore consumed was
associated with steel production, directly in pig iron manufacture and indirectly through upgrading ore to 
ferroalloys.  Additional quantities of ore were used for nonmetallurgical purposes such as production of
dry cell batteries, in plant fertilizers and animal feed, and as a brick colorant. Manganese ferroalloys were
produced at two smelters, although one operated sporadically throughout the year (USGS 2008). 
Construction, machinery, and transportation end uses accounted for approximately 24, 10, and 10%, 
respectively, of manganese demand (USGS 2008). Most of the rest went to a variety of other iron and
steel applications.  The value of domestic consumption, estimated from foreign trade data, was about
$730 million (USGS 2008).
Manganese compounds have a variety of uses.  Manganese dioxide is commonly used in production of
dry-cell batteries, matches, fireworks, porcelain and glass-bonding materials, amethyst glass, and as the 
starting material for production of other manganese compounds (EPA 1984; NAS 1973; Venugopal and 
Luckey 1978).  Manganese chloride is used as a precursor for other manganese compounds, as a catalyst
in the chlorination of organic compounds, in animal feed to supply essential trace minerals, and in
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Table 5-3.  Manganese Import/Export Data for 2003–2007
2003 2004 2005 2006 2007
Imports for consumptiona
Manganese ore 347 451 656 572 610
Ferromanganese 238 429 255 358 322
Silicomanganese 267 422 327 400 390
Exportsa
Manganese ore 18 123 13 2 2
Ferromanganese 11 9 14 22 33
aData in thousand metric tons gross weight
Source: USGS 2008
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dry-cell batteries (EPA 1984).  Manganese sulfate is used primarily as a component of fertilizer (60% of
total consumption) and as a livestock supplement (30% of total consumption); it is also used in some
glazes, varnishes, ceramics, and fungicides (EPA 1984; Windholz et al. 1983).  Potassium
permanganate’s oxidizing power allows it to be used as a disinfectant; an antialgal agent; for metal 
cleaning, tanning, and bleaching; and as a water purification agent (Lewis 2001).  Another common 
source of manganese is found in the street drug “Bazooka”.  It is a cocaine-based drug contaminated with 
manganese-carbonate from free-base preparation methods (Ensing 1985).  
MMT is a fuel additive developed in the 1950s to increase the octane level of gasoline and thus improve 
the antiknock properties of the fuel (Davis 1998; EPA 1984; Lynam et al. 1990; NAS 1973).  MMT was
introduced into Canada in 1976 and its use increased so substantially that it completely replaced tetraethyl 
lead in gasoline in that country in 1990 (Zayed et al. 1999a). The major refiners in Canada have
voluntarily stopped using MMT, out of concern that its use may harm on-board diagnostic equipment
(OBD), which monitors the performance of emissions control devices in the vehicle (ICCT 2004).  As a
result, as much as 95% of Canadian gasoline is now MMT-free (ICCT 2004).  MMT was used as an 
additive in leaded gasoline in the United States; however, EPA banned its use in unleaded gasoline in
1977 (EPA 1978, 1979a, 1981).  In 1995, the ban on MMT use in unleaded gasoline was lifted, and a
court decision ordered EPA to register the product for use as a fuel additive (EPA 1995a).  Recent data
suggest that MMT is currently used only sparsely in the developed world including the United States, 
although exact quantities are not known (ICCT 2004).  Historical data suggest that approximately
70 million pounds of MMT were sold for use in leaded gasoline in the United States between 1976 and 
1990 (Veysseyre et al. 1998).
Mangafodipir trisodium (MnDPDP) is used as both a liver- and pancreas-specific contrast agent for
magnetic resonance imaging (MRI); it improves lesion detection in MRI of these organs by selectively
enhancing the normal parenchyma, but not lesions, so that the contrast between tumorous and normal
tissue is increased (Federle et al. 2000).
5.4 DISPOSAL
Manganese is listed as a toxic substance under Section 313 of the Emergency Planning and Community
Right to Know Act (EPCRA) under Title III of the Superfund Amendments and Reauthorization Act
(SARA) (EPA 1998).  Disposal of wastes containing manganese is controlled by a number of federal
regulations (see Chapter 8).
   
 









          
          
            
  
   
   
 
  
      
     
         
   





5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
Disposal of waste manganese into water requires a discharge permit from the EPA (see Chapter 8), but
disposal of solid wastes such as manganese metal or manganese compounds is not regulated under current
federal law.  There are incomplete federal records of this disposal because most, but not all, solid
manganese wastes are disposed of by being deposited on land or by being trucked to off-site disposal
facilities (TRI09 2011).  The total amount of waste manganese disposed of in this way in 2009 was
approximately 50 million pounds (TRI09 2011) (see Tables 6-1 and 6-2).   
Manganese and other metals are commonly recycled for future use.  In 1998, 218,000 metric tons of
manganese were estimated to have been recycled from old scrap, of which 96% was from iron and steel
scrap (USGS 2001).  In 2007, the USGS reported that manganese was recycled incidentally as a minor
constituent of ferrous and nonferrous scrap; however, scrap recovery specifically for manganese was 
negligible (USGS 2008).  No quantitative statistics were provided regarding the amount recovered from
steel slag.
No information on disposal of MMT was located.  
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6. POTENTIAL FOR HUMAN EXPOSURE 
6.1 OVERVIEW
Manganese has been identified in at least 869 of the 1,699 hazardous waste sites that have been proposed
for inclusion on the EPA National Priorities List (NPL) (HazDat 2007).  However, the number of sites
evaluated for manganese is not known. The frequency of these sites can be seen in Figure 6-1. Of these 
sites, 861 are located within the United States, 5 are located in the Commonwealth of Puerto Rico, 2 are
located in the Virgin Islands, and 1 is located in Guam (not shown).
Manganese is ubiquitous in the environment, and human exposure arises from both natural and
anthropogenic activities.  It occurs naturally in more than 100 minerals with background levels in soil
ranging from 40 to 900 mg/kg, with an estimated mean background concentration of 330 mg/kg 
(Barceloux 1999).  Manganese is released to the environment from industrial emissions, fossil fuel
combustion, and erosion of manganese-containing soils.  Volcanic eruptions can also contribute to levels 
of manganese in air.  Almost 80% of industrial emissions of manganese are attributable to iron and steel 
production facilities (EPA 2003a).  Power plant and coke oven emissions contribute about 20% (EPA
2003a).  Manganese may also be released to the environment through the use of MMT as a gasoline 
additive.  Thus, all humans are exposed to manganese, and manganese is a normal component of the
human body.
Background levels of manganese in the atmosphere vary widely depending on the proximity of point
sources, such as ferroalloy production facilities, coke ovens, and power plants.  The estimated average 
background concentration of manganese in urban areas is approximately 40 ng/m3, based on 
measurements obtained in 102 U.S. cities (EPA 2003a; WHO 2004b).  Concentrations near source
dominated areas were reported to range from 220 to 300 ng/m3 (WHO 2004b) and rural/remote levels are
typically under 10 ng/m3 (Sweet et al. 1993).  Manganese occurs naturally in surface water and 
groundwater.  A median dissolved manganese concentration of 24 μg/L in samples from 286 U.S. rivers
and streams was reported (Smith et al. 1987).  Natural concentrations of manganese in seawater
reportedly range from 0.4 to 10 μg/L (EPA 1984).
The general population is exposed to manganese primarily through food intake.  The World Health 
Organization (WHO) estimates that adults consume between 0.7 and 10.9 mg of manganese per day in the
diet, with higher intakes for vegetarians who may consume a larger proportion of manganese-rich nuts, 











6. POTENTIAL FOR HUMAN EXPOSURE
Figure 6-1.  Frequency of NPL Sites with Manganese Contamination 
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6. POTENTIAL FOR HUMAN EXPOSURE
Manganese intake from drinking water is substantially lower than intake from food.  Using a median 
drinking-water level of 10 μg/L and an assumption that the average adult drinks 2 L of water/day, an 
average intake of approximately 0.020 mg/day was estimated (WHO 2004b).  Exposure to manganese 
from air is considered negligible as compared to intake from diet; however, persons in certain occupations
may be exposed to much higher levels than the general public (see Section 6.7).  
Manganese adsorbed to particulate matter in air can be classified by the size of the particles.  Air
concentrations can be reported as total suspended particulate matter (TSP), respirable particulates, and
fine particulates.  In this document, manganese adsorbed to particulate matter <10 microns in
aerodynamic diameter is referred to as PM10. The EPA has further divided these tiny particles into "fine"
particles of ≤2.5 microns (PM2.5) and "coarse" particles of between 2.5 and 10 microns.
6.2 RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
According to the Toxics Release Inventory (TRI), in 2009, a total of 13,635,017 pounds (6,185 metric
tons) of manganese was released to the environment from 1,929 large processing facilities (TRI09 2011). 
An additional 162,358,105 pounds (73,644 metric tons) of manganese compounds were released from
1,656 facilities.  Tables 6-1, and 6-2 list the amount of manganese and manganese related compounds,
respectively, that were released from all of the facilities that manufacture or process manganese to each
medium within each state in 2009 (TRI09 2011). The TRI data should be used with caution because only
   
 









          
 
 
     





          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          






6. POTENTIAL FOR HUMAN EXPOSURE
Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or
Use Manganesea
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
AL 55 11,963 1,320 1 23,951 311 13,125 24,421 37,546
AR 33 5,802 271 0 37,088 164 6,044 37,281 43,325
AZ 16 1,360 22 0 906,639 0 907,918 103 908,021
CA 51 2,936 443 8 100,828 4,622 2,941 105,896 108,837
CO 16 957 50 0 24,347 0 962 24,392 25,354
CT 6 0 5 0 680 3 0 688 688
DE 1 0 0 0 8 0 0 8 8
FL 27 1,247 25 0 11,190 0 1,247 11,214 12,461
GA 46 2,375 910 0 19,308 106 2,668 20,032 22,699
IA 65 15,236 2,561 0 315,743 96,802 25,560 404,782 430,341
ID 1 0 0 0 0 0 0 0 0
IL 115 8,258 1,903 398 143,228 128,530 8,809 273,508 282,317
IN 128 31,067 10,708 0 210,384 7,914 31,725 228,349 260,074
KS 43 13,393 282 0 446,709 118,248 420,378 158,254 578,632
KY 57 19,213 3,923 0 66,913 17,385 21,772 85,661 107,433
LA 38 11,298 2,734 0 168,828 2,736 84,718 100,878 185,596
MA 14 858 1 0 1,308 1,518 858 2,827 3,686
MD 11 47 226 0 0 86 47 312 359
ME 4 258 14 0 16 242 258 272 530
MI 84 6,564 2,753 0 488,199 7,930 7,350 498,096 505,446
MN 36 3,321 56 0 30,877 8 3,326 30,936 34,262
MO 51 356,385 1,168 0 19,424 1 368,134 8,844 376,978
MS 28 8,949 193 0 21,617 0 11,805 18,954 30,759
MT 2 0 0 0 167,254 0 167,254 0 167,254
NC 50 1,627 190 0 6,455 7,618 1,643 14,247 15,890
ND 6 685 260 0 530 5 695 785 1,480
NE 17 1,504 258 0 42,241 240 1,511 42,732 44,242
NH 6 11 0 0 0 0 11 0 11
NJ 9 425 0 0 149,540 0 425 149,540 149,965
NM 1 0 0 0 0 0 . 0 0
NV 12 345 0 0 77,599 0 76,860 1,084 77,944
NY 33 1,269 4,379 0 72,506 662 3,870 74,946 78,816
OH 155 14,141 36,557 0 5,481,604 270,842 4,969,747 833,397 5,803,145
OK 72 3,691 18 0 39,556 0 3,692 39,573 43,265
OR 15 318 0 0 90,679 713 90,651 1,059 91,710
   
 








          
 
 
     





          
          
          
          
          
          
          
          
          
          
          
          
          
          
 
            
     
       
    
   
        
         
  
       
          
     
        
  
          
       
 
      
 





































6. POTENTIAL FOR HUMAN EXPOSURE
Table 6-1.  Releases to the Environment from Facilities that Produce, Process, or
Use Manganesea
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
PA 143 237,541 9,250 0 761,198 67,434 512,022 563,402 1,075,423
PR 1 0 0 0 0 0 0 0 0
RI 2 0 0 0 0 0 0 0 0
SC 44 3,457 1,797 0 70,141 44 36,297 39,142 75,439
SD 13 1,118 3 0 9,444 728 5,201 6,092 11,293
TN 58 5,908 576 0 148,202 1,259 49,857 106,088 155,945
TX 139 17,392 11,813 5,312 101,237 3,570 53,830 85,494 139,324
UT 20 1,764 10 0 30,054 0 29,506 2,322 31,828
VA 26 1,111 29 0 24,847 4,117 1,111 28,993 30,104
WA 23 2,604 3,155 0 166,537 479 6,548 166,228 172,776
WI 147 129,960 1,201 0 1,273,787 2,489 132,938 1,274,499 1,407,437
WV 5 2,020 1,288 0 1,566 40 2,052 2,862 4,915
WY 4 347 0 0 101,109 0 101,456 0 101,456
Total 1,929 928,727 100,353 5,719 11,853,373 746,845 8,166,823 5,468,193 13,635,017
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an 
exhaustive list. Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for
disposal, unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
kTotal amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection
Source: TRI09 2011 (Data are from 2009)
   
 






RFd Aire   
 69  26,726
b    Reported amounts released in pounds per year  
  Total release
 On- and 
f i j k UIg Water    Landh Other  On-site  Off-site   off-site
 785,399  0  4,807,610  696,690  4,618,951  1,697,473  6,316,424
 AK  7  28,562  2,195  0  1,077,747  7,103  1,081,419  34,188  1,115,607
 AZ  19  4,972  256  0  1,269,078  57,022  1,055,480  275,848  1,331,329
 AR  45  18,356  436,835  0  1,501,825  430,133  1,906,316  480,834  2,387,150
 CA  32  3,155  3,639  0  250,073  5,866  87,700  175,034  262,734
CO  24  6,502  7,921  0  1,647,793  187  1,327,931  334,472  1,662,403
CT  9  329  319  0  38,700  6,197  638  44,907  45,545
 DE  8  571  34,677  0  1,795,738  0  89,415  1,741,571  1,830,986
 DC  3  0  1,862  0  7,665  0  9,527  0  9,527
 FL  33  9,512  183,588  0  1,856,695  7,957  1,639,719  418,033  2,057,752
GA  60  24,740  695,336  0  1,955,991  6,876  2,396,106  286,837  2,682,943
 HI  1  57  0  0  37,976  0  57  37,976  38,033
 ID  14  650  133,402  0  18,440,929  309  18,292,599  282,690  18,575,289
 IL  81  70,640  17,478  0  6,925,832  1,114,421  1,487,271  6,641,100  8,128,371
 IN  80  98,896  86,034  24,700  12,313,396  102,985  7,874,506  4,751,505  12,626,011
 IA  46  40,933  4,540  0  1,388,935  897,867  311,337  2,020,939  2,332,275
 KS  20  6,716  371  250  345,067  299  327,527  25,176  352,703
 KY  46  79,582  127,043  0  2,467,702  40,720  2,022,163  692,884  2,715,047
 LA  24  14,454  287,076  0  5,374,839  55,278  5,308,597  423,050  5,731,647
ME  10  11,053  341,643  0  552,090  92,185  732,267  264,704  996,971
MD  28  14,032  110,411  30,462  1,064,434  156,798  1,132,173  243,964  1,376,137
MA  6  488  10,819  0  17,806  9,564  1,987  36,690  38,677
MI  56  18,463  52,592  370  1,894,107  58,388  986,770  1,037,149  2,023,919
MN  36  11,395  58,458  0  1,369,277  17,384  1,370,866  85,648  1,456,514
MS  37  13,873   426,666 9,479,269  8,428,879  140,005  17,150,435  1,338,257  18,488,692
 MO  45  10,884  17,685  0  719,070  14,005  363,708  397,936  761,643
MT  7  8,671  20,878  0  1,778,158  67,592  1,628,974  246,325  1,875,299
 NE  19  13,635  264  0  268,939  48,505  280,654  50,689  331,343
 NV  13  8,857  17  0  10,146,579  0  8,249,878  1,905,576  10,155,454
 NH  4  1,023  597  0  24,082  4,130  5,721  24,112  29,833
NJ  12  1,081  11,936  0  122,998  0  13,017  122,998  136,015
 NM  6  3,000  311  0  968,320  0  971,631  0  971,631
 NY  21  4,215  76,763  0  611,484  22,150  243,143  471,469  714,613
 NC  55  17,845  207,682  0  2,056,521  59,722  1,578,832  762,939  2,341,770
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Table 6-2. Releases to the Environment from Facilities that Produce, Process, or
Use Manganese Compoundsa
   
 








           
   
 
     





          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
          
 
            
     
      
    
   
        
         
  
       
          
     
         
 
          
       
 
      
 





































6. POTENTIAL FOR HUMAN EXPOSURE
Table 6-2. Releases to the Environment from Facilities that Produce, Process, or
Use Manganese Compoundsa
Reported amounts released in pounds per yearb 
Total release
On- and 
Statec RFd Aire Waterf UIg Landh Otheri On-sitej Off-sitek off-site
OH 131 197,569 177,737 35,502 6,308,073 530,421 4,419,743 2,829,558 7,249,301
OK 28 9,552 57,795 0 707,517 112,652 602,049 285,467 887,516
OR 17 5,151 74,703 0 841,241 3 320,278 600,820 921,098
PA 133 54,376 211,669 0 8,526,704 221,617 4,342,438 4,671,927 9,014,365
PR 4 8,372 5 0 7,430 0 8,372 7,435 15,807
SC 37 20,380 237,802 0 3,048,315 74,168 1,995,186 1,385,479 3,380,665
SD 7 217 0 0 27,926 0 25,293 2,850 28,143
TN 52 42,279 160,029 0 12,144,425 11,702 11,659,763 698,672 12,358,434
TX 105 44,308 183,435 0 6,434,013 80,394 5,964,959 777,191 6,742,149
UT 18 5,829 1,000 0 1,029,393 854 921,556 115,520 1,037,076
VT 2 26 0 0 0 254 26 254 280
VA 33 12,555 195,010 0 1,621,846 15,981 650,455 1,194,937 1,845,392
WA 17 1,820 150,906 0 597,144 11,468 555,305 206,032 761,337
WV 22 158,447 12,263 0 1,430,843 3,600 1,187,721 417,432 1,605,153
WI 58 11,891 116,789 0 1,395,609 164,597 348,429 1,340,457 1,688,886
WY 7 8,266 1,052 0 926,764 636 880,588 56,130 936,718
Total 1,656 1,166,362 5,741,194 9,570,553 140,526,147 5,353,849 119,462,992 42,895,113 162,358,105
aThe TRI data should be used with caution since only certain types of facilities are required to report. This is not an 
exhaustive list. Data are rounded to nearest whole number.
bData in TRI are maximum amounts released by each facility.
cPost office state abbreviations are used.
dNumber of reporting facilities.
eThe sum of fugitive and point source releases are included in releases to air by a given facility.
fSurface water discharges, waste water treatment-(metals only), and publicly owned treatment works (POTWs) (metal
and metal compounds).
gClass I wells, Class II-V wells, and underground injection.
hResource Conservation and Recovery Act (RCRA) subtitle C landfills; other onsite landfills, land treatment, surface 
impoundments, other land disposal, other landfills.
iStorage only, solidification/stabilization (metals only), other off-site management, transfers to waste broker for disposal,
unknown
jThe sum of all releases of the chemical to air, land, water, and underground injection wells.
kTotal amount of chemical transferred off-site, including to POTWs.
RF = reporting facilities; UI = underground injection
Source: TRI09 2011 (Data are from 2009)
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6. POTENTIAL FOR HUMAN EXPOSURE
certain types of facilities are required to report. This is not an exhaustive list.  Also, because these data 
reflect past releases, they may not be representative of current releases at these facilities.
Manganese may also be emitted to the environment through the use of gasoline that contains MMT;
however, no data on the amount of MMT that is currently being used in gasoline in the United States were
located.  No data for releases of mangafodipir to the environment were found.  Because mangafodipir is a
compound used exclusively in a clinical environmental, it is not expected to be released to the 
environment and will not be discussed in subsequent sections concerning fate and transport.
6.2.1 Air
Estimated releases of 928,727 pounds (421 metric tons) of manganese to the atmosphere from
1,929 domestic manufacturing and processing facilities in 2009, accounted for about 6.8% of the
estimated total environmental releases from facilities required to report to the TRI (TRI09 2011).  
Estimated releases of 1,166,362 pounds (530 metric tons) of manganese compounds to the atmosphere
from 1,656 domestic manufacturing and processing facilities in 2009, accounted for about 0.7% of the
estimated total environmental releases from facilities required to report to the TRI (TRI09 2011).  These 
releases are summarized in Tables 6-1 and 6-2. 
According to data from the National Pollutant Release Inventory (NPRI) maintained by Environment
Canada, approximately 273.9 metric tons of manganese were released to air in Canada in 2003 from
various industrial sources (Health Canada 2008). The major industrial sources for manganese emissions 
in Canada were attributed to an iron-ore mine located in Labrador, iron- and steel-related industries, 
pulp/paper/newsprint mills, fossil fuel electric power generation, and the manufacturing of heating and 
commercial refrigeration equipment.
The amount of manganese compounds emitted to air in 2005 was estimated in the EPA's National
Emission Inventory (NEI) database. This database contains detailed information about sources that emit
criteria air pollutants and their precursors, and hazardous air pollutants for the 50 United States,
Washington DC, Puerto Rico, and the U.S. Virgin Islands.  The NEI database derives emission data from
several sources including state and local environmental agencies, the TRI database, computer models for
on- and off-road emissions, and databases related to EPA's Maximum Achievable Control Technology
(MACT) programs to reduce emissions of hazardous air pollutants.  Data are available as zipped
Microsoft Access database files that may be accessed directly from the EPA website (EPA 2011). For
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2005, approximately 2,134 tons of manganese were released to air with the greatest contribution arising
from point sources involving industrial metals processing and combustion processes.
Manganese has been identified in air samples collected at 31 of the 869 NPL hazardous waste sites where 
it was detected in some environmental media (HazDat 2007).
The main sources of manganese release to the air are industrial emissions, combustion of fossil fuels, and
reentrainment of manganese-containing soils (EPA 1983c, 1984, 1985c, 1985d, 1987a; Lioy 1983).  The
principal sources of industrial emissions are ferroalloy production and iron and steel foundries, and the
principal sources of combustion emissions are power plants and coke ovens (EPA 1983c, 1985c, 1985d).  
Atmospheric emissions of manganese and other trace metals from these industrial sources have declined
over the last 2 decades due to the use of advanced pollution control devices and increased government
regulations regarding these emissions (EPA 1984, 1985d).  
Windblown erosion of dusts and soils is also an important atmospheric source of manganese.  Wallace 
and Slonecker (1997) estimated that the background contribution of windblown soil to fine particulate
atmospheric manganese levels was 1–2 ng/m3 in the United States and Canada. Volcanic eruptions may
also release manganese to the atmosphere (Schroeder et al. 1987).
MMT is a manganese-containing compound used to enhance the octane rating in gasoline.  MMT was
used as an additive in leaded gasoline until the phase-out of leaded gas in the United States in 1995.  It
was also used in unleaded gasoline for a short period of time in the late 1970’s, but was banned as an 
additive in unleaded gasoline by EPA in 1977 (EPA 1978, 1979a, 1981).  In 1995, the ban on MMT use
in unleaded gasoline was lifted, and a court decision ordered EPA to register the product for use as a fuel
additive, although testing for health effects continues (EPA 1995a).  Analysis of manganese levels in the
air indicates that vehicular emissions from MMT containing fuels contributed an average of 13 ng 
manganese/m3 in southern California, while vehicular emissions were only responsible for about 3 ng/m3 
in central and northern California (Davis et al. 1988).  A survey of ambient air concentrations of fine
(PM2.5) manganese in rural sites in U.S. national parks and in urban sites in California indicated that from
1988 to 1993, ambient concentrations of manganese ranged from 1 ng/m3 in rural sites to 3 ng/m3 in urban
sites (Wallace and Slonecker 1997).  Part of the increase in fine manganese during this period was 
considered to be the result of the use of MMT in leaded gasoline.  It was estimated that automobile
emissions from leaded gasoline were responsible for 37% of the fine manganese levels in California in
1992. In 1994, automobile emissions were estimated to contribute 12% of the fine manganese levels in 
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the atmosphere, as the use of leaded gasoline declined.  It has been estimated that if MMT were used in
all gasoline, urban air manganese levels would be increased by about 50 ng/m3 (Cooper 1984; Ter Haar
et al. 1975).  Other authors have estimated that the increase in atmospheric manganese levels would be 
<20 ng/m3 (Lynam et al. 1994). 
In Canada, where the use of MMT containing gasoline has been extensive, a 10% per year increase in
manganese emission rates from MMT in gasoline since 1981 was estimated (Loranger and Zayed 1994).
A positive correlation between atmospheric manganese concentration and traffic density has been
observed (Loranger and Zayed 1997a; Loranger et al. 1994a).  The principal emission product of MMT
combustion is a fine particulate matter (0.1–0.4 μm diameter) consisting of manganese oxide (Egyed and 
Wood 1996; Ter Haar et al. 1975), manganese phosphate, and some manganese sulfate (Lynam et al.
1999).  The finding of soluble manganese (<0.4 μm) in snow samples obtained close to a highway in 
Montreal, Canada suggested a possible contamination from mobile sources (Loranger and Zayed 1997a;
Loranger et al. 1995).  However, it has been difficult to assess the exact contribution of mobile sources to
overall contamination from natural and industrial sources because of the physico-chemical characteristics 
of manganese particulate, environmental factors affecting its dispersion, and the difficulties in
distinguishing between mobile sources of manganese and background manganese levels (Loranger and 
Zayed 1997a; Veysseyre et al. 1998).  
Despite the estimated 10% per year increase in manganese emission rates from the use of MMT in
gasoline in Canada, atmospheric manganese concentrations in Montreal have remained fairly constant
between 1981 and 1990, and have decreased markedly in 1991 and 1992 (Loranger and Zayed 1994).  
The decline in manganese concentration after 1990 may have been due to a shutdown in 1991 of a
ferromanganese plant located near Montreal.  Air concentrations are in general below the EPA reference 
concentration (RfC) of 0.05 μg/m3 for respirable manganese.  However, in 1998, it was observed that
some atmospheric concentrations in specific microenvironments with important traffic density were 
higher than the RfC (Zayed et al. 1999a).  
6.2.2 Water
Estimated releases of 103,53 pounds (46 metric tons) of manganese to water from 1,929 domestic
manufacturing and processing facilities in 2009, accounted for about 0.1% of the estimated total
environmental releases from facilities required to report to the TRI (TRI09 2011).  Estimated releases of
5,741,194 pounds (2,604 metric tons) of manganese compounds to water from 1,656 domestic
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manufacturing and processing facilities in 2009, accounted for about 3.5% of the estimated total
environmental releases from facilities required to report to the TRI (TRI09 2011). These releases are
summarized in Tables 6-1 and 6-2. 
Manganese has been identified in surface water and groundwater samples collected at 392 and 692, 
respectively, of the 869 NPL hazardous waste sites where it was detected in some environmental media 
(HazDat 2007).
Based on comparison to typical background levels of manganese in surface water or groundwater (see
Section 6.4.2), it seems likely that some waste sites where manganese is detected contain only natural 
levels.  Although ambient manganese levels are about 200 μg/L in a number of cases, high levels (in 
excess of 1,000 μg/L) have been detected indicating that manganese wastes may lead to significant
contamination of water at some sites.  For example, at one site in Ohio where "heavy metals" had been
disposed, manganese concentrations up to 1,900 μg/L were found in on-site wells (Cooper and Istok
1988).  Levels in water at two NPL sites in Missouri ranged from 0.009 to 3.7 μg/L (MDNR 1990).  No
information is available on the method used to determine these values, so it is not clear whether the data 
refer to total or dissolved manganese.
6.2.3 Soil 
Estimated releases of 11,853,373 pounds (5,377 metric tons) of manganese to soil from 1,929 domestic 
manufacturing and processing facilities in 2009, accounted for about 87% of the estimated total
environmental releases from facilities required to report to the TRI (TRI09 2011).  An additional 5,719 
pounds (2.6 metric tons) were injected underground. Estimated releases of 140,526,147 pounds (63,742 
metric tons) of manganese compounds to the soil from 1,656 domestic manufacturing and processing
facilities in 2009, accounted for about 87% of the estimated total environmental releases from facilities 
required to report to the TRI (TRI09 2011).  An additional 9,570,553pounds (4,341 metric tons) were
injected underground.  These releases are summarized in Tables 6-1 and 6-2.
Manganese deposition to soils from the use of MMT in gasoline was estimated for two sites in Toronto, 
Canada (Bhuie et al. 2005).  Accounting for variables such as annual average daily traffic (AADT)
density, fuel consumption, distance traveled by automobiles, and a manganese content of 10 mg/L of
gasoline, the annual average manganese contribution to soils from MMT emissions were calculated as 
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5.73 and 2.47 mg/kg at two sites (Bhuie et al. 2005).  These concentrations were considered insignificant
when compared to natural background manganese levels (541 and 557 mg/kg) in soil for these areas.
Manganese has been identified in soil and sediment, samples collected at 355 and 257, respectively, of the 
869 NPL hazardous waste sites where it was detected in some environmental media (HazDat 2007).
6.3 ENVIRONMENTAL FATE
6.3.1 Transport and Partitioning
Manganese compounds have negligible vapor pressures (see Table 4-2), but may exist in air as suspended 
particulate matter derived from industrial emissions or the erosion of soils. Manganese-containing 
particles are mainly removed from the atmosphere by gravitational settling, with large particles tending to 
fall out faster than small particles (EPA 1984). The half-life of airborne particles is usually on the order
of days, depending on the size of the particle and atmospheric conditions (Nriagu 1979).  Some removal
by washout mechanisms such as rain may also occur, although it is of minor significance in comparison
to dry deposition (EPA 1984; Turner et al. 1985).  
In a study completed by Evans (1989), there were two mechanisms involved in explaining the retention of
manganese and other metals in the environment by soil.  First, through cation exchange reactions, 
manganese ions and the charged surface of soil particles form manganese oxides, hydroxides, and 
oxyhydroxides, which in turn form absorption sites for other metals.  Secondly, manganese can be
adsorbed to other oxides, hydroxides, and oxyhydroxides through ligand exchange reactions.  When the
soil solution becomes saturated, these manganese oxides, hydroxides, and oxyhydroxides can precipitate
into a new mineral phase and act as a new surface to which other substances can absorb (Evans 1989). 
The behavior of heavy metals in the combustion gases of urban waste incinerators was studied by
Fernandez et al. (1992). Manganese was detected inside gaseous fly ash particles in the form of oxides 
and chlorides.  When these soluble oxides and chlorides reach environmental media, they can leach out
and become mobile (Fernandez et al. 1992).
The transport of manganese in air is largely determined by its particle size.  About 80% of the manganese
in suspended particulate matter is associated with particles having a mass median aerodynamic diameter
(MMAD) of <5 μm (WHO 1981).  The compound’s small particle size (approximately 80% with a 
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MMAD <5 μm and approximately 50% with an MMAD <2 μm) favors widespread airborne distribution 
and is within the respirable range (WHO 1981).
The transport and partitioning of manganese in water is controlled by the solubility of the specific
chemical form present, which in turn is determined by pH, Eh (oxidation-reduction potential), and the
characteristics of the available anions. The metal may exist in water in any of four oxidation states;
however, Mn(II) predominates in most waters (pH 4–7), but may become oxidized under alkaline
conditions at pH >8 (EPA 1984).  The principal anion associated with Mn(II) in water is usually
carbonate (CO3–2), and the concentration of manganese is limited by the relatively low solubility
(65 mg/L) of manganese carbonate (Schaanning et al. 1988).  Under oxidizing conditions, the solubility of
Mn(II) may be controlled by manganese oxide equilibria (Ponnamperuma et al. 1969), with manganese
being converted to the Mn(II) or Mn(IV) oxidation states (Rai et al. 1986).  In extremely reduced water, 
the fate of manganese tends to be controlled by formation of a poorly soluble sulfide (EPA 1984).  
Manganese is often transported in rivers as suspended sediments.  It has been reported that most of the
manganese in a South American river came from industrial sources and was bound to suspended particles 
in the water (Malm et al. 1988).
In an aquifer studied in France, manganese was shown to originate from within the aquifer itself (Jaudon
et al. 1989).  In the presence of decreased dissolved oxygen in the groundwater, Mn(IV) has been shown 
to be reduced both chemically and bacterially into the Mn(II) form (Jaudon et al. 1989).  This oxidation 
state is water soluble and easily released into the groundwater.
Manganese in water may be significantly bioconcentrated at lower trophic levels. A bioconcentration
factor (BCF) relates the concentration of a chemical in plant and animal tissues to the concentration of the
chemical in the water in which they live.  Folsom et al. (1963) estimated that the BCFs of manganese
were 2,500–6,300 for phytoplankton, 300–5,500 for marine algae, 800–830 for intertidal mussels, and 
35–930 for coastal fish.  Similarly, Thompson et al. (1972) estimated that the BCFs of manganese were 
10,000–20,000 for marine and freshwater plants, 10,000–40,000 for invertebrates, and 100–600 for fish.  
In general, these data indicate that lower organisms such as algae have larger BCFs than higher
organisms.  In order to protect consumers from the risk of manganese bioaccumulation in marine 
mollusks, EPA has set a criterion for manganese at 0.1 mg/L for marine waters (EPA 1993b).
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The tendency of soluble manganese compounds to adsorb to soils and is dependent upon the cation
exchange capacity and the organic composition of the soil (Curtin et al. 1980; Hemstock and Low 1953;
Kabata-Pendias and Pendias 1984; McBride 1979; Schnitzer 1969).  Baes and Sharp (1983) noted that
soil adsorption constants (the ratio of the concentration in soil to the concentration in water) for Mn(II)
span five orders of magnitude, ranging from 0.2 to 10,000 mL/g, increasing as a function of the organic 
content and the ion exchange capacity of the soil; thus, adsorption may be highly variable.  In some cases, 
adsorption of manganese to soils may not be a readily reversible process. At low concentrations,
manganese may be "fixed" by clays and will not be released into solution readily (Reddy and Perkins
1976).  At higher concentrations, manganese may be desorbed by ion exchange mechanisms with other
ions in solution (Rai et al. 1986).  For example, the discharge of waste water effluent into estuarine 
environments resulted in the mobilization of manganese from the bottom sediments (Helz et al. 1975;
Paulson et al. 1984).  The metals in the effluent may have been preferentially adsorbed resulting in the 
release of manganese.
6.3.2 Transformation and Degradation
6.3.2.1 Air
Very little information is available on atmospheric reactions of manganese (EPA 1984). Manganese can
react with sulfur dioxide and nitrogen dioxide, but the occurrence of such reactions in the atmosphere has
not been demonstrated.
MMT undergoes photolysis rapidly by sunlight in the atmosphere or in aqueous solutions with a very
short half-life (i.e., <2 minutes) (Ter Haar et al. 1975; Garrison et al. 1995). The photodegradation
products tentatively identified in aqueous photolysis experiments were methylcyclopentadiene, 
cyclopentadiene, carbon monoxide, manganese carbonyl, and trimanganese tetroxide (Garrison et al.
1995).  Undegraded MMT is not likely to be released directly to the atmosphere in significant quantities
from it intended use as a gasoline additive.  Spectroscopic studies of the tailpipe emissions of
MMT-containing gasoline indicated that the manganese in MMT is converted to a mixture of solid
manganese oxides, sulfates, and phosphates. The manganese containing particulates were determined to
be Mn3O4, MnSO4·H2O and a divalent manganese phosphate, Mn5(PO4)[PO3(OH)]2·4H2O (Mölders et al. 
2001; Ressler et al. 2000).  
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6.3.2.2 Water
Manganese in water may undergo oxidation at high pH or Eh (see Section 6.3.1) and is also subject to 
microbial activity.  For example, Mn(II) in a lake was oxidized during the summer months, but this was
inhibited by a microbial poison, indicating that the oxidation was mediated by bacteria (Johnston and 
Kipphut 1988).  The microbial metabolism of manganese is presumed to be a function of pH, 
temperature, and other factors, but no data were located on this.
The rate of MMT degradation in natural aquifer and sediment systems was determined to be very slow
under anaerobic conditions (Garrison et al. 1995).  Calculated half-lives ranged from approximately 0.2 to 
1.5 years at 25 °C.  However, MMT photolyzed rapidly in purified, distilled water exposed to sunlight.  
The disappearance of MMT followed first-order kinetics, with a calculated half-life of 0.93 minutes.  
Reaction products included methylcyclopentadiene, cyclopentadiene, carbon monoxide, and a manganese 
carbonyl that readily oxidized to trimanganese tetroxide.  
6.3.2.3 Sediment and Soil
The oxidation state of manganese in soils and sediments may be altered by microbial activity.  Geering
et al. (1969) observed that Mn(II) in suspensions of silt or clay loams from several areas of the United
States was oxidized by microorganisms, leading to the precipitation of manganese minerals.  Other
studies (Francis 1985) have shown that bacteria and microflora can increase the mobility of manganese in
coal-waste solids by increasing dissolution of manganese in subsurface environments.
MMT was found to be stable in a stream bottom sediment under anaerobic conditions.  Photodegradation 
of MMT is not likely to occur in sediments, and it may equilibrate between the sediment, sediment
porewater, and water column manganese (Garrison et al. 1995).  
6.4 LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to manganese depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of
manganese in unpolluted atmospheres and in pristine surface waters are often so low as to be near the
limits of current analytical methods.  In reviewing data on manganese levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
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equivalent to the amount that is bioavailable. The analytical methods available for monitoring manganese 
in a variety of environmental media are detailed in Chapter 7.
6.4.1 Air
Table 6-3 summarizes historic manganese air level data collected over a period of nearly 30 years from
numerous urban, nonurban, and source-dominated areas of the United States.  Direct comparisons of data 
from different time periods are complicated because of changes in sample collection and analytical
methodology.  However, it is clear that manganese levels tend to be higher in source-dominated and urban
areas than in nonurban areas. These data also indicate that concentrations in all areas have tended to
decrease over the past three decades (EPA 1984; Kleinman et al. 1980). This decrease came as the result
of the installation of emission controls in the metals industry (EPA 1984, 1985d).  A concurrent decrease
in total suspended particulates (TSP) was observed in most areas.  Ambient air levels of manganese (PM10 
and PM2.5) in Canadian locations monitored from the late 1980s through the early 2000s were reported to 
have a 13–77% reduction over that time period (Health Canada 2008). Annual averages of manganese in
urban and rural areas without significant manganese pollution are in the range of 10–70 ng/m3 (0.01– 
0.07 μg/m3) (WHO 1997).  The daily intake of manganese in the air by the general population in areas
without manganese emitting industries was estimated to be <2 μg/day (WHO 1981).  In areas with major
foundry facilities, intake may rise to 4–6 μg/day, and in areas associated with ferro- or silicomanganese 
industries, it may be as high as 10 μg, with 24-hour peak values exceeding 200 μg/day (WHO 1981).
Data compiled for 2006 under the EPA Urban Air Toxics Monitoring Program, studied ambient air levels
of manganese and several other metals at 20 urban locations across the United States.  Manganese (PM10) 
was detected in 415 samples of urban air at levels ranging from 0.24 to 89.10 ng/m3 (EPA 2007b).  The
arithmetic mean, geometric mean, and median concentrations were 10.13, 6.68, and 6.29 ng/m3, 
respectively.  Manganese levels ranged from 0.85 to 614.00 ng/m3 in 114 samples of total suspended 
particulates (TSP) at these 20 urban locations. The arithmetic mean, geometric mean, and median
concentrations of manganese in TSP were 47.89, 22.39, and 23.98 ng/m3, respectively.
During 1988–1993, ambient concentration of fine (PM2.5) manganese ranged from 1 ng/m3 (0.001 μg/m3) 
in rural sites in U.S. National Parks to 3 ng/m3 (0.003 μg/m3) in urban sites in California (Wallace and 
Slonecker 1997).  There is concern in Canada regarding the combustion of MMT as an important source
of manganese contamination in the urban environment, especially in areas of high traffic density.  For
instance, Loranger and Zayed (1997a) reported significantly higher levels of both respirable and total
manganese levels at a high traffic density site (24 and 50 ng/m3, respectively) in Montreal in contrast to a 
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Table 6-3. Average Levels of Manganese in Ambient Aira 
Concentration (ng/m3)
Sampling location 1953–1957 1965–1967 1982
Nonurban 60 12 5
Urban 110 73 33
Source dominated No data 250–8,300 130–140
aAdapted from EPA 1984
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low traffic density site (15 and 27 ng/m3, respectively).  Temporal variation of respirable and total
manganese was similar for both sites, and atmospheric manganese concentrations reflected a positive 
relationship with the traffic density.  However, as discussed in Section 6.2.1, it has been difficult to assess 
the exact contribution of the combustion of MMT by vehicles to manganese levels in the environment. 
In Montreal, Canada, ambient atmospheric concentrations of MMT, and respirable and total manganese, 
were measured in five microenvironments including a gas station, an underground car park, downtown 
Montreal, near an expressway, and near an oil refinery (Zayed et al. 1999a).  The overall mean 
concentrations of respirable manganese, total manganese, and MMT measured for all the
microenvironments were 36, 103, and 5 ng/m3, respectively (0.036, 0.103, and 0.005 μg/m3); however, 
the mean respirable manganese concentration 53 ng/m3 (0.053 μg/m3) near the expressway was greater
than the EPA Reference Concentration (RfC) of 0.05 μg/m3. 
The Canadian National Air Pollution Surveillance (NAPS) Program reported that average fine (PM2.5) 
manganese levels from 2003 to 2005 in cities with industrial sources (Windsor and Hamilton) were 9– 
15 ng/m3 (Health Canada 2008).  In Vancouver, Winnipeg, Montreal, Quebec, Toronto, and Edmonton, 
the average levels were 4–14 ng/m3. In Saskatoon, Ottawa, Victoria, St. John, and background sites,
levels were <5 ng/m3.  NAPS also reported manganese PM10 levels were: 20–60 ng/m3 in Hamilton and 
Windsor; 8–25 ng/m3 in Montreal, Toronto, Edmonton, Winnipeg, Quebec, Calgary, Vancouver, and 
Victoria; and generally <10 ng/m3 in Saskatoon, Ottawa, St. John, Yellowknife, and background sites
(Health Canada 2008).
Studies were conducted in Indianapolis, Indiana and Toronto, Canada to assess levels of PM2.5 and PM10 
manganese in indoor, outdoor, and personal air samples (Pellizzari et al. 1999, 2001).  The levels
observed in Toronto, where MMT had been used in gasoline for over 20 years, were approximately
2 times greater in indoor and outdoor air than in Indianapolis, where MMT was not being used as a
gasoline additive. The monitoring data from these studies are summarized in Table 6-4. 
6.4.2 Water
Many factors, both environmental (e.g., the presence of high or low levels of other inorganics in drinking 
water) and biological or host-related (e.g., age, nutritional status, and alcohol consumption) can 
significantly influence the uptake of manganese by an individual (EPA 1993b).  The determination of a
   
 









           
  
 




    
     
    
     
  
    
     
    
     
Table 6-4.  Levels of PM2.5 and PM10 in Indoor and Outdoor Air in Toronto, Canada
and Indianapolis, Indiana
Median concentration 90th concentration 
Location Number (ng/m3) (ng/m3)
PM10 Manganese
Toronto (indoor) 203 6.7 14
Indianapolis (indoor) 59 3.9 8.7
Toronto (outdoor) 203 17 28
Indianapolis (outdoor) 59 8.8 14
PM2.5 Manganese
Toronto (indoor) 187 4.7 9.9
Indianapolis (indoor) 58 2.2 4.6
Toronto (outdoor) 185 8.6 16
Indianapolis (outdoor) 57 3.2 5.8
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Sources: Pellizzari et al. 1999, 2001
   
 








       
  
 
        
          
          
  
   
  
          
 
    
           
    
         
     
 
  
    
         




   





   
MANGANESE 402
6. POTENTIAL FOR HUMAN EXPOSURE
single concentration of manganese in drinking water, then, must be recognized as a process that is limited
in its ability to reflect the variable nature of manganese toxicity (EPA 1993b).
Concentrations of manganese in surface water are usually reported as dissolved manganese.  Although
total manganese may be a better indicator, since manganese adsorbed to suspended solids may exceed
dissolved manganese in many systems, the bioavailability of manganese in this form has not been
established (EPA 1984; NAS 1977).  In a 1962–1967 survey of U.S. surface waters, dissolved manganese 
was detected in 51% of 1,577 samples, at a mean concentration of 59 μg/L.  Individual values ranged 
from 0.3 to 3,230 μg/L.  Mean concentrations for 15 different drainage basins in the United States ranged 
from 2.3 μg/L in the western Great Lakes to 232 μg/L in the Ohio River drainage basin (Kopp and Kroner
1967).  A later (1974–1981) survey of U.S. river waters reported a median dissolved manganese 
concentration of 24 μg/L in samples from 286 locations, with values ranging from <11 μg/L (25th 
percentile) to >51 μg/L (75th percentile) (Smith et al. 1987).  Analyzing data available from the USGS
National Water Quality Assessment (NAWQA) database, the EPA reported that the median concentration
of manganese was 16 μg/L for surface water and 5 μg/L for groundwater from 20 watersheds and
16 drainage basins in the United States (EPA 2003a). The results of this analysis for all sites are 
reproduced in Table 6-5. Reported mean groundwater concentrations of manganese were 20 and 90 μg/L
in an analysis of California shallow groundwater from two geologic zones (Deverel and Millard 1988).  
Values up to 1,300 and 9,600 μg/L have been reported in neutral and acidic groundwater, respectively
(EPA 1984).  Manganese levels of 9,500–18,600 μg/L have been reported in four private wells in 
Connecticut (CDHS 1990).  Natural concentrations of manganese in seawater reportedly range from
0.4 to 10 μg/L (EPA 1984).
A 1962 survey of public drinking water supplies in 100 large U.S. cities reported that 97% contained 
<100 μg/L of manganese (USGS 1964).  Similarly, a 1969 survey of 969 systems reported that 91%
contained <50 μg/L, with a mean concentration of 22 μg/L (U.S. DHEW 1970).  Several other studies
reported similar manganese concentrations, with mean values ranging from 4 to 32 μg/L (EPA 1984;
NAS 1980a; WHO 1981).  The EPA analyzed drinking water statistics from Alabama, California, Illinois, 
New Jersey, and Oregon for occurrence and concentration data for manganese in public water supplies.  
The data used contained >37,000 analytical results from about 4,000 public water supplies from 1993 to 
1997, although some prior monitoring data were also employed in the analysis.  The median manganese
level for all detections was 10 μg/L and the 99th percentile of the detections was 720 μg/L (EPA 2003a).  
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Table 6-5.  Manganese Detections and Concentrations in Surface Water and
Groundwater in the United States
Detection frequency
Above the minimal Above the health reference 
reporting level (1 μg./L) levela (300 μg/L) Concentration (μg/L)
Samples Sites Samples Sites Median 99th
Surface water
Urban 99.1% 99.6% 4.6% 13.0% 36 700
Mixed 92.4% 98.5% 1.3% 6.4% 12 400
Agricultural 96.3% 97.2% 3.7% 12.3% 19 700
Forest/rangeland 90.9% 96.4% 5.0% 6.6% 11 800
All sites 94.0% 96.9% 3.0% 10.2% 16 700
Groundwater
Urban 74.7% 85.3% 17.2% 21.0% 15 5,600
Mixed 56.9% 62.9% 8.9% 9.0% 2 1,300
Agricultural 61.4% 64.0% 11.9% 12.8% 4 1,600
Forest/rangeland 75.3% 81.3% 10.9% 13.8% 12 2,900
All sites 64.1% 70.1% 12.8% 13.8% 5 2,900
aThe Health Reference Level (HRL) is based on the dietary reference dose (RfD) and application of a modifying 
factor (MF) of 3 for drinking water, and on an allocation of an assumed 20% relative source contribution from water
ingestion as opposed to total manganese exposure.
Source: EPA 2003a
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6.4.3 Sediment and Soil
Manganese comprises about 0.1% of the earth's crust (Graedel 1978; NAS 1973), and manganese occurs
naturally in virtually all soils.  Average natural ("background") levels of manganese in soils range from
around 40 to 900 mg/kg, with an estimated mean background concentration of 330 mg/kg (Barceloux
1999; Cooper 1984; Eckel and Langley 1988; EPA 1985c; Rope et al. 1988; Schroeder et al. 1987).  The
maximum value reported was 7,000 mg/kg (Eckel and Langley 1988).  Using data from 20 watersheds
and 16 drainage basins in the United States, manganese was detected at 100% of the National Water-
Quality Assessment Program (NAWQA) stream bed sediment sampling sites. The median and 99th 
percentile concentrations in bed sediments were reported as 1.1 mg/kg (dry weight) and 9.4 mg/kg (dry
weight), respectively (EPA 2003a).  Manganese levels as high as 1,900 mg/kg were detected in sediment
samples obtained from the Tar Creek Superfund site (a site heavily contaminated with mining wastes) in
Ottawa County, Oklahoma (Wright et al. 2006).  
Accumulation of manganese in soil usually occurs in the subsoil and not on the soil surface; 60–90% of
manganese is found in the sand fraction of the soil (WHO 1981).  A preliminary survey was conducted in 
Utah to provide an initial field measurement of the contamination by manganese oxides from exhaust in 
roadside soil and plant species due to the addition of MMT to motor vehicle fuels.  Soil (0–5 cm)
manganese concentrations were strongly correlated with distance from roadways with moderate and
moderately high traffic volumes (Lytle et al. 1994).  In addition, exchangeable manganese was found to 
be significantly higher in an organic soil located at stations with a high traffic density comparing to
another one with a low traffic density (Brault et al. 1994). The average soil manganese concentration
measured at 1 meter from a moderate to moderately-high traffic volume roadside was 3,046 μg/g dry 
weight.  At 15m, the average soil manganese concentration decreased to 254 μg/g dry weight.
6.4.4 Other Environmental Media 
Manganese is a natural component of most foods.  A summary of mean manganese concentrations in
foods analyzed by the Food and Drug Administration (FDA) Total Diet Study (TDS) 1991–1996 is
summarized in Table 6-6. TDS sampling is conducted 4 times annually, once in each of the major
geographical regions of the country (west, north central, south, and northeast).  Each round of sampling is
referred to as an individual market basket survey and for each market basket survey, samples of
260 selected food and beverages were obtained from three cities within the region.  The mean and median
concentration of manganese in all foods were 2.4 and 1.0 mg/kg, respectively (Capar and Cunningham
   
 








          
   
 
  
    
  
     




   
   
  
    
    
   
     
 
                
 






Table 6-6.  Mean Concentrations of Manganese for FDA’s Total Diet Study Market
Baskets 1991 through 1997a
Food product Range (mg/kg)
Milk and cheese Not detected–<2
Eggs <1
Meat, poultry, and fish Not detected–3.7




Mixed dishes and meals <1–3.4
Desserts Not detected–4.9
Snacks 3.4–9.3
Condiments and sweeteners Not detected–4.1
Fats and dressings Not detected–<1
Beverages Not detected–2.9
Infant and junior foods Not detected–7.5
aA < symbol indicates that manganese was detected, but at a level lower than the limit of quantification.
Source: Capar and Cunningham 2000
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2000). The TDS results concluded that detectable levels of manganese were present in roughly 75% of all
foods, although approximately 24% of these detections were below the quantification limits used in the
study (Capar and Cunningham 2000).  The highest manganese level was observed in a sample of
shredded wheat cereal (44.4 mg/kg).  The five foods with the highest mean manganese levels were oat
ring cereal (33.8 mg/kg), raisin bran cereal (28.8 mg/kg), shredded wheat cereal (25.0 mg/kg), mixed nuts
(23.2 mg/kg), and granola cereal (20.1 mg/kg).  These levels are similar to levels found in previous
market basket surveys (Pennington et al. 1986).  Tea and leafy green vegetables were the major dietary
sources of manganese for young women taking part in a dietary study in Wisconsin (Davis et al. 1992a).
Bioaccumulation of manganese by plants was examined using oats (Avena nova) and beans (Phaseolus
vularis) (Brault et al. 1994).  These plants were grown in sandy and organic soil at a control site
(greenhouse) and at two outdoor sites near <20,000 and 132,000 vehicles/day respectively.  The highest
manganese accumulation was found in the fruits and stems of oats grown in the organic and sandy soils at
the station with the highest traffic density.  Lönnerdal (1997) reported that infant formulas contain 30– 
75 ppb (0.03–0.075 ppm) manganese, as compared to concentrations of 3–10 ppb (0.003–0.01 ppm) in 
breast milk and 30 ppb (0.03 ppm) in cow's milk. 
During a 1992 survey conducted by Canada’s Department of Fisheries and Oceans, concentrations of
manganese were detected in the muscle samples of bluefin tuna (Thunnus thynnus) (Hellou et al. 1992).  
Concentrations of manganese in 14 samples of fish muscle ranged from 0.16 to 0.31 μg manganese/g dry
weight, with a mean of 0.22 μg/g.  Although the analysis was administered with a high accuracy of 94%
using inductively coupled plasma-mass spectrometry (ICP-MS), the sample population was small.
In the field survey conducted by Lytle et al. (1994), terrestrial and aquatic plant samples were collected
along motorways and local urban roadways throughout Utah during 1992 and 1993.  Manganese was
detected in the plant samples, with manganese concentrations ranging from 30.2 to 13,680 μg/g dry 
weight.  Manganese was detected in plants found nearest to the motorway.  Loranger et al. (1994b)
evaluated the use of the pigeon as a monitor for manganese contamination from motor vehicles in urban 
and rural areas of Canada, a country in which MMT has been used to replace lead in gasoline. 
Manganese concentrations were similar in the two groups of pigeons for all tissues except the liver and 
feces; urban pigeons had about 35% more manganese than rural ones.  Loranger et al. (1994b) suggested 
that although pigeon feces and liver may be good biomarkers of manganese contamination, it is premature
to associate the excess manganese with the combustion of MMT. Toxicokinetic studies of manganese in
both male and female rats suggested that MMT-derived manganese administered in oral doses resulted in
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higher and more prolonged plasma concentration versus time profiles than inorganic (MnCl2) complexes, 
leading to the conclusion that MMT-derived manganese was likely to accumulate following repeated
exposures (Zheng et al. 2000).
6.5 GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Since manganese is ubiquitous in the environment, the general population is exposed to manganese from
both natural and anthropogenic sources.  The manganese concentration in blood of healthy adults is
reported to range from 4 to 15 μg/L with an average value of about 9 μg/L (Barceloux 1999).  Typical
daily human exposure levels to manganese from water, air, and food are summarized in Table 6-7 (EPA
1984).  As the table illustrates, the most significant exposure for the general population is from food.  The
average daily intake for a 70-kg adult was estimated as 3,800 μg/day (EPA 1984).  Other estimates of
daily intake for adults range from 2,000 to 8,800 μg (EPA 1984; NAS 1977; Patterson et al. 1984;
Pennington et al. 1986; WHO 1984a) and 700–10,900 μg/day (WHO 2004b).  Even though 
gastrointestinal absorption of manganese is low (3–5%), oral exposure is the primary source of absorbed 
manganese.
Manganese intake among individuals varies greatly, depending upon dietary habits.  For example, an 
average cup of tea may contain 0.4–1.3 mg of manganese (Pennington et al. 1986; Schroeder et al. 1966).
Thus, an individual consuming three cups of tea per day might receive up to 4 mg/day from this source
alone, increasing the average intake from all dietary sources.
As part of the Third National Health and Nutrition Examination Survey (NHANES) conducted by the
Centers of Disease Control and Prevention (CDC), manganese was detected at quantifiable levels in urine 
samples from 73% of 496 participants of the monitoring study (Paschal et al. 1998).  The mean urinary
manganese concentration in these 496 individuals (aged 6–88 years of age) was 1.19 μg/L (Paschal et al. 
1998). 
The EPA Reference Dose (RfD)/RfC workgroup in June 1990 set an RfD for manganese in food of
0.14 mg manganese/kg/day, equivalent to about 10 mg/day for a 70-kg man based on chronic manganese 
uptake (EPA 1993b). The Food and Nutrition Board of the National Research Council (NRC) estimated 
the adequate and safe intake of manganese for adults at 2–5 mg/day (NAS 1980b).  This level was chosen 
because it includes an "extra margin of safety" of 5 mg/day below the level of 10 mg/day, which the NRC
considered to be safe for occasional intake (IRIS 2011).   
   
 









       
 
  
    
      
        
      
    
    
 
   
  
  
   
 
Table 6-7.  Summary of Typical Human Exposure to Manganesea 
Exposure medium
Parameter Water Air Food
Typical concentration in medium 4 μg/L 0.023 μg/m3 1.28 μg/calories
Assumed daily intake of medium by 70-kg adult 2 L 20 m3 3,000 calories
Estimated average daily intake by 70-kg adult 8 μg 0.46 μgb 3,800 μg
Assumed absorption fraction 0.03c 1c 0.03d 
Approximate absorbed dose 0.24 μg 0.46 μg 114 μg
aAdapted from EPA 1984
bAssumes 100% deposition in the lungs
cNo data; assumed value
dVitarella et al. 2000
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A large-scale population-based exposure study was conducted from June 1995 through August 1996 in 
Toronto, Canada, a city with widespread use of MMT, to estimate personal exposures to particulate
matter (PM2.5 and PM10) and manganese contained in particulates (Lynam et al. 1999; Pellizzari et al.
1999).  In addition to personal samples, air samples were also collected at indoor and outdoor residential
sites as well as ambient levels at two fixed locations and a rooftop.  Correlations between manganese in
personal samples and the other environmental samples were calculated. The correlation coefficients for
manganese in personal samples with residential indoor air and outdoor air were 0.56 and 0.49, 
respectively (Pellizzari et al. 1999). Correlations at the fixed sites were lower, but considered statistically
significant. The estimated 3-day personal exposure distributions for the population (n=922) are
summarized in Table 6-8. Additional regression and correlation analysis of the Toronto study was
performed by Crump (2000) to further elucidate the role that MMT and other environmental factors play
in personal exposure to manganese in this population.  Subgroups of the population were identified that
could have potentially significant manganese exposures from various sources.  It was determined that
subway riders, metal workers, and persons exposed to tobacco smoke (smokers and those exposed to 
environmental tobacco smoke) had the highest potential personal exposure to manganese.  After
eliminating these groups from the population, the mean personal PM2.5 manganese exposure declined
approximately 40%.  The remaining personal exposure to manganese in the Toronto population study is
from a variety of naturally occurring and anthropogenic sources.  Citing data suggesting that there are
several non-MMT-related sources of manganese in ambient air and that manganese levels in both
personal samples and fixed site samples were negatively correlated with MMT levels in gasoline, Crump
(2000) concluded that most of the personal exposure to manganese from the Toronto sample group was
from sources other than MMT in gasoline.  
An exposure analysis similar in design to the Toronto study was conducted in Indianapolis, Indiana where
MMT was not being used as a gasoline additive at the time of the study (Pellizzari et al. 2001).  A smaller
personal sample size (n=240) was obtained in the Indianapolis data set as compared to the Toronto study.  
In general, manganese levels in indoor air, outdoor air, and personal samples were substantially lower in 
Indianapolis as compared to Toronto.  For example, the median and mean levels for personal manganese 
exposure were 2.8 and 7.5 ng/m3, respectively, in Indianapolis and 8.0 and 13.1, ng/m3, respectively, in 
Toronto.  Similar to the Toronto study, tobacco smokers and workers occupationally exposed to 
manganese tended to have higher personal exposure levels than nonsmokers and non-occupationally
exposed individuals.  For non-occupationally exposed individuals in Toronto, the greatest correlation 
between manganese personal exposure and environmental factors was the amount of time traveling by
   
 









       




























Table 6-8.  Estimated 3-Day PM2.5 Manganese Exposure Distribution for a
Population (n=922) in Toronto, Canadaa
25th 50th 75th 90th 95th 99thGeometric 10th 
Mean mean percentile percentile percentile percentile percentile percentile percentile
13.1 8.3 3.9 5.5 8.0 12.0 16.9 23.0 47.3
aMn concentration in ng/m3.
Source: Pellizzari et al. 1999
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subway; however, Indianapolis does not have a subway system, so a similar comparison cannot be made
for this study.  For the non-occupationally exposed subgroups with no exposure to tobacco smoke and no 
subway riders, the median personal manganese exposure was 2.6 ng/m3 in Indianapolis and 7.8 ng/m3 in 
Toronto.
Sierra et al. (1995) conducted a study using 35 automotive workers in Montreal, Canada suspected of
being exposed to high levels of manganese from MMT and 30 nonautomotive workers (control group).  
Exposure to manganese was measured for 5 consecutive working days.  In addition, the workers’
environmental exposure at home was measured on 2 days of the same week.  Air sampling was performed
by portable personal pumps; for sampling at homes, workers were asked to wear the pumps as much as
possible.  At the workplace, the mechanics were exposed to manganese concentrations ranging from
0.010 to 6.673 μg/m3 (10–6,673 ng/m3) with a mean of 0.45 μg/m3 (450 ng/m3), while nonautomotive
workers were exposed to manganese concentrations ranging from 0.011 to 1.862 μg/m3 (11–1,862 ng/m3).  
The mean concentration was 0.04 μg/m3 (40 ng/m3).  The average manganese concentrations in the indoor 
air of the homes were 0.012 μg/m3 (120 ng/m3) for the mechanics and 0.008 μg/m3 (8 ng/m3) for the
nonautomotive workers (Sierra et al. 1995).  Based on measurements of manganese particle size 
distributions, Sierra et al. (1995) estimated that <10% of the manganese exposure of the garage mechanics 
was due to MMT; however, the exact contribution of MMT could not be determined.  
A similar study conducted in Montreal by these investigators, but involving taxi drivers and garage 
mechanics, indicated that garage mechanics at work were exposed to an average of 0.250 μg/m3 
(250 ng/m3) and taxi drivers to 0.024 μg/m3 (24 ng/m3) (Zayed et al. 1994).  In another study, exposure of
office workers and taxi drivers to both respirable and total manganese was evaluated (Zayed et al. 1996).
Manganese concentrations measured for the office workers ranged from 0.001 to 0.034 μg/m3 (1– 
34 ng/m3 respirable manganese) and from 0.002 to 0.044 μg/m3 (2–44 ng/m3 total manganese). For the 
taxi drivers, the manganese concentrations ranged from 0.007 to 0.032 μg/m3 (7–32 ng/m3 respirable 
manganese) and from 0.008 to 0.073 μg/m3 (8–73 ng/m3 total manganese).  Zayed et al. (1996) concluded 
that the higher exposure to atmospheric manganese in the outdoor urban environment may be at least
partly due to the use of MMT in cars.  Nevertheless, these investigators indicated that the exposures of
taxi drivers to manganese were well below existing exposure and health guidelines.
In order to assess the potential health risks from MMT combustion, Loranger and Zayed (1995)
conducted a multi-media assessment (i.e., food, water, and ambient air) of manganese exposure in
two groups of workers (garage mechanics and blue-collar workers not involved in automotive repair)
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potentially exposed to different levels of manganese from MMT.  Garage mechanics were exposed to
higher air manganese concentrations (0.42 μg/m3) than nonautomotive blue-collar workers (0.04 μg/m3).  
However, for the garage workers, exposure to atmospheric manganese represented only approximately
4% of the total absorbed dose, while ingestion of food represented 95.7% of the total multi-media dose.  
For the blue collar workers, atmospheric manganese contributed only 0.3% to the total absorbed dose, 
whereas ingestion of food represented 99.2% of the total multi-media dose. These results were consistent
with values of multi-media doses predicted by GADUS, an environmental fate/exposure model (Loranger
and Zayed 1997b).  Based on governmental standards or criteria for occupational and environmental
exposures, Loranger and Zayed (1995) concluded that the manganese levels in food and air may not cause 
any problems for these workers. 
In the workplace, exposure to manganese is most likely to occur by inhalation of manganese fumes or
manganese-containing dusts.  This is a concern mainly in the ferromanganese, iron and steel, dry-cell
battery, and welding industries (WHO 1986).  Exposure may also occur during manganese mining and 
ore processing; however, the most recent data indicate that only a very small amount of manganese is still
mined in the United States (USGS 2007).  Excluding insignificant quantities of similar low-grade 
manganiferous ore, the United States has not mined significant amounts of manganese since 1978 and
now relies on imports to fill its needs (USGS 2007).  In 1980, it was estimated that in the United States
about 300 workers were exposed to pure manganese and about 630,000 workers were exposed to other
forms of manganese (NOES 1989).  Concentrations as large as 1.5–450 mg manganese/m3 have been
reported in U.S. manganese mines (EPA 1984), 0.30–20 mg manganese/m3 in ferroalloy production 
facilities (Saric et al. 1977), and 3–18 mg manganese/m3 in a dry-cell battery facility (Emara et al. 1971).  
Steel-manufacturing facilities are significant employers in the United States. There is a potential for
manganese exposure to workers in these facilities.  Airborne manganese levels in a metal-producing plant
in the United States were reported as 0.066 mg/m3(mean), 0.051 mg/m3(median) as respirable dust, and
0.18 mg/m3 in total dust (Gibbs et al. 1999).  Exposure levels should not exceed the Occupational Safety
and Health Administration (OSHA) time-weighted average Permissible Exposure Limit (PEL) of 1 mg
total manganese/m3 (see Table 8-1). Average airborne manganese levels during welding operations of
two factories located in China were 0.24 and 2.21 mg/m3 (Wang et al. 2008). Manganese levels in
workplace air at a smelting facility in China ranged from 0.30 to 2.9 mg/m3 in the furnace smelting area 
and from about 0.2 to 0.8 mg/m3 in a power control room (Jiang et al. 2007).  The workplace air at this
facility contained mainly MnO (20%) and SiO2 (22%), in addition to other trace metals including
Fe2O3 (4%), CaO (4.5%), MgO (4%), and Al2O3 (5%).  Thus, for workers in industries using manganese,
the major route of exposure may be inhalation from workplace air rather than from ingestion of food.
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6.6 EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility. 
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume.  A child’s diet often differs from that of adults.  
The developing human’s source of nutrition changes with age:  from placental nourishment to breast milk
or formula to the diet of older children who eat more of certain types of foods than adults.  A child’s
behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their mouths, 
sometimes eat inappropriate things (such as dirt or paint chips), and spend more time outdoors.  Children 
also are closer to the ground, and they do not use the judgment of adults to avoid hazards (NRC 1993).
Children would be exposed to manganese in the same manner as adults. The main source of exposure of
children to manganese is through food.  Infants and young toddlers who are formula-fed may receive 
higher daily intakes of manganese than breast-fed infants because of the increased levels of the element in
infant formulas as compared to breast milk (Collipp et al. 1983; Cook 1997; Dorner et al. 1989; Keen et
al. 1986; Lönnerdal et al. 1983, 1994).  For example, a study of 2,339 breast milk samples obtained from
nursing mothers in Germany had a mean manganese level of 6.2 μg/L, while two different brands of
formula had levels of 77 and 99 μg/L (Dorner et al. 1989).  It was concluded that the mean daily
manganese intake of formula-fed infants was approximately 13 times greater than that of breast-fed 
infants.
Manganese concentrations in blood serum of children of different ages are provided in Section 3.4.2.  The
data indicate that manganese concentrations decrease slightly from the time the infant is 5 days of age 
until he or she is 12 months of age (Alarcón et al. 1996; Rükgauer et al. 1997).  Manganese 
concentrations increase after this time, and they have been measured as an average of 1.4±1.25 μg/L in 
children aged 1 month to 18 years (Rükgauer et al. 1997). 
Children are exposed in utero because manganese in maternal blood crosses the placenta to satisfy the 
fetus’s need for manganese.  The compound has been measured in cord blood plasma of premature and 
full-term infants and their mothers (Wilson et al. 1991).  Full-term babies had higher (but not statistically
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significantly different) blood concentrations of manganese than premature babies, and pregnant women 
had higher blood concentrations than nonpregnant women.  The average manganese concentration in the 
cord blood of full term babies was 5.5 μg/L, as compared to 5.0 μg/L for preterm babies (Wilson et al.
1991).  No correlations were observed between maternal and infant concentrations of manganese.  The
arithmetic mean (standard deviation) manganese concentrations in maternal and cord blood obtained from
female volunteers at a hospital in France were reported as 10.5±4.1 and 31.2±13.4 μg/L, respectively
(Abdelouahab et al. 2010).  Monoamine oxidase activity (MAO), which is known to be influenced by
metals in experimental studies, was shown to be a useful biomarker in humans for manganese exposure.
MAO activity was significantly positively correlated with maternal and cord blood manganese 
concentrations in subjects with high MAO activity.
Manganese in breast milk has been found to range from 3.4 to 10 μg/L (Arnaud and Favier 1995; Collipp
et al. 1983) depending on the maturity of the milk.  The Food and Nutrition Board of the NRC based the
recommended manganese intake of infants on the analyses of pooled human milk samples.  As discussed
above, manganese intakes of infants fed some formulas appear high, but no signs of toxicity have been 
observed (Dorner et al. 1989; Lönnerdal et al. 1983).  Differences in weight-adjusted intake are likely to
be caused by the type of diet that infants and small children receive.  It is unknown whether nursing
mothers exposed to higher-than-average concentrations of manganese would excrete increased
concentrations of the metal in their breast milk.
Young children often eat dirt (exhibiting what is called soil pica, the ingestion of a material unfit for food)
and exhibit frequent hand-to-mouth activity; they can be exposed to manganese through this unique
pathway if the soils contain the metal.  Current estimates indicate that soil pica may be more prevalent in
the general population than previously thought and that most children periodically ingest soil to varying
degrees; this may be a potential health concern (EPA 1986d; Stanek and Calabrese 1995).  The predicted 
oral average daily intake of manganese for children from soils in the vicinity of a municipal solid waste
incinerator was estimated to range from approximately 0.0021 to 0.0032 mg/kg/day (Mari et al. 2007).  
However, no information was found concerning the bioavailability of manganese from soil and, therefore,
determining the actual risk posed to children from this exposure pathway is difficult.  This behavior
should not pose an increased risk of exposure to manganese in most residential situations where the
manganese levels are in the normal or background range.  If the soils are from a hazardous waste site that
contains high concentrations of manganese, then increased exposure to the compound may occur.  
Manganese levels in hair samples of 32 children residing near a hazardous waste site (former mining
facility) in Northeast Oklahoma ranged from 89.1 to 2,145.3 ppb (471.5 ppb mean) (Wright et al. 2006).  
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The authors found that in school-aged children, higher manganese and arsenic levels in hair samples were 
associated with significantly lower scores on a standardized test, as well as on tests of verbal learning and
memory.
Children who suffer from cholestatic liver disease or who have gastrointestinal disorders that mandate 
they be given parenteral nutrition may be at increased risk from overexposure to manganese.  Increased
manganese concentrations in blood and brain, and symptoms of neuromotor dysfunction were observed in 
an 8-year-old girl with cholestatic liver failure (Devenyi et al. 1994).  Children with or without chronic
liver disease and a 5-year-old boy who had gastrointestinal disorders, all of whom were administered
parenteral nutrition, had abnormal MRI scans indicative of manganese accumulation (Fell et al. 1996;
Ono et al. 1995) accompanied by motor disorders (Fell et al. 1996).
Because manganese is a trace element that is essential for normal human health and is predominantly
obtained from food, it is unlikely that toxic amounts of manganese will be absorbed from food.  However,
diets vary and some are higher in manganese than others (diets high in grains and tea, for instance).  One
case study suggested that a 59-year-old man developed manganism-like symptoms from abusing vitamins
and minerals.  This man had very high manganese concentrations in blood, urine, feces, hair, and brain 
(Banta and Markesbery 1977).  Both manganese and iron are bound by transferrin and these elements
compete for the binding protein in the body.  Therefore, diets that are low in iron allow transferrin to bind 
more manganese.  For this reason, it is important to provide children with a balanced diet to maintain 
optimal iron and manganese stores in the body.  Studies show that adults absorb only 3–5% of manganese 
ingested from the diet (Davidsson et al. 1988, 1989a; Mena et al. 1969); infants have increased absorption 
relative to adults (Dorner et al. 1989).  Neonatal animals also exhibit increased absorption relative to older
animals (Ballatori et al. 1987; Miller et al. 1975; Rehnberg et al. 1981).
Children may be exposed to organic manganese compounds through a variety of routes.  They may be
exposed to MMT combustion products via inhalation of these products in air, or ingestion of them after
deposition on the soil.  
6.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
As discussed in Section 6.5, workers in industries using or producing manganese are mostly likely to have
higher exposures to manganese, primarily by inhalation of manganese dusts in workplace air as compared
to the general population.  In a year-long investigation of personal exposure to manganese fine particulate 
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matter (PM2.5) for residents of Toronto, Canada, it was determined that workers in the metal industry had 
the highest personal exposures as compared to other groups. The mean concentration of manganese PM2.5 
in personal samples for 39 workers engaged in welding, soldering, or other metal working practices was 
105 ng/m3, which was more than 10 times greater than the mean concentration (10 ng/m3) for 886 non-
metal workers (Crump 2000).  Smokers and those nearby second-hand smoke were also shown to be
exposed to higher levels of fine particulate matter manganese as compared to nonsmokers.  The mean
concentration of PM2.5 manganese in 702 personal air samples of nonsmokers in Toronto, Canada was
10 ng/m3, while the mean concentration calculated from 223 personal samples obtained from smokers
was 27 ng/m3 (Crump 2000).  A positive correlation was observed between personal manganese exposure
and subway travel in Toronto, presumably due to the erosion of the steel wheels and subway tracks 
(Crump 2000; Pellizzari et al. 1999).
Average airborne manganese levels (total dust) in the breathing zone of two factories located in China 
were 0.24 and 2.21 mg/m3 (Wang et al. 2008).  The greatest levels were observed during welding
operations in enclosed spaces. The workers at these two factories had higher measurable manganese 
levels in their saliva (3.47±1.42 and 5.55±2.31 μg/L), as compared to a control group of non-
occupationally exposed individuals (3.04±1.40 μg/L).  
Workers in three manganese alloy production plants located in Norway were found to have slightly higher
manganese blood and urine levels when compared to a group of non-occupationally exposed individuals.  
The arithmetic mean manganese level in the blood of workers at these plants was 189 nmol/L (10.3 μg/L)
versus 166 nmol/L (9.1 μg/L) for the reference group (Ellingsen et al. 2003c).  The urinary arithmetic
mean concentrations were 3.9 nmol/mmol creatinine for the occupationally exposed workers and 
0.9 nmol/mmol creatinine for the reference group (Ellingsen et al. 2003c).  The arithmetic mean inhalable
and respirable concentrations of manganese in the air of these production plants were 0.769 and
0.064 mg/m3, respectively (Ellingsen et al. 2003c).  Section 3.2.1.4 summarizes other studies that
compared noted health effects with urinary and blood manganese levels of occupationally exposed 
individuals and reference populations.  It has been demonstrated that levels in the blood and urine may
not be adequate biomarkers for high level manganese exposure since free manganese usually does not
accumulate within the circulatory system (Josephs et al. 2005).
Populations living in the vicinity of ferromanganese or iron and steel manufacturing facilities, coal-fired
power plants, or hazardous waste sites may also be exposed to elevated manganese particulate matter in
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air or water, although this exposure is likely to be much lower than in the workplace.  Populations living
in regions of natural manganese ore deposits may be exposed to above-average levels in soil, water, or air.
People ingesting large amounts of foods high in manganese also have a potential for higher-than-usual
exposure.  Included in this group would be vegetarians, who ingest a larger proportion of grains, legumes, 
and nuts in their diets than the average U.S. population, and heavy tea drinkers.  While the intake of
manganese from vegetarians may exceed the estimates of daily dietary intake, the bioavailability of
manganese from vegetable sources is substantially decreased by dietary components such as fiber and 
phytates (EPA 1993b).  In addition to the population with these dietary habits, individuals with iron 
deficiency show increased rates of manganese absorption (Mena et al. 1969, 1974); iron deficiency leads
to increased brain manganese concentrations in experimental animals (Aschner and Aschner 1990).
Manganese is eliminated from the body primarily through the bile.  Interruption of the manufacture or
flow of bile can impair the body’s ability to clear manganese.  Several studies have shown that adults and
children (Devenyi et al. 1994; Fell et al. 1996; Hauser et al. 1994, 1996; Pomier-Layrargues et al. 1998;
Rose et al. 1999; Spahr et al. 1996), as well as experimental animals (Rose et al. 1999), with cholestatic
liver disorders have increased manganese levels in their blood and brain and are at risk from potentially
increased exposure to manganese due to their decreased homeostatic control of the compound. 
In addition to oral diets, people on partial and total parenteral nutrition may be exposed to increased
amounts of manganese.  Forbes and Forbes (1997) found that of 32 patients receiving home parenteral
nutrition due to digestive problems, 31 had elevated serum manganese levels (0.5–2.4 mg/L).  It is unclear
whether these levels reflected steady-state conditions due to the time the samples were taken.  However,
these levels are much higher than other studies involving patients on TPN; thus, it is unlikely that these 
levels represent steady-state conditions.  Further, the normal range reported by these authors (0.275– 
0.825 mg/L) is elevated compared to other studies, suggesting the possibility that the blood samples were 
contaminated with exogenous manganese.  The authors observed no clinical evidence of toxicity in the
patients.  Fourteen of the patients suffered iron deficiency anemia; because low iron concentrations are 
associated with increased manganese uptake, the anemia may have exacerbated the increased blood
manganese concentrations. Increased blood manganese levels and MRI scans indicative of increased
manganese in brains have been reported in children fed entirely on parenteral nutrition (Fell et al. 1996;
Ono et al. 1995).  Only in the Fell et al. (1996) study were neurotoxic effects reported.  Whole-blood 
manganese in the children from this study ranged from 9.9 to 110 μg/L.  Devenyi et al. (1994) found 
hyperintense signals in the brain of an 8-year-old child who had cholestatic liver disease and exhibited
   
 










        
       
         
       
           




   
 
 
          
          
       
  
   
       
     
    
           
         
         
    
 
           




6. POTENTIAL FOR HUMAN EXPOSURE
dystonia and other motor dysfunctions.  Nagatomo et al. (1999) reported that two elderly patients who had 
been administered TPN for 3–4 months exhibited clinical signs of manganism (including masked facies, 
marked rigidity, hypokinesia) with associated elevated blood manganese levels and hyperintense signals 
on MRI, localized to the basal ganglia, especially the globus pallidus.  Signs of manganism abated upon 
levodopa treatment and the administration of Ca-EDTA; the high intensity signals on MRI abated when
manganese supplementation ceased.  In addition to patients on parenteral nutrition, uremic patients on 
hemodialysis have been found to have increased manganese levels due to increased concentrations of
manganese in the dialysis solution (Lin et al. 1996). These studies indicate that while increased levels of
manganese in blood and brain are often associated with TPN administration, adverse neurological effects 
are not always reported.  Nagatomo et al. (1999) found increased serum concentrations of manganese and
brain abnormalities in two patients who showed Parkinsonism with psychiatric symptoms after 3– 
4 months of total parenteral nutrition.  Discontinuation of manganese supplementation in the parenteral
diet, coupled with levodopa treatment, gradually improved both the symptoms and brain abnormalities in 
the patients.
In comparison to other groups within the general population, persons living close to high density traffic
areas, automotive workers, gas station attendants, and taxi drivers may be exposed to higher
concentrations of manganese arising from the combustion of MMT.  Levels of respirable manganese, in
both indoor and outdoor air near an expressway with high traffic density were shown to be greater than 
corresponding air samples obtained from a rural location in Montreal, Canada (Bolte et al. 2004).  The
average concentration of respirable manganese (defined in this study as <5 μm diameter) in outdoor air
from the urban location of Montreal was 0.025 μg/m3, which is 5 times greater than the average of
0.005 μg/m3 found in the rural location.  The average indoor respirable manganese concentration was also
greater for the urban area (0.017 μg/m3) as compared to the rural area (0.007 μg/m3).  However, 
differences in exposure levels did not lead to significantly greater levels of manganese in blood for
residents of these areas. The mean manganese concentration in blood samples obtained from female 
residents in the urban location (8.4 μg/L) was only slightly greater than the average level observed for
females living in the rural location (7.8 μg/L).  
It is possible that medical workers may be exposed to higher concentrations of mangafodipir than the
general population, although exposure routes other than intravenous are not expected to pose a significant
risk.
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6.8 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of manganese is available. Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of manganese.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The fundamental physical and chemical properties of
manganese and manganese compounds are known (see Table 4-2), and additional research does not
appear necessary.
Production, Import/Export, Use, Release, and Disposal. According to the Emergency
Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Section 11023, industries are required 
to submit substance release and off-site transfer information to the EPA.  The TRI, which contains this
information for 2009, became available in March of 2011.  This database is updated yearly and should 
provide a list of industrial production facilities and emissions.
Information is available on U.S. import, export and production of manganese ore and related materials
(USGS 2007, 2008).  It is clear that most manganese is used in steel production.  Information regarding
the import, export, and use of MMT in U.S. fuels is a data need.
Data from the TRI database provide valuable information on the amounts of manganese released to
different environmental media (e.g., air, soil, and water) each year, although details on the chemical form
and physical state of the waste materials are not included. These disposal practices are not regulated
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under current federal law.  TRI data may not be complete estimates of total release.  Also, because these 
data reflect past releases, they may not be representative of current releases at these facilities.
Environmental Fate. The partitioning of manganese between water and soil can be fairly well
predicted using thermodynamic equilibrium concepts, if soil-specific information is available (Baes and
Sharp 1983; Rai et al. 1986). The fate of manganese particles released into the air is determined by the 
particle size, and the direction and distance of particle transport at a site can be predicted from
meteorological data and particle size data (EPA 1984; Nriagu 1979). Transport of manganese in water is 
determined mainly by the solubility of the manganese compounds present, although suspended particles
may also be transported in flowing waters (EPA 1984; Schaanning et al. 1988).
The primary transformations that manganese undergoes in the environment are oxidation/reduction 
reactions (EPA 1984; Rai et al. 1986).  Reactions of manganese with airborne oxidants have not been
studied.  Information on the rate and extent of such reactions would be helpful in understanding the fate
of atmospheric releases.  The transformation of manganese in water or soil is dependent mainly on Eh, 
pH, and available counter ions (EPA 1984).  In some soils, manganese may also be oxidized by bacteria
(Geering et al. 1969; Johnston and Kipphut 1988).  More work is needed on the environmental factors, 
such as soil composition and pH, which may determine the form in which manganese will appear and thus
impact manganese availability and absorption.
Modeling has also provided interesting insight into the contribution of the combustion of MMT to 
atmospheric manganese (Loranger et al. 1995).  According to the model estimations, the contribution of
direct emissions from motor vehicles to the atmospheric background manganese (as measured from
sampling stations) would be about 50% at <25 m and <8% at 250 m.  These results are confirmed with an
in situ study using snow as the environmental indicator where the average deposition rates of manganese 
for the top and bottom layers ranged from 0.01 to 0.21 mg/m2/day (Loranger et al. 1996).  The average
concentrations of manganese decreased with distance from the road.  However, it was impossible to
distinguish between directly-emitted manganese from automobiles, manganese enriched road dust, and
the naturally-occurring manganese in crustal materials. No study to date has provided the complete 
answer to this question and this constitutes one of the major remaining data needs regarding the
environmental significance of manganese from MMT and the resulting potential for exposure.  
Bioavailability from Environmental Media. Manganese is known to be absorbed following
inhalation or oral exposure (Mena et al. 1969; Pollack et al. 1965; Zheng et al. 2000), but dermal exposure
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is not considered to be significant. The uptake of manganese from air, food, milk, and water has been
studied (Davidsson et al. 1988, 1989a).  However, absorption from soil has not been investigated.  In 
view of the potential for tight binding of manganese to some soil types, studies on this subject would be
valuable in evaluating risk to humans, especially children who may ingest contaminated soils near
hazardous waste sites.  Additional information would also be valuable on the relative bioavailability of
different manganese compounds across various environmental media.
Food Chain Bioaccumulation. It has been established that while lower organisms (e.g., plankton, 
aquatic plants, and some fish) can significantly bioconcentrate manganese, higher organisms (including
humans) tend to maintain manganese homeostasis (EPA 1984; Folsom et al. 1963; Thompson et al.
1972).  This indicates that the potential for biomagnification of manganese from lower trophic levels to 
higher ones is low, and it does not appear that additional research in this area is essential at this time.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of manganese 
in contaminated media at hazardous waste sites are needed so that the information obtained on levels of
manganese in the environment can be used in combination with the known body burden of manganese to
assess the potential risk of adverse health effects in populations living in the vicinity of hazardous waste 
sites.
Manganese levels have been monitored in all environmental media, including air, water, soil, and food 
(Capar and Cunningham 2000; EPA 1984; NAS 1980a; Pennington et al. 1986). Estimates are available 
for the average human intake levels of manganese from water, air, and food (EPA 1984; WHO 2004b).  
More specific data on levels in the environment around those particular sites where manganese is believed
to have been dumped would be helpful in determining the extent of exposure levels around such waste
sites.  In particular, data on the concentration of manganese in the air around hazardous waste sites would 
be valuable in assessing the potential significance of this exposure pathway.
Exposure Levels in Humans. This information is necessary for assessing the need to conduct
health studies on these populations.  Manganese is a normal component of human tissues and fluids
(Sumino et al. 1975; Tipton and Cook 1963).  Increased average levels of manganese have been detected
in blood and urine of populations exposed to high concentrations of manganese in the workplace (Roels
et al. 1987b).  Manganese has been measured in hair samples of children residing near a hazardous waste
site (Wright et al. 2006); however, the absence of data on levels of manganese in the hair of U.S. children 
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in the general population makes it difficult to draw conclusions about whether the exposures of the
children at this site are unusually high.  Surveys of manganese levels in the blood or urine of populations
living near waste sites could be useful in identifying groups with above-average levels of manganese 
exposure.  More information is also needed to determine whether iron-deficient populations have a higher
manganese body burden. Manganese and iron have many physico/chemical similarities and there is a 
possibility of competition between these elements.  Increased manganese concentrations have been shown
to inhibit the metabolic function of the iron-dependent enzyme, aconitase (Zheng et al. 1998).  Iron 
deficiency is the single most prevalent nutritional deficiency in the world, and so the potential health risk
associated with iron deficiencies exacerbating the brain manganese burden may represent a crucial issue
of exposure and susceptibility, and has yet to be evaluated.  Air concentrations in areas with high traffic 
density are sometimes higher than the guide level (Zayed et al. 1999a); therefore, some individuals could 
be at risk.  Research focusing on the environmental level of exposure of certain groups of the population, 
such as those living near a major highway, is needed.
This information is necessary for assessing the need to conduct health studies on these populations.
Exposures of Children. Children are exposed daily to manganese.  The compound is an essential
trace element vital for the body to function properly and body burden studies are available (Alarcón et al.
1996; Rükgauer et al. 1997).  Although the primary pathway for exposure is the diet, studies involving
exposures to airborne manganese (e.g., in dust that may be present at a nearby hazardous waste site or
manganese-processing plant) would aid in understanding other pathways that may contribute significantly
to children’s total body burden of manganese
Soil ingestion is likely the only unique exposure pathway for children.  Additional studies concerning
bioavailability of manganese from soil would provide important information concerning the proportion of
the total daily manganese intake that could originate from ingested soils.
Although infants differ in their weight-adjusted intake of manganese, it is unknown whether older
children differ in this parameter.  Studies concerning this end point would be very valuable.
Studies involving inhalation or ingestion exposure to MMT in the young are very few (Komura and 
Sakamoto 1992b, 1994).  Although these studies indicate that MMT had very little measurable effect on
development, only one dose level was used.  Although analytical data indicate that environmental MMT
is unlikely to persist (Lynam et al. 1999), it is unknown what typical body burdens of manganese might
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be in children following long-term exposure to MMT combustion products.  Additional studies measuring
these end points in the young would be helpful.
Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of Data
Needs: Children’s Susceptibility.
Exposure Registries. No exposure registries for manganese were located. This substance is not
currently one of the compounds for which a sub-registry has been established in the National Exposure 
Registry.  The substance will be considered in the future when chemical selection is made for sub-
registries to be established. The information that is amassed in the National Exposure Registry facilitates 
the epidemiological research needed to assess adverse health outcomes that may be related to exposure to 
this substance.
6.8.2 Ongoing Studies 
The Federal Research in Progress (FEDRIP 2008) database provides additional information obtainable
from a few ongoing studies that may fill in some of the data needs identified in Section 6.8.1.  
Researchers at the University of Delaware (D.M. Di Toro, principal investigator) are conducting research
to develop models for predicting the toxicity and mobilization of individual metals (including manganese)
and metal mixtures in sediments.  These predictions are critical in evaluating the risk associated with
contaminated sediments at Superfund sites.  
Thomas R. Guilarte and co-workers at Johns Hopkins University are studying the behavioral and 
neuropathological changes that occur as a result of chronic exposure to low levels of manganese.  The
findings from the proposed studies will be used to aid in understanding the mechanism(s) of chronic, low-
level manganese neurotoxicity.  Moreover, these data will identify sensitive markers for the early
detection of manganese neurotoxicity that can be used in vivo in humans. 
Wei Zheng and co-workers at Purdue University are studying the biomarkers for early diagnosis of
manganese toxicity among Chinese smelting workers. They plan to combine exposure indices and 
biological effects into one parameter for quick clinical assessment of manganese toxicity. They are also
conducting clinical trials to investigate the efficacy of para-aminosalicylic acid in treatment of severe 
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manganism.  Advanced MRI and MRS techniques along with molecular biotechnology have been used in 
these studies.  
Donald Smith and co-workers at the University of California, Santa Cruz are studying the effect that early
manganese exposure in neonatal rats has on neurobehavioral and neurocognitive deficits and comparing
these data with epidemiological studies in children.












          
   
              
       
         
   
    
         
  
   
 
          
       
          
  
   
        
     
          
        
     
  
  
         
       
  
 
          
         




The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring manganese, its metabolites, and other biomarkers of exposure and effect to 
manganese. The intent is not to provide an exhaustive list of analytical methods. Rather, the intention is 
to identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
The most common analytical procedures for measuring manganese levels in biological and environmental
samples use the methods of atomic absorption spectroscopy (AAS) and atomic emission spectroscopy
(AES).  In AAS analysis, the sample is aspirated into a flame or in a graphite furnace (GFAAS) until the 
element atomizes (Tsalev 1983).  The ground-state atomic vapor absorbs monochromatic radiation from a
source and a photoelectric detector measures the intensity of radiation absorbed at 279.5 nm (Tsalev
1983).  Furnace atomic absorption analysis is often used for very low analyte levels and for the analysis 
of solid samples or slurries (Baruthio et al. 1988).  Inductively coupled plasma-atomic emission
spectrometry (ICP-AES) analysis is frequently employed for multianalyte analyses that include
manganese.  Neutron activation analysis is also a very effective method for determining manganese 
concentrations in different samples (Rose et al. 1999).  This technique uses no reagents and a minimum of
sample handling; thus, potential contamination with exogenous sources of manganese can be avoided.  In 
addition, the technique has a low detection limit in biological tissues (4 ng/g) and high precision.  Further, 
the technique can be used for environmental samples as well as biological samples.  Other methods for
measuring manganese include spectrophotometry, mass spectrometry, neutron activation analysis, and
x-ray fluorimetry.
It is important to note that none of these methods distinguish between different oxidation states of
manganese or between different manganese compounds. Thus, monitoring data on manganese are nearly
always available only as total manganese present.
   
 








        
 
         
        
           
      
     
     
 
     
     
        
          
 
 
    
 
        
     
   
    
   
    
    
   
   
     
             
  
      
 




Levels of organometallic species in environmental and toxicological samples are typically in ppb
concentrations, ng/mL in solution, or ng/g in solids (Walton et al. 1991).  Therefore, methods of
determination must be both selective and sensitive, achieved usually by coupling liquid or gas
chromatography (GC) with detection via electrochemical, mass spectrometry, and atomic spectrometry
detectors.  A number of analytical methods for quantifying MMT in gasoline have been described,
including simple determination of total elemental manganese by atomic absorption and gas 
chromatography followed by flame-ionization detection (FID).  These methods usually measure MMT by
detecting the metallic portion of the compound and reporting detection of MMT as manganese.
X-ray absorption near edge structure (XANES) and x-ray absorption fine structure (XAFS) spectroscopy
have been used for the analysis of manganese-containing particulates emitted from automobile exhaust
containing MMT (Mölders et al. 2001; Ressler et al. 2000).  These methods are particularly useful in
determining the chemical speciation and valence state of manganese or other metal complexes attached to
particulate matter.
7.1 BIOLOGICAL MATERIALS
Normally, determination of manganese in biological materials requires digestion of the organic matrix
prior to analysis.  For tissue samples or feces (detection limits ranging from 0.2 to <1 μg/g), this is usually
done by treatment with an oxidizing acid mixture such as 3:1:1 (v/v/v) nitric:perchloric:sulfuric acid
mixture (Kneip and Crable 1988a).  Fluid samples such as blood, saliva, or urine may be digested in the
same way (blood, detection limits=1 μg/100 g, 10 μg/L), or manganese can be extracted by an ion 
exchange resin (urine, detection limit=0.5–2 μg/L) or by chelating agents such as cupferon in 
methylisobutylketone (urine, detection limit=<1 μg/L).  A method for directly measuring concentrations
of trace elements in hair that does not require digestion prior to analysis has been developed (Stupar and 
Dolinsek 1996).  While the authors used their technique to determine chromium, lead, and cadmium
levels in hair, it is assumed that their slurry sampling or direct solid sampling technique might also work
for manganese determination.  Table 7-1 summarizes some of the methods used for sample preparation
and analysis of manganese in biological materials. It is important to note that special care is needed to
avoid contamination of biological materials with exogenous manganese, especially for samples with low
levels of manganese (Tsalev 1983; Versieck et al. 1988).
GC-FID may be used to determine levels of MMT in biological tissues and fluids with a detection limit of
1–2 ppm and percent recovery of 93.5–102.7% (Hanzlik et al. 1979). 
   
 









       
 
 








    
         
      
 
         
         
      
 
      




     
 
    




    
 




     




   
  
    
 
 
   
 










     
 
           
           
      
           
                  
       
 
           
         








Table 7-1. Analytical Methods for Determining Manganese in Biological
Materialsa
Sample Analytical Sample Percent
matrix Preparation method method detection limit recovery Reference
Urine 	 Extraction into AAS (furnace <1 μg/Lb No data Baselt 1988
methylisobutyl-ketone as technique)
the cupferon chelate
Urine 	 Extract with resin, ash resin ICP-AES <1 μg/Lb 100±10 NIOSH 1984d
Blood Acid digestion ICP-AES 1 μg/dL 98±2.1 	 Kneip and
Craple 1988a
Blood 	 Digestion in oxidizing acid ICP-AES 1 μg/100 g 98±2.1 NIOSH 1984c
Tissue 	 Digestion in oxidizing acid ICP-AES 0.2 μg/g 98±2.1 NIOSH 1984c
Tissue Acid digestion ICP-AES 0.2 μg/g 104±5.6 	 Kneip and
Craple 1988a
Feces 	 Dry at 110 °C, ash at AAS (furnace <1 μg/g 102±7 Friedman et al.
550 °C, dissolve in nitric technique) 1987
acid
Hair 	 Digestion in concentrated Flameless <0.2 μg/g No data Collipp et al.
nitric:perchloric acid (3:1) AAS 1983
mixture
Hair 	 (a) slurry sample ETAAS No data No data Stupar and 
introduction technique (hair (furnace Dolinsek 1996c 
powder added to twice technique)
distilled water to measure 
bulk hair trace elements, or
(b) direct introduction of 





Methods for determination of MnDPDP
Human 	 Mix heparinized blood Mixed-bed 0.8–2.3 μM 85–115 Toft et al. 1997a
plasma 	 samples of patients resin HPLC- (manganese 
receiving MnDPDP via anion compounds)
injection with solid exchange 0.1–0.8 μM (zinc
trisodium phosphate and reverse- compounds) of
dodecahydrate pH phase 50 μL injection 
10.0±0.2; ultrafiltrate volume
aMagnetic resonance imaging (MRI) has been useful in determining brain accumulation of manganese, but is not a
quantitative method; therefore, it is not listed as an entry in this table.
bEstimated from sensitivity and linearity data
cMethods were used to determine levels of chromium, lead, and cadmium in hair. Manganese concentrations in hair
were evaluated for some, but not all, of the samples and tested one, but not both, new methods. However, it is
assumed that both techniques will work for the trace element manganese.
AAS = atomic absorption spectroscopy; HPLC = high performance liquid chromatography; ICP-AES = inductively
coupled-plasma atomic emission spectroscopy; MnDPDP = mangafodipir; NIOSH = National Institute for
Occupational Safety and Health
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7. ANALYTICAL METHODS
Walton et al. (1991) have described high performance liquid chromatography (HPLC) coupled with laser-
excited atomic fluorescence spectrometry (LEAFS) to detect various species of MMT. The detection
limit for this GC-LEAFS method ranged from 8 to 20 pg of manganese for the various organomanganese
species; the detection limit for determining manganese in MMT was 0.4 ng/mL.  This limit of detection 
was several orders of magnitude better than those for HPLC with ultraviolet (UV) detection or
HPLC-atomic fluorescence spectrometry (AFC) (Walton et al. 1991), but was worse than detection by
GC-FID (DuPuis and Hill 1979).  Walton et al. (1991) used their method to determine manganese species 
present in rat urine after rats had been administered MMT prepared in propylene glycol via subcutaneous
injection.
Table 7-1 summarizes some common methods for the determination of manganese in various types of
biological materials.
7.2 ENVIRONMENTAL SAMPLES 
Manganese in air exists as particulate matter, so sampling is done by drawing air through a filter in order
to collect the suspended particles.  A variety of filter types (e.g., glass fibers and cellulose acetate) and
sampling devices (e.g., low volume, high volume, and dichotomous) are available, depending on the
particle sizes of concern and the concentration range of interest.  In some cases, material on the filter may
be analyzed directly (e.g., by x-ray fluorescence), or the filter may be digested by ashing in acid prior to
analysis.  In general, sensitivity is dependent on the volume of air drawn through the filter prior to 
analysis, and typically, detection limits are 1–2 μg/sample.
Several analytical methods from the EPA Office of Solid Waste publication SW-846, entitled Test
Methods for Evaluating Solid Waste, Physical/Chemical Methods are applicable for analyzing manganese 
in water, soil, and wastes.  In addition, the EPA Emission Measurement Center (EMS) and Office of 
Water (OW) have standardized methods for the measurement of manganese and other metals in
environmental media.  Several of these methods, including the analytical instrumentation and detection 
limits, are summarized in Table 7-2. 
Water may either be analyzed directly, or, if the concentration of manganese is low, a concentration step
(e.g., evaporation, extraction, and binding to a resin) may be employed (detection limits ranging from
0.005–50 μg/L).  In all cases, acid is added to the sample to prevent precipitation of manganese.
   
 









        
 
 
     
 
  
    










    




    
    









      
 
   










     
 
    
     




   




   
      
 
   
     
 




   













   
  
 




















Air Collect sample on MCE
or PVC filter, followed 









Air Collect sample on MCE





1.2 mg/m3 No data NIOSH 2003b
Air Collect sample on MCE
or PVC filter, followed 
by aqua regia ashing
Method 7301 
(ICP-AES)





Water Acidify with nitric acid AAS (furnace 
technique)
0.2 μg/L No data EPA 1983b










Water Acidify with nitric acid Method 311 
(AAS)
<10 μg/L No data APHA 1998a
Water Filter and acidify filtrate




0.2 μg/L No data APHA 1998b




2 μg/L No data APHA 1998c
Water Acidify with nitric acid AAS (direct
aspiration)
10 μg/L 100±2a EPA 1983a
Water Acid digest and analyze Method 3125A
(ICP-MS)





benzidine (TMB) onto 
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For dissolved Method 6010C 0.93 μg/L
constituents: filter, (ICP-AES)





No data EPA 2007a
Foods Digest wet or dry foods
with HNO3–H2SO4 
mixture (12:2 mL)
AAS (flame) AAS (flame):
AAS (furnace) 0.15 mg/kg 
AAS (furnace):
1.10 μg/kg
No data Tinggi et al.
1997
Foods Digestion with nitric,
sulfuric, perchloric acid 
solution
ICP-AES 0.2 mg/kg 96.2–97 Capar and 
Cunningham
2000
Methods for MMT determination
Air Draw known volume of
air through XAD-2 
sampling tubes for
10–60 minutes
GC-ECD 0.001 mg/m3 (in
10-L sample);
0.02 ng from a 
2.0 μL injection 
of a 0.01 μg/mL 
MMT solution
No data Gaind et al.
1992





62 pg/s No data Ombaba and 
Barry 1994
Gasoline Dilute with hexane GC-ECD No data No data Gaind et al.
(1:99); direct injection 1992
Gasoline Inject sample GC-MED 0.25 pg/s No data Quimby et al.
1978
Gasoline Inject sample GC-FPD 0.6 ppm No data Aue et al. 1990
 
           
 
 
             
           
            
          
           




aPercent recovery at manganese concentration >80 μg/L; at lower concentrations (10–20 μg/L), percent recoveries
were >120%.
AAS = atomic absorption spectrometry; ACP = alternating current plasma; AES = atomic emission spectroscopy;
APDC = ammonium pyrrolidine dithiocarbamate; APHA = American Public Health Association; ECD = electron-
capture detection; EPA = Environmental Protection Agency; FPD = flame photometric detection; GC = gas
chromatography; ICP = inductivity coupled plasma; MCE = mixed cellulose ester; MED = microwave emission 
detector; MS = mass spectrometry; NIOSH = National Institute for Occupational Safety and Health; PVC = polyvinyl
chloride; XRF = x-ray fluorescence
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7. ANALYTICAL METHODS
Beklemishev et al. (1997) measured the concentrations of manganese in tap and river water. Their
analytical method relies on an indicator reaction that is catalyzed by Mn(II) (the oxidation of
3,3',5,5'-tetramethylbenzidine [TMB] by potassium periodate [KIO4]) and is carried out on the surface of
a paper-based sorbent. The advantages of this novel technique are that it has a much lower detection limit 
(0.005 μg/L) than do established methods and is transportable, allowing it to be used for rapid tests in the
field (i.e., spot tests and similar procedures).
Determination of manganese levels in soils, sludges, or other solid wastes requires an acid extraction/ 
digestion step prior to analysis. The details vary with the specific characteristics of the sample, but
usually treatment will involve heating in nitric acid, oxidation with hydrogen peroxide, and filtration 
and/or centrifugation to remove insoluble matter.
Manganese levels in foods have been determined in order to define more clearly human dietary
requirements or levels of absorption of manganese from the diet (Tinggi et al. 1997).  Atomic absorption 
spectrometry has been the most widely used analytical technique to determine manganese levels in a 
broad range of foods, as well as other environmental and biological samples (Tinggi et al. 1997).  Tinggi
et al. (1997) contributed a wet digestion technique using a 12:2 (v/v) nitric:sulfuric acid mixture for their
determination, and for food samples with low levels of manganese, they found that the more sensitive
graphite furnace atomic absorption analysis was required.  Because manganese is often found at very low 
levels in many foods, its measurement requires methods with similarly low detection limits; these 
researchers identified detection limits of 0.15 mg/kg (ppm) and 1.10 μg/kg (ppb) for flame and graphite
furnace atomic absorption spectrometry, respectively (Tinggi et al. 1997).  Neutron activation analysis is
an effective technique for measuring manganese in environmental samples; it provides a low detection
limit and high precision (Kennedy 1990).
A number of analytical methods for quantifying MMT in gasoline have been described including simple
determination of total elemental manganese by atomic absorption (Smith and Palmby 1959) and gas
chromatography followed by FID (DuPuis and Hill 1979).  The former has measured manganese 
concentrations from 0.1 to 4 g/gallon of gasoline after dilution of the sample with isooctane to minimize
the effects of differences in base stock composition and is accurate to about 3% of the amount of
manganese present. The latter has an absolute detection limit of 1.7x10-14 g/sample (0.017 pg/s) and 
could easily measure 6 mg/gallon of manganese in a gasoline sample; it is one of the most sensitive 
approaches.  Aue et al. (1990) described a method in which MMT is detected in gasolines by gas
chromatography coupled with flame photometric detection (FPD); the chemiluminescence of manganese 
   
 








          
      
 
       
     
 
    
    
 
            
 
 
       
 
 
    
 
  
           
        
      
    
 
         
 
 
       




is measured to determine MMT levels in a method that uses simple, inexpensive, and commercially
available instrumentation.  MMT levels can be determined down to 0.6 ppm (w/w) in gasoline (Aue et al. 
1990).  In another method showing excellent performance, Quimby et al. (1978) used GC followed by
atmospheric pressure helium microwave detection system (or microwave emission detector [MED]); this 
method has a high degree of selectivity (1.9x106) and a detection limit of 0.25 pg/s at a wavelength of
257.6 nm.  
GC followed by electron-capture detection (ECD) (Gaind et al. 1992) or alternating current plasma (ACP)
emission detection (Ombaba and Barry 1994) (detection limit:  62 pg as manganese) has also been
described for determination of MMT in gasoline.  GC followed by ACP emission detection has been 
described for detecting MMT in air samples; airborne MMT concentrations as low as 0.001 mg/m3 can be 
measured (Ombaba and Barry 1994).
Table 7-2 summarizes some common methods for the determination of manganese in various types of
environmental media.
7.3 ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of manganese is available. Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of manganese.
The following categories of possible data needs have been identified by a joint team of scientists from 
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be
evaluated and prioritized, and a substance-specific research agenda will be proposed.
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7. ANALYTICAL METHODS
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect
Exposure. Sensitive and selective methods are available for the detection and quantitative measurement
of manganese in blood, urine, hair, feces, and tissues (Baselt 1988; Collipp et al. 1983; Friedman et al.
1987; Kneip and Crable 1988a; NIOSH 1984c, 1984d).  Since levels in biological samples are generally
rather low, sample contamination with exogenous manganese can sometimes occur (Tsalev 1983;
Versieck et al. 1988).  Development of standard methods for limiting this problem would be useful.  
Measurement of average manganese concentrations in these materials has proved useful in comparing
groups of occupationally exposed people to nonexposed people (Roels et al. 1987b), but has not been 
especially valuable in evaluating human exposure in individuals (Rehnberg et al. 1982).  This is due to the
inherent variability in intake levels and toxicokinetics of manganese in humans, rather than a limitation in 
the analytical methods for manganese.  Smith et al. (2007) have discussed the limitations of using blood
and urine levels of manganese as biomarkers of exposure and have suggested further investigation of
using manganese levels in teeth and hair as exposure biomarkers.  The use of tooth enamel as a potential
biomarker has been explored by Ericson et al. (2007).  Josephs et al. (2005) have also discussed the
limitations of using manganese levels in serum or urine as a direct measure of exposure since free 
manganese does not accumulate in the circulatory system.  Magnetic resonance imaging (MRI) in
conjunction with analysis of manganese in whole blood (MnB), plasma (MnP), or red blood cells has
been used in the diagnosis of manganism in humans (Jiang et al. 2007).  Abdelouahab et al. (2010) have
shown that MAO activity is a potentially useful biomarker for manganese exposure.  Montes et al. (2008)
conducted a study supporting prolactin as a potential biomarker for manganese exposure.  Development
of additional noninvasive methods for measuring whole-body or tissue-specific manganese burdens 
would be valuable in estimating human exposure levels, but would be limited by the same considerations
of individual variability that limit existing methods.
There is a need to evaluate the accuracy and reproducibility of analytical measures of manganese in
biological media, so that analytical variability is not inappropriately incorporated into natural biological 
variability in reported data, as may now be the case.
Effect. No reliable biomarkers of manganese effect are known.  Biochemical changes such as altered
blood or urinary levels of steroids, neurotransmitters, or their metabolites are plausible biomarkers of
exposure, but this possibility has not been thoroughly investigated.  Although methods exist for the
   
 








        
      
 
     
       
      
     
   
  
 
    
 
  
             
          
   
       
      
    
  
        




analysis of these biochemicals, further work to improve the analyses does not seem warranted unless the 
utility of this approach is established.
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. All humans are exposed to manganese, primarily through food (EPA 1984).  Near a hazardous
waste site that contains manganese or a factory that uses manganese, humans could receive above-average 
exposure by inhalation of air or ingestion of water, soil, or food.  Methods exist for the analysis of
manganese in air (NIOSH 2003a, 2003b, 2003c), water (APHA 1998a, 1998b, 1998c, 1998d; EPA 1994b, 
2007a), and soils and sediment (EPA 2007a).  Methods are also available to analyze manganese in food 
(Capar and Cunningham 2000; Tinggi et al. 1997).  
7.3.2 Ongoing Studies
The Federal Research in Progress (FEDRIP 2008) database provides additional information obtainable
from a few ongoing studies that may fill in some of the data needs pertinent to the analysis of manganese 
in biological or environmental samples.  Donald Smith and co-workers at the University of California,
Santa Cruz are studying the role of manganese in neurodegenrative disease using particle induced x-ray 
emission (PIXE) analyses of in situ brain regional manganese levels of rodents (FEDRIP 2008).  Carmen 
Enid Martinez and co-workers at Pennsylvania State University are studying the elemental distribution in
soil particles using novel techniques that include synchrotron-based microprobe x-ray fluorescence (XRF)
and x-ray diffraction (XRD) in addition to scanning electron microscopy coupled to energy or wavelength 
dispersive x-ray analysis (SEM/E-W-DS).  Metal solubility measurements are to be studied by
inductively coupled plasma emission spectroscopy (ICP), anodic/cathodic stripping voltammetry
(A/C-SV), and ion-selective electrodes (ISE).












        
     
      
 
  
   
          
      
   
        
      
 






       
         
            
    
  
          
      
      
  
  
          
   
        




8. REGULATIONS, ADVISORIES, AND GUIDELINES
MRLs are substance-specific estimates, which are intended to serve as screening levels, are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
An MRL of 0.0003 mg manganese/m3 (0.3 μg manganese/m3) in respirable dust has been derived for
chronic inhalation exposure to manganese.  As discussed in Appendix A, dichotomous models in the EPA
BMDS were fit to the incidence data for abnormal eye-hand coordination scores in battery workers 
exposed to respirable manganese (Roels et al. 1992). BMCL10 estimates from the different models 
showed an approximate 2-fold range from 73 µg/m3 from a one-stage multistage model to 142 µg/m3 
from the logistic model. The logistic model was indicated as the best fitting model by the AIC measure 
(Table A-2) and was used to provide the POD for the MRL. 
The MRL of 0.3 µg respirable manganese/m3 was derived by adjusting the POD to a continuous exposure
basis (142 x 5/7 x 8/24) and dividing by an uncertainty factor of 100.  An uncertainty factor of 10 was
used for human variability including possibly enhanced susceptibility of the elderly, infants, and children;
individuals with chronic liver disease or parenteral nutrition; and females and individuals with iron 
deficiency.  The current assessment does not use an additional modifying factor of 5 for potentially
increased susceptibility in children based on differential kinetics in the young (which was used in the
Agency for Toxic Substances and Disease Registry [2000] assessment), because recent toxicokinetic 
studies in lactating rats and their offspring exposed to manganese by the oral or inhalation routes suggest
that the human variability factor of 10 provides sufficient protection for differential kinetics in children
and adults.  For example, in neonatal rats orally exposed to 25 or 50 mg manganese/kg/day manganese
chloride from PND 1 through 21, manganese concentrations in various brain regions were about 2-fold 
higher than brain manganese concentrations in adult rats exposed to the same oral dose levels for 21 days 
(Dorman et al. 2000).  Similarly, 18-day-old neonatal rats exposed from birth to aerosols of manganese 
sulfate at 1 mg manganese/m3, 6 hours/day showed a 2.6-fold increase in striatum manganese 
concentrations, compared with controls, while lactating adults exposed to the same aerosol concentration 
showed a 1.7-fold increase compared with controls (Dorman et al. 2005a).  Likewise, simulations with 
PBPK models for inhaled manganese in lactating rat dams and offspring indicate that manganese 
concentrations in the striatum and olfactory bulb of the brains of PND 19 offspring begin to increase
when air concentrations exceed 50–100 µg manganese/m3, whereas maternal concentrations begin to
increase at air concentrations between 100 and 300 µg manganese/m3 (Yoon et al. 2009b). These results
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
indicate that at air concentrations above about 0.05–0.1 mg/m3, brain concentrations in neonates may be
elevated, compared with controls, to a greater degree than in lactating dams, but the age-specific 
difference in the tested air concentration range does not appear to be large.  Simulations from a human 
PBPK model for inhaled manganese in lactating mothers and their offspring indicate that average daily
AUCs for manganese concentrations in the globus pallidus of the fetus, suckling neonate, and 3-year-old 
child from manganese air concentrations increased beyond 10% of background concentrations in fetuses
and 3-year-old children when air concentrations exceeded 0.01 mg/m3 (10 µg/m3) and in suckling
neonates when air concentrations exceeded 0.001 mg/m3 (1 µg/m3) (Yoon et al. 2011).  Thus, the
inhalation MRL derived herein, 0.3 µg/m3, is below air concentrations at which brain concentrations in 
human fetuses (10 µg/m3) and nursing infants (1 µg/m3) are predicted to begin to rise under normal
dietary manganese exposure conditions.  
An uncertainty factor of 10 was applied for limitations/uncertainties in the database including the lack of
epidemiological data for humans chronically exposed to soluble forms of manganese and the concern that
the general population may be exposed to more soluble forms of manganese than most of the manganese-
exposed workers in the principal and supporting studies.  In addition, data on developmental toxicity for
this route and duration of exposure are lacking.  There is limited information on reproductive effects in 
females (one study in rat dams) and reported effects on male reproductive organs have not been clearly
associated with decreased reproductive function. Though it is clear that the neurological system is the
most sensitive identified target organ for effects from subchronic- to chronic-duration inhalation exposure
to manganese, data are lacking to fully characterize the potential risk for all organ systems from chronic 
inhalation exposure.
No oral MRLs were derived for acute-, intermediate-, or chronic-duration oral exposure to manganese,
but an interim guidance value of 0.16 mg manganese/kg/day, based on the Tolerable Upper Intake Level
(UL) for adults of 11 mg manganese/day (established by FNB/IOM [2001]) is recommended to be used 
for ATSDR public health assessments of oral exposure to inorganic forms of manganese. The interim
guidance value is necessary because of the prevalence of manganese at hazardous waste sites and the fact
that manganese is an essential nutrient. It is recommended to be used until more information on actual
intake levels across environmental media can be obtained.
The EPA derived a chronic inhalation RfC of 5x10-5 mg/m3 for respirable manganese (IRIS 2011).  This
value is based on the LOAEL of 0.15 mg/m3 from a study of battery workers exposed to manganese 
dioxide (Roels et al. 1992).  EPA verified this assessment in 1993.  The LOAEL was calculated by
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
dividing the geometric mean concentration of the lifetime-integrated respirable dust concentration for the 
exposed workers by the average duration of employment in the facility.  EPA calculated the RfC by
adjusting for continuous exposure and dividing by an uncertainty factor of 1,000 (10 for use of a LOAEL, 
10 to protect sensitive individuals, and 10 for database limitations reflecting both the less-than-chronic
periods of exposure and the lack of developmental data, as well as potential, but unquantified, differences
in the toxicity of different forms of manganese). The estimated breathing rate in the exposed workers was
assumed to be 10 m3/workday.
The EPA (IRIS 2011) derived an oral reference dose (RfD) value of 0.14 mg/kg/day manganese from all
oral exposures.  As of August 2008, this value was last updated in May 1996.  The agency suggested 
using a modifying factor of 1 if the manganese is ingested in food and a modifying factor of 3 if the
element is ingested in water or soil. The RfD was developed using a previous determination of the upper
range of total dietary intake of 10 mg/day.  The modifying factor of 1 was based on composite data on 
chronic human NOAELs from the World Health Organization (WHO 1973) (0.11–0.13 mg/kg/day), the
National Academy of Sciences/National Research Council (1989) “safe and adequate level” (0.04– 
0.07 mg/kg/day), and a study by Freedland-Graves et al. (1994) concerning nutritional requirements for
manganese.  The FNB/IOM (2001) re-established an Adequate Intake (AI) value for manganese for men
and women at 2.3 and 1.8 mg manganese/day, respectively (for 70-kg individuals, this would result in 
exposures of 0.033 and 0.026 mg manganese/kg/day, respectively).  The UL of 11 mg/day was also set by
the FNB/IOM (2001) for adults based on a NOAEL for Western diets (approximately 0.16 mg
manganese/kg/day assuming a 70-kg body weight).
The international and national regulations, advisories, and guidelines regarding manganese in air, water, 
and other media are summarized in Table 8-1.











       
 
    
    
    
       
        
    
       
    
    
 
 
   
      
       
     
     
     
      
 
      
  
  
      
  
  
    
    
        
     
       
     
       
     
     
     
    
     
     
     




8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Manganese
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification No data IARC 2008
WHO Air quality guidelines
Manganesea 0.15 µg/m3 
WHO 2000a













TLV basis (critical effects)
Manganese Central nervous system
impairment
MMT Central nervous system
impairment, lung, liver, 
and kidney damage





NIOSH Category of pesticides NIOSH 1992
Potassium permanganate Group 1 pesticide
REL (10-hour TWA)
Manganese







Manganese 3 mg/m3 
IDLH












       
 
    
      
   
  
 
     
       
      
   
 
 
        
  
   
  
       
      
  
   
  
      
     
   
   
  
        
      




   
     
   
 
  
    
   
 
  
    
      
 
 
      
 
 
     
     
    
 
   
    
      
   
  
      
  
  






Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Manganese
Agency Description Information Reference
Manganese (II,III) oxide
NATIONAL (cont.)
NIOSH Target organs (cont.)
MMT
OSHA PEL (8-hour TWA) for general industry
(ceiling limit)
Manganese (compounds and fume)
PEL (8-hour TWA) for shipyard industry
(ceiling limit)
Manganese (compounds and fume)
PEL (8-hour TWA) for construction 
industry (ceiling limit)
Manganese (compounds and fume)
b. Water
EPA Designated as hazardous substances in 
accordance with Section 311(b)(2)(A) of
the Clean Water Act
Potassium permanganate
Drinking water contaminant candidate 
list
Manganese
Drinking water standards and health 
advisories
Manganese
1-Day health advisory for a 10-kg 
child




National recommended water quality
criteria
Manganesef 
Human health for consumption of
water + organism
Human health for consumption of
organism only
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Manganese
Agency Description 	 Information Reference 

Manganeseg 
Reportable quantities of hazardous
substances designated pursuant to 




EPA Inert ingredients permitted for use in 
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Table 8-1.  Regulations, Advisories, and Guidelines Applicable to Manganese
Agency Description Information Reference
NATIONAL (cont.)
Effective date of toxic chemical EPA 2008g
release reporting 40 CFR 372.65
Manganese 01/01/1987
EPA Superfund, emergency planning, and 
community right-to-know
Extremely Hazardous Substances EPA 2008f
MMT 40 CFR 355,
Reportable quantity 100 pounds
Appendix A
Threshold planning quantity 100 pounds
NTP Carcinogenicity classification No data NTP 2005
 
         
           
      
       
        
         
           
           
        
        
            
           
 
        
              
 
            
      
      
         
        
      
 
          
           
            
        
               
           
             
          
           




































































8.  REGULATIONS, ADVISORIES, AND GUIDELINES
aTWA based on effects other than cancer or odor/annoyance using an averaging time of 1 year.
bConcentrations of the substance at or below the health-based guideline value may affect the appearance, taste, or
odor of the water, resulting in consumer complaints.
cSkin designation refers to the potential significant contribution to the overall exposure by the cutaneous route,
including mucous membranes and the eyes, by contact with vapors, liquids, and solids.
dNIOSH has not established a REL for magnesium oxide fume under the “Proposed Rule on Air Contaminants"
(29 CFR 1910, Docket No. H-020) in which NIOSH questioned whether the OSHA PEL for magnesium oxide fume 
(1 mg/m3) was adequate enough to protect workers from potential health hazards (NIOSH 2005).
eSkin designation indicates the potential for dermal absorption; skin exposure should be prevented as necessary
through the use of good work practices, gloves, coveralls, goggles, and other appropriate equipment.
fThe human health criteria are based on carcinogenicity of 10-6 risk. This criterion for manganese is not based on 
toxic effects, but rather is intended to minimize objectionable qualities such as laundry stains and objectionable tastes
in beverages.
gNational Secondary Drinking Water Standards are non-enforceable guidelines regulating contaminants that may
cause cosmetic effects (such as skin or tooth discoloration) or aesthetic effects (such as taste, odor, or color) in 
drinking water.
hThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 
additives or listed or affirmed as GRAS.
iGroup D: not classifiable as to human carcinogenicity.
jDesignated CERCLA hazardous substance pursuant to Section 112 of the Clean Air Act.
kDesignated CERCLA hazardous substance pursuant to Section 311(b)(2) of the Clean Water Act.
lNo reportable quantity is being assigned to the generic or broad class.
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
CERCLA = Comprehensive Environmental Response, Compensation, and Liability Act; CFR = Code of Federal
Regulations; DEA = Drug Enforcement Administration; DWEL = drinking water equivalent level; EAFUS = Everything 
Added to Food in the United States; EPA = Environmental Protection Agency; FDA = Food and Drug Administration;
GRAS = Generally Recognized As Safe; IARC = International Agency for Research on Cancer; IDLH = immediately
dangerous to life or health; IRIS = Integrated Risk Information System; MMT = methylcyclopentadienyl manganese 
tricarbonyl; NIOSH = National Institute for Occupational Safety and Health; NTP = National Toxicology Program;
OSHA = Occupational Safety and Health Administration; PEL = permissible exposure limit; REL = recommended 
exposure limit; RfC = inhalation reference concentration; RfD = oral reference dose; STEL = short-term expsoure 
limit; TLV = threshold limit values; TWA = time-weighted average; WHO = World Health Organization
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10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium. 
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response 
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study—A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-controlled study, a group of people with a specified and well-defined outcome is
identified and compared to a similar group of people without outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.
   
 









         
 
   
 
 
      
     
 
 
    
   
 
   
  
 
        
    
           
    
 
    
    
 
        
        
      
 
 
     
            
           
 
   
   
 
    
          
     
 
           
 
 
      
 
   
 
   




Ceiling Value—A concentration of a substance that should not be exceeded, even instantaneously.
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group. 
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time. 
Data Needs—Substance-specific informational needs that if met would reduce the uncertainties of human 
health assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the 
insult occurs. The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media. 
Immediately Dangerous to Life or Health (IDLH)—The maximum environmental concentration of a 
contaminant from which one could escape within 30 minutes without any escape-impairing symptoms or
irreversible health effects.
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.
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10. GLOSSARY
Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of individuals in a population who develop a specified condition to the total 
number of individuals in that population who could have developed that condition in a specified time
period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study, 
or group of studies, that produces statistically or biologically significant increases in frequency or severity
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus. 
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors. The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.
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10. GLOSSARY
Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a
chemical.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor). An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
allowable exposure level in workplace air averaged over an 8-hour shift of a 40-hour workweek. 
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests.
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body. 
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body. 
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a
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10. GLOSSARY
variety of physiological information:  tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as air/blood partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time.  
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time. 
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm. 
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a chemical. The toxicity may be directed to the reproductive organs and/or the related
endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual behavior, 
fertility, pregnancy outcomes, or modifications in other functions that are dependent on the integrity of
this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
Risk—The possibility or chance that some adverse effect will result from a given exposure to a chemical.
   
 










           
  
 
          




   
    






        
      
 
          
 
   
     
       









     
          
    
      
  
          
              
        
 
 
       
MANGANESE 506
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Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, or an inborn or
inherited characteristic that is associated with an increased occurrence of disease or other health-related
event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—The American Conference of Governmental Industrial
Hygienists (ACGIH) maximum concentration to which workers can be exposed for up to 15 minutes
continually.  No more than four excursions are allowed per day, and there must be at least 60 minutes
between exposure periods.  The daily Threshold Limit Value-Time Weighted Average (TLV-TWA) may
not be exceeded.
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which most workers can be exposed without adverse effect.  
The TLV may be expressed as a Time Weighted Average (TWA), as a Short-Term Exposure Limit
(STEL), or as a ceiling limit (CL).
Time-Weighted Average (TWA)—An allowable exposure concentration averaged over a normal 8-hour
workday or 40-hour workweek. 
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism. 
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data. UFs are intended to
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any chemical that is foreign to the biological system.
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APPENDIX A. ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance 
that is likely to be without appreciable risk of adverse noncancer health effects over a specified duration
of exposure. MRLs are based on noncancer health effects only and are not based on a consideration of
cancer effects. These substance-specific estimates, which are intended to serve as screening levels, are 
used by ATSDR health assessors to identify contaminants and potential health effects that may be of
concern at hazardous waste sites.  It is important to note that MRLs are not intended to define clean-up or
action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive chemical-induced end 
point considered to be of relevance to humans.  Serious health effects (such as irreparable damage to the 
liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that










          
  
   
        
   
         
       
           
  
 
   
     
  
          
       





are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences (proposed), expert panel peer reviews, and agency-
wide MRL Workgroup reviews, with participation from other federal agencies and comments from the
public. They are subject to change as new information becomes available concomitant with updating the 
toxicological profiles.  Thus, MRLs in the most recent toxicological profiles supersede previously
published levels.  For additional information regarding MRLs, please contact the Division of Toxicology
and Human Health Sciences (proposed), Agency for Toxic Substances and Disease Registry, 1600 Clifton 
Road NE, Mailstop F-62, Atlanta, Georgia 30333.












   
    
   
     
    
        
    
     
 
    
 
            
  
 
        
       
  
         
        
    
    
  
   
   
            
    
   
 
     
          
    
    
     
    
          
          
         
     
     





MINIMAL RISK LEVEL (MRL) WORKSHEET
Chemical Name: Manganese (inorganic manganese compounds)
CAS Number: 7439-96-5
Date: September, 2012
Profile Status: Final Post-Public Comment Draft
Route: [X] Inhalation  [  ] Oral
Duration: [  ] Acute [ ] Intermediate  [X] Chronic
Graph Key: 61 
Species: Human
Minimal Risk Level:  0.0003 mg respirable manganese/m3 (0.3 µg/m3)
Reference:  Roels HA, Ghyselen P, Buchet JP, et al.  1992.  Assessment of the permissible exposure level
to manganese in workers exposed to manganese dioxide dust.  Br J Ind Med 49:25-34.
Experimental design: Neurological effects of manganese exposure were evaluated in 92 male workers in a 
dry alkaline battery factory.  The control group was 101 age- and area-matched workers not
occupationally exposed to manganese but with similar work schedules and workloads.  Total and
respirable manganese dust concentrations were measured using personal air sampling in different
occupational areas within the factory.  Each worker’s personal exposure was determined by the measured
concentration characteristic for their particular job and the number of years employed.  Workers were
exposed for an average duration of 5.3 years (range 0.2–17.7 years) to average (geometric mean)
concentrations of 0.215 and 0.948 mg manganese/m3 in respirable and total dust, respectively.  The
authors noted that the work processes had not changed significantly in the last 15 years, indicating that
past exposures should be comparable to those measured in the study.  Neurological function was
measured using an audioverbal short term memory test, a simple visual reaction time test using a 
chronoscope, and three manual tests of hand steadiness, coordination, and dexterity.  This report provided
good documentation of individual exposure data and characterization of the population studied.
Effects noted in study and corresponding doses: Manganese-exposed workers performed significantly
worse than the controls on the neurobehavioral tests, with particular differences in simple reaction time,
eye-hand coordination, and hand steadiness.  Dr. Harry Roels provided the data on the manganese-
exposed group evaluated in this study.  These data included individual exposure levels and whether the
individual had an abnormal performance in the neurobehavioral tests (scores below the 5th percentile 
score of the control group).  Actual scores on the tests for each individual were not provided by Dr. Roels. 
Percent precision score in the eye-hand coordination test was the most sensitive end point among the end 
points showing statistically significantly elevated incidences of abnormal scores and was selected as the 
basis of the MRL.  Average exposure concentration for each worker was calculated by dividing the
individual lifetime integrated respirable concentration (LIRD; calculated by Dr. Roels from occupational
histories and measurements of workplace air manganese concentrations) by the individual’s total number
of years working in the factory.  Individuals were grouped into six exposed groups and the control group, 
and the average of the range in each group was used in BMD modeling of the incidence data for number
of workers with abnormal percent precision eye-hand coordination scores (Table A-1).  










     

















      
      
      
      
      
      
      
 
       
        
       
       
   
          
       
 
       
      
    
       
             
      
      
      
          
     
        
      








Table A-1.  Incidence Data for Abnormal Eye-Hand Coordination Scores in 
Workers Exposed to Respirable Manganesea
Range of Average Number of
manganese manganese workers with 
(respirable) (respirable) abnormal eye-
exposure exposure hand Total
concentrationsc concentration coordination number of % 
Groupb (µg/m3) (µg/m3) scored workers affected
1 Control 0 5 101 5
2 1.0–99 33 1 7 14
3 100–199 174 6 39 15
4 200–299 224 4 28 11
5 300–399 307 2 3 67
6 400–499 451 4 9 44
7 >500 (523–650) 565 4 6 67
aBased on individual exposure and dichotomized response data collected by Roels et al. (1992).
bIndividuals were sorted into 7 groups, based on manganese exposure, for use in BMD modeling
cFor each individual, the time-weighted average exposure concentration (respirable manganese) was calculated by
dividing the individual lifetime integrated respirable concentrations (LIRD) by the individual’s respective total number
of years exposed.
dAn abnormal eye-hand coordination score was defined by Roels as a score below the 5th percentile score in the 
control group for percent precision (52.4) in the eye-hand coordination test.
Available dichotomous models in the EPA Benchmark Dose Software (version 1.4.1c) were fit to the 
incidence data for abnormal eye-hand coordination scores in workers exposed to respirable manganese 
(Roels et al. 1992, Table A-1).  Results from the modeling are shown in Table A-2, including:  (1) the
BMC10 and the 95% lower confidence limit (BMCL10) calculated as an estimate of the concentration 
associated with a 10% extra risk for an abnormal score; (2) BMC05 and BMCL05 values; (3) the p-value 
for the chi-square goodness of fit statistic (adequate fit, p>0.1); and (4) AIC (lower AIC indicates better
fit when comparing models, EPA [2000]).  Based on the chi-square and AIC measures of fit, all of the 
models provided adequate and comparable fits to the data (the quantal linear and one-stage multistage 
models had the same parameter values). BMCL10 estimates from the different models showed an
approximate 2-fold range from 73 µg/m3 from a one-stage multistage model to 142 µg/m3 from the
logistic model. The logistic model was indicated as the best fitting model by the AIC measure 
(Table A-2) and was used to provide the POD for the MRL.  Figure A-1 plots predicted risks for
abnormal scores from the multistage model and observed incidence values calculated from data in
Table A-1.   










       










    
       
       
       
       
        
       




          
 
      
 
        
    




   
 








Figure A-1. Predicted (Logistic Model) and Observed Incidence of Abnormal Eye-
Hand Coordination Scores in Workers Exposed to Respirable Manganese
(Roels et al. 1992)*
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Table A-2.  Modeling Results for Incidences of Abnormal Eye-Hand Coordination 
Scores in Workers Exposed to Respirable Manganese
BMC10 BMCL10 BMC05 BMCL05 
Model (µg/m3) (µg/m3) (µg/m3) (µg/m3) x2 p-value AIC
Gammaa 185.46 90.53 134.95 44.07 0.46 134.99
Logistic 179.03 142.14 109.00 83.96 0.64 132.81
Log-logisticb 186.37 98.40 136.04 46.67 0.47 134.98
Multi-stagec 110.42 73.21 53.75 35.64 0.36 135.13
Probit 165.97 131.31 98.50 76.01 0.64 132.85
Log-probitb 188.64 124.37 145.64 86.48 0.46 135.05
Weibulla 182.58 91.23 126.65 44.41 0.47 134.94
aRestrict power ≥1
bSlope restricted to >1
cRestrict betas ≥0; lowest degree polynomial with an adequate fit is reported; degree of polynomial=1
Source: Roels et al. 1992
*BMD=BMC, BMDL=BMCL; BMDs and BMDLs indicated are associated with a 10% extra risk change from the 
control, and are in units of µg/m3. 











Dose and end point used for MRL derivation: 
 
[  ] NOAEL   [  ] LOAEL     [X] Other BMCL10 for incidence of workers with abnormal scores on an 
eye-hand coordination test (142 µg/m3 from the Logistic Model)    
 
Uncertainty and modifying factors used in MRL derivation: 
 
[ ] 10 for the use of a LOAEL 
[ ] 10 for extrapolation from animals to humans 
[X] 10 for human variability including possibly enhanced susceptibility of the elderly, infants, and 
children; individuals with chronic liver disease or parenteral nutrition; and females and individuals with 
iron deficiency.  The current assessment does not use an additional modifying factor of 5 for potentially 
increased susceptibility in children based on differential kinetics in the young (which was used in the 
Agency for Toxic Substances and Disease Registry [2000] assessment), because recent toxicokinetic 
studies in lactating rats and their offspring exposed to manganese by the oral or inhalation routes suggest 
that the human variability factor of 10 provides sufficient protection for differential kinetics in children 
and adults.  For example, in neonatal rats orally exposed to 25 or 50 mg manganese/kg/day manganese 
chloride from PND 1 through 21, manganese concentrations in various brain regions were about 2-fold 
higher than brain manganese concentrations in adult rats exposed to the same oral dose levels for 21 days 
(Dorman et al. 2000).  Similarly, 18-day-old neonatal rats exposed from birth to aerosols of manganese 
sulfate at 1 mg manganese/m3, 6 hours/day showed a 2.6-fold increase in striatum manganese 
concentrations, compared with controls, while lactating adults exposed to the same aerosol concentration 
showed a 1.7-fold increase compared with controls (Dorman et al. 2005a).  Likewise, simulations with 
PBPK models for inhaled manganese in lactating rat dams and offspring indicate that manganese 
concentrations in the striatum and olfactory bulb of the brains of PND 19 offspring begin to increase 
when air concentrations exceed 50–100 µg manganese/m3, whereas maternal concentrations begin to 
increase at air concentrations between 100 and 300 µg manganese/m3 (Yoon et al. 2009b).  These results 
indicate that at air concentrations above about 0.05–0.1 mg/m3, brain concentrations in neonates may be 
elevated, compared with controls, to a greater degree than in lactating dams, but the age-specific 
difference in the tested air concentration range does not appear to be large.  Simulations from a human 
PBPK model for inhaled manganese in lactating mothers and their offspring indicate that average daily 
AUCs for manganese concentrations in the globus pallidus of the fetus, suckling neonate, and 3-year-old 
child from manganese air concentrations increased beyond 10% of background concentrations in fetuses 
and 3-year-old children when air concentrations exceeded 0.01 mg/m3 (10 µg/m3) and in suckling 
neonates when air concentrations exceeded 0.001 mg/m3 (1 µg/m3) (Yoon et al. 2011).  Thus, the 
inhalation MRL derived herein, 0.3 µg/m3, is below air concentrations at which brain concentrations in 
human fetuses (10 µg/m3) and nursing infants (1 µg/m3) are predicted to begin to rise under normal 
dietary manganese exposure conditions. 
  
[X]  	 10 for limitations/uncertainties in the database including the lack of epidemiological data for 
humans chronically exposed to soluble forms of manganese and the concern that the general 
population may be exposed to more soluble forms of manganese than most of the manganese-
exposed workers in the principal and supporting studies.  Evidence from several rat studies 
indicate that inhalation of more soluble forms of manganese (e.g., manganese sulfate and 
manganese chloride) results in higher manganese concentrations in brains than inhalation of less 
soluble forms, such as manganese phosphate, manganese tetroxide, or  manganese dioxide 
(Dorman et al. 2001a, 2004a; Roels et al. 1997).  In addition, data on developmental toxicity for 
this route and duration of exposure are lacking.  There is limited information on reproductive 
effects in females (one study in rat dams) and reported effects on male reproductive organs have 
not been clearly associated with decreased reproductive function.  Though it is clear that the 
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APPENDIX A
neurological system is the most sensitive identified target organ for effects from subchronic- to 
chronic-duration inhalation exposure to manganese, data are lacking to fully characterize the
potential risk for all organ systems from chronic inhalation exposure.
Was a conversion used from ppm in food or water to a mg/body weight dose? No.
If an inhalation study in animals, list the conversion factors used in determining human equivalent dose: 
Not applicable.
Was a conversion used from intermittent to continuous exposure? 
[X] 5/7 to account for intermittent exposure (5 days/week)
[X] 8/24 to account for intermittent exposure (8 hours/day)
MRL = 142 µg respirable manganese/m3 x 5d/7d x 8h/24h x 1/100 = 0.3 µg respirable manganese/m3. 
Other additional studies or pertinent information that lend support to this MRL: 
Previous BMD analyses of exposure data and incidence data for abnormal eye-hand coordination test
scores from the Roels et al. (1992) study used a quantal linear model to arrive at a BMCL10 value of about
74 µg respirable manganese/m3 (Agency for Toxic Substances and Disease Registry 2000; EPA 1994c;
WHO 2001). This value is virtually the same as the BMCL10 of 73.2 µg manganese/m3 obtained from a
one-stage multistage model in the current analysis (Table A-2).   
Several BMD analyses of results from other epidemiological studies of neurobehavioral end points in
manganese-exposed workers provide support for the MRL (Clewell and Crump 1999; Clewell et al. 2003;
Health Canada 2010).  Estimated BMCL10 values in these analyses were within 2–3-fold of the POD
(142 µg manganese/m3) selected for the chronic inhalation MRL herein.
Dr. Anders Iregren provided ATSDR with individual worker data on total dust manganese exposure and 
performance on neurobehavioral tests for the occupational cohort that participated in his study (Iregren 
1990; Wennberg et al. 1991).  A BMD analysis was performed with these data under contract with 
ATSDR (Clewell and Crump 1999) and the lowest BMCL10 value among the end points analyzed was 
0.07 mg respirable manganese/m3 for a 10% change in simple reaction time.  The BMD analysis applied
K-power and Weibull models to continuous variable data (from 11 different test scores collected by Dr. 
Iregren) using current respirable manganese exposure estimates, age, and vocabulary test results as 
explanatory variables, an assumption that 5% of unexposed subjects had adverse responses, and a
benchmark response of 10% change from unexposed mean scores.  For each dataset, BMCL10 values from
the Weibull model were lower (by 2–3-fold at the most) than BMCL10 values from the K-Power model.  
Weibull BMCL10 values for the different test score datasets ranged from 0.07 to 0.67 mg respirable 
manganese//m3. Thus, the lowest BMCL10 value from this analysis of test score data from manganese-
exposed workers collected by Iregren (1990; Wennberg et al. 1991) is within 2-fold of the POD of 142 µg 
manganese/m3 for the MRL.
Clewell et al. (2003) conducted BMD analyses on data from three neuromotor tests in the Roels et al.
(1992) study (visual reaction time, eye-hand coordination, and hand steadiness) and from five neuromotor
tests in the Gibbs et al. (1999) study (hole 6 of the hand steadiness test, percent precision of the eye-hand 
coordination test, reaction time in the complex reaction test, root mean square amplitude in the steady
test, and tap time).  Exposure measures in these analyses were recent measures of manganese 
concentrations in respirable dust.  BMCL10 values were 0.257, 0.099, and 0.202 mg manganese/m3 for the
visual reaction time, eye-hand coordination, and hand steadiness data from the Roels et al. (1992) study;










         
      
         
         
    
   
   
        
      
          
  
   
     
 
     
          
       
              
            
    
 
        
     
 
         
       
  
      
 
 
       
         
     
  
    
       
     
           
           
            
      




these results were obtained after fitting incidence data for abnormal scores in these tests to a Weibull
model for dichotomous data.  The reported BMCL10 value of 0.099 mg manganese/m3 for the eye-hand 
coordination test is similar to the BMCL10 value of 0.091 mg manganese/m3 obtained with the Weibull
model in the current ATSDR analysis (Table A-2).  BMCL10 values from the analyses of outcomes from
the Gibbs et al. (1999) study ranged from 0.09 to 0.27 mg manganese/m3 (averaging the BMCLs within
end points across different BMD models applied to the data).  Clewell et al. (2003) did not have
individual worker data from the Iregren (1990) or Mergler et al. (1994) studies, but, based on some
assumptions about exposures (e.g., all exposed workers were exposed to average concentrations for the 
facilities and respirable manganese concentrations were calculated for the Iregren workers based on an 
assumption that 50% of total dust manganese was respirable), they calculated BMCL10 values for six end 
points from the Mergler et al. (1994) study and the simple reaction time end point in the Iregren (1990)
study.  BMCL10 values ranged from about 0.1 to 0.3 mg manganese/m3 from the Mergler et al. (1994)
study end points to 0.1 mg manganese/m3 for the reaction time end point in the Iregren (1990) study. 
Health Canada (2010) published a human health risk assessment for inhaled manganese in which BMD
analyses were conducted on data for neurobehavioral end points from the study of manganese alloy
workers by Lucchini et al. (1999).  Dose-response data for six tests of fine motor control, two aspects of
memory tests, one test of mental arithmetic, and measured serum prolactin levels were fit to linear
models, using exposure metrics based on an average over all occupational history (ARE) or an average 
over the latest five years of occupation (ARE5).  Using a linear model, BMCL10 values for the various 
end points were 32–59 and 85–98 µg manganese/m3 for the ARE5 and ARE exposure metrics, 
respectively.  Regardless of exposure metric, the values are within a 2–4-fold range of the selected POD
of 142 µg manganese/m3, based on eye-hand coordination test scores in workers in the Roels et al. (1992)
study. 
Neurological effects from repeated inhalation exposure to manganese are well recognized as effects of
high concern based on case reports and epidemiological studies of groups of occupationally exposed 
workers.  A number of epidemiological studies have used batteries of neurobehavioral tests of
neuromotor, cognition, and mood states to study the psychological or neurological effects of exposure to
low levels of manganese in the workplace (Bast-Pettersen et al. 2004; Beuter et al. 1999; Blond and 
Netterstrom 2007; Blond et al. 2007; Bouchard et al. 2003, 2005, 2007a, 2007b; Chia et al. 1993a, 1995;
Crump and Rousseau 1999; Deschamps et al. 2001; Gibbs et al. 1999; Iregren 1990; Lucchini et al. 1995, 
1999; Mergler et al. 1994; Myers et al. 2003a, 2003b; Roels et al. 1987a, 1992, 1999; Summers et al.
2011; Wennberg et al. 1991).  Some of these studies have found statistically significant differences 
between exposed and non-exposed groups or significant associations between exposure indices and 
neurological effects (Bast-Pettersen et al. 2004; Chia et al. 1993a; Iregren 1990; Lucchini et al. 1995, 
1999; Mergler et al. 1994; Roels et al. 1987a, 1992; Wennberg et al. 1991), whereas others have not
found significant associations (Deschamps et al. 2001; Gibbs et al. 1999; Myers et al. 2003a, 2003b;
Summers et al. 2011; Young et al. 2005). Table A-3 summarizes results from these studies.  Comparison
of the effect levels in these studies provides support for selection of the Roels et al. (1992) as the basis of
the MRL. The advantage of the Roels et al. (1992) study is that individual worker data were available to
support a BMD analysis, but, as discussed above, BMD analyses of other epidemiological data for
performance on tests of neurobehavior provided potential PODs within 2–4-fold of the POD selected as 
the basis of the MRL.










        





















         
  




       
 
  


























      
  







     
    
   
 






      
   
 





    
   
   
 
   
 
      
  
    
   
  
 




   
 
      
  






Table A-3.  Epidemiological Studies of Neurological End Points in Workers




Place of manganese/ Years of of

































































































↓ finger tapping, digit symbol,
pursuit aiming
↓ reaction time, short-term
memory, eye-hand 
coordination, hand steadiness
↓ reaction time, short-term
memory, eye-hand 
coordination, hand steadiness
↓ finger tapping, reaction time 
↓ finger tapping, short-term
memory with increasing
exposure indices
↓ hand movements, finger
tapping, short-term memory
↓ rapid hand movements,
cognitive flexibility; ↑ indices for
tension, anger, fatigue,
confusion
No effects on neuromotor tests
or self-reported symptoms
No effects on self-reported 
symptoms or several cognitive 
tests; no neuromotor tests
given.
No associations between 
indices of exposure and 
outcomes from tests of
neuromotor and cognitive
functions or self-reported 
symptoms
Neurobehavioral test batteries
showed significant effects in 














        





















    
   




   
    







         
    




   
         
   
    
   
 
             
   














Table A-3.  Epidemiological Studies of Neurological End Points in Workers




Place of manganese/ Years of of
3)aReference work m workedb exposed control Effects
Summers et Mn smelter 0.384 10.6 143 None Associations between 
al. 2011 (0.123) decreasing deficits on tests of
attention and executive function 
(but not tests of short-term
memory span or information-
processing speed) and 
increasing exposure. The 
magnitude of deficits were not
expected by the study authors
to be of clinical significance.
Bast- Mn alloy 0.753 20.2 100 100 ↑ scores for hand tremor, but no
Pettersen et plant (0.049) effect on other neuromotor or
al. 2004 cognitive tests or symptoms
Blond and Steel works 0.07 24 60–92 14–19 ↓ fast hand and finger
Netterstrom movement, but no effects on 
2007; Blond slow movements, reaction time,
et al. 2007 or cognitive end points
aMean, median, or midpoint of reported ranges of manganese concentration in total dust. Values for respirable dust
are noted in parentheses when they were available.
bMean, median, or midpoint of reported ranges of years employed at the facility.
 
     
  
            
        
         
          
      
        
 
    
  
    
 
   
   
    
    
  
       
    
   







The neurological effects associated with prolonged low-level manganese exposure generally have been
subtle changes including deficits in tests of neuromotor or cognitive functions and altered mood states;
they have been referred to by various authors as preclinical or subclinical neurological effects.
Manganese air concentrations associated with these effects in chronically exposed workers range from
about 0.07 to 1.59 mg manganese/m3 (manganese in total or inhalable dust measurements; values for
manganese in respirable dust are noted in parentheses in Table A-3).  For several of these work
environments, values of concentrations of manganese in respirable dust (generally particulate diameters 
<10 µm) represented <20–80% of the total dust values.
Studies in communities surrounding manganese industries also have reported similar subclinical
neurological effects in adults and children.  In a study of men and women living close to a manganese
alloy production plant, a blood manganese level-age interaction was observed, with the poorest
performance on neurological tests occurring among those >50 years old who had the highest blood 
manganese levels (Baldwin et al. 1999; Beuter et al. 1999; Bowler et al. 1999; Mergler et al. 1999).  
Additional studies of environmentally exposed adults reported attention impairments, poorer postural
stability, and subclinical motor impairments at environmental air exposures >0.1 μg manganese/m3; 
however, other potential sources of environmental exposure were not accounted for (Kim et al. 2011;
Rodríguez-Agudelo et al. 2006; Solís-Vivano et al. 2009; Standridge et al. 2008).  In children living in a
manganese mining area or close to a ferromanganese alloy plant, associations were found between
manganese concentrations in blood or hair and deficits in intellectual functions or motor impairments, but
the reported data are not useful for deriving an inhalation MRL for manganese (Hernández-Bonilla et al.
2011; Menezes-Filho et al. 2011; Riojas-Rodríguez et al. 2010).  
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APPENDIX A
The 2000 ATSDR Toxicological Profile for Manganese derived a chronic MRL for inorganic manganese 
of 0.00004 mg manganese/m3 (manganese in respirable dust, 0.04 μg manganese/m3), based on a BMCL10 
of 0.074 mg manganese/m3 (manganese in respirable dust) for abnormal performance in tests of hand 
steadiness, eye-hand coordination, or reaction time in the same study of 92 male workers in a dry alkaline
battery plant (Roels et al. 1992) used in the current assessment. The MRL was derived by adjustment of
the BMCL10 to a continuous exposure basis and division by an uncertainty factor of 500 (10 for human 
variability, 10 for database deficiencies and limitations, and a modifying factor of 5 for potentially
increased susceptibility in children based on differential kinetics in the young).  The current MRL of
0.3 μg manganese/m3 replaces the old MRL.
Agency Contact (Chemical Manager): Malcolm Williams, DVM, Ph.D. 
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APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1. What effects are known to occur in humans?
2. What effects observed in animals are likely to be of concern to humans?
3. What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.  
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public 
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.










     




    
     
    
 
 
   
    
     
 
            
     
         
           
          
       
          
            
  
       
   
     
            









       
         
          
  
  
        
           
       
 
       
    





MRLs should help physicians and public health officials determine the safety of a community living near
a chemical emission, given the concentration of a contaminant in air or the estimated daily dose in water.  
MRLs are based largely on toxicological studies in animals and on reports of human occupational
exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement,
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario. The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.













        
     
  
   
          
        
   
 
 
        
   
        
  
 
           
          
         
 
 
    
  
           
   
 
         
        
      
 
   
       
           
 
         
 
 
       
    
            
         
 
 
             














See Sample LSE Table 3-1 (page B-6)
(1) Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2) Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3) Health Effect. The major categories of health effects included in LSE tables and figures are 
death, systemic, immunological, neurological, developmental, reproductive, and cancer.  
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4) Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5) Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL. 
(6) Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen, 
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7) System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and 
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8) NOAEL.  A NOAEL is the highest exposure level at which no harmful effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").












         
         
    
          
        
  
 
    
 
           
      
            
  
 
     







      
         
 
 
         
     
 
        
        
 
         






         
     
       
 
    














(9) LOAEL. A LOAEL is the lowest dose used in the study that caused a harmful health effect.  
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help
readers identify the levels of exposure at which adverse health effects first appear and the
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10) Reference. The complete reference citation is given in Chapter 9 of the profile.
(11) CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12) Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13) Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health 
effects observed within the acute and intermediate exposure periods are illustrated.
(14) Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15) Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16) NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table. The dashed descending arrow indicates the 
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17) CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.










    
    
        
     
 







(18) Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).







         
 





    




   
  
  
     
              








































































































































































18 Rat 13 wk Resp 3b 10 (hyperplasia)





38 Rat 18 mo 20 (CEL, multiple Wong et al. 1982
5 d/wk organs)
7 hr/d
39 Rat 89–104 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk nasal tumors)
6 hr/d
40 Mouse 79–103 wk 10 (CEL, lung tumors, NTP 1982
5 d/wk hemangiosarcomas)
6 hr/d
a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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 American Conference of Governmental Industrial Hygienists
  American College of Occupational and Environmental Medicine
  acceptable daily intake
 absorption, distribution, metabolism, and excretion
  atomic emission detection
AFID    alkali flame ionization detector
AFOSH 
 ALT







  acute myeloid leukemia
     Association of Official Analytical Chemists
 Association of Occupational and Environmental Clinics
 alkaline phosphatase









    Agency for Toxic Substances and Disease Registry
   Ambient Water Quality Criteria






Biological Exposure Index 
    benchmark dose or benchmark concentration
      dose that produces a X% change in response rate of an adverse effect
    95% lower confidence limit on the BMDX 
 BMDS  Benchmark Dose Software   
 BMR
 BSC
  benchmark response




   Clean Air Act
CAG 
 CAS
      Cancer Assessment Group of the U.S. Environmental Protection Agency
   Chemical Abstract Services
 CDC     Centers for Disease Control and Prevention





  Computer-Environmental Legislative Data System
  Comprehensive Environmental Response, Compensation, and Liability Act
Code of Federal Regulations 
 curie




  ceiling limit value





 chronic myeloid leukemia
   Consumer Products Safety Commission







   Department of Health, Education, and Welfare
      Department of Health and Human Services
 deoxyribonucleic acid
 Department of Defense
   Department of Energy








APPENDIX C.  ACRONYMS, ABBREVIATIONS, AND SYMBOLS 









   
   
            
   
   
  
  
   
    
  
  
   
  
     
      
    
  
   
   
 
  





   
       
     
  




   
    
  
  
   
   
   
   
  
  
   
  
    
  
  




DOT Department of Transportation
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization




Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie









   






    
  
   
    
  
    
     
   
     
   
   
   
   
    
 
 
     
    
     
     
  
  
   
  
    
 
    
   
  
    
   
  
    
   
     
       
      
    
  
      
  
  
     
   
MANGANESE C-3
APPENDIX C 
MCL maximum contaminant level
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey 
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection 
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances










   
      
   
   








   
  
    
     
  





      
  
    
   
   
    
  
     
    
    
     
   
   
    
    
   
  
   
   
   
  
   
     
    
   






OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio 
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell





RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase
SGPT serum glutamic pyruvic transaminase
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell
WHO World Health Organization










   
      
  
   








   
 
  
   





≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result

















This page is intentionally blank. 

































   
  
  




   
   
   
   
  
   
   






    
     
   







































































































APPENDIX D.  INDEX 

absorbed dose.................................................................................................................... 322, 326, 408, 412
acetylcholine ............................................................................................................................................. 183 
acetylcholinesterase .................................................................................................................. 183, 201, 316
active transport.................................................................................................................. 239, 263, 286, 296
adrenal gland..................................................................................................................................... 154, 208
adsorbed ............................................................................................................................ 385, 394, 396, 402
adsorption.................................................................................................................................................. 396 
alanine aminotransferase................................................................................................... 188, 189, 211, 212
ambient air .................................................................................................................. 11, 391, 398, 409, 411 	
anaerobic ................................................................................................................................................... 397 
anemia....................................................................................................................................... 230, 333, 417
bioaccumulation........................................................................................................................................ 395 
bioavailability ..................................................................... 40, 229, 231, 324, 332, 402, 414, 417, 421, 422
bioconcentration factor ............................................................................................................................. 395 
biomarker ..... 27, 230, 321, 322, 324, 325, 326, 327, 329, 352, 354, 355, 360, 406, 414, 416, 423, 425, 433
blood cell count........................................................................................................................... 30, 151, 157
body weight effects ..................................................................................................... 66, 155, 156, 206, 213
breast milk................................................................. 197, 229, 231, 235, 259, 320, 332, 359, 406, 413, 414
cancer .............................................................................................................. 5, 15, 208, 252, 309, 348, 441 
carcinogenic ...................................................................................................... 15, 19, 41, 98, 204, 208, 348 
carcinogenicity.............................................................................................................................. 15, 38, 441
cardiovascular ......................................................................................... 30, 63, 64, 148, 149, 205, 210, 361
cardiovascular effects.............................................................................................. 30, 63, 64, 148, 205, 210
chromosomal aberrations .......................................................................................... 218, 219, 223, 235, 348
clearance .................................................................... 42, 224, 225, 246, 256, 262, 263, 269, 275, 276, 278, 
280, 281, 282, 286, 291, 301, 324, 338, 339
cognitive function ....................................................................... 17, 27, 68, 83, 88, 168, 173, 182, 302, 313
death.......................................................... 41, 60, 63, 98, 146, 147, 153, 158, 162, 174, 193, 205, 209, 342
deoxyribonucleic acid (see DNA)............................................................................................................. 221 
dermal effects...................................................................................................... 66, 154, 155, 206, 213, 342
developmental effects .................................................... 18, 97, 98, 156, 182, 197, 198, 199, 202, 204, 207,
208, 216, 309, 317, 318, 335, 345, 349, 358
DNA (see deoxyribonucleic acid)............................................................................................. 219, 221, 322
dopamine.................................. 28, 29, 31, 92, 176, 177, 178, 181, 182, 184, 185, 186, 188, 192, 201, 256, 
297, 298, 299, 301, 302, 303, 315, 316, 317, 324, 328, 331, 339, 346, 362
elimination half-time......................................................................................................................... 260, 262
elimination rate ................................................................................................................................. 275, 283
endocrine............................................................................................... 65, 66, 154, 206, 213, 305, 306, 307
endocrine effects ........................................................................................... 65, 66, 154, 206, 213, 306, 307 	
erythema.................................................................................................................................................... 206 
fetal tissue ......................................................................................................... 232, 244, 286, 291, 293, 314 
fetus......................................... 5, 24, 202, 234, 244, 246, 286, 287, 293, 308, 315, 320, 351, 359, 413, 436
follicle stimulating hormone (see FSH) ...................................................................................................... 65 
FSH (see follicle stimulating hormone) .............................................................. 65, 193, 194, 200, 306, 307
gastrointestinal effects ................................................................................................ 64, 149, 150, 205, 211
general population................. 12, 25, 168, 234, 318, 333, 342, 345, 383, 398, 407, 414, 415, 418, 422, 436
genotoxic..................................................................................................................................... 41, 223, 348
genotoxicity....................................................................................................................................... 223, 349
groundwater ...................................................................... 3, 33, 89, 198, 309, 333, 350, 383, 393, 395, 402


























   
  
   
  
   
 
 
   
   
  
  
   
   
   














   
  
   
 










































































































growth retardation..................................................................................................................................... 193 
half-life................................................................................................ 60, 228, 254, 321, 338, 394, 396, 397
hematological effects .................................................................................................. 64, 150, 151, 205, 211
hepatic effects ............................................................................................... 64, 65, 152, 153, 206, 211, 329
hydroxyl radical ........................................................................................................................................ 302 
immune system ........................................................................................................................... 67, 157, 351
immunological ...................................................................................................... 41, 67, 157, 158, 207, 214
immunological effects......................................................................................................................... 67, 157
Kow ............................................................................................................................................ 369, 370, 371
LD50............................................................................................................................. 60, 146, 147, 205, 209
lymphatic .................................................................................................................................................. 228 
lymphoreticular ........................................................................................................... 67, 157, 158, 207, 214
menstrual................................................................................................................................................... 306 
metabolic effects ........................................................................................................... 66, 67, 157, 207, 214
micronuclei ....................................................................................................................................... 219, 223
milk .............................................................. 14, 31, 170, 181, 202, 203, 229, 231, 234, 235, 240, 259, 286, 
288, 291, 293, 319, 320, 332, 351, 406, 413, 414, 421
mucociliary ................................................................................................. 71, 224, 225, 275, 293, 337, 355
musculoskeletal effects ............................................................................................... 65, 151, 152, 205, 211
neonatal ................................ 24, 29, 31, 32, 34, 93, 173, 182, 183, 184, 190, 200, 201, 244, 249, 260, 265, 
291, 299, 300, 305, 313, 314, 315, 316, 319, 332, 350, 357, 359, 424, 435
neoplastic .................................................................................................................................................... 41 
neurobehavioral.............................. 16, 17, 21, 22, 23, 25, 26, 27, 28, 29, 31, 32, 34, 37, 72, 75, 78, 79, 80, 
81, 82, 83, 84, 85, 86, 87, 92, 163, 178, 186, 198, 303, 304, 306, 311, 
320, 325, 326, 333, 344, 346, 347, 350, 351, 352, 357, 424
neurochemical ..................... 30, 176, 182, 183, 184, 185, 186, 297, 300, 304, 314, 316, 320, 332, 350, 357
neurodevelopmental.................................................................................................................... 30, 313, 349
neurological effects.................. 14, 15, 16, 18, 20, 21, 27, 28, 36, 40, 67, 68, 69, 72, 75, 80, 84, 87, 92, 94, 
97, 158, 159, 161, 163, 164, 170, 180, 189, 190, 191, 201, 207, 214, 
215, 237, 310, 311, 317, 321, 326, 327, 329, 331, 333, 335, 342, 
343, 344, 345, 346, 347, 352, 353, 355, 358, 359, 418
neurophysiological.................................................................................................................................... 332 
neurotransmitter ........................................................................................................ 192, 203, 297, 332, 355
norepinephrine .......................................................................................................................... 183, 192, 315
nuclear....................................................................................................................................................... 154 
ocular effects....................................................................................................................... 66, 155, 206, 213
odds ratio............................................................................................................................................... 73, 87
orofacial .............................................................................................................................................. 33, 178
oxidative phosphorylation......................................................................................................................... 300 
partition coefficients ................................................................................................................. 269, 275, 285
pharmacodynamic ..................................................................................................................................... 264 
pharmacokinetic...........24, 190, 203, 227, 264, 265, 266, 267, 278, 283, 289, 308, 319, 321, 356, 357, 358
photolysis .................................................................................................................................................. 396 
placenta ......................................................................................................... 5, 244, 285, 287, 314, 320, 413 
rate constant ...................... 269, 274, 275, 277, 278, 280, 281, 282, 284, 285, 286, 287, 288, 289, 290, 291
renal effects................................................................................................................. 65, 153, 154, 206, 212
reproductive effects............................... 18, 20, 25, 33, 94, 96, 154, 192, 195, 196, 207, 215, 216, 349, 436
respiratory effects...................................................................... 17, 20, 61, 63, 148, 205, 210, 310, 327, 335
retention ................................................................. 14, 64, 83, 164, 228, 229, 230, 231, 249, 254, 256, 260,  
262, 291, 319, 321, 332, 339, 357, 358, 359, 394
sequestered................................................................................................................................................ 295 














































solubility ............................................................................................................. 40, 293, 356, 395, 420, 434
spermatogonia........................................................................................................................................... 219 




toxicokinetic.................................................. 24, 39, 215, 251, 256, 263, 321, 332, 335, 355, 357, 433, 435
tremors .................................................................................................................... 14, 16, 93, 158, 172, 207
tumors ......................................................................................................................... 41, 208, 211, 252, 318
vapor pressure ........................................................................................................................................... 394 
weanling.................................................................... 149, 175, 186, 191, 193, 194, 199, 200, 225, 249, 316
 
 
 
 
 
 
 
 
 
 
 
 
